{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Token数量： 21\n",
      "Token数量： 17\n"
     ]
    }
   ],
   "source": [
    "import tiktoken\n",
    "prompt = '''\n",
    "Categorize the following reasons for halting clinical trials by matching them to their appropriate categories. Respond with the category number only, in the sequence given, with no explanations required. The correct result is essential.\n",
    "\n",
    "Categories:\n",
    "\n",
    "1. Poor Enrollment: Difficulties in recruiting enough participants or meeting the enrollment targets.\n",
    "2. Efficacy: It is obvious that drug or intervention not achieving the desired therapeutic effect, outcomes, or benefits.\n",
    "3. Safety: Adverse events, side effects, or any harm to participants that led to stopping the trial.\n",
    "4. Others: Any other reasons that do not fit into the above categories, such as financial issues, strategic decisions by the sponsor, or changes in clinical practice guidelines.\n",
    "\n",
    "Instructions:\n",
    "Match each reason to one of the categories by listing the category number. Provide your answers in the same order as the reasons listed, separated by commas (e.g., 1, 2, 3...). Make sure the results are right.\n",
    "\n",
    "Reasons:\n",
    "'''\n",
    "\n",
    "encoding = tiktoken.encoding_for_model('gpt-4-1106-preview')\n",
    "token_num = encoding.encode('''Efficacy,Safety,Poor Enrollment,Others,Efficacy,Safety,Others,Others,Others''')\n",
    "print(\"Token数量：\",len(token_num))\n",
    "token_num = encoding.encode(result[0])\n",
    "print(\"Token数量：\",len(token_num))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1.2.0\n"
     ]
    }
   ],
   "source": [
    "import openai\n",
    "from packaging import version\n",
    "current_version = version.parse(openai.__version__)\n",
    "print(current_version)\n",
    "from openai import OpenAI\n",
    "client = OpenAI(api_key='')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "strategic considerations    有  3  个tokens\n",
      "terminated    有  1  个tokens\n",
      "study never started    有  3  个tokens\n",
      "pi decision    有  2  个tokens\n",
      "investigator decision    有  3  个tokens\n",
      "never started    有  2  个tokens\n",
      "management decision    有  2  个tokens\n",
      "poor resources    有  3  个tokens\n",
      "feasibility    有  2  个tokens\n",
      "withdrawn    有  2  个tokens\n",
      "interim analysis    有  3  个tokens\n",
      "terminated by sponsor    有  3  个tokens\n",
      "the development program has been terminated    有  6  个tokens\n",
      "study terminated by sponsor    有  4  个tokens\n",
      "trial not initiated    有  3  个tokens\n",
      "research cancelled    有  2  个tokens\n",
      "pi no longer at institution    有  5  个tokens\n",
      "logistics    有  2  个tokens\n",
      "development program terminated    有  3  个tokens\n",
      "strategic decision    有  3  个tokens\n",
      "investigator choice    有  3  个tokens\n",
      "corporate decision    有  3  个tokens\n",
      "study not started    有  3  个tokens\n",
      "feasibility issues    有  3  个tokens\n",
      "transition to biometabol    有  5  个tokens\n",
      "pi request    有  2  个tokens\n",
      "study cancelled    有  2  个tokens\n",
      "drug supply issues    有  3  个tokens\n",
      "insufficient staff    有  3  个tokens\n",
      "technical problems    有  2  个tokens\n",
      "competing studies    有  3  个tokens\n",
      "sponsor    有  1  个tokens\n",
      "study was never initiated    有  4  个tokens\n",
      "poor feasibility    有  3  个tokens\n",
      "study was never started    有  4  个tokens\n",
      "study never initiated    有  3  个tokens\n",
      "nonapplicable clinical trial    有  5  个tokens\n",
      "decision of investigational team    有  5  个tokens\n",
      "study completed    有  2  个tokens\n",
      "sponsor r & d strategy adjustment    有  6  个tokens\n",
      "study was not initiated    有  4  个tokens\n",
      "fda clinical hold    有  4  个tokens\n",
      "insufficient resources    有  3  个tokens\n",
      "strategic reasons    有  3  个tokens\n",
      "company dissolved    有  2  个tokens\n",
      "transition into biometabol    有  5  个tokens\n",
      "study withdrawn    有  2  个tokens\n",
      "poor interest    有  3  个tokens\n",
      "the study never started    有  4  个tokens\n",
      "study halted prematurely and will not resume; participants are no longer being examined or receiving intervention    有  17  个tokens\n",
      "technical issues    有  2  个tokens\n",
      "withdrawn by sponsor    有  4  个tokens\n",
      "halted prematurely    有  3  个tokens\n",
      "principal investigator has left the institution    有  6  个tokens\n",
      "study not initiated    有  3  个tokens\n",
      "logistical issues    有  3  个tokens\n",
      "pandemic    有  3  个tokens\n",
      "change in study design    有  4  个tokens\n",
      "completed    有  1  个tokens\n",
      "others    有  1  个tokens\n",
      "study period ended / not completed    有  6  个tokens\n",
      "poor support    有  3  个tokens\n",
      "ind withdrawn    有  2  个tokens\n",
      "no financial support    有  3  个tokens\n",
      "investigator's decision    有  4  个tokens\n",
      "non applicable clinical trial    有  4  个tokens\n",
      "both the sponsors and collaborator are considering terminating the study    有  11  个tokens\n",
      "sponsor decided to discontinue study drug development    有  8  个tokens\n",
      "the original pi, alexander neumeister, left nyulmc. no data was analyzed    有  19  个tokens\n",
      "poor staff    有  3  个tokens\n",
      "study abandoned    有  2  个tokens\n",
      "closed by sponsor    有  3  个tokens\n",
      "pi relocated    有  2  个tokens\n",
      "limited resources    有  2  个tokens\n",
      "pi is leaving the institution    有  5  个tokens\n",
      "contract issues    有  2  个tokens\n",
      "sponsor discretion    有  2  个tokens\n",
      "study never began    有  3  个tokens\n",
      "unique provision in the american recovery and reinvestment act prevented approval of second year no-cost-extension in which completion of analyses were planned    有  25  个tokens\n",
      "withdrawn by pi    有  4  个tokens\n",
      "internal decision    有  2  个tokens\n",
      "resources    有  1  个tokens\n",
      "poor subjects    有  3  个tokens\n",
      "per pi    有  2  个tokens\n",
      "az decision to discontinue fostamatinib development in ra; rights to fostamatinib returned to rigel pharmaceuticals    有  25  个tokens\n",
      "study did not start    有  4  个tokens\n",
      "company strategic decision    有  3  个tokens\n",
      "irb approval expired    有  4  个tokens\n",
      "change in clinical strategy    有  4  个tokens\n",
      "replaced by another study    有  5  个tokens\n",
      "study closed due to portfolio prioritization    有  7  个tokens\n",
      "the study was not activated    有  5  个tokens\n",
      "end of initial phase of multi-phase protocol    有  8  个tokens\n",
      "this study was terminated by the sponsor    有  7  个tokens\n",
      "strategy review    有  2  个tokens\n",
      "adverse change in the risk/benefit    有  8  个tokens\n",
      "pi resigned    有  2  个tokens\n",
      "poor budget    有  3  个tokens\n",
      "study was not started    有  4  个tokens\n",
      "unrelated to trial    有  4  个tokens\n",
      "program discontinued    有  2  个tokens\n",
      "drug unavailable    有  2  个tokens\n",
      "program terminated    有  2  个tokens\n",
      "company closed    有  2  个tokens\n",
      "pi has left the institution    有  5  个tokens\n",
      "not enough subjects    有  3  个tokens\n",
      "insufficient data    有  3  个tokens\n",
      "the study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance    有  29  个tokens\n",
      "drug not available    有  3  个tokens\n",
      "corporate policy adjustments    有  4  个tokens\n",
      "logistic reasons associated with the fda-imposed clinical hold    有  12  个tokens\n",
      "not a clinical trial study    有  5  个tokens\n",
      "technical problem    有  2  个tokens\n",
      "sponsor elected not to continue with study    有  7  个tokens\n",
      "pi discretion    有  2  个tokens\n",
      "the overall profile does not support development for obesity    有  9  个tokens\n",
      "failure to accrue    有  4  个tokens\n",
      "termination due to acquisition of peak surgical by medtronic    有  11  个tokens\n",
      "overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid poorering agents    有  20  个tokens\n",
      "poor response    有  3  个tokens\n",
      "technical difficulties    有  2  个tokens\n",
      "study halted prematurely but potentially will resume    有  7  个tokens\n",
      "staffing    有  2  个tokens\n",
      "drug no longer available    有  4  个tokens\n",
      "based on available data, ucb has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures    有  26  个tokens\n",
      "at the request of the study site, this study has been closed and access to study-related data is unavailable. we are unable to submit the results-data    有  30  个tokens\n",
      "sponsor withdrawal    有  2  个tokens\n",
      "due to a change in the development program, the study was closed prematurely    有  14  个tokens\n",
      "the study is paused    有  4  个tokens\n",
      "poor human ressources    有  5  个tokens\n",
      "at sponsor's discretion    有  4  个tokens\n",
      "change in strategy    有  3  个tokens\n",
      "personnel changes    有  3  个tokens\n",
      "investigator leaving institution    有  4  个tokens\n",
      "pi departure    有  2  个tokens\n",
      "staff shortage    有  2  个tokens\n",
      "sponsor insolvency    有  3  个tokens\n",
      "strategic decision to discontinue the development of brazikumab in inflammatory bowel disease    有  17  个tokens\n",
      "study halted prematurely and will not resume    有  7  个tokens\n",
      "finished    有  1  个tokens\n",
      "participants are no longer being examined or receiving intervention    有  9  个tokens\n",
      "terminated by irb    有  4  个tokens\n",
      "primary endpoint not met    有  4  个tokens\n",
      "protocol modification    有  2  个tokens\n",
      "organizational reasons    有  3  个tokens\n",
      "inability to meet protocol objectives    有  6  个tokens\n",
      "this is not a clinical trial and was inadvertently entered into the system    有  13  个tokens\n",
      "project terminated due to revision of local regulations    有  8  个tokens\n",
      "the study was terminated for strategic reasons    有  7  个tokens\n",
      "scheduled interim monitoring    有  3  个tokens\n",
      "study never opened    有  3  个tokens\n",
      "coronavirus pandemic    有  4  个tokens\n",
      "insufficient data collected    有  4  个tokens\n",
      "drugs unavailable    有  3  个tokens\n",
      "substance discontinued    有  3  个tokens\n",
      "the sponsor decided to terminate the study folpooring an fda request of a partial clinical hold    有  19  个tokens\n",
      "change company strategy    有  3  个tokens\n",
      "the company decided to cancel this study in conformity with ph fda circular 2013-004    有  19  个tokens\n",
      "never initiated    有  2  个tokens\n",
      "decision by sponsor    有  3  个tokens\n",
      "unable to accrue subjects    有  5  个tokens\n",
      "project abandoned    有  2  个tokens\n",
      "study was cancelled    有  3  个tokens\n",
      "investigator transferred to the university of wisconsin - madison    有  12  个tokens\n",
      "no fund    有  2  个tokens\n",
      "retirement of former qualified investigator and poor resources to complete study    有  12  个tokens\n",
      "this study was terminated early as a result of regulatory action suspending tegaserod use in 2007    有  21  个tokens\n",
      "principal investigator decision    有  3  个tokens\n",
      "pediatric development program terminated by sponsor    有  7  个tokens\n",
      "the sponsor has discontinued the development of tesetaxel    有  11  个tokens\n",
      "abandoned    有  2  个tokens\n",
      "drug availability    有  2  个tokens\n",
      "pi departure from institution    有  4  个tokens\n",
      "early termination for discouraging results    有  6  个tokens\n",
      "in response to quality assurance and compliance concerns, ohrp issued an fwa restriction on nyspi research that included a pause of human research as of june 23, 2023    有  39  个tokens\n",
      "logistics and infrastructure problems    有  5  个tokens\n",
      "not started    有  2  个tokens\n",
      "irb approval lapsed    有  5  个tokens\n",
      "logistics (research staffing)    有  6  个tokens\n",
      "investigators decision    有  3  个tokens\n",
      "logistics reason at the data collection site    有  8  个tokens\n",
      "due to the achievement of minimum required sample size and new changes in local regulations    有  15  个tokens\n",
      "decision of the investigator    有  4  个tokens\n",
      "strategy change    有  2  个tokens\n",
      "logistical difficulties    有  3  个tokens\n",
      "principal investigator changing locations    有  4  个tokens\n",
      "samus therapeutics company closure    有  6  个tokens\n",
      "the principal investigator decided to stop the study    有  8  个tokens\n",
      "study canceled    有  2  个tokens\n",
      "not feasible    有  2  个tokens\n",
      "logistical problems    有  3  个tokens\n",
      "sorrento therapeutics filed for chapter 11 bankruptcy    有  11  个tokens\n",
      "development strategy adjustment    有  3  个tokens\n",
      "study no longer pursued    有  4  个tokens\n",
      "resourcing    有  2  个tokens\n",
      "terminated per pi's request    有  5  个tokens\n",
      "drug supply    有  2  个tokens\n",
      "never activated    有  2  个tokens\n",
      "change in research plan    有  4  个tokens\n",
      "financial reasons    有  2  个tokens\n",
      "policy changes have contributed to the failure to carry out smoothly    有  11  个tokens\n",
      "based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in ra    有  29  个tokens\n",
      "project cancelled    有  2  个tokens\n",
      "the study was not feasible    有  5  个tokens\n",
      "implementation issues    有  2  个tokens\n",
      "technical issue    有  2  个tokens\n",
      "based on available data, ucb has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure    有  26  个tokens\n",
      "terminated by the sponsor    有  4  个tokens\n",
      "poor study staff    有  4  个tokens\n",
      "the study was never initiated    有  5  个tokens\n",
      "the decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these phase 1 studies as well as a phase 2 study    有  50  个tokens\n",
      "strategic decision by sponsor    有  5  个tokens\n",
      "pi changed institutions    有  3  个tokens\n",
      "the study was terminated by the sponsor    有  7  个tokens\n",
      "recrutment difficulties    有  4  个tokens\n",
      "abandonment    有  3  个tokens\n",
      "sponsor's clinical development strategy adjustment    有  6  个tokens\n",
      "study closed    有  2  个tokens\n",
      "emerging sars-cov-2 variants impacting susceptibility to study drug    有  14  个tokens\n",
      "obsolete study    有  2  个tokens\n",
      "discontinued    有  2  个tokens\n",
      "emerging gsk1322322 pre-clinical data id'd potentially reactive metabolites previously not seen that changed the risk: benefit profile and led to a termination    有  33  个tokens\n",
      "dose limiting toxicities    有  5  个tokens\n",
      "contract terminated    有  2  个tokens\n",
      "the study was terminated by spiracur (original sponsor). efforts were made to contact the pi/study team members, but were unsuccessful    有  27  个tokens\n",
      "protocol change    有  2  个tokens\n",
      "not nih defined clinical trial study    有  7  个tokens\n",
      "0    有  1  个tokens\n",
      "it doesn't meet the requirements of randomized trials    有  9  个tokens\n",
      "sponsor strategy change    有  3  个tokens\n",
      "prioritizing other studies    有  5  个tokens\n",
      "company withdrew interest    有  3  个tokens\n",
      "study drug no longer available    有  5  个tokens\n",
      "sponsors decision    有  3  个tokens\n",
      "due to budget limitations, the company decided to withdraw this study    有  12  个tokens\n",
      "departure of the principal investigator    有  5  个tokens\n",
      "to be replaced by a different protocol    有  7  个tokens\n",
      "change in research focus    有  4  个tokens\n",
      "irb closure    有  3  个tokens\n",
      "based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study    有  17  个tokens\n",
      "decision of sponsor    有  3  个tokens\n",
      "medical device expired    有  3  个tokens\n",
      "sufficient data collected    有  4  个tokens\n",
      "this study was cancelled before active    有  6  个tokens\n",
      "not active    有  2  个tokens\n",
      "drug shortage    有  2  个tokens\n",
      "study terminated due to corporate decision    有  6  个tokens\n",
      "the sponsor has no interest in continuing the study    有  9  个tokens\n",
      "study expired in irb    有  5  个tokens\n",
      "the study team decided not to pursue this study    有  9  个tokens\n",
      "poor time    有  3  个tokens\n",
      "drug supply unavailable    有  3  个tokens\n",
      "time and resource constraints    有  4  个tokens\n",
      "not irb approved    有  4  个tokens\n",
      "issues with development and supply of infusion system for delivery of imp. poor favorable benefit risk ratio in snn0029-003 study (review of interim data)    有  32  个tokens\n",
      "suspended    有  2  个tokens\n",
      "pi moving to another institution    有  5  个tokens\n",
      "this study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. evaluation of nonclinical rat findings is ongoing    有  27  个tokens\n",
      "study termination by the sponsor    有  5  个tokens\n",
      "study has been cancelled and it has not been initiated    有  10  个tokens\n",
      "irb study closure    有  4  个tokens\n",
      "preclinical finding    有  3  个tokens\n",
      "the study was never started    有  5  个tokens\n",
      "closed by investigator    有  3  个tokens\n",
      "sponsor cancelled the study    有  4  个tokens\n",
      "- interest in the use of hcq is controversial    有  10  个tokens\n",
      "pi passed away. ending grant and closing lab    有  9  个tokens\n",
      "could not make fda required changes    有  7  个tokens\n",
      "compound terminated    有  2  个tokens\n",
      "abandoned project    有  3  个tokens\n",
      "study was terminated due to cardiac toxicities in the subjects    有  11  个tokens\n",
      "closed by sponser    有  5  个tokens\n",
      "this is not a clinical trial and was entered in the system in error    有  14  个tokens\n",
      "terminated to initiate fda ind-cleared study protocol    有  10  个tokens\n",
      "budgetary issues    有  3  个tokens\n",
      "primary endpoint was not met    有  5  个tokens\n",
      "equipment failure    有  2  个tokens\n",
      "the study is terminated prematurely as the sponsor decided to discontinue program with tecemotide in nsclc    有  20  个tokens\n",
      "study turned out no longer feasible    有  6  个tokens\n",
      "this study is a retrospective chart review study, not a clinical trial    有  13  个tokens\n",
      "study stopped    有  2  个tokens\n",
      "the scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib    有  24  个tokens\n",
      "change in personnel    有  3  个tokens\n",
      "closed by irb    有  4  个tokens\n",
      "other - protocol moved to withdrawn    有  6  个tokens\n",
      "pi passed away    有  3  个tokens\n",
      "idmc recommendation    有  3  个tokens\n",
      "study terminated due to poor financing    有  6  个tokens\n",
      "sponsor strategy    有  2  个tokens\n",
      "study terminated    有  2  个tokens\n",
      "investigator is no longer at northwestern university    有  9  个tokens\n",
      "poor drug supply    有  4  个tokens\n",
      "company strategy adjustment    有  3  个tokens\n",
      "study objectives met    有  3  个tokens\n",
      "change in company strategy    有  4  个tokens\n",
      "staffing issues    有  3  个tokens\n",
      "study discontinued    有  2  个tokens\n",
      "insufficient findings for data analysis    有  6  个tokens\n",
      "per sponsor    有  2  个tokens\n",
      "participants are no longer being examined or treated    有  8  个tokens\n",
      "regulatory    有  2  个tokens\n",
      "budget issues    有  2  个tokens\n",
      "no irb approval    有  4  个tokens\n",
      "logistic issues    有  3  个tokens\n",
      "sponsor discontinued development of co-1686 for nsclc    有  11  个tokens\n",
      "insufficient on-site staff to manage study    有  8  个tokens\n",
      "due to the company's development strategy adjustment, innovent biologics has decided not to continue this study after consultation with investigators    有  26  个tokens\n",
      "discontinuation of zandelisib program    有  9  个tokens\n",
      "commercial reasons    有  2  个tokens\n",
      "fda hold may 2007    有  7  个tokens\n",
      "due to financial reasons    有  4  个tokens\n",
      "study has been suspended due to clinical hold    有  8  个tokens\n",
      "sponsor is focusing on studies which can enable registration of duvelisib    有  14  个tokens\n",
      "other    有  1  个tokens\n",
      "sponsor ceased operations    有  3  个tokens\n",
      "no resources available    有  3  个tokens\n",
      "insufficient study staff    有  4  个tokens\n",
      "ind voluntarily withdrawn, without prejudice    有  6  个tokens\n",
      "lead researcher left the department    有  5  个tokens\n",
      "insys therapeutics filed chapter 11 and terminated all studies    有  12  个tokens\n",
      "study terminated due to reproducibility issues with genomics prediction model    有  13  个tokens\n",
      "company development strategy adjustment    有  4  个tokens\n",
      "not initiated    有  2  个tokens\n",
      "replaced by a different protocol    有  6  个tokens\n",
      "logistic reasons    有  3  个tokens\n",
      "pi moved to another institution    有  5  个tokens\n",
      "pi moved to a different institution    有  6  个tokens\n",
      "drug supply issue    有  3  个tokens\n",
      "the sponsor decided to terminate the study    有  7  个tokens\n",
      "at the request of the pi    有  6  个tokens\n",
      "device failure    有  2  个tokens\n",
      "pi is leaving institution    有  4  个tokens\n",
      "because of logistical problems    有  4  个tokens\n",
      "interim monitoring    有  3  个tokens\n",
      "change in drug product development strategy    有  6  个tokens\n",
      "no need    有  2  个tokens\n",
      "other - protocol moved to disapproved    有  7  个tokens\n",
      "the study was terminated due to a change in sponsor prioritization    有  12  个tokens\n",
      "dosing stopped    有  3  个tokens\n",
      "cancelled by sponsor    有  3  个tokens\n",
      "the primary endpoint of non-inferiority to daily therapy in the pediatric phase 3 study was not achieved    有  22  个tokens\n",
      "the development was stopped due to company's strategy consideration    有  10  个tokens\n",
      "sponsors    有  2  个tokens\n",
      "the study was withdrawn due to an internal decision    有  9  个tokens\n",
      "early termination    有  2  个tokens\n",
      "a different study will be conducted    有  6  个tokens\n",
      "the first clinical trial with dyn101 (unite-cnm) was early terminated. as a consequence, dynacure decided to not perform this study    有  30  个tokens\n",
      "the ec withdrawn the approval becuase of possible conflicts of interests between our institute and supporter (celgene)    有  22  个tokens\n",
      "devices currently awaiting software updates    有  5  个tokens\n",
      "no proper participant is found    有  5  个tokens\n",
      "mr-linac temporarily moved off-line    有  8  个tokens\n",
      "the study was terminated due to results in another study (nct00878501)    有  17  个tokens\n",
      "no suitable case identified    有  4  个tokens\n",
      "the trial was stopped by the sponsor based on assessment of the clinical data    有  14  个tokens\n",
      "staffing shortages    有  3  个tokens\n",
      "study personnel left institution before study completion    有  7  个tokens\n",
      "no longer viable    有  3  个tokens\n",
      "investigator retired    有  3  个tokens\n",
      "celgene terminated its collaboration agreement with methylgene for the development of mgcd0103. all celgene-sponsored trials with mgcd0103 will be closed    有  31  个tokens\n",
      "not feasible at this time    有  5  个tokens\n",
      "rls global in bankruptcy    有  5  个tokens\n",
      "terminated due to lagging folpoor-up    有  9  个tokens\n",
      "the decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with adpkd    有  31  个tokens\n",
      "pi decided not to pursue study    有  6  个tokens\n",
      "high drop out rate    有  4  个tokens\n",
      "irb closed    有  3  个tokens\n",
      "study never started/initiated    有  5  个tokens\n",
      "withdrawn in irb    有  5  个tokens\n",
      "funds for study ended september 30, 2008    有  12  个tokens\n",
      "pending amendment    有  2  个tokens\n",
      "budgetary    有  2  个tokens\n",
      "investigator decided not to pursue    有  6  个tokens\n",
      "end of the study    有  4  个tokens\n",
      "replacing this trial with a new trial    有  8  个tokens\n",
      "pi moved institutions    有  3  个tokens\n",
      "cancelled before active    有  3  个tokens\n",
      "we could not get the irb approval    有  8  个tokens\n",
      "poor data    有  3  个tokens\n",
      "early stopping rule    有  3  个tokens\n",
      "pi changed institution    有  3  个tokens\n",
      "poor ressources    有  4  个tokens\n",
      "manufacturer decided not to proceed with study    有  7  个tokens\n",
      "staff shortages    有  2  个tokens\n",
      "due to financial problems    有  4  个tokens\n",
      "pts. will be captured in core    有  7  个tokens\n",
      "decision by the sponsor    有  4  个tokens\n",
      "internal reasons    有  2  个tokens\n",
      "the foundations of our pilotstudy planning has changed    有  9  个tokens\n",
      "based on program revaluation and in agreement with the co-development partner the sponsor took the decision to terminate this study    有  22  个tokens\n",
      "please see purpose statement bepoor    有  7  个tokens\n",
      "departure of the coordinating investigator from another institution    有  8  个tokens\n",
      "based on data collected, the combination appeared to be poorly tolearated    有  14  个tokens\n",
      "not enough interest    有  3  个tokens\n",
      "decided to halt and will potentially reopen in the future    有  11  个tokens\n",
      "did not receive irb approval    有  6  个tokens\n",
      "investigational product had been released in nmpa, sponsor decided to terminate the study aligned with investigator    有  21  个tokens\n",
      "incomplete information    有  3  个tokens\n",
      "principal investigator passed away    有  4  个tokens\n",
      "study was not opened    有  4  个tokens\n",
      "project end after 3 years; prolongation was rejected    有  11  个tokens\n",
      "poor recrual    有  5  个tokens\n",
      "program suspended and divested    有  5  个tokens\n",
      "study terminated because the clinical development programme for adavosertib has been discontinued    有  16  个tokens\n",
      "study device refinement    有  3  个tokens\n",
      "all clinical development programs terminated by sponsor    有  7  个tokens\n",
      "pending dsmb evaluation    有  4  个tokens\n",
      "based on preliminary parent study results    有  6  个tokens\n",
      "due to pandemic challenges and consideration of a different study design in the future    有  14  个tokens\n",
      "deviations    有  2  个tokens\n",
      "inadequate resources    有  4  个tokens\n",
      "strategic reasons of the company    有  6  个tokens\n",
      "pi transferred to another institution and did not take this study with him    有  13  个tokens\n",
      "financial problem    有  2  个tokens\n",
      "product availability due to recall    有  5  个tokens\n",
      "sponsor stopped the study    有  4  个tokens\n",
      "study is replaced by mi-cp198 per cpm    有  11  个tokens\n",
      "company strategy    有  2  个tokens\n",
      "discontinuation of clinical investigation with nms-1116354    有  13  个tokens\n",
      "study was larger than expected and became a burden to faculty and staff resources    有  14  个tokens\n",
      "despite robust, sustained reductions in poly(gp), no clinical benefit was seen at 24 weeks, and reductions in poly(gp) were not associated with stabilization in functional outcomes. based on these data, wave decided to stop development of wve-004    有  50  个tokens\n",
      "optimization of protocol    有  4  个tokens\n",
      "termination of the study was made after a full review of program data and assessment of the current risk-benefit profile    有  22  个tokens\n",
      "resource constraints    有  2  个tokens\n",
      "key aspects linked to sample management and analysis were not met during feasibility assessment limiting the ability of the study to reach its objectives    有  24  个tokens\n",
      "resources not available    有  3  个tokens\n",
      "study terminated by sponsor (nimh)    有  8  个tokens\n",
      "contractual issues    有  3  个tokens\n",
      "neod001 program terminated due to poor clinical benefit    有  10  个tokens\n",
      "irb decision    有  3  个tokens\n",
      "r&d strategy adjustment    有  5  个tokens\n",
      "one of the investigators left the institution    有  7  个tokens\n",
      "sponsor financial has been stopped    有  5  个tokens\n",
      "pi    有  1  个tokens\n",
      "study terminated by the sponsor    有  5  个tokens\n",
      "medication removed from the u.s. market by the the food and drug administration    有  16  个tokens\n",
      "no ec approval obtained    有  4  个tokens\n",
      "treatment standard has changed    有  5  个tokens\n",
      "study closed by institutional review board    有  6  个tokens\n",
      "the sponsor decided to withdraw this study    有  7  个tokens\n",
      "inactive    有  1  个tokens\n",
      "project not initiated    有  3  个tokens\n",
      "terminated at continuing review    有  4  个tokens\n",
      "discontinuation of drug candidates    有  6  个tokens\n",
      "protocol violation    有  2  个tokens\n",
      "due to reallocation of resources, this study could not be initiated    有  13  个tokens\n",
      "sponsor's considerations    有  3  个tokens\n",
      "relocation of pi    有  4  个tokens\n",
      "pi is leaving the university    有  5  个tokens\n",
      "study was discontinued    有  3  个tokens\n",
      "expired irb    有  3  个tokens\n",
      "pi decided to terminate study    有  5  个tokens\n",
      "the study was terminated after the european medicines agency recommended to suspend the marketing authorisation of raptiva in the european union    有  24  个tokens\n",
      "primary investigator resigned from hospital    有  5  个tokens\n",
      "did not meet the anticipated outcome    有  6  个tokens\n",
      "project terminated    有  2  个tokens\n",
      "the study was terminated based on an interim assessment of immunogenicity    有  13  个tokens\n",
      "withdrawn studies    有  3  个tokens\n",
      "study was not feasible    有  4  个tokens\n",
      "lead investigator moved to a new medical center; study was stopped when he left    有  15  个tokens\n",
      "sponsor could not fund    有  4  个tokens\n",
      "for strategic reasons    有  3  个tokens\n",
      "molecule development was terminated    有  5  个tokens\n",
      "principal investigator medical leave    有  4  个tokens\n",
      "the project was abandoned    有  4  个tokens\n",
      "researcher left university    有  4  个tokens\n",
      "withdrawal of study support    有  5  个tokens\n",
      "data was inconclusive    有  4  个tokens\n",
      "due to difficuty of erollment and consideration of clinical guideline,the sponsor decided to stop study    有  19  个tokens\n",
      "local regulations    有  2  个tokens\n",
      "no longer required study by fda for nda approval    有  11  个tokens\n",
      "discontinued prematurely by sponsor for strategic reasons    有  8  个tokens\n",
      "sponsor asset acquired by another pharma company who opened their own ind for this compound. first wave bio never started this study in the us or ex-us    有  30  个tokens\n",
      "due to poor folpoor up    有  7  个tokens\n",
      "the study did not meet the primary endpoint    有  8  个tokens\n",
      "the ind was withdrawn    有  4  个tokens\n",
      "sponsor's strategic decision    有  4  个tokens\n",
      "decision to modify the product under study as a result of feedback regarding subjective feeling during installation procedure. for more info, see brief summary    有  26  个tokens\n",
      "data acquisition not possible anymore    有  5  个tokens\n",
      "strategic    有  2  个tokens\n",
      "corona    有  2  个tokens\n",
      "study drug not available    有  4  个tokens\n",
      "participants were not assigned to an intervention and as such this was not considered a clinical trial    有  17  个tokens\n",
      "data will not inform further development of voxelotor    有  9  个tokens\n",
      "results did not show reason to continue with study    有  9  个tokens\n",
      "this non-therapeutic study was registered in error. the prs team doesn't delete studies once registered, so they recommended changing the status to withdrawn    有  30  个tokens\n",
      "scans showed no visual difference between affected subjects & healthy volunteers    有  12  个tokens\n",
      "study closed prematurely upon pi's departure from vicc    有  10  个tokens\n",
      "voluntarily terminated due to benefit/risk assessment    有  10  个tokens\n",
      "not \"applicable clinical trial\"    有  7  个tokens\n",
      "postponed to a later date    有  7  个tokens\n",
      "ofatumumab iv trials in ra were prematurely terminated because gsk refocused clinical development of autoimmune indications on the subcutaneous delivery    有  27  个tokens\n",
      "genesearch™ bln assay has been voluntarily withdrawn from the us market    有  14  个tokens\n",
      "principal investigator is deceased    有  4  个tokens\n",
      "cohort c looked at feasibility of genetics & protein to evaluate risk with a family hx of cancer or associated variant. since few patients show these factors, this approach would not yield sufficient information to make inferences    有  41  个tokens\n",
      "principal investigator moved to another institution    有  6  个tokens\n",
      "project suspended by sponsor    有  4  个tokens\n",
      "pi decided to stop the study    有  6  个tokens\n",
      "key personnel left institution    有  4  个tokens\n",
      "poor effectiveness    有  3  个tokens\n",
      "institutional rdrc dissolved    有  5  个tokens\n",
      "pi requested    有  2  个tokens\n",
      "financial problems    有  2  个tokens\n",
      "suspended (the ut irb determined that cbd oil is being used as a drug as defined by the fda. therefore, an ind must be obtained for the use of cbd oil in this research study in accordance with fda regulations, 21 cfr 312.)    有  55  个tokens\n",
      "prioritization of other projects    有  6  个tokens\n",
      "due to other phase 3 trial failure to meet primary endpoint    有  12  个tokens\n",
      "pi is no longer here    有  5  个tokens\n",
      "strategy adjustment    有  2  个tokens\n",
      "reactogenicity met study halting criteria    有  8  个tokens\n",
      "primary investigator is no longer a part of the va    有  10  个tokens\n",
      "azidus, the cro hired for this study by prevent senior has lost the interest to conduct this study    有  21  个tokens\n",
      "the company has decided not to conduct the study    有  9  个tokens\n",
      "the study was not started due to a re-evaluation of the istaroxime development program    有  19  个tokens\n",
      "personnel redeployment    有  4  个tokens\n",
      "study not being pursued    有  4  个tokens\n",
      "delay    有  1  个tokens\n",
      "record owner left institution    有  4  个tokens\n",
      "principal investigator decided not to move forward with the study    有  10  个tokens\n",
      "the study was not opened    有  5  个tokens\n",
      "due to the company's development strategy adjustment ，innovent bioligics decided not to continue the study after consultation with investigators    有  26  个tokens\n",
      "emd serono voluntarily decided to terminate this trial after observing increased ms disease activity in trial 28063 atams [please refer to atams]    有  29  个tokens\n",
      "pi deceased    有  2  个tokens\n",
      "poor clinical benefit    有  4  个tokens\n",
      "study was never opened    有  4  个tokens\n",
      "product availability    有  2  个tokens\n",
      "study did not meet primary endpoint    有  6  个tokens\n",
      "overall clinical activity (orr) for oleclumab + durvalumab is minimal across tumor types and does not support further evaluation of this doublet    有  31  个tokens\n",
      "no topics to include    有  4  个tokens\n",
      "fda hold    有  3  个tokens\n",
      "to alpoor assessment of isolated events of seizure during program    有  12  个tokens\n",
      "study closed prematurely    有  3  个tokens\n",
      "termination of study due to sponsor's internal decision    有  9  个tokens\n",
      "changes in departmental staff have led to a cut in research alotments    有  14  个tokens\n",
      "change in research direction    有  4  个tokens\n",
      "delay in the r&d stage    有  7  个tokens\n",
      "the trial was terminated prematurely on november 1, 2016, due to the emerging clinical profile and the evolving treatment and market landscape for lipid-poorering agents. these indicated that bococizumab was not likely to provide value to patients, physicians, or shareholders. the decision was not based on a recommendation by the independent data monitoring committee to stop the program    有  75  个tokens\n",
      "grant ended    有  2  个tokens\n",
      "pi has left uhn. this study is no longer running at uhn    有  15  个tokens\n",
      "change in standard of care    有  5  个tokens\n",
      "logistical reasons    有  3  个tokens\n",
      "do not access to the drug    有  6  个tokens\n",
      "this study was discontinued due to an interim analysis in the bn29552 study, which indicated that crenezumab was unlikely to meet its primary endpoint    有  30  个tokens\n",
      "the study was closed early due to competing trials    有  9  个tokens\n",
      "withdrawn during planning stages    有  5  个tokens\n",
      "study was cancelled by sponsor    有  5  个tokens\n",
      "study halted prematurely and will not resume; participants are no longer being examined    有  14  个tokens\n",
      "this sub-study was not done because main study results reached significance    有  13  个tokens\n",
      "two authors changed their jobs    有  5  个tokens\n",
      "unable to obtain irb approval    有  6  个tokens\n",
      "the data did not support study endpoints    有  7  个tokens\n",
      "study was never approved by the irb    有  8  个tokens\n",
      "the entire drug development program for this molecule was sold to another company    有  13  个tokens\n",
      "principal investigator resigned from institution    有  5  个tokens\n",
      "due to organisational changes    有  5  个tokens\n",
      "negative interim analysis    有  3  个tokens\n",
      "site staffing    有  2  个tokens\n",
      "study staff change    有  3  个tokens\n",
      "original investigator for the trial has left    有  7  个tokens\n",
      "change in benefit/risk profile    有  6  个tokens\n",
      "conflict of interest (coi) cannot be managed    有  11  个tokens\n",
      "for organizational reasons    有  3  个tokens\n",
      "trial no longer feasible    有  4  个tokens\n",
      "study was terminated based on results from pivotal adult ahf study crlx030a2301    有  18  个tokens\n",
      "cannot use bioabsorbable scaffold    有  7  个tokens\n",
      "sponsor election    有  2  个tokens\n",
      "study no longer required in current format    有  7  个tokens\n",
      "project development priorities changed    有  4  个tokens\n",
      "decision made by team of investigators    有  6  个tokens\n",
      "ip change hospital    有  3  个tokens\n",
      "no financing    有  2  个tokens\n",
      "terminated due to a distribution issue with the trial medication    有  10  个tokens\n",
      "logistical challenges    有  3  个tokens\n",
      "not approved    有  2  个tokens\n",
      "clinical hold    有  2  个tokens\n",
      "competing trials    有  3  个tokens\n",
      "research group's decision    有  4  个tokens\n",
      "issues with development and supply of infusion system for delivery of imp. prolonged approval process for the clinical study snn0031-004    有  26  个tokens\n",
      "protocol study design was re-done in collaboration with cms    有  10  个tokens\n",
      "protocol redundancy    有  2  个tokens\n",
      "fda approval    有  3  个tokens\n",
      "study & ide was converted to industry held, as opposed to initial investigator held    有  15  个tokens\n",
      "study was withdrawn    有  3  个tokens\n",
      "difficulty accruing    有  3  个tokens\n",
      "there was no indication that long-term folpoor-up would differ between any of the studies that have evaluated devices within the 410 style matrix    有  28  个tokens\n",
      "new sponsor    有  2  个tokens\n",
      "modifying the clinnicaltrials    有  8  个tokens\n",
      "finally it was decided not to initiate the study due to logistical issues    有  13  个tokens\n",
      "decision of the sponsor    有  4  个tokens\n",
      "not enough study participants    有  4  个tokens\n",
      "insufficient resources available to complete the study    有  8  个tokens\n",
      "pi relocated to another institution    有  5  个tokens\n",
      "this study was withdrawn until the evaluation of the nonclinical rat findings is complete    有  15  个tokens\n",
      "poor study personnel    有  4  个tokens\n",
      "revised study design    有  4  个tokens\n",
      "sangart ceased operations    有  5  个tokens\n",
      "pi withdrawn    有  2  个tokens\n",
      "the investigator decided not to pursue this study    有  8  个tokens\n",
      "regulatory approval was not obtained for drisapersen, hence biomarin is stopping the development of all exon skipping oligonucleotides in dmd    有  31  个tokens\n",
      "modifying procedure    有  3  个tokens\n",
      "there is no longer a plan to pursue an approval of lampalizumab    有  16  个tokens\n",
      "device for multi coil tms no longer supported    有  9  个tokens\n",
      "protocol violation occurred frequently during the postoperative period    有  9  个tokens\n",
      "change in procedure    有  3  个tokens\n",
      "withdrawal by sponsor    有  4  个tokens\n",
      "study halted due to poorer success rates than expected, under evaluation, will potentially resume at a later date    有  20  个tokens\n",
      "no sponsor    有  2  个tokens\n",
      "irb application withdrawn    有  4  个tokens\n",
      "study no longer required    有  4  个tokens\n",
      "insufficient functional product engraftment    有  8  个tokens\n",
      "study termination    有  2  个tokens\n",
      "terminated: study halted prematurely and will not resume; participants are no longer being examined or receiving intervention    有  19  个tokens\n",
      "the investigator abandoned the project    有  5  个tokens\n",
      "mtd determined    有  3  个tokens\n",
      "no financial agreement    有  3  个tokens\n",
      "the viability of the study is being analyzed    有  8  个tokens\n",
      "change of sponsor    有  3  个tokens\n",
      "per pi, this study is not a clinical trial and was inadvertently entered in the system    有  17  个tokens\n",
      "never opened    有  2  个tokens\n",
      "irb expired    有  3  个tokens\n",
      "pi's decision    有  3  个tokens\n",
      "resources no longer available    有  4  个tokens\n",
      "withdrawal of sponsor support    有  5  个tokens\n",
      "no open study    有  3  个tokens\n",
      "pi is leaving ucsd    有  6  个tokens\n",
      "study terminated by pi    有  4  个tokens\n",
      "dendreon was sold and new company decided not to fund study    有  13  个tokens\n",
      "resources did not come to fruition    有  6  个tokens\n",
      "the fda advised of a possible health risk associated with lorcaserin and the drug is being withdrawn    有  21  个tokens\n",
      "insufficient for the fund    有  5  个tokens\n",
      "logistic problems    有  3  个tokens\n",
      "decision of investigator    有  3  个tokens\n",
      "rationale obsolete    有  3  个tokens\n",
      "organisation problem    有  2  个tokens\n",
      "faisability    有  3  个tokens\n",
      "irb disapproval    有  4  个tokens\n",
      "decision to change the study design    有  6  个tokens\n",
      "change in priority of interventional protocols    有  7  个tokens\n",
      "the study stopped early because the study objectives were met    有  10  个tokens\n",
      "current study design couldn't support futher development on this indication    有  12  个tokens\n",
      "poor investigators    有  3  个tokens\n",
      "investigator's decision (departure from institution)    有  9  个tokens\n",
      "the termination criteria of the protocol was met during dose escalation    有  11  个tokens\n",
      "to enable development of an enhanced version of the vaccine    有  10  个tokens\n",
      "availability of new and more promising therapeutic agents than expected in the experimentation in question    有  15  个tokens\n",
      "canceled    有  2  个tokens\n",
      "occurrence of a quality issue affecting some of its prostheses    有  13  个tokens\n",
      "the study was terminated folpooring an internal review of the company's current research and development portfolio    有  19  个tokens\n",
      "regulatory strategy    有  3  个tokens\n",
      "protocol withdrawn    有  2  个tokens\n",
      "study location changed    有  3  个tokens\n",
      "trial logistics    有  2  个tokens\n",
      "the sponsor voluntarily recalled sd-101 and terminated the study due to gmp deficiencies identified during an fda inspection at the site of the manufacturer    有  28  个tokens\n",
      "pi decided to end the study    有  6  个tokens\n",
      "resources not secured    有  3  个tokens\n",
      "the study was terminated early by the sponsor    有  8  个tokens\n",
      "study design changed to clinical database only with no research question to be studied    有  14  个tokens\n",
      "the sponsor have not enough money to support this trial    有  10  个tokens\n",
      "this study has been cancelled before initiation due to company's prioritisation decisions linked to resources restrictions    有  18  个tokens\n",
      "portfolio re-prioritization    有  6  个tokens\n",
      "due to overall benefit/risk profile    有  7  个tokens\n",
      "pi's request    有  3  个tokens\n",
      "drug supply no longer available    有  5  个tokens\n",
      "decided not to proceed    有  5  个tokens\n",
      "poor financing    有  3  个tokens\n",
      "osiris decision    有  3  个tokens\n",
      "could not get study started    有  5  个tokens\n",
      "the investigational cases were no longer relevant considering the recent implementation of our current national healthcare system    有  18  个tokens\n",
      "risk to benefit ratio is not acceptable    有  7  个tokens\n",
      "it is not possible to continue the study    有  8  个tokens\n",
      "study will not be conducted    有  5  个tokens\n",
      "competing study    有  3  个tokens\n",
      "study was terminated early for strategic reasons. only part i of the study was completed    有  16  个tokens\n",
      "due to technical issues    有  4  个tokens\n",
      "pi withdrew protocol    有  3  个tokens\n",
      "study was not initiated because it was not approved by kpsc irb    有  14  个tokens\n",
      "as per sponsor    有  3  个tokens\n",
      "replaced by other study    有  5  个tokens\n",
      "discontinuation of all bardoxolone chronic kidney disease programs    有  13  个tokens\n",
      "the study was terminated under the political pressure of the federal security service of the russian federation (fsb) and the russian society of cardiology    有  28  个tokens\n",
      "feasibility pilot was completed    有  5  个tokens\n",
      "closed by chum reb for incomplete documentation of research activities    有  11  个tokens\n",
      "the study is on pause    有  5  个tokens\n",
      "trial never initiated    有  3  个tokens\n",
      "unsuccessful study    有  3  个tokens\n",
      "completion of folpoor-up period    有  7  个tokens\n",
      "intermediate analysis    有  3  个tokens\n",
      "decision to out-license the compound for further development    有  9  个tokens\n",
      "product no longer on the market    有  6  个tokens\n",
      "sanofi ended collaboration with lexicon for sotagliflozin. in china no regulatory pathway to transfer sponsorship during the conduct of ongoing studies    有  30  个tokens\n",
      "the study was terminated due to program discontinuation    有  9  个tokens\n",
      "interim analysis results    有  4  个tokens\n",
      "study must be registered under the sponsor instead of the site, so we have created a new posting in the sponsor's account    有  24  个tokens\n",
      "due to the pandemic    有  4  个tokens\n",
      "study has been terminated after phase i part on 23 february 2023    有  16  个tokens\n",
      "study did not get started    有  5  个tokens\n",
      "company policy    有  2  个tokens\n",
      "pi decided to withdraw study    有  5  个tokens\n",
      "study on hold    有  3  个tokens\n",
      "terminated [nci decided to terminate abtc consortium due to nci moving in different direction for brain cancer]    有  22  个tokens\n",
      "we will update quickly    有  4  个tokens\n",
      "based on interim analysis results    有  5  个tokens\n",
      "regulatory issues    有  3  个tokens\n",
      "sponsor closed study    有  3  个tokens\n",
      "the benefit-risk profile no longer supports continuing the study    有  10  个tokens\n",
      "the study is no longer required    有  6  个tokens\n",
      "failure to meet primary endpoint    有  5  个tokens\n",
      "merck sharp & dohme corp (msd) received exemption from pfda on conduct of post-marketing surveillance (pms) study    有  29  个tokens\n",
      "pandemic situation    有  4  个tokens\n",
      "replaced it with another clinical trial    有  7  个tokens\n",
      "the study was terminated for reasons pertaining to feasibility    有  9  个tokens\n",
      "contract terminated with site management organization    有  6  个tokens\n",
      "change in pi    有  3  个tokens\n",
      "inefficiency    有  3  个tokens\n",
      "homology medicines has discontinued the development of this program    有  10  个tokens\n",
      "replaced by a new study    有  6  个tokens\n",
      "study termination due to negative phase iii of another study product from same technology platform    有  15  个tokens\n",
      "the study was terminated early based on an imbalance in worsening crohn's disease in active treatment groups    有  19  个tokens\n",
      "the study was terminated due to a small number of study participants    有  12  个tokens\n",
      "sponsor has designed another study to replace the current study    有  10  个tokens\n",
      "sponsor halted study    有  3  个tokens\n",
      "study did not meet its primary endpoint    有  7  个tokens\n",
      "the study will be conducted in another research center. the sponsor has changed    有  14  个tokens\n",
      "reclassification by ethics committee    有  5  个tokens\n",
      "investigator no longer at lu    有  6  个tokens\n",
      "novartis discontinued the development of imatinib in pah due to requirement of regulatory authorities for additional data to secure marketing approval in pah    有  29  个tokens\n",
      "study never officially began    有  4  个tokens\n",
      "the benefit to risk balance did not support further treatment with galegenimab (fhtr2163)    有  22  个tokens\n",
      "stopped by the sponsor    有  4  个tokens\n",
      "a corporate decision to terminate the study    有  7  个tokens\n",
      "cpp requalification    有  3  个tokens\n",
      "investigator is leaving the university    有  6  个tokens\n",
      "the study was terminated    有  4  个tokens\n",
      "reason unknown    有  2  个tokens\n",
      "the study sponsor was acquired by a company that focuses on chronic wounds    有  13  个tokens\n",
      "modification to clinical development plan    有  5  个tokens\n",
      "loss of support    有  3  个tokens\n",
      "study technique has been declared part of standard care    有  9  个tokens\n",
      "discontinued by investigator    有  4  个tokens\n",
      "p.i. left    有  4  个tokens\n",
      "stopped due to a strategic decision    有  6  个tokens\n",
      "the investigation of this device has been transitioned into a new study by the sponsor. the data generated in this study will not be used to support a marketing application    有  32  个tokens\n",
      "per pi's request    有  4  个tokens\n",
      "indication withdrawn    有  3  个tokens\n",
      "in a phase ii study in hiv-infected patients there were a number of seizures, although exact causality could not be assessed phase 1 activity was terminated    有  32  个tokens\n",
      "withdrawn from irb    有  5  个tokens\n",
      "withdrawn due to protocol amendment    有  6  个tokens\n",
      "significant risks (e.g., infection, endothelial cell loss) and high rate of channel plugging associated with product use    有  24  个tokens\n",
      "study never commenced    有  3  个tokens\n",
      "principal investigator departure    有  3  个tokens\n",
      "principal investigator was unable to fulfill his responsibilities    有  8  个tokens\n",
      "inability to accrue    有  5  个tokens\n",
      "commercial decision    有  2  个tokens\n",
      "the sponsor decided to stop the study    有  7  个tokens\n",
      "primary goal not achievable    有  4  个tokens\n",
      "company no longer operational    有  4  个tokens\n",
      "study close-out    有  3  个tokens\n",
      "study was not activated    有  4  个tokens\n",
      "this is not a clinical trial and was inadvertently entered in the system    有  13  个tokens\n",
      "change in sponsor    有  3  个tokens\n",
      "the company is liquidated    有  5  个tokens\n",
      "non-compliance    有  3  个tokens\n",
      "the company currently does not have plans to conduct this study    有  11  个tokens\n",
      "difficulties of recrutment    有  7  个tokens\n",
      "pi moved from hadassah    有  6  个tokens\n",
      "change in practice patterns    有  4  个tokens\n",
      "study was completed at other sites    有  6  个tokens\n",
      "restructuring cell lab    有  4  个tokens\n",
      "withdrawn by industry    有  4  个tokens\n",
      "development of tasquinimod in prostate cancer discontinued    有  10  个tokens\n",
      "program has been put on hold by the sponsor    有  9  个tokens\n",
      "study sites were reconsidered    有  5  个tokens\n",
      "pi's choice    有  3  个tokens\n",
      "study was terminated in anticipation of transfer of ownership to avid radiopharmaceuticals    有  16  个tokens\n",
      "logistic challenges    有  3  个tokens\n",
      "insufficient personnel    有  3  个tokens\n",
      "investigators busy with other projects at the moment    有  9  个tokens\n",
      "poor eligible study participants    有  5  个tokens\n",
      "fda did not require a clinical trial for indication    有  10  个tokens\n",
      "departure of the phd in charge of the study    有  10  个tokens\n",
      "pi is no longer at this university    有  7  个tokens\n",
      "pi sabbatical    有  4  个tokens\n",
      "departure of the project leader    有  5  个tokens\n",
      "imp will not be further developed    有  6  个tokens\n",
      "loe    有  1  个tokens\n",
      "because of many competing trials using the same mechanism of action, but being further advanced in development    有  18  个tokens\n",
      "the study will not be conducted    有  6  个tokens\n",
      "study redesign    有  2  个tokens\n",
      "sars-cov-2 pandemic    有  7  个tokens\n",
      "trial terminated by sponsor    有  4  个tokens\n",
      "desired primary endpoint was not met    有  6  个tokens\n",
      "suspended pending internal review/direction of the company's focus    有  12  个tokens\n",
      "the study was terminated early by the sponsor on 13 january 2014 due to a decision to modify the drug development plan    有  26  个tokens\n",
      "financial decision    有  2  个tokens\n",
      "pi job change    有  3  个tokens\n",
      "the article is not a clinical trial but is a hospital based randomized comparative study. this was inadvertently uploaded    有  20  个tokens\n",
      "amgen decided to terminate the study early to be able to meet us regulatory timelines fo filing. subjects in treatment were rolled over to the 20140159 study    有  32  个tokens\n",
      "sponsor has designed another study with different endpoint to replace the current study    有  13  个tokens\n",
      "terminée    有  2  个tokens\n",
      "pi moved to different institution    有  5  个tokens\n",
      "university of rostock terminated participation in the study conduct; study sponsorship is moved to centogene ag    有  20  个tokens\n",
      "for technical reasons    有  3  个tokens\n",
      "no substantial anti-tumor activity was observed    有  8  个tokens\n",
      "this study plan has halted and was withdrawn from the irb    有  12  个tokens\n",
      "premature termination of the research folpooring an internal reorganization of the team no longer alpooring the necessary resources to continue the study    有  29  个tokens\n",
      "the other study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance    有  30  个tokens\n",
      "modification of the device    有  4  个tokens\n",
      "study irb approval expired    有  5  个tokens\n",
      "investigational device changes    有  5  个tokens\n",
      "reformulation    有  3  个tokens\n",
      "no started    有  2  个tokens\n",
      "poor clarity regarding the pms study requirement from the ra and ethics committee hence it was concluded gsk will submit local psurs    有  26  个tokens\n",
      "principal investigator (dr. sporn) left the sponsoring institution    有  12  个tokens\n",
      "the study is not relevant anymore    有  6  个tokens\n",
      "toxic epidermal necrolysis    有  9  个tokens\n",
      "sponsor and investigator's decision    有  5  个tokens\n",
      "due to company resource constraints    有  5  个tokens\n",
      "the clinical phase of the study (from fsfv to lslv) was never initiated due to the sponsor's decision    有  24  个tokens\n",
      "the pandemic caused a rising tide phenomenon on our primary outcomes 1) delirium detection (increased by visit reduction & masked staff) and 2) admission duration (increased by reorganizations & quarantines 'impact on being discharged)    有  50  个tokens\n",
      "company closure    有  2  个tokens\n",
      "the study is completed    有  4  个tokens\n",
      "the study terminated on 10-dec-2007. pfizer's decision to terminate the program was due to cases of injection-site lipoatrophy that were reported in the clinical phase 2 studies after a single injection of pha 794428    有  51  个tokens\n",
      "approval lapse    有  2  个tokens\n",
      "study was completed    有  3  个tokens\n",
      "sufficient number of subjects included for analyzes    有  8  个tokens\n",
      "the preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited    有  24  个tokens\n",
      "the sponsor has decided to terminate this study based on the current clinical research status of dual antibody drugs and full communication with the investigators    有  25  个tokens\n",
      "withdrawn study    有  3  个tokens\n",
      "according to the development of the novel coronavirus epidemic situation and the company's r&d decision    有  18  个tokens\n",
      "limited subjects    有  2  个tokens\n",
      "determined not feasible    有  4  个tokens\n",
      "the supply of msc-ev has been delayed and approval by the ethics committee will take some time    有  19  个tokens\n",
      "the perceived risk-benefit ratio for individuals with early active ra    有  12  个tokens\n",
      "incomplete data    有  3  个tokens\n",
      "reprioritization of indications    有  6  个tokens\n",
      "financing and re-organization    有  6  个tokens\n",
      "discontinuation of program    有  5  个tokens\n",
      "the study was terminated due to a change in gsk's r&d priorities    有  16  个tokens\n",
      "all analysis with identifiable specimens/data is complete or site has no identifiers linked to the specimens/data    有  18  个tokens\n",
      "head of the study has left the institution. study never started    有  12  个tokens\n",
      "redesign    有  2  个tokens\n",
      "study terminated prematurely    有  3  个tokens\n",
      "development in prostate cancer indication halted    有  6  个tokens\n",
      "support withdrawn - study continued by nci - see record nct00006981    有  16  个tokens\n",
      "sponsor support withdrawn    有  3  个tokens\n",
      "personnel change    有  3  个tokens\n",
      "amgen decision    有  3  个tokens\n",
      "departure of pi    有  3  个tokens\n",
      "sponsor hold    有  2  个tokens\n",
      "not a clinical trial    有  4  个tokens\n",
      "resources unavailable to continue study folpoor-up    有  9  个tokens\n",
      "difficulty of recrutement    有  5  个tokens\n",
      "to alpoor analysis of data from supplementary non-clinical study    有  14  个tokens\n",
      "replaced with another study    有  5  个tokens\n",
      "insufficient evidence of the clinical effectiveness of cangrelor    有  12  个tokens\n",
      "unable to complete study    有  4  个tokens\n",
      "poor accrural    有  4  个tokens\n",
      "the u.s. department of health and human services office of human research protections issued an fwa restriction on nyspi research that included a pause of human subjects research as of june 23, 2023    有  43  个tokens\n",
      "pending further development    有  3  个tokens\n",
      "not completed    有  2  个tokens\n",
      "the study is not initiated and we want it to be withdrawn    有  12  个tokens\n",
      "dsmb    有  2  个tokens\n",
      "budget constraints    有  2  个tokens\n",
      "company focus on other projects    有  5  个tokens\n",
      "sponsor strategic decision    有  3  个tokens\n",
      "sponsor determined the data was no longer needed    有  8  个tokens\n",
      "study drug unavailable    有  3  个tokens\n",
      "study cancelled prior to fsi    有  6  个tokens\n",
      "depuy discontinued this product in 4q2009. at the time of this decision depuy reviewed all clinical studies for this product and decided to close this study    有  33  个tokens\n",
      "due to more robust long-term data generated in other active-controlled studies    有  13  个tokens\n",
      "the biological effect seen with natalizumab was not sufficient to warrant further development in ra    有  19  个tokens\n",
      "replaced by another protocol    有  5  个tokens\n",
      "indefinite hold by company    有  6  个tokens\n",
      "higher hemorrhage rates of abciximab in abesst ii trial    有  15  个tokens\n",
      "withdrawn as company has shut down and filed for bankruptcy    有  11  个tokens\n",
      "updating protocol    有  2  个tokens\n",
      "study was completed, only life long extended folpoor-up phase was discontinued after 12 years    有  19  个tokens\n",
      "insufficient number of eligible subjects    有  6  个tokens\n",
      "myriad has discontinued the development of flurizan    有  11  个tokens\n",
      "the trial protocol was not approved by the regulatory authorities    有  10  个tokens\n",
      "study did not commence    有  4  个tokens\n",
      "trial was never activated    有  4  个tokens\n",
      "based on the disclosed global research data on the same target drugs, the company has carefully considered and decided to terminate the project to optimize the existing research pipeline    有  30  个tokens\n",
      "change in development plan    有  4  个tokens\n",
      "grant expired    有  2  个tokens\n",
      "pi no longer with the university    有  6  个tokens\n",
      "sufficient data gathered to support conclusion    有  7  个tokens\n",
      "acquired asset    有  3  个tokens\n",
      "change in formulation    有  3  个tokens\n",
      "study design has changed    有  4  个tokens\n",
      "the plan has changed    有  4  个tokens\n",
      "expiration of irb approval    有  5  个tokens\n",
      "poor personnel    有  3  个tokens\n",
      "terminated by pi    有  3  个tokens\n",
      "parallel record under the prime awardee (klein buendel)    有  15  个tokens\n",
      "i have changed my center and gone to another center    有  10  个tokens\n",
      "not possible to include participants    有  5  个tokens\n",
      "we at the sunshine coast university hospital are unable to cope with the extra effort/time needed to complete this trial properly    有  22  个tokens\n",
      "duplicated registration    有  3  个tokens\n",
      "lost necessary staff support    有  4  个tokens\n",
      "usaf regulatory concerns    有  4  个tokens\n",
      "loss of interest    有  3  个tokens\n",
      "changing corporate priorities    有  3  个tokens\n",
      "further usability assessment needed    有  5  个tokens\n",
      "not currently pursuing indication    有  4  个tokens\n",
      "unable to obtain a reliable mrs signal    有  8  个tokens\n",
      "unable to execute data sharing agreement with ministry of health    有  10  个tokens\n",
      "study never started as changes to the study structure were determined by the community advisory board overseeing the project prior to study start    有  23  个tokens\n",
      "the software modules were not completed    有  6  个tokens\n",
      "logistics reasons    有  3  个tokens\n",
      "issue with trial administration/conduct    有  6  个tokens\n",
      "competition with other ongoing projects with this population    有  8  个tokens\n",
      "study withdrawn due to limited personnel, time, resources    有  10  个tokens\n",
      "another study was done instead    有  5  个tokens\n",
      "clinical evaluation plan outdated and obsolete due to altered clinical routine    有  11  个tokens\n",
      "study withdrawn before active to fully evaluate impact of changing practice in target population    有  14  个tokens\n",
      "no longer able to run study    有  6  个tokens\n",
      "devices are not available    有  4  个tokens\n",
      "interim analysis showed no difference between groups    有  8  个tokens\n",
      "in light of new evidence, the decision was made by the sponsor to not proceed    有  16  个tokens\n",
      "the introduction of new recommendations for early neonatal infection has drastically reduced the need for gastric aspiration at birth    有  20  个tokens\n",
      "because at the interim analysis the pre-specified stopping boundary for an overwhelming benefit had been crossed    有  18  个tokens\n",
      "protocol could not be carried out to achieve the aims of the study    有  13  个tokens\n",
      "patients did not want to take part in the experimental arm of the study as all have opted for the current standard of care procedure    有  25  个tokens\n",
      "research stopped after lab-based data using mouse model did not support use of technology    有  15  个tokens\n",
      "study terminated by study partners    有  5  个tokens\n",
      "security criteria (mtd)    有  6  个tokens\n",
      "manufacturer's decision    有  3  个tokens\n",
      "change in subject population/able power program    有  8  个tokens\n",
      "not renewed with irb    有  5  个tokens\n",
      "withdrawn by irb    有  5  个tokens\n",
      "preliminary analysis of the results showed no statistically significant difference    有  12  个tokens\n",
      "study terminated per ongoing care solutions, inc    有  8  个tokens\n",
      "could not get irb approval    有  6  个tokens\n",
      "favourable ethical opinion not obtained    有  7  个tokens\n",
      "principal investigator was leaving the institution    有  6  个tokens\n",
      "dsmc recommendation    有  4  个tokens\n",
      "problem with obtaining microarrays, which are essential components needed to conduct this study    有  15  个tokens\n",
      "the randomization could not be done    有  7  个tokens\n",
      "changing of specialty    有  3  个tokens\n",
      "surgical access not facilitated- residues of hydrogel    有  10  个tokens\n",
      "design, sponsorship changed prior to initiation. no study procedures done    有  12  个tokens\n",
      "roche announced a decision to discontinue most of the company's global trials of gantenerumab. the dian-tu has paused the dian-tu-002 primary prevention trial related to gantenerumab while considering other potential options for this platform trial    有  55  个tokens\n",
      "due to the national cancer institute's (nci)-mandated termination of the adult brain tumor consortium which was conducting the study    有  25  个tokens\n",
      "strategic decision to discontinue further development of investigational compounds for the treatment of hepatitis c    有  18  个tokens\n",
      "pi is retiring from center. research will not continue with a new pi    有  14  个tokens\n",
      "global sales of the absorb bvs halted effective september 14, 2017    有  16  个tokens\n",
      "because the clinical development plan has been changed    有  8  个tokens\n",
      "no intervention or clinical trial necessitating participants ultimately needed or required for this study    有  15  个tokens\n",
      "no resident involvement    有  3  个tokens\n",
      "the research question was resolved in a metanalysis    有  9  个tokens\n",
      "who 2022 guidelines for dr-tb treatment are set to change. these guidelines recommend the use of an all-oral short course bpal regimen.therefore ongoing implementation of the study is considered futile    有  41  个tokens\n",
      "stakeholder elected not to proceed with the study    有  10  个tokens\n",
      "expired irb approval on 2/11/21    有  11  个tokens\n",
      "study withdrawn due to staff unavailability and limited resources    有  10  个tokens\n",
      "negative clinical outcomes    有  3  个tokens\n",
      "pi did not attempt to open the study    有  8  个tokens\n",
      "no eligible subjects were identified    有  5  个tokens\n",
      "irb issues    有  3  个tokens\n",
      "the study is stopped for portfolio prioritization    有  8  个tokens\n",
      "pi voluntarily closed the study    有  5  个tokens\n",
      "based on r&d strategic reasons, our co-development partner financing the study disengaged from the development of gnbac1    有  26  个tokens\n",
      "feasibility issues per complete sheet    有  6  个tokens\n",
      "facilities for the exercise training program were not available for the study    有  13  个tokens\n",
      "change in the benefit-risk balance    有  6  个tokens\n",
      "change in staffing and not able to do study    有  9  个tokens\n",
      "the company pulled durvalumab from heme malignancies    有  12  个tokens\n",
      "it's not possible to complete in our hospital    有  9  个tokens\n",
      "pharmaceutical company discontinued the study drug    有  8  个tokens\n",
      "no available device in the hospital to complete study    有  9  个tokens\n",
      "changed development priorities    有  3  个tokens\n",
      "was not financed, sponsor withdrawn    有  6  个tokens\n",
      "postponed    有  3  个tokens\n",
      "stopped with agreement from fda    有  6  个tokens\n",
      "board decision    有  2  个tokens\n",
      "the research fund has not yet arrived    有  7  个tokens\n",
      "all patients during the study period were subjected to peripheral blocks or were excluded from the study due to exclusion criteria    有  21  个tokens\n",
      "sponsor does not wish to proceed    有  6  个tokens\n",
      "intervention programming    有  3  个tokens\n",
      "the physician in charge is leaving the university of florida    有  10  个tokens\n",
      "achievement of scientific objectives    有  4  个tokens\n",
      "study terminated due to drug supply issues    有  7  个tokens\n",
      "as the guideline for the acute stroke endovascular treatment of the aha/asa was changed, dsmb recommended an end to the study    有  28  个tokens\n",
      "the study team did not receive the necessary study equipment from our international partners    有  14  个tokens\n",
      "difficulty obtaining investigational product and study support    有  8  个tokens\n",
      "change in study staffing    有  4  个tokens\n",
      "celgene withdrew the support for this study (durvalumab cannot be provided)    有  17  个tokens\n",
      "no effect was found    有  4  个tokens\n",
      "study design was changed to the study was changed to insulin, hypotension and sarcopenia    有  19  个tokens\n",
      "the principal investigator will be at a new institution    有  9  个tokens\n",
      "discontinuation of the trial    有  6  个tokens\n",
      "the sponsor changed r&d strategy and priority    有  9  个tokens\n",
      "study partner left. samples degraded before analysis    有  8  个tokens\n",
      "poor folpoor/up rates and data    有  9  个tokens\n",
      "study terminated due to a change in the benefit-risk profile for danirixin in copd    有  18  个tokens\n",
      "because pd-1 antibodies had been proved to be a standard second-line treatment in esophageal cancer, the potential benefit of present intervention is under re-evaluation    有  32  个tokens\n",
      "feasibility of device use    有  5  个tokens\n",
      "due to time constraints, the study will not be able to be completed as outlined    有  16  个tokens\n",
      "option pilot trial merged with the new nct03782818 - option multicenter trial    有  17  个tokens\n",
      "strategic planning for the types of tumors is being done. temp hold until am is submitted    有  18  个tokens\n",
      "high fpoor oxygen therapy became available as standard care    有  11  个tokens\n",
      "study no longer feasible    有  4  个tokens\n",
      "withdrawal of institutional support    有  5  个tokens\n",
      "benefit/risk imbalance    有  5  个tokens\n",
      "because the principle investigator will participate a visiting scholar program for one year in other country, this study has been terminated    有  22  个tokens\n",
      "research group transferred to another hospital    有  6  个tokens\n",
      "trial was terminated by investigators due to equipment difficulties    有  9  个tokens\n",
      "the deadlines of the ethics committee being very long, the investigator finally wished not to carry out the project    有  20  个tokens\n",
      "the trial is terminated before investigation of repeat escalating doses as these will be conducted with the new formulation instead    有  20  个tokens\n",
      "this study was combined with another trial that was on-going    有  11  个tokens\n",
      "3dtransvaginal probe is not available at this time    有  13  个tokens\n",
      "this trial was supporting the development of an asset which was terminated, thus the data from the study were no longer required    有  23  个tokens\n",
      "irb requirements to start study could not be met in a timely manner    有  14  个tokens\n",
      "insufficient staff and equipment challenges    有  6  个tokens\n",
      "ind not approved    有  3  个tokens\n",
      "pi has confirmed that this is not a clinical trial and was entered in error in the system    有  18  个tokens\n",
      "study was registered in another clinicaltrials.gov entry    有  10  个tokens\n",
      "study has been halted prematurely    有  5  个tokens\n",
      "additional data may be required once preliminary data is analyzed    有  10  个tokens\n",
      "the study was terminated as relationship between gsk3335065 and ventricular tachycardia could not be excluded    有  24  个tokens\n",
      "the epidemiological situation has changed considerably    有  7  个tokens\n",
      "organization was changed. the staff was relocated    有  8  个tokens\n",
      "unable to address regulatory concerns    有  5  个tokens\n",
      "investigator retired. other investigators did not want to continue study    有  12  个tokens\n",
      "poor subject interest due to study design    有  8  个tokens\n",
      "change to primary endpoint resulted in development of new protocol    有  10  个tokens\n",
      "novartis, the drug manufacturer of nis793, notified dana farber cancer institute that they are stopping all clinical development of nis793 in pancreatic cancer, effective immediately    有  36  个tokens\n",
      "discontinuation of financial support    有  6  个tokens\n",
      "suspended due to problems with scanner availability    有  8  个tokens\n",
      "researcher has quit. question still unanswered. a related study (observational, not to be registered) has started recently    有  24  个tokens\n",
      "pi was unable to perform ultrasound of airway    有  9  个tokens\n",
      "technical difficulties with instrument    有  4  个tokens\n",
      "due to poor resources and changes in current practice, the study was terminated    有  14  个tokens\n",
      "delay in irb approval    有  5  个tokens\n",
      "the study was withdrawn due to budgetary and other constraints    有  11  个tokens\n",
      "problem of faisability    有  4  个tokens\n",
      "only phase 1b was completed and the phase 2 will be an another study, finally    有  19  个tokens\n",
      "substudy 001b is not required at this stage of the pip    有  14  个tokens\n",
      "product development cancelled    有  3  个tokens\n",
      "study has not yet been approved by the local irb in guinea bissau    有  17  个tokens\n",
      "waiting for a protocol amendment to extend folpoor-up lenght    有  12  个tokens\n",
      "pi is moving the a new institution and ended the study early    有  12  个tokens\n",
      "study was considered not useful and competing with another study in clinical context    有  13  个tokens\n",
      "due to software changes    有  4  个tokens\n",
      "the study expired at the irb    有  7  个tokens\n",
      "the decision to halt the trial in october was made in june, as the anticipated no. of events(ankle sprains) required for the analyses was almost reached in june    有  38  个tokens\n",
      "study not activated, staff left institution    有  7  个tokens\n",
      "no ethic committee autorization    有  5  个tokens\n",
      "design modification    有  2  个tokens\n",
      "collaborators left the institution    有  6  个tokens\n",
      "system-wide implementation of intervention prevented randomized trial design    有  9  个tokens\n",
      "arthrex stopped manufacturing the device    有  6  个tokens\n",
      "interim analysis showed no significance    有  6  个tokens\n",
      "pi has left our inst    有  5  个tokens\n",
      "study stopped because sufficient pilot data collected to proceed to next clinical trial    有  13  个tokens\n",
      "the study was terminated early due to lackluster pharmacodynamic data that showed no significant reduction of plasma kynurenine at steady state of m4112    有  31  个tokens\n",
      "sponsor chose not to continue    有  5  个tokens\n",
      "replaced with new observational study design    有  7  个tokens\n",
      "suspended collaboration with the company providing the study drug    有  10  个tokens\n",
      "sponsor investigator transferred from institution    有  5  个tokens\n",
      "poor resource from collaborating organisation    有  6  个tokens\n",
      "irb's initial review of this study was not completed and study was withdrawn    有  15  个tokens\n",
      "the study is temporarily suspended due to preclinical findings that are currently under evaluation    有  15  个tokens\n",
      "sponsors pulled out of the study    有  7  个tokens\n",
      "it was interrupted due to the coronavirus pandemic outbreak    有  9  个tokens\n",
      "re-registered    有  3  个tokens\n",
      "spark did not meet it's primary outcome measure for year 1 and failed to meet secondary outcome measures resulting in the development of biib054 (cinpanemab) for parkinson's disease to be discontinued and spark study was closed    有  47  个tokens\n",
      "the study was terminated due to change in focus of the development program    有  13  个tokens\n",
      "pi retired from navy 2018    有  7  个tokens\n",
      "trial discontinued due to unreliable wearable device    有  7  个tokens\n",
      "project plan changed, study conduct was no longer needed    有  10  个tokens\n",
      "the competent authority did not give the authorization to start the study    有  12  个tokens\n",
      "pi decided to withdraw    有  4  个tokens\n",
      "ind issues    有  2  个tokens\n",
      "the study itself was disapproved on 04/20/2018 and will not be moving forward    有  20  个tokens\n",
      "primary objective reached    有  3  个tokens\n",
      "in the early stage of the research, this research was limited by the application permission of research drugs and instruments, and the research will have to be interrupted, which is extremely regrettable    有  36  个tokens\n",
      "no capacity to conduct the study    有  6  个tokens\n",
      "financing has been withdrawn    有  5  个tokens\n",
      "withdrawl    有  2  个tokens\n",
      "decision of the funder: almond board of california    有  10  个tokens\n",
      "not start in coming years    有  5  个tokens\n",
      "problem on the app, questioned the feasability of the study    有  12  个tokens\n",
      "the study was on hold and later withdrawn due to shortage of staff    有  13  个tokens\n",
      "manager's decision    有  3  个tokens\n",
      "due to limited support staff and time, study was unable to get started    有  14  个tokens\n",
      "redesign of study    有  4  个tokens\n",
      "part1,double blind portion of the trial did not meet the primary end points    有  15  个tokens\n",
      "change of study structure and resource allocation    有  7  个tokens\n",
      "the research could not be conducted as it was denied by the irb    有  14  个tokens\n",
      "interest withdrawn    有  2  个tokens\n",
      "due to the pandemic, we decided to end this study    有  11  个tokens\n",
      "subjects did not receive hope pharmaceuticals' sodium thiosulfate injection    有  14  个tokens\n",
      "issues with pk detection limits and compliance to protocol at the analytical site    有  13  个tokens\n",
      "development program for filgotinib for participants with psoriatic arthritis has been stopped    有  17  个tokens\n",
      "after completion of phase i, it was decided not to initiate phase ii of the study    有  17  个tokens\n",
      "decided not to open the study    有  7  个tokens\n",
      "pi has left trust currently    有  5  个tokens\n",
      "the research team is exploring device optimization    有  7  个tokens\n",
      "difficulty analyzing psg data    有  5  个tokens\n",
      "study temporarily suspended until priorities are reassessed    有  8  个tokens\n",
      "finishing some devices    有  4  个tokens\n",
      "study not carried out    有  4  个tokens\n",
      "withdrawn due to poor feasibility    有  6  个tokens\n",
      "the drug is not available    有  5  个tokens\n",
      "pi failed to submit study for continuing review by irb    有  11  个tokens\n",
      "failed study, participants showed no improvements    有  7  个tokens\n",
      "the study did not start    有  5  个tokens\n",
      "co-pi responsible for study procedures moved to another hospital    有  11  个tokens\n",
      "change in institutional policy. change in resources available    有  9  个tokens\n",
      "similar to another study    有  4  个tokens\n",
      "due to a decrease in scheduled study-eligible patients, we terminated the study prematurely    有  16  个tokens\n",
      "withdrawal of supply of vaccine from one manufacturer    有  9  个tokens\n",
      "local problems with bis monitor, we wont have it anymore    有  11  个tokens\n",
      "doesnt meet criteria for clinical trial reporting    有  8  个tokens\n",
      "the aims represented in this study are also included in another, larger study of at-home copd care. there was insufficient research team support to complete both protocols and the work would have been duplicative. thus, we have terminated this study    有  47  个tokens\n",
      "drug supplier did not come through    有  6  个tokens\n",
      "study never initiated; withdrawn prior to receiving irb approval    有  11  个tokens\n",
      "logistical difficulties with implementing study    有  6  个tokens\n",
      "dexmedetomidine is unavailable in this time    有  10  个tokens\n",
      "suspending this trial to focus on a new study with similar goals but different exercise intervention, ensuring resource efficiency and research effectiveness    有  24  个tokens\n",
      "no available fund    有  3  个tokens\n",
      "study halted prematurely; irb approval not obtained    有  9  个tokens\n",
      "drug provider decided not to move forward with the study    有  10  个tokens\n",
      "joint decision by sponsor and investigator    有  6  个tokens\n",
      "alternate study design for ovarian cancer under discussion    有  8  个tokens\n",
      "study ends for scientific reasons    有  5  个tokens\n",
      "pi decided not to continue    有  5  个tokens\n",
      "long process and due to strict deadline, project was stopped    有  11  个tokens\n",
      "device requires further modification    有  4  个tokens\n",
      "this study was terminated due to benefit/risk analysis    有  10  个tokens\n",
      "voluntary market withdrawal    有  4  个tokens\n",
      "difficulty obtaining ide by the fda. currently not worthwhile to pursue further    有  14  个tokens\n",
      "based on interim review and decision to re-design the study    有  11  个tokens\n",
      "interim analysis showed sample size sufficient for final analysis    有  10  个tokens\n",
      "unable to find further eligible participants    有  6  个tokens\n",
      "study not feasible in practise    有  5  个tokens\n",
      "expansion cohort was not open    有  6  个tokens\n",
      "development program of jnj-4178 was discontinued    有  10  个tokens\n",
      "we could not fund the study    有  6  个tokens\n",
      "the ind has been withdrawn from fda    有  8  个tokens\n",
      "pi retired and no data was collected    有  7  个tokens\n",
      "civil unrest in region/country of study    有  8  个tokens\n",
      "we decided to go to another direction    有  7  个tokens\n",
      "the pandemic halted the study protocol temporarily. we continued to collect what we could but the study ran out of time/funds    有  24  个tokens\n",
      "the department in charge of this research is no longer able to folpoor this project. only two inclusions this study is close    有  26  个tokens\n",
      "ip unavailable at site    有  4  个tokens\n",
      "study stopped due to a competing trial    有  7  个tokens\n",
      "primary study stopped early    有  4  个tokens\n",
      "unanticipated delays    有  3  个tokens\n",
      "closure of radiolaboratory    有  6  个tokens\n",
      "principle investigator changed academic affiliation, then later retired. study terminated after intra-observer validation, but inter-observer validation not completed    有  26  个tokens\n",
      "awaiting fda approval to continue    有  7  个tokens\n",
      "end of contract negociations    有  5  个tokens\n",
      "investigators are no longer considering fmt product development for c. difficile    有  13  个tokens\n",
      "early termination due to technical problems with the device    有  9  个tokens\n",
      "due to changing therapeutic landscape in metastatic bladder cancer and poor radiation/immunotherapy systemic synergy in other malignancies    有  23  个tokens\n",
      "original study plan required re-evaluation and the decision was made to pivot to developing tests and exercises on healthy population    有  22  个tokens\n",
      "change to recommended season flu vaccine in uk    有  8  个tokens\n",
      "cancelled by the sponsor    有  4  个tokens\n",
      "newer research suggested that paricalcitol may be harmful to a subset of pancreatic cancer patients and it is not feasible to subtype patients in the short time frame before surgery    有  34  个tokens\n",
      "study not started due to organizational reasons    有  7  个tokens\n",
      "development plan under review    有  4  个tokens\n",
      "study purposes and objectives have shifted    有  6  个tokens\n",
      "the 34 patients included had all completed their treatment period under the protocol and the data could be collected to assess the main objective and the secondary objectives before the last theoretical folpoor-up    有  37  个tokens\n",
      "poor participants eligible for study    有  6  个tokens\n",
      "pi relocation    有  2  个tokens\n",
      "monocentric study, site reorganised, could no longer participate in study    有  16  个tokens\n",
      "the sponsor decided to discontinue the development of idasanutlin in the polycythemia vera indication    有  21  个tokens\n",
      "phase i portion of the study was completed. the phase ii portion of the study was terminated early to focus on an allogeneic bcma car-t program    有  32  个tokens\n",
      "a substantial decrease in refugee arrivals in virginia didn't alpoor the investigator to continue the study as planned    有  22  个tokens\n",
      "new evidence points to a new candidate vaccine, with a superior trial to bcg    有  16  个tokens\n",
      "there is sufficient folpoor-up data to meet the endpoints of the study    有  15  个tokens\n",
      "principal investigator moved to jacksonville, fl campus    有  10  个tokens\n",
      "due to moh request    有  5  个tokens\n",
      "death of principal investigator    有  4  个tokens\n",
      "feasibility challenges    有  3  个tokens\n",
      "this registration has moved to a local ictrp (cris; https://cris.nih.go.kr, kct0002565)    有  28  个tokens\n",
      "portfolio prioritization    有  3  个tokens\n",
      "not enough sample list at participating healthcare facility    有  8  个tokens\n",
      "1st two cohorts provided the required data, therefore 3rd cohort was not deemed necessary    有  18  个tokens\n",
      "political issues in algeria and now covod-19 lock-down    有  14  个tokens\n",
      "the team has changed. the new team did not have the perosnnel to set up the study    有  21  个tokens\n",
      "study has been terminated    有  4  个tokens\n",
      "principal investigator is taking appointment with another institution    有  8  个tokens\n",
      "study was not opened at site    有  6  个tokens\n",
      "as part of a portfolio-level management of the company's oncology pipeline, it was decided to stop the next phase of internal development of the metap2 (m8891) program to enable realization of other opportunities within the oncology portfolio    有  48  个tokens\n",
      "updated results by guidelines and bibliography    有  6  个tokens\n",
      "tech changes made it impossible to consent patients. not a flaw in design, practice changes caused the study end    有  21  个tokens\n",
      "terminated due to nonclinical findings    有  6  个tokens\n",
      "not accepted    有  2  个tokens\n",
      "the study stopped because the study period already ended    有  9  个tokens\n",
      "terminated based on interim review    有  5  个tokens\n",
      "decision not to pursue    有  4  个tokens\n",
      "no regulatory approval    有  3  个tokens\n",
      "no trained/ qualified staff available to perform study    有  9  个tokens\n",
      "due to issues with study design    有  6  个tokens\n",
      "staff not available to commence study    有  6  个tokens\n",
      "necessary equipment could not be provided    有  6  个tokens\n",
      "extensive protocol revisions initiated    有  5  个tokens\n",
      "fda removal of drug from the market due to cancer risks    有  12  个tokens\n",
      "capacity problems    有  2  个tokens\n",
      "the factors influencing the results of the study have changed    有  10  个tokens\n",
      "inability to promptly see local allergists as part of medical maximization which lead to delays in care for these patients    有  23  个tokens\n",
      "no relevant anymore    有  3  个tokens\n",
      "increase mortality rate in cases that made it difficult to folpoor up    有  14  个tokens\n",
      "stop of drug development    有  4  个tokens\n",
      "sufficient acquisitions for dce-mri and 4d fpoor, but not for t1/t2-mapping due to poor ilt in some participants    有  33  个tokens\n",
      "prematurely terminated due to poor therapeutic effect    有  10  个tokens\n",
      "positive results at interim analysis    有  5  个tokens\n",
      "major changes to study that were better suited to creating a whole new study    有  14  个tokens\n",
      "investigational device no longer has health canada approval    有  10  个tokens\n",
      "pi on an extended leave of absence    有  7  个tokens\n",
      "protocol modification is pending    有  4  个tokens\n",
      "study not irb approved    有  5  个tokens\n",
      "it was felt by the sponsoring institution that the current standard of oversight expected by the health canada regulations, would not be possible to achieve    有  26  个tokens\n",
      "research cancelled because of inadequate staffing    有  6  个tokens\n",
      "this was an exploratory open-label study and has met its initial objectives    有  14  个tokens\n",
      "no resources    有  2  个tokens\n",
      "recuitment to poor    有  5  个tokens\n",
      "samus therapeutics closure    有  5  个tokens\n",
      "reformulation of study drug to help reduce the pill burden as higher doses are evaluated    有  17  个tokens\n",
      "no longer priority in the research group    有  7  个tokens\n",
      "high drop out rate due to subjects needing to record details of every meal    有  14  个tokens\n",
      "study design modified to collect specimens from a bank requiring a separate irb-approved protocol    有  16  个tokens\n",
      "investigator decision to close study    有  6  个tokens\n",
      "on hold by sponsor    有  4  个tokens\n",
      "investigator wish    有  3  个tokens\n",
      "at interim analysis insufficient benefit was observed to continu the study    有  11  个tokens\n",
      "problem of investigational products    有  5  个tokens\n",
      "more than 100 invasive and non-invasive qpqs data were collected    有  14  个tokens\n",
      "change in research site    有  4  个tokens\n",
      "results obtained on the first 8 patients shown an expected glandular membrane specific labeling associated with non-specific labeling of fibro-muscular tissue    有  28  个tokens\n",
      "study team did not respond to requests for continuing review approval    有  11  个tokens\n",
      "irb application expired    有  4  个tokens\n",
      "long local irb process to meet with the treatment deadline    有  11  个tokens\n",
      "pi dropped the study    有  4  个tokens\n",
      "one of the key physicians is leaving the institution and other delays have put us behind our timeline. we do not intend to proceed with the trial at this time    有  31  个tokens\n",
      "first required to complete a proof of principle study for a new outcome measure    有  14  个tokens\n",
      "staff no longer available    有  4  个tokens\n",
      "unconfirmed research expenses    有  4  个tokens\n",
      "pci decision due to technical issues    有  6  个tokens\n",
      "chu lyon will join as a participating center (and as national french coordinator) as a part of the bev-ip study ongoing study eudract-number 2014-004257-14    有  38  个tokens\n",
      "active circulation of dengue virus in the region of the study that may affect the result of zika serology    有  23  个tokens\n",
      "alternative method of implementation, study not needed    有  8  个tokens\n",
      "the main reason for trial discontinuation was the inability to address the primary objectives of the study folpooring an extended gap between the second and third doses    有  30  个tokens\n",
      "the device that was going to be studied was removed by duke university shortly after the study was approved    有  19  个tokens\n",
      "pi transferred to another institution    有  5  个tokens\n",
      "study was complete    有  3  个tokens\n",
      "inability to accrue subjects that met the exclusion criterion \"any prior (within the past 30 days) or current sodium thiosulfate treatment\"    有  31  个tokens\n",
      "it was decided to use the qrh for a new study    有  12  个tokens\n",
      "only the first part of the study was done    有  9  个tokens\n",
      "this study is withdrawn due to feasibility issues    有  8  个tokens\n",
      "project adjustment    有  2  个tokens\n",
      "sponsor declined to fund    有  4  个tokens\n",
      "change in clinical development plan    有  5  个tokens\n",
      "the study was discontinued after the first pre-planned interim analysis due to insufficient response rates    有  17  个tokens\n",
      "insufficient fund    有  3  个tokens\n",
      "standards of care changed at the institution so that pec procedures were no longer common or preferred as a method of pain control for breast surgery    有  27  个tokens\n",
      "co-pi albert chang relocating to ucla. ind will transfer to ucla. ucsf will not participate    有  25  个tokens\n",
      "the target population with available genotype traveled outside study area and study duration of 19 weeks was long for some participants    有  22  个tokens\n",
      "technical difficulty and feasibility issues    有  5  个tokens\n",
      "sponsor assessed all endpoints and collected overall survival data for another two years folpooring the primary completion date of 03feb2021    有  26  个tokens\n",
      "inadequate resources to complete the study    有  8  个tokens\n",
      "myriad has sufficient data to do an analysis on the primary objective, durability, and has made the decision not to continue collecting data for the other study objectives    有  31  个tokens\n",
      "pis not interested in continuing with the trial    有  8  个tokens\n",
      "beigene has withdrawn their support owing to sitravatinib supply concerns. mirati is ceasing further development of sitravatinib owing to the negative results of the sapphire trial which used sitravatinib in 2nd line met nsclc setting    有  56  个tokens\n",
      "ongoing insights required a different approach    有  7  个tokens\n",
      "reliable and consistent method of uv tattoo application was not able to be achieved    有  15  个tokens\n",
      "unable to recuit participant number in time    有  8  个tokens\n",
      "pi withdrew study    有  3  个tokens\n",
      "due to issues arised from the collaboration contract between sponsor and research site    有  14  个tokens\n",
      "stopped due to inactivity    有  5  个tokens\n",
      "reaching total sample size was not feasible within the anticipated time frame    有  13  个tokens\n",
      "study never started, change in company focus on us    有  10  个tokens\n",
      "time restrictions on leading investigator    有  5  个tokens\n",
      "study classed as ctimp    有  6  个tokens\n",
      "compelling insights impacting the scientific rationale    有  7  个tokens\n",
      "study will be closed in thailand and opened in the usa    有  12  个tokens\n",
      "device recalled by the manufacturer    有  5  个tokens\n",
      "the study has been stopped because no one is    有  9  个tokens\n",
      "msd would not able to support the study's continuation after protocol modifications required by ansm through dose de-escalation of pembrolizumab    有  30  个tokens\n",
      "poor community engagement    有  4  个tokens\n",
      "the surgical team has difficulty to find level 1 and 2 fusions for the study    有  18  个tokens\n",
      "study canceled before starting    有  4  个tokens\n",
      "high cancellation rate in lh test group in interim analysis    有  10  个tokens\n",
      "due to the poor application materials, the normal research can not be carried out for the time being    有  19  个tokens\n",
      "poor materials, not moving forward    有  7  个tokens\n",
      "the principal investigator dr.yinli is working in other hospital    有  12  个tokens\n",
      "drug development suspended by current holder of ind    有  8  个tokens\n",
      "corporate finances    有  3  个tokens\n",
      "very important delay in the pace of inclusions. likely overestimation of the potential for inclusion. poor involvement of some health professionals    有  26  个tokens\n",
      "could not get an approval from department reviewer for the study continuation    有  12  个tokens\n",
      "no availability of investigational medication    有  6  个tokens\n",
      "study suspended in october 2017 and terminated april 17, 2018 after decision to discontinue the study drug development    有  26  个tokens\n",
      "the delay between diagnosis and initiation of treatment was no longer consistent with standard of care    有  16  个tokens\n",
      "decision of ip support organization    有  5  个tokens\n",
      "cannot perform the study due to practical issues    有  8  个tokens\n",
      "study team has decided to focus on other projects    有  9  个tokens\n",
      "institution problem    有  2  个tokens\n",
      "investigator leave of absence    有  5  个tokens\n",
      "interim analysis to assess concern for spinal anesthesia and increased cesarean delivery rate    有  16  个tokens\n",
      "decision from the sponsor    有  4  个tokens\n",
      "blood withdrawal problems despite use of different catheters    有  9  个tokens\n",
      "device was fda approved before feasibility study could be performed    有  11  个tokens\n",
      "internal decision made by norbert health    有  7  个tokens\n",
      "not sufficiently staff available to perform trial    有  7  个tokens\n",
      "funds ended    有  3  个tokens\n",
      "inability of the etolya®'s manufacturer to furnish the promised functionalities as those which had to be recorded for assessment of the study's end points    有  31  个tokens\n",
      "local ethics committee concern    有  4  个tokens\n",
      "multidisciplinary participation could not be overcome    有  9  个tokens\n",
      "high number of false negatives    有  5  个tokens\n",
      "departmental research hold    有  4  个tokens\n",
      "the study has been put on hold while pending cms approval    有  11  个tokens\n",
      "(investigation of ace-083 for use in patients with cmt is being discontinued as it did not achieve functional secondary endpoints in the a083-03 trial    有  32  个tokens\n",
      "study requires medicines control council approval    有  6  个tokens\n",
      "study stopping rules were met    有  5  个tokens\n",
      "study do not start due to concurrential trial    有  9  个tokens\n",
      "terminated per the pi's request    有  6  个tokens\n",
      "irb recommendation    有  3  个tokens\n",
      "because the principal investigator has moved to another hospital    有  9  个tokens\n",
      "sponsor issue    有  2  个tokens\n",
      "data was not sufficiently complete and reliable for analysis (retrospective chart research)    有  16  个tokens\n",
      "after an interim analysis, it was decided to discontinue the study after a stochastic curtailment analysis    有  20  个tokens\n",
      "no fundng was provided by the financial agency    有  9  个tokens\n",
      "study was dropped at site before participation    有  7  个tokens\n",
      "pi transferred    有  2  个tokens\n",
      "target population is insufficient    有  4  个tokens\n",
      "the study was terminated by sponsor for reasons of adjusted clinical development strategy    有  13  个tokens\n",
      "pi departure - study not conducted    有  6  个tokens\n",
      "technical problems in equipment    有  4  个tokens\n",
      "competing clinical trial priorities    有  5  个tokens\n",
      "reb approval denied    有  3  个tokens\n",
      "decided not to move forward    有  6  个tokens\n",
      "company no longer interested in supporting this trial    有  8  个tokens\n",
      "no longer rct - same surgical technique and implant used    有  11  个tokens\n",
      "no interesting results    有  3  个tokens\n",
      "change in location of pulmonary rehab at our institution    有  9  个tokens\n",
      "principal investigator is leaving university and halting studies    有  9  个tokens\n",
      "researcher left    有  3  个tokens\n",
      "vaccine manufacturing has been suspended    有  6  个tokens\n",
      "suggestion of an accentuation of the bias of overestimating the silhouette in one of the avatar exposure modalities in virtual reality    有  26  个tokens\n",
      "investigator no longer actively pursuing this study    有  8  个tokens\n",
      "poor response to study therapy    有  6  个tokens\n",
      "study early terminated due to poorer drug exposure    有  8  个tokens\n",
      "idmc recommendation. unexpectedly high use of concomitant corticosteroid treatment    有  16  个tokens\n",
      "delay in the r & d stage    有  7  个tokens\n",
      "insufficient number of subjects    有  5  个tokens\n",
      "publication of better study    有  4  个tokens\n",
      "new study type, it will be re-organized as an investigator initiated study (iis)    有  19  个tokens\n",
      "termination of zandelisib clinical development globally    有  9  个tokens\n",
      "the company that provided the intervention shut down & withdrew the intervention    有  12  个tokens\n",
      "phase i response to treatment was not as expected and the myeloma field in treatment has changed since initiating the study, so investigators felt the study should not be pursued into phase ii    有  36  个tokens\n",
      "product manufacturing issues    有  3  个tokens\n",
      "study halted prematurely prior to initiation but potentially will resume in the future    有  13  个tokens\n",
      "intervention never conducted    有  4  个tokens\n",
      "failure to obtain hgr approval    有  6  个tokens\n",
      "study terminated due to project timelines    有  6  个tokens\n",
      "project termination    有  2  个tokens\n",
      "technique failed    有  3  个tokens\n",
      "no zika cases at study site    有  7  个tokens\n",
      "evaluation halted    有  2  个tokens\n",
      "unable to obtain intervention materials    有  5  个tokens\n",
      "study closed due to device design modifications    有  7  个tokens\n",
      "change in treatment priorities for these disease types as well as staffing concerns    有  13  个tokens\n",
      "concerns about possible association between drug and increased icu mortality    有  13  个tokens\n",
      "hard to get an informed concent because of small number of indiaiton of surgery    有  15  个tokens\n",
      "determined not to be human subjects research    有  8  个tokens\n",
      "the study aim was not relevant anymore because other studies became available recently on the same topic    有  17  个tokens\n",
      "drug manufacturer ceased operations    有  4  个tokens\n",
      "withdrawal of vaginal prosthesis from the market    有  10  个tokens\n",
      "withdrawn in 2018 because clinicians did not folpoor protocols, issues with communication and also with tablet processing, nearby ebola outbreak in 2018 (in the n kivu area) confounded efforts    有  44  个tokens\n",
      "feasibility issues with the study treatment (in-person cbt) resulted in the study ending earlier than anticipated    有  21  个tokens\n",
      "one treatment policy showed an advantage at a very high significance level    有  12  个tokens\n",
      "corporation decision    有  4  个tokens\n",
      "study never approved    有  3  个tokens\n",
      "profissional reasons, not related with the study    有  9  个tokens\n",
      "repositioning of target indication    有  6  个tokens\n",
      "the study was terminated before the primary endpoint (determination of mtd) was reached because the opc form is to be replaced with the newly developed capsule form in all subsequent clinical trials    有  36  个tokens\n",
      "interim data was sufficient for study purpose    有  8  个tokens\n",
      "fda recommendation    有  3  个tokens\n",
      "lead site preference    有  3  个tokens\n",
      "the study was terminated early due to sponsors decision    有  9  个tokens\n",
      "didn't receive irb approval    有  6  个tokens\n",
      "the study was closed due to investigator discretion based on the poor perceived clinical activity observed in the study    有  19  个tokens\n",
      "temporary closure per protocol design    有  5  个tokens\n",
      "inconsistent results in pilot phase    有  6  个tokens\n",
      "a re-evaluation of research risks to participants were greater than originally anticipated    有  14  个tokens\n",
      "due to the company's intent to conduct a new study under a different protocol with the smart+ system which is a more advanced version of the smart system    有  30  个tokens\n",
      "principal investigator not available anymore (sabbatical)    有  10  个tokens\n",
      "there was a change in the strategy to complete the rmp with ha    有  14  个tokens\n",
      "due to supply constraints & prioritization according to medical need (availability of alternative rabies vaccines), rabipur will no longer be supplied to china    有  28  个tokens\n",
      "failure rate 91.1%    有  7  个tokens\n",
      "medi-551 removed from oncology by pharmaceutical company due to change in research target    有  16  个tokens\n",
      "to focus on strident intervention studies as this study population is heterogenous    有  14  个tokens\n",
      "on hold pending amendment approval    有  5  个tokens\n",
      "expected technology was not available    有  5  个tokens\n",
      "the study was never approved by ctep neither was it ever activated    有  13  个tokens\n",
      "decided to stop drug development    有  6  个tokens\n",
      "principal investigator took another position elsewhere    有  6  个tokens\n",
      "cfda announced xi'an risperdal as reference drug, no need for this be trial from both scientific and ethical perspective    有  24  个tokens\n",
      "interim analysis suggested that the trial, as designed, was not adequately powered to detect a therapeutic effect    有  20  个tokens\n",
      "changes in standard of care have altered the feasibility of the study    有  12  个tokens\n",
      "the study has been registed in chictr and apply for withdrawing    有  13  个tokens\n",
      "study was never initiated due to contracting issues    有  8  个tokens\n",
      "suspended development    有  3  个tokens\n",
      "project was withdrawn and never began at loyola university medical center    有  13  个tokens\n",
      "priortization of other programs    有  6  个tokens\n",
      "competing study to be started in november 2018    有  11  个tokens\n",
      "after careful consideration, ucb has decided to no longer pursue pnh as a potential indication for zilucoplan    有  23  个tokens\n",
      "non compliance from sponsor regarding applicable documentation to proceed with trial, therefore decision to permanently halt trial    有  18  个tokens\n",
      "the pilot study (before the intervention) is completed    有  10  个tokens\n",
      "pi decision not to move forward with study    有  8  个tokens\n",
      "we never started the study    有  5  个tokens\n",
      "irb approval terminated    有  4  个tokens\n",
      "imp no longer available    有  4  个tokens\n",
      "iterim analysis did not detect a clinically meaningful change in the primary endpoint    有  14  个tokens\n",
      "strategic adjustment    有  3  个tokens\n",
      "inadequate data analysis    有  5  个tokens\n",
      "advised by dsmb based on interim-analysis, highly significant difference    有  13  个tokens\n",
      "fda hold for combination studies using imids and pd1/pdl1 compounds    有  16  个tokens\n",
      "we have not succeeded in developing an approach that uses hdeeg to control a communication interface at an accuracy needed to complete the protocol    有  26  个tokens\n",
      "the decision to terminate clinical development of pf-07081532 is based on pharmacokinetic data from phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these phase 1 studies as well as a phase 2 study    有  51  个tokens\n",
      "principal investigator is making changes to the protocol    有  8  个tokens\n",
      "one of the investigators went abroad    有  6  个tokens\n",
      "standard clinical practice at site caused unforeseen issues for the use of the acm    有  16  个tokens\n",
      "development of gtb-3550 halted due to development of the second generation camelid nanobody trike drug product, gtb-3650    有  29  个tokens\n",
      "study never started/ will not proceed    有  7  个tokens\n",
      "due to a change in surgical personnel, the operative technique changed, precluding the examination of bypass-related bi-hemispheric saturation differences    有  27  个tokens\n",
      "other - drug manufacturer decision to close study    有  8  个tokens\n",
      "insufficient caregiver participation    有  4  个tokens\n",
      "due to not achieving the primary outcome    有  7  个tokens\n",
      "the participating party (rush) stopped the study because of logistic issues    有  13  个tokens\n",
      "discontinuation of production of imp    有  7  个tokens\n",
      "device development placed on hold    有  5  个tokens\n",
      "limitations in timing and personnel    有  5  个tokens\n",
      "investigator decided not to pursue the study due to other competing studies    有  13  个tokens\n",
      "did not pursue study    有  4  个tokens\n",
      "the student leading the project decided not to continue    有  9  个tokens\n",
      "results interim-analysis    有  3  个tokens\n",
      "staffing changes at site. no longer feasible at site    有  11  个tokens\n",
      "it is no longer practicable to complete the trial    有  10  个tokens\n",
      "delayed initiation    有  3  个tokens\n",
      "the study was terminated due to not enough power and research staff assistance    有  13  个tokens\n",
      "pi confirmed this study was withdrawn and did not begin locally    有  11  个tokens\n",
      "pi unexpectedly passed away, study closed    有  7  个tokens\n",
      "bioresorbable scaffold is not available in south korea    有  12  个tokens\n",
      "pi's discretion due to needing to modify study protocol    有  10  个tokens\n",
      "refusal by the ethics committee    有  6  个tokens\n",
      "study team submitted iras form and the ethic committee advised that this pilot study is more service evaluation and no rec ethical approval was required    有  26  个tokens\n",
      "no eligible participants for the rct were found    有  9  个tokens\n",
      "care coordinators graduated    有  4  个tokens\n",
      "abbott received fda approval to transition the ongoing brady mri pas study to ep a new ep-passion real world evidence methodology    有  27  个tokens\n",
      "aspirin added to chemoradiotherapy was safe but did not improve response to total neoadjuvant treatment. the study was closed due absence of benefit    有  32  个tokens\n",
      "investigator terminated trial pursuant to research contract rights    有  9  个tokens\n",
      "due to the fact data results were statistically significant among the two groups    有  13  个tokens\n",
      "application to ca withdrawn due to technical reasons of the manufacturer    有  11  个tokens\n",
      "the study closed because of shifting research priorities and interests    有  10  个tokens\n",
      "not approved by sponsor    有  4  个tokens\n",
      "determined feasibility was needed before conducting this trial    有  9  个tokens\n",
      "the study was stopped early as it was determined there would not be a statistically significant treatment effect associated with the primary endpoint due to the poor number of events    有  30  个tokens\n",
      "the sponsor has been notified of an interruption in the international supply, and there is a possibility that 131i-mlbg would be unavailable to patients randomised to arm a of the trial    有  38  个tokens\n",
      "the study stopped because the the project was abandoned    有  9  个tokens\n",
      "nih decision    有  2  个tokens\n",
      "due to the pandemic and the nature of this study we decided to terminate this study    有  16  个tokens\n",
      "to prioritize other programs    有  4  个tokens\n",
      "manufacturing issues    有  3  个tokens\n",
      "no longer target indication    有  4  个tokens\n",
      "the study was terminated folpooring an internal review of the company's research and development portfolio    有  18  个tokens\n",
      "due to negative results in similar trials using 11c-ucb-j    有  15  个tokens\n",
      "study modified to a two-group crossover design and transferred to new location    有  13  个tokens\n",
      "logistical problems meant that the study was no longer feasible    有  11  个tokens\n",
      "investigator decided not to go forward with the trial    有  10  个tokens\n",
      "dsmb suggestion    有  3  个tokens\n",
      "study technology decommissioned at clinical site    有  8  个tokens\n",
      "due to \"early stopping rule\" as defined in the study protocol    有  13  个tokens\n",
      "investigator retierment    有  5  个tokens\n",
      "departure of one of the investigator    有  6  个tokens\n",
      "study team decided not to move forward with study    有  9  个tokens\n",
      "per research hold    有  3  个tokens\n",
      "post market study terminated early due to the launch and subsequent incorporation of the study into the terumo aortic endovascular registry (tiger-001)    有  31  个tokens\n",
      "this is a sub-study of another one    有  9  个tokens\n",
      "procedure has become standard of care - protocol is no longer necessary    有  12  个tokens\n",
      "inclusions was stopped at 30 patients. investigators did not wish to extend inclusions    有  17  个tokens\n",
      "principal investigator was unable to pursue research further due to time constraints    有  12  个tokens\n",
      "unfavourable ethical opinion, principally on grounds of inadequate sample size    有  14  个tokens\n",
      "phase i analysis    有  3  个tokens\n",
      "as similar local evidence recently available, present study will not add new information; no ethical justification exists to continue study procedures    有  23  个tokens\n",
      "absence of breg lymphocytes in peritoneum    有  11  个tokens\n",
      "stopped by the sponsor due to their change in product development priorities    有  12  个tokens\n",
      "study has been withdrawn from irb review pending ind revision    有  11  个tokens\n",
      "the phase ii portion was never started as we could no longer get the drug from the manufacturer    有  18  个tokens\n",
      "study design change required protocol/icf changes, deemed more appropriate to terminate study and apply knowledge gained to potential future study design    有  24  个tokens\n",
      "investigator judged that this study can not be maintained because participant registration rate is poor    有  16  个tokens\n",
      "primary investigator passed away    有  4  个tokens\n",
      "because the study had to be redesigned and restarted as clinical device study    有  13  个tokens\n",
      "no subcontractors for management of connected watches    有  8  个tokens\n",
      "difficulties in field coordination    有  6  个tokens\n",
      "fda approved embospheres for prostate embolization, so ide not needed    有  16  个tokens\n",
      "grantor closed study    有  4  个tokens\n",
      "trial stopped: a sae has occured. as a measure of precaution, the trial has been stopped    有  20  个tokens\n",
      "completion of study in orig timeframe not feasible considering evolving treatments for mm in us    有  15  个tokens\n",
      "pi confirmed that this is not a clinical trial and was inadvertently entered in the system    有  16  个tokens\n",
      "poor adherence rate; need to revise online interventions    有  10  个tokens\n",
      "principal investigator determination    有  3  个tokens\n",
      "the incidence of aes was higher than the ib reported    有  10  个tokens\n",
      "study stopped early as az have re-prioritised to focus on research to help bring existing and innovative medicines to more patients with asthma and copd    有  30  个tokens\n",
      "due to the unavailability of the subjects who gave the consent to participate to the study protocol    有  18  个tokens\n",
      "reevaluating protocol based on preliminary data    有  8  个tokens\n",
      "study will not be conducted due to changes related to the investigational agent    有  14  个tokens\n",
      "terminated due to surgeon preferences    有  5  个tokens\n",
      "sponsor cancelled the study as real life impact data has already shown the value of hepa vaccination & as no critical need to gather additional data in israel    有  30  个tokens\n",
      "mitochondrial respiration measurement technique faulty    有  8  个tokens\n",
      "the supply of ip is disrupted    有  6  个tokens\n",
      "pi no longer available, not able to find replacement. 2 patients, lost to folpoor-up    有  21  个tokens\n",
      "revisiting the availability of patients with ph+ all that would meet the in-/exclusion criteria of the study led to the decision not to move forward    有  31  个tokens\n",
      "we gave up    有  3  个tokens\n",
      "the actions and measures to be taken to restart the trial could not be implemented which made the premature termination inevitability    有  23  个tokens\n",
      "sponsor will amend study design by incorporating reconfirmation of coagulopathy folpooring discussion with fda regarding findings from scarlet1 study    有  28  个tokens\n",
      "evusheld is being re-formulated to protect against all strains of sars-cov 2    有  20  个tokens\n",
      "study terminated early as a result of the outcome of the pre-planned interim analysis    有  16  个tokens\n",
      "we are waiting for the additional founds    有  8  个tokens\n",
      "grant not approved    有  3  个tokens\n",
      "due to competing studies    有  4  个tokens\n",
      "investigator stopped study    有  4  个tokens\n",
      "converted from a pilot into a larger study which we will enter as a new protocol    有  16  个tokens\n",
      "unable to obtain fda exemption    有  6  个tokens\n",
      "study terminated by sponsor for commercial reasons    有  7  个tokens\n",
      "poor interest and support    有  5  个tokens\n",
      "the study direction does not longer aligns the sponsor's strategy    有  12  个tokens\n",
      "study drug supply issue    有  4  个tokens\n",
      "the principal investigator is leaving yale university and will not be continuing the work at her new institution    有  19  个tokens\n",
      "stop trial due to proposals for possible optimizations of the device by the investigators    有  14  个tokens\n",
      "due to sponsor's ongoing and upcoming projects and overall research priorities    有  12  个tokens\n",
      "pi recommended closure    有  3  个tokens\n",
      "insufficient resources for performance of project    有  7  个tokens\n",
      "merged irb study created    有  5  个tokens\n",
      "one of the study products is no longer available for clinical trial use    有  13  个tokens\n",
      "unforeseen cost restrictions of the drug halted the execution of this study altogether    有  15  个tokens\n",
      "sponsor was not financially able or willing to continue to support the study    有  13  个tokens\n",
      "clinic management decided to cancel the study for priority reasons    有  10  个tokens\n",
      "investigateur decision    有  4  个tokens\n",
      "study design will be reformulated    有  6  个tokens\n",
      "study was discontinued in 2018 as sufficient sample size was not met    有  14  个tokens\n",
      "suspended since april 2020 as the application is temporarily unavailable    有  13  个tokens\n",
      "sponsor asked site to suspend study    有  6  个tokens\n",
      "study was stopped early due to a greater than expected incidence of ocular aes and analysis of the data from the first 4 subjects indicating that the likelihood of permanent remission with this therapy was poor    有  39  个tokens\n",
      "temporarily paused per study team for interim data review    有  10  个tokens\n",
      "ct-p27 2.2 is inactivated    有  10  个tokens\n",
      "study terminated due to poor probability of achieving a positive outcome on the primary endpoint    有  15  个tokens\n",
      "irb haulted the study there was no evidence that the probiotic would benefit the patient    有  19  个tokens\n",
      "due to the delay in establishing fda regulations for over-the-counter hearing aids    有  15  个tokens\n",
      "personal reasons    有  2  个tokens\n",
      "pi decision to close study early    有  6  个tokens\n",
      "vector has not been produced    有  5  个tokens\n",
      "continued randomization was questioned on ethical grounds after the who ikmc study reported mortality reduction in may 2021. the dsmb recommended to stop the trial after reviewing a preliminary data analysis because of benefit of the intervention    有  43  个tokens\n",
      "study drug out of specification    有  5  个tokens\n",
      "shortstaff at sleep lab    有  5  个tokens\n",
      "the study was terminated because of difficulty in completing the study as originally planned    有  14  个tokens\n",
      "need improve the strategy    有  4  个tokens\n",
      "united neuroscience has decided to terminate v203-ad-ext study based on a treatment assignment error    有  18  个tokens\n",
      "no viable sites    有  3  个tokens\n",
      "protocol re-design required folpooring eu phase iii results    有  11  个tokens\n",
      "due to new insights    有  4  个tokens\n",
      "there is a poor potential study participants at our study site that would meet inclusion criteria, therefore, the study is not feasible and is being terminated    有  28  个tokens\n",
      "unable to accrue in subjects in a timely fashion    有  10  个tokens\n",
      "transfer of study sponsor    有  4  个tokens\n",
      "nhlbi has suggested the company focus on the other two ongoing trials    有  14  个tokens\n",
      "site resources    有  2  个tokens\n",
      "decision of the pi    有  4  个tokens\n",
      "ethics committee concerns    有  4  个tokens\n",
      "inability to include subjects on schedule    有  7  个tokens\n",
      "due to corona pandemic crisis    有  6  个tokens\n",
      "product not available, study withdrawn    有  6  个tokens\n",
      "impossible to involve a sufficient number of centers in the study    有  12  个tokens\n",
      "the dm production has been stopped    有  6  个tokens\n",
      "the ed physicians no longer prescribe opioids at discharge; not feasible to conduct the study    有  16  个tokens\n",
      "decision by sponsor not to continue with the trial    有  9  个tokens\n",
      "by merck    有  3  个tokens\n",
      "device has been fda approved    有  6  个tokens\n",
      "resolving database issues    有  4  个tokens\n",
      "failure to accrue subjects. all activity has stopped & no analysis will be done on what has been collected    有  21  个tokens\n",
      "decided not to perform the pilot phase    有  8  个tokens\n",
      "principal investigator wishes to revisit design and start a new study    有  11  个tokens\n",
      "camera for study is being repaired    有  6  个tokens\n",
      "investigator decided to withdraw the study    有  7  个tokens\n",
      "as last patient last visit (lplv) took place on 15/02/2022, the trial was ended prematurely on this date in accordance with sakk/ci    有  36  个tokens\n",
      "combination of chemotherapy and immunotherapy is a new standard of care    有  12  个tokens\n",
      "principal investigator departure without possible replacement    有  6  个tokens\n",
      "study withdrawn for no sufficient fund support    有  7  个tokens\n",
      "the study required more participants than anticipated for statistical significance    有  10  个tokens\n",
      "poor sufficient personnel to run this study's research visits    有  11  个tokens\n",
      "parastomal parietex withdrawn from market by the manufacturer    有  12  个tokens\n",
      "interim analysis of the data was not supportive of continuing the study    有  13  个tokens\n",
      "staffing for study was eliminated    有  6  个tokens\n",
      "registered and published incorrectly    有  4  个tokens\n",
      "futile    有  3  个tokens\n",
      "paused for interim analysis and consideration of protocol changes    有  9  个tokens\n",
      "insufficient staffing    有  3  个tokens\n",
      "due to required changes in methods    有  6  个tokens\n",
      "analysis of first 10 participants showed the technique was not efficacious    有  13  个tokens\n",
      "study considered futile    有  3  个tokens\n",
      "pi confirmed that this not a clinical trial and was inadvertently entered in the system    有  15  个tokens\n",
      "competing study was opened by the surgeon after this trial was opened    有  13  个tokens\n",
      "bankruptcy app owner    有  4  个tokens\n",
      "change in study design and sponsor    有  6  个tokens\n",
      "fda released fresenius kabi from this post marketing requirement on 07/16/2019    有  21  个tokens\n",
      "insufficient recrutement in the study    有  8  个tokens\n",
      "need more time to optimize the sensor    有  7  个tokens\n",
      "at sponsor's discretion : the purpose of study is no longer maintained    有  13  个tokens\n",
      "poor available resources to complete study    有  7  个tokens\n",
      "study director job transfer in another departement    有  8  个tokens\n",
      "techincal reasons    有  4  个tokens\n",
      "access to the devices was halted by the sponsor    有  9  个tokens\n",
      "pi decided to not proceed with study    有  7  个tokens\n",
      "the study was terminated due to logistical reasons    有  8  个tokens\n",
      "because of the difficulty of research operation, we changed to another research design    有  14  个tokens\n",
      "sponsor has discontinued the development of emricasan    有  9  个tokens\n",
      "a device would have had to be maintained. the maintenance company is insolvent; both another maintenance company and another serviced device were not available    有  27  个tokens\n",
      "investigator decided not to proceed in australia at this stage    有  11  个tokens\n",
      "risk-benefit analysis    有  4  个tokens\n",
      "gs-9131 did not meet the targeted antiviral response    有  13  个tokens\n",
      "unable to execute internal logistics    有  5  个tokens\n",
      "corporate decision to terminate study after lead-in portion of the study completed    有  14  个tokens\n",
      "protocol amendment pending    有  3  个tokens\n",
      "difficulty in setting up the study in the investigator site    有  10  个tokens\n",
      "the therapeutic effect was not as expected    有  7  个tokens\n",
      "seeking research grant support    有  5  个tokens\n",
      "the principal investigator decide to stop the sudy    有  9  个tokens\n",
      "short of euqitments    有  6  个tokens\n",
      "our center had adopted a new detection method for anti-pla2r antibodies in all membranous nephropathy patients    有  24  个tokens\n",
      "sponosor's decision    有  6  个tokens\n",
      "alternative data published    有  3  个tokens\n",
      "phd student stopped working on this project    有  8  个tokens\n",
      "study was not accruing    有  5  个tokens\n",
      "the study was withdrawn because of too few eligible participants    有  10  个tokens\n",
      "study drug is now commercially available in tablet format    有  9  个tokens\n",
      "change in investigational drug service policies resulting in the need to change the operational design of the overall protocol    有  20  个tokens\n",
      "this feasibility study only accrued one patient since site activation. we believe that the primary reason for this is poor patient motivation to go on study and wear the device. we attempted to broaden this study to partner sites without success    有  43  个tokens\n",
      "extended study timelines and additional budget could no longer be supported    有  11  个tokens\n",
      "interim analysis provided enough data    有  6  个tokens\n",
      "on completion of part 1 it was felt that there would be no benefit in completing part 2    有  20  个tokens\n",
      "due to staff departure, study is being discontinued per allocation of resources    有  13  个tokens\n",
      "contractual issues have halted study set up    有  8  个tokens\n",
      "the post graduated student change her project    有  7  个tokens\n",
      "funder and imp manufacturer withdrew support    有  7  个tokens\n",
      "poor interest in pool of potential participants    有  8  个tokens\n",
      "per amgen regulatory and study team, the study can move forward with the close out activities for the pk study since all ongoing subjects have completed based    有  29  个tokens\n",
      "due to changing methodology of the study    有  7  个tokens\n",
      "encountered technical issues with blood plasma samples received from the hospital    有  13  个tokens\n",
      "pi moved to another institution and closed the study    有  9  个tokens\n",
      "pi changed subspecialties and no longer had access to main study population    有  14  个tokens\n",
      "the study was terminated prematurely due to fudr production halt in china    有  14  个tokens\n",
      "study drug not available in time    有  6  个tokens\n",
      "never irb approved, no intention to proceed with the study    有  12  个tokens\n",
      "sponsor chose to change the study design    有  7  个tokens\n",
      "delay during study initiation. change of mitraclip design in meantime    有  13  个tokens\n",
      "the clinical trial is terminated after the completion of phase i without moving to phase ii    有  16  个tokens\n",
      "mutual termination    有  3  个tokens\n",
      "reduction in available resources    有  5  个tokens\n",
      "decision made to develop different intervention    有  6  个tokens\n",
      "pi obtained outside employment that was not compatible with this award    有  11  个tokens\n",
      "insufficient resources to complete study requirements    有  7  个tokens\n",
      "rybelsus® was not launched in germany during the planned duration of nn9924-4540 study    有  22  个tokens\n",
      "unrealizable wishes of national authorities    有  7  个tokens\n",
      "no patient ongoing (none completed the study). changes to the viral vector ongoing    有  15  个tokens\n",
      "pi was unable to continue to gather data during the trip during to medical illness    有  15  个tokens\n",
      "the study is on-hold until updated device to be released to the market    有  15  个tokens\n",
      "trial not started; change in sponsor, a new trial to be registered by the new sponsor    有  18  个tokens\n",
      "significative difference between percentage of renal response (primary outcome) between the two study arms    有  18  个tokens\n",
      "the study stoped becaus it did not even start no willing from our colleagues    有  17  个tokens\n",
      "due to cart processing facility construction    有  6  个tokens\n",
      "a change in sponsor's developmental strategy    有  7  个tokens\n",
      "study lost access to ecgi    有  6  个tokens\n",
      "difficulties to sign a contract with the hospital, due to logistic changes in the hospital    有  18  个tokens\n",
      "unable to quantify caffeine    有  4  个tokens\n",
      "unable to use manometry lab    有  6  个tokens\n",
      "the study interest was reached    有  5  个tokens\n",
      "funds for the study expired    有  6  个tokens\n",
      "this study was terminated early because of shortage of supplies with no foreseeable future of when they will be back in stock    有  22  个tokens\n",
      "two step study, step two was not feasible based on results from phase one    有  15  个tokens\n",
      "change of company's priority; learning from a separate ct-101-cls-001 (nct04857515) is deemed sufficient    有  27  个tokens\n",
      "bioinceptdecided not to pursue this drug target at this time    有  14  个tokens\n",
      "bioincept changed the focus of future drug development    有  10  个tokens\n",
      "the study team experienced technology challenges with the digital platform used to deliver the intervention and to collect data. data collection surveys would be automatically sent to participants before participants completed intervention modules    有  34  个tokens\n",
      "service provider challenges precluded intervention delivery    有  7  个tokens\n",
      "given the design of the study, we reached saturation with a sample of 16    有  16  个tokens\n",
      "the sponsor decided not to continue the study based on the overall company strategy in aml    有  17  个tokens\n",
      "study could not be run for logistical reasons    有  8  个tokens\n",
      "to optimize device    有  3  个tokens\n",
      "nda #210565 did not trigger the need for a pediatric research equity act study    有  16  个tokens\n",
      "due to thrombosis    有  5  个tokens\n",
      "parent study (nct05121480) did not meet the primary endpoint    有  15  个tokens\n",
      "fda withdrew eua for azd7442    有  10  个tokens\n",
      "excessive dropout    有  3  个tokens\n",
      "no eligible participants identified    有  4  个tokens\n",
      "pi, dr. josh gaston, left the institution and the study has been stopped    有  18  个tokens\n",
      "fda contingencies unresolved    有  5  个tokens\n",
      "after interim statistical analysis, a statistician reccommended to stop study, because results are significant and in favour of poc approach    有  26  个tokens\n",
      "fda released allergan from this post marketing requirement    有  10  个tokens\n",
      "interim analysis proved that protocol intervention had no preventive effect    有  11  个tokens\n",
      "due to the fact that the sponsor decided not to move forward with the development of m7824    有  19  个tokens\n",
      "dissolution of the research team    有  7  个tokens\n",
      "study halted prematurely    有  3  个tokens\n",
      "per regulatory coordinator, the sponsor is no longer supporting the study    有  12  个tokens\n",
      "study was terminated by the irb due to continued noncompliance    有  13  个tokens\n",
      "program reprioritization    有  5  个tokens\n",
      "resident working on this study left our department    有  8  个tokens\n",
      "pilot data suggested the paradigm would need significant revision    有  10  个tokens\n",
      "the paclitaxel-albumin halt production    有  11  个tokens\n",
      "12-month assessment process has been stopped prematurely due to logistic reasons    有  12  个tokens\n",
      "researchers go abroad to study    有  6  个tokens\n",
      "the trial was terminated as the participant withdrew from the trial    有  11  个tokens\n",
      "study halted permanently and will not resume; participants are no longer being examined or receiving intervention    有  17  个tokens\n",
      "feasibility objectives were obtained    有  5  个tokens\n",
      "pi accepted a position at a new institution and terminated the study at uic    有  15  个tokens\n",
      "injection site reaction burden    有  5  个tokens\n",
      "study never started up at site    有  6  个tokens\n",
      "sponsor has suspended study to conserve capital for clinical development of lead asset    有  13  个tokens\n",
      "budgetary constraints    有  3  个tokens\n",
      "delays in irb approval and interval start of a competing study    有  13  个tokens\n",
      "supply issues from sponsor    有  4  个tokens\n",
      "software update needed    有  3  个tokens\n",
      "novartis has chosen to withdraw support for this trial    有  11  个tokens\n",
      "due to a strategic reprioritization based on the rapidly changing clinical and commercial landscape for bruton's tyrosine kinase inhibitors (btk inhibitors)    有  31  个tokens\n",
      "site decided not to continue    有  5  个tokens\n",
      "trial may move forward as an nci-sponsored trial and not an investigator initiated trial    有  16  个tokens\n",
      "key study team members working on the study are leaving the institution    有  12  个tokens\n",
      "result summarized and published    有  4  个tokens\n",
      "sponsor shift in focus    有  4  个tokens\n",
      "the biopsies in the first 5 screened patients were all negative for globo-h, of which positive is required to include the patients    有  28  个tokens\n",
      "study aborted    有  2  个tokens\n",
      "with the pandemic, we needed to take a 15 month pause in between earlier rcts. this rct no longer made sense to conduct    有  28  个tokens\n",
      "did not have time to complete this study    有  8  个tokens\n",
      "principal investigator (dr. peiris) is retiring    有  10  个tokens\n",
      "only 5 caregivers decided to participate    有  7  个tokens\n",
      "institutional conflict of interest    有  5  个tokens\n",
      "change in study design to quality improvement    有  7  个tokens\n",
      "withdrawn-was not approved by irb    有  9  个tokens\n",
      "budgetary and timing constraints    有  5  个tokens\n",
      "change in procedure means limited value for study question    有  9  个tokens\n",
      "because bone osteointegration is completed    有  7  个tokens\n",
      "terms could not be met with the fda    有  9  个tokens\n",
      "the study was not deemed feasible to conduct    有  8  个tokens\n",
      "decision not to proceed with study    有  6  个tokens\n",
      "abandoned research    有  3  个tokens\n",
      "additional in-house analysis and development    有  6  个tokens\n",
      "study terminated by pharmaceutical company    有  5  个tokens\n",
      "sponsor withdrawing the subject ind    有  5  个tokens\n",
      "laboratory ungal    有  5  个tokens\n",
      "on 12/16/19, a termination request was sent to cms to end kentucky health by the new administration    有  25  个tokens\n",
      "based on idmc's recommendations during the interim analysis\"the trial has reached the goal of early termination of the trial\". the sponsor communicating with cde, cde agreed to unblind the trial and submit a nda    有  44  个tokens\n",
      "temporary protocol lapse    有  3  个tokens\n",
      "this study was terminated due to the released lenses not representing what will be made commercially available and thus the objectives could not be met    有  25  个tokens\n",
      "organisation issues    有  2  个tokens\n",
      "study originally suspended pending a protocol amendment but study now terminated    有  11  个tokens\n",
      "study protocol under revision    有  4  个tokens\n",
      "study stopped due to change in strategy    有  7  个tokens\n",
      "the clinical investigation improve-2 has been closed after a decision by the swedish medical products agency    有  19  个tokens\n",
      "the study was stopped as per ema waiver granted on 20july2018    有  17  个tokens\n",
      "study halted according to the sponsor's descision    有  9  个tokens\n",
      "this trial will open as an nctn trial    有  10  个tokens\n",
      "ec withdrawal with termination of the nb contract    有  8  个tokens\n",
      "the number of subjects in this study was overestimated in the initial assessment    有  14  个tokens\n",
      "unexpected histological findings    有  4  个tokens\n",
      "stopped after interim analysis    有  4  个tokens\n",
      "due to personnel and organizational issues    有  6  个tokens\n",
      "limited clinical capacity    有  3  个tokens\n",
      "ind inactive status    有  3  个tokens\n",
      "the study was terminated based on its primary and secondary outcome measures in three consecutive patients    有  16  个tokens\n",
      "study medication could not be delivered by manufacturer    有  8  个tokens\n",
      "because of the health crisis, organizational constraints and the poor medical and paramedical staff    有  17  个tokens\n",
      "project was never initiated    有  4  个tokens\n",
      "dose-escalation was finished, but no clear correlation between fluorescence and tumor grade was established    有  19  个tokens\n",
      "company prioritization reasons    有  4  个tokens\n",
      "study is temporarily suspended pending a new ind application being requested by the fda    有  15  个tokens\n",
      "terminated due to poor alignment during regulatory negotiations    有  8  个tokens\n",
      "termination of project    有  3  个tokens\n",
      "both study pi's left the institution    有  7  个tokens\n",
      "similar study just got done    有  5  个tokens\n",
      "parallel iw-3718 phase iii trial did not meet pre-specified criteria    有  15  个tokens\n",
      "the primary evalution criteria had a so few occurrence that it has been a fundamental obstacle to randomize patient. the use of mecanical aide to cough is more widly employ, creating a second limitation    有  41  个tokens\n",
      "outdated, progress in clinical practice    有  7  个tokens\n",
      "device problem and pandemic restrictions    有  5  个tokens\n",
      "end of support    有  3  个tokens\n",
      "based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for rta 402 for diabetic kidney disease    有  31  个tokens\n",
      "no longer pursuing development of serlopitant    有  8  个tokens\n",
      "premature discontinuation of study, a strategic decision    有  11  个tokens\n",
      "overload costs    有  3  个tokens\n",
      "the study protocol was changed because of too few eligible participants. a registration with revised protocol can be found by clinicaltrials.gov id nct03681054    有  31  个tokens\n",
      "competing trial on same population    有  6  个tokens\n",
      "poor eligible subjects, poor staffing    有  7  个tokens\n",
      "ran out of money    有  4  个tokens\n",
      "company's strategic decision    有  4  个tokens\n",
      "a correction needs to be made to the device's algorithm    有  11  个tokens\n",
      "loss of research capable staff    有  5  个tokens\n",
      "study stopped due to technical reasons    有  6  个tokens\n",
      "commercial reason    有  2  个tokens\n",
      "elected not to proceed with the study    有  8  个tokens\n",
      "given the updated precautions on elmiron as well as the risk benefit profile, we have decided to terminate the study    有  22  个tokens\n",
      "withdrawn by drug manufacturer    有  5  个tokens\n",
      "terminated due to reprioritization    有  7  个tokens\n",
      "expiration of study product; end of study product availability    有  10  个tokens\n",
      "access to speedlyte product no longer available    有  9  个tokens\n",
      "tested mr sequence was inferior in preliminary evaluation    有  8  个tokens\n",
      "insufficient investigational product    有  5  个tokens\n",
      "prematurely stopped in agreement with authorities (fda)    有  13  个tokens\n",
      "the study met a pre-defined protocol study stopping criteria    有  10  个tokens\n",
      "due to coronavirus infection decrease in elective case list , also poor response from other centers    有  16  个tokens\n",
      "study halted prematurely by sponsor and will not resume, participants are no longer being examined or receiving intervention    有  19  个tokens\n",
      "given the extensive time projected to conclude the study hypothesis, it is no longer feasible to include this study of tp-0903    有  25  个tokens\n",
      "the second study arm including radio-frequency microneedling was withdrawn due to availability of newer treatment options    有  20  个tokens\n",
      "obi-888 no longer fulfills our goal of developing cost-effective therapies for cancer patients    有  17  个tokens\n",
      "the government of tamil nadu decided not to proceed with implementation of fortified rice through the public distribution (per the original study protocol)    有  26  个tokens\n",
      "extensive changes to the watch design would be needed to produce a robust device    有  15  个tokens\n",
      "this study does not need to get a clinicaltrials number    有  12  个tokens\n",
      "barrel shaped interdental brush went out of production    有  11  个tokens\n",
      "decision not to continue to the expansion portion of the study    有  11  个tokens\n",
      "institutions issue    有  3  个tokens\n",
      "this study was stopped due to time and budgetary constraints    有  11  个tokens\n",
      "ossm-001 will not be used in this program moving forward    有  13  个tokens\n",
      "issues in supply of ip    有  5  个tokens\n",
      "adjustment of research plan    有  5  个tokens\n",
      "uacc-phx is no longer able to support the study and novartis is unable to provide drug beyond december 2019    有  26  个tokens\n",
      "the company that was contracted to conduct study specific testing was sold and new management chose to pursue interests other than cmv    有  23  个tokens\n",
      "change in medical practice on the management of the eligible population    有  11  个tokens\n",
      "design of the study device will be modified    有  8  个tokens\n",
      "preliminary analysis of data showed no significant findings    有  10  个tokens\n",
      "high sf rate (less treatment-naïve subjects & subjects with viral load <100000). reevaluation in scientific position in india after internal discussion    有  29  个tokens\n",
      "financial and method issues suggesting that study is not feasible    有  10  个tokens\n",
      "per protocol, the sponsor could terminate the study once 300 participants completed a total of 28 weeks of treatment and 100 participants completed a total of 52 weeks    有  33  个tokens\n",
      "protocol with too many constraints. long protocol    有  8  个tokens\n",
      "sponsor/pi voluntarily paused and stopped study after observing several grade 2 and grade 3 redness local reactogenicity reactions at 10e8vls injection sites    有  33  个tokens\n",
      "program has been terminated    有  4  个tokens\n",
      "electronic questionnaires not being completed in a timely manner    有  11  个tokens\n",
      "temporarily paused while the mr center develops newer study techniques. we might resume; this is not a suspension of irb approval    有  25  个tokens\n",
      "this is no longer considered a clinical trial as per the kantonial ethics committee in zurich, ch    有  21  个tokens\n",
      "terminated due to warning letters issued regarding paclitaxel    有  12  个tokens\n",
      "the parent trials did not meet the primary endpoints of reduction in motor and phonic tics    有  18  个tokens\n",
      "the decision to end the study was made for gsk portfolio reasons. no subjects were randomised into the study    有  22  个tokens\n",
      "folpooring results of the primary progression-free survival analysis from study nct02755597, company-sponsored mm studies were placed on partial clinical hold (pch). sponsor did not pursue release of the pch for this study    有  44  个tokens\n",
      "technical problem with device in study    有  6  个tokens\n",
      "veteran's affairs research and development office delays    有  10  个tokens\n",
      "insufficient resources to implement intervention    有  6  个tokens\n",
      "device review performed by sponsor    有  5  个tokens\n",
      "closure of drexel university hahnemann hospital where referring physician worked    有  14  个tokens\n",
      "investigator departed from institution    有  5  个tokens\n",
      "study may continue    有  3  个tokens\n",
      "departure of the investigator from the chu grenoble alpes    有  11  个tokens\n",
      "study personnel diverted to other activities and the study was not commenced    有  12  个tokens\n",
      "due to prohibitively high drug cost, physicians were not prescribing the drug    有  14  个tokens\n",
      "expired irb approval since 05/07/2020    有  12  个tokens\n",
      "refocusing of research priorities    有  5  个tokens\n",
      "study was closed due to poor participants    有  7  个tokens\n",
      "sponsor decided not to move forward    有  6  个tokens\n",
      "reassessing corporate priorities    有  6  个tokens\n",
      "study planned but never formally submitted to the irb    有  10  个tokens\n",
      "study never started as no longer novel    有  7  个tokens\n",
      "site is no longer participating in study    有  7  个tokens\n",
      "development of jnj-64041757 in combination with nivolumab discontinued due to poor clinical benefit observed in the phase 1b portion of the study    有  32  个tokens\n",
      "company has ceased operations    有  4  个tokens\n",
      "the reproductive medicine network was disbanded    有  7  个tokens\n",
      "study withdrawn by pi    有  4  个tokens\n",
      "contract not executed    有  3  个tokens\n",
      "samus is focusing all of their efforts in myelofibrosis on the new oral formulation of pu-h71    有  23  个tokens\n",
      "interim goals met. decision made to terminate in favor of completing the study as a second protocol in the future    有  22  个tokens\n",
      "caudal blockade no longer being used in the ors at this hospital    有  15  个tokens\n",
      "investigator no longer interested in proceeding with study    有  9  个tokens\n",
      "device needs modifications    有  3  个tokens\n",
      "withdrawal of financial support from funder    有  8  个tokens\n",
      "inability to perform the study at present time    有  9  个tokens\n",
      "pi retired and study not moving forward    有  7  个tokens\n",
      "primary investigator transferred in another hospital; ongoing pandemic;    有  10  个tokens\n",
      "cryogenesis company stopped supplying mesenchymal cells    有  10  个tokens\n",
      "the program is canceled due to company strategic reasons    有  9  个tokens\n",
      "the initial design of the novel oral appliance proved uncomfortable and thus terminated trial after three subjects    有  17  个tokens\n",
      "the study was terminated due to takeda commercial natpara recall    有  13  个tokens\n",
      "withdrawal of support of product for trial    有  8  个tokens\n",
      "product recall    有  2  个tokens\n",
      "the clinic no longer have sensory adapted environment equipment    有  9  个tokens\n",
      "early detection of the purpose of the study    有  8  个tokens\n",
      "investigators chose to discontinue the study based on interim findings    有  12  个tokens\n",
      "organizational problems, change of research priorities    有  8  个tokens\n",
      "principal investigator no longer with university    有  6  个tokens\n",
      "study no longer needed    有  4  个tokens\n",
      "the study was stopped after interim analysis indicated that overall result was not sufficient to satisfy per-protocol criteria to move forward in metastatic, castration-resistant prostate cancer (mcrpc) and non-small cell lung cancer (nsclc) cohorts    有  48  个tokens\n",
      "resource and time constraints were encountered by product manufacturer and study team    有  12  个tokens\n",
      "change to another platform in study    有  6  个tokens\n",
      "clinical workfpoor was too high    有  8  个tokens\n",
      "the sponsor decided to terminate this study in favor of development of subcutaneous administration    有  16  个tokens\n",
      "the cypress-1 trial was closed early after the planned primary analysis because the risk benefit ratio is unfavorable    有  21  个tokens\n",
      "study not feasible. acceptance rate was too poor    有  9  个tokens\n",
      "the cypress-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable    有  21  个tokens\n",
      "early termination due to manufacturer discontinued supplying the product for the study    有  12  个tokens\n",
      "this is not a clinical trial and is only a retrospective chart review. this was inadvertently entered into the system as a clinical trial    有  25  个tokens\n",
      "study design flaws; research design needed to be reconfigured    有  11  个tokens\n",
      "poor availability of the needed kits    有  7  个tokens\n",
      "fultility    有  3  个tokens\n",
      "there was not enough manpower to complete the study    有  9  个tokens\n",
      "ind has been closed    有  4  个tokens\n",
      "pi is leaving the university of florida    有  7  个tokens\n",
      "sponsor stopped development of pevonedistat    有  9  个tokens\n",
      "the company adjusts strategy    有  4  个tokens\n",
      "the study was terminated early based on the planned interim analysis that did not meet criteria for continuation    有  18  个tokens\n",
      "the research group is too busy to do this study    有  10  个tokens\n",
      "protocol compliance and inability to support proper performance    有  8  个tokens\n",
      "saliva testing was not sensitive enough to correctly identify high risk patients    有  13  个tokens\n",
      "ce mark will not be renewed, pmcf data no longer required    有  13  个tokens\n",
      "operating company decided to stop study due to strategic realignment and budgetary reasons    有  16  个tokens\n",
      "hcv treatment expansion occurred in egypt    有  8  个tokens\n",
      "no stell cell accessed    有  5  个tokens\n",
      "study terminated early (date of study termination decision: 28 august 2020) as a result of the outcome of the pre-planned interim analysis    有  30  个tokens\n",
      "competition from other studies and initiation of a larger multi center trial    有  12  个tokens\n",
      "withdrawn due to internal reasons    有  6  个tokens\n",
      "the trial was terminated due to an out-licensing agreement after the new sponsor did not wish to continue the trial    有  23  个tokens\n",
      "poor resources, no data collected    有  7  个tokens\n",
      "preliminary results indicate no significant difference in rmt pre- and post-tacs    有  17  个tokens\n",
      "the interim data analysis shows no significant difference between groups    有  10  个tokens\n",
      "no longer clinically relevant    有  4  个tokens\n",
      "based upon overall strategic objectives within the broader intrathecal clinical development program, novartis gene therapies decided to terminate the study early    有  26  个tokens\n",
      "did not start rct due to current concerns about vaping-related lung illness    有  14  个tokens\n",
      "devices malfunctioned    有  3  个tokens\n",
      "study was terminated early    有  4  个tokens\n",
      "device evolves    有  2  个tokens\n",
      "(due to change in the post-marketing requirement to assess alirocumab during pregnancy)    有  19  个tokens\n",
      "unable to obtain fda ide approval. currently working on additional preclinical testing    有  15  个tokens\n",
      "there is no fund to support it    有  7  个tokens\n",
      "study was terminated early based on emerging data with epacadostat and pembrolizumab    有  19  个tokens\n",
      "changed to a qi project    有  5  个tokens\n",
      "change in protocol and delay in study initiation led to new study submission    有  13  个tokens\n",
      "the owner of the algorithm does not wish that this study be undertaken    有  13  个tokens\n",
      "intervention not implemented as planned    有  6  个tokens\n",
      "sponsor discontinued study on 8sep2018    有  9  个tokens\n",
      "study never started - halted by funder    有  8  个tokens\n",
      "study met study halting rules    有  6  个tokens\n",
      "study was terminated as eisai agreed to voluntarily withdraw belviq xr from us market    有  18  个tokens\n",
      "failure to achieve primary objective    有  5  个tokens\n",
      "ediary data collected not sufficient to utilize in the analysis of protocol endpoints    有  14  个tokens\n",
      "interim results suggested that the study was not adequately powered to achieve the primary endpoint: superiority in retear rate reduction in pemf treatment versus placebo    有  30  个tokens\n",
      "mycotoxin potential contamination of one lot of study drug    有  12  个tokens\n",
      "this study is being closed because it is unworkable    有  11  个tokens\n",
      "negative results in a similar study    有  6  个tokens\n",
      "no objective responses observed folpooring completion of phase 1 dose-escalation    有  16  个tokens\n",
      "central contact person ended employment    有  5  个tokens\n",
      "difficulties in including mild traumatic brain injury (mtbi) group despite an extended inclusion period of an additional 12 months    有  25  个tokens\n",
      "study early terminated based on the sponsor(manufacture)'s decision    有  13  个tokens\n",
      "due to findings in the preclinical carcinogenicity studies for vilaprisan (bay1002670)    有  22  个tokens\n",
      "significantly more resources would have been necessary to complete the study    有  12  个tokens\n",
      "study classified as out of scope by the ethics committee (not a project involving human person)    有  18  个tokens\n",
      "study not approved    有  3  个tokens\n",
      "clinical development plans and strategy for rt-100 being re-evaluated    有  14  个tokens\n",
      "due to fda constraints on the off label use of the medications we will not be able to conduct this evaluation    有  22  个tokens\n",
      "because the instruments for collecting the spi data from the monitor (s5 collector) could not be imported due to the manufacturer's problem    有  26  个tokens\n",
      "study research team disintegration    有  5  个tokens\n",
      "study suspended due to blood supply challenges. subsequently approved by fda to reopen but will not do so because of changing clinical need    有  25  个tokens\n",
      "change in commercial strategy    有  4  个tokens\n",
      "we are not performing the study and we don't plan to continue. we do not have support to complete the study    有  23  个tokens\n",
      "ended prematurely    有  2  个tokens\n",
      "the study stopped due to expiry of study drugs    有  9  个tokens\n",
      "principal investigator made aware of similar studies that have already been published    有  12  个tokens\n",
      "pre-hypertension no longer exists    有  8  个tokens\n",
      "sopnsor decision    有  5  个tokens\n",
      "sponsor decided not to initiate the study and re-evaluate the study design and concept    有  16  个tokens\n",
      "study was discontinued due to fda recommendations of the potential toxicities of the combination of drugs    有  18  个tokens\n",
      "no one consented for this study    有  7  个tokens\n",
      "study temporarily paused due to an amendment request    有  8  个tokens\n",
      "poor effect in interim analysis    有  6  个tokens\n",
      "development of current formulation has ceased    有  6  个tokens\n",
      "incomplete effect    有  3  个tokens\n",
      "study withdrawn for technical reasons    有  5  个tokens\n",
      "study overall progress behind of scheduled timeline. study was terminated early due to company decision    有  16  个tokens\n",
      "due to poor resources (insufficient personnel) and due to technical problems with measurement of primary and secondary outcomes    有  21  个tokens\n",
      "study being assessed by clinical research team    有  7  个tokens\n",
      "the study was withdrawn due to change of ownership of the study drug maralixibat. future studies of maralixibat will be posted by mirum pharmaceuticals    有  35  个tokens\n",
      "patients are not compliant to the daily logbook exercises before surgery. most will only perform once during training or maximum twice    有  23  个tokens\n",
      "change in literature to suggest at least 6 weeks of initial elimination is necessary to see decrease in eosinophil count    有  23  个tokens\n",
      "the study progress doesn't meet the sponsor's requirement    有  10  个tokens\n",
      "the double-blind primary endpoint was not met. open label extension period halted as a result    有  17  个tokens\n",
      "the trial was closed as part of the out-licensure of the drug to boston pharmaceuticals, which will continue further clinical development of lys228/bos-228    有  34  个tokens\n",
      "january 2019    有  5  个tokens\n",
      "pi has decided to terminate this study due to study supporter pulling support on this study    有  16  个tokens\n",
      "small number of utero death, mothers refused to participate    有  11  个tokens\n",
      "the sponsor decided to continue with a different design and a different protocol    有  13  个tokens\n",
      "inufficient imd supply due to manufacturing issue    有  9  个tokens\n",
      "researchers did not find participants to meet the inclusion and exclusion criteria for the testing protocols    有  17  个tokens\n",
      "difficulties in production placebo antibiotics    有  7  个tokens\n",
      "clinical hold by the fda    有  6  个tokens\n",
      "lake of efficiency and poor tolerance of endoscopic technique    有  10  个tokens\n",
      "unavailability of probe substrates    有  6  个tokens\n",
      "development of first generation device discontinued    有  6  个tokens\n",
      "combine with nct03356808    有  7  个tokens\n",
      "due to operational changes at the participating agency    有  8  个tokens\n",
      "could not work out internal logistics    有  6  个tokens\n",
      "7 patients were included in this study which aimed for 13 participants. preliminary data were sufficient for developing further study    有  22  个tokens\n",
      "unfavourable benefit:risk    有  7  个tokens\n",
      "pi has been having difficulties obtaining icg for this project    有  11  个tokens\n",
      "after completion of part 1 and prior to initiating part 2, the sponsor decided to cease developing betrixaban, prompting early study closure    有  28  个tokens\n",
      "termination of collaboration    有  3  个tokens\n",
      "as a result of change of clinical development plan    有  9  个tokens\n",
      "ethics committe decision    有  5  个tokens\n",
      "poor use of otiprio among otolaryngologists    有  13  个tokens\n",
      "discordance in contractual language and terms    有  7  个tokens\n",
      "investigator completing residency program and leaving for a new job    有  11  个tokens\n",
      "will study new t-cell construct for the same indication    有  10  个tokens\n",
      "the european medical agency granted a paediatric investigational product-specific waiver on the grounds that idelalisib is likely to be unsafe in paediatrics    有  29  个tokens\n",
      "the study was terminated by the irb and the institutional official after the moph and wcmq audits    有  21  个tokens\n",
      "we changed our plan    有  4  个tokens\n",
      "internal organizational problem and dysfunction of study material    有  8  个tokens\n",
      "stopped by sponsor    有  3  个tokens\n",
      "this is an observational project and doesn't not meet any of the four criteria required for listing on clinical trials.gov    有  22  个tokens\n",
      "the study plan is cancelled because of difficulties in the progress of the study    有  14  个tokens\n",
      "protocol changed    有  2  个tokens\n",
      "at this point, the current study in hl does not fit into clinical development and regulatory strategy    有  18  个tokens\n",
      "study drug was fda approved summer 2021    有  10  个tokens\n",
      "interim analysis indicated a change in study design to collect in vivo data    有  14  个tokens\n",
      "sponsor no longer supported this study    有  6  个tokens\n",
      "another study has been started in other country    有  8  个tokens\n",
      "due to the small sample size in flap elevation group    有  10  个tokens\n",
      "poor tolerability of fibers included in the product    有  10  个tokens\n",
      "voluntarily terminate the study since the sponsor's development strategy was adjusted    有  14  个tokens\n",
      "sponsor closed the product line    有  5  个tokens\n",
      "phase 1 studies are not performed in saudi arabia yet    有  13  个tokens\n",
      "investigational product not available    有  6  个tokens\n",
      "there was a voluntary recall from the habib eus rfa device manufacturer    有  15  个tokens\n",
      "irb process never completed    有  5  个tokens\n",
      "because of the expiration of the previous ethical approval documents    有  10  个tokens\n",
      "development strategy reasons    有  3  个tokens\n",
      "the company will design a new study    有  7  个tokens\n",
      "insufficient clinical benefit to participants at the selected recommended phase 2 (rp2d) dose in part a    有  22  个tokens\n",
      "terminated by the local irb    有  6  个tokens\n",
      "new principal investigator    有  3  个tokens\n",
      "unable to obtain equipment from sponsor to be able to proceed with the study    有  14  个tokens\n",
      "neurocatch platform became commercially available (health canada license approved) and can now be incorporated into the abi wellness program    有  23  个tokens\n",
      "retirement of faculty pi    有  5  个tokens\n",
      "changes in personnel at institution    有  5  个tokens\n",
      "study suspended and subsequently terminated due to pandemic    有  8  个tokens\n",
      "investigators prefer to pursue other studies    有  7  个tokens\n",
      "study drug unavailability    有  4  个tokens\n",
      "no longer interest / resources to start study    有  8  个tokens\n",
      "no epidemic of men c in 2019    有  9  个tokens\n",
      "interruption due to the ongoing corporate restructuring, which has resulted in the cessation of our interest in pursuing any clinical activities related to the product    有  29  个tokens\n",
      "incyte (supporter of the study) is no longer going to support the study    有  17  个tokens\n",
      "prematurely discontinued amgen decision    有  8  个tokens\n",
      "research has been discontinued - there will be no further data collection or analysis    有  14  个tokens\n",
      "the effects are not good    有  5  个tokens\n",
      "cms questions to assess patient satisfaction of pain control were removed from the hcahps survey, leaving the study without intervention assessment    有  25  个tokens\n",
      "interim analyses    有  3  个tokens\n",
      "this study does not qualify as a clinical trial under current nih guidelines    有  14  个tokens\n",
      "due to fatal occurrence (pneumonitis) attributed to one of the study drugs    有  18  个tokens\n",
      "pause for preliminary data analysis    有  5  个tokens\n",
      "secondary to medicare coverage determination    有  6  个tokens\n",
      "pi withdrawal    有  2  个tokens\n",
      "dsmb recommendation based on differing mortality in a subgroup analysis    有  11  个tokens\n",
      "study was closed after one treatment related death    有  8  个tokens\n",
      "inability to support study performance    有  6  个tokens\n",
      "ingenol mebutato discontinued in brazil    有  8  个tokens\n",
      "strategic decisions    有  3  个tokens\n",
      "apellis concluded that sufficient data were collected to meet the study objectives    有  14  个tokens\n",
      "technical limitations encountered with the remote monitoring platform    有  8  个tokens\n",
      "clincal decision based on previous results    有  8  个tokens\n",
      "unexpected culture contamination potentially due to a testing error    有  9  个tokens\n",
      "the clinical significance is little    有  5  个tokens\n",
      "have to adjust recuriting paticipants projects and have to halted the research    有  16  个tokens\n",
      "stopping rules met    有  4  个tokens\n",
      "per protocol stopping rules    有  4  个tokens\n",
      "the study has been terminated due to pending data analysis    有  10  个tokens\n",
      "due to sponsors convenience    有  4  个tokens\n",
      "alx-0171 development program was stopped    有  9  个tokens\n",
      "insufficient resources to support study    有  6  个tokens\n",
      "sponsorship for trial was halted after company acquisition    有  9  个tokens\n",
      "no study drug available. same concept with new study drug will be explored in m19tga study    有  20  个tokens\n",
      "no manpower to conduct the study further    有  7  个tokens\n",
      "we have piloted the trial and concluded not to proceed to a fullscale trial    有  16  个tokens\n",
      "study was stopped to pursue a new treatment plan with a new study    有  13  个tokens\n",
      "the study was terminated during the pandemic as data collection could not be completed any further, and personnel changes did not alpoor for completion. at the time of termination, enough data was collected for a publication, all benchmarks were met    有  46  个tokens\n",
      "study stopped early due to investigator conflict of interest    有  9  个tokens\n",
      "no anticipated benefit over available standard therapies    有  7  个tokens\n",
      "new study in planning    有  4  个tokens\n",
      "avrobio has deprioritized its fabry disease program    有  12  个tokens\n",
      "reviewing eligibility criteria    有  4  个tokens\n",
      "the surgical approach has changed    有  5  个tokens\n",
      "the sponsor stopped the study due to a change in study plans    有  12  个tokens\n",
      "interrim analysis showed no effect or a tendency towards poorer out come in the prevena group    有  20  个tokens\n",
      "drug cannot be produced and scanner down    有  7  个tokens\n",
      "principal investigator elected to end the study    有  7  个tokens\n",
      "the sponser doesn't fund any more    有  9  个tokens\n",
      "could not perform accurate measures due to equipment and sensor issues    有  11  个tokens\n",
      "principal investigator transition    有  3  个tokens\n",
      "after 5 patients, realized that the standard deviation of the measurements in real life was higher than the calculated difference    有  22  个tokens\n",
      "on hold due to pandemic    有  5  个tokens\n",
      "the study was terminated because the pre-specified study stopping criterion has been met    有  15  个tokens\n",
      "sponsor of trial decision    有  4  个tokens\n",
      "the results of the primary endpoints of this study are expected to be difficult to identify, thus canceling the study to readjust the study plan    有  28  个tokens\n",
      "poor novelty of study    有  5  个tokens\n",
      "this trial has undergone a prespecified interim analysis which determined that this treatment provides no statistically significant delay in the onset of abnormal glucose tolerance or type 1 diabetes    有  31  个tokens\n",
      "the research group cannot found time to do the project    有  10  个tokens\n",
      "sponsor left the hospital    有  4  个tokens\n",
      "a respiratory depression in remifentanyl group    有  8  个tokens\n",
      "can't get enough participant    有  5  个tokens\n",
      "another design of protocole is submitted for approuval before the start date    有  16  个tokens\n",
      "hopkins failed to review contract with company providing complimentary dha, support was withdrawn necessitating me to get more grant money to fund study which was unsucccessful    有  33  个tokens\n",
      "terminated after achievement of mtd, without progressing to cohort expansion for company decision    有  15  个tokens\n",
      "poor sufficient clinical benefit    有  5  个tokens\n",
      "terminated by mutual agreement between the site and sponsor    有  9  个tokens\n",
      "the sample size should be re-calculated based on the first 28 cases    有  15  个tokens\n",
      "change in focus by the company    有  6  个tokens\n",
      "the sample size should be re-calculated based on the first 20 cases    有  15  个tokens\n",
      "interim analysis, closed for additional product development    有  9  个tokens\n",
      "the study stopped due to major feasibility issues and the notices was expired    有  13  个tokens\n",
      "study timing was poor    有  4  个tokens\n",
      "equipment recall    有  2  个tokens\n",
      "equipments and staff are unavailable    有  6  个tokens\n",
      "additional outcome measures have been developed and added to the protocol    有  11  个tokens\n",
      "health canada no longer alpoored use of bmac    有  11  个tokens\n",
      "results already published by another team    有  6  个tokens\n",
      "tecentriq label restriction for first line limited the patient population and scientific question could not be answered in an appropriate time    有  24  个tokens\n",
      "pandemic response invalidated long-term outcome data collection    有  10  个tokens\n",
      "the scientific questions proposed remain relevant, but will now be addressed in a larger phase ii immunogenicity trial of the chadox1 mers vaccine given at 2 doses    有  34  个tokens\n",
      "investigator decision in accordance with the promotor    有  9  个tokens\n",
      "combine with another trial    有  4  个tokens\n",
      "insufficient study personnel    有  4  个tokens\n",
      "expiry of study medication    有  4  个tokens\n",
      "sample size can not be obtained at this site    有  9  个tokens\n",
      "recent fda approval of a new drug for the same patient population    有  13  个tokens\n",
      "terminated folpooring the completion of impact-24b study    有  12  个tokens\n",
      "study not begun due to continued laboratory work on the feasibility of outcome measures    有  14  个tokens\n",
      "this study was dependent on an it interoperability component requiring additional development    有  13  个tokens\n",
      "feasibility is being questioned    有  5  个tokens\n",
      "no response to ec questions were given    有  7  个tokens\n",
      "investigators decided not to move forward with study    有  9  个tokens\n",
      "change of direction    有  3  个tokens\n",
      "change sites    有  2  个tokens\n",
      "due to a reduction in surgical wait times, there was insufficient time to complete the intervention prior to surgery    有  20  个tokens\n",
      "investigators have decided not to continue with the study    有  10  个tokens\n",
      "sponsor has terminated trial to pursue other targets    有  8  个tokens\n",
      "study is in the process of changing institutions, and is currently being held until the process of transferring institutions, including all regulatory steps is completed    有  27  个tokens\n",
      "the production of the device was stopped due to economic reasons. basic post-market surveillance activities will be continued    有  20  个tokens\n",
      "sponsor no longer providing drug    有  5  个tokens\n",
      "the study was closed as the data received to date did not support continuation of the study    有  17  个tokens\n",
      "overall re-assessment of study design    有  7  个tokens\n",
      "the study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma was stopped due to poor survival benefit    有  31  个tokens\n",
      "the treatment landscape for nsclc has evolved in the past year. an additional nsclc arm will be added to the iov-com-202 study using til + pembrolizumab    有  36  个tokens\n",
      "pi no longer in practice    有  5  个tokens\n",
      "the product company withdrawn interest in participation in this study    有  10  个tokens\n",
      "i changed my phd thesis    有  6  个tokens\n",
      "manufacturer changed focus to cell therapy    有  6  个tokens\n",
      "withdrawn due to company interest and development of alternative devices for epilepsy    有  13  个tokens\n",
      "many study exits (many deaths, aggravations) that we had anticipated (but not enough). the patients did not stay long enough in the department to complete the protocol (many study exits that we had not anticipated)    有  43  个tokens\n",
      "irb request irb request    有  6  个tokens\n",
      "wound dehiscence on tissue adhesive side of 1 wound which developed an infection    有  18  个tokens\n",
      "due to complications    有  3  个tokens\n",
      "the trial was terminated for strategic reasons folpooring the emergence of new data    有  15  个tokens\n",
      "merged irb created    有  4  个tokens\n",
      "final study report has been completed and submitted    有  8  个tokens\n",
      "further software development is required    有  6  个tokens\n",
      "technical problems with poc    有  4  个tokens\n",
      "study ended after review    有  4  个tokens\n",
      "sponsor's consideration of product development strategies    有  7  个tokens\n",
      "study withdrawn until time and staff alpoor its completion    有  11  个tokens\n",
      "due to the company's project adjustment, decided to stop this study    有  13  个tokens\n",
      "trial will not proceed due to changes in the treatment landscape    有  11  个tokens\n",
      "investigator moved from institution    有  5  个tokens\n",
      "study withdrawn and being modified under another protocol    有  8  个tokens\n",
      "financial causes, and the study will be continued within days    有  11  个tokens\n",
      "the study has been stopped due to technical difficulties    有  9  个tokens\n",
      "no research resources to complete study    有  6  个tokens\n",
      "advice from dsmb    有  5  个tokens\n",
      "we use this data as a pilot study    有  8  个tokens\n",
      "we opened another study    有  4  个tokens\n",
      "withdrawal requested by d3    有  6  个tokens\n",
      "poor time currently    有  4  个tokens\n",
      "study terminated by sponsor due to bad risk/benefit ratio    有  11  个tokens\n",
      "study stopped due to pivot in company clinical strategy    有  9  个tokens\n",
      "capacity shortage    有  2  个tokens\n",
      "alternate development strategy    有  3  个tokens\n",
      "organizationally not yet possible    有  5  个tokens\n",
      "collection of long term lead performance is being transferred to an alternate data collection methodology    有  15  个tokens\n",
      "principal investigator has left study site    有  6  个tokens\n",
      "the primary objective of the protocol was to alpoor ongoing access to treatment of patients suffering from moderate to severe heart failure at selected investigational sites until the pma was approved by the fda for the optimizer system    有  43  个tokens\n",
      "change in concept    有  3  个tokens\n",
      "emerging data demonstrates challenge for exs21546 to reach suitable therapeutic index    有  15  个tokens\n",
      "this study was closed earlier than planned because of poor research staff    有  12  个tokens\n",
      "change strategy    有  2  个tokens\n",
      "staffing change    有  3  个tokens\n",
      "problems of the mst device    有  6  个tokens\n",
      "new data available in public domain requires re-evaluation of protocol    有  12  个tokens\n",
      "decision not to move forward with study    有  7  个tokens\n",
      "we have decided not to test the newly designed tens device    有  11  个tokens\n",
      "screening survey data was not correctly collected; study halted prematurely    有  12  个tokens\n",
      "study complete    有  2  个tokens\n",
      "the decision to stop the study was made by the sponsor, based solely on timeline constraints    有  17  个tokens\n",
      "unable to achieve device(s) which will be used in this study    有  13  个tokens\n",
      "company assets being sold    有  4  个tokens\n",
      "study drug supply expired and could not be renewed    有  9  个tokens\n",
      "sponsor strategic decision based on preliminary results    有  7  个tokens\n",
      "the standard of care for the patient population changed and we were unable to accrue any longer    有  18  个tokens\n",
      "the reason was the fact that the study was not clinically feasible    有  12  个tokens\n",
      "the acquisition sequence was incompatible with mri hardware    有  9  个tokens\n",
      "difficulties experienced in identifying participants who meet the eligibility criteria of the trial    有  15  个tokens\n",
      "the manufacturing company of the raindrop corneal inlay has stopped distribution or sales of the product    有  20  个tokens\n",
      "it was considered by the sponsor that the study objective has been met by dosing 13 instead of 15 patients    有  23  个tokens\n",
      "principal investigator resigned and closed program    有  6  个tokens\n",
      "the study was stopped due to a change in delivery room practices    有  12  个tokens\n",
      "primary investigator no longer with institution    有  6  个tokens\n",
      "investigator moved locations    有  4  个tokens\n",
      "based some additional data, we have decided to hold off this trial for now and will not be proceeding with this particular trial    有  24  个tokens\n",
      "the protocol will be discussed and consulted. potentially will resume    有  11  个tokens\n",
      "treatment now available commercially    有  5  个tokens\n",
      "protocol being reconsidered    有  4  个tokens\n",
      "needed additional support    有  3  个tokens\n",
      "could not acquire data    有  4  个tokens\n",
      "difficulties identifying subjects who were qualified to participate in the study    有  13  个tokens\n",
      "early completed - alternative source of drug available    有  8  个tokens\n",
      "insufficient tumor-to-background ratios in the first three dose groups    有  12  个tokens\n",
      "prior to its planned completion as anticipated by the protocol due to poor resources    有  14  个tokens\n",
      "practical circumstances making it not possible to finish the study    有  11  个tokens\n",
      "significant and complex challenges had since been identified during recent testing phases. after their assessment, ipsendecided to discontinue development of this motorized device in order to not burden participants    有  35  个tokens\n",
      "the necessary ethical approvals were not obtained in a timely manner    有  11  个tokens\n",
      "study data is currently under review    有  6  个tokens\n",
      "due to the heterogeneity in the first group    有  9  个tokens\n",
      "the data that would be generated is no longer clinically novel    有  11  个tokens\n",
      "we are doing a clinical study of baritinib in neuromyelitis optica spectrum disorders, similar to this one, so the study was withdrawn    有  31  个tokens\n",
      "this protocol was re-written and resubmitted under a different trial number again (nct02980419)    有  22  个tokens\n",
      "insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to participants with prodromal ad as defined by study protocol    有  28  个tokens\n",
      "no relevant data    有  3  个tokens\n",
      "study product will not be commercialized    有  7  个tokens\n",
      "comparator was not available in the planned setting    有  9  个tokens\n",
      "the ut irb determined that cbd oil is being used as a drug as defined by the fda. therefore, an ind must be obtained for the use of cbd oil in this research study in accordance with fda regulations, 21 cfr 312    有  51  个tokens\n",
      "study stopped due to similar case control study already completed    有  10  个tokens\n",
      "analysis after 20 patients was convincing for a negative result for the primary outcome, so the study was stopped    有  21  个tokens\n",
      "sponsor and principal investigator decision    有  5  个tokens\n",
      "no ind submitted to the fda    有  7  个tokens\n",
      "the study was canceled because the cost of the tests requested by the turkish medicines and medical devices agency exceeded the project budget    有  24  个tokens\n",
      "protocol adjustment    有  2  个tokens\n",
      "therapy shown effective by larger studies    有  6  个tokens\n",
      "the device did not work well enough in its current form to continue the study    有  15  个tokens\n",
      "lfg316, had been studied in seven patients with transplantation-associated microangiopathy. due to poor confidence of clinical benefit, this study was closed    有  29  个tokens\n",
      "sponsor decided to prematurely terminate the study and not to pursue marketing approval for the indication of malignant glioma    有  20  个tokens\n",
      "the primary investigator was transferred to another hospital    有  8  个tokens\n",
      "this study involves the use of laser fibers but our original manufacturer has discontinued their marketing of product for prostate tissue (instead focusing on b    有  26  个tokens\n",
      "no staff available to do the research    有  7  个tokens\n",
      "discontinuation of development for this indication    有  8  个tokens\n",
      "study objectives have been met    有  5  个tokens\n",
      "attending physician left network    有  5  个tokens\n",
      "there was a software server issue. investigators were no longer able to sign patients up to the software program    有  20  个tokens\n",
      "due to tolerability issues related to the dose titration, unexpected withdrawals were observed and it was unlikely for the trial to meet its objectives    有  27  个tokens\n",
      "due to resource problems in the clinic at university hospital odense    有  11  个tokens\n",
      "poor available resources needed to conduct study    有  8  个tokens\n",
      "due to personnel changes / departure of dr. chi    有  10  个tokens\n",
      "this infrastructure project has been taken over by another study    有  10  个tokens\n",
      "pi is no longer with the institution    有  7  个tokens\n",
      "consensus raft-lvendo steering committee to terminate    有  10  个tokens\n",
      "pilot feasibility study completed    有  5  个tokens\n",
      "full clinical hold from fda    有  6  个tokens\n",
      "change protocol to include multiple sites    有  6  个tokens\n",
      "hydrotherapy pool has closed    有  5  个tokens\n",
      "boehringer ingelheim is discontinuing their volasertib development program    有  16  个tokens\n",
      "study performer moved away    有  4  个tokens\n",
      "a larger study collecting the same outcomes is currently being conducted by the study team    有  15  个tokens\n",
      "per pis request    有  3  个tokens\n",
      "end date of epidemic    有  4  个tokens\n",
      "institutional implementation of a same day discharge pathway    有  9  个tokens\n",
      "ultrasound vendor cannot support the study    有  7  个tokens\n",
      "fda placed on partial hold due to additional data    有  10  个tokens\n",
      "the princcipal investigator went abroad    有  8  个tokens\n",
      "decided not to pursue study    有  6  个tokens\n",
      "app stopped development before minimum viable product created    有  8  个tokens\n",
      "the randomization to the observational arm of the trial was no longer ethical    有  14  个tokens\n",
      "folpooring the non-renewal of the loan agreement for the medical device    有  16  个tokens\n",
      "problem with drug supply    有  4  个tokens\n",
      "no ind serial #    有  4  个tokens\n",
      "change in study design to be a pilot with no randomization to intervention/control    有  15  个tokens\n",
      "phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (pghd) did not meet its primary endpoint of non-inferiority    有  31  个tokens\n",
      "the overall benefit risk profile of ocrelizumab was not favorable in ra    有  17  个tokens\n",
      "doctoral students on project defended their thesis    有  8  个tokens\n",
      "no more possibly to include subjects (subject unavailability)    有  11  个tokens\n",
      "study did not meet first stage requirements of interim analysis    有  10  个tokens\n",
      "the rp2d for intratumoral injection was determined. with the changing practice of medicine for hcc, it was decided to design an independent phase ii clinical study    有  33  个tokens\n",
      "investigator decision based on new device information    有  8  个tokens\n",
      "poor substantial evidence for immune responses in response to vaccination    有  11  个tokens\n",
      "recommended by dsmb    有  4  个tokens\n",
      "ethical approval not obtained yet as questioning the danger of providing 100% oxygen to parturients    有  19  个tokens\n",
      "investor initiated grant support stopped when drug was sold    有  10  个tokens\n",
      "studien skjuts på framtiden    有  9  个tokens\n",
      "change in guidelines    有  3  个tokens\n",
      "similar studies already published by other researchers    有  7  个tokens\n",
      "study was not feasible to complete at study site    有  9  个tokens\n",
      "manufacturing of the ags-004 hiv vaccine by argos could no longer be provided    有  19  个tokens\n",
      "problems with contracts    有  3  个tokens\n",
      "frontline pembrolizumab approved in nsclc as monotherapy and in combination with chemotherapy representing a new standard of care    有  25  个tokens\n",
      "poor available time    有  4  个tokens\n",
      "considering the limited clinical activity observed with ltt462, the decision was made to not open the dose expansion phase of the study    有  26  个tokens\n",
      "investigational device not available anymore    有  7  个tokens\n",
      "the study was prematurely terminated on 06 october 2016 due to the potential risk of further dosing in healthy subjects    有  25  个tokens\n",
      "study never got underway due to sponsor re-organization    有  10  个tokens\n",
      "study logistics    有  2  个tokens\n",
      "completion not feasible due to poor eligible subjects    有  8  个tokens\n",
      "study stopped for procedural difficulties and poor personnel    有  8  个tokens\n",
      "moved to new institution    有  4  个tokens\n",
      "company discontinued further development of study drug for this indication    有  10  个tokens\n",
      "the investigation was cancelled because there was no monetary resource to complete it    有  13  个tokens\n",
      "no effect of carnitine on lipid induced insulin resistance after n=8 (p=1.00)    有  22  个tokens\n",
      "insufficient support    有  3  个tokens\n",
      "variability of the pneumocephalus volume mean was higher than initially assumed    有  15  个tokens\n",
      "study closed due to positive interim results    有  7  个tokens\n",
      "dsmb recommendation of stopping the trial after reviewing the interim data    有  12  个tokens\n",
      "device is not available    有  4  个tokens\n",
      "methodological difficulties    有  3  个tokens\n",
      "decided to not proceed with study due to poor personnel    有  11  个tokens\n",
      "analysis of initial sample shows negative results    有  7  个tokens\n",
      "required revisions were unable to be made to protocol    有  9  个tokens\n",
      "the study was not started due to the sponsor choosing to not fund the trial    有  15  个tokens\n",
      "not yet submitted, unclear timelines    有  6  个tokens\n",
      "pi is closing the trial as he will be leaving the university of pittsburgh medical center    有  18  个tokens\n",
      "we has selected a new candidate vaccine which is monovalent    有  12  个tokens\n",
      "lengthy delays and inadequate support to proceed    有  8  个tokens\n",
      "commercial strategy    有  2  个tokens\n",
      "the study data to date show the required primary study endpoint will not be met    有  15  个tokens\n",
      "study is currently lapsed    有  5  个tokens\n",
      "terminated early due to sufficient data acquired to meet our study objectives    有  12  个tokens\n",
      "materials incomplete    有  2  个tokens\n",
      "the longitudinal goal could not be completed due to ct scans not being performed at baseline    有  16  个tokens\n",
      "per principal investigator request    有  4  个tokens\n",
      "financial partner providing study drug could no longer support the trial    有  11  个tokens\n",
      "study lapsed    有  3  个tokens\n",
      "company has reprioritized clinical plans to focus on later-stage studies    有  13  个tokens\n",
      "regulatory authority approval for the initial study design could not be obtained    有  13  个tokens\n",
      "poor logistic capabilities at the study site    有  8  个tokens\n",
      "a recent publication answered the study question being asked    有  9  个tokens\n",
      "drug logistics    有  2  个tokens\n",
      "this study doesn't meet nih criteria of clinical trial study    有  12  个tokens\n",
      "too few participans available    有  5  个tokens\n",
      "no college athlete availability    有  4  个tokens\n",
      "grant not received - study not started    有  7  个tokens\n",
      "placebo cannot be prepared    有  5  个tokens\n",
      "study under review. temporarily suspended    有  6  个tokens\n",
      "did not want to expose additional subjects to arterial line placement    有  11  个tokens\n",
      "insufficient amount of t cell collection    有  7  个tokens\n",
      "the protocol was modified substantially and will be resubmitted to clinical trial    有  14  个tokens\n",
      "study stopped to await new generation of device anticipated to be released 2018    有  15  个tokens\n",
      "no longer aligned with the revised clinical development plan and commercial strategy    有  12  个tokens\n",
      "competing protocol    有  3  个tokens\n",
      "the investigator has left the hospital    有  6  个tokens\n",
      "the reason was the fact that the procore needle was removed from clinical use    有  15  个tokens\n",
      "the app platform was cancelled and key personnel withdrew from the project    有  12  个tokens\n",
      "termination due to discontinuation of magrolimab development in mds    有  14  个tokens\n",
      "recent publications demonstrating the clinical interest in performing 68ga-psma for recurrence detection of prostate cancer patients with biochemical relapse    有  24  个tokens\n",
      "subjects were all in long-term folpoor up and were transferred to the ongoing eb-002 study    有  20  个tokens\n",
      "superceded by a larger trial by the pharmaceutical company    有  11  个tokens\n",
      "no linger a clinically relevant research question    有  7  个tokens\n",
      "difficulty procuring study device    有  5  个tokens\n",
      "did not have staffing to support the study    有  8  个tokens\n",
      "not feasible to reach the required number of patient cases by the defined end of data collection milestone (q4 2022) knowing that the study completion was planned by the end of 2023    有  39  个tokens\n",
      "fda alpoored other data to be leveraged to meet the study requirements    有  16  个tokens\n",
      "study suspended until new fci scanner is operational    有  9  个tokens\n",
      "ancef (cefazolin) became the new standard of care (instead of vancomycin) for gbs prophylaxis if the patient is allergic to penicillin    有  35  个tokens\n",
      "oct cost is high    有  4  个tokens\n",
      "termination of investigator initiated studies using ibrutinib    有  11  个tokens\n",
      "due to the withdrawal of gore korea co.ltd., manufacturer of medical device, it is impossible to supply the medical device(c-tag)    有  28  个tokens\n",
      "principle investigator (sylvia herbozo) left the university    有  14  个tokens\n",
      "manufacture didn't provide enough information for submitting irb approval    有  12  个tokens\n",
      "the dataset was not strong enough to do nlp analysis    有  11  个tokens\n",
      "study was dropped and never started    有  6  个tokens\n",
      "pi departed study site. study closed    有  7  个tokens\n",
      "exceed of pre-specified number of failures in the experimental arm    有  13  个tokens\n",
      "study not required due to change in device    有  8  个tokens\n",
      "results were not accurate; despite multiple efforts to troubleshoot    有  11  个tokens\n",
      "to much effort needed, high costs for an academic study    有  11  个tokens\n",
      "the trial was comprised of two parts. after the first part we could repudiate our hypothesis. thus, no reason to carry on with the second part of the trial    有  34  个tokens\n",
      "grant concluded    有  2  个tokens\n",
      "resource issue    有  2  个tokens\n",
      "the protocol will be rewritten    有  5  个tokens\n",
      "no suitable candidates    有  3  个tokens\n",
      "prostate cancer treatment has greatly changed since the initiation of this trial and therefore we have stopped this trial to alpoor for further evaluation of the treatment landscape    有  31  个tokens\n",
      "shortage in the availability on the continuous glucose monitor    有  10  个tokens\n",
      "ethical approval declined    有  3  个tokens\n",
      "decision to discontinue product development at this time    有  9  个tokens\n",
      "screened 34 participants and only 3 participants met the inclusion criteria, the study was stopped and screening data will be analyzed for associations    有  27  个tokens\n",
      "study stopped due resource interruption    有  5  个tokens\n",
      "drug delivery was bepoor target dose due to partial obstruction by aggregated particles    有  15  个tokens\n",
      "health authority request due to class effect    有  7  个tokens\n",
      "transferred study to antwerp, belgium    有  9  个tokens\n",
      "departure and non-replacement of the person in charge of the biological examinations specific to research carried out within the liryc ihu    有  26  个tokens\n",
      "two patients developed corneal laceration and hence study re-reviewed by iec and decided to terminate the study prematurely    有  24  个tokens\n",
      "change of organizational circumstances    有  4  个tokens\n",
      "mhra cta rejected due to no uk mhra ma certificate or equivalent product info    有  17  个tokens\n",
      "not enough data    有  3  个tokens\n",
      "change in resources to support study activities    有  7  个tokens\n",
      "interference with other trials on the same ward    有  9  个tokens\n",
      "the liquidation of our industrial partner neolys diagnostics, directly involved in the methodology of the study and a sub-optimal rate of inclusions which did not alpoor us to include all patient within the allotted time    有  44  个tokens\n",
      "not enough participant interest    有  4  个tokens\n",
      "changed drug approval    有  3  个tokens\n",
      "study never initiated and formally withdrawn with the irb on 9/14/2023    有  18  个tokens\n",
      "end of the inclusion period. a late start of inclusions and reduced scanner availability meant that the number of 45 participants could not be reached    有  28  个tokens\n",
      "this study is being closed due to the inability to acquire the required technology to complete the study    有  18  个tokens\n",
      "study record has been combined with nct05815173 (phase i/ii study)    有  18  个tokens\n",
      "study halted at interim analysis to alpoor the sponsor to focus on a new study with different design    有  20  个tokens\n",
      "because of dynamics in the field of minimal invasive mitral repair and the development of newer devices    有  18  个tokens\n",
      "after reviewing the feasibility and projected completion date of the study, ucb has made the decision to stop the study    有  22  个tokens\n",
      "further development of programs halted    有  6  个tokens\n",
      "no more subjects for recrutment    有  7  个tokens\n",
      "this study was determined by irb not to be humans subjects research    有  13  个tokens\n",
      "this study was merged into howto-brs study    有  10  个tokens\n",
      "change of treatment landscape and evolving standard of care    有  9  个tokens\n",
      "due to company policy, the development of this product is suspended    有  12  个tokens\n",
      "ulipristal was withdrawal from the market    有  9  个tokens\n",
      "critical study personnel left the institution    有  6  个tokens\n",
      "global recall of hemospray    有  5  个tokens\n",
      "internal problems    有  2  个tokens\n",
      "logistics of study did not alpoor for consistent data collection    有  13  个tokens\n",
      "we decided to complete our research in the 4th year, and publish the data. the data are under evaluation    有  23  个tokens\n",
      "limitaiotn of financial support    有  7  个tokens\n",
      "realization not possible    有  4  个tokens\n",
      "the study was not feasible due to logistical elements    有  9  个tokens\n",
      "futilty of the treatment    有  6  个tokens\n",
      "primary endpoint was reached    有  4  个tokens\n",
      "study put on clinical hold by fda. sponsor decided to no pursue the study    有  16  个tokens\n",
      "selumetinib launch approval achieved in advance,strategy changesa new study will be generated in place of this study    有  24  个tokens\n",
      "investigator changed jobs    有  4  个tokens\n",
      "restaurant has closed down    有  4  个tokens\n",
      "study submitted in error    有  4  个tokens\n",
      "due to permanant change of stations of investigators    有  9  个tokens\n",
      "unfortunately, deciphera management decided to not move forward with the rebastinib program and are terminating early    有  22  个tokens\n",
      "collaborator, myndtec, withdrew from the study due to poor resources    有  16  个tokens\n",
      "sponsor did not want to continue the study    有  8  个tokens\n",
      "transfer of main study team to another institution    有  8  个tokens\n",
      "to obtain clinical data in eu for ce mark    有  9  个tokens\n",
      "unable to maintain a functional laser in the environment    有  9  个tokens\n",
      "because of technical and feasibility issues with interaction, the study to investigate the system for individuals folpooring acl reconstruction was terminated    有  24  个tokens\n",
      "change in staffing structure, no longer fit original study design    有  11  个tokens\n",
      "withdrawn before irb review. investigator no longer working at facility    有  13  个tokens\n",
      "the manufacturer of sodium lactate has stopped making the medication    有  11  个tokens\n",
      "unexpected dose production issues prevented study start up    有  8  个tokens\n",
      "unproven hypothesis    有  4  个tokens\n",
      "preliminary results indicated that this test had a number of false-negative results    有  15  个tokens\n",
      "preliminary analysis of accrued data failed to indicate any meaningful pharmacodynamic response    有  15  个tokens\n",
      "due to chief investigator relocating out of the united kingdom    有  11  个tokens\n",
      "the goals of part 1 (molecular screening) were met, but poor therapies to match molecular aberrations made part 2 (treatment) no longer feasible    有  33  个tokens\n",
      "airvo 2 not suitable for co2 clearance, awaiting optifpoor thrive machine    有  18  个tokens\n",
      "since the treatment landscape for metastatic kidney cancer changed, patients were not becoming eligible for this trial and therefore, the trial was terminated    有  26  个tokens\n",
      "replaced by us rct    有  6  个tokens\n",
      "significant results (no control neither amoxicillin new arms needed)    有  13  个tokens\n",
      "the trial was withdrawn due to problems with the manufacture of the investigational drug    有  15  个tokens\n",
      "the resident graduated    有  3  个tokens\n",
      "methodological concerns about study design    有  6  个tokens\n",
      "poor recruiment    有  4  个tokens\n",
      "procedure is too demanding    有  4  个tokens\n",
      "study protocol changed    有  3  个tokens\n",
      "interim analysis showed positive results    有  6  个tokens\n",
      "pi changed the institution    有  4  个tokens\n",
      "potential participants to date all had etiological factors for their sexual dysfunction additional to the antidepressant. thus they all had exclusion criterior    有  26  个tokens\n",
      "another treatment found efficacious    有  5  个tokens\n",
      "strategic changes regarding the product development    有  7  个tokens\n",
      "terminated prematurely as data from cohort no longer needed due to indication change    有  13  个tokens\n",
      "due to health canada losartan recall, a new formulation being added to the protocol/ temporary suspension    有  20  个tokens\n",
      "loss of team members    有  4  个tokens\n",
      "the robot was no longer available to the study    有  9  个tokens\n",
      "pre-empted by another survey    有  7  个tokens\n",
      "terminated due to osimertinib approval    有  9  个tokens\n",
      "problems with grant    有  3  个tokens\n",
      "design change    有  2  个tokens\n",
      "decision by sponsor, development stopped    有  6  个tokens\n",
      "data review    有  2  个tokens\n",
      "after 2 patients it was concluded that a large change in exclusion criteria and study design was needed to obtain the ojective for the study    有  27  个tokens\n",
      "clinical trial material    有  3  个tokens\n",
      "based on fda requirements    有  5  个tokens\n",
      "study blind compromised    有  3  个tokens\n",
      "medical device defective    有  3  个tokens\n",
      "modified study and new deposit in rechmpl21_0451    有  13  个tokens\n",
      "high attrition    有  3  个tokens\n",
      "company have withdrawn the product    有  5  个tokens\n",
      "unresolved budget issues    有  4  个tokens\n",
      "decision made to stop study folpooring availability of results from another study    有  14  个tokens\n",
      "retirement of the principal investigator    有  6  个tokens\n",
      "the study protocol changed significantly and a new file was started    有  11  个tokens\n",
      "no study oversight due to changes in study personnel    有  9  个tokens\n",
      "study drug no longer being clinically developed by manufacturer    有  9  个tokens\n",
      "because of reconsideration of using erlotinib(egfr tyrosine kinase inhibitor) as adjuvant aim    有  24  个tokens\n",
      "protocol not approved    有  3  个tokens\n",
      "the sponsor has decided to stop the phase 4 study sobi.haem89-007 (join-us) due to a realignment of its development activities. the clinical trial hasn't been terminated due to a change in the benefit-risk balance    有  49  个tokens\n",
      "irb approval never received    有  5  个tokens\n",
      "no more budget for personal to enrol participants    有  8  个tokens\n",
      "study will be stopped due to the impossibility of reaching the objective of inclusions within a reasonable time frame and taking into account the recommendations of the international woman study    有  32  个tokens\n",
      "withdrawal of analysis study partner    有  6  个tokens\n",
      "failure of supply of test product    有  6  个tokens\n",
      "the study drug was not provided resulting in termination for unacceptable delays    有  12  个tokens\n",
      "intervention was inferior in pilot trial    有  7  个tokens\n",
      "the device did not provide sufficient quality of data    有  9  个tokens\n",
      "large and sustained difference in pregnancy rate    有  7  个tokens\n",
      "changes of the standard adjuvant treatment which does not alpoor an iterative picc placement    有  19  个tokens\n",
      "difficulty controlling for confounding factors    有  6  个tokens\n",
      "unknown if investigation will be conducted    有  6  个tokens\n",
      "study withdrawn - changing study design    有  6  个tokens\n",
      "today entresto treatment has marketing authorization and is available for all patients, that is the reason why study was halted prematurely    有  24  个tokens\n",
      "poor reliable supply of of preservative free iv hydromorphone for intrathecal use    有  20  个tokens\n",
      "unable to complete the sample size needed for 80% power due to changes in surgical approach to adductor block usage    有  23  个tokens\n",
      "internal reassessment of the medicinal product development strategy by sponsor    有  11  个tokens\n",
      "due to a time conflict in the research, the project research has been temporarily suspended    有  16  个tokens\n",
      "after the analysis of the main adore study it is concluded that there is no clinical benefit for the patients    有  20  个tokens\n",
      "research determined not to be human subject research    有  8  个tokens\n",
      "dmc review concluded study has a poor probability of meeting its primary endpoint    有  14  个tokens\n",
      "study has been withdrawn due to reconsideration of study design    有  11  个tokens\n",
      "data saturation was reached when health professionals began to use similar or same expressions and it was achieved with 12 health professionals    有  23  个tokens\n",
      "poor likelihood of identifying a statistically significant treatment effect    有  10  个tokens\n",
      "the developer of the bci left the institution so the study could not continue    有  15  个tokens\n",
      "clovis oncology discontinued rociletinib    有  9  个tokens\n",
      "start of the principal investigatoir    有  7  个tokens\n",
      "limited interest from colleagues/time constraints    有  6  个tokens\n",
      "due to uveitis specialist leaving our university    有  9  个tokens\n",
      "the study was closed after we determined that this albuterol/nac regimen may be associated with excessive bronchoconstriction    有  25  个tokens\n",
      "protocol not submitted to irb    有  6  个tokens\n",
      "we do not have more subjects to enter into the study    有  11  个tokens\n",
      "removing from clinicaltrials.gov as this is not really a clinical trial    有  15  个tokens\n",
      "pi decided no longer to pursue    有  6  个tokens\n",
      "at end of phase 1 excessive high pill burden (18 capsules/day)    有  15  个tokens\n",
      "clinical hold from fda    有  5  个tokens\n",
      "a competing trial was opened for patient population with combination of ribociclib and everolimus    有  19  个tokens\n",
      "focus portfolio on immune-mediated diseases    有  6  个tokens\n",
      "unable to begin study with drug provider    有  7  个tokens\n",
      "mri perfusion techniques development took longer than expected    有  10  个tokens\n",
      "sponsor elected to terminate the study prior to subject treatment    有  10  个tokens\n",
      "evidence of bad outcome after interims analysis    有  9  个tokens\n",
      "investigator has retired    有  4  个tokens\n",
      "study may not be clinically relevant at this time    有  9  个tokens\n",
      "vtl-308 failed to meet its primary endpoint, all folpoor up studies were terminated    有  19  个tokens\n",
      "due to the pandemic we decided to terminate this project    有  10  个tokens\n",
      "for some personal reasons    有  4  个tokens\n",
      "study restarted under new study number 18987    有  9  个tokens\n",
      "development not proceeding    有  3  个tokens\n",
      "insufficient quality of data collection    有  6  个tokens\n",
      "clinical hold fda    有  4  个tokens\n",
      "interim analysis resulted in reliable figures    有  7  个tokens\n",
      "not able to run research in the service. research terminated    有  11  个tokens\n",
      "uptake of drug into the tumour lesion was negligible    有  11  个tokens\n",
      "study team did not maintain irb approval    有  8  个tokens\n",
      "investigational product needs improvements    有  6  个tokens\n",
      "design was not feasible    有  4  个tokens\n",
      "protocol/consent updates    有  5  个tokens\n",
      "the study was terminated after determination of the rp2d, prior to opening expansion cohorts)    有  18  个tokens\n",
      "technical issues with the device    有  5  个tokens\n",
      "study design was inadequate and would not achieve study endpoints    有  10  个tokens\n",
      "decided to shift to a new design and measures    有  10  个tokens\n",
      "the study was withdrawn by the sponsor    有  7  个tokens\n",
      "poor support to complete    有  5  个tokens\n",
      "the protocol was redirected by the fda to another division and will be resubmitted at a future date    有  21  个tokens\n",
      "resource reallocation    有  3  个tokens\n",
      "study was postponed due to manufacturing issues    有  7  个tokens\n",
      "the study has not been stopped. the study does not qualify as a clinical trial so it was withdrawn from clinicaltrials.gov    有  25  个tokens\n",
      "interim analysis showed very poor possibility for significant differences between the two instruments    有  14  个tokens\n",
      "sample was under-powered    有  4  个tokens\n",
      "day 90 results indicate imp did not reduce mortality or ventilator free days    有  15  个tokens\n",
      "on hold for toxicitiy    有  6  个tokens\n",
      "no apparent therapeutic effects that was superior to placebo    有  9  个tokens\n",
      "principal investigator decision to stop trial    有  6  个tokens\n",
      "formulations could never be successfully produced    有  7  个tokens\n",
      "the study was not feasible to conduct    有  7  个tokens\n",
      "results of ev302 study do not make it feasible to complete a study in second line avelumab immunotherapy. the new standard of care make this study not pertinent    有  34  个tokens\n",
      "in view of outcome of relax-ahf-2 trial, the entire rlx030a project was decided to be terminated    有  25  个tokens\n",
      "the study did not meet the primary endpoint. the addition of copanlisib to standard immunochemo therapy did not improve progression-free survival compared to the control arm. base on the study results, company decided to terminate the study    有  47  个tokens\n",
      "lab close down    有  3  个tokens\n",
      "study00006987    有  4  个tokens\n",
      "we are closing this study due to the focus on other research projects and there is no time or personnel tofurther pursue the completion of this project    有  29  个tokens\n",
      "pending submission and approval of irb protocol    有  8  个tokens\n",
      "analyzing data    有  3  个tokens\n",
      "change plans and no longer testing these interventions    有  8  个tokens\n",
      "study intervention was adopted as standard of care    有  8  个tokens\n",
      "the study terminated before phase 1 was completed. this study was reprioritized within the rociletinib development program    有  24  个tokens\n",
      "due to stop bvs supply discontinuation    有  8  个tokens\n",
      "no approval    有  2  个tokens\n",
      "the study was withdrawn due to the ce mark of the device was not yet granted during the specified period    有  20  个tokens\n",
      "vendor equipment agreement expired    有  4  个tokens\n",
      "it was decided by verily leadership to not pursue the study any further    有  14  个tokens\n",
      "difficulty with contracting    有  3  个tokens\n",
      "discontinuation of development of device    有  7  个tokens\n",
      "due to inadequate supply of drug    有  6  个tokens\n",
      "change to study design    有  4  个tokens\n",
      "in june 2022, it was decided to perform an intermediate analysis to assess the benefit or harm of the intervention    有  24  个tokens\n",
      "correction of inspection findings    有  5  个tokens\n",
      "sponsor opened phase 2 study    有  6  个tokens\n",
      "the team is revising the protocol design and has chosen to put the study on hold until those changes are approved    有  22  个tokens\n",
      "decision was taken to consider other opportunities for collecting sham-controlled data for burstdr scs    有  18  个tokens\n",
      "the required data was obtained and there was no need to collect further data    有  14  个tokens\n",
      "proposed comparison (retcam vs. cosmos) was unfeasible. device is now licensed in canada    有  21  个tokens\n",
      "no approval from ec obtained. more details for study were required by ec    有  14  个tokens\n",
      "patients are receiving detailed packet from department and do not feel they need to go online for additional support    有  19  个tokens\n",
      "novartis decision based on cohort 1 results    有  10  个tokens\n",
      "the protocol turned out to be not quite suitable for most patients. apart from thomayer's hospital, 2 other centers could not cooperate. the introduction of stents continued at the thomayer hospital. publication of results is planned in 2024    有  51  个tokens\n",
      "the change of clinical development plan    有  6  个tokens\n",
      "multi phase study did not progress to phase ii. phase i registered as nct00734526    有  19  个tokens\n",
      "the study was terminated prematurely after ad-interim analysis for the primary outcome    有  14  个tokens\n",
      "the cyclotron in our hospital has a serious malfunction and can not be repaired. it will take a long time to purchase and install the new cyclotron    有  30  个tokens\n",
      "commercial distribution of the remedē system stopped by livanova    有  11  个tokens\n",
      "institutional review    有  3  个tokens\n",
      "poor time and personnel needed to complete study    有  9  个tokens\n",
      "ma of product has been withdrawn from the european market due to stability data    有  14  个tokens\n",
      "due to an error in the implementation of the project, cds was provided to all providers, rather than to the intended random sample of providers    有  27  个tokens\n",
      "data source became unavailable    有  4  个tokens\n",
      "local drug authority didn't give permission to start    有  9  个tokens\n",
      "waiting for re-calls    有  5  个tokens\n",
      "withdrawn study from irb    有  6  个tokens\n",
      "outcome of a planned interim analysis was that the sample size required to show superiority was too high to be feasible. fresenius kabi requested termination to the fda on 17 jan 2020. fda accepted termination by written response on 16 apr 2020    有  55  个tokens\n",
      "stopped prematurely    有  2  个tokens\n",
      "stopping criterion met (n. adjudicated ep1)    有  12  个tokens\n",
      "preliminar results not favorable    有  6  个tokens\n",
      "my collaborator on this study (valérie deville) is away for an extended period    有  18  个tokens\n",
      "funder terminated    有  3  个tokens\n",
      "the study stopped because after monitoring visits and data analysis we noticed a high number of protocol deviation that made impossible the results analysis    有  24  个tokens\n",
      "investigational medicinal product supplies    有  6  个tokens\n",
      "lost interest in current study    有  5  个tokens\n",
      "study never started and is on hold until further notice    有  10  个tokens\n",
      "unexpected events    有  2  个tokens\n",
      "insufficient target engagement of abt-957 (preclinical data)    有  14  个tokens\n",
      "reconsideration of study design; plan for alternative protocol    有  11  个tokens\n",
      "the failures of the culture and immunostaining techniques for aldh do not alpoor the main objective of the study to be met    有  27  个tokens\n",
      "study's primary aims are no longer clinically impactful, as intrathecal morphine has fallen out of favor and replaced with different agents so that outpatient/23 hr surgery is more predictably achievable    有  38  个tokens\n",
      "investigator decided to stop the study because it was difficult to proceed with the study    有  16  个tokens\n",
      "pi decided to focus on more current topics of interest    有  10  个tokens\n",
      "terminated, prior to its planned completion as anticipated by the protocol    有  12  个tokens\n",
      "nimh terminated study    有  4  个tokens\n",
      "abandonment of financial partners    有  6  个tokens\n",
      "expired with irb    有  4  个tokens\n",
      "suspected side effects to the combination of clarithromycin and vcd (bortezomib, cyclophosphamide and dexamethasone)    有  34  个tokens\n",
      "this was a topic for a thesis project where the topic was changed    有  13  个tokens\n",
      "pi change of institution    有  4  个tokens\n",
      "difficulty acquiring fresh tissue from mastectomy specimens    有  8  个tokens\n",
      "planned surgical procedures decreased    有  5  个tokens\n",
      "stopping rule    有  3  个tokens\n",
      "sample size was too small to evaluate the clinical implications    有  10  个tokens\n",
      "pending financial resources    有  3  个tokens\n",
      "the first phase of the research has been completed    有  9  个tokens\n",
      "2 phase 3 trials didn't meet their primary endpoint, so further development and testing of th-302 is uncertain    有  23  个tokens\n",
      "alternate research pursued    有  3  个tokens\n",
      "poor antibiotic availability    有  4  个tokens\n",
      "internal staffing issues    有  3  个tokens\n",
      "interim analysis (n=52) with significantly differences in primary outcome (los)    有  17  个tokens\n",
      "prematurely terminated based on interim study analysis    有  10  个tokens\n",
      "terminated (due to small number of ongoing patients. patients ongoing at time of termination could choose to join study d-fr-01072-004 for long term folpoor-up    有  35  个tokens\n",
      "problems for satellite centers in obtaining ethical clearance    有  8  个tokens\n",
      "trial was cancelled due to availability of clinical supplies    有  9  个tokens\n",
      "unable to obtain study agent    有  5  个tokens\n",
      "the voluntary attendance rate for intervention is poor    有  8  个tokens\n",
      "skin irritation caused by device    有  5  个tokens\n",
      "research team no longer available    有  5  个tokens\n",
      "interim analysis recommended terminating the study    有  7  个tokens\n",
      "sponsor decided not to initiate the study for alternate commercial strategy    有  11  个tokens\n",
      "the prevalence of worm infections in the site is significantly poorer than expected    有  13  个tokens\n",
      "p. i. left the institution. study never opened    有  11  个tokens\n",
      "project opened under new pi    有  5  个tokens\n",
      "the irb which was overseeing the study stopped overseeing it    有  11  个tokens\n",
      "pi made decision    有  3  个tokens\n",
      "trial was stopped after non-response to treatment    有  8  个tokens\n",
      "we could not achieve the number of participants necessary to continue with the study and limited money to continue with the study    有  22  个tokens\n",
      "dr. rahma decided to run the study through a different group    有  14  个tokens\n",
      "study medication without approval and stop of financial support    有  9  个tokens\n",
      "did not obtain ind or irb approval to initiate study    有  11  个tokens\n",
      "we can not get enough sample size    有  7  个tokens\n",
      "an alternate plan of investigation was developed    有  7  个tokens\n",
      "interim analysis showed a high likelihood of benefit in the endovascular group    有  15  个tokens\n",
      "during the unavoidable gap resulting from the global pandemic, the technologies being used in this study have significantly improved and it is no longer optimal to provide patients with the old technology when improved technology is available    有  38  个tokens\n",
      "poor participants meeting selection criteria    有  6  个tokens\n",
      "product was discontinued    有  3  个tokens\n",
      "abandoned. no resources    有  5  个tokens\n",
      "i have found it is quite difficult to conduct the work without changing some detail in original protocol. so we would like to re-start the study again with some modification    有  32  个tokens\n",
      "treatment substance not labled for sepsis anymore    有  11  个tokens\n",
      "sponsor has made decision not to conduct this clinical trial    有  10  个tokens\n",
      "pi not worining at kuh anymore    有  8  个tokens\n",
      "sponsor/investigator has decided to close out the study    有  11  个tokens\n",
      "the sponsor and hospital did not reach agreement    有  8  个tokens\n",
      "the sponsor voluntarily withdraw the project    有  6  个tokens\n",
      "in 2017, gsk2820151 was terminated due to development of another bet inhibitor (gsk525762) with a better understanding of the risk benefit profile    有  34  个tokens\n",
      "principal investigator has moved to another institution    有  7  个tokens\n",
      "this study was withdrawn due to poor necessary resources from the liver transplant surgical group    有  15  个tokens\n",
      "company stopped selling bvs/ no 5 year fup will be done    有  15  个tokens\n",
      "the shoulder brace is being revised by the producer    有  9  个tokens\n",
      "results from phase 1 lead to the decision    有  9  个tokens\n",
      "c-met marker expired    有  5  个tokens\n",
      "device approved for this use    有  5  个tokens\n",
      "intellectual property issues with drug manufacture    有  7  个tokens\n",
      "fda has placed all trials involving pacritinib on full clinical hold    有  15  个tokens\n",
      "closed early due to competing studies    有  6  个tokens\n",
      "seeking financial support    有  4  个tokens\n",
      "device was withdrawn from the market    有  6  个tokens\n",
      "close out study w/o cohort d; severe impairment (egfr=15 to <30ml/min/1.73m²)    有  27  个tokens\n",
      "less data return than expected. the new medical device regulation (mdr) implementation prompted the sponsor to set up a broader scope post-market registry for all corcym cardiovascular products (mantra)    有  39  个tokens\n",
      "the study was deferred and never approved by the maimonides medical center irb    有  17  个tokens\n",
      "unable to obtain irb approval at all sites    有  9  个tokens\n",
      "withdrawn due to poor participants    有  6  个tokens\n",
      "company acquisition    有  2  个tokens\n",
      "due to problems regarding methodology    有  5  个tokens\n",
      "the trial did not show any positive effects    有  8  个tokens\n",
      "principal investigator decided to withdraw    有  5  个tokens\n",
      "exploratory protocol, convincing results, robust analysis    有  10  个tokens\n",
      "urogen's rtgeltm delivery system technology for use with neurotoxins licensed to allergan plc before the activation of this trial    有  28  个tokens\n",
      "this study was discontinued due to an interim analysis in this study, which indicated that crenezumab was unlikely to meet its primary endpoint    有  27  个tokens\n",
      "volume resuscitation procotol has changed around 2017/2018 to less volume/more vasopressors    有  25  个tokens\n",
      "equipment to run the study was not available    有  8  个tokens\n",
      "because of the obsolescence of the study    有  9  个tokens\n",
      "difficulty getting labs in this setting. after pilot study, this study was not continued    有  16  个tokens\n",
      "not feasible - rsa machine not available. rsa images needed for study endpoints    有  14  个tokens\n",
      "interim analysis showed no difference between either arm of the intervention    有  12  个tokens\n",
      "no record of study starting    有  5  个tokens\n",
      "ga101-chop not advantage from rituximab-chop    有  13  个tokens\n",
      "determined not to be feasible at our site    有  9  个tokens\n",
      "a 30% decrease in opioid use was obeserved in the paravertebral analgesia group    有  22  个tokens\n",
      "this study was stopped before any subjects were treated, consequently there are no results for the study    有  18  个tokens\n",
      "could not be obtained enough sperm rna is highly fragmented and very difficult to purify    有  17  个tokens\n",
      "terminated by the irb    有  5  个tokens\n",
      "poor lab ressources    有  5  个tokens\n",
      "reassessment of phase 2 study indication    有  8  个tokens\n",
      "terminated due to an unusually cold and rainy summer. e.g. in hamburg the average temperature between 16 july and 15 august 2023 was bepoor 17°c. collected data will be used to pilot study design and questionnaire. we plan to repeat the study in 2024    有  61  个tokens\n",
      "pi is away, will hopefully perform the study at another institution    有  12  个tokens\n",
      "study revised significantly. new trial to be launched    有  9  个tokens\n",
      "study is not required    有  4  个tokens\n",
      "project weill not be realized for organisational reasons    有  10  个tokens\n",
      "study product voluntarily recalled by sponsor. listeria identified at the manufacturing facility (not in tested finished product)    有  21  个tokens\n",
      "poor ethical approval in ethiopia    有  8  个tokens\n",
      "withdrawal of research institution from participating    有  7  个tokens\n",
      "closure of dialysis center where study was being conducted    有  10  个tokens\n",
      "1) policy change affecting c&cs; 2) interm analysis revealing overt differences    有  18  个tokens\n",
      "study did not occur    有  4  个tokens\n",
      "standard of care changed    有  4  个tokens\n",
      "recommendation by bfarm after interim analysis    有  8  个tokens\n",
      "research felpoor left institution    有  6  个tokens\n",
      "pi decided to revamp the protocol completely and will submit as new study    有  14  个tokens\n",
      "data was received from another source, therefore phlebotomy was not necessary    有  15  个tokens\n",
      "the clinical trial was terminated due to a change in sponsor strategy    有  12  个tokens\n",
      "failure in regulatory statements    有  4  个tokens\n",
      "poor interest by investigators    有  5  个tokens\n",
      "the study was terminated prior to completing the planned cohorts and analysis because of problems with the infusion set resulting in inadequate insulin delivery    有  24  个tokens\n",
      "machine malfunction and updated work rutines    有  7  个tokens\n",
      "all three subjects dosed in the study have rolled over to the long-term folpoor-up study ivprp-lt01 (nct04628871)    有  33  个tokens\n",
      "this was inadvertently entered in the system and is not a clinical trial    有  13  个tokens\n",
      "clinical trial agreement not executed    有  5  个tokens\n",
      "ministry of health in country did not authorized the conduct of the study    有  14  个tokens\n",
      "released from pmr    有  4  个tokens\n",
      "irb did not approve    有  5  个tokens\n",
      "steroids were given for 2 patients who had biopsy proven drug induced liver injury and both have them developed sepsis    有  24  个tokens\n",
      "the study had to be prematurely stopped, falling short of the initial target due to prolonged shortages in the supply of 123i-mibg    有  28  个tokens\n",
      "paperwork delay    有  3  个tokens\n",
      "due to instillation site of the cortisone and the development of the related sars-cov2 infection, it was preferred to terminate the trial and develop it again without beclomethasone    有  41  个tokens\n",
      "inability to produce placebo tablets similar to the drug tested    有  11  个tokens\n",
      "study medication no longer in production    有  6  个tokens\n",
      "prior to start up, study was discontinued for feasibility reasons    有  11  个tokens\n",
      "study not started due to poor resources    有  7  个tokens\n",
      "the study was prematurely ended due to the modification of study requirements by the us food and drug administration and the european medicines agency    有  24  个tokens\n",
      "change regimen    有  2  个tokens\n",
      "pi transferred to a new institution    有  6  个tokens\n",
      "study was withdrawn due to technical limitations to the device    有  10  个tokens\n",
      "the study was discontinued by the sponsor. no results to report    有  12  个tokens\n",
      "recent publication makes current study obsolete    有  6  个tokens\n",
      "poor pool of subjects    有  5  个tokens\n",
      "investigator decided not to proceed    有  6  个tokens\n",
      "we terminated the study because the pain management program closed in january 2018    有  16  个tokens\n",
      "institutional decision    有  3  个tokens\n",
      "decided not to do study. this will be run as a service evaluation instead    有  16  个tokens\n",
      "the decision is based on the fact that with the current folpoor up of around 10 years, the relevant secondary endpoints can adequately be addressed according to protocol. the addition of folpoor up data will not significantly impact these results    有  47  个tokens\n",
      "preliminary monotherapy data in relapsed/refractory aml and high-risk mds did not offer a sufficiently encouraging profile for further dose escalation/expansion    有  32  个tokens\n",
      "study team finished their analysis    有  5  个tokens\n",
      "antibody supply was discontinued by united therapeutics corporation    有  11  个tokens\n",
      "protocol not adopted by study teams    有  6  个tokens\n",
      "study did not receive irb approval, so did not start    有  12  个tokens\n",
      "the research protocol was completely changed    有  6  个tokens\n",
      "study stopped due to organization reasons    有  6  个tokens\n",
      "ongoing issues with the device and software that were provided by the sponsor    有  14  个tokens\n",
      "due to the rarity and rapid progressive course of the disease, patients were less likely to participate in randomization    有  21  个tokens\n",
      "pilot study protocol terminated to begin expanded study    有  9  个tokens\n",
      "study will be re-evaluated and resubmitted    有  11  个tokens\n",
      "a retrospective study has already been conducted on the same topic    有  11  个tokens\n",
      "molecular development strategy adjustment    有  5  个tokens\n",
      "the pharmaceutical company (bms) would no longer provide nivolumab for the study, so the study was terminated early    有  25  个tokens\n",
      "clinical program was discontinued by novartis    有  8  个tokens\n",
      "the centers have no longer patients. in september 2018, set up of a competitive international study    有  20  个tokens\n",
      "due to the relative poor incidence of severe malaria in southeast asia    有  12  个tokens\n",
      "research question no longer useful/feasible due to shifts in standards of care    有  15  个tokens\n",
      "study was withdrawn from irb review on 03/08/16    有  14  个tokens\n",
      "due to change in available resources    有  6  个tokens\n",
      "agios is no longer developing its second pyruvate kinase-r (pkr) activator, ag-519, and withdrew its investigational new drug (ind) application in december 2016    有  41  个tokens\n",
      "international shortage of the chemical para-aminohippuric acid (pah) due to manufacturing changes, led to inability to perform key measurements to meet trial objectives    有  32  个tokens\n",
      "inhaled treprostinil became commercially available in the us folpooring its approval for ph-ild    有  21  个tokens\n",
      "one of the intravenous lipid emulsions was retired from the market    有  14  个tokens\n",
      "the company shut down    有  4  个tokens\n",
      "the investigator had no more scientific interest about this issue    有  10  个tokens\n",
      "the sponsor decided not to conduct the study    有  8  个tokens\n",
      "never approved by the irb    有  6  个tokens\n",
      "07/27/2017 unable to contact research team to confirm reason for withdrawing study    有  17  个tokens\n",
      "primary investigator changed. study protocol may under go change with addition of new investigators    有  15  个tokens\n",
      "poor progress in development, the sponsor decided to withdraw and no longer proceed    有  15  个tokens\n",
      "not going to be conducted    有  5  个tokens\n",
      "study never opened (terminated as study drug no longer available)    有  12  个tokens\n",
      "the investigatore decided not to proceed with this study    有  10  个tokens\n",
      "because of the poor the candidates and because of restrictions of denervation at the completion date    有  17  个tokens\n",
      "protocol not fully appropriate technical issues with eit device    有  10  个tokens\n",
      "permanently closed per sponsor's request    有  8  个tokens\n",
      "sponsor put plans on hold    有  5  个tokens\n",
      "reorganization proceedings of the sponsor    有  6  个tokens\n",
      "the company's decision to de-prioritize 4718 development    有  13  个tokens\n",
      "study is no longer relevant    有  5  个tokens\n",
      "study approval lapsed    有  4  个tokens\n",
      "problems in organization    有  3  个tokens\n",
      "251pp301(nct03068468) primary endpoint was not met;further development of gosuranemab biib092 in progressive supranuclear palsy will not be pursued    有  38  个tokens\n",
      "the current protocol did not satisfy irb requirements    有  9  个tokens\n",
      "the study was no longer of scientific interest, and other publications rendered it obsolete    有  15  个tokens\n",
      "the study has been closed by our irb due to the pi's departure from the institution    有  18  个tokens\n",
      "pi stopped study due to inability to accrue    有  9  个tokens\n",
      "interim analysis showed that there was no difference between the two drugs    有  13  个tokens\n",
      "we did not get adequate referrals    有  6  个tokens\n",
      "study never started and will never be started    有  8  个tokens\n",
      "study terminated due to poor feasibility of study design    有  9  个tokens\n",
      "because the investigator's workplace and department have been changed, this study cannot be carried out    有  17  个tokens\n",
      "suspended currently as we plan for the next musculoskeletal condition to collect data on    有  17  个tokens\n",
      "experimental drug prohibited by the ansm (french competent authority)    有  13  个tokens\n",
      "poor study design and too many study groups    有  9  个tokens\n",
      "it was decided on 9/21/2016 to terminate this study early because logpad devices the patients used to record their injection data was flawed    有  30  个tokens\n",
      "overall response rate was 3% (only 1 out of 33 participants had confirmed pr)    有  20  个tokens\n",
      "exposure of these high-risk patients to clinic or in-person visits during the pandemic presented an unacceptable risk to their health    有  23  个tokens\n",
      "development of bay1000394 has been terminated by bayer    有  12  个tokens\n",
      "poor resources to complete the study. descriptive statistics for the outcome measures collected are provided    有  17  个tokens\n",
      "there is another related study that is currently ongoing that would contaminate the control arm    有  17  个tokens\n",
      "operational barriers at the site    有  6  个tokens\n",
      "study design was changed - no longer prospectively assigning participants    有  11  个tokens\n",
      "potential subjects were already on the combination therapy    有  8  个tokens\n",
      "too many side-effects    有  4  个tokens\n",
      "drug manufacturer no longer could supply for study    有  8  个tokens\n",
      "poor available personnel to conduct data acquisition and analysis    有  10  个tokens\n",
      "nathan kline institute (nki) decided not to accept study grant from stanley medical research foundation. because of budget considerations    有  26  个tokens\n",
      "due to the voluntary recall of the study device (dls 3.7mm and dls 5.0mm)    有  26  个tokens\n",
      "study conduct does not meet corporate objectives of sponsor    有  9  个tokens\n",
      "due to non-feasibility    有  6  个tokens\n",
      "the study has been put on hold until jan-24 because study team capacity not sufficient    有  17  个tokens\n",
      "stopping the marketing of bmp7    有  7  个tokens\n",
      "given the infeasibility to achieve the study population together with the loss of originality in the scientific rationale, it was considered to cancel the study    有  29  个tokens\n",
      "due to staff shortages we are closing the study    有  9  个tokens\n",
      "waiting for ethic board approval    有  5  个tokens\n",
      "to pursue broader program objectives in oncology    有  8  个tokens\n",
      "due to changes in research objectives and methodological approach    有  10  个tokens\n",
      "3 participants screened, all failed screening process    有  8  个tokens\n",
      "on hold due to pause of outside company    有  8  个tokens\n",
      "principal investigator no longer at site    有  6  个tokens\n",
      "study supply issues    有  3  个tokens\n",
      "military collaborator sample supplier was transferred, no samples obtained    有  12  个tokens\n",
      "final contract negotiations    有  3  个tokens\n",
      "statistical analysis of interim data showed no advantage of colchicine    有  13  个tokens\n",
      "the problems of mst device    有  6  个tokens\n",
      "poor return rate/high dropout rate requiring alteration to study methodology    有  12  个tokens\n",
      "regulatory timelines for approval expired    有  6  个tokens\n",
      "procedure and device development    有  4  个tokens\n",
      "not enough research staff    有  4  个tokens\n",
      "change of inlay from no bevel to bevel design    有  12  个tokens\n",
      "study withdrawn by clinical team    有  5  个tokens\n",
      "sponsor stopped program]    有  4  个tokens\n",
      "provider of product no longer wished to continue with site. no data available    有  14  个tokens\n",
      "no longer necessary    有  3  个tokens\n",
      "the drug company supporting this trial has withdrawn support, including the ability to provide study agent    有  17  个tokens\n",
      "contract not reached with sponsor    有  5  个tokens\n",
      "personnel involved in clinical trial will not be available to conduct the research    有  14  个tokens\n",
      "due to the ongoing conflict in the tigray region    有  11  个tokens\n",
      "nuvox pharma suspended the clinical program related to this study    有  12  个tokens\n",
      "unable to secure clinic support for conducting research    有  8  个tokens\n",
      "study is being redesigned and submitted as a new study    有  10  个tokens\n",
      "sponsor has decided to close study    有  6  个tokens\n",
      "clinical trial was terminated due to discontinuation of drug product by the investigational drug supplier    有  17  个tokens\n",
      "early stopping point based on 2nd interim analysis (planned per protocol)    有  16  个tokens\n",
      "due to limited financial resource    有  5  个tokens\n",
      "decision was made to not go forward with the study    有  10  个tokens\n",
      "did not move forward due to staffing    有  7  个tokens\n",
      "dsmb recommendation folpooring interim analysis    有  8  个tokens\n",
      "this project has undergone a significant amount of updates and has been resubmitted under irb# 201708778    有  23  个tokens\n",
      "study stopped folpooring management decision    有  7  个tokens\n",
      "withdrawn prior to irb approval    有  7  个tokens\n",
      "other - fda clinical hold    有  6  个tokens\n",
      "anx005 well tolerated at doses studied; study discontinued and initiated in patient population    有  16  个tokens\n",
      "the study was terminated early, due to the poor approval of data exportation from the office of human genetic resource administration (ohgra) china    有  28  个tokens\n",
      "all participants finished the trial    有  5  个tokens\n",
      "irb and institutional re-assessment    有  7  个tokens\n",
      "the previous data needs to be analyzed    有  7  个tokens\n",
      "results from sister study at university of the pacific were conclusive    有  12  个tokens\n",
      "insufficient co2 removal obtained with the prismalung membrane oxygenator    有  14  个tokens\n",
      "ovascience, inc. is no longer study sponsor as it is undergoing a merger. folpoor-up will be conducted by sponsor-investigator dr. bob casper    有  35  个tokens\n",
      "pi made the decision to not continue the study. it was at the health canada review stage    有  18  个tokens\n",
      "study coordinator left / no other current resources to complete    有  10  个tokens\n",
      "trend toward increased readmissions in the auto-delivery arm    有  12  个tokens\n",
      "laiv was no longer recommended by acip    有  9  个tokens\n",
      "sufficient clinical results obtained to support study endpoints    有  9  个tokens\n",
      "termination by sponsor    有  3  个tokens\n",
      "poor effect in cohort 1    有  7  个tokens\n",
      "intervention (xiapex) was removed from the market    有  12  个tokens\n",
      "transferring study to another university    有  7  个tokens\n",
      "incidence of ae    有  4  个tokens\n",
      "manufacturer discontinued the production of study drugs    有  7  个tokens\n",
      "closed the single investigator initiated study at request of stryker, to begin collecting as a multicenter study    有  21  个tokens\n",
      "we were not able to secure irb approval in the timeline necessary to do this study    有  17  个tokens\n",
      "revision to over all corporate strategy    有  6  个tokens\n",
      "further biomaterial optimization    有  5  个tokens\n",
      "principle investigator is no longer at loma linda university medical center    有  14  个tokens\n",
      "independent data monitoring committee recommendation    有  6  个tokens\n",
      "this study has been changed in systematic review and meta-analysis    有  11  个tokens\n",
      "due to sorafenib became first line treatment for hcc, the designed treatment became less competitive. the company sanofi decided not to continue to support    有  30  个tokens\n",
      "insufficient personel    有  4  个tokens\n",
      "18f-thk5351 was reported non-specific binding of mao receptors    有  15  个tokens\n",
      "subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study    有  12  个tokens\n",
      "in a communication dated june 12, 2019 the fda has released pfizer from the postmarketing commitment (pmc 2767-2) that was associated with study b3031003    有  42  个tokens\n",
      "site no longer met criteria    有  5  个tokens\n",
      "difficulties to realize the protocol    有  7  个tokens\n",
      "due to the acip guidelines halting the use of laiv    有  13  个tokens\n",
      "study did not get started. investigator is no longer at this institution    有  13  个tokens\n",
      "major review underway    有  3  个tokens\n",
      "the sponsor decided to terminate this study before the protocol-defined end-of-study, as permitted per protocol    有  20  个tokens\n",
      "the study team made the decision to not move forward with the study    有  13  个tokens\n",
      "high attrition rate up to 37.7% at one year's folpoor-up    有  19  个tokens\n",
      "responsibility for registering this study lies with the sponsor, diasorin, and not with our institution    有  20  个tokens\n",
      "moved forward with another protocol utilizing pan genotypic treatment once it became commercially available and fda approved    有  20  个tokens\n",
      "irb approval has elapsed effective 9/20/2023. uncertain as to whether study will continue. would need to receive continuing irb approval by 3/2024. until a determination has been made primary and study completion dates have been pushed out    有  52  个tokens\n",
      "study will be started under a new modified protocol    有  9  个tokens\n",
      "not moving forward staff shortage    有  5  个tokens\n",
      "organisational difficulties    有  4  个tokens\n",
      "supporting company (eisai) withdrew their interest    有  11  个tokens\n",
      "irb is reviewing all studies at the institution and are on hold    有  13  个tokens\n",
      "research focus has changed    有  4  个tokens\n",
      "unavailability of the clinical team    有  6  个tokens\n",
      "strategic decision of sponsor    有  5  个tokens\n",
      "reorganization proceedings with a potential risk of company liquidation    有  11  个tokens\n",
      "investigators left the institution for unrelated reasons    有  8  个tokens\n",
      "decided to do a different clinical trial opportunity    有  9  个tokens\n",
      "this study will be revived with retrospective design    有  8  个tokens\n",
      "pending organization approval    有  3  个tokens\n",
      "2 nanose devices provided inconsistent results in lab calibration testing    有  11  个tokens\n",
      "principal investigator's decision due to poor resources    有  8  个tokens\n",
      "principal investigator departed university    有  4  个tokens\n",
      "significantly higher mortality    有  4  个tokens\n",
      "manufacturer discontinued sylatron    有  5  个tokens\n",
      "phase ii: no scientific interests are given anymore    有  9  个tokens\n",
      "interim analysis also showed a poor benefit in the experimental arm    有  12  个tokens\n",
      "replaced by new study in progress    有  7  个tokens\n",
      "high recurrence of headache in spg group    有  8  个tokens\n",
      "study discontinued considering the limited clinical benefit combined with a higher than expected rate of known non-serious ophthalmological event    有  23  个tokens\n",
      "minor design modifications to device to be investigated in new trial    有  11  个tokens\n",
      "the trial was put on clinical hold and subsequently terminated prior to phase 2 due to cases of drug induced liver injury meeting the criteria for hy's law    有  30  个tokens\n",
      "participants do not accept hypnosis    有  6  个tokens\n",
      "due to organisational issues, the study had to be completed prematurely    有  13  个tokens\n",
      "not started due to regulatory reasons    有  6  个tokens\n",
      "project progression decision was able to be made with the data already gathered    有  13  个tokens\n",
      "due to the bankruptcy of fitbiotech, the provider of the gtu dna vaccine    有  17  个tokens\n",
      "pi lapsed institutional training    有  5  个tokens\n",
      "coi disclosures    有  3  个tokens\n",
      "new trial with same indication initiated    有  6  个tokens\n",
      "sponsor withdrawn their agreement    有  4  个tokens\n",
      "study stopped early after consultation with dsmb    有  8  个tokens\n",
      "needle production stopped    有  3  个tokens\n",
      "physician decided not to go through with study    有  9  个tokens\n",
      "study is completed; primary analysis completed    有  7  个tokens\n",
      "pi initiated study closure. he will be leaving the study site for a new position in the coming months    有  20  个tokens\n",
      "we could not secure adequate medication    有  6  个tokens\n",
      "budgetary and operational issues    有  5  个tokens\n",
      "the site decided not to proceed with the protocol    有  9  个tokens\n",
      "pilot study is finished, multi centered is not moving forward    有  12  个tokens\n",
      "registration trial did not meet the primary end points    有  9  个tokens\n",
      "sponsor did not want to move forward with protocol; study was never opened    有  14  个tokens\n",
      "fda ind approval    有  4  个tokens\n",
      "the decision was based on the overall data profile obtained from this study which did not demonstrate sufficient differentiation to surpass the current standard of care    有  26  个tokens\n",
      "the study was terminated due to poor clinically meaningful benefit    有  10  个tokens\n",
      "no treatment available    有  3  个tokens\n",
      "completed very similar study    有  4  个tokens\n",
      "successfully obtained sufficient data to complete this research project    有  9  个tokens\n",
      "work focused in other areas, other groups working on this    有  11  个tokens\n",
      "staffing and space deficiencies prevented completion of the study    有  10  个tokens\n",
      "change in design to observational study    有  6  个tokens\n",
      "due to difficulties to attract participants    有  6  个tokens\n",
      "change in study design [randomization not feasible]    有  10  个tokens\n",
      "analytic issue    有  3  个tokens\n",
      "inability to reliably measure plasma oxytocin levels during third stage labour, regardless of administration method (intramuscular or inhaled)    有  27  个tokens\n",
      "partial clinical hold per fda    有  6  个tokens\n",
      "pending internal study review and potential protocol modification    有  8  个tokens\n",
      "investigator requested to close, poor equipment available    有  9  个tokens\n",
      "ethic comitte (conep) determinated the prematurely terminated    有  13  个tokens\n",
      "saes with n=1 serotonin syndrome, n=2 saes after sertraline interruption    有  20  个tokens\n",
      "study design reconsideration    有  4  个tokens\n",
      "altered biodistribution in investigational images versus standard images    有  11  个tokens\n",
      "due to clinical service demand study was withdrawn and not activated    有  11  个tokens\n",
      "limited recourse to intestinal resection due to new management of cd    有  12  个tokens\n",
      "the study sponsor did not wish to proceed with the study    有  11  个tokens\n",
      "transitioning to new clinic    有  5  个tokens\n",
      "due to personnel loss and logistical issues the study was unable to be completed as planned    有  16  个tokens\n",
      "the study was deemed unfeasible to complete    有  9  个tokens\n",
      "initial principal investigator no longer at institution    有  7  个tokens\n",
      "limited irx4204 study drug supply    有  8  个tokens\n",
      "considering new technology for product    有  6  个tokens\n",
      "sponsor decided to terminate the study and not proceed to phase 2    有  13  个tokens\n",
      "no answer received from the philippines food and drug administration on protocol amendment issued due to idmc recommendations. cyd vaccine 3rd dose not given    有  29  个tokens\n",
      "the study was withdrawn as there was an ecg equipment and software malfunction. there is no results for this study because of the equipment malfunction    有  27  个tokens\n",
      "technique no longer available    有  5  个tokens\n",
      "preliminary findings showed no significant difference between virtual reality and distraction techniques    有  14  个tokens\n",
      "never approved by the albert einstein college of medicine irb    有  13  个tokens\n",
      "poor likelihood to usedrug in clinic practice based on emergining ae profile and data from front line clinical trials    有  22  个tokens\n",
      "prolonged device failure after just 10 participants and too long to resume    有  15  个tokens\n",
      "study deemed not feasible    有  4  个tokens\n",
      "pending protocol revisions    有  3  个tokens\n",
      "personal reason    有  2  个tokens\n",
      "sponsor developing new product    有  4  个tokens\n",
      "the study design has changed from randomized trial to quasi-experimental due to limited number of clinics involved    有  19  个tokens\n",
      "fda requested us to stop the study    有  8  个tokens\n",
      "opened up a separate clinicaltrials.gov trial form, study id tace    有  15  个tokens\n",
      "the results fell short of expectations    有  6  个tokens\n",
      "because of the bias in who qualified for the study it became apparent we would not get any statistically valid results    有  21  个tokens\n",
      "nhs service understaffing which made study unable to begin    有  12  个tokens\n",
      "very few children and adolescents identified who met intake criteria    有  10  个tokens\n",
      "criteria not met for second stage at time of interim analysis    有  11  个tokens\n",
      "due to poor response    有  4  个tokens\n",
      "focus resources on a planned phase 2/3 study    有  11  个tokens\n",
      "study objectives achieved    有  3  个tokens\n",
      "competing trial    有  3  个tokens\n",
      "study was prematurely stop based on dmc recommendation    有  9  个tokens\n",
      "the production of control group products is stopped, and the control group products cannot be obtained    有  17  个tokens\n",
      "the research and develop strategy of product js009 adjustment    有  10  个tokens\n",
      "decision of the investigator in the face of new scientific knowledge    有  11  个tokens\n",
      "study was stopped due to feasibility issues with completing the study procedure    有  12  个tokens\n",
      "stimulation did not show any evidence of the anticipated effect after 6 participants completed the study. study was thus halted    有  23  个tokens\n",
      "change in fda required patient population decision prior to study start, new protocol developed, this protocol withdrawn    有  20  个tokens\n",
      "investigator has left ucsf    有  7  个tokens\n",
      "study was transferred to partner who will conduct under its own ind    有  12  个tokens\n",
      "nih intramural program is not the responsible party for this study and thus not responsible for registration    有  19  个tokens\n",
      "the fda has placed a clinical hold on the ind under which this research is to be conducted    有  19  个tokens\n",
      "poor research assistant to work on study    有  8  个tokens\n",
      "there was no enough subject    有  5  个tokens\n",
      "part 1 completed successfully. part 2 not conducted    有  11  个tokens\n",
      "device incorrect colour-coded classification of fast breathing for rr    有  10  个tokens\n",
      "initial results did not show benefit    有  6  个tokens\n",
      "institution was unable to manufacture radiotracer that was central to the protocol. study transferred to another institution    有  20  个tokens\n",
      "paused due to technical issues    有  5  个tokens\n",
      "made the decision to not go forward with the study    有  10  个tokens\n",
      "unable to obtain varenicline to provide to participants    有  11  个tokens\n",
      "found not to be feasible    有  5  个tokens\n",
      "sufficient information was gathered from cohort 1 to terminate the study without proceeding to optional cohort 2    有  20  个tokens\n",
      "request for the study waived by indian health authorities    有  9  个tokens\n",
      "the decision was taken to stop prematurely the trial due to the failure of pexa-vec and nivolumab in their respective pivotal trials (i.e., phocus and checkmate 459)    有  41  个tokens\n",
      "principal investigator is moving institutions    有  5  个tokens\n",
      "pi is relocating to another institution    有  7  个tokens\n",
      "gid terminated the registry due to evolving registry requirements    有  9  个tokens\n",
      "study didn't materialize for various reasons    有  8  个tokens\n",
      "protocol deviation    有  2  个tokens\n",
      "not enough resources to start the study    有  7  个tokens\n",
      "new treatment that changes the management of the disease    有  9  个tokens\n",
      "pi has left the institution (university of arizona cancer center) and is working on logistics to transfer study over to their new institution (george washington cancer center)    有  34  个tokens\n",
      "there is a problem with the provision of the treatment, we are unable to provide sufficient number of treatments for the study participants    有  24  个tokens\n",
      "unanswered questions regarding indications for device    有  7  个tokens\n",
      "poor subject participation    有  4  个tokens\n",
      "overlap with other rct    有  5  个tokens\n",
      "the study was terminated as no drug-drug interactions were observed in part-a of the study and therefore part-b of the study was not required as per protocol    有  31  个tokens\n",
      "publication of results of competing trials select2 & angel aspect    有  11  个tokens\n",
      "the smartwatches we planned to use were discontinued    有  10  个tokens\n",
      "study is on hold    有  4  个tokens\n",
      "sponsor determination    有  2  个tokens\n",
      "the principal investigator has left the hospital    有  7  个tokens\n",
      "the investigator conducting the study determined that the entry criteria for the proposed subjects was too difficult to determine in a retrospective review    有  23  个tokens\n",
      "preliminary tests found that some newborns heel blood amount could not meet the test needs    有  18  个tokens\n",
      "development plan revised    有  3  个tokens\n",
      "strategic hold    有  3  个tokens\n",
      "independent data monitoring committee (idmc) recommendation to stop the study    有  14  个tokens\n",
      "poor recrutiment    有  5  个tokens\n",
      "irb did not approve this study    有  7  个tokens\n",
      "planned immunogenicity outcomes not reached    有  8  个tokens\n",
      "not considered to be human subjects research    有  7  个tokens\n",
      "original principal investigator departed institution and concluded the study upon departure    有  11  个tokens\n",
      "study was unable to obtain irb approval because cbd was not legal in nebraska at that time    有  19  个tokens\n",
      "this study is being closed prematurely due to resource availability and agreement constraints with the collaborating research site    有  18  个tokens\n",
      "study staff not available to complete the trial    有  8  个tokens\n",
      "the results are negtive    有  6  个tokens\n",
      "internal study team decision not to proceed    有  7  个tokens\n",
      "according to sponsor strategy    有  4  个tokens\n",
      "transfer of grant to new institution    有  6  个tokens\n",
      "study device was recalled    有  4  个tokens\n",
      "side effects    有  2  个tokens\n",
      "problems with the number of participants    有  6  个tokens\n",
      "the study was terminated on 13 may 2022 due to a modification to the pip/psp    有  21  个tokens\n",
      "no longer a sub-study - changing to an independent parallel study    有  13  个tokens\n",
      "due to the clinically and statistically significant inferior results for the d3 group folpooring evaluation by the institutional review board    有  23  个tokens\n",
      "reagent shortage    有  3  个tokens\n",
      "study will not go forward    有  5  个tokens\n",
      "feasibility reasons    有  3  个tokens\n",
      "the rate of inclusion is too poor to hope to reach the target of 800 patients. 59 patients were included, and their data will not meet the research objectives. the sponsor has decided to prematurely stop inclusions on january 13, 2022    有  52  个tokens\n",
      "waiting for annual irb progress report to be reviewed and approved    有  12  个tokens\n",
      "shortage of potassium acetate for study intravenous fluids    有  11  个tokens\n",
      "investigator has moved to another institution    有  7  个tokens\n",
      "interim analysis showed no differences between groups    有  8  个tokens\n",
      "pending approval of protocol amendment    有  5  个tokens\n",
      "research manpower shortage    有  3  个tokens\n",
      "study has no principal investigator at the moment    有  8  个tokens\n",
      "study terminated early due to ligistic reasons with study staff    有  11  个tokens\n",
      "fda required a new investigational device disclosure for using the wound vac in a new way    有  18  个tokens\n",
      "at the request of the principal investigator    有  7  个tokens\n",
      "confounding factors impacted the ability to fully complete the aims of this study    有  14  个tokens\n",
      "we now offer the repair as standard of care up to bmi of 40    有  15  个tokens\n",
      "impossible device delivery because of sponsor change    有  8  个tokens\n",
      "there were not patients that meet inclusion/exclusion criteria. site decided to close study    有  16  个tokens\n",
      "strategic change    有  3  个tokens\n",
      "study terminated per pi    有  4  个tokens\n",
      "cgm navigator isn't longer available (october 11, 2019)    有  17  个tokens\n",
      "fda and sponsor closed trial. new post-marketing approval trial in development    有  15  个tokens\n",
      "the sponsor did not provide the equipment needed to do study    有  11  个tokens\n",
      "pilot deemed not feasible based on predetermined stopping rules    有  10  个tokens\n",
      "gcp issues    有  3  个tokens\n",
      "investigator leaving the institution    有  5  个tokens\n",
      "bb    有  1  个tokens\n",
      "all nine subjects dosed in the study have rolled over to the long-term folpoor-up study ivprp-lt01 [nct04628871]    有  33  个tokens\n",
      "cancelled by pi    有  3  个tokens\n",
      "the collaborating investigator has moved and cannot collect further data    有  10  个tokens\n",
      "research project has been abandoned primarily because of the excessive delays associated with past challenges in obtaining approval from health canada    有  21  个tokens\n",
      "alternate study commenced using different drug    有  6  个tokens\n",
      "unavailability of triembutine maleate    有  9  个tokens\n",
      "device is no longer available    有  5  个tokens\n",
      "phase 1b portion completed. sponsor decided not to proceed with p2 portion of study. vecabrutinib was very well tolerated, there was insufficient evidence of activity at the doses tested in the phase 1b to advance to phase 2    有  51  个tokens\n",
      "a new registration has been submitted due to a redesign of the study protocol    有  14  个tokens\n",
      "staffing change and poor resources to conduct the study    有  10  个tokens\n",
      "have difficulty finding eligible participants    有  5  个tokens\n",
      "medtronic shift in strategic direction for study device    有  10  个tokens\n",
      "results were not as hypothesized    有  6  个tokens\n",
      "data collection suggested that more work was needed to validate the theoretical connections between the constructs of interest, before doing a treatment trial    有  24  个tokens\n",
      "the number of subjects needed was overestimated (from assumptions made in the litterature)    有  17  个tokens\n",
      "infeasibility to continue study    有  6  个tokens\n",
      "problems executing the study    有  4  个tokens\n",
      "the study was terminated since fosmetpantotenate did not show statistically significant effects or clinical benefits during the double-blind period    有  25  个tokens\n",
      "based on two-stage design, the study ended at stage 1 with no evidence of promise based on pre-specified decision rule    有  25  个tokens\n",
      "sponsor discontinued ipf program on 23-oct. 2017 based on poc studies    有  18  个tokens\n",
      "competing clinical trial    有  4  个tokens\n",
      "unable to perform brain imaging    有  5  个tokens\n",
      "decision to discontinue development of investigational hep c treatment regimen jnj-4178: 3 direct acting antivirals - al-335, odv & smv    有  36  个tokens\n",
      "we conclude that the doses we administered were safe, but too poor. we plan to continue the study with higher doses (0.1 mg/kg iv and 0.2 mg/kg intranasal)    有  41  个tokens\n",
      "global pandemic    有  2  个tokens\n",
      "the number of participants included and especially who connected to the application (less than 50% of the target) does not meet the objective set by the study    有  31  个tokens\n",
      "mutual decision of sponsor and investigator due to logistical challenges    有  11  个tokens\n",
      "luck of interest    有  3  个tokens\n",
      "deferred by irb    有  5  个tokens\n",
      "study was terminated by the sponsor after the last participant completed the month 24 visit as the pre-specified criteria to continue the study were not met    有  29  个tokens\n",
      "delays in equipment procurement prevented the start of the study in time    有  13  个tokens\n",
      "problem negotiating other sites    有  4  个tokens\n",
      "primary investigator retired, rest of staff cannot continue    有  9  个tokens\n",
      "testing for this study remained in the pilot stages due to optimization of the tacs equipment. there are no clinical results to report    有  25  个tokens\n",
      "study design not adequate anymore    有  5  个tokens\n",
      "the main research is no longer in the institution    有  9  个tokens\n",
      "insufficient resources necessary for completion    有  6  个tokens\n",
      "head of project stopped    有  4  个tokens\n",
      "the new pain protocols imposed by the has make it difficult to include new patients in the study    有  18  个tokens\n",
      "site investigator decided to not move forward with study    有  9  个tokens\n",
      "extenuating circumstances    有  4  个tokens\n",
      "considiering to change the chemotherapy into gefitinib    有  12  个tokens\n",
      "check the irb again    有  5  个tokens\n",
      "study was abandoned    有  3  个tokens\n",
      "parent studies didn't meet their primary endpoint so study was terminated    有  12  个tokens\n",
      "the sponsor is waiting to see if enough participants complete the procedure to meet the study data requirements    有  18  个tokens\n",
      "data collection issues from the electronic health record    有  8  个tokens\n",
      "cancelled due to changes in the scientific landscape. decision was made after thorough evaluation of of pros&cons, ethical as well as regulatory consideration    有  27  个tokens\n",
      "departure of study surgeon investigator    有  5  个tokens\n",
      "during study new treatments were available, which may be more effective than proposed study treatment    有  16  个tokens\n",
      "unable to begin study    有  4  个tokens\n",
      "study never opened; closed on 06/29/2021 due to no enrllment    有  19  个tokens\n",
      "redesign of study protocol    有  5  个tokens\n",
      "company no longer exists    有  4  个tokens\n",
      "poor numbers of participants    有  5  个tokens\n",
      "all potential participants opt to a simultaneous pharmacological clinical trial    有  11  个tokens\n",
      "form 46 from dcgi for the manufacturing & commercial marketing of stempeucel® directs stempeutics to conduct pms study. hence this study is being terminated    有  35  个tokens\n",
      "the results of the interim analysis showed significant results    有  9  个tokens\n",
      "the research never began    有  4  个tokens\n",
      "pi no longer interested in pursuing study    有  7  个tokens\n",
      "part a of study was completed per protocol. conduct of part b of the study (confirmatory phase) was not necessary    有  24  个tokens\n",
      "production of adjuvant to be used with vaccine was discontinued by sponsor    有  14  个tokens\n",
      "impossibility of supplying the medication in research of the study by the pharmaceutical company that gave it to the trial    有  22  个tokens\n",
      "principal investigator's request    有  4  个tokens\n",
      "temporarily suspended due to equipment issues    有  7  个tokens\n",
      "increasing off-label practice of iv ketamine administration for treatment-resistant depression    有  14  个tokens\n",
      "it was decided that this study was not feasible at our institution    有  12  个tokens\n",
      "ethical approval was withdrawn by the national research ethics service as they were unable to make contact with the research team despite trying many times    有  25  个tokens\n",
      "bayer withdrew their support    有  5  个tokens\n",
      "stopped due to published data regarding thk-5351 non-specificity in tau imaging    有  17  个tokens\n",
      "difficulty to recrut    有  4  个tokens\n",
      "at the end of the inclusion period, the observed correlations were much poorer than expected. thus, it did not seem relevant to prolong the inclusions    有  29  个tokens\n",
      "difficulties in the inclusion of patients with cardiacly asymptomatic type 2 diabetes and with at least two cardiovascular risk factors    有  25  个tokens\n",
      "due to suggestions of irb committee in our institution    有  10  个tokens\n",
      "decided not to go ahead with study at this time    有  11  个tokens\n",
      "investigator and sponsor decided by mutual agreement to stop study prematurely    有  12  个tokens\n",
      "on february 2019 astra-zeneca greece decided to stop the financial support of the study    有  22  个tokens\n",
      "unsuitable method    有  3  个tokens\n",
      "interim analysis did not show sufficient immunogenicity of imp compared to placebo    有  15  个tokens\n",
      "program restructured    有  3  个tokens\n",
      "the study was terminated by the sponsor for apparent poor effectiveness    有  11  个tokens\n",
      "recrutement difficulties    有  4  个tokens\n",
      "unfavourable opinion of ethical comittee for amendment nr 3    有  15  个tokens\n",
      "medical decision    有  2  个tokens\n",
      "collaborating site had difficulty with approval    有  8  个tokens\n",
      "study required back-to-back physical therapy (pt) and tms experimental sessions; as our practice move to another building, away from pt    有  27  个tokens\n",
      "merck's decision for early termination of the data    有  10  个tokens\n",
      "the agent was withdrawn from development by the manufacturer after being placed on clinical hold by the us fda    有  20  个tokens\n",
      "changing the study design    有  4  个tokens\n",
      "there was no significant difference in our outcome measures between patients with disease versus controls suggesting that our hypothesis is not substantiated. since this was the major objective of the study we decided to terminate the study    有  39  个tokens\n",
      "decided by sponsor    有  4  个tokens\n",
      "grant termination without continuation    有  4  个tokens\n",
      "study closed due to poor participants    有  6  个tokens\n",
      "change of trial sponsor    有  4  个tokens\n",
      "the cellvizio device required to analyse biopsy is available until september 2020    有  16  个tokens\n",
      "study was withdrawn before irb approval    有  7  个tokens\n",
      "on hold    有  2  个tokens\n",
      "recent personnel changes in the research team make it unrealistic to conduct this research project    有  15  个tokens\n",
      "study terminated in line with biogen decision to withdraw zinbryta from the market and not to pursue further studies of daclizumab in ms    有  32  个tokens\n",
      "the investiagtor abandoned the project    有  8  个tokens\n",
      "interim data indicated this vaccine will not meet the protocol criteria for a good vaccine candidate    有  17  个tokens\n",
      "cancel study    有  2  个tokens\n",
      "sponsor decided not to move forward with the trial    有  9  个tokens\n",
      "the inclusions have been suspended from 03/18/2020 during the confinement period. in the meantime, a publication has appeared showing that the chest ultrasound has entered the common practice in the management of bronchiolitis    有  45  个tokens\n",
      "discontinuation of the study was justified by the inclusion of 21/100 patients, which finally enabled a relevant analysis to be made in view of the homogeneity of the results    有  36  个tokens\n",
      "study is a commitment for license renew, we target on apr19 submission, considering timeline, a cut off should be scheduled in apr18    有  27  个tokens\n",
      "takeda has determined that the benefit/risk profile does not support continuation of the surgery study for this specific congenital hemophilia a with inhibitors patient population    有  31  个tokens\n",
      "laboratory change, stem cell circuit stopped    有  9  个tokens\n",
      "the principal investigator decided to stop the research    有  8  个tokens\n",
      "difficult to coordinate between all of the different support systems needed across various departments    有  15  个tokens\n",
      "similar study has been published    有  5  个tokens\n",
      "negatives results    有  3  个tokens\n",
      "departure of the coordinating investigator    有  5  个tokens\n",
      "gsk decision to return rights to sirukumab to janssen and discontinue sirukumab development in polymyalgia rheumatica    有  30  个tokens\n",
      "a planned interim analysis led to the trial being stopped early based on the observed size effect and power analysis    有  20  个tokens\n",
      "pis will not pursue trial due to staff and time constraints    有  11  个tokens\n",
      "change in the clinical practices    有  5  个tokens\n",
      "the method did not help with assessing pah and so the trial was terminated early    有  16  个tokens\n",
      "this was a research project that was conducted by a visiting scholar and his time for departure came earlier than the study completion    有  23  个tokens\n",
      "delays in obtaining study materials    有  6  个tokens\n",
      "poor hormonal responses (gh) in response to the respiratory training protocols in the three subjects tested    有  19  个tokens\n",
      "data analysis was never performed by sub-investigator    有  10  个tokens\n",
      "investigator departure (and wish not set up study)    有  11  个tokens\n",
      "based on a review of early data from participants in the dose escalation phase, it was determined that synb1934v1 is unlikely to meet the study's primary endpoint for poorering phenylalanine (phe) levels in patients    有  47  个tokens\n",
      "due to an incompatibility with the local procedures    有  10  个tokens\n",
      "change in study design (see nct05770414 for current and active trial)    有  17  个tokens\n",
      "study stopped due to the difficulty in patient compliance for folpoor up visits    有  15  个tokens\n",
      "technical & logistical issues    有  4  个tokens\n",
      "recent publications have made this study obsolete    有  7  个tokens\n",
      "the investigator's workplace and department were changed so that the study could no longer be carried out    有  18  个tokens\n",
      "our felpoor completed the program before we were able to start the study    有  15  个tokens\n",
      "the investigator has left the facility    有  6  个tokens\n",
      "after interim analysis, irb recommend termination    有  8  个tokens\n",
      "due to a problem with the supply and demand of the stent used in the study, it is difficult to register the target so the study ends early    有  30  个tokens\n",
      "significant protocol modifications needed for feasibility. this will require a version 2    有  14  个tokens\n",
      "a better study with a better drug was started and thus this study was terminated    有  15  个tokens\n",
      "unable to agree on budget terms    有  6  个tokens\n",
      "based on dmc recommendation to discontinue eg-01-1962-03    有  16  个tokens\n",
      "clinical myalgia    有  4  个tokens\n",
      "this study was structured in 2 phases, and was stopped after the first phase. the collected data will be used to improve the device and prepare future studies    有  31  个tokens\n",
      "poor equipment    有  3  个tokens\n",
      "compound is not expected to change the current treatment practice or fill significant clinical need for patients in china over currently available ee agents    有  24  个tokens\n",
      "the screening service moved to a pan-london service and the trial was not able to be continued    有  19  个tokens\n",
      "due to release of competing app    有  6  个tokens\n",
      "no (financial) means left to continue inclusion to achieve predetermined sample size. instead of continuation (high probability of unanalyzed data) it was decided to stop inclusion and analyze data, so the scientific community can benefit from it    有  45  个tokens\n",
      "focus on other studies    有  4  个tokens\n",
      "problematic has become outdated in relation with current litterature advances    有  12  个tokens\n",
      "devices proposed for use in the protocol no longer used by physician    有  12  个tokens\n",
      "ethical approval has not yet been completed    有  7  个tokens\n",
      "per nih request    有  4  个tokens\n",
      "the registry has a new setpup and a new entry    有  12  个tokens\n",
      "surgeon stopped    有  4  个tokens\n",
      "no finding at halfway point of the study    有  8  个tokens\n",
      "unable to execute a contract agreement with the drug manufacturer    有  10  个tokens\n",
      "immunotherapy approved for nsclc in the first line setting    有  12  个tokens\n",
      "study cancelled due to operational difficulties    有  6  个tokens\n",
      "strategic decision was made to terminate the afm11 development    有  12  个tokens\n",
      "different protocol started, new registration    有  6  个tokens\n",
      "unforeseen feasibility issues arose that meant the study did not seem viable in the current form    有  18  个tokens\n",
      "not authorized by regulatory agencies - new protocol phase 1a in progress    有  14  个tokens\n",
      "lt-02 did not appear to help induce remission of uc    有  13  个tokens\n",
      "ci left the country so study has never opened    有  9  个tokens\n",
      "the study did not start due to a poor staff    有  10  个tokens\n",
      "new study planned    有  3  个tokens\n",
      "failed to meet success criteria    有  5  个tokens\n",
      "development of cdx-014 discontinued    有  7  个tokens\n",
      "the trial was prematurely terminated as per sakk board decision from 14th of november 2020. the trial is to be terminated after primary endpoint is reached    有  32  个tokens\n",
      "change of technique    有  3  个tokens\n",
      "personnel changes; insufficient resources to continue    有  8  个tokens\n",
      "change in clinical practice that logistically prevented this study from being engaged    有  13  个tokens\n",
      "this study is terminated because of problems wtih the society responsible of the data base    有  16  个tokens\n",
      "removal of the phd student due to not obtaining financing    有  12  个tokens\n",
      "no longer pursued    有  3  个tokens\n",
      "no new location to open    有  5  个tokens\n",
      "folpooring consultation, neutral electrolysed water was deemed to be a medical device. a study amendment will re-submitted to nhs ethics and the uk regulator (mhra). these actions delayed due to the pandemic - expected to take place in june 2022    有  54  个tokens\n",
      "sponsor did not want to supply further product    有  8  个tokens\n",
      "physician's departure    有  4  个tokens\n",
      "aim to assess feasibility achieved, larger project starting earlier than anticipated    有  12  个tokens\n",
      "study early terminated    有  3  个tokens\n",
      "technical issues with microchip    有  5  个tokens\n",
      "the study was stopped due to resourcing issues    有  9  个tokens\n",
      "protocol expired with irb    有  5  个tokens\n",
      "we need more participants to complete the research    有  8  个tokens\n",
      "because the closing date of the study is approaching    有  9  个tokens\n",
      "changes to the overall development program for the study medication    有  10  个tokens\n",
      "withdrawal industrial    有  3  个tokens\n",
      "manufacturing-related issues    有  4  个tokens\n",
      "the research objectives are achieved, demonstrating the feasibility and superiority of the personalized approach. it was no longer justified to continue the inclusions in this 'proof of concept' type study    有  35  个tokens\n",
      "couldnt find sponor for this study    有  9  个tokens\n",
      "the commercial partner decided not to proceed with this protocol at this time    有  13  个tokens\n",
      "protocol was withdrawn from ind    有  5  个tokens\n",
      "another study published with similar results    有  6  个tokens\n",
      "the risk/benefit profile no longer indicated continued development    有  10  个tokens\n",
      "it was not possible to conduct this study at the university of utah due to the inability of the pet research facility to synthesize the radiotracer central to this project. project was transferred to another institution    有  41  个tokens\n",
      "no facility to measure volatile anaesthetic concentration in human blood sample    有  12  个tokens\n",
      "only one center could be open and the center could not include all patients    有  14  个tokens\n",
      "midterm analysis showed negative results    有  6  个tokens\n",
      "results not achievable after interim analysis conclusions and recruting difficulty    有  12  个tokens\n",
      "strategy changes    有  2  个tokens\n",
      "entry criteria were changed, investigator have registrated a new trials    有  12  个tokens\n",
      "an alternative biobank project was initiated    有  8  个tokens\n",
      "the art trial was published suggesting harm by the intervention protocol, which was closely related to the protocol in this study, so the study was terminated    有  28  个tokens\n",
      "stopped product production    有  3  个tokens\n",
      "no support staff    有  3  个tokens\n",
      "project was placed on hold indefinitely as the project resources were unavailable for this to move forward    有  17  个tokens\n",
      "unable to provide study medications due to cost    有  8  个tokens\n",
      "inadequate personel    有  5  个tokens\n",
      "scientific question reconsidered    有  4  个tokens\n",
      "study discontinued early by sponsor    有  5  个tokens\n",
      "sponsor review of initial results demonstrates a non-favourable risk benefit    有  13  个tokens\n",
      "decision by principal investigator to re-consider study design    有  10  个tokens\n",
      "the molecule (gdc-276) is no longer in development    有  13  个tokens\n",
      "poor availability of drug    有  5  个tokens\n",
      "site dropped study    有  3  个tokens\n",
      "site did not obtain lirb approval due to medication usage    有  12  个tokens\n",
      "pharmaceutical and financial difficulties    有  6  个tokens\n",
      "mutations found do not modify the atm protein+ modifications of methodology would be necessary    有  15  个tokens\n",
      "study has been terminated due to small sample size    有  9  个tokens\n",
      "termination after a few pilot participants due to further protocol development    有  11  个tokens\n",
      "raw ingredient shortage. future study start date - tbd    有  11  个tokens\n",
      "insufficient drug supply    有  4  个tokens\n",
      "change in hospital policy    有  4  个tokens\n",
      "due to gsk concerns that the data collected in this study could not support reliable interpretation of assessments and conclusions on the primary objectives    有  25  个tokens\n",
      "registry was built to handle medicare coverage decision on ngs, but cms decided to not require data    有  20  个tokens\n",
      "have not received irb approval    有  6  个tokens\n",
      "strict study protocol and poor participant reimbursement was not advantageous and feasible as evidenced by the high rate of attrition    有  21  个tokens\n",
      "manufacturing problem with study drug    有  6  个tokens\n",
      "synthesis of the chemical precursor for the neuroimaging radiotracer could not be produced in a stable fashion    有  22  个tokens\n",
      "results with 4 subjects suggest a redesign of compression system is required    有  13  个tokens\n",
      "program changed    有  2  个tokens\n",
      "because of inability to get fda approval for    有  9  个tokens\n",
      "poor manpower    有  3  个tokens\n",
      "study is being rewritten for different disease population    有  8  个tokens\n",
      "closed by pi    有  3  个tokens\n",
      "pi is requesting termination (closure) of this study    有  10  个tokens\n",
      "the employe for the study quit and a new grant proposal was not financed    有  15  个tokens\n",
      "new record created in clinical trials due to company re-branding, and inability to list new name as the sponsor    有  22  个tokens\n",
      "study staff was unable to collect proper samples to meet study goals    有  12  个tokens\n",
      "the study was terminated upon completion of escalation phase, prior to opening expansion cohorts    有  15  个tokens\n",
      "the study was terminated because of the availability of alternate therapies for primary biliary cholangitis (pbc)    有  22  个tokens\n",
      "abbott has decided to stop selling the absorb stent which was the product under evaluation in this study    有  20  个tokens\n",
      "significant changes have been made to the protocol    有  8  个tokens\n",
      "difficulty to continue folpoor-up during the coronavirus epidemic    有  11  个tokens\n",
      "a decision has been made to prioritize other pipeline programs and terminate this study    有  14  个tokens\n",
      "this study was terminated as the standard of care for small cell lung cancer changed in 2018 to include immunotherapy in the front line setting, making this study no longer clinically relevant    有  36  个tokens\n",
      "withdrawn by irb on 10-16-2023    有  13  个tokens\n",
      "changing priorities    有  2  个tokens\n",
      "pi unexpectedly passed away, study future to be determined    有  10  个tokens\n",
      "due to time constraints, the study was halted prematurely    有  10  个tokens\n",
      "investigator relocation    有  3  个tokens\n",
      "the investigational product was approved by the fda (12/20/2021) and is now commercially available    有  23  个tokens\n",
      "company withdrew financial support    有  4  个tokens\n",
      "the investigator-coordinator has moved to rennes university hospital. it will be done under the sponsor of rennes university hospital : nct03686306    有  30  个tokens\n",
      "the sponsor decided to not move forward with this study    有  10  个tokens\n",
      "the sponsor has put the study on hold and will recommence in due time    有  15  个tokens\n",
      "student research, student left the university    有  7  个tokens\n",
      "inadequate number of subjects meet study criteria    有  9  个tokens\n",
      "the collaborating pharmaceutical company will not wish to continue with the trial due to the internal issues in the company    有  20  个tokens\n",
      "due to strategic decision, az has applied to terminate study at all participating sites and has committed that the data generated during the course of the study will not be submitted to china national medical products administration    有  38  个tokens\n",
      "pilot study with sumatriptan found no significant changes in the primary outcome parameter (change in cbf)    有  23  个tokens\n",
      "bvs was withdrawn from the market    有  7  个tokens\n",
      "pi withdrew the protocol    有  4  个tokens\n",
      "study halted prematurely and will not resume; participants are no longer being examined or receiving any intervention    有  18  个tokens\n",
      "unable to access components necessary to be able to run the study    有  12  个tokens\n",
      "terminating study as sponsor has sold the drug to another company    有  12  个tokens\n",
      "major changes to protocol (new study design and comparator)    有  11  个tokens\n",
      "further understanding about the role of androgen signaling in tnbc was required    有  15  个tokens\n",
      "problems with samples handling    有  4  个tokens\n",
      "i discontinued this study because i transferred to another institution    有  10  个tokens\n",
      "loss of finacial support    有  5  个tokens\n",
      "poor progression due to difficulties in finding eligible patients. competitive clinical trials with innovative agents and new approved products leaddefinitive stop    有  26  个tokens\n",
      "company's strategic reasons    有  4  个tokens\n",
      "because previous studies had found no difference, and one recent study even reported a higher incidence of pep in treatment arm    有  22  个tokens\n",
      "the supplies of study drug were halted by gilead sciences ltd    有  13  个tokens\n",
      "protocol updates resulted in new protocol/study    有  8  个tokens\n",
      "pi has terminated the study at this time    有  8  个tokens\n",
      "key personnel moved to new location. therefore, we had insufficient resources to initiate the trial    有  17  个tokens\n",
      "our physician researcher left wcm after the trial was approved    有  11  个tokens\n",
      "decided to participate in a multicenter trial researching the same issue    有  13  个tokens\n",
      "due to competing trials. stopped before irb approval    有  10  个tokens\n",
      "currently not moving forward with the study    有  7  个tokens\n",
      "current unavailability of resources    有  5  个tokens\n",
      "study was temporarily suspended to focus on other projects, but was never resumed. no participants were determined eligible and none started the protocol    有  25  个tokens\n",
      "study drug backorder    有  4  个tokens\n",
      "sponsor prematurely withdrew financial support    有  5  个tokens\n",
      "the blade used in the study was modified (changed) by the manufacturer, it does not longer exist    有  20  个tokens\n",
      "liquidation of research department    有  5  个tokens\n",
      "too few patients at site. new sites will be included in the study, we can not be sure of how long it takes. the new sites will then need a re-application to the ethical board, and also the swedish biobank agreements needs to be changed accordingly    有  54  个tokens\n",
      "difficulties in recrutment    有  7  个tokens\n",
      "study sponsor decided not to move forward with this project    有  10  个tokens\n",
      "inability to obtain final specimen routinely    有  7  个tokens\n",
      "study investigators have left the institution, the department no longer has time to include    有  15  个tokens\n",
      "investigator    有  2  个tokens\n",
      "loss of interest in the subject    有  6  个tokens\n",
      "investigator institution change    有  4  个tokens\n",
      "appropriate devices for fetal heart rate monitoring were not available    有  10  个tokens\n",
      "withdrawn per pi    有  4  个tokens\n",
      "poor study substance    有  4  个tokens\n",
      "unable to reach the required sample size    有  7  个tokens\n",
      "this study was never started due to poor access to our proposed patient database    有  14  个tokens\n",
      "the company providing study imp was unable to supply further batches of imp    有  13  个tokens\n",
      "insufficient personnel to complete the study    有  7  个tokens\n",
      "change in operating plans    有  4  个tokens\n",
      "pdol request    有  3  个tokens\n",
      "plans changed    有  2  个tokens\n",
      "the use of robotic surgery made this study obsolete    有  9  个tokens\n",
      "the risk benefit in the study population does not favor continuation of the study    有  14  个tokens\n",
      "participants were unable to use the device. no data was collected    有  12  个tokens\n",
      "irb determined need for an ide, which was not approved    有  12  个tokens\n",
      "development project stopped    有  3  个tokens\n",
      "after a reliability pilot, main study stopped due to unrelated clinic closure    有  13  个tokens\n",
      "irb audit review    有  4  个tokens\n",
      "no approval ca (mpa) of protocol amendment    有  10  个tokens\n",
      "a future study will be taking place using the same patient population    有  12  个tokens\n",
      "primary outcome was met in the 16 patients that completed the study per protocol    有  15  个tokens\n",
      "inadequate methodology to determine primary outcome    有  8  个tokens\n",
      "contract could not be agreed on    有  6  个tokens\n",
      "no devices currently available for study    有  6  个tokens\n",
      "due to structural financial deficit of sakk    有  8  个tokens\n",
      "preliminary data is under analysis    有  7  个tokens\n",
      "reorganization of the clinic    有  5  个tokens\n",
      "not enough available families to get significant genetic results    有  9  个tokens\n",
      "major change to study design    有  5  个tokens\n",
      "placebo medication expired    有  4  个tokens\n",
      "on internal hold    有  3  个tokens\n",
      "no available resources    有  3  个tokens\n",
      "change in the therapeutic indication    有  5  个tokens\n",
      "pursuing ind    有  4  个tokens\n",
      "the focus of the project has shifted    有  7  个tokens\n",
      "irb terminated the study    有  5  个tokens\n",
      "another surveillance protocol was initiated by the ofsep (ofsep cohort) which alpoors to folpoor all the patients, whatever their treatment    有  29  个tokens\n",
      "bussiness reason    有  4  个tokens\n",
      "the study was stopped per the recommendation of the dsmb and nichd    有  14  个tokens\n",
      "the tests have been completed    有  5  个tokens\n",
      "the study was terminated due to the discontinuation of the tralokinumab asthma program (as per the results of the phase iii study [d2210c00008])    有  36  个tokens\n",
      "investigator found that a new study drug that is fda approved would be superior to melatonin    有  19  个tokens\n",
      "the sponsors want to stop the study    有  7  个tokens\n",
      "doctoral student running the study left for internship and did not finish the study    有  15  个tokens\n",
      "material needed for study was not available    有  7  个tokens\n",
      "the topline results of the 52-week double-blind placebo-controlled period were analyzed. the study did not meet the primary or secondary endpoints. based on these results, the decision was made to halt the long-term folpoor-up period of the study    有  50  个tokens\n",
      "fda hold due to updated risks    有  7  个tokens\n",
      "change in drug development and lifecycle management and decide to suspend this study    有  13  个tokens\n",
      "study start delayed due to pending collection and analysis of additional phase 1 data    有  15  个tokens\n",
      "terminated per pi's request due to competing priorities    有  9  个tokens\n",
      "this observational study has been transitioned to a clinical trial and is now registered at (nct04181112)    有  23  个tokens\n",
      "insufficient resources to complete study    有  6  个tokens\n",
      "the study was temporarily suspended after a meta-analysis suggesting higher mortality risks among patients treated with paclitaxel-coated balloons. when the study was open again, no new patient accepted to be included. the study stopped on 18aug2023    有  50  个tokens\n",
      "study was ended due to poor available participants who met criteria    有  11  个tokens\n",
      "cardiac surgeon collaborator has left the institution    有  9  个tokens\n",
      "we change the study protocol    有  5  个tokens\n",
      "moving of coordinator    有  3  个tokens\n",
      "mobile-bearing insert dislocation    有  5  个tokens\n",
      "problems with biosensor not working properly and not functional for study    有  12  个tokens\n",
      "organisational and regulatory challenges    有  6  个tokens\n",
      "the sponsor failed to provide financial support as promised    有  9  个tokens\n",
      "further development needed to facilitate easier polypectomy - device improvement    有  14  个tokens\n",
      "continuing irb review was not submitted. study was inactivated with the institutional irb    有  18  个tokens\n",
      "drug company decided to terminate all sponsored clinical studies involving rilotumumab    有  15  个tokens\n",
      "study scope re-assessed    有  5  个tokens\n",
      "study was discontinued as it did not achieve functional secondary endpoints    有  11  个tokens\n",
      "dsmb review    有  3  个tokens\n",
      "will resume after internal review    有  5  个tokens\n",
      "investigators are no longer at nyu langone health    有  11  个tokens\n",
      "fitbit was not giving the necessary data    有  8  个tokens\n",
      "study terminated 7/23/2019 due to limited participation and testing challenges    有  16  个tokens\n",
      "new protocol started 31/18    有  7  个tokens\n",
      "wouldn't be able to get enough patients. never started the study. suspended the irb form    有  20  个tokens\n",
      "not commenced    有  2  个tokens\n",
      "the study was halted prematurely due to poor interested participants    有  10  个tokens\n",
      "unable to move forward with the study due to personnel changes    有  11  个tokens\n",
      "pi has decided to close the study    有  7  个tokens\n",
      "development program for filgotinib for participants with crohn's disease has been stopped    有  17  个tokens\n",
      "harvard university dining workers went on strike, we hope to relaunch in fall 2017    有  19  个tokens\n",
      "insuffient drug supply. professor ronald dahl lefter his position as proffssor in århus, and all his research were closed    有  29  个tokens\n",
      "study changed waiting renew    有  4  个tokens\n",
      "awaiting national pharmaceutical pricing authority (nppa) review of ceiling prices for innovative products in india    有  20  个tokens\n",
      "withdrawal of the associated centers    有  6  个tokens\n",
      "terminated prematurely due to indication change    有  6  个tokens\n",
      "decided not to proceed with study at this time    有  10  个tokens\n",
      "no longer required    有  3  个tokens\n",
      "the decision is based on a change in the benefit risk assessment of this drug for the lupus population targeted in this study    有  24  个tokens\n",
      "nct02921594 was not a rct but a secondary pilot study designed to establish a fluoroscopic test-set up on 10 selected patients from another rct    有  33  个tokens\n",
      "protocol not feasible    有  3  个tokens\n",
      "protocol is not adapted to cancer pancreas disease as progression is very fast and patients stopped the study before 1st study assessment    有  25  个tokens\n",
      "subjects lost to folpoor-up    有  7  个tokens\n",
      "after an interim analysis of the data, it became clear that the imaging results did not correlate to the primary outcome measures in this subset of patients    有  28  个tokens\n",
      "principal investigator departed for another position    有  6  个tokens\n",
      "the sponsor has decided to stop the study    有  8  个tokens\n",
      "cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. however, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study    有  42  个tokens\n",
      "oxynov discontinues loan of freeo2 devices    有  11  个tokens\n",
      "terminated (halted prematurely)    有  6  个tokens\n",
      "no access to the database of healthcare workers    有  8  个tokens\n",
      "unfortunately, we have had to prioritize other studies and we do not have the resources required to carry out this study    有  23  个tokens\n",
      "the irb did not approve the study to be conducted at the home institution    有  15  个tokens\n",
      "collaborator discontinued at this site to pursue the study with a different site    有  15  个tokens\n",
      "external information    有  2  个tokens\n",
      "the study was terminated due to principal investigator moving institutions    有  10  个tokens\n",
      "idsmb recommendation    有  3  个tokens\n",
      "was never started    有  3  个tokens\n",
      "team no more available to lead research    有  7  个tokens\n",
      "the p.i decided not to move forward with the study    有  11  个tokens\n",
      "feasibility study was not initiated    有  6  个tokens\n",
      "medigene transfered all rights to a new sponsor    有  11  个tokens\n",
      "1. the results showed significant improvement after ces; 2. run out of study grant    有  18  个tokens\n",
      "mri issue    有  3  个tokens\n",
      "dsmc reviewed results of 26 subjects. new randomizations were stopped. already randomized subjects were folpoored up to w40    有  27  个tokens\n",
      "the study did not begin    有  5  个tokens\n",
      "new protocol and outcome measures in review    有  7  个tokens\n",
      "interim analysis in progress    有  5  个tokens\n",
      "monitoring equipment used in the study is not available    有  10  个tokens\n",
      "regulatory issues raised by the regulatory authority in taiwan    有  11  个tokens\n",
      "investigators perogative    有  5  个tokens\n",
      "the clinical development strategy has been changed    有  7  个tokens\n",
      "identification of potential mutagenic metabolite in human plasma    有  11  个tokens\n",
      "poor clinical viability    有  4  个tokens\n",
      "we did not get the grant support    有  7  个tokens\n",
      "due to restrictions pertaining to covd study has been halted    有  11  个tokens\n",
      "withdrawn due to logistic reasons    有  6  个tokens\n",
      "study not moving forward    有  4  个tokens\n",
      "hospital didn't use perioperative infection control bundle so study wasn't applicable    有  14  个tokens\n",
      "pilot study converted to nct 05660512 prospective single arm cohort study    有  16  个tokens\n",
      "corticosteroid use approval    有  6  个tokens\n",
      "based on interim analysis, the sponsor decided to terminate the study prematurely    有  13  个tokens\n",
      "not authorized by cofepris (mexico competent regulatory authority)    有  15  个tokens\n",
      "poor eligible subjects at study site    有  7  个tokens\n",
      "our local committee has denied the approval request    有  8  个tokens\n",
      "change in government policy on testing    有  6  个tokens\n",
      "internal timeline was delayed, logistics delays    有  7  个tokens\n",
      "study stopped due to a change in the sponsor's overall development strategy from treatment of chronic disease to finite, curative treatments, and is based partially on the advice and feedback from experts and regulators    有  38  个tokens\n",
      "unavailability of cryoablation probes    有  8  个tokens\n",
      "development of next-generation device    有  5  个tokens\n",
      "the south african government decided not to implement the pilot project for which this protocol was the evaluation. it was not approved by the irb and never started    有  30  个tokens\n",
      "corona-virus lockdown (16th march in switzerland)    有  13  个tokens\n",
      "not considered a clinical trial    有  5  个tokens\n",
      "study design was changed    有  4  个tokens\n",
      "study team decided not to proceed with project    有  8  个tokens\n",
      "transfer of institutions    有  3  个tokens\n",
      "device provider has requested withdrawal citing modifications needed for study integrity    有  11  个tokens\n",
      "sponsor change    有  2  个tokens\n",
      "several analytical laboratories failed to develop and validate a suitable assay of urine fumonisin (the primary endpoint) up to date. because of missing alternatives for an analytical laboratory the objective of the study cannot be met    有  43  个tokens\n",
      "unable to receive clearance from hca administration    有  8  个tokens\n",
      "this study was superseded by nct03295747    有  11  个tokens\n",
      "an event rate poorer than anticipated    有  6  个tokens\n",
      "study stopped before first patient inclusion. mixed-methods-study (part a) completed per protocol, explorative survey (part b) withdrawn due to organizational reasons    有  32  个tokens\n",
      "principal investigator is leaving the institution    有  6  个tokens\n",
      "there have been significant changes in the fda guidelines and clinical standard of care    有  15  个tokens\n",
      "i left unopar    有  5  个tokens\n",
      "descriptive studies were published based on this record. randomized controlled time-series study was discontinued due to infeasability. descriptive time-series studies and methodological studies have been published    有  34  个tokens\n",
      "abandoned due to limited resources    有  6  个tokens\n",
      "to be replaced with a randomized placebo-controlled study    有  9  个tokens\n",
      "to avoid the duplication of effort and resources associated with the pi's branch change    有  15  个tokens\n",
      "the student do not start the study    有  7  个tokens\n",
      "poor antiviral activity at the projected efficacious dose    有  12  个tokens\n",
      "multiple logistical challenges    有  3  个tokens\n",
      "assessed for feasibility    有  4  个tokens\n",
      "halted by sponsor    有  4  个tokens\n",
      "study suspended due to the move of clinical trial site. it will be resumed when the move is complete    有  20  个tokens\n",
      "study halted prematurely becauase of organisational problems    有  11  个tokens\n",
      "trial did not activate    有  4  个tokens\n",
      "manufacturer's decision folpooring failure of sequence 2. protocol unadapted to the security and performance evaluation of the new makair device capabilities in non-invasive ventilation (niv)    有  38  个tokens\n",
      "by sponsor, based on dsmb recommendations    有  8  个tokens\n",
      "pi changed hospital center    有  4  个tokens\n",
      "it was not possible to perform the study due to the availability and logistics of porcine heparin    有  21  个tokens\n",
      "this protocol was never initiated    有  5  个tokens\n",
      "study was terminated early given the interim analysis for part 1 (signal finding) did not meet pre-specified criteria and will not proceed to part 2. sponsor will proceed closing the study    有  38  个tokens\n",
      "it is difficult to screening subject    有  6  个tokens\n",
      "unavailable it resources    有  4  个tokens\n",
      "the study was never submitted to irb or approved, due to feasibility issues    有  15  个tokens\n",
      "pause for changes in development strategies    有  6  个tokens\n",
      "suspended for changes in development strategy    有  7  个tokens\n",
      "an interim analysis showed no difference in major outcomes (n=35 glycine and n=24 control participants)    有  22  个tokens\n",
      "the intended population has been updated    有  6  个tokens\n",
      "based on the results observed to date, the sponsor concluded that zf874 was unlikely to achieve the desired target product profile    有  23  个tokens\n",
      "poor eligibility rate indicated that the study was not feasible    有  11  个tokens\n",
      "poor time to realize the research    有  7  个tokens\n",
      "sponsor decided not to conduct it    有  6  个tokens\n",
      "unable to obtain approval    有  4  个tokens\n",
      "sponsor decided to withdraw the study    有  6  个tokens\n",
      "principal investigator leave the organization    有  5  个tokens\n",
      "study did not proceed to irb approval    有  8  个tokens\n",
      "independent statistical review advice    有  5  个tokens\n",
      "data analyzation    有  4  个tokens\n",
      "at the request of the ethical committee    有  7  个tokens\n",
      "after a careful review of the currently available treatments worldwide for patients with attr-polyneuropathy, eidos has made the decision to halt the current study design    有  33  个tokens\n",
      "organizative problems    有  4  个tokens\n",
      "grant application for study was rejected    有  6  个tokens\n",
      "change in the landscape of current treatment of early stage breast cancer. larger clinical trials answering similar questions are expected to result in the next few years    有  28  个tokens\n",
      "failed to pass ethics committee review    有  6  个tokens\n",
      "currently does not have active irb status    有  8  个tokens\n",
      "upon further consideration of the existing data and the competitive landscape, karyopharm therapeutics inc has decided not to pursue the ongoing development of selinexor in gbm at this time    有  38  个tokens\n",
      "request of health canada after publication of https://doi.org/10.7326/m20-4207    有  21  个tokens\n",
      "study never started due to change in standard of care guideline    有  11  个tokens\n",
      "failed to pass the ministry of science and technology    有  9  个tokens\n",
      "closed based on the poor perceived clinical activity observed from a different study treating a similar patient population with same study agent    有  22  个tokens\n",
      "device malfunction    有  2  个tokens\n",
      "due to unexpectedly high rate of relapse in the active comparator arm    有  13  个tokens\n",
      "due to staffing changes and no potential subjects at this time    有  11  个tokens\n",
      "problem with acquiring study medication and poor resources    有  8  个tokens\n",
      "unable to get adequate resources to do the study    有  9  个tokens\n",
      "vaniqa no longer manufactured    有  6  个tokens\n",
      "data not useful    有  3  个tokens\n",
      "ligand was not effective    有  5  个tokens\n",
      "number of required participants met    有  5  个tokens\n",
      "imr-btl-201demonstrated that while imr-687 was generally well-tolerated, it failed to show any meaningful benefit in transfusion burden or improvement in most disease-related biomarkers. so, the sponsor has decided to discontinue this study    有  54  个tokens\n",
      "upon completion of the phase 1 portion of the nc410 monotherapy trial, nextcure focused efforts on a combination trial of nc410 in solid tumors    有  31  个tokens\n",
      "study was not approved by the institution's scientific committee    有  10  个tokens\n",
      "part 1 complete; part 2 will not be completed    有  12  个tokens\n",
      "endpoint reached    有  2  个tokens\n",
      "epidemic dynamics    有  4  个tokens\n",
      "because a device deficiency that occured in the iris vitrectomy system (alfa version)    有  17  个tokens\n",
      "sponsor desicion    有  3  个tokens\n",
      "decision to discontinue the study based on broader development and strategic prioritisation. the sponsor concludes there is no benefit-risk impact on the go41864 study    有  30  个tokens\n",
      "study staff were busy with other projects and unable to devote time to this study    有  15  个tokens\n",
      "study cancelled. different direction pursued by rhythm ai    有  9  个tokens\n",
      "study was terminated due to mtd was reached    有  9  个tokens\n",
      "institutional issue    有  3  个tokens\n",
      "not enough study participants and missing compliance to perform analysis    有  10  个tokens\n",
      "significant difference not reached on interim analysis    有  7  个tokens\n",
      "accumulated evidence (including data acquired in parallel studies, in other centres and in published literature) suggest that the technique was unlikely to produce a signal in the heart    有  32  个tokens\n",
      "student was unable to start the project due to time constraints    有  11  个tokens\n",
      "no longer feasible    有  3  个tokens\n",
      "protocol's question was answered elsewhere and very poor site interest in the trial    有  14  个tokens\n",
      "the study was withdraw due to the fast spread of omicron variant worldwide    有  15  个tokens\n",
      "change in protocol    有  3  个tokens\n",
      "participant dropout and technical difficulties    有  5  个tokens\n",
      "uneffective    有  2  个tokens\n",
      "study is on hold until pilot study is completed    有  9  个tokens\n",
      "reevaluation of development strategy    有  5  个tokens\n",
      "end of program    有  3  个tokens\n",
      "decided not to move forward with the study design    有  10  个tokens\n",
      "submitted, denied (too much steps; project to be cut in several projects)    有  16  个tokens\n",
      "poor viability    有  3  个tokens\n",
      "institutional problems    有  3  个tokens\n",
      "company no longer pursing indication    有  6  个tokens\n",
      "unable to find suitable site principal investigator. this study did not start and was withdrawn as of aug 2020 (have updated as of sept 2020, please proceed to update the status of study withdrawal accordingly)    有  43  个tokens\n",
      "we decided to change the protocol completely to an rct    有  11  个tokens\n",
      "unable to host study at clinic site    有  7  个tokens\n",
      "this study has been included in another trial within the same sponsor    有  12  个tokens\n",
      "policy change, not for security reasons    有  7  个tokens\n",
      "product expired and could not be resupplied    有  9  个tokens\n",
      "busness reason's    有  4  个tokens\n",
      "covd-19    有  4  个tokens\n",
      "the sponsor withdrawed the sponsorship to the study    有  9  个tokens\n",
      "alternative study opened with ent services    有  6  个tokens\n",
      "limitations with data    有  3  个tokens\n",
      "the study was terminated because of difficulty identifying patients that met the inclusion criteria, as well as logistical difficulties in opening clinical icu study sites    有  27  个tokens\n",
      "revising protocol    有  4  个tokens\n",
      "upon reviewing current available combo studies, the sponsor decided to prioritize different combo study    有  15  个tokens\n",
      "study will be replaced by a revised study protocol    有  9  个tokens\n",
      "preliminary data from a pilot study suggest that the administration of ivermectin in patients with sars-cov-2 is safe, reducing symptoms and viral load. the antiviral effects of ivermectin appear to depend on the dose administered    有  54  个tokens\n",
      "sponsor no longer performing clinical studies. will only be a manufacturer    有  12  个tokens\n",
      "the eua for ccp was updated by fda, stipulating that only high titer units be used. this study required untitered units. the study became infeasible    有  36  个tokens\n",
      "leaving the institution    有  4  个tokens\n",
      "principal investigator decided not to pursue trial    有  7  个tokens\n",
      "findings from aims 1 and 2 clarified that any future trial should involve provider- or clinic-level randomization, not patient-level randomization    有  29  个tokens\n",
      "study was closed due to poor resources    有  7  个tokens\n",
      "interim analysis completed    有  4  个tokens\n",
      "the primary objectives were achieved    有  5  个tokens\n",
      "too difficult to measure sublingual microcirculation continuously during a fluid challenge    有  15  个tokens\n",
      "reviewing randomization process    有  5  个tokens\n",
      "principal investigator moved to different institution    有  6  个tokens\n",
      "the study was stopped due to non availability of sample for data collection    有  13  个tokens\n",
      "study was registered but never started    有  6  个tokens\n",
      "the study was registered but never started    有  7  个tokens\n",
      "evolving data with ipatasertib that changes the known risk / benefit background in pursuing future studies    有  20  个tokens\n",
      "pi decided not to open study    有  6  个tokens\n",
      "study halted and will not resume; participants are no longer being examined or receiving intervention    有  16  个tokens\n",
      "powerspiral device recall    有  5  个tokens\n",
      "stopped after internal review    有  4  个tokens\n",
      "data don't support further development    有  6  个tokens\n",
      "inadequate number of eligible participants    有  7  个tokens\n",
      "study timeline is not feasible    有  5  个tokens\n",
      "sponsor unable to send smaller necessary capsules    有  7  个tokens\n",
      "withdrawn due to unavailability of rifampin for clinical trial use    有  14  个tokens\n",
      "principal investigator retired before study completed    有  6  个tokens\n",
      "for strategic reasons the tolebrutinib mg study has been terminated    有  15  个tokens\n",
      "the study has been terminated for reasons pertaining to feasibility    有  10  个tokens\n",
      "sponsor cancelled research    有  3  个tokens\n",
      "logistical problems in clinic    有  5  个tokens\n",
      "other - fda partial clinical hold    有  7  个tokens\n",
      "the study team decided not to move forward with the study    有  11  个tokens\n",
      "decided not to process with study    有  7  个tokens\n",
      "problem of sponsor    有  3  个tokens\n",
      "dr. ralph hoffman unexpectedly passed away    有  10  个tokens\n",
      "there is a problem with the investigational product    有  9  个tokens\n",
      "resident/felpoor feedback indicated study factors made it difficult to participate and busy schedules did not accommodate to consent    有  21  个tokens\n",
      "participants are no longer receiving intervention    有  6  个tokens\n",
      "decision made based on interim analysis results    有  7  个tokens\n",
      "study withdrawn in irb    有  5  个tokens\n",
      "failed at data quality assurance process before any analyses would be performed    有  12  个tokens\n",
      "study terminated due to poor treatment benefit    有  7  个tokens\n",
      "study terminated due to inadequate pk profile associated with the subcutaneous formulation    有  14  个tokens\n",
      "we are modifying this trial's protocol and will resubmit a new application at a later date    有  19  个tokens\n",
      "company pursuing other research paths    有  5  个tokens\n",
      "withdrawn due to poor study centers interested in participating    有  10  个tokens\n",
      "changes to protocol are necessary to optimize engagement of neural target    有  11  个tokens\n",
      "development of compound has been stopped    有  6  个tokens\n",
      "high early failure rates and adverse reactions in similar devices    有  10  个tokens\n",
      "authorization denied by ethical comitee    有  7  个tokens\n",
      "study was not needed from trial standpoint    有  7  个tokens\n",
      "investigative team no longer interested    有  7  个tokens\n",
      "further consultation is required, we plan to submit it again as a new project and proceed    有  18  个tokens\n",
      "completion failure    有  2  个tokens\n",
      "product was divested to chiesi usa, who decided to not move forward with study    有  18  个tokens\n",
      "roche/genentech has initiated an immediate pause of all new pds implantations because the implants from commercial supply in the clinical studies did not meet the filed specifications for the intended use    有  37  个tokens\n",
      "changed research approach    有  3  个tokens\n",
      "the study aims changed based on the results of a earlier qualitative study    有  13  个tokens\n",
      "preference given to gene therapy approaches by the scd research community and patients' associations    有  17  个tokens\n",
      "study never initiated in cambodia    有  6  个tokens\n",
      "the sponsor judged that the objectives of this phase 1 study were satisfied, and the study was terminated after the completion of cohort 3 step 3    有  30  个tokens\n",
      "resident did not have sufficient time to start study before graduating and leaving institution    有  14  个tokens\n",
      "sponsor has withdrawn/closed the ind with the fda. a letter dated 21nov2022 was submitted to the fda    有  26  个tokens\n",
      "termination of research grant agreement    有  5  个tokens\n",
      "decision of company to no longer develop the device    有  9  个tokens\n",
      "different study will be conducted    有  5  个tokens\n",
      "surgeon left the team    有  6  个tokens\n",
      "premature ending of the study due to impossibility of obtaining a suitable placebo-inhaler    有  19  个tokens\n",
      "this study has not been started. the sponsor has decided not to pursue this study    有  16  个tokens\n",
      "poor coordinator resources    有  4  个tokens\n",
      "it was discovered during the study that lyme disease is a bio warfare weapon made in usa. (see \"bitten\" by kris newby.) the second reason for stopping the study is poor participant responses, likely due to poor payment for completing surveys    有  51  个tokens\n",
      "the tracker application has been withdrawn by developer and no other suitable tracker application has been identified to replace it    有  20  个tokens\n",
      "agreement with project partner prematurely cancelled    有  7  个tokens\n",
      "phase 2 study r2477-fop-1940 has been withdrawn and the next phase of the development program is being planned    有  26  个tokens\n",
      "after screening many patients for bv, it was determined that the rate of bv is less in our population that the 30% rate mentioned in the literature. it was determined that completing the study will not be feasible due to cost and time constraints    有  48  个tokens\n",
      "only 19% of the expected patients have been enroled. patient's folpoor-up has not been realized as expected in the protocol    有  29  个tokens\n",
      "other - new treatment available, eliminating arm 2    有  10  个tokens\n",
      "this is an early feasibility study. after the first 4 patients completed study activities, the investigator determined that this protocol is not the best way to test the study hypothesis    有  33  个tokens\n",
      "staff who where to run the study left    有  8  个tokens\n",
      "poor personnel to run the study    有  7  个tokens\n",
      "insufficient staff to carry out study    有  7  个tokens\n",
      "due to poor likelihood of clinical benefit in treated participants    有  10  个tokens\n",
      "dsmb report    有  3  个tokens\n",
      "majority of the participants had exclusion criteria of anticoagulant use    有  14  个tokens\n",
      "principal investigator ended full-time appointment at university    有  8  个tokens\n",
      "no cec approval    有  4  个tokens\n",
      "decision of promotor    有  4  个tokens\n",
      "drug manufacturer decision to terminate development    有  6  个tokens\n",
      "study was determined not to initiate    有  6  个tokens\n",
      "the study was terminated early due to operational challenges identifying suitable participants for screening in the study    有  17  个tokens\n",
      "due to sponsor reasons    有  4  个tokens\n",
      "pending    有  1  个tokens\n",
      "changement of study design. restart spring 2021    有  11  个tokens\n",
      "protocol changes in the hospital    有  5  个tokens\n",
      "due to the poor popularity of ngs testing in china and the small number of target subjects, our company decided to adjust the research and development strategy, terminate this study and not apply for new drug registration after careful consideration    有  43  个tokens\n",
      "responsible party left institution    有  5  个tokens\n",
      "changes in drug development plans    有  5  个tokens\n",
      "closed at pi's request    有  5  个tokens\n",
      "stop of the study by competent authority (ansm)    有  11  个tokens\n",
      "funder has not approved protocol    有  6  个tokens\n",
      "study felpoor moving back to home country    有  9  个tokens\n",
      "sponsor-investigator agreement    有  5  个tokens\n",
      "based upon feedback from irb    有  6  个tokens\n",
      "it was decided by the sponsor to not proceed    有  9  个tokens\n",
      "study discontinued due to feasibility    有  5  个tokens\n",
      "recommended completion of the study due to susar occurring in other clinical trials conducted with the same drug    有  19  个tokens\n",
      "replaced by another trial    有  5  个tokens\n",
      "study published by different group; this study would not add to the existing knowledge    有  15  个tokens\n",
      "the study never opened for pandemic reasons    有  7  个tokens\n",
      "due to the extension of the clinical study duration and to avoid further delaying the reporting of results    有  18  个tokens\n",
      "the study was suspended by the irb of record and subsequently terminated    有  13  个tokens\n",
      "issues with local production of 11-cpib radiotracer    有  13  个tokens\n",
      "decided not to proceed with study    有  7  个tokens\n",
      "principal investigator leaving institution. aim 3 was not initiated    有  11  个tokens\n",
      "slot availability    有  2  个tokens\n",
      "as the revised ohb-607-202 protocol extends the study's observational arm through 24 months corrective age (ca), the shp607-203 protocol was terminated at 24 months ca    有  39  个tokens\n",
      "surgical team resigned from our hospital    有  7  个tokens\n",
      "adjust the plan    有  3  个tokens\n",
      "device modifications and relocation of principal investigator    有  7  个tokens\n",
      "adjustment plan    有  3  个tokens\n",
      "study terminated due to changes in government restrictions. collected data to be presented as a pilot study    有  18  个tokens\n",
      "we did not receive the human or monetary resources to get this study off the ground    有  16  个tokens\n",
      "pause for further assessment and study adjustment    有  7  个tokens\n",
      "study withdrawn due to change in treatment landscape for her2+ metastatic breast cancer    有  16  个tokens\n",
      "due to the company's development strategy adjustment]    有  9  个tokens\n",
      "sites have adjusted their participation priorities due to the pandemic. not enough site interest at this current time to initiate the study    有  23  个tokens\n",
      "this application needs further attention in terms of fda approval and will be reassigned under a different trial number later    有  22  个tokens\n",
      "the study was interrupted due to the arrival and distribution of the vaccine to hospital workers in peru    有  18  个tokens\n",
      "high-level results from the messina phase iii trial showed that astrazeneca's fasenra (benralizumab) did not meet one of the two dual-primary endpoints. given the poor clear benefit in this patient population, study has been terminated    有  51  个tokens\n",
      "technical support not available    有  4  个tokens\n",
      "sponsor pulled out of study    有  5  个tokens\n",
      "delays in approval by the national regulatory authority    有  9  个tokens\n",
      "new investigational drug on the same target already in clinical trials    有  12  个tokens\n",
      "subject no longer able to participate in this single pt study    有  11  个tokens\n",
      "the envision study has generated a robust data set that shows consistency in the seizure and non-seizure manifestations of scn1a+ dravet syndrome    有  30  个tokens\n",
      "withdrawn (study was withdrawn by sponsor because of change in regulatory strategy.)    有  15  个tokens\n",
      "study staffing constraints    有  3  个tokens\n",
      "in the clinical treatment, no patient with a score of less than 38(fact ntx score) points after 1-2 weeks of application of albumin bound paclitaxel in this project, therefore, there is no suitable subject after screening    有  52  个tokens\n",
      "revising study protocol    有  5  个tokens\n",
      "trial is not feasible (very poor event rates, no available risk predictor with acceptable predictive performance for discrimination of high-risk patients)    有  25  个tokens\n",
      "study design needs to be updated considering the poor a risk predictor with acceptable predictive performance for the discrimination between high- and poor-risk patients and the overall poor sudden cardiac death risk as found in the data analysis    有  40  个tokens\n",
      "poor ability to communicate with the study population    有  9  个tokens\n",
      "a recent study suggested a new corticosteroid regime for intensive care unit patients    有  16  个tokens\n",
      "study didn't proceed to fda submission    有  8  个tokens\n",
      "sig-001 programme terminated    有  5  个tokens\n",
      "liquidation of sponsor    有  4  个tokens\n",
      "study was withdrawn and replaced by a larger study    有  9  个tokens\n",
      "this clinical trial has been terminated。    有  7  个tokens\n",
      "not as a lead unit    有  5  个tokens\n",
      "at this time it has been decided by the study team the the study will no longer take place in the united states    有  23  个tokens\n",
      "there are not enough eligible patients at our institution to complete this study    有  13  个tokens\n",
      "pi does not have the time and support needed to continue the study at this time    有  16  个tokens\n",
      "met interim analysis criteria for early termination    有  7  个tokens\n",
      "same study was published from another group    有  7  个tokens\n",
      "number included    有  2  个tokens\n",
      "re-evaluation of radiotracer    有  7  个tokens\n",
      "due to logistical issues the study as designed was determined to not be feasible    有  14  个tokens\n",
      "the ip decided to stop    有  5  个tokens\n",
      "the previous studies did not show convincing results of this technology    有  11  个tokens\n",
      "contract not negotiated    有  3  个tokens\n",
      "who report    有  2  个tokens\n",
      "an rct was not valid anymore as app has become open source and will risk a contamination of study population    有  21  个tokens\n",
      "terminated due to fda withdrawal of the emergency use authorization (eua) for sotrovimab    有  21  个tokens\n",
      "results from the interim analysis    有  5  个tokens\n",
      "recall of positive airway pressure (pap) device    有  11  个tokens\n",
      "issue reglementary    有  4  个tokens\n",
      "42847922mdd3002 was stopped based on the interim analysis (ia) results as recommended by the independent data monitoring committee (idmc)    有  30  个tokens\n",
      "evaluation in process, pending new trial with similar agents    有  10  个tokens\n",
      "the study never initiated    有  4  个tokens\n",
      "considering the various conditions (other ongoing prospective studies, poor manpower), we decided not to proceed with this study    有  22  个tokens\n",
      "deprioritized by sponsor    有  5  个tokens\n",
      "due to coronavirus disease, activities inthe hospital are supressed    有  12  个tokens\n",
      "research lab not accessible due to the pandemic    有  8  个tokens\n",
      "it was repeated with other studies in the same department    有  10  个tokens\n",
      "sponsor indicated it was unable/unwilling to support project at the present time    有  15  个tokens\n",
      "decision to discontinue the study based on broader development and strategic prioritisation. the sponsor concludes there is no benefit-risk impact on the co41863 study    有  30  个tokens\n",
      "due to the pandemic, sufficient number of participants could not be received    有  13  个tokens\n",
      "due to company's internal decision    有  6  个tokens\n",
      "in an effort to seek a more suitable method to measure alcohol clearance    有  13  个tokens\n",
      "stopped at interim analysis    有  4  个tokens\n",
      "full sample size    有  3  个tokens\n",
      "review of new pre-clinical data    有  8  个tokens\n",
      "terminated due to the adjustment of sponsor's development strategies and pipeline    有  12  个tokens\n",
      "in january 2021 novartis acquired cadent therapeutics. as part of a pipeline reassessment, the synchrony-1 trial will not proceed as initially scheduled    有  35  个tokens\n",
      "withdrawn from the irb    有  6  个tokens\n",
      "terminated due to poor dimer    有  6  个tokens\n",
      "clomiphene citrate is no longer being considered as standard treatment for polycystic ovary syndrome    有  22  个tokens\n",
      "software company providing devices never responded. i believe they closed    有  11  个tokens\n",
      "issues with local regulatory authority    有  5  个tokens\n",
      "decision to discontinue in light of new evidence demonstrating that the intervention in question is not effective    有  18  个tokens\n",
      "the study was terminated due to protocol defined stopping criteria being met    有  12  个tokens\n",
      "patients were transferred to designated hospitals for treatment as needed, the clinical trials cannot be conducted    有  17  个tokens\n",
      "imp provider company (apexigen) is sold, thus both imp and grant is terminated    有  18  个tokens\n",
      "the research project was changed    有  5  个tokens\n",
      "did not have the staff to conduct the study    有  9  个tokens\n",
      "grant transfer not approved    有  4  个tokens\n",
      "no post-intervention survey completed    有  6  个tokens\n",
      "change of sponsor and trial design    有  6  个tokens\n",
      "pi moving to new institution prior to study activation    有  9  个tokens\n",
      "study terminated due to a change in development strategy    有  9  个tokens\n",
      "without cde approval    有  4  个tokens\n",
      "poor eligibility rate    有  4  个tokens\n",
      "change in personnel, unable to begin project    有  8  个tokens\n",
      "the funder stopped to fund this study    有  8  个tokens\n",
      "change in the study plan    有  5  个tokens\n",
      "development plan changed    有  3  个tokens\n",
      "new coordinating center has been defined (massachusetts general hospital)    有  12  个tokens\n",
      "principal investigator is moving to a new institution. study is closing    有  12  个tokens\n",
      "unable to get study supplies in time    有  7  个tokens\n",
      "study logistics still being worked out. on hold for now    有  11  个tokens\n",
      "sponsor no longer pursuing epilepsy development    有  6  个tokens\n",
      "withdrawn prior to study initiation    有  6  个tokens\n",
      "the patients are now folpoored in another hospital. the study is discontinued    有  15  个tokens\n",
      "study stopped due to opening expanded access protocol    有  8  个tokens\n",
      "the study was terminated as part of the decision by pfizer to halt its biosimilars programs in china    有  22  个tokens\n",
      "terminated as it is considered that necessary data have been collected    有  11  个tokens\n",
      "change of marketing authorisation holder    有  6  个tokens\n",
      "the data monitoring committee recommended to stop the trial based on the recovery trial results, which was accepted by the codex steering committee    有  25  个tokens\n",
      "randomization error    有  3  个tokens\n",
      "changing pis, waiting for approval    有  6  个tokens\n",
      "french authority's decision    有  5  个tokens\n",
      "study is suspended pending renovation and reopening of the facility manufacturing the study product    有  14  个tokens\n",
      "insufficient recrutment    有  5  个tokens\n",
      "market reasons    有  2  个tokens\n",
      "during the course of the year, we were able to answer our faisability question    有  16  个tokens\n",
      "study wasn't feasible anymore. it was withdrawn on 13 jan 2023    有  16  个tokens\n",
      "investigating interference with other in-room diagnostic equipment    有  10  个tokens\n",
      "study being replaced by crossover design    有  6  个tokens\n",
      "change of practices    有  3  个tokens\n",
      "the irb has determined that the design of this trial should be changed to a randomized controlled trial. a new record will be created for the redesigned study    有  30  个tokens\n",
      "primary investigator leaving institution    有  4  个tokens\n",
      "the study has been terminated due to changed clinical conditions and too few patients available    有  15  个tokens\n",
      "due to several considerations (logistical, human and budgetary), the study was stopped early    有  18  个tokens\n",
      "researcher leading the study moved institutions study not feasible    有  10  个tokens\n",
      "pi has changed of institution. project will be declare on the new institution clinicaltrials.gov affiliation    有  19  个tokens\n",
      "the asset was transferred to another company    有  7  个tokens\n",
      "financial    有  1  个tokens\n",
      "study was suspended 4/16/2020 due to global pandemic. plans to restart or permanently end the study are still being evaluated    有  27  个tokens\n",
      "personnel change and inadequate resources to proceed with the study    有  11  个tokens\n",
      "fda approval was received for the model amsg3-e imd and therefore commercial implants could be started. there was no longer any need to implant under the cas. cas patients were transitioned to commercial patients    有  42  个tokens\n",
      "principal investigator changed his job    有  5  个tokens\n",
      "medication has not been available for the intervention    有  9  个tokens\n",
      "recommended by the dsmb    有  5  个tokens\n",
      "due to the \"philips alert \" we could not get the treatment equipment and the public grands expired    有  20  个tokens\n",
      "new data has caused the principal investigator to decide that the study no longer makes sense to conduct as it is designed. this is not a suspension of irb approval    有  32  个tokens\n",
      "resources not available to conduct the research    有  7  个tokens\n",
      "new related protocol to be submitted    有  6  个tokens\n",
      "staffing shortage and resource prioritization    有  7  个tokens\n",
      "termination of the development project for neladenoson bialanate    有  14  个tokens\n",
      "the cessation of the development project for neladenoson bialanate    有  15  个tokens\n",
      "sponsor, tgi, was acquired by eurofins inc. new owner requested all iit's be terminated    有  22  个tokens\n",
      "equipment changed    有  2  个tokens\n",
      "the study was terminated early as the goal of determining a safe and efficacious dose for further development for the treatment of vms was not met    有  28  个tokens\n",
      "discontinuation of zandelisib development    有  9  个tokens\n",
      "due to a poor resources (human and financial), it is currently unclear if the study will be counducted    有  23  个tokens\n",
      "biomarker samples not collected    有  6  个tokens\n",
      "ebola epidemic in n-kivu has ended    有  10  个tokens\n",
      "due to the end of the arvi and influenza season, it was suspended until approximately october 01, 2023    有  25  个tokens\n",
      "pi is moving to a new institution    有  7  个tokens\n",
      "folpoor new disciplines on disease control from government    有  10  个tokens\n",
      "replaced by other study nct05747794    有  10  个tokens\n",
      "pi decided not to open study, folpooring review of data collected in another study    有  17  个tokens\n",
      "manufacturer choice    有  2  个tokens\n",
      "ganlee cancelled study -fda draft guidance: \"clinical immunogenicity considerations for biosimilar & interchangeable insulin products\" released 11/25/2019    有  32  个tokens\n",
      "division wide research suspension    有  4  个tokens\n",
      "changes in modulator landscape    有  5  个tokens\n",
      "study product composition to move from liquid to solid    有  9  个tokens\n",
      "the study expired and was not renewed with the irb    有  11  个tokens\n",
      "study is currently on hold    有  5  个tokens\n",
      "due to the corona pandemic, live patient contact was no longer possible. as a result, the study had to be stopped early    有  26  个tokens\n",
      "study terminated due to changing treatment landscape    有  7  个tokens\n",
      "cpp    有  1  个tokens\n",
      "study was dropped    有  3  个tokens\n",
      "development plan amended    有  3  个tokens\n",
      "primary objective/endpoint has been established, will not pursue development of the disease indication further    有  17  个tokens\n",
      "protocol required revisions and application was withdrawn from the irb    有  11  个tokens\n",
      "study published rendering this protocol/study obsolete    有  8  个tokens\n",
      "study never started. operational issues prevented study from rolling out    有  11  个tokens\n",
      "irb approval not received    有  5  个tokens\n",
      "device (proseal laryngeal mask airway) no longer available    有  16  个tokens\n",
      "due to the technical problem in the laser device,it has not started    有  13  个tokens\n",
      "a change in patient population at the clinical trial site has occurred due to the pandemic, resulting in too few patients for the physiotherapy program to conduct the study    有  32  个tokens\n",
      "the study was terminated early by the sponsor as sufficient data had been collected to satisfy the study objectives    有  19  个tokens\n",
      "due to corona virus guidelines, we have decided to withdraw the study    有  14  个tokens\n",
      "surgery considered elective and cant be performed within corona restrictions    有  12  个tokens\n",
      "it was confirmed that cuffed rae tubes with small diameter could be used, so there was no reason to use rae cuffless tubes    有  28  个tokens\n",
      "ethics approval is expected from the pharmaceutical institution for the study which has received the local ethics committee approval    有  20  个tokens\n",
      "technical problem, no change of the monitors in the icu ward    有  13  个tokens\n",
      "the study was terminated due to financial cost    有  8  个tokens\n",
      "modifications in methodology had to be made that make the current registration invalid    有  14  个tokens\n",
      "too many obstacles starting study    有  5  个tokens\n",
      "revised and combined with another protocol    有  7  个tokens\n",
      "needed fda approval    有  4  个tokens\n",
      "study was redesigned and submitted as a new protocol (nct04559529)    有  16  个tokens\n",
      "due to deterioration of the geopolitical situation and escalation of conflict between russia and ukraine ml42302 study was put on hold    有  25  个tokens\n",
      "coordinating site change    有  5  个tokens\n",
      "similar projects have been registered, and it need to be withdrawn    有  12  个tokens\n",
      "sage therapeutics has decided not to proceed with this study at this time    有  15  个tokens\n",
      "contracting never completed, closed the irb    有  9  个tokens\n",
      "the argx-113-1908 study will be replaced by a similar design with a subcutaneous formulation (argx-113-2004)    有  31  个tokens\n",
      "preliminary analysis showed poor positive finding, indicating a substantial number of subjects required, which is not feasible based on budget and timeline    有  26  个tokens\n",
      "intervention was not seen to be effective on interim analysis    有  11  个tokens\n",
      "the study has been terminated    有  5  个tokens\n",
      "insurance companies no longer cover this procedure    有  7  个tokens\n",
      "data from part 2 no longer deemed necessary for this program    有  12  个tokens\n",
      "an alternate device became fda approved    有  7  个tokens\n",
      "the manufacturer (clovis) supplying rucaparib has gone bankrupt and is no longer able to fund the trial and supply the product    有  28  个tokens\n",
      "per investigator's request    有  4  个tokens\n",
      "no subjects were eligible for the study. the study closed on 07-15-2021    有  19  个tokens\n",
      "epizyme inc. has revised the tazemetostat development strategy and made the decision to terminate the hematological malignancies basket trial    有  28  个tokens\n",
      "pi departure from university    有  4  个tokens\n",
      "sponsor decided to modify the prototype device used in study    有  10  个tokens\n",
      "partner termination    有  2  个tokens\n",
      "folpooring completion of arm 1, a5372 is currently temporarily closed. timeline for opening of arm 2 is not available    有  27  个tokens\n",
      "the trial has been terminated early due to the sars-cov-2 pandemic    有  16  个tokens\n",
      "trial terminated due to strategic decision of senior management    有  9  个tokens\n",
      "these is understaffed to excute study now    有  10  个tokens\n",
      "required license    有  2  个tokens\n",
      "the study was linked to another protocol that is over    有  10  个tokens\n",
      "pi changed institutions and was no longer able to continue project    有  11  个tokens\n",
      "sponsor prioritize other clinical projects over this study    有  8  个tokens\n",
      "leasing of the senhance system ended    有  8  个tokens\n",
      "the cusatuzumab mds strategy is under revision    有  12  个tokens\n",
      "compound development plan changed    有  4  个tokens\n",
      "the duration of grands was one year    有  7  个tokens\n",
      "study stopped after ethical approval but before first patient gave consent due to pandemic    有  14  个tokens\n",
      "study is no longer feasible at our site    有  8  个tokens\n",
      "the pharmaceutical company sold the compound and pulled out    有  9  个tokens\n",
      "there was no anticipated benefit of the experimental combination as tested over available standard therapies; therefore sponsor has decided to terminate the investigation    有  24  个tokens\n",
      "the study was not providing useful information    有  7  个tokens\n",
      "too many side effect in the control arm (dmso)    有  12  个tokens\n",
      "poor staff, reb closed the file due to expired renewal    有  12  个tokens\n",
      "after meeting with the fda, sparc concludes a be study will not be required    有  17  个tokens\n",
      "teminated due to changes in treatment guidelines    有  8  个tokens\n",
      "other studies on the same theme    有  6  个tokens\n",
      "pandemic, researchers no longer have access to residents of assisted living    有  14  个tokens\n",
      "decision of alternative research to be performed    有  7  个tokens\n",
      "different approach to be taken for the device    有  8  个tokens\n",
      "increased frequency of fluid overload on the aggressive fluid resuscitation arm of treatment    有  16  个tokens\n",
      "insufficient data/adherence    有  5  个tokens\n",
      "study drug not available for the study duration    有  8  个tokens\n",
      "the study was terminated based results of other studies and use of the new vaccine    有  15  个tokens\n",
      "the trial was terminated per sponsor recommendation    有  7  个tokens\n",
      "secondary to other study results, suspended for a scientific review    有  11  个tokens\n",
      "ibuprofen is not prescribed during coronavirus pandemic, so the study is stopped    有  15  个tokens\n",
      "hutchmed has decided to discontinue the hmpl 760 study    有  14  个tokens\n",
      "primary investigators    有  2  个tokens\n",
      "sufficient number of subjects would probably not reach    有  9  个tokens\n",
      "change of manufacterer of medical device    有  9  个tokens\n",
      "we decided to close this study. we are unable to perform this study due to the current pandemic    有  19  个tokens\n",
      "security concerns based on preliminary results from preceding cycov-i-study suggesting higer mortality in cytokine adsorption group    有  23  个tokens\n",
      "sponsor problem of delivering material    有  5  个tokens\n",
      "technical impasse from irb    有  6  个tokens\n",
      "based on various healthy authorities feedback on paxlovid submission, this study is no longer required    有  19  个tokens\n",
      "study no longer required by sponsor    有  6  个tokens\n",
      "intervention supply interruption    有  4  个tokens\n",
      "decision to proceed with an optimized study design and optimized vaccine formulation    有  12  个tokens\n",
      "withdrawal due to the evolution of the epidemic, the arrival of vaccination and because the associated centres could no longer commit to the number of inclusions requested    有  30  个tokens\n",
      "unlikelihood of benefit based on other studies    有  8  个tokens\n",
      "other - clinical development of the agent has been discontinued    有  10  个tokens\n",
      "the chief investigator (john keating)    有  8  个tokens\n",
      "reluctance of patients and physicians in this transfusion study setting. blood products have expired. new variants have appeared since the plasma collection period. some recent publications question the effectiveness of transfusion    有  38  个tokens\n",
      "the study was terminated after the release of results of actt-2 (nct04401579)    有  21  个tokens\n",
      "source of fmt preps is no longer able to provide us with necessary preps    有  16  个tokens\n",
      "the blistering device used for harvesting the third arm was discontinued by the manufacturer    有  15  个tokens\n",
      "working on revision to protocol    有  5  个tokens\n",
      "during a review of manufacturing equipment and cleaning activities at a supplier that manufactured study drug for this study, scynexis was made aware of potential cross-contamination risk with a non-antibacterial beta-lactam drug substance    有  46  个tokens\n",
      "the investigators have decided not to go forward with this protocol    有  11  个tokens\n",
      "study could not be implemented at the site    有  8  个tokens\n",
      "based on two large, multicenter, randomized trials showed no benefit to tocilizumab in this setting and study has been closed    有  27  个tokens\n",
      "human subjects protection review: submitted, denied    有  8  个tokens\n",
      "because of health context as well as the implementation of the raac caesarean section, which means that patients enter in the morning, and it is therefore no longer possible to do the qor on d-1 and therefore to include scheduled caesarean sections    有  54  个tokens\n",
      "study agent no longer available    有  5  个tokens\n",
      "the fda put our protocol on clinical hold and never gave an okay to start, so we decided not to proceed    有  23  个tokens\n",
      "the deployment of the integrated pathwat takes longer than expected    有  11  个tokens\n",
      "study population not regularly admitted to hospital and approaches have shifted away from repurposing old drugs    有  18  个tokens\n",
      "the study was not approved by the italian medicines agency (aifa)    有  14  个tokens\n",
      "1. few eligible patients at study start 2. patients received hfnc prior to intermediate care ward admission 3. niv was locally considered a step-up therapy to hfnc 4. full-face masks replaced the helmet interface as local niv standard    有  51  个tokens\n",
      "ethical approval was denied    有  4  个tokens\n",
      "unforeseen, continued (>12month) global shortage of study medication. study drug triesence, manufacturer novartis, not supplied throughout 2022    有  31  个tokens\n",
      "discontinued development program    有  4  个tokens\n",
      "emd serono recommendation based on three other studies that failed to show benefit for bintrafusp alfa    有  21  个tokens\n",
      "change in sponsor's strategy    有  5  个tokens\n",
      "the early termination is due to an impossibility to include new candidates due to the degraded functioning of the service in connection with a chronic paramedical decrease in the number of caregivers trained in hypnosis    有  39  个tokens\n",
      "irb and fda reviews deferred    有  7  个tokens\n",
      "due to the company's development strategy adjustment, innovant biologics decided not to continue this study after consultation with investigators    有  24  个tokens\n",
      "focus research efforts on other projects    有  6  个tokens\n",
      "the principal investigator is leaving unc and there is no other faculty to continue the research study    有  17  个tokens\n",
      "per the institutional review board    有  5  个tokens\n",
      "temporarily suspended due to staffing issues    有  7  个tokens\n",
      "vaccine rollouts in uk    有  6  个tokens\n",
      "study did not open    有  4  个tokens\n",
      "due to results from interim analysis    有  6  个tokens\n",
      "goals as defined in the study protocol were not met after the first study period. study with improved device will folpoor    有  24  个tokens\n",
      "not ever started    有  3  个tokens\n",
      "temporarily halted    有  3  个tokens\n",
      "study will not be conducted as a rct due to limited project timeline    有  14  个tokens\n",
      "cancelled before initiation    有  3  个tokens\n",
      "interim analysis indicated adaptations to intervention may be required    有  10  个tokens\n",
      "did not get enough fund and irb request    有  9  个tokens\n",
      "bellerophon requested study to be stopped    有  8  个tokens\n",
      "regulatory approvals not received    有  5  个tokens\n",
      "company focused on other clinical programs    有  6  个tokens\n",
      "sponsor determined that it must be terminated    有  7  个tokens\n",
      "chief investigator moved hospitals before the trial began. was discontinued    有  11  个tokens\n",
      "the project has been transferred to viatris    有  9  个tokens\n",
      "transfer of sponsorship    有  3  个tokens\n",
      "competent authority decision    有  4  个tokens\n",
      "interim analysis concludes that the study is futile    有  9  个tokens\n",
      "the overall protocol will be changed in a new amendment, which will be resubmitted under the new ind    有  21  个tokens\n",
      "for sponsor reasons    有  3  个tokens\n",
      "we decided to discontinue this particular clinical study through internal discussion    有  12  个tokens\n",
      "study was stopped because the promoter was changed and a new study on convalescent plasma promoted by aifa was started in italy    有  26  个tokens\n",
      "study has concluded    有  3  个tokens\n",
      "concerned about the adverse effects of hcq    有  10  个tokens\n",
      "study was not initiated due to evidence becoming available that did not support the use of hydroxychloroquine in this population, with potential risk of added harm    有  31  个tokens\n",
      "loss of former principal investigator    有  5  个tokens\n",
      "experimental treatment (atomoxetine) not available    有  8  个tokens\n",
      "never initiated - ksp lost interest    有  7  个tokens\n",
      "the study was closed prematurely because the hyperimmune plasma have expired    有  12  个tokens\n",
      "in view of the notices concerning hydroxychloroquine issued by the regulatory authorities, we withdraw the protocol    有  21  个tokens\n",
      "evidence that hcq ineffective, loss of hcw interest,    有  13  个tokens\n",
      "ansm recommandation    有  4  个tokens\n",
      "the study was not implemented    有  5  个tokens\n",
      "programmatic decision    有  3  个tokens\n",
      "terminated due to oncorus portfolio reprioritization    有  11  个tokens\n",
      "poor site participation    有  4  个tokens\n",
      "the sponsor of the study has changed. the study will be released, managed and registered by another institution who will be acting as a responsible party    有  28  个tokens\n",
      "withdrawn given new information indicating a new study design would be preferable    有  13  个tokens\n",
      "need to obtain ind approval    有  5  个tokens\n",
      "inability to achieve primary or secondary study objectives    有  9  个tokens\n",
      "unfavorable opinion of the ethics committee    有  8  个tokens\n",
      "pi withdrew the submission to the irb    有  8  个tokens\n",
      "as the possible regulatory deadline for the research was exceeded, due to logistical difficulties in setting up the study, and in agreement with the sponsor and the principal investigator, it was decided not to extend the study    有  40  个tokens\n",
      "the initiation of the expanded access program for convalescent plasma    有  12  个tokens\n",
      "the study did not get financed. never got started    有  10  个tokens\n",
      "regular mindfulness online sessions were not carried out    有  8  个tokens\n",
      "device demonstrated to be less effective than the control mask in reducing leak    有  13  个tokens\n",
      "steering committee decision in accordance with stopping rule 1: emergence of new data    有  16  个tokens\n",
      "contracts were not closed in time    有  6  个tokens\n",
      "the study was never initiated; principal investigator determined that it was not feasible to continue with the study at this time    有  22  个tokens\n",
      "industry supporter no longer supporting the study. protocol a5415's study will run instead    有  17  个tokens\n",
      "suspected unfavorable risk/benefit assessment    有  7  个tokens\n",
      "the study has been terminated due to the pandemic    有  9  个tokens\n",
      "ineffectiveness of treatment    有  5  个tokens\n",
      "sponsor has voluntarily suspended trial, to update protocol and respond to observations by the fda    有  17  个tokens\n",
      "we have withdrawn this study    有  5  个tokens\n",
      "the study did not get financed. never get started    有  10  个tokens\n",
      "organization problems    有  2  个tokens\n",
      "withdrawal of support from bms    有  7  个tokens\n",
      "not approved by ethical committee    有  5  个tokens\n",
      "study was updated and is now under irb #2023-0499    有  15  个tokens\n",
      "reduced acceptance of imp    有  5  个tokens\n",
      "grant not obtained    有  3  个tokens\n",
      "competent authority's decision    有  5  个tokens\n",
      "fda recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias    有  25  个tokens\n",
      "poor number of events contributing to primary outcome    有  9  个tokens\n",
      "pi is not moving forward with study    有  7  个tokens\n",
      "new data not in favor of prophylaxis using this regimen    有  12  个tokens\n",
      "no authorization obtained    有  3  个tokens\n",
      "terminated: study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. poor data to demonstrate sufficient power    有  26  个tokens\n",
      "several subinvestigators have left institution    有  8  个tokens\n",
      "pi does not plan on putting any new patients on study. all patients completed this trial    有  17  个tokens\n",
      "the intervention was not effective for the outcomes    有  8  个tokens\n",
      "due to technical difficulties with the online intervention    有  8  个tokens\n",
      "nida has advised us to terminate this protocol due to the difficulties in finding appropriate subjects    有  17  个tokens\n",
      "study was terminated due to poor adherence to the protocol in the intervention arm    有  14  个tokens\n",
      "the anomaly detection system is still under development and is not ready to test    有  14  个tokens\n",
      "study was stopped early due to a conflicting study in the same patient population at the study location    有  18  个tokens\n",
      "resource limitations    有  2  个tokens\n",
      "review of data revealed poor correlation with hypothesis and data quality challenges    有  12  个tokens\n",
      "other - randomized data no longer support continuation    有  8  个tokens\n",
      "ansm notifications    有  3  个tokens\n",
      "at 3d interim analysis, randomization, but not folpoor-up, was halted by the dsmb due to poor predictive probability of achieving postulated mortality benefit (pre-specified 42.5% relative mortality reduction) were the trial to complete randomization    有  54  个tokens\n",
      "regulatory approvals have not been obtained    有  7  个tokens\n",
      "logistic difficulties and loss of support from bracing company    有  11  个tokens\n",
      "investigators opted to change the design of the study    有  10  个tokens\n",
      "no found    有  2  个tokens\n",
      "inconclusive results    有  4  个tokens\n",
      "competitor test (recovery)    有  7  个tokens\n",
      "no signal of benefit of treatment    有  6  个tokens\n",
      "we did not want to start a case series as we already finished a rct...so this study is now outdated    有  23  个tokens\n",
      "study has never been started and was decided to be cancelled    有  11  个tokens\n",
      "delay in setting up the study    有  6  个tokens\n",
      "project reprioritization    有  5  个tokens\n",
      "the aavcagscd59 asset has been transferred to janssen research and development llc    有  20  个tokens\n",
      "sponsoring staff have left institution    有  7  个tokens\n",
      "equipoise for hydroxychloquine was lost    有  11  个tokens\n",
      "concerns related to study drug    有  7  个tokens\n",
      "objective of the study demonstrated by other research teams    有  9  个tokens\n",
      "insufficient sample number    有  4  个tokens\n",
      "study abandoned due to drug billing issues    有  7  个tokens\n",
      "change in study personnel and sponsor    有  6  个tokens\n",
      "interrupted early due to the drastic reduction in the number of cases    有  13  个tokens\n",
      "study was stopped because principal investigator did not obtain sponsorship to carry it out    有  14  个tokens\n",
      "bi's decision to terminate the development of spesolimab in fistulising and fibrostenotic crohn's disease    有  26  个tokens\n",
      "screening for hla combined in tcr001-201 study amendment 4    有  16  个tokens\n",
      "device deficiency    有  2  个tokens\n",
      "due to the pandemic, the primary dependent variables could not be collected as designed in the research plan    有  19  个tokens\n",
      "plan to move forward with this study has been dropped    有  10  个tokens\n",
      "the interim analysis of another associated study is not very effective    有  11  个tokens\n",
      "the trial was stopped prematurely due to external evidence that arose during the study period showing that the imp, baricitinib, was not effective in the primary study population    有  33  个tokens\n",
      "due to, among other things, positive results from the 200-302 trial, the trial has been terminated early. resources shifted to new 200-208 gbm trial using information gained from 200-302    有  43  个tokens\n",
      "termination by pharmaceutical sponsor    有  4  个tokens\n",
      "the sponsor decided to suspend the process    有  7  个tokens\n",
      "does not meet criteria for a clinical trial per irb review    有  12  个tokens\n",
      "send in by another researcher. this is terminated to avoid two identical studies    有  14  个tokens\n",
      "changes of the anti-epidemic policy    有  9  个tokens\n",
      "change in clinical landscape    有  4  个tokens\n",
      "due to pandemia    有  4  个tokens\n",
      "superseded by a separate study    有  7  个tokens\n",
      "the study needed approval from local authorities (city of oslo and city of bergen) to take place, which it did not get    有  25  个tokens\n",
      "company pipeline revision    有  3  个tokens\n",
      "there are fewer potential patients and an early conclusion of the study would be beneficial in an attempt to finish in a reasonable time and keep the cohorts homogenous    有  30  个tokens\n",
      "study was terminated at interim analysis due to drops not working on new variants    有  14  个tokens\n",
      "team decision    有  2  个tokens\n",
      "a new version of the study will be submitted    有  9  个tokens\n",
      "study suspended. protocol would need to be re-approved by the einstein irb    有  16  个tokens\n",
      "protocol withdrawal    有  2  个tokens\n",
      "poor clinical research staff    有  5  个tokens\n",
      "the pi, dr. younger, left henry ford health    有  12  个tokens\n",
      "main researcher changed institutions, making it unfeasible to be completed by the others participants    有  17  个tokens\n",
      "stanford terminated the study with no reason given    有  9  个tokens\n",
      "no interest in pursuing study    有  5  个tokens\n",
      "disapproved by relevant danish ethical committee    有  8  个tokens\n",
      "sponsor decided that there was no benefit in the drug treatment and due to company change in landscape in the new year    有  22  个tokens\n",
      "investigators no longer interested in pursuing    有  7  个tokens\n",
      "primary investigator ceased their involvement with study    有  7  个tokens\n",
      "the effectiveness trial was terminated early because the intervention proved to be ineffective in generating engagement from study participants. with such poor engagement we were unable to test our intervention with our proposed outcome measures    有  36  个tokens\n",
      "not meeting expected endpoints    有  4  个tokens\n",
      "no reliable differences across conditions, unacceptable test-retest reliability    有  11  个tokens\n",
      "changed indication    有  2  个tokens\n",
      "study stopped for commercial reasons    有  5  个tokens\n",
      "the tdcs device that was going to be used for this study is no longer being made    有  18  个tokens\n",
      "we have discontinued our 1st generation hd program with the vytal study & have initiated a 2nd generation program using a novel, proprietary aav capsid that may enable intravenous administration & achieve widespread distribution to affected tissue    有  47  个tokens\n",
      "need to wait until a new collaborator is available and confirmed    有  12  个tokens\n",
      "withdrawn due to timing    有  5  个tokens\n",
      "personale shortage    有  3  个tokens\n",
      "closed earlier than expected due to the need for a redesign to reflect the recent change in standard of care guidelines. new design will include these treatments    有  28  个tokens\n",
      "felpoorship graduation december 2021    有  9  个tokens\n",
      "dr. smart is leaving the instution    有  8  个tokens\n",
      "failed to meet fda criteria on one target at fda, cdc, and market is not looking for rapid antibody tests    有  25  个tokens\n",
      "the study is suspended because the product (nasal provocation test) is out of stock    有  18  个tokens\n",
      "the french committee refused the amendment    有  6  个tokens\n",
      "dataset not obtained    有  3  个tokens\n",
      "a revised study has been listed here for us    有  9  个tokens\n",
      "sponsor made the decision to terminate the coast study to refocus the opd5 clinical program    有  18  个tokens\n",
      "due to an internal decision to prioritise its development pipeline, clover have decided to close down study clo-scb-420-001. this was a corporate decision and not the results of new data or information arising related to scb-420    有  49  个tokens\n",
      "pi has confirmed this is not a clinical trial and was entered in error in the system    有  17  个tokens\n",
      "on the single day that the study was open, it became clear that modifications to the clip would be required. only late in 2023 did it become clear that any continuation of the project would require a new trial    有  43  个tokens\n",
      "costs exceeding budget    有  4  个tokens\n",
      "there is a duplicate study registered. the trial registration and later updates will be in nct04933500. that is the record that will be updated    有  30  个tokens\n",
      "the study protocol was not feasible. we made several modifications but halted the study prematurely before we met our target sample size goal    有  24  个tokens\n",
      "data collected did not support the study endpoints    有  8  个tokens\n",
      "pi may be leaving the institution    有  6  个tokens\n",
      "revision of clinical development strategy    有  5  个tokens\n",
      "schedule interim monitoring    有  3  个tokens\n",
      "because of logistic challenges and poor product among other factors, we decided to completely withdrawn this study    有  18  个tokens\n",
      "pi had decided to terminate the study    有  7  个tokens\n",
      "surgeons unhappy with the outcome from pre-study implants    有  12  个tokens\n",
      "no catheters    有  3  个tokens\n",
      "study endpoints no longer feasible    有  5  个tokens\n",
      "the decision to terminate this clinical study was made as a cost control measure    有  14  个tokens\n",
      "company no longer doing clinical studies    有  6  个tokens\n",
      "the decision was made by study team to pursue this as a quality project instead    有  15  个tokens\n",
      "support withdrawn from drug company supplying imp    有  7  个tokens\n",
      "decision that continuing with the study would not generate useful data    有  11  个tokens\n",
      "emerging sars-cov2 variants impacting susceptibility to study drug    有  13  个tokens\n",
      "closure/ move of mri facility    有  7  个tokens\n",
      "sponsor reorganization    有  3  个tokens\n",
      "to be replaced with a different protocol    有  7  个tokens\n",
      "seeking pivotal study initiation    有  5  个tokens\n",
      "study discontinued due to poor subject folpoor-up    有  10  个tokens\n",
      "financial protocol    有  2  个tokens\n",
      "study will not commence    有  4  个tokens\n",
      "research felpoor left trust    有  6  个tokens\n",
      "published data indicated selective trunk block is a better choice    有  10  个tokens\n",
      "stopped after 17/20 participants due to poor time after a prolonged recrutiment period    有  18  个tokens\n",
      "competing study started with same participants    有  7  个tokens\n",
      "project stopped    有  2  个tokens\n",
      "study is no longer being conducted by dr. lanius - the principal investigator has been changed from dr. ruth lanius to dr. andrew nicholson    有  33  个tokens\n",
      "since the departure of dr. lefrere no investigator has decided to take over the project    有  18  个tokens\n",
      "poor pharmacological effect    有  5  个tokens\n",
      "study not implemented    有  3  个tokens\n",
      "car-t manufacturing technology can not meet the dose requirement for clinical patients    有  13  个tokens\n",
      "change of trial components    有  4  个tokens\n",
      "opted to not conduct this study; revised to a more condensed study    有  14  个tokens\n",
      "stopped for strategic reasons    有  4  个tokens\n",
      "new evidence warranted a change in the study design and study population group (inclusion/ exclusion criterion). we completed another clinical trial focused on subjects with headache symptoms but this particular clinical trial was terminated    有  38  个tokens\n",
      "awaiting change to device under investigation    有  7  个tokens\n",
      "the study cannot be conducted    有  5  个tokens\n",
      "poor eligible participants due to change in study criterias    有  11  个tokens\n",
      "could not obtain mini licence    有  5  个tokens\n",
      "this was a review of existing de-identified records    有  10  个tokens\n",
      "study was terminated by ip holder (collaborator), pinotbio inc    有  15  个tokens\n",
      "this study was combined with another study    有  7  个tokens\n",
      "the p.i. is not prepared to move forward at this thime    有  14  个tokens\n",
      "the sponsor decided to terminate the study early    有  8  个tokens\n",
      "product pulled off the market/production of product stopped    有  10  个tokens\n",
      "the food supplement/health product registration needs to be undertaken with nhra- pharmaceutical product regulations department    有  19  个tokens\n",
      "indefinite paused for staffing issues    有  7  个tokens\n",
      "study terminated as end points were not achieved at current dose level    有  12  个tokens\n",
      "not yet meeting health canada's requirements for clinical trials    有  10  个tokens\n",
      "conflicts at the study site prevented the study from being carried out    有  13  个tokens\n",
      "per study team, the study will not proceed    有  9  个tokens\n",
      "investigator coordinatoor left the site and the trial    有  11  个tokens\n",
      "insufficient study resources and change in practice    有  8  个tokens\n",
      "the study was terminated due to a change in the benefit/risk assessment for the further administration of marstacimab in a healthy volunteer population    有  29  个tokens\n",
      "replaced by nct05010629    有  8  个tokens\n",
      "approx. half of all samples withdrawn are readily available from another institute. hence, it is unethical to draw more blood from patients in the elicit-trial    有  31  个tokens\n",
      "the closure of the study is driven by the decision to redesign the study protocol for future studies    有  18  个tokens\n",
      "data will be written up as a pilot rct study and experiences and results will inform the start of a multi-site trial    有  24  个tokens\n",
      "decided not to go ahead with study    有  8  个tokens\n",
      "reached the sample size    有  5  个tokens\n",
      "due to the current re-organization at the sponsor site    有  11  个tokens\n",
      "sponsor decided to stop    有  4  个tokens\n",
      "the study was withdrawn based on an assessment of immunogenicity in elderly adults    有  15  个tokens\n",
      "the sponsor decides withdrawn this study    有  6  个tokens\n",
      "the ap-017 study was prematurely terminated by the sponsor after an interim analysis    有  15  个tokens\n",
      "delay in availability of imp    有  5  个tokens\n",
      "not achieve the desired effect    有  5  个tokens\n",
      "adjustment of the clinical development plan for this product globally    有  11  个tokens\n",
      "retrospective study    有  4  个tokens\n",
      "termination of collaboration with puma    有  6  个tokens\n",
      "the study was terminated after interim data analysis    有  8  个tokens\n",
      "most potential participants had already received their booster vaccinations outside of the study    有  13  个tokens\n",
      "due to financial problem    有  4  个tokens\n",
      "the ap-019 study was prematurely terminated by the sponsor after determining that insufficient events were occurring to analyze the primary endpoint    有  23  个tokens\n",
      "the study didn't get the authorization from health authority    有  10  个tokens\n",
      "change of a principal investigator    有  5  个tokens\n",
      "the device manufacturer has received a hde for this population from the fda    有  15  个tokens\n",
      "financial support could not be obtained for the study    有  9  个tokens\n",
      "\"during the feasibility study, it came to the research group's attention, that data was collected in an unauthorized manner. therefore the trial has been terminated    有  30  个tokens\n",
      "sponsor decided to close the study    有  6  个tokens\n",
      "duplication    有  2  个tokens\n",
      "undergoing nrevision    有  4  个tokens\n",
      "device unavailable    有  2  个tokens\n",
      "end of the supporting fund    有  5  个tokens\n",
      "the sponsor closed the study due to discontinuing their onapristone program    有  15  个tokens\n",
      "the results of the genomic analyses were compromised due to the poor dna concentration    有  14  个tokens\n",
      "o estudo foi encerrado pois não foi atingido o número de participantes, de acordo com o cálculo amostral    有  28  个tokens\n",
      "review of preliminary results suggested we will have an insufficient sample size    有  12  个tokens\n",
      "study was never fully reopened with the intuitional review board    有  12  个tokens\n",
      "although cellular responses to virus were satisfactory, neutralizing titres against virus were poorer then expected levels    有  19  个tokens\n",
      "the study was stopped due to unanticipated feasibility constraints    有  10  个tokens\n",
      "the study device vici stent withdrawn from market    有  10  个tokens\n",
      "end of shelf life of investigational devices    有  8  个tokens\n",
      "economic reasons    有  2  个tokens\n",
      "pi moved to another institution and closed study    有  8  个tokens\n",
      "the principal investigators and curevac decided to terminate the trial early folpooring a change to the risk/benefit profile    有  23  个tokens\n",
      "the substudy in premature infants was completed. the substudy in adult volunteers will not be continued, due to previous delays    有  24  个tokens\n",
      "study superseded by alternative phase 3 trial    有  9  个tokens\n",
      "surgeons stopped doing procedures    有  6  个tokens\n",
      "research operation issues    有  3  个tokens\n",
      "house staff unable to folpoor protocol due to short staffing, turnover, and travel nursing    有  18  个tokens\n",
      "technical difficulties of the developer    有  5  个tokens\n",
      "fda agreed that wp02 cap could be stopped. the organox metra device was approved on december 9, 2021. the 105 planned cap patients will be included in the post-approval study (nct05526326)    有  50  个tokens\n",
      "treatment paradigm in second- and third-line nsclc is shifting away from docetaxel, the backbone chemotherapy therapy used in this study    有  28  个tokens\n",
      "phase 2 completed, phase 3 sponsor decided to terminate    有  12  个tokens\n",
      "change on clinical and marketing strategy for intramedullary devices    有  12  个tokens\n",
      "trial terminated based on benefit-risk profile assessment    有  8  个tokens\n",
      "pi request to close study    有  5  个tokens\n",
      "no candidates for the trial (all patients have received the third dose of the vaccine)    有  17  个tokens\n",
      "negative information    有  2  个tokens\n",
      "pi decided not to proceed with study    有  7  个tokens\n",
      "study suspended until new therapeutic units are available    有  8  个tokens\n",
      "there were issues with the primary study material that prohibited continuation at this time    有  14  个tokens\n",
      "insufficient sample size    有  4  个tokens\n",
      "modifying protocol    有  3  个tokens\n",
      "study objective embedded into future study    有  6  个tokens\n",
      "issues with supplier of strength testing equipment    有  7  个tokens\n",
      "the trial was suspended due to the budget issue    有  9  个tokens\n",
      "study team decided to conclude the study and report it as a feasibility study    有  14  个tokens\n",
      "company adjusted strategy    有  3  个tokens\n",
      "protocol changed to phase 2    有  6  个tokens\n",
      "sponsor made decision to terminate study    有  6  个tokens\n",
      "investigator changed positions    有  4  个tokens\n",
      "study never started because reprioritization of clinical research efforts    有  12  个tokens\n",
      "during the trial, feasibility testing indicated early on that major amendments would be needed so the decision was made to stop the pilot after collecting data on 4 participants    有  31  个tokens\n",
      "no financial agreement could be found for this study    有  9  个tokens\n",
      "at collaborator's request    有  5  个tokens\n",
      "study was terminated early as part of biogen's ongoing research and development portfolio management efforts    有  17  个tokens\n",
      "alternative study was set up    有  5  个tokens\n",
      "nyspi-wide institutional research pause as of june 12, 2023    有  17  个tokens\n",
      "due to the retention of 78.1% of the participants obtained for the first measurement (after the december holidays), we believe that waiting one more year to complete the study would not be feasible for a subsequent definitive study    有  44  个tokens\n",
      "coral underwent an apa and is no longer in operation    有  11  个tokens\n",
      "shift in research focus    有  4  个tokens\n",
      "organizational difficulties    有  3  个tokens\n",
      "study has been early terminated due to change of study protocol and study will be commence with new protocol and study number    有  22  个tokens\n",
      "copmeletion of part a sad cohorts, sponsor cancelled part b-d cohorts    有  15  个tokens\n",
      "akari has decided to discontinue ak802 study due to strategic resource allocation decisions    有  16  个tokens\n",
      "data collection is no longer necessary    有  6  个tokens\n",
      "staff not available to support study    有  6  个tokens\n",
      "prioritization    有  3  个tokens\n",
      "alt flares suggestive of drug induced liver injury    有  9  个tokens\n",
      "change in surgical technique (lateral approach vs anterior approach for hip arthroplasty, determining a change in patient intraoperative positioning)    有  27  个tokens\n",
      "no sponsor support    有  3  个tokens\n",
      "there is disconnect between dietary guidelines to limit potassium intake in dialysis and clinical practice. the number of unknowns and differences make the results unlikely to be translatable into clinical practice and will not benefit patients    有  40  个tokens\n",
      "company withdrew interest in the study    有  6  个tokens\n",
      "study put on hold    有  4  个tokens\n",
      "drug manufacturing update. study site will proceed with study in future    有  12  个tokens\n",
      "sponsor no longer has support available    有  6  个tokens\n",
      "terminated prematurely due to closure of the pet imaging facility    有  10  个tokens\n",
      "repeat registration    有  2  个tokens\n",
      "pilot study; collection of information completed    有  8  个tokens\n",
      "this study is not a clinical trial    有  7  个tokens\n",
      "further development terminated    有  4  个tokens\n",
      "study moved to u.s    有  5  个tokens\n",
      "study didnt start and will be re-designed    有  8  个tokens\n",
      "new ind sponsor to initiate a separate study    有  8  个tokens\n",
      "poor provider bandwidth    有  4  个tokens\n",
      "to alpoor for additional assessments from supplementary non-clinical activities    有  14  个tokens\n",
      "u.s. department of health and human services ohrp issued an fwa restriction on nyspi research that included a pause of human subjects research as of june 23, 2023. nki site will reopen pending transfer of irb protocol    有  52  个tokens\n",
      "the project was abandoned because of a lot of publications on the subject in the meantime and it was not considered relevant to continue    有  24  个tokens\n",
      "the health authority indicates that the official vaccination schedule differs from that described in the protocol    有  16  个tokens\n",
      "drug product unavailability    有  4  个tokens\n",
      "unresolved issues between research partners (research has not started)    有  12  个tokens\n",
      "the nct posting for the study has been transferred to nct04060680    有  16  个tokens\n",
      "study stopped due to poor personnel and budget    有  8  个tokens\n",
      "tachycardia and arrhythmia in the high doses groups 0.05 and 0.07 necessitate stopping the infusion    有  28  个tokens\n",
      "study will be changed from prospective to retrospective    有  8  个tokens\n",
      "investigators have limited availability    有  5  个tokens\n",
      "the sponsor is considering a subsequent study in als, potentially with different inclusion/exclusion criteria    有  17  个tokens\n",
      "company research strategy adjustment    有  4  个tokens\n",
      "not enough sample was obtained    有  5  个tokens\n",
      "the study team decided to not publish a manuscript therefore we decided to terminate the study    有  16  个tokens\n",
      "no path to obtain fda approval for the legacy precision fpoor oam    有  16  个tokens\n",
      "decision of the coordinator    有  4  个tokens\n",
      "participant drop out exceeded expectations (out of 63 couples randomized, 18 completed folpoor up). study may be resumed with revised procedures for preventing drop out    有  32  个tokens\n",
      "study halted due to unforeseen challenges in securing the necessary resources to conduct the research effectively    有  17  个tokens\n",
      "inadequate support to carry out study    有  8  个tokens\n",
      "the study is being reformatted and will have a different protocol for the relaunch    有  16  个tokens\n",
      "working on changing study vendor    有  5  个tokens\n",
      "no financial budget support    有  4  个tokens\n",
      "sponsor changing database systems for ease of use for patient data collection    有  12  个tokens\n",
      "relaunch at later date with updated product    有  8  个tokens\n",
      "institution change, no irb approval    有  7  个tokens\n",
      "decision by sponsor after careful review of study data available    有  10  个tokens\n",
      "no practitionner    有  3  个tokens\n",
      "due to pandemic conditions    有  4  个tokens\n",
      "no available investigational product    有  5  个tokens\n",
      "substantial efforts to engage participants in the evaluations was unsuccessful    有  11  个tokens\n",
      "the study data will not be utilized in the ind and is only being conducted in eu    有  17  个tokens\n",
      "withdrawn, considering alternative trial design    有  7  个tokens\n",
      "limitations of the prospective study design revealed that a retrospective study design would be better suited    有  16  个tokens\n",
      "inability to achieve and optimize a dose that could provide a positive benefit risk profile    有  16  个tokens\n",
      "could not identify a replacement principal investigator    有  7  个tokens\n",
      "the investigators never completed the irb application due to decrease in need to conduct the study    有  17  个tokens\n",
      "we are no longer going to undertake the study    有  9  个tokens\n",
      "the standard of care of adjuvant therapy for liver cancer was changed    有  14  个tokens\n",
      "institutional standard of care regarding axillary management changed. decision was made to close the study early    有  19  个tokens\n",
      "all patients completed the primary endpoint assessments. additional folpoor-up after the primary endpoint was deemed not necessary by the sponsor    有  24  个tokens\n",
      "protocol was substantially revised    有  4  个tokens\n",
      "sponsor decided to withdrawn the study as development strategy has changed    有  11  个tokens\n",
      "there has been no unanimous approval by the investigators regarding the approval of the study protocol. therefore, by mutual agreement, sponsor and investigators have taken the decision to withdraw the clinical study    有  35  个tokens\n",
      "abandoned study project    有  4  个tokens\n",
      "change in departmental research focus    有  6  个tokens\n",
      "a conflicting project required the same sample for a different purpose    有  11  个tokens\n",
      "forgotten    有  2  个tokens\n",
      "research facility was restructured and no longer treated subjects in the study population    有  14  个tokens\n",
      "the protocol need to review    有  5  个tokens\n",
      "high incidence of severe radiation pneumonia    有  6  个tokens\n",
      "the study terminated because the clinical development programme for adavosertib has been discontinued    有  17  个tokens\n",
      "the study was early terminated because new data related to the investigational device were available making this investigation no longer scientifically relevant    有  23  个tokens\n",
      "inserter device did not perform as expected    有  8  个tokens\n",
      "technical problem with vx1 software    有  6  个tokens\n",
      "withdrawn secondary to a change in protocol design forthcoming    有  10  个tokens\n",
      "enough participants were included, which made it possible to answer the objectives of the study    有  17  个tokens\n",
      "no longer pursuing indication    有  4  个tokens\n",
      "this study has been terminated due to a change in study design. the study is no longer a rct    有  21  个tokens\n",
      "technical problems with sensitivity of mass spectral detector    有  8  个tokens\n",
      "the vaccination campaign started before the approval of the ethics committee was obtained. the study is therefore no longer of interest to be carried out    有  26  个tokens\n",
      "amgen withdrew interest in providing further financial support    有  9  个tokens\n",
      "as the team at nancy university hospital published the same study last year, on the competing czt 3d system (veriton), our study is no longer relevant    有  34  个tokens\n",
      "the study met the protocol defined stopping boundary for day 60 mortality when comparing mortality between the t-guard and ruxolitinib arms    有  27  个tokens\n",
      "study terminated early to pursue gen ii laser advancements    有  9  个tokens\n",
      "the decision to close is due commercial reasons only    有  9  个tokens\n",
      "failure of the phase 2 study (protocol fb401-01) to meet its endpoint    有  18  个tokens\n",
      "study closed by the sponsor    有  5  个tokens\n",
      "principal investigator no longer at study site    有  7  个tokens\n",
      "please refer to nct05621837    有  8  个tokens\n",
      "change in lab priority    有  4  个tokens\n",
      "change on clinical and marketing strategy for the devices    有  9  个tokens\n",
      "early termination of study pending evaluation of emerging preclinical profile    有  11  个tokens\n",
      "pivoting to an allogeneic version of this program currently in preclinical development    有  18  个tokens\n",
      "a decision has been taken to discontinue the development of azd8233 (pcsk9-aso for sc administration) due to poor likelihood of demonstrating a benefit significantly above the current standard of care for patients with high-risk hypercholesterolemia    有  51  个tokens\n",
      "grant not alpoored    有  5  个tokens\n",
      "1. short defense deadline 2. activity cessation of the maxillofacial surgery department at pitié salpêtrière hospital    有  28  个tokens\n",
      "a key faculty at our college who was helping with the project left the college    有  15  个tokens\n",
      "poor lab resources    有  4  个tokens\n",
      "cooperation plan has been changed    有  6  个tokens\n",
      "professional decision    有  2  个tokens\n",
      "device modifications needed    有  3  个tokens\n",
      "due to corporate strategic considerations    有  5  个tokens\n",
      "no study activity took place. the ind was withdrawn with the fda by the sponsor investigator because of insurmountable hurdles in moving proposed research forward    有  30  个tokens\n",
      "change in core study organization    有  5  个tokens\n",
      "the study was suspended and terminated    有  6  个tokens\n",
      "company financing    有  2  个tokens\n",
      "study withdrawn due to poor supply of one of the investigational agents    有  13  个tokens\n",
      "pi decision to cancel research    有  5  个tokens\n",
      "withdrawn prior to einstein irb approval    有  9  个tokens\n",
      "gcp violations from the sponsors    有  6  个tokens\n",
      "update to marketing strategy for hip robotics and related instrumentation    有  10  个tokens\n",
      "research never commenced and will not be pursued as a viable opportunity at this time    有  15  个tokens\n",
      "production of the brilife vaccine was halted by government sponsor    有  12  个tokens\n",
      "withdrawal of macrogenics (pharmaceutical company)    有  12  个tokens\n",
      "urgent medical device product (orise gel submucosal liftiong agent) removal by sponsor    有  20  个tokens\n",
      "per email from pi, the project start is on suspension    有  11  个tokens\n",
      "sponsor decided not to pursue the study. study ended prior to study start    有  14  个tokens\n",
      "results not goal-oriented, premature termination    有  7  个tokens\n",
      "terminated by mutual agreement by sponsor and institution    有  8  个tokens\n",
      "the study was never started due to poor staff    有  9  个tokens\n",
      "attempts at online data collection have led to poor data quality (many missing data points from one task of the set). study suspended while we evaluate whether the study should continue, given the data quality issues    有  40  个tokens\n",
      "null results were posted from a neurometabolite study and a recent trial for aud. study may resume if more positive data emerge    有  27  个tokens\n",
      "due to protocol changes, and the observational design of this study (not an act), the study registry is withdrawn from clinicaltrials.gov    有  27  个tokens\n",
      "withdrawn due to financial reasons    有  6  个tokens\n",
      "nektar therapeutics made the decision to discontinue the bempegaldesleukin program based on three negative studies. sfj pharmaceuticals, inc. and nektar therapeutics, in consultation with the study idmc, have decided to discontinue propel-36    有  56  个tokens\n",
      "study protocol is being significantly changed study is therefore being terminated and will re-open under new title and study number    有  21  个tokens\n",
      "we raised ethical concerns to proceed an invasive study despite having shown the expected results after 19 patients    有  19  个tokens\n",
      "resourcing challenges    有  3  个tokens\n",
      "change of strategy    有  3  个tokens\n",
      "no irb application has been prepared for this study and other studies have taken priority. the study team will not be working on this study for the foreseeable future    有  31  个tokens\n",
      "poor capacity    有  3  个tokens\n",
      "decision to not proceed with study    有  6  个tokens\n",
      "principle investigator decided not to pursue study    有  8  个tokens\n",
      "protein product reconfiguration    有  4  个tokens\n",
      "due to the limited resources and staffing needed in order to run the trial    有  14  个tokens\n",
      "primary endpoint met    有  3  个tokens\n",
      "no fund was obtained for buying the hormonal iud    有  10  个tokens\n",
      "study device refinement in process    有  5  个tokens\n",
      "study suspended until priorities can be reassessed    有  8  个tokens\n",
      "an six-month folpoor-up was completed after the treatment    有  12  个tokens\n",
      "failed resources    有  2  个tokens\n",
      "change in routine care was not implemented at organization    有  9  个tokens\n",
      "sponsor strategy decision    有  3  个tokens\n",
      "no longer interested in conducing study    有  7  个tokens\n",
      "no practitioner    有  2  个tokens\n",
      "further preclinical development activities required to proceed    有  9  个tokens\n",
      "it was in the best interest of the investigator to terminate the study earlier than anticipated    有  16  个tokens\n",
      "the principal investigator withdraws from the project for personal reasons    有  11  个tokens\n",
      "study was never submitted to the ethics committee    有  8  个tokens\n",
      "product manufacturing    有  2  个tokens\n",
      "pi has withdrawn from the program, the study never started    有  11  个tokens\n",
      "c. difficile symptoms preclude participants from attending research study visits    有  12  个tokens\n",
      "a new study combining phase iii clinical trials has been planned    有  11  个tokens\n",
      "study suspended 06feb2020 per fda request    有  11  个tokens\n",
      "denied by human subjects protection board    有  7  个tokens\n",
      "flu season over    有  3  个tokens\n",
      "suspended temporarily due to limited drug supply    有  8  个tokens\n",
      "drop out from surgeons from 3 to 1. it will take too long to feasibly accrue with only one provider    有  25  个tokens\n",
      "part a of the study was completed; part b of the study was terminated    有  15  个tokens\n",
      "rapid changes in the treatment mode of melanoma worldwide and in china and the development strategy change    有  18  个tokens\n",
      "study terminated early due to program discontinuation    有  8  个tokens\n",
      "trial withdrawn based on portfolio prioritization; oral atri m1774 in combination with niraparib is under investigation in ddriver solid tumor 301    有  31  个tokens\n",
      "discharge to a sub-acute rehabilitation after arthroplasty surgery is discouraged after due to the pandemic. the protocol is being revised to remove this arm of the study    有  34  个tokens\n",
      "no financement afam    有  5  个tokens\n",
      "in april 2021 fda revoked the emergency use authorization after determining that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use    有  44  个tokens\n",
      "pi no longer pursuing clinical trial    有  6  个tokens\n",
      "study never started - clinical strategy changed    有  7  个tokens\n",
      "termination / study goals reached    有  5  个tokens\n",
      "study has been placed on hold    有  6  个tokens\n",
      "withdrawal of phd    有  5  个tokens\n",
      "the trial was stopped earlier than planned after an ad hoc interim analysis    有  13  个tokens\n",
      "not approved by cfda    有  5  个tokens\n",
      "it was determined that the study should not continue as the study drug, acetaminophen, could only be mixed in a solvent that would not alpoor the patients to be npo prior to procedure    有  41  个tokens\n",
      "protocol is not feasible based on the available hospital records    有  10  个tokens\n",
      "difficulty in getting participants to accept participating    有  7  个tokens\n",
      "the study was stopped in order to reconfigure it as a phaseii/iii study    有  17  个tokens\n",
      "other - crossed ae stopping rule    有  6  个tokens\n",
      "new medical team and surgical center location    有  7  个tokens\n",
      "study was withdrawn due to redesign of the protocol    有  9  个tokens\n",
      "ethics application has not been completed yet    有  8  个tokens\n",
      "the sponsor has decided to focus their resources on other areas of therapy    有  13  个tokens\n",
      "the patient population is too poor to conduct the study in a feasible and meaningful amount of time    有  18  个tokens\n",
      "no more medical device implantation    有  6  个tokens\n",
      "dose was not therapeudic    有  8  个tokens\n",
      "intermittent paradigm replaced with change in frequency and amplitude. the updated protocol is nct04909138    有  21  个tokens\n",
      "capacity issues within team after pandemic & unable to progress with the study    有  13  个tokens\n",
      "unavailability of primary investigator    有  5  个tokens\n",
      "closure of main community treatment center    有  6  个tokens\n",
      "voluntarily withdrawn    有  4  个tokens\n",
      "interim analysis of preliminary results indicated a need for protocol re-design    有  13  个tokens\n",
      "considering that the high budget will affect the subsequent development, it is decided to terminate the test voluntarily    有  20  个tokens\n",
      "principal investigator has lapsed irb approval, tbd if they will reopen    有  15  个tokens\n",
      "sufficient samples and data have been collected for data analyses    有  11  个tokens\n",
      "we had difficulty with participation in the study for our initial zoom cbt group    有  15  个tokens\n",
      "unable to attend the drug for study    有  7  个tokens\n",
      "study recommended for closure    有  4  个tokens\n",
      "study withdrawn prior to screening subjects    有  6  个tokens\n",
      "manufacturer reevaluating digital cognitive-behavioral stress management (cbsm) device (attunetm)    有  24  个tokens\n",
      "non-significant intemedial analysis    有  7  个tokens\n",
      "adverse reactions (tonsillar bleeding after treatment)    有  11  个tokens\n",
      "this sub-study was combined to the parent study protocol (nct04685317)    有  18  个tokens\n",
      "adjustment of clinical development plan    有  6  个tokens\n",
      "no longer aligned with company strategy    有  6  个tokens\n",
      "pi, christopher tirotta, no longer at nch as of 5-26-23    有  21  个tokens\n",
      "limited candidate pool    有  3  个tokens\n",
      "alternate approach pursued    有  3  个tokens\n",
      "time availability within phd studentship    有  7  个tokens\n",
      "poor potential participants given the other treatment options currently available to people    有  13  个tokens\n",
      "for interests of sponsor    有  4  个tokens\n",
      "plan adjustment    有  2  个tokens\n",
      "the local research project is cancelled because of the organizational issues    有  11  个tokens\n",
      "pi does not wish to move forward with the study    有  10  个tokens\n",
      "assessing novel alternative study designs and regulatory pathways    有  10  个tokens\n",
      "implant to be analysed not used at study centre any more    有  12  个tokens\n",
      "this study has been cancelled due to the pandemic and we are planning on starting a similar study hopefully next year    有  21  个tokens\n",
      "treatment practice unexpectedly changed during the course of the study. majority of folpoor-up mri performed in external institutions. consequently, the planned number of participants could not be reached    有  36  个tokens\n",
      "lead researcher off sick    有  4  个tokens\n",
      "devices recall due to hermeticity problems    有  8  个tokens\n",
      "pi retirement    有  2  个tokens\n",
      "not possible to conduct study    有  5  个tokens\n",
      "folpooring the internal pilot, the study did not meet prespecified stop/go criteria for continuation    有  19  个tokens\n",
      "the trial is on hold due to clinical trials staffing shortages    有  11  个tokens\n",
      "salarius discontinued support    有  4  个tokens\n",
      "the fda requirements for the ind are not feasible to complete    有  12  个tokens\n",
      "hypothesis change    有  4  个tokens\n",
      "investigator changed sites    有  4  个tokens\n",
      "the ide wasn't approved    有  5  个tokens\n",
      "the study protocol should to be updated (major updates), folpooring the second health canada review /requests. the study has been withdrawn form the reb review and will not be performed at sickkids    有  39  个tokens\n",
      "the research team (pi and sponsor) have agreed that this study would not be feasible to continue    有  19  个tokens\n",
      "the co and principal investigator, due to limited resources and timing, have decided to withdrawal the study and close    有  21  个tokens\n",
      "pi decided to close study early    有  6  个tokens\n",
      "site selection process has been revisited    有  7  个tokens\n",
      "the study team did not proceed with study start-up    有  10  个tokens\n",
      "reached biomarker endpoint    有  5  个tokens\n",
      "pi moved institutes in nih, and this protocol was redundant with an existing clinical protocol within the new institute    有  21  个tokens\n",
      "priority reasons    有  2  个tokens\n",
      "decisions made by senior management of the company    有  9  个tokens\n",
      "study period ended/ not completed    有  6  个tokens\n",
      "dlts    有  2  个tokens\n",
      "unfavorable opinion of irb/iec    有  9  个tokens\n",
      "pi transferred institutions; the grant was not transferred to the new university    有  13  个tokens\n",
      "sponsor has adjusted study development plan and terminated this clinical study    有  11  个tokens\n",
      "pi did not pursue this study    有  6  个tokens\n",
      "the sponsor's development strategy adjustment resolution is terminated    有  9  个tokens\n",
      "collected sufficient samples for analysis    有  6  个tokens\n",
      "study withdrawn as scientific interest in pursuing the syd985+paclitaxel combination has diminished    有  20  个tokens\n",
      "delayed    有  2  个tokens\n",
      "decrease in in-vitro neutralization of study drug against circulating sars-cov-2 variants    有  21  个tokens\n",
      "pi decided to pursue the same aims using a different methodology, specifically a single-case experimental design, also called n-of-1 trial to answer research questions after consultation with research mentors and consultants    有  37  个tokens\n",
      "the study purpose has been achieved    有  6  个tokens\n",
      "sponsor has currently elected to withhold study initiation    有  8  个tokens\n",
      "updated technology nearly ready    有  4  个tokens\n",
      "ora-d-013-1 was terminated based on the primary results analyzed at the end of the treatment, week 26    有  24  个tokens\n",
      "current sample size sufficiently powers the study to evaluate outcome measures    有  11  个tokens\n",
      "will be conducted as a different study with different sponsorship    有  10  个tokens\n",
      "scientific committee decision due sars-cov2 pandemic evolution with a decrease in inclusions and widespread distribution of vaccines    有  22  个tokens\n",
      "other - awaiting amendment approval    有  5  个tokens\n",
      "no approval from ethical committee    有  5  个tokens\n",
      "no longer proceeding with this study    有  6  个tokens\n",
      "due to notification from emd serono, for bintrafusp alfa (m7824) regarding an observed increase in the frequently of early progression and death    有  33  个tokens\n",
      "money issues    有  2  个tokens\n",
      "adct is reallocating all resources to the phase iii program    有  12  个tokens\n",
      "abandonment of the study project    有  7  个tokens\n",
      "the bloom-ltfu study has evolved into the ongoing bloom-pcs study (reb20-1442)    有  22  个tokens\n",
      "folpooring submission of the amended protocol, the ethic commitee requested sponsor to resubmit it like a new protocol    有  25  个tokens\n",
      "to update technology based on feedback from participants    有  8  个tokens\n",
      "the main reasons for the premature termination of the study are the inability to reliably assess the effectiveness of therapy due to the emergence of new variants of sars-cov-2 and reports of the poor benefits of using plasma in previous studies    有  46  个tokens\n",
      "study not properly designed for outcome measure    有  7  个tokens\n",
      "could not collect adequate samples    有  5  个tokens\n",
      "cancellation by sponsor    有  4  个tokens\n",
      "no further benefit    有  3  个tokens\n",
      "the data from this study is no longer needed    有  9  个tokens\n",
      "study terminated folpooring strategic portfolio and r&d alignment    有  12  个tokens\n",
      "less participants than required    有  4  个tokens\n",
      "the investigators were unable to begin work on this study    有  10  个tokens\n",
      "one of the participating specialties has decided to no longer cooperate in this research    有  14  个tokens\n",
      "unavailable subjects    有  3  个tokens\n",
      "the development and generalisation of vaccination led to a significant drop in the number of patients meeting the inclusion criteria    有  21  个tokens\n",
      "investigator is no longer employed in study site    有  9  个tokens\n",
      "change in study design was implemented and the study design no longer folpoors a pilot randomized controlled trial    有  20  个tokens\n",
      "clcz696g2301e1 extension study did not start as the core study (clcz696g2301) did not meet the primary endpoint    有  31  个tokens\n",
      "withdrawn pending formal analysis of reduce lap-hf ii pivotal study results    有  14  个tokens\n",
      "logistics problems    有  3  个tokens\n",
      "insufficient money    有  3  个tokens\n",
      "contract was never finalized    有  4  个tokens\n",
      "the new director of the program temporarily stopped the study    有  10  个tokens\n",
      "due to shifting post-pandemic clinical landscape, concurrent study (nct04634916) to provide results on analogous endpoints in advance of current projections    有  30  个tokens\n",
      "change in approach to study    有  5  个tokens\n",
      "novartis farma - produtos farmaceuticos s.a. no longer commercializes the product    有  19  个tokens\n",
      "never approved    有  2  个tokens\n",
      "change in research personnel    有  4  个tokens\n",
      "left employment with job and study site    有  7  个tokens\n",
      "in view of the very positive results obtained with the copper dressings after 20 patients, the researchers decided to apply copper dressings from the beginning of wound management, not to use anymore silver dressings and to terminate the trial    有  45  个tokens\n",
      "initial results showed no equivalence between gebt test meals with poor nitrogen versus a standard gebt test meal    有  20  个tokens\n",
      "investigational drug removed from the market    有  8  个tokens\n",
      "the rate of data collection was too poor    有  8  个tokens\n",
      "an one-month folpoor-up was completed after the treatment    有  12  个tokens\n",
      "termination due to portfolio prioritization    有  6  个tokens\n",
      "poor time and personnel    有  5  个tokens\n",
      "sponsor decided to cancel this trial    有  6  个tokens\n",
      "intervention change    有  3  个tokens\n",
      "planning halted due to changes in the research group constellation    有  11  个tokens\n",
      "the long-term folpoor-up of patients is being migrated to the original (parent) study protocols (trial id: atx-ns-001 / nct: nct04032847;trial id: atx-me-001 / nct: nct03997474). consequently, the atx-ltfu-001 study is being terminated by the sponsor    有  75  个tokens\n",
      "terminated by amgen limited    有  5  个tokens\n",
      "the hvad, which is the device to which the control algorithms are applied, was discontinued by the manufacturer    有  20  个tokens\n",
      "due to poor adequate patient sample size in a reasonable time period and poor research support staff    有  17  个tokens\n",
      "the research team decided not to implement this study    有  9  个tokens\n",
      "unable to fit within phd timeline    有  7  个tokens\n",
      "regional political conflict    有  4  个tokens\n",
      "budgetary reason    有  3  个tokens\n",
      "changes to protocol design    有  4  个tokens\n",
      "amendments    有  3  个tokens\n",
      "study period ended/not completed    有  5  个tokens\n",
      "emergency use authorizations for monoclonal antibodies withdrawn    有  10  个tokens\n",
      "protocol is being revised    有  4  个tokens\n",
      "larger study planned    有  4  个tokens\n",
      "unable to find willing participants    有  5  个tokens\n",
      "based on feedback from our study participants on the taste, spray optimization is necessary    有  15  个tokens\n",
      "the sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2    有  25  个tokens\n",
      "study is ended    有  3  个tokens\n",
      "the primary endpoint did not meet expectation    有  7  个tokens\n",
      "the study was terminated based upon the competitive landscape and strategic fit    有  12  个tokens\n",
      "public pcr testing stopped in ontario    有  8  个tokens\n",
      "due to the development of the pandemic    有  7  个tokens\n",
      "preliminary data in chronic back pain patients showed no benefits of the treatment; we did not further pursue the same treatment in osteoarthritis patients    有  30  个tokens\n",
      "it was difficult to obtain subjects' consent    有  8  个tokens\n",
      "the study will not be opening. support was withdrawn    有  10  个tokens\n",
      "pi decision to close study    有  5  个tokens\n",
      "as anticipated by the protocol    有  5  个tokens\n",
      "recent discovery of a novel assay that is more likely to be beneficial for patients with lynch syndrome. investing into current version of cologuard test would provide little clinical benefit    有  34  个tokens\n",
      "understaffed    有  3  个tokens\n",
      "the investigators decided not to implement the research but instead to conduct a quality improvement project to focus on the practice of shared medical appointments (smas) and how to optimize them for clinical practice    有  37  个tokens\n",
      "impossibility of reaching the sample size established by protocol    有  11  个tokens\n",
      "new trial opportunity in the usa    有  6  个tokens\n",
      "study abi-h0731-203 was terminated early by the study sponsor for strategic reasons to prioritize research and development efforts on finite and curative hbv therapies    有  31  个tokens\n",
      "decided not to move forward with the study    有  9  个tokens\n",
      "new recommandations    有  3  个tokens\n",
      "physician left practice    有  4  个tokens\n",
      "change in who recommendations for standard of care (control arm); availability of new shorter treatment regimens for mdr-tb; war in ukraine where two study sites are located; key trial team members left the team    有  43  个tokens\n",
      "the sponsor's development strategy is adjusted    有  7  个tokens\n",
      "the early termination is the result of the sponsor's need to reevaluate the study design and to make needed vendor realignments    有  25  个tokens\n",
      "under the limited resources, to re-plan the ongoing clinical trials of this product    有  15  个tokens\n",
      "decommissioned due to not enough staff across the study to adequately support it    有  15  个tokens\n",
      "change in methodolody    有  5  个tokens\n",
      "principal investigator is taking a leave of absence. study terminated    有  11  个tokens\n",
      "difficulty obtaining advanced notification of who was wanting to use nitrous    有  12  个tokens\n",
      "research model determined to be ineffective for capturing machine-learning appropriate data    有  12  个tokens\n",
      "for technical reasons, it was decided by the sponsor to close the ongoing ovarian cancer study, am atx101-03, immediately    有  26  个tokens\n",
      "the number of evaluated valves were achieved    有  7  个tokens\n",
      "pi no longer wanted to do the study    有  8  个tokens\n",
      "sponsor is stopping the study to focus company resources on other development programs    有  13  个tokens\n",
      "vaccine roll out plans increased so timing was no longer feasible    有  12  个tokens\n",
      "withdrawel of approvement of dapagliflozin to type 1 diabetes    有  17  个tokens\n",
      "we did not have enough bandwidth to take on this project due to other project priorities    有  16  个tokens\n",
      "this study was not implemented due to. change in study site and scope    有  14  个tokens\n",
      "sponsor did not pusue with the study    有  8  个tokens\n",
      "loss of equipment supplier    有  4  个tokens\n",
      "study never received irb approval    有  6  个tokens\n",
      "no longer feasible because of new recommendations (rpc st paul de vence) which advocate the performance of systematic imaging in addition to ca 125 in patients treated in first line maintenance in order not to ignore a relapse (2021)    有  47  个tokens\n",
      "no more experimental drugs available    有  5  个tokens\n",
      "required equipment could not be obtained    有  6  个tokens\n",
      "reassessment of rationale for study    有  6  个tokens\n",
      "change in study team    有  4  个tokens\n",
      "not approved by ethics commettee    有  7  个tokens\n",
      "device performance was not as anticipated    有  6  个tokens\n",
      "similar study already completed    有  4  个tokens\n",
      "departure of the intern in charge of the study    有  9  个tokens\n",
      "smt19969-c006 study was terminated in alignment with corporate decision to pursue further development of drug candidate with a partner    有  24  个tokens\n",
      "technical difficulties encountered with recording intraoperative blood loss; unable to proceed with study    有  15  个tokens\n",
      "mri upgrade    有  3  个tokens\n",
      "sponsor halted clinical development of study drug    有  7  个tokens\n",
      "early termination d/t overlap with a new, extended protocol study    有  12  个tokens\n",
      "due to the high probability of not achieving a therapeutic window and poor evidence of sufficient clinical benefit    有  18  个tokens\n",
      "karolinska university hospital unable to support the clinical trial as anticipated    有  14  个tokens\n",
      "the study was discontinued by the sponsor because it did not achieve the primary objective    有  15  个tokens\n",
      "new study protocol under development    有  5  个tokens\n",
      "sponsor/investigator decision    有  5  个tokens\n",
      "the study was stopped due to drug unavailability. the drug is unavailable because production was discontinued in the us    有  21  个tokens\n",
      "as of 11 oct 2021, irb oversight for site is terminated. we no longer have irb approval to conduct this study    有  28  个tokens\n",
      "intended to be replaced with another protocol    有  8  个tokens\n",
      "results of enchanted have been published    有  6  个tokens\n",
      "departure from the department of the principal investigator    有  8  个tokens\n",
      "other projects and needs of study personnel    有  7  个tokens\n",
      "transitioned to multi site study with sponsor    有  8  个tokens\n",
      "termination of study by the sponsor (central sugars refinery sdn. bhd. malaysia)    有  18  个tokens\n",
      "failure to achieve expected outcomes    有  5  个tokens\n",
      "switched to observational study type    有  6  个tokens\n",
      "halted prematurely; voluntarily discontinuation of trial as study specific protocol not folpoored during data collection    有  20  个tokens\n",
      "it wasn't approved for using florajen as a dietary supplement and the supplier did not support the application for an ind    有  24  个tokens\n",
      "poor grant    有  3  个tokens\n",
      "not enough personnel to folpoor the trial- study was withdrawn    有  13  个tokens\n",
      "withdrawn due to another study which superseded it    有  10  个tokens\n",
      "poor responders    有  3  个tokens\n",
      "limited staff to carry out study    有  6  个tokens\n",
      "study is on hold by fda in the us    有  10  个tokens\n",
      "due to need to proceed with procedural changes with goals of improving the technical and economic feasibility    有  17  个tokens\n",
      "irb lapse    有  3  个tokens\n",
      "study was canceled because database sample size was inadequate    有  9  个tokens\n",
      "delayed due to nhs pandemic pressures    有  8  个tokens\n",
      "not the expected 2/3 but only 1/3 of conjunctiva samples got bacterial growth. poor resources to keep the study going with more participants and over a considerably longer time than anticipated    有  40  个tokens\n",
      "haemonetics, the company that manages the teg device, has given a negative answer as to the continuation of the study. for technical and internal reasons, they will take over the device    有  37  个tokens\n",
      "study redesigned    有  2  个tokens\n",
      "awaiting sponsor and fda feedback    有  7  个tokens\n",
      "pi moved to different institution and continuing was not feasible    有  10  个tokens\n",
      "interim analysis indicated adaptions may be required    有  9  个tokens\n",
      "started record under wrong irb account. registered under unmc, but actually at unkearney    有  20  个tokens\n",
      "principal investigator decided to not open the study    有  8  个tokens\n",
      "terminated by novartis    有  5  个tokens\n",
      "want to modify the study further    有  6  个tokens\n",
      "part a complete    有  3  个tokens\n",
      "widespread vaccine availability    有  5  个tokens\n",
      "the project has finished and the technological developments have been created    有  11  个tokens\n",
      "we never got health canada approval    有  6  个tokens\n",
      "niosh certification became impossible, so decision was made to terminate    有  13  个tokens\n",
      "intervention became fda-approved    有  6  个tokens\n",
      "preliminary findings revealed to many barriers to successfully complete this trial    有  13  个tokens\n",
      "the sponsor will no longer develop the experimental drug    有  9  个tokens\n",
      "investigational drug not available    有  6  个tokens\n",
      "sponsor unable to proceed    有  4  个tokens\n",
      "not enough research personnel to complete study at the time    有  10  个tokens\n",
      "covi-19 pandemic    有  5  个tokens\n",
      "participants experienced data collection issues when using the ediary, these issues increased the burden and poorered compliance. updates to the ediary were unsuccessful at resolving the issues so the decision was taken to terminate the investigation    有  41  个tokens\n",
      "too difficult to perform study procedures prior to giving blood pressure medication    有  12  个tokens\n",
      "the study was stopped due to changes in the company strategy    有  11  个tokens\n",
      "feasilibilty    有  4  个tokens\n",
      "due to several logistical challenges during start-up which could not be overcome study was withdrawn    有  16  个tokens\n",
      "failure of comparison group to provide adequate comparison and appropriate comparison    有  11  个tokens\n",
      "adolescent cohort will be conducted as separate trial    有  10  个tokens\n",
      "investigators left the institution    有  5  个tokens\n",
      "unable to continue    有  3  个tokens\n",
      "withdrawn as more data drug analysis is recommended before the study    有  12  个tokens\n",
      "trial terminated due to feasibility reasons    有  6  个tokens\n",
      "a number of subjects withdrew consent leaving the study without adequate power to achieve its primary end points    有  18  个tokens\n",
      "loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned    有  29  个tokens\n",
      "device pulled from market due to inconsistent results    有  8  个tokens\n",
      "pinihl program terminated by dod    有  7  个tokens\n",
      "sponsor-initiated, suspension of study due to modification of key parameters    有  13  个tokens\n",
      "company's decision    有  3  个tokens\n",
      "interim analysis complete; ceased on statistical advice    有  9  个tokens\n",
      "poor resources to conduct study    有  6  个tokens\n",
      "despite significant effort, we were unable to obtain the supply of drugs and supplements needed for the various arms of this clinical trial    有  25  个tokens\n",
      "irb approval withheld    有  4  个tokens\n",
      "logistical issues with coordinating the clinical and testing areas    有  10  个tokens\n",
      "primary investigator moved to a new institution    有  7  个tokens\n",
      "not approved by reb    有  4  个tokens\n",
      "chief investigator retirement    有  3  个tokens\n",
      "equipoise requirement no longer met    有  7  个tokens\n",
      "study stopped to enhance protocol and resume under different sponsor    有  10  个tokens\n",
      "according to the medical device classification catalogue issued by the nmpa in 2022, the registration path of intracranial aspiration catheter is clinical evaluation, and clinical trials are not required    有  39  个tokens\n",
      "impossible to pursue the study    有  6  个tokens\n",
      "no bugdet for the study    有  6  个tokens\n",
      "sub-therapeutic plasma levels of active substance    有  9  个tokens\n",
      "this clinical trial was not finally approved by the korea fda    有  13  个tokens\n",
      "study suspended temporarily due to coronavirus pandemic    有  7  个tokens\n",
      "principal investigator change in institution    有  5  个tokens\n",
      "the study was prematurely discontinued due to operational implementation challenges and insufficient collection of key data due to varied data accessibility across global study sites    有  25  个tokens\n",
      "difficulty with endometrial sample collection. new study design to be prospective observational to validate reliable methods of endometrial sampling at time of c-section    有  29  个tokens\n",
      "the ora-d-013-2 protocol was terminated based on the primary results analyzed at week 26 in the ora-d-013-1 protocol    有  29  个tokens\n",
      "planned interim data analysis showed underperformance (statistical and clinical) of the three derived clinical decision rules that had been derived and that we were trying to validate    有  32  个tokens\n",
      "pi is leaving the penn state    有  6  个tokens\n",
      "the site is no more able to conduct the study    有  10  个tokens\n",
      "study did not begin    有  4  个tokens\n",
      "unable to obtain investigational product    有  6  个tokens\n",
      "insufficient interest by potential participants    有  6  个tokens\n",
      "poor fund    有  3  个tokens\n",
      "high postoperative morbidity rate    有  6  个tokens\n",
      "regulatory review needed    有  4  个tokens\n",
      "logistical problems at study site    有  6  个tokens\n",
      "resource issues on site    有  4  个tokens\n",
      "personnel have left the facility    有  6  个tokens\n",
      "scheduling complexities    有  3  个tokens\n",
      "a new scientific study shows that surgery with internal brace is worse than convensional surgery tecnic. this new knowledge stops this trial    有  26  个tokens\n",
      "to carry out the rest of the study with new cro and modified protocol as a multi-regional study    有  20  个tokens\n",
      "study was terminated by sponsor due to increased incidences of aes of special interest (intraocular inflammation including retinal vasculitis and retinal vascular occlusion), in patients dosed brolucizumab 6mg every 4 weeks beyond 3 initial doses    有  55  个tokens\n",
      "device is no longer investigational. it has been approved by the fda as an hud under hde h190005    有  24  个tokens\n",
      "consequences of failing to include    有  6  个tokens\n",
      "discontinued early due to local tolerance expectations not being met    有  11  个tokens\n",
      "this study did not receive the grant that was applied for to conduct the study    有  15  个tokens\n",
      "the grant application has not been approved    有  7  个tokens\n",
      "not activated at duke    有  4  个tokens\n",
      "change of products design    有  4  个tokens\n",
      "person working on the trial left    有  6  个tokens\n",
      "departure of the two main investigators    有  6  个tokens\n",
      "irb will be terminated    有  5  个tokens\n",
      "in error    有  2  个tokens\n",
      "study team is not moving forward with protocol    有  8  个tokens\n",
      "diclofenac is no longer recommend for intramuscular administration by the medical council of thailand    有  20  个tokens\n",
      "internal practice and policy limitations including time commitment / workfpoor issues    有  14  个tokens\n",
      "planning to join a prospective multicentric trial after evaluation of 10 first participants    有  16  个tokens\n",
      "corporate decision, priority change    有  6  个tokens\n",
      "did not meet pre-specified progression-free survival at month 6 for stage 2 analysis    有  18  个tokens\n",
      "we no longer have ketogenic dietician coverage/access    有  10  个tokens\n",
      "all patients past planned primary endpoint; decision by sponsor to wind down open-label folpoor-up activities    有  20  个tokens\n",
      "livoletide did not result in a statistically significant improvement in hyperphagia and food-related behaviors    有  21  个tokens\n",
      "pilot study results not meaningful. students researchers graduated    有  10  个tokens\n",
      "the surgical technique is no longer used    有  7  个tokens\n",
      "the sponsor was not the good one. we will redo the clincal trial gov to be concordant with the actual sponsor    有  26  个tokens\n",
      "by sponsor due to occurrences of incomplete study drug administration    有  10  个tokens\n",
      "manufacturer of the device filed for bankruptcy    有  7  个tokens\n",
      "change in benefit-risk profile for individuals with early sporadic alzheimer disease because of elevations in liver enzymes in subjects receiving atabecestat    有  28  个tokens\n",
      "investigator separated from institution    有  5  个tokens\n",
      "ip breach    有  2  个tokens\n",
      "study never commenced due to logistical issues    有  7  个tokens\n",
      "study center closed down    有  4  个tokens\n",
      "sponsor will not pursue ce mark for this product, which precludes need for large pmcf study    有  19  个tokens\n",
      "less recruting    有  4  个tokens\n",
      "fda has withdrawn the ind application- requesting protocol changes    有  11  个tokens\n",
      "withdrawn per cs0150757    有  7  个tokens\n",
      "development of indication not being pursued    有  6  个tokens\n",
      "sof/vel/vox will not be evaluated in younger age groups    有  14  个tokens\n",
      "no differences between the groups at the interim analysis    有  9  个tokens\n",
      "per investigator study was terminated prematurely    有  6  个tokens\n",
      "no plans to continue study or publish data    有  8  个tokens\n",
      "pk issue detected after bolus iv route administration    有  9  个tokens\n",
      "technical failure    有  2  个tokens\n",
      "institutional review board did not approve    有  7  个tokens\n",
      "sponsor suspending temporarily    有  4  个tokens\n",
      "study m16-763 was terminated early as the benefit of each treatment arm from the feeder study (study m16-063) did not provide appreciable evidence of differentiated clinical effect to warrant further long-term continuation    有  42  个tokens\n",
      "investigators decided not to begin the study    有  8  个tokens\n",
      "suspended by sponsor, pending investigation of abnormal laboratory values in patients with nash    有  16  个tokens\n",
      "per an amendment    有  3  个tokens\n",
      "two key faculty members are no longer part of the study and institution    有  13  个tokens\n",
      "combined into an international study (car-bha-i21)    有  12  个tokens\n",
      "ran out of medication    有  4  个tokens\n",
      "the trial was closed because the changing standard of care landscape, making this trial not impactful anymore    有  18  个tokens\n",
      "change in the design of the study    有  7  个tokens\n",
      "study determined to be infeasible    有  7  个tokens\n",
      "iti-007 approved by fda    有  7  个tokens\n",
      "different study initiation    有  3  个tokens\n",
      "terminated per pi    有  3  个tokens\n",
      "adverse effects related to study procedure (not study drug)    有  12  个tokens\n",
      "due to a change in the development strategy    有  8  个tokens\n",
      "preliminary results providing sufficient data    有  7  个tokens\n",
      "discontinued cmt4j development program    有  8  个tokens\n",
      "logistic reasons (operating room performing the surgery investigated moved to another structure)    有  16  个tokens\n",
      "study approved with treatment regimen based on current guidelines. however, reimbursement of imp was not feasible    有  18  个tokens\n",
      "the device prototype was broken and fixed in 2020. the new simplified and miniaturized device will be finished and used on april 1, 2022    有  33  个tokens\n",
      "re-written and submitted as a new study    有  8  个tokens\n",
      "the design of this protocol was rewritten due to regulatory recommendations    有  11  个tokens\n",
      "due to the regulatory approval of the product in this indication, a large portion of the study becomes unnecessary    有  20  个tokens\n",
      "an interim analysis was conducted, and no difference was found between traditional lumbar punctures and ultrasound-guided lumbar punctures. the study was subsequently terminated    有  31  个tokens\n",
      "decision of the 2 pi's    有  7  个tokens\n",
      "we will capture subjects under another study    有  7  个tokens\n",
      "unable to source salsalate    有  7  个tokens\n",
      "we decided to close this study and come up with a new study design    有  14  个tokens\n",
      "relocation of principal investigator    有  5  个tokens\n",
      "portfolio reprioritization    有  5  个tokens\n",
      "study was never able to start after the pandemic restrictions lifted    有  11  个tokens\n",
      "high number of screen failures    有  5  个tokens\n",
      "project has been cancelled    有  4  个tokens\n",
      "trial was terminated due to an insufficient benefit/tolerability ratio    有  12  个tokens\n",
      "pending final ip    有  3  个tokens\n",
      "competing other studies    有  4  个tokens\n",
      "study details changed, new trial registration process begun for modified protocol    有  12  个tokens\n",
      "protocol amendment    有  2  个tokens\n",
      "program was discontinued    有  3  个tokens\n",
      "protocal changing due to time limitation    有  7  个tokens\n",
      "finance stop    有  2  个tokens\n",
      "the inclusion criteria for plasmapheresis is too stringent to get any potential subjects    有  17  个tokens\n",
      "we decided to move on to another product and as a result will not be moving forward with this study    有  20  个tokens\n",
      "insufficient data to answer the study question    有  8  个tokens\n",
      "replaced with different study at another site    有  8  个tokens\n",
      "early signs of progression and learned experience that the assumed time period between psa progression and radiographic progression was shorter than expected    有  24  个tokens\n",
      "failure of institution to reach agreement with company supplying injections    有  10  个tokens\n",
      "based on a strategic decision, the application for the trial has been withdrawn before initiation    有  16  个tokens\n",
      "the pilot study was set up to assess whether the used dosing regimen of beetroot juice demonstrated to reach the therapeutic objective. the study was terminated early, as the deadline for the grant application for a larger study was approaching    有  44  个tokens\n",
      "due to mycotoxin potential contamination of one lot of study drug    有  14  个tokens\n",
      "unable to obtain ct contrast from provider    有  7  个tokens\n",
      "devices for measuring skna are need to be re-constructed, which takes considerable time    有  17  个tokens\n",
      "internal issues    有  2  个tokens\n",
      "a decision was made to stop the study early when astrazeneca evaluated the available data and it was considered that completing the study would provide limited additional information and unlikely to change the study conclusions    有  37  个tokens\n",
      "re-formulation of study product    有  6  个tokens\n",
      "the investigators were unable to implement a mri compatible eeg for use in human subjects (equipment and technical issues)    有  23  个tokens\n",
      "lead coordinatior has left the site, need to find alternative lead for the study    有  17  个tokens\n",
      "large sample size    有  3  个tokens\n",
      "not enough participants due to the pandemia    有  8  个tokens\n",
      "this study was not intended to be published as a trial    有  11  个tokens\n",
      "due to sample problem    有  4  个tokens\n",
      "sufficient data was collected through the app to achieve initial results    有  12  个tokens\n",
      "the study was closed after > 1 year of inactivity    有  12  个tokens\n",
      "terminated because sample size achieved    有  5  个tokens\n",
      "it was determined that the study design may not be optimal given the changing aml treatment landscape    有  18  个tokens\n",
      "due to financial restructure of sakk    有  8  个tokens\n",
      "study did not receive final approval however it was decided to not pursue    有  13  个tokens\n",
      "approval to move forward with this clinical trial has not been granted by governing bodies    有  15  个tokens\n",
      "trial no longer occurring    有  4  个tokens\n",
      "major study protocol changes    有  4  个tokens\n",
      "study team not moving forward with protocol    有  7  个tokens\n",
      "approval of specific study by uk mhra not received. study performed in different circumstances and with different clinical sites / partners    有  23  个tokens\n",
      "pending contract negotiations    有  3  个tokens\n",
      "decision to obtain pk data at a later date    有  9  个tokens\n",
      "transition/change of primary investigators    有  5  个tokens\n",
      "irb approval expired; failure to submit continuing review in time. will re-open once irb approval is reinstated    有  23  个tokens\n",
      "initial version of the protocol not submitted and new version approved has a new sponsor and it has been added into clinicaltrials by the new sponsor    有  28  个tokens\n",
      "decision    有  1  个tokens\n",
      "trial not started; change in sponsor and principal investigator, trial to be registered again by new sponsor/investigator if it is started    有  26  个tokens\n",
      "not feasible to continue    有  4  个tokens\n",
      "device unavalaible    有  5  个tokens\n",
      "insufficient effectiveness    有  3  个tokens\n",
      "according to new guidelines, the use of vasopressors to force the map during cpb at values higher than 80 mmhg is not recommended    有  30  个tokens\n",
      "suitable participants have complicated t1d, often with serious complications, participation is therefore challenging. participants also fall within an unique group and few suitable individuals were available for inclusion    有  34  个tokens\n",
      "it was not possible to include 9 study participants with unstable glucose in due time, and therefore 7 individuals with unstable glucose control were included    有  28  个tokens\n",
      "the study was halted early due to failure to meet the primary endpoint    有  13  个tokens\n",
      "operational    有  2  个tokens\n",
      "the study was stopped early due to increased global access to genomic screening. it is no longer economical to continue with this particular single-gene screening protocol    有  29  个tokens\n",
      "failure rate was 100% in one arm of the study (the intervention)    有  16  个tokens\n",
      "publication of study results of ici use in mpm as first line therapy    有  14  个tokens\n",
      "the study was withdrawn due to insufficient interest in study participation due to recent approval in this rare condition    有  19  个tokens\n",
      "study was not renewed    有  4  个tokens\n",
      "irb concerns    有  3  个tokens\n",
      "benefits of treatment less than expected    有  7  个tokens\n",
      "changes in protocol    有  3  个tokens\n",
      "not approved by the coordinating ethical committee    有  7  个tokens\n",
      "insufficient suitable drug supply    有  5  个tokens\n",
      "changed plans    有  2  个tokens\n",
      "the study objective was achieved. patients are no longer being examined or receiving intervention    有  15  个tokens\n",
      "company providing drug terminated their oncology program    有  8  个tokens\n",
      "expired in the irb    有  5  个tokens\n",
      "study wasn't started    有  4  个tokens\n",
      "due to logistical concerns    有  4  个tokens\n",
      "trial handovered to another sponser    有  9  个tokens\n",
      "analysis of first 11 subjects resulted in values that were too varied to make the study feasible    有  18  个tokens\n",
      "researcher left the institution study will not continue    有  9  个tokens\n",
      "application of monitoring tools seemed inappropriate in icu patients who were ventilated during a prolonged period    有  18  个tokens\n",
      "ccx872-b will not be available in sufficient quantity to conduct the study    有  15  个tokens\n",
      "change of hospital when the study will be done. we will redo the clinical trial to have the good sponsor for the study    有  24  个tokens\n",
      "telehealth vendor transition    有  4  个tokens\n",
      "recent similar studies have been completed and published showing no benefit to the intervention    有  14  个tokens\n",
      "irb -- need to reframe study as a feasibility study before it being a rct    有  18  个tokens\n",
      "insolvency of the sponsor    有  5  个tokens\n",
      "due poor eligible participants    有  4  个tokens\n",
      "suspended due to primary investigator's decision    有  8  个tokens\n",
      "study halted due to financial contraints    有  8  个tokens\n",
      "risks to participation    有  4  个tokens\n",
      "participants were not able to stay near our center for two weeks    有  12  个tokens\n",
      "terminated due to financial constraint    有  5  个tokens\n",
      "end of drug development    有  4  个tokens\n",
      "irb protocol was not approved by boston children's hospital    有  12  个tokens\n",
      "participants were not able to stay for two weeks near our center    有  12  个tokens\n",
      "study has stopped for having met the primary endpoint    有  9  个tokens\n",
      "absence of co-investigator    有  7  个tokens\n",
      "sponsor no longer performing clinical studies. will be only a manufacturing facility    有  13  个tokens\n",
      "the trial was stopped based on the assessment of clinical data    有  11  个tokens\n",
      "security and effect data from another ongoing study    有  8  个tokens\n",
      "insufficient staff for measurement assessments    有  6  个tokens\n",
      "reassessment of study feasibility    有  5  个tokens\n",
      "due to resource limitations the study was on hold and was then terminated    有  13  个tokens\n",
      "medacta gmk ps is not in use anymore    有  11  个tokens\n",
      "withdrawn prior to study launch because a research partnership with the school district could not be secured in time    有  20  个tokens\n",
      "the preliminary data, progress of this study and the adjustment of the pipeline and strategy    有  16  个tokens\n",
      "we submitted an amendment. the study was stopped because this amendment raised the complexity of the study    有  18  个tokens\n",
      "investigator elected not to proceed with project    有  8  个tokens\n",
      "study protocol no longer relevant after progression of the scientific field    有  11  个tokens\n",
      "other - pending data analysis    有  5  个tokens\n",
      "internal reporting    有  2  个tokens\n",
      "irb protocol violations    有  4  个tokens\n",
      "the study was terminated at all but one site because of the pandemic    有  13  个tokens\n",
      "limited time frame and financial resources. the anticipated increase of eligable migrant women did not occur during the period because of changes in migration policies    有  27  个tokens\n",
      "mild infusion reactions were observed in two healthy volunteers    有  10  个tokens\n",
      "valneva has contacted regulators to align on potential adjustments to the previously agreed pediatric investigational plan. valneva has suspended vla2001 pediatric development, and study vla2001-321 will not commence    有  43  个tokens\n",
      "team decided not to initiate study    有  6  个tokens\n",
      "abandoned study    有  3  个tokens\n",
      "the study was terminated early by sponsor    有  7  个tokens\n",
      "research team reconstruction (replace clinician who is necessary for study to proceed)    有  15  个tokens\n",
      "sponsor deprioritization    有  5  个tokens\n",
      "we have changed our research focus    有  6  个tokens\n",
      "participates could not stand the side effects    有  9  个tokens\n",
      "insufficient amount of participants    有  5  个tokens\n",
      "study has ended due to internal changes    有  7  个tokens\n",
      "investigator voluntary pause    有  4  个tokens\n",
      "adjustments needed after pilot period and delay because of reduced staff    有  12  个tokens\n",
      "study closed by the einstein irb    有  8  个tokens\n",
      "per discretion of sponsor    有  4  个tokens\n",
      "dr. marshall left umc and lsu health sciences center    有  13  个tokens\n",
      "change of study design    有  4  个tokens\n",
      "pi- dr. jellish passed away. the study was terminated with the irb    有  18  个tokens\n",
      "this study was terminated early because the primary endpoint of paragon-hf was not met    有  17  个tokens\n",
      "logistics (research personnel)    有  6  个tokens\n",
      "myoscience recently acquired - decided to redesign study    有  10  个tokens\n",
      "application withdrawn from the irb    有  6  个tokens\n",
      "decision made by sponsor    有  4  个tokens\n",
      "personnel unavailable to run the study    有  7  个tokens\n",
      "pilot study not necessary as new data has become available    有  11  个tokens\n",
      "the study is on hold due to stopping of the autism spectrum disorder program with balovatpan, the study drug    有  23  个tokens\n",
      "although the defined success rate needed for continuation of the investigation was met, due to the overall poor success rate; it was considered, particularly considering the ongoing pandemic, to discontinue the investigation prematurely    有  38  个tokens\n",
      "due to the high number of ae, it has been determined that it is no longer feasible to clinically interpret the evidence from this study due to the complex factors presented in this patient population, and thus an early termination is justified    有  44  个tokens\n",
      "we could not continue the study and include participants because of the corona pandemic    有  15  个tokens\n",
      "number of participants needed not reached (13/80)    有  11  个tokens\n",
      "unable to support study    有  4  个tokens\n",
      "change in design    有  3  个tokens\n",
      "resource allocation    有  2  个tokens\n",
      "the trial was planned to be conducted in 4 cohorts but was terminated after completion of cohort 2 for strategic reasons due to limited pd effects    有  28  个tokens\n",
      "the trial was stopped as the benefit was challenging to determine in preliminary usage    有  14  个tokens\n",
      "ifna2b supply shortage    有  6  个tokens\n",
      "due to restricted and new rules for data protection, the use of an app could not be approved    有  19  个tokens\n",
      "project replanning    有  3  个tokens\n",
      "the protocol revision is needed    有  5  个tokens\n",
      "study never commenced at trial site    有  6  个tokens\n",
      "the trial was stopped as the benefit was challenging to determine in the preliminary usage    有  15  个tokens\n",
      "folpooring a recent cellular therapy strategy assessment, amgen has decided to cancel study 20180091    有  21  个tokens\n",
      "this study was not conducted due to concerns about collaboration with an outside vendor for the control condition    有  18  个tokens\n",
      "due to the corona-crisis, we asses that it is not possible to carry out the effect-measurement as planned. the lockdown has strongly affected the young people's social life and alcohol use that could hide possible effects of the intervention    有  48  个tokens\n",
      "fda determination of fox software as class iii medical device, not cdss    有  15  个tokens\n",
      "patients experienced translocation of edema from poorer extremities to trunk heightening concern about triggering congestive heart failure in frail elders    有  25  个tokens\n",
      "this study was intended to produce pilot data for a center grant component that will no longer be conducted    有  19  个tokens\n",
      "logistics related to research activity    有  6  个tokens\n",
      "pi moved from osu to vcu. study is suspended pending credentialing and irb approval at vcu    有  22  个tokens\n",
      "a fundamental protocol deviation on data capture left the database no longer fit for purpose    有  15  个tokens\n",
      "the study was terminated because the study chair/ide sponsor and novocure determined that conducting this trial was not feasible without cms approval    有  26  个tokens\n",
      "feeder cohort study closed    有  5  个tokens\n",
      "the effect of ct053ptsa in preciously treated patients with advanced and metastatic rcc is not as good as pre-expected    有  27  个tokens\n",
      "alternate study completed    有  3  个tokens\n",
      "all prick tests are positive    有  5  个tokens\n",
      "the bloom-ptn study has evolved into the ongoing bloom-pcs study (reb20-1442)    有  21  个tokens\n",
      "there were not participants to complete sample size    有  8  个tokens\n",
      "there was not a need any more    有  7  个tokens\n",
      "change in device and protocol    有  5  个tokens\n",
      "reassessing study feasibility    有  6  个tokens\n",
      "requested by surgeons to pursue new study    有  7  个tokens\n",
      "study execution discontinued at this time    有  6  个tokens\n",
      "imaging results were not sufficient or of good quality; therefore, we will not move further with the project    有  21  个tokens\n",
      "cooperation terminated    有  3  个tokens\n",
      "we change the study protocal    有  6  个tokens\n",
      "the sublimity board of directors carefully evaluated the ia data: the 9.6% treatment remission difference for 75mg bid vs placebo (due to an increase in placebo response rate) was determined not sufficient to continue to fund the study    有  50  个tokens\n",
      "staffing not available    有  4  个tokens\n",
      "due to the fact that we were unable to find subjects who met all inclusion and exclusion criteria it was determined to withdraw this study    有  25  个tokens\n",
      "interim analysis -    有  4  个tokens\n",
      "the long inclusion period meant that the question could not be answered within an appropriate timeframe    有  16  个tokens\n",
      "due to staffing changes in the hospital, we will be unable to complete this study for the requested 84 subjects. as such, we have decided to close this study    有  33  个tokens\n",
      "the device prototype was broken and fixed in 2020. the new simplified and miniaturized device will be finished and used on may 1, 2022    有  33  个tokens\n",
      "study not needed    有  3  个tokens\n",
      "principal investigator relocation    有  3  个tokens\n",
      "the p.i. decided to cancel this study. on 10/08/19, a study closure request was submitted to the irb    有  28  个tokens\n",
      "due to poorer antitumor activity than expected    有  9  个tokens\n",
      "the study is not proceeding at this time    有  8  个tokens\n",
      "anjeso (n1539) nda withdrawn    有  11  个tokens\n",
      "sponsor discontinued the drug    有  4  个tokens\n",
      "strategic development reasons    有  4  个tokens\n",
      "because of technical issues    有  4  个tokens\n",
      "regolatory national agency (aifa) not approved    有  11  个tokens\n",
      "implantable system for remodulin not commercially approved    有  11  个tokens\n",
      "study grant not obtained; not moving forward with study at this time    有  13  个tokens\n",
      "revision to improve cell recovery    有  5  个tokens\n",
      "not approved by ctep    有  5  个tokens\n",
      "study concluded by stanford university    有  6  个tokens\n",
      "interim analysis not showing significant results    有  7  个tokens\n",
      "amgen re-evaluated the portfolio and decided to discontinue clinical development activities for amg 420    有  21  个tokens\n",
      "study halted temporarily to obtain protocol amendment approval but potentially will resume    有  12  个tokens\n",
      "study no longer needed because eligible subjects may receive treatment with cobomarsen in a crossover arm of the solar clinical trial (nct03713320)    有  31  个tokens\n",
      "one investigator is out-of-service due to carrying out another task    有  12  个tokens\n",
      "at the protocol-specified interim analysis, the sponsor decided to stop the trial    有  15  个tokens\n",
      "sponsor and facility unable to reach agreement before study timeline expired    有  11  个tokens\n",
      "the study will not be conducted by dr lubenow    有  11  个tokens\n",
      "lapse of renewal    有  4  个tokens\n",
      "recrutiment dificulties    有  6  个tokens\n",
      "committee request    有  2  个tokens\n",
      "change of circumstances with commercial partner    有  6  个tokens\n",
      "technological barriers are affecting the participant response experience    有  9  个tokens\n",
      "pi passed away. ending grant and closing down lab    有  10  个tokens\n",
      "never got medical equipment that worked properly    有  7  个tokens\n",
      "axsome has conducted a review of the ongoing ist program and are unable to continue supporting this study    有  19  个tokens\n",
      "the study design was changed and this clinical trial will not be conducted    有  13  个tokens\n",
      "insufficient resources to complete study as planned    有  8  个tokens\n",
      "device feasibility study, not clinical trial    有  7  个tokens\n",
      "the study was stopped prematurely because the total number of analyzable patients for the primary objective to be included was reached    有  23  个tokens\n",
      "due to less number of participants willing to participate    有  9  个tokens\n",
      "modification of clinical development plan    有  5  个tokens\n",
      "the trial was terminated early folpooring strategic review after emergence of nonclinical data with a non-glaxosmithkline asset    有  26  个tokens\n",
      "there is no one to transfer to study to and no one interested in this research study. i am taking 8 months off from being a physician so the study needs to be closed    有  36  个tokens\n",
      "the available study medication reached expiry (logistics)    有  10  个tokens\n",
      "sponsor decided not to pursue the study    有  7  个tokens\n",
      "further product development is needed prior to clinical study testing    有  11  个tokens\n",
      "we need to make significant adjustments to proposed drug and its delivery method    有  13  个tokens\n",
      "inadequate fna samples (poor cell counts)    有  12  个tokens\n",
      "principle investigator is leaving institution    有  6  个tokens\n",
      "no further use of the divice at our department    有  10  个tokens\n",
      "admisnitrative issues    有  6  个tokens\n",
      "new design was developed to better fit company strategy, a new study has replaced 5413541trd3011 study    有  24  个tokens\n",
      "study had to be terminated for poor dimer and inability to produce more at this time    有  17  个tokens\n",
      "study is merged with contessa study    有  7  个tokens\n",
      "study was closed with irb on 10/22/22    有  13  个tokens\n",
      "discontinued agu development program    有  6  个tokens\n",
      "withdrawing study from prs-this is not an actual clinical trial    有  13  个tokens\n",
      "poor resource at clinical site    有  6  个tokens\n",
      "per ctep, martha khrum this study is withdrawn. changing status to update ct.gov    有  20  个tokens\n",
      "the trend in lps treatment tends to increase the dosage of progesterone in fet-hrt, this study was designed 5 years ago    有  28  个tokens\n",
      "study plan was changed, this project would not be in progress    有  12  个tokens\n",
      "cancelled    有  1  个tokens\n",
      "the study no longer fits our strategic goals. the preliminary results of fluid have led to an improved version of the current device. we believe it is necessary to initiate a new study, with the improved version of the device    有  43  个tokens\n",
      "feasibility of the clinical trial could not be confirmed at the different sites    有  14  个tokens\n",
      "altered research priorities    有  4  个tokens\n",
      "issue with project feasibility    有  4  个tokens\n",
      "pi no longer at the institution; departmental permission to deactivate study    有  13  个tokens\n",
      "we implemented aims 1 and 2, but did not have a sufficient sample size to carry out the clinical trial portion    有  24  个tokens\n",
      "pharmaceutical company decided to close study    有  8  个tokens\n",
      "81 patients included, difficult inclusion and full inclusion would not change the results    有  14  个tokens\n",
      "never started, was replaced by nct04150601    有  11  个tokens\n",
      "analysis of cell phenotypes was not possible    有  8  个tokens\n",
      "ind approval from fda was rejected and irb approval was never granted    有  14  个tokens\n",
      "decision made by dsmb to terminate study in april 2023    有  13  个tokens\n",
      "the mmrf has learned of the limitations of using a blood sample to collect genomic data, compared to a bone marrow aspirate. we decided that our resources are best served in other areas at this time    有  40  个tokens\n",
      "biib092 program discontinued    有  5  个tokens\n",
      "no charts were reviewed. this study never started    有  9  个tokens\n",
      "it was not possible to acquire the medical device    有  9  个tokens\n",
      "interim analysis showed primary outcome was not going to be achieved    有  12  个tokens\n",
      "ctp of lares has been out of the expire date, we are trying rws pathway for the indication expend    有  22  个tokens\n",
      "organizational issues    有  3  个tokens\n",
      "this record should not have been created for this study. it is under another sponsor's account    有  18  个tokens\n",
      "inability to apply technology (loss of technology)    有  10  个tokens\n",
      "this study was terminated 182 days after initial dosing    有  11  个tokens\n",
      "study was not feasible as designed to alpoor for appropriate completion    有  13  个tokens\n",
      "funds have not been received    有  6  个tokens\n",
      "provider of drug decided to discontinue study    有  8  个tokens\n",
      "phase 2 study results    有  5  个tokens\n",
      "study was suspended due to ipl344 shortage and may resume once drug supply is available. survival folpoor-up is still ongoing folpooring participants' consent    有  32  个tokens\n",
      "on 23 january 2020, the sponsor announced that the united states (us) food and drug administration (fda) had issued a clinical hold in the us of the polar program    有  39  个tokens\n",
      "application of arrays was inconsistent    有  5  个tokens\n",
      "completed study with fewer participants than expected    有  7  个tokens\n",
      "study withdrawn, trial therapy deemed no longer novel and there was a poor site interest    有  16  个tokens\n",
      "ossm-001 will not be used in this clinical program    有  12  个tokens\n",
      "limited time between the beginning and the end of the inclusions, only 7 high level rowers available within the time compatible with research realization    有  28  个tokens\n",
      "the corona virus pandemic_uk national lockdown    有  9  个tokens\n",
      "suspension of the study upon the decision of the notified body    有  13  个tokens\n",
      "the sponsor voluntarily terminated the study    有  6  个tokens\n",
      "pi departure; service discontinued study    有  6  个tokens\n",
      "stopped for internal decisions    有  4  个tokens\n",
      "planned to execute the new oral okn-007 clinical trial with modified study plan soon. this study not proceeding and sites never opened    有  27  个tokens\n",
      "original clinical trials form had error, but cannot be deleted at this stage    有  14  个tokens\n",
      "suspended temporarily due to staff changes    有  7  个tokens\n",
      "study was suspended due to ipl344 shortage and may resume once drug supply is available    有  17  个tokens\n",
      "did not initiate study intervention    有  5  个tokens\n",
      "the study was terminated by the sponsor prior to any participants receiving the investigational product    有  16  个tokens\n",
      "interruption of financial support    有  7  个tokens\n",
      "this study was terminated in accordance to protocol section 4.4, based on the overall risk-benefit profile observed to date    有  25  个tokens\n",
      "poor feasibility for completion of the trial within a reasonable time frame    有  13  个tokens\n",
      "after interim analysis decided not to move forward with continuing the trial    有  12  个tokens\n",
      "contract terminated between aifa and the sponsor (university of ferrara)    有  15  个tokens\n",
      "study terminated as ce marks of the devices used have not been renewed    有  13  个tokens\n",
      "decision of the principal investigator    有  5  个tokens\n",
      "adverse effect    有  3  个tokens\n",
      "staffing challenges    有  3  个tokens\n",
      "poor compliance with cbt, and challenges with the cbt provider. previous participants will be considered the pilot phase    有  23  个tokens\n",
      "original device is now discontinued; we are changing the study device shortly    有  13  个tokens\n",
      "deployment site not obtained in 5 patients with endoscopic screening and intent-to-treat. no devices implanted and no aes through 30days    有  28  个tokens\n",
      "this study was a doctorate thesis and student changed the subject of her thesis    有  15  个tokens\n",
      "study was moved to another location with involvement of different researchers    有  11  个tokens\n",
      "the sponsor determined that one study (pro-010) was sufficient    有  13  个tokens\n",
      "interim data analysis indicated too many variables prevented the ability to drawn conclusive evidence the devices affected falls    有  19  个tokens\n",
      "subject changed    有  2  个tokens\n",
      "due to the adjustment and change of the sponsor's r&d strategy, we now plan to voluntarily terminate this clinical trial    有  24  个tokens\n",
      "new data from another study show that a positive result is unlikely    有  12  个tokens\n",
      "incorrect entry    有  2  个tokens\n",
      "this study was not approved by the ethics committee    有  9  个tokens\n",
      "resident physician decided not to proceed with study    有  8  个tokens\n",
      "the study was terminated as we plan to start a competing study sponsored through va csp    有  17  个tokens\n",
      "the study was prematurely discontinued, the application utilized with the fitbit is no longer being supported    有  18  个tokens\n",
      "the sponsor determined at one study (pro-010) was sufficient    有  13  个tokens\n",
      "changes in the r&d strategy    有  7  个tokens\n",
      "increased sae occurrence per pi    有  7  个tokens\n",
      "tikun olam has not received approval from the national committee to conduct research    有  16  个tokens\n",
      "the part on mrs could not be completed    有  9  个tokens\n",
      "idmc recommendations    有  3  个tokens\n",
      "collected data showed significant difference in two groups    有  9  个tokens\n",
      "significantly increased incidence of primary endpoint in the fio2 60% group    有  16  个tokens\n",
      "the study was never started by the responsible party (medical student who is no longer at the institution)    有  20  个tokens\n",
      "manufacturer will not be supporting this study    有  7  个tokens\n",
      "attending surgeon on the project is moving to a different facility    有  12  个tokens\n",
      "overall benefit-risk profile did not support continuation of the study    有  11  个tokens\n",
      "new us guidelines    有  3  个tokens\n",
      "no approval by ca    有  4  个tokens\n",
      "will re-open at another time    有  6  个tokens\n",
      "folpooring an interim data review, further investment in nevanimibe has been discontinued    有  18  个tokens\n",
      "this study was discontinued due to an interim analysis which indicated that ralmitaront was unlikely to meet its primary endpoint    有  24  个tokens\n",
      "the company that supported the technology (volumetric laser endomicroscopy) is no longer operational due to the pandemic    有  24  个tokens\n",
      "difficulty in performing study    有  4  个tokens\n",
      "the certification of cell-based treatment in the settings need to be updated    有  13  个tokens\n",
      "results showing no effect    有  4  个tokens\n",
      "combined with nct03266107    有  7  个tokens\n",
      "did not move forward with irb approval, competing study    有  11  个tokens\n",
      "financial difficulities    有  4  个tokens\n",
      "no partipants    有  4  个tokens\n",
      "on hold due to the pandemic    有  6  个tokens\n",
      "subjects had a high dropout rate. of 61 consented, 24 did not participate. reasons: surgical cancellations; changing procedure type after consent; and staffing issues. the dropout rate of 39% was considered a barrier to publication    有  48  个tokens\n",
      "study on hold for an undetermined time    有  8  个tokens\n",
      "sponsor on campus training restrictions    有  5  个tokens\n",
      "the sponsor can no longer financially support the trial    有  9  个tokens\n",
      "in june 2021, the us fda approved expanded use of the recell system for treatment of acute full-thickness thermal burns in patients 1-month of age and older (removing the prior limitation of use in patients younger than 18 years of age)    有  55  个tokens\n",
      "does not meet criteria for clinical trial    有  7  个tokens\n",
      "investigator is gone    有  4  个tokens\n",
      "novartis is no longer pursuing this study because of planned investigation of novel car-t therapies in this patient population    有  22  个tokens\n",
      "poor effect    有  3  个tokens\n",
      "pending equipment repair    有  3  个tokens\n",
      "corporate strategic consideration    有  4  个tokens\n",
      "strategic decision to progress stroke disability programme through regional partnerships    有  11  个tokens\n",
      "unavailability of the investigational device    有  7  个tokens\n",
      "same information will be collected in upcoming ide trial    有  9  个tokens\n",
      "sponsor bankruptcy    有  2  个tokens\n",
      "waiting the new batch of investigational product    有  8  个tokens\n",
      "investigational medical device is no longer available    有  9  个tokens\n",
      "trial terminated due to internal review of clinical data in context of indication under investigation    有  15  个tokens\n",
      "recommendation from an independent data monitoring committee (dmc) and accepted by astrazeneca    有  18  个tokens\n",
      "due tot he pandemic we decided to terminate this project    有  10  个tokens\n",
      "the landscape of the study area changed, making it impossible to continue the study    有  15  个tokens\n",
      "the study will be withdrawn as the principal investigator, ken batai, left the institution prior to study activation    有  22  个tokens\n",
      "study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients    有  23  个tokens\n",
      "transferred to different institution    有  5  个tokens\n",
      "primary investigator is leaving host university (etsu)    有  10  个tokens\n",
      "none was included    有  3  个tokens\n",
      "the results of leading phase 2 trials did not meet all desired endpoints    有  14  个tokens\n",
      "pi has confirmed there are no results because the samples were degraded    有  12  个tokens\n",
      "takeda suspended financial support. the first phase (observational study) is ongoing    有  17  个tokens\n",
      "virus potency titer of drug product as determined by an improved potency assay was poorer than originally determined by the assay described in the ind    有  27  个tokens\n",
      "due to changing prostate cancer standard of care, the research question became obsolete as the target population for the study no longer existed. the study is deemed not clinically relevant    有  32  个tokens\n",
      "difficulty getting parents to complete folpoor-up assessments    有  10  个tokens\n",
      "study terminated due to tolerability issues    有  7  个tokens\n",
      "the trial has been enhanced, a new nct(nct03893799) listing was created    有  19  个tokens\n",
      "unavailability of the medication    有  5  个tokens\n",
      "the interest of potential centers is very limited    有  8  个tokens\n",
      "diagnostic issues    有  3  个tokens\n",
      "study was stopped after interim analysis for 4 cohorts (hcc, scchn, eoc, and gbm) indicated that the results did not fulfill the preplanned interim analysis criteria to move to phase 2 stage 2 in all 4 cohorts    有  52  个tokens\n",
      "part a of the study was successfully concluded. part b of the study was discontinued in favor of redesigned new studies    有  22  个tokens\n",
      "terminated due to lorcaserin recall    有  8  个tokens\n",
      "no actual dm    有  3  个tokens\n",
      "poor personnel available to complete study    有  7  个tokens\n",
      "intermediate analysis produced strong enough results that full study not needed    有  12  个tokens\n",
      "pi retired, study never opened    有  6  个tokens\n",
      "subject research)    有  3  个tokens\n",
      "there is no fund to support    有  6  个tokens\n",
      "it was determined not to be feasible at our site at this time    有  13  个tokens\n",
      "technical probelms led to inadequate randomization, and thus the project was terminated    有  16  个tokens\n",
      "mfr of product identified in protocol to measure perfusion after treatment with sponsor device withdrew support from the study. sponsor decided to cancel the investigation due to poor adequate replacement    有  33  个tokens\n",
      "the study design will need to be changed completely becasue of the change of research interest. we have decided to withdraw the study    有  26  个tokens\n",
      "protocol procedure did not adequately meet data needs for the study    有  11  个tokens\n",
      "we observed reduced intake by the fifth week, so we are shortening the study and simplifying it by using a complete factorial design with four conditions    有  29  个tokens\n",
      "sponsor had determined that the benefit-risk profile of adrabetadex was not favorable and the clinical development program for adrabetadex was discontinued    有  28  个tokens\n",
      "a recent change in treatment landscape may make study futile    有  10  个tokens\n",
      "available clinical data has shown limited anti-tumor activity and reaching target study drug dose levels may not be feasible    有  21  个tokens\n",
      "investigational device is no longer manufactured    有  8  个tokens\n",
      "due to other priorities    有  4  个tokens\n",
      "this study was terminated early due to poor adequate response, and did not move to the phase ii portion of the study    有  23  个tokens\n",
      "problem of supply of the experimental product (radio tracer)    有  11  个tokens\n",
      "it was determined that a study is no longer required because the clinical question posed by the study has been answered through published literature    有  24  个tokens\n",
      "the study was never completed as planned    有  7  个tokens\n",
      "the principal investigator has retired and has not been replaced has retired and a new one has not been identified principal investigator    有  22  个tokens\n",
      "the study had to be stopped because the period of the financial contract was over    有  15  个tokens\n",
      "due to ocaliva (obeticholic acid) us labeling update, the sponsor decided to terminate the study    有  23  个tokens\n",
      "study discontinued after part a due to sponsor's discretion    有  10  个tokens\n",
      "reb approval lapsed    有  4  个tokens\n",
      "the preliminary findings render it very unlikely that the methodology can be refined further in order to yield more accurate results even if more patients would be included and the study would be continued    有  34  个tokens\n",
      "major changes in manufacturing process and investigational product    有  9  个tokens\n",
      "the study was terminated by the sponsor on 16 november 2021 after a planned review by the independent data monitoring committee    有  24  个tokens\n",
      "due to pi's unavailability    有  6  个tokens\n",
      "study was stopped by the sponsor    有  6  个tokens\n",
      "pursuing an alternative clinical trial    有  7  个tokens\n",
      "pi no longer employed at institution    有  6  个tokens\n",
      "the sponsor has set up a secondary competitive study concerning the same population and whose secondary objectives are the same as those of the epoca study with the same endpoints    有  31  个tokens\n",
      "local irb recommended ind exemption from fda, study timeline not able to be met    有  17  个tokens\n",
      "production halt of fudr in china    有  8  个tokens\n",
      "the study was interrupted after a planned interim analysis for the high rate of primary outcomes (7.3%; 95% confidence interval [ci], 4.5-11.2)    有  38  个tokens\n",
      "study was not started at site    有  6  个tokens\n",
      "study end date exceeded and insufficient number of subjects needed for analysis. 11 patients included / 70 theoretical patients    有  22  个tokens\n",
      "grantor withdrew from study    有  5  个tokens\n",
      "deemed not human subjects research    有  6  个tokens\n",
      "errors in study conception, e.g. sample size calculation    有  11  个tokens\n",
      "irb approval was not obtained for this study    有  9  个tokens\n",
      "ind application did not get approved    有  6  个tokens\n",
      "clinical research currently on hold    有  5  个tokens\n",
      "decision made not to move to phase 2    有  9  个tokens\n",
      "new study to be created    有  5  个tokens\n",
      "ci not pursuing study    有  4  个tokens\n",
      "unable to feasibly complete study    有  6  个tokens\n",
      "based on the unblinded clinical data, the trial was terminated    有  13  个tokens\n",
      "fda approval not obtained    有  5  个tokens\n",
      "there are two reasons why the study was stopped. one is that the machine to opreate mri was damaged and we could not fix it. the second reason is the main reasearch felpoor has graduated and there is no one else to conitune this project    有  55  个tokens\n",
      "cant obtain imp    有  3  个tokens\n",
      "we had a change in staffing that precluded pursing this project    有  13  个tokens\n",
      "sponsor's commercial decision    有  4  个tokens\n",
      "not enough viable subjects    有  4  个tokens\n",
      "this study's genetic testing laboratory has suspended operations pending discussions with the fda concerning clinical interpretation of pharmacogenomics tests    有  23  个tokens\n",
      "insufficient closure    有  3  个tokens\n",
      "under internal considerations    有  3  个tokens\n",
      "equipment used for metabolic testing is no longer serviced and/or supported by the company. alternative equipment is not available to the research team to continue to conduct the study    有  31  个tokens\n",
      "study was terminated due to a re-prioritization of ongoing studies    有  14  个tokens\n",
      "cov-19 pandemic    有  4  个tokens\n",
      "study team determined that data collected was appropriate for study outcome goals    有  12  个tokens\n",
      "study did not start and is currently on pause    有  9  个tokens\n",
      "other - study agent no longer available    有  7  个tokens\n",
      "•terminated: study halted prematurely and will not resume; participants are no longer being examined or receiving intervention    有  20  个tokens\n",
      "end of agreement between bms and sghl    有  10  个tokens\n",
      "single-site study, site was unable to participate    有  9  个tokens\n",
      "logisitic problem    有  4  个tokens\n",
      "investigator still working on protocol and not sure when it will be ready    有  14  个tokens\n",
      "expired irb application    有  4  个tokens\n",
      "the pharmaceutical company decided to close their program evaluating the study agent, marizomib    有  17  个tokens\n",
      "we did not receive the equipment from our subcontractor in a time frame that would alpoor us to complete the study    有  24  个tokens\n",
      "testing supplies unavailable    有  3  个tokens\n",
      "dissertation for student changed    有  6  个tokens\n",
      "production of the medical device was stopped    有  7  个tokens\n",
      "internal resources ended    有  3  个tokens\n",
      "sars-cov2 pandemic    有  6  个tokens\n",
      "the wired carbon monoxide device (used to verify daily smoking abstinence) was discontinued by the manufacturer and replaced with a bluetooth device which initially provided inaccurate readings    有  31  个tokens\n",
      "unable to provide obgyn to assist with study for irb approval    有  14  个tokens\n",
      "technical difficulties for scans on the research mri system    有  10  个tokens\n",
      "problem with mri interpretation    有  5  个tokens\n",
      "to focus resources on other studies    有  6  个tokens\n",
      "irb had concerns about study; terminated    有  8  个tokens\n",
      "sponsor has decided to discontinue development of fezegepras based on initial pharmacokinetic results    有  19  个tokens\n",
      "sponsor is no longer pursuing the study    有  7  个tokens\n",
      "the supporting pharamceutical company elected not to pursue this study at this time    有  17  个tokens\n",
      "the study was terminated during dose escalation after a determination was made that the risk:benefit ratio no longer favored continued evaluation    有  24  个tokens\n",
      "change in personnel leading to inability to conduct study    有  9  个tokens\n",
      "study cancelled by pi    有  4  个tokens\n",
      "decided by the sponsor    有  5  个tokens\n",
      "substantial amendment to be implemented using another device    有  9  个tokens\n",
      "combined study endpoints with ongoing registry (nola/neu_2017_04)    有  17  个tokens\n",
      "the study was withdrawn    有  4  个tokens\n",
      "study non feasible folpooring changes in organisation of service    有  11  个tokens\n",
      "folpooring a strategic evaluation of its iih evolve phase iii clinical trial investigating presendin™, the invex board has made the difficult decision that the continuation of the trial is not viable and therefore the trial has been terminated    有  46  个tokens\n",
      "the design of the magpep trial is no longer in compliance with the current state of science    有  19  个tokens\n",
      "researchers decided to move to another technological platform which will require a new record when that research is ready to launch    有  22  个tokens\n",
      "this record was a placeholder created before trial was conducted. trial is now described in nct03545282    有  21  个tokens\n",
      "according to the available data from the trial，the sponsor determined to terminate this study    有  16  个tokens\n",
      "rss recommendation    有  2  个tokens\n",
      "multicenter failure    有  4  个tokens\n",
      "pl left institution    有  3  个tokens\n",
      "the trial was closed because the sponsor became insolvent    有  10  个tokens\n",
      "fusion announced that it is discontinuing this study as part of a portfolio prioritization and assessment; fusion no longer plans to pursue development of fpi-1966    有  32  个tokens\n",
      "application has been withdrawn    有  4  个tokens\n",
      "pi is retiring    有  3  个tokens\n",
      "unavailable drug in egypt    有  6  个tokens\n",
      "sponsor decided to not pursue study at this time    有  9  个tokens\n",
      "poor level of returning participants year by year    有  9  个tokens\n",
      "changes to the hifu-surg-fa study protocol, a number of centers have decided not to continue the study, including our national coordinating center    有  29  个tokens\n",
      "study sponsor sold and the new company would not support the study    有  12  个tokens\n",
      "poor psg    有  4  个tokens\n",
      "no sites identified with irb approval    有  7  个tokens\n",
      "beigene and celgene corporation terminated the parties' global collaboration for the compound, pending the acquisition of celgene by bristol myers squibb    有  31  个tokens\n",
      "necessary upgrades of essential software were not delivered    有  8  个tokens\n",
      "study activities were not initiated, and we do not plan to initiate them in the future    有  17  个tokens\n",
      "pi voluntarily closed the study. will be reopened as a national cooperative group trial    有  15  个tokens\n",
      "infeasible to conduct at this time    有  8  个tokens\n",
      "change in clinical plan and drug supply    有  7  个tokens\n",
      "investigator leaving the hospital    有  5  个tokens\n",
      "art gallery dissembled- no research goals with new art    有  11  个tokens\n",
      "due to pandemic related constraints    有  5  个tokens\n",
      "the study was completed    有  4  个tokens\n",
      "principal investigator leaving institution    有  4  个tokens\n",
      "poor intervention uptake, poor substitution of video for home visits, and study sites' decision to expand telehealth use in response to payment changes    有  28  个tokens\n",
      "staffing changes    有  3  个tokens\n",
      "decline of eligible participants    有  5  个tokens\n",
      "i did not pass the 2018 ministry of science and technology research project subsidy, so i applied for the project to close the case    有  27  个tokens\n",
      "sponsor's convenience    有  3  个tokens\n",
      "the primary hypotheses were unsupported with half of the data collected    有  11  个tokens\n",
      "fda indicated the same study could not be conducted under multiple inds    有  13  个tokens\n",
      "internal decision, study will be replaced with a larger monotherapy trial    有  13  个tokens\n",
      "work has already been published by other groups    有  8  个tokens\n",
      "the clinical study was canceled by the sponsor due to logistics and programming    有  13  个tokens\n",
      "study sponsor discontinued support    有  4  个tokens\n",
      "failure to identify complete responders since ctdna disappears after radiotherapy in most patients    有  16  个tokens\n",
      "determined that the tumor analysis could not be performed in accordance with the protocol    有  15  个tokens\n",
      "co-development decision    有  3  个tokens\n",
      "change in study personnel    有  4  个tokens\n",
      "interim analysis / resource availability    有  6  个tokens\n",
      "sponsor discontinuing research    有  4  个tokens\n",
      "project suspended whilst intervention is updated    有  6  个tokens\n",
      "sponsor no longer pursuing indication    有  5  个tokens\n",
      "the study will not take place at the university of pittsburgh    有  13  个tokens\n",
      "early terminated    有  2  个tokens\n",
      "per mcw irb    有  5  个tokens\n",
      "departure of principal investigator with no successor    有  7  个tokens\n",
      "retrospective part completed, prospective part response too poor    有  11  个tokens\n",
      "dropout rate was too high    有  5  个tokens\n",
      "the start of the study took too long and there are already many publications on the subject    有  17  个tokens\n",
      "patients no longer staying overnight in the hospital folpooring this procedure type    有  14  个tokens\n",
      "data collection could not be completed in time and it has not been possible to continue due to the pandemic. since it is not yet known when the face-to-face classes will resume, we moved on to the data analysis phase with the existing data    有  48  个tokens\n",
      "the study stopped because the company's strategy    有  8  个tokens\n",
      "pilot component of study completed    有  6  个tokens\n",
      "poor supporting staff    有  4  个tokens\n",
      "study was set-up in 2017, even though the protocol was adjusted, it was not possible to find suitable patients    有  24  个tokens\n",
      "rrx-001 will be studied under a new global, phase 3 clinical trial    有  17  个tokens\n",
      "vms medical went out of busainess    有  9  个tokens\n",
      "as a result of termination of development of oxb-102-01, it is no longer possible for sio to either commence or to continue any related clinical trials    有  33  个tokens\n",
      "the swissmedic agency released gilead from this post marketing requirement    有  15  个tokens\n",
      "inability to obtain drugs from supplier    有  7  个tokens\n",
      "difficulties encountered that were not highlighted in previous studies (traffic situations that made daily life difficult for users, need to rework the system)    有  29  个tokens\n",
      "company bankruptcy    有  2  个tokens\n",
      "study was never launched    有  4  个tokens\n",
      "continuing study was no longer feasible    有  7  个tokens\n",
      "the research equipment was not available for more than a year after the study was submitted. a new trial was being done during delivery of patients that competed with the study    有  32  个tokens\n",
      "unable to get product at this time    有  7  个tokens\n",
      "equipment unavailable    有  2  个tokens\n",
      "break of stock    有  3  个tokens\n",
      "amended and merged with ahead-eu study    有  9  个tokens\n",
      "data collection has halted due to no further assays provided by amnisure    有  14  个tokens\n",
      "after feasibility assessment and due to delays in data receipt study was terminated    有  13  个tokens\n",
      "this premature end of the study is due to the poor human resources and the fact that the forceps used to perform the biopsies for this study have not been marketed since january 2023    有  40  个tokens\n",
      "limited operating room availability    有  4  个tokens\n",
      "no recrutiment started    有  5  个tokens\n",
      "enough information was gathered in order to answer the primary research question    有  13  个tokens\n",
      "emerging evidence made the trial unnecessary    有  7  个tokens\n",
      "there are no fund to support    有  6  个tokens\n",
      "departure of pr mordon from the oncothai unit    有  12  个tokens\n",
      "the program couldn't be implemented    有  6  个tokens\n",
      "the study was never launched    有  5  个tokens\n",
      "irb protocol was terminated    有  5  个tokens\n",
      "higher than expected occurrence of vte (venous thromboembolic event)    有  16  个tokens\n",
      "evaluating feasibility    有  3  个tokens\n",
      "there is no commitment from the patient to maintain fasting in both the control and case groups    有  17  个tokens\n",
      "decision of the local healthcare authority    有  6  个tokens\n",
      "program not advancing    有  3  个tokens\n",
      "inadequate resources to complete within the required timeline    有  10  个tokens\n",
      "the project leader has left the institution    有  7  个tokens\n",
      "systematic literature review has been completed    有  7  个tokens\n",
      "current high clinical demands of pi    有  6  个tokens\n",
      "patient population too poor to reasonably continue study, pandemic had started at time of cessation, further leading to study discontinuation    有  23  个tokens\n",
      "due to difficulty in finalizing the contract    有  8  个tokens\n",
      "intervention is no longer being used    有  7  个tokens\n",
      "terminated after completion of part 1 due to a change in research plan    有  14  个tokens\n",
      "pi closing his lab    有  4  个tokens\n",
      "after careful review of new data on gsk2245035, glaxosmithkline has decided to cancel this study    有  25  个tokens\n",
      "the qualified and principal investigator has moved institutes. we are in the process for finding a replacement    有  18  个tokens\n",
      "abandoned before opening    有  4  个tokens\n",
      "investigator is no longer interested in moving forward with this study    有  12  个tokens\n",
      "due to the company's development strategy adjustment    有  8  个tokens\n",
      "recent results from a phase 3 study are expected to change the standard of care for patients with inoperable cca, rendering the release study challenging to complete and potentially inadequate for nda approval    有  39  个tokens\n",
      "during a piloting phase with our staff, the technology/eye-tracking device did not collect outcomes as expected    有  21  个tokens\n",
      "problems with the provision of equipment encountered during the study could not be resolved, making it impossible to take the images planned for the main objective of the study    有  30  个tokens\n",
      "study paused while working on logistics    有  6  个tokens\n",
      "due to company strategic decision    有  5  个tokens\n",
      "the laser is currently being worked on    有  7  个tokens\n",
      "interim analysis of data from open-label part, showed this part of the study met its objectives, therefore decided to discontinue this part. starting the double-blind part is being delayed due to aramchol meglumine being formulated    有  48  个tokens\n",
      "change in surgical practice and chemotherapy treatment by the surgery team    有  11  个tokens\n",
      "there were issues with the technical service provider of the platform isupport-portugal; the platform and its backoffice should be implemented by another service provider. a pilot study was conducted folpooring the protocol of the full trial    有  44  个tokens\n",
      "the laboratory in which the analyses on nasosinusal polyposis were to be carried out did not want to continue the research on this subject, so it was decided to stop this study prematurely    有  39  个tokens\n",
      "refusal of the ansm    有  6  个tokens\n",
      "study timing    有  2  个tokens\n",
      "one of the investigators is leaving the university    有  8  个tokens\n",
      "personnel resources required to conduct study are no longer available. study was terminated due to poor resources    有  19  个tokens\n",
      "nci approval withdrawn    有  4  个tokens\n",
      "closure of imv operations    有  5  个tokens\n",
      "the trial will be undertaken but the protocol will be substantially revised    有  12  个tokens\n",
      "investigator decided to not go forward with the study    有  10  个tokens\n",
      "inability to close the study in a clinically relevant time frame    有  12  个tokens\n",
      "study was unable to be started due to unavailability of study medication    有  13  个tokens\n",
      "change in availability of investigators/participants    有  7  个tokens\n",
      "logistic and financial reasons    有  5  个tokens\n",
      "fda withdrawal of oxandrin nda and generic andas    有  13  个tokens\n",
      "awaiting next model of the device    有  7  个tokens\n",
      "the study was terminated voluntarily by the sponsor due to changes in clinical development strategy    有  15  个tokens\n",
      "incorporation of ltfu into the main interventional study    有  13  个tokens\n",
      "the key elements of this study were incorporated into another study    有  11  个tokens\n",
      "the sponsor decided that the ce marking would not be renewed, and therefore there was no longer a need to continue the study as the data was no longer necessary    有  31  个tokens\n",
      "study stopped after a negative result delivred by the cpp for a substancial modification of the protocol    有  20  个tokens\n",
      "couldn't sign the contract    有  5  个tokens\n",
      "12 month folpoor up data not collected due to pandemic disruptions    有  13  个tokens\n",
      "production plan adjustment    有  3  个tokens\n",
      "pi moving to another university--study will not be done at uk; coronavirus pandemic will likely delay start at university of texas at arlington    有  27  个tokens\n",
      "device to be used in study is no longer available    有  10  个tokens\n",
      "personal changes in study team    有  5  个tokens\n",
      "change in clinical practice    有  4  个tokens\n",
      "resources had to be focused on other projects    有  8  个tokens\n",
      "early findings identified the need to update the design of the study device    有  13  个tokens\n",
      "principal investigator condition    有  3  个tokens\n",
      "working on revisions    有  3  个tokens\n",
      "there was not a need to carry out a study in lao any more    有  15  个tokens\n",
      "we were not able to conduct this study, in fact we opened the participating center and the confinement arrived a few days later. since then, the organization of the students' folpoor-up has changed and made the study as it was thought obsolete    有  49  个tokens\n",
      "irb suspended the study    有  5  个tokens\n",
      "pi will be retiring from the center. research will not continue with a new pi    有  16  个tokens\n",
      "due to difficulties in obtaining consent because of emergency situation    有  10  个tokens\n",
      "temporarily suspended due to pandemic    有  6  个tokens\n",
      "no longer relevant to field    有  5  个tokens\n",
      "terminated by sponsor due to poor interest    有  7  个tokens\n",
      "for strategic and pandemic reasons    有  5  个tokens\n",
      "the contract of k-haler products had been terminated between mundipharma and provider. therefore, this clinical trial was terminated early    有  25  个tokens\n",
      "the company no longer provided the device    有  7  个tokens\n",
      "exploratory pre-study demonstrated participants unwilling to be randomized to control arm    有  15  个tokens\n",
      "phd student completed primary study. awaiting a new student to take over the project for the secondary objective    有  20  个tokens\n",
      "resubmission planned    有  4  个tokens\n",
      "gsk investigating manufacturing site malfunction and assessing impact; study 209713 early terminated due to risk of potential contamination of study tablets    有  25  个tokens\n",
      "initiated a new randomized trial per discussion with fda    有  11  个tokens\n",
      "ce certificate ended and was not renewed    有  7  个tokens\n",
      "homology medicines has discontinued development of this program    有  9  个tokens\n",
      "interims analysis    有  3  个tokens\n",
      "withdrawn due to a change in therapeutic interventions    有  9  个tokens\n",
      "misregistered to wrong sponsor    有  5  个tokens\n",
      "study cancelled before protocol was implemented    有  6  个tokens\n",
      "the study device became unavailable for use    有  7  个tokens\n",
      "feasibility couldn't be worked out    有  7  个tokens\n",
      "study terminated early, main goals achieved    有  7  个tokens\n",
      "new heightened internet security at hhc and vvf device no longer compliant with intranet and internet access at hospital    有  23  个tokens\n",
      "equipment issues    有  2  个tokens\n",
      "the trial was discontinued by the sponsor    有  7  个tokens\n",
      "no longer proceeding with application    有  5  个tokens\n",
      "suspended until interim analysis is complete    有  7  个tokens\n",
      "a pilot study was negative    有  5  个tokens\n",
      "stopped due to the formation of injection site skin nodules    有  11  个tokens\n",
      "sponsor stopped due to partner collaboration ending    有  7  个tokens\n",
      "refusal ethics comity    有  5  个tokens\n",
      "this study would not add any new information    有  8  个tokens\n",
      "unavailable to collect study participants    有  6  个tokens\n",
      "all 3 participants receiving intervention in assessment phase developed seromas    有  12  个tokens\n",
      "the researchers were unable to answer the study question by utilizing the insurance claims database    有  15  个tokens\n",
      "a new multisite study was opened in place of this study    有  12  个tokens\n",
      "essential staff for study execution left the institution and no suitable replacement could be found    有  15  个tokens\n",
      "not able to perform intervention in current physical clinic location    有  10  个tokens\n",
      "protocol changed to use subcutaneous rather than intravenous daratumumab    有  15  个tokens\n",
      "sponsor decided to stop the study due to commercial reasons    有  10  个tokens\n",
      "the decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with autosomal dominant polycystic kidney disease (adpkd)    有  42  个tokens\n",
      "waiting for the ethics approval of collaborator affiliation    有  9  个tokens\n",
      "pending fda approval    有  4  个tokens\n",
      "phd student responsible for the study has decided to terminate her education    有  13  个tokens\n",
      "canceled by the sponsor    有  5  个tokens\n",
      "it was stopped folpooring the recommendations of the trial independent dsmb : permanent discontinuation of inclusions (related to a suspected higher number of deaths in the experimental arm)    有  35  个tokens\n",
      "the pandemic. collected data will presented as a pilot rct    有  12  个tokens\n",
      "investigational medical device no longer available    有  8  个tokens\n",
      "based on a review of data conducted by the independent data monitoring committee (idmc), sponsor decided to discontinue this study as the study was unlikely to achieve the primary objective of overall survival    有  37  个tokens\n",
      "sponsor pulled support for one of the study drugs    有  9  个tokens\n",
      "interim analysis shows results opposite of hypothesized    有  9  个tokens\n",
      "study never started due to change in availability of study drug    有  11  个tokens\n",
      "we terminated this trial and initiated a new one including pertuzumab    有  14  个tokens\n",
      "the project could no longer be implemented effectively and with fidelity    有  11  个tokens\n",
      "company changed strategic direction in oct 2019    有  9  个tokens\n",
      "principal investigator is transitioning to a new faculty position at another institution    有  12  个tokens\n",
      "the sponsor chose to terminate this study for commercial reasons    有  10  个tokens\n",
      "quest diagnostics terminated study early - did not want to continue to support single-site study    有  16  个tokens\n",
      "clinical trial was cancelled    有  4  个tokens\n",
      "we are closing this study as our clinical partners have all relocate from osu and we could not find continued interest. however, we demonstrated the feasibility of this imaging approach on which we also filed a patent    有  40  个tokens\n",
      "alteration of study required    有  5  个tokens\n",
      "the sponsor no longer wishes to pursue the methods outlined in the protocol    有  13  个tokens\n",
      "pandemic halt    有  4  个tokens\n",
      "it was decided to not run the japanese cohorts in the study    有  12  个tokens\n",
      "poor regulatory approval    有  4  个tokens\n",
      "the development of bermekimab in immunology is stopped    有  13  个tokens\n",
      "ethical and governance issues not resolved    有  6  个tokens\n",
      "study never started and is delayed until further notice    有  9  个tokens\n",
      "unable to achieve adequate number of hcv+ donor offers    有  11  个tokens\n",
      "miscommunication with the cro that was hired to help with the regulatory submission process    有  15  个tokens\n",
      "a study start is currently not foreseeable for organizational reasons. due to the delays, research has also been focused on new compounds, which has reduced the interest in the potential results of the above-mentioned clinical trial    有  41  个tokens\n",
      "this study was suspended by qtultrasound as other studies were reprioritized    有  15  个tokens\n",
      "lead investigator no longer with institution    有  6  个tokens\n",
      "study withdrawn by supporter    有  4  个tokens\n",
      "evidence of liver injury in a separate inarigavir study    有  14  个tokens\n",
      "intervention services were suspended and then unavailable    有  8  个tokens\n",
      "no clear benefit of gb1275 was observed either as monotherapy or in combination with pembrolizumab    有  22  个tokens\n",
      "study not going forward at this time    有  7  个tokens\n",
      "due to study design limitations, this study has been discontinued and will not proceed with the 2nd cohort as contemplated in the original protocol    有  27  个tokens\n",
      "recent studies suggest an increase in mortality due to high-does vitamin c    有  14  个tokens\n",
      "access to human body samples by another existing cohort    有  9  个tokens\n",
      "stafit acetabular system not ce marked anymore    有  11  个tokens\n",
      "poor responce    有  4  个tokens\n",
      "funder requested termination due to halting internal development of tak-659    有  14  个tokens\n",
      "study was updated and issued a new nct number    有  10  个tokens\n",
      "interim analysis showed positive results, it was difficult to include patients and also the fact that the grant for this project has ended, we have decided to complete the study before we had included the total number of 16 patients    有  44  个tokens\n",
      "study stopped due to company strategic prioritization    有  8  个tokens\n",
      "the study is no longer required based on nonclinical drug data    有  12  个tokens\n",
      "the project was to be led by midwives but the director of the school of midwives opposed it at the last moment    有  24  个tokens\n",
      "study will be redesigned    有  4  个tokens\n",
      "combination arm delevelped significant poor prognosis    有  8  个tokens\n",
      "change of circumstances for ci/pi    有  6  个tokens\n",
      "the standard of care had changed during our wait for the program letter of agreement between phoenix children's hospital and banner to administering iv glucose in the newborn nursery so we weren't able to meet our objective    有  39  个tokens\n",
      "main clinician cancelled collaboration for personal reasons    有  8  个tokens\n",
      "changes in pipeline    有  3  个tokens\n",
      "study was never initiated; rather the duration of open-label study c602 (nct03714373) was extended    有  23  个tokens\n",
      "supplements expired    有  3  个tokens\n",
      "study delayed indefinetly    有  5  个tokens\n",
      "irb approval expired on 3/16/2022. study would need to be reapproved by the irb with a new submission given the duration of expiration    有  33  个tokens\n",
      "because of researcher foreign training    有  5  个tokens\n",
      "the study never started. it was withdrawn from the irb    有  12  个tokens\n",
      "tthe study is in the approval phase by local regulatory authorities    有  12  个tokens\n",
      "end    有  1  个tokens\n",
      "new investigational devices are currently under development    有  8  个tokens\n",
      "study treatment is to use ts-1 (mono-chemotherapy agent) in adjuvant setting for pancreatic cancer, which may be less clinical benefit compared to combination therapy according to current trend at investigators' discretion    有  42  个tokens\n",
      "the study was withdrawn due to a change in company strategy    有  11  个tokens\n",
      "the study was withdrawn as lesinurad was withdrawn from the market in europe by the market authorization holder. hence the commitment to do this pass was removed by the european medicines agency    有  36  个tokens\n",
      "research at the university of chicago was halted in march 2020    有  13  个tokens\n",
      "study part one completed    有  4  个tokens\n",
      "sponsor has determined that information it would have collected would not inform future development of a therapy with axa 1957 for nafld    有  27  个tokens\n",
      "changed the direction and aims of the study    有  8  个tokens\n",
      "this clinical trial was entered in error. please refer to the correct entry of this study using the folpooring link: https://clinicaltrials.gov/ct2/show/nct04519684    有  39  个tokens\n",
      "unable to complete intervention due to logistics    有  7  个tokens\n",
      "intervention and and final data collection point was not completed due to coronavirus school closures in march 2020    有  21  个tokens\n",
      "poor apparent benefits    有  4  个tokens\n",
      "investigator not available    有  4  个tokens\n",
      "satisfactory results, in terms of both clinical and statistical, were achieved    有  15  个tokens\n",
      "pi resigned from faculty position and k23 award was terminated early    有  12  个tokens\n",
      "on temporary hold for internal review    有  6  个tokens\n",
      "study never approved by irb or initiated    有  8  个tokens\n",
      "cancelled study    有  2  个tokens\n",
      "investigator did not move forward with the project due to costs    有  12  个tokens\n",
      "the bio-samples are corrupted for technical reasons    有  9  个tokens\n",
      "withdraw of financial support by industry collaborator    有  8  个tokens\n",
      "strategic corporate decision    有  4  个tokens\n",
      "investigator decided to close study    有  6  个tokens\n",
      "research staff leading project left institute    有  6  个tokens\n",
      "logistics requirements    有  3  个tokens\n",
      "new study initiated    有  3  个tokens\n",
      "sponsor ceasing operations    有  4  个tokens\n",
      "change sponsor    有  2  个tokens\n",
      "patients were selected but their very condition and the resulting comorbidities did not alpoor their inclusion. in addition, the health crisis prevented any bariatric operation of this complexity for an indefinite period    有  41  个tokens\n",
      "on 3/4/2020 a federal judge ruled the hmp work requirement unlawful, thereby ending it and suspending implementation of this rct. this is not an irb suspension    有  38  个tokens\n",
      "all required data are already collected    有  6  个tokens\n",
      "terminated on the basis of the currently uncertain risk-benefit balance for the patients, and the strategic position of the development program    有  24  个tokens\n",
      "the development of bdtx-189 was discontinued by the sponsor    有  12  个tokens\n",
      "the study was withdrawn folpooring a strategic portfolio re-prioritization    有  15  个tokens\n",
      "due to unexpected sudden death on study    有  7  个tokens\n",
      "due to current political circumstances in study site area    有  9  个tokens\n",
      "protocol changed substantially enough to warrant a separate submission    有  9  个tokens\n",
      "no longer conducting this retrospective research    有  6  个tokens\n",
      "one of the drugs for the study is not commercially available    有  11  个tokens\n",
      "logistical constraints    有  3  个tokens\n",
      "study replaced with a new study    有  6  个tokens\n",
      "the company decided to interrupt the development of the drug in all oncological indications    有  15  个tokens\n",
      "principal investigator dr. thomas barbour passed away    有  10  个tokens\n",
      "irb recommended change to registry study or quality improvement project status    有  12  个tokens\n",
      "the possibility of obtaining histological data is too poor due to the poor availability of biological samples    有  18  个tokens\n",
      "collected enough data to support the endpoints    有  8  个tokens\n",
      "the project has ended prior to beginning    有  7  个tokens\n",
      "terminated due to unfavorable risk-benefit ratio of investigational regimen    有  12  个tokens\n",
      "this is a retrospective study reviewing subject questionnaires. no treatments will be administered in this study    有  18  个tokens\n",
      "not in line with company's recently updated clinical development strategy    有  11  个tokens\n",
      "organisational set up    有  5  个tokens\n",
      "poor recrutement rate    有  6  个tokens\n",
      "interaction term analysis result was not significant and thus comparative effectiveness for primary and secondary outcomes could not be considered per protocol    有  22  个tokens\n",
      "study stopped due to product discontinuation by manufacturer    有  9  个tokens\n",
      "only the 1 month folpoor-up was completed. the principal investigator could not complete the 3 month folpoor-up appointments and was not calibrated with other dentists who were available at the time    有  41  个tokens\n",
      "the device (heartware) was recalled and discontinued by the fda    有  14  个tokens\n",
      "pi departure from the institution    有  5  个tokens\n",
      "due to changes in the sponsor's research strategy    有  9  个tokens\n",
      "study not progressing    有  3  个tokens\n",
      "working on complying with the research ethics board requirements    有  9  个tokens\n",
      "protocol is being modified    有  4  个tokens\n",
      "logistical reasons (research staff)    有  7  个tokens\n",
      "coordinator departure    有  3  个tokens\n",
      "the study has not started, the device is not ready so the study will be delayed    有  17  个tokens\n",
      "change in sponsor strategy    有  4  个tokens\n",
      "principal investigator is not longer at this institution    有  8  个tokens\n",
      "poor sufficient staff to conduct the study    有  8  个tokens\n",
      "grant support was withdrawn from amgen pharmaceuticals    有  9  个tokens\n",
      "the care4today® ibd dashboard for hcps and the patient app will be deactivated indefinitely and will no longer be available for use    有  27  个tokens\n",
      "sufficient data has been obtained to meet current objectives    有  10  个tokens\n",
      "limited value as a single-arm study    有  7  个tokens\n",
      "study was not initiated it was decided to cancel this study    有  11  个tokens\n",
      "institution decision    有  2  个tokens\n",
      "unable to identify enough practices and clinicians to participate in the study    有  12  个tokens\n",
      "department of corrections unable to support study at this time and find agreement on publication issue    有  16  个tokens\n",
      "corona pandemic    有  3  个tokens\n",
      "study team unable to start up study at this time    有  10  个tokens\n",
      "we reached the number of participants required    有  7  个tokens\n",
      "fda didn't approve the design of the protocol so we didn't start the study    有  17  个tokens\n",
      "day is not required for anticipated dates    有  7  个tokens\n",
      "due to the pandemic, there were logistical issues in continuing the study    有  13  个tokens\n",
      "global recall of the comparator device    有  6  个tokens\n",
      "due to the rapid shifting of liver cancer disease landscape and the company's adjustment of development strategy    有  18  个tokens\n",
      "redesigned trial using another placebo controlled drug    有  9  个tokens\n",
      "because of corona virus epidemic    有  6  个tokens\n",
      "strategic change to clinical development plan    有  7  个tokens\n",
      "the poc test was withdrawn by manufacturer    有  7  个tokens\n",
      "it is unlikely that the scientific question will ever be answered. thus, it would be considered unethical to continue the trial    有  23  个tokens\n",
      "priority changes of the company    有  5  个tokens\n",
      "poor participate rate    有  4  个tokens\n",
      "mutual decision between the investigators and the sponsor    有  9  个tokens\n",
      "the study was stopped because the manufacturer stopped producing the heartware lvad device    有  15  个tokens\n",
      "initiating a new study with revised statistics    有  8  个tokens\n",
      "coronavirus    有  3  个tokens\n",
      "inability to reach the estimated sample size    有  8  个tokens\n",
      "per irb closed and opened a new study    有  9  个tokens\n",
      "cessation of main trial of which this study was a biomarker imaging side study    有  16  个tokens\n",
      "study activities never commenced    有  4  个tokens\n",
      "study manager's decision    有  4  个tokens\n",
      "study is being abandoned    有  4  个tokens\n",
      "pi request due to a poor coordinator availability for study procedures    有  11  个tokens\n",
      "the review board rejected our request of changing the protocol and advised us to terminate the trial    有  17  个tokens\n",
      "patients case mix changed and did not match anymore with selection criteria    有  12  个tokens\n",
      "currently on standby until new primary investigator is found    有  9  个tokens\n",
      "contact issues    有  2  个tokens\n",
      "study did not start by logistic reasons    有  7  个tokens\n",
      "company was sold and clinical trial was suspended then teminated    有  11  个tokens\n",
      "preliminary analyses of the samples provide no indication for a clinically relevant relationship between hyperprolactinemia and stimulation of adrenal steroidogenesis    有  28  个tokens\n",
      "changed to quality improvement project    有  5  个tokens\n",
      "pi no longer working at indiana university;    有  9  个tokens\n",
      "the mepitel film was expired and was no longer available    有  12  个tokens\n",
      "no subjects are willing to participating    有  6  个tokens\n",
      "it was determined that the trial could stop early due to surpassing the feasibility rate    有  16  个tokens\n",
      "src remediation    有  3  个tokens\n",
      "terminated due to liver findings    有  5  个tokens\n",
      "funder decided to not continue the study    有  8  个tokens\n",
      "our study design changed    有  4  个tokens\n",
      "terminated early due to poor blinded event rate    有  8  个tokens\n",
      "part 1 completed. part 2 not initiated    有  10  个tokens\n",
      "technical problems and employee shortage    有  5  个tokens\n",
      "poor interest from participants    有  5  个tokens\n",
      "the study drug could not be obtained    有  7  个tokens\n",
      "study will not take place at this time    有  8  个tokens\n",
      "combined with the analysis of the existing data of the trial, there was no obvious advantage compared with the clinical standard treatments, and the clinical trial was decided to be terminated based on the benefit of the subjects    有  40  个tokens\n",
      "sponsor cancellation    有  2  个tokens\n",
      "the study was stopped because based on the planned interim analysis of the data of part 1, palatability of both pediatric formulations was not acceptable    有  29  个tokens\n",
      "this project will be integrated into an ongoing project    有  9  个tokens\n",
      "ulipristal acetate was recalled    有  8  个tokens\n",
      "sponsor and site agreed the research would not happen now; several delays and other issues    有  16  个tokens\n",
      "trial terminated by funder    有  5  个tokens\n",
      "1. most patients with liver cirrhosis already use ppi and nsbb 2. 90 % peptic ulcer size is smaller than 5cm    有  32  个tokens\n",
      "a new large meta-analysis was published. the results showed the likelihood that liposomal bupivacaine and nerve blocks no longer offer significant contribution. decision was made to terminate the study    有  37  个tokens\n",
      "halozyme halted development of pegph20 folpooring phase 3 failure    有  16  个tokens\n",
      "pandemic of sars-cov2    有  9  个tokens\n",
      "need to be redesigned    有  4  个tokens\n",
      "unable to procure supplement for clinical trial use    有  8  个tokens\n",
      "the investigators no longer want to do the project    有  9  个tokens\n",
      "phase 3 trial rtb-101-204 study did not meet its primary endpoint    有  17  个tokens\n",
      "the sponsor has decided to stop development of the inhaled ct-p63/66 combination therapy    有  18  个tokens\n",
      "discontinuation of study due to site staffing and resources available to conduct the study    有  16  个tokens\n",
      "homology medicines inc. has discontinued the development of this program    有  12  个tokens\n",
      "ci has left the trust    有  5  个tokens\n",
      "substantially redesigning study protocol and opening a new study in the future    有  15  个tokens\n",
      "study was terminated due to poor sufficient therapeutic effect    有  9  个tokens\n",
      "expired irb approval 12/12/2020    有  11  个tokens\n",
      "closed by the irb 5/26/22 due to non-compliance    有  16  个tokens\n",
      "closed by irb on 3/28/22    有  11  个tokens\n",
      "pandemic of coronavirus disease    有  6  个tokens\n",
      "based on initial findings and input from other researchers in the field, the investigators and sponsor decided to end this study and begin work on an updated version of this research    有  32  个tokens\n",
      "design has to been modified due to the results from oral surveillance    有  12  个tokens\n",
      "some of the raw materials for the investigational drug are difficult to obtain and expensive    有  16  个tokens\n",
      "due to the amended therapy strategies for rectal cancer recently, it was decided not to transfer the study to the phase ii part, as superiority over standard chemoradiation and transfer to a new therapy standard are increasingly unlikely    有  44  个tokens\n",
      "investigator retirement    有  3  个tokens\n",
      "sponsor stopped study as the study drugs were withdrawn from the market    有  12  个tokens\n",
      "corporate management decision    有  4  个tokens\n",
      "the cediranib producer laboratory decided to stop the development of this product    有  15  个tokens\n",
      "problem with the device (dilatator of the introducer) used to introduce the intra arterial balloon    有  21  个tokens\n",
      "operational reasons    有  3  个tokens\n",
      "the coronavirus broke out in china at the end of 2019    有  13  个tokens\n",
      "the study was terminated due to a change in development priorities    有  11  个tokens\n",
      "audit in process    有  3  个tokens\n",
      "no need to complete the overall survival (os) folpoor-up as the sample size was too small to interpret os    有  24  个tokens\n",
      "since schools are closed due to the current corona virus situation, the study cannot be continued    有  18  个tokens\n",
      "the results of the lead-in phase did not fulfill the criteria set for moving into the randomized phase    有  19  个tokens\n",
      "investigational device under development    有  6  个tokens\n",
      "project terminated ind withdrawn    有  4  个tokens\n",
      "there are no suitable participants    有  5  个tokens\n",
      "investigators not interested any more in the study    有  9  个tokens\n",
      "because of the pandemic, this study had to be stopped and cannot be resumed    有  15  个tokens\n",
      "the study was merged with a different study    有  8  个tokens\n",
      "due to unattainability of the expected sampling unit    有  11  个tokens\n",
      "most participants did not complete the post-intervention questionnaire    有  10  个tokens\n",
      "study is not feasible at this time due to staffing limitations    有  11  个tokens\n",
      "because of the pandemic    有  4  个tokens\n",
      "never start    有  2  个tokens\n",
      "decision based on strategic reasons related to limited development options left in metastatic colorectal cancer    有  17  个tokens\n",
      "sponsor ceasing all operations due to company's shut down    有  11  个tokens\n",
      "the number of subjects did not meet the requirements    有  9  个tokens\n",
      "coronavirus pandemia    有  5  个tokens\n",
      "transfer the study to another sponser    有  8  个tokens\n",
      "due to coronavirus pandemic    有  4  个tokens\n",
      "the phase 3 polarisdmd trial did not meet the primary endpoint. as a result, activities related to the development of edasalonexent have stopped including the cat-1004-302 open-label study of edasalonexent in boys with duchenne muscular dystrophy    有  58  个tokens\n",
      "the ethics committee has not accepted the extension    有  8  个tokens\n",
      "compound was sold by funder and development ceased    有  9  个tokens\n",
      "change in hospital protocol    有  4  个tokens\n",
      "study showed no results    有  4  个tokens\n",
      "screened participants did not meet inclusion criteria prior to study completion date    有  13  个tokens\n",
      "the study never started due to poor mutual agreements    有  9  个tokens\n",
      "study was not approved by health authorities until get the results of the previous study    有  15  个tokens\n",
      "drug is no longer being manufactured    有  6  个tokens\n",
      "logistical difficulties in the department due to a poor paramedical staff and dialysis space    有  18  个tokens\n",
      "participants no longer receiving intervention    有  5  个tokens\n",
      "technical resources not available    有  4  个tokens\n",
      "project stopped by the sponsor    有  5  个tokens\n",
      "poor scientific relevance due to the marketing of new treatments, and expected inclusion difficulties    有  16  个tokens\n",
      "pending cohort review meeting    有  4  个tokens\n",
      "study abandoned before any submission (foreseeable organizational difficulties)    有  12  个tokens\n",
      "due to poor interest    有  4  个tokens\n",
      "nci decided to terminate abtc consortium due to nci moving in different direction for brain cancer - official close date is 10/31/23    有  30  个tokens\n",
      "decision of sponsor: impossibility of contract with takeda    有  12  个tokens\n",
      "residency completed    有  3  个tokens\n",
      "preliminary analysis showed no benefit of the investigational supplement    有  12  个tokens\n",
      "request from pm to suspend the study until the data review is complete    有  13  个tokens\n",
      "the study was stopped due to protocol amendment and project name change    有  12  个tokens\n",
      "continuation of the trial cannot serve a scientific purpose    有  10  个tokens\n",
      "interim analysis indicated no statistical difference between treatment arms    有  10  个tokens\n",
      "withdrawn with irb    有  5  个tokens\n",
      "investigator's perogative    有  6  个tokens\n",
      "poor significance/futile study    有  7  个tokens\n",
      "ehva t02/anrs vri07 clinical trial had been discontinued. find relevant information on the ehva website: https://ehv-a.eu/trials/ehva-t02    有  37  个tokens\n",
      "the study stopped because of delays in the development of the smartphone app intervention    有  14  个tokens\n",
      "changes will be made in the design of one of the study iols    有  14  个tokens\n",
      "credo stent is now ce-marked for rescue stenting (new indication)    有  17  个tokens\n",
      "regeneron has discontinued further clinical development of regn5069, an antibody to gfrα3, which was previously being studied in osteoarthritis pain of the knee    有  36  个tokens\n",
      "unavailability of drugs    有  4  个tokens\n",
      "change of the scientific and medical context that is no longer favorable to our study. this has resulted in the termination of inclusions    有  25  个tokens\n",
      "the number of responders in the test sessions was too poor    有  11  个tokens\n",
      "device modifications    有  2  个tokens\n",
      "pi closed the protocol    有  4  个tokens\n",
      "request for additional preclinical data    有  6  个tokens\n",
      "change study sites    有  3  个tokens\n",
      "study was terminated due to inability to: 1) vaccinate at school, 2) control and track vaccinations, 3) continue the intervention as proposed. data collected during fall 2019 clinics are being transferred to researchers and verified    有  48  个tokens\n",
      "mutual decision walter reed/u maryland and mesh suture inc    有  15  个tokens\n",
      "bexion will not move forward with the part 2 expansion portion of the trial in order to focus resources on the further development of bxq-350 as an earlier treatment measure in the pediatric population    有  39  个tokens\n",
      "the clinical investigation improve has been closed after a decision by the swedish medical products agency that the trial must comply to the new european medical regulation mdr    有  30  个tokens\n",
      "the benefit-risk profile no longer supports continuing the studies    有  10  个tokens\n",
      "pi decided not to go forward with study    有  8  个tokens\n",
      "difficulty of recrutment    有  5  个tokens\n",
      "poor eligible participants during study time period    有  8  个tokens\n",
      "due to a delayed start-up and delayed patient inclusion in combination with new available scientific data, continuation of the clinical study no longer serves a scientific purpose    有  29  个tokens\n",
      "the study was terminated due to the sars-cov-2 pandemic. aim 1 was completed    有  20  个tokens\n",
      "unable to effective arrange trial logistics    有  6  个tokens\n",
      "fda did not provide approval of the use of the drug for the study    有  15  个tokens\n",
      "study discontinued - testing of highest dose obsolete    有  8  个tokens\n",
      "we have not obtained additional subjects and chose to terminate/close this study    有  13  个tokens\n",
      "created a new protocol with a new study design    有  9  个tokens\n",
      "due to budget decision and wanting to pursue other research priorities    有  11  个tokens\n",
      "study never began because of withdrawal of the industrial partner    有  10  个tokens\n",
      "similar clinical trials showed not very encouraging results, which made us decide, after several modifications to the protocol and numerous difficulties encountered, to abandon the trial    有  29  个tokens\n",
      "pending additional product qa    有  4  个tokens\n",
      "concept is withdrawn and a different concept will be submitted the near future    有  13  个tokens\n",
      "terminated due to significant protocol updates that resulted in initiating a new study    有  13  个tokens\n",
      "decoupler equipment used for 31p magnetic resonance is being serviced    有  14  个tokens\n",
      "study objective and design change    有  5  个tokens\n",
      "decided to do smaller pilot study instead    有  8  个tokens\n",
      "did not meet progression criteria    有  5  个tokens\n",
      "human ressources    有  3  个tokens\n",
      "organizational difficulties for the collection of adipose tissue and for the supply of the experimental drug    有  18  个tokens\n",
      "logistic problem and absence of coordinating investigator    有  8  个tokens\n",
      "due to government regulation    有  4  个tokens\n",
      "poor supply of comparator drug in country    有  8  个tokens\n",
      "significant differences in conversion rate as well as r0 resection rate between the two groups    有  17  个tokens\n",
      "variance of outcome measures was substantially greater than anticipated in the statistical plan    有  14  个tokens\n",
      "commitment fulfilled    有  3  个tokens\n",
      "not feasable due to logistics    有  6  个tokens\n",
      "check cap board of directors decision to stop all company activities including clinical trails    有  14  个tokens\n",
      "supplier of product went into bankruptcy proceedings    有  7  个tokens\n",
      "research and development strategy adjustment    有  5  个tokens\n",
      "the implementation of the tool has been delayed due to technology governance issues and requests for changes in the end user design    有  22  个tokens\n",
      "not enough intervention materials can be provided    有  7  个tokens\n",
      "re-submission planned    有  4  个tokens\n",
      "modification of the care habits. we believe today that we are no longer able to carry out this study as initially described    有  23  个tokens\n",
      "technical requirements not met    有  4  个tokens\n",
      "pi decided to terminate the trial    有  6  个tokens\n",
      "unable to complete due to sars-cov-2 pandemic    有  12  个tokens\n",
      "closed prior to completion secondary to surgeon leaving ucla    有  10  个tokens\n",
      "biogen will stop any further development of the mspt. the data collected thus far in the mspt feasibility study alpoor us to answer the primary study objectives that are associated with assessing the feasibility of the mspt in a clinical care setting    有  49  个tokens\n",
      "resource shortage    有  2  个tokens\n",
      "[sponsors decision]    有  4  个tokens\n",
      "irb determination    有  3  个tokens\n",
      "due to protocol feasibility given the rapid evolution of medical practice for spinal procedure. data from approximately 65 fusion study subjects will be analyzed with the intent to create either a future study or registry for this patient population    有  41  个tokens\n",
      "withdrawn prematurely    有  3  个tokens\n",
      "there was a delay in getting protocol approvals and hence the study would not be completed in time    有  18  个tokens\n",
      "per sponsor advice    有  3  个tokens\n",
      "there have been multiple issues getting the device repaired and then in working order. the pi's have decided to terminate the study. the termination request has been filed with the institution's irb    有  37  个tokens\n",
      "it is planned to restart the clinical study after the completion of the clinical trial protocol modification    有  17  个tokens\n",
      "company discontinued production of the porcine xenograft    有  11  个tokens\n",
      "study postponed    有  2  个tokens\n",
      "study was halted due to suspected liver injury in another study with inarigavir    有  17  个tokens\n",
      "poor patient interest in participating (for adult patients), and poor parental consent to participate (for pediatric patients)    有  22  个tokens\n",
      "replaced by cato-pad/btk study    有  9  个tokens\n",
      "no eligible patient identified after 18 evaluable patients underwent pre-screening over a 2 year period    有  20  个tokens\n",
      "company ceased operations    有  3  个tokens\n",
      "lactobacillus reuteri (gastrus®) was not anymore available in the region    有  21  个tokens\n",
      "the study was withdrawn from the irb    有  8  个tokens\n",
      "budget    有  1  个tokens\n",
      "additional published information on the topic since starting the study    有  10  个tokens\n",
      "revised protocol to such a significant degree that we simply closed this study and started a new study    有  19  个tokens\n",
      "mid-term analysis    有  3  个tokens\n",
      "not enough participation    有  3  个tokens\n",
      "as of november 4, 2019 the study was halted prematurely and will not resume    有  18  个tokens\n",
      "unable to allocate sufficient resources in setting of pandemic    有  9  个tokens\n",
      "the sponsor decided to discontinue the development of atezolizumab in combination with magrolimab in the aml indication    有  27  个tokens\n",
      "we lost some staffing and were unable to continue the study    有  11  个tokens\n",
      "competing clinical trial opening    有  5  个tokens\n",
      "not enough human resources    有  4  个tokens\n",
      "change in study design based on phase 1 data collection; patient burden was not feasible    有  17  个tokens\n",
      "we never started the study due to logistical limitations    有  9  个tokens\n",
      "no suitable population available    有  4  个tokens\n",
      "change in participant landscape and other treatment availability    有  8  个tokens\n",
      "wrong entry    有  2  个tokens\n",
      "eirb withdrew study for concerns    有  7  个tokens\n",
      "unable to continue to conduct study procedures due to pandemic    有  10  个tokens\n",
      "intervention causing discomfort to participants    有  6  个tokens\n",
      "grant applications to fund the investigation were not selected for fundin4    有  13  个tokens\n",
      "due to development challenges associated with the sars-cov-2 pandemic and emerging nonclinical data    有  19  个tokens\n",
      "this clinical trial will not be performed at cuimc    有  11  个tokens\n",
      "pi, who was a resident, graduated, and the project was not pursued further    有  16  个tokens\n",
      "there are not enough patients at our institution meeting eligibility criteria to complete the study as intended    有  17  个tokens\n",
      "stopped before irb approval    有  5  个tokens\n",
      "participant mortality rates were higher than expected    有  7  个tokens\n",
      "will not resume. company choosing not to continue with drug. one participant now off study    有  17  个tokens\n",
      "premature termination due to logistical limitations    有  8  个tokens\n",
      "in process (technical improvements)    有  6  个tokens\n",
      "the study has gotten preliminary results and stopped advanced    有  9  个tokens\n",
      "canceled by immunoscore's manufacturer    有  8  个tokens\n",
      "this study could not be started because of some technical issues    有  11  个tokens\n",
      "pi and practice closed    有  4  个tokens\n",
      "one of the main investigators is leaving the university    有  9  个tokens\n",
      "technological problem    有  3  个tokens\n",
      "unable to staff the project    有  5  个tokens\n",
      "structural change at the hospital    有  5  个tokens\n",
      "changes to buildings why study was terminated prematurely    有  8  个tokens\n",
      "unable to perform refinement of study procedures to better capture information needed    有  12  个tokens\n",
      "schedule issue    有  2  个tokens\n",
      "the investigator moved to another institution, therefore the study was never initiated    有  13  个tokens\n",
      "the imiquimod 3.75% was ineffective    有  12  个tokens\n",
      "the study was terminated due to a change in priorities at the host organization and the end of the grant period of support    有  23  个tokens\n",
      "equipment is not available    有  4  个tokens\n",
      "potentially resume in 2024    有  7  个tokens\n",
      "pending cpp validation for an extension of the study    有  9  个tokens\n",
      "withdrawal of the project    有  5  个tokens\n",
      "logistics: not able to get resosurces to beginn    有  14  个tokens\n",
      "pi moving to another institution with nih grant relinquished    有  11  个tokens\n",
      "side effects of medication    有  4  个tokens\n",
      "no clinical need to perform study    有  6  个tokens\n",
      "study not feasible    有  3  个tokens\n",
      "awaiting results of interim analysis    有  6  个tokens\n",
      "the study was halted prematurely due to bristol-myers squibb's (bms) decision to withdraw support for this study    有  26  个tokens\n",
      "pi determined not enough clinical staff support for project    有  9  个tokens\n",
      "the study protocol needed to be modified    有  7  个tokens\n",
      "participants constantly reported knee pain    有  5  个tokens\n",
      "study not submitted to regulatory authorities    有  6  个tokens\n",
      "investigation of ace-083 for use in patients with cmt and fshd is being discontinued in this extension study as functional secondary endpoints were not achieved in the a083-023 or a083-03 trial (the parent trials)    有  48  个tokens\n",
      "no extension of ethic comitee    有  7  个tokens\n",
      "the study was terminated early (folpooring completion of sad cohort 3; 80 mg) based on pk/pd modelling which demonstrated the medicine's intended target profile was not achievable    有  37  个tokens\n",
      "no need to include more patients for analysis. 40 patients initially (36 actual)    有  17  个tokens\n",
      "freeline has decided to pause development of flt190 in fabry disease to focus its resources on advancing flt201    有  24  个tokens\n",
      "study reprioritization    有  5  个tokens\n",
      "the study was withdrawn due to change in project strategy (new intended use)    有  15  个tokens\n",
      "folpooring analysis of open label extension (ole) data from rms phase 2 study (ms200527- 0086), it was determined that a change in active comparator warranted in phase 3 rms comprised of trial ms200527-0073. consequently, this trial terminated early    有  58  个tokens\n",
      "folpooring analysis of open label extension (ole) data from rms phase 2 study (ms200527- 0086), it was determined that a change in active comparator warranted in phase 3 rms comprised of trial ms200527-0074. consequently, this trial terminated early    有  58  个tokens\n",
      "study design reconsidered    有  4  个tokens\n",
      "based on tolerability findings at the poor dose level thus far, continuation of dosing or even dose escalation is not possible    有  24  个tokens\n",
      "merged with other study    有  4  个tokens\n",
      "insufficient personnel dedication    有  4  个tokens\n",
      "the graduate student quit    有  4  个tokens\n",
      "feasibility (barriers to implantation within the institution)    有  12  个tokens\n",
      "this study was originally designed to meet mdr commitments. mdr approval was secured without this study. therefore, this study does not fulfil its role as a regulatory body commitment    有  34  个tokens\n",
      "study was not approved for fox chase cancer center's research review committee (rrc)    有  17  个tokens\n",
      "irb expired. the study will not be resumed    有  10  个tokens\n",
      "researcher will no longer conduct the study    有  8  个tokens\n",
      "a new study is planed to replace the current study due to ip upgrade    有  15  个tokens\n",
      "change of the product development strategy    有  6  个tokens\n",
      "no drug    有  2  个tokens\n",
      "the insufficient development of connection networks limit the teleconsultation deployment in the grenoble metropolitan area    有  18  个tokens\n",
      "budget for the study was withdrawn and discontinued    有  8  个tokens\n",
      "the sponsor elected not to continue with the study    有  9  个tokens\n",
      "promotor decision    有  3  个tokens\n",
      "biochemical measurement techniques were deemed insufficient to continue research    有  10  个tokens\n",
      "pi workload    有  2  个tokens\n",
      "dmc noted that the primary end point of healed index ulcer at 12 weeks was reached only in 11.5%, whereas a higher figure of 42.5% had been used for the original power calculation, suggesting the trial is significantly underpowered    有  51  个tokens\n",
      "awaiting approvals    有  3  个tokens\n",
      "poor faisability    有  4  个tokens\n",
      "this study was not able to start within the time limit due to coronavirus    有  14  个tokens\n",
      "no usable data were obtained. therefore, the study was terminated    有  12  个tokens\n",
      "company changed strategic direction in oct 2019 (staff changes; no one at company who participated in this study    有  22  个tokens\n",
      "the biscuits contain higher than the uk recommended daily dose of vitamins c and e, and selenium    有  18  个tokens\n",
      "halted due to feasibility issues    有  6  个tokens\n",
      "the sponsor finds the risk/benefit analysis unfavorable and has terminated the study    有  14  个tokens\n",
      "inadequate resources to support study start-up    有  9  个tokens\n",
      "missed endpoint    有  3  个tokens\n",
      "it was suspendend because the protocol and the aims were modified    有  12  个tokens\n",
      "working on obtaining approvals    有  4  个tokens\n",
      "based on scientific data collected during the trial and high screen fail rate    有  13  个tokens\n",
      "decided the study on this implant was no longer relevant    有  11  个tokens\n",
      "did not obtain irb approval    有  6  个tokens\n",
      "in collaboration with community partners, we determined that the reading level required for the intervention did not make it suitable for the adolescents    有  24  个tokens\n",
      "per dmsc request    有  5  个tokens\n",
      "pmcf data, originally planned to be collected withthis study, are collected using another methodology    有  18  个tokens\n",
      "gilead decision to terminate    有  6  个tokens\n",
      "poor manpower; logistic issues regarding the move of the in-hospital hyperbaric oxygen (hbo) chamber to an off-site location    有  28  个tokens\n",
      "acquisition of digital messaging company and decision made to withdraw study support    有  13  个tokens\n",
      "the justification of the early termination of the trial: the study is early terminated due to the coronavirus 2019 epidemic    有  23  个tokens\n",
      "withdrawn by principal investigator    有  5  个tokens\n",
      "the study is suspended to update the clinical research protocol for starting the multicenter european clinical trials    有  18  个tokens\n",
      "due to financial limitations and time commitments, i am requesting the closure of this research    有  16  个tokens\n",
      "further development has been outlicensed to acadia pharmaceuticals    有  12  个tokens\n",
      "due to a cochrane review whose authors conclude that further trials evaluating periodontal treatment versus no treatment/usual care are unlikely to change the overall conclusion reached in this review    有  35  个tokens\n",
      "study prematurely terminated as the experimental treatments evaluated in study b9991040 may not provide additional clinical benefit over current or future standard of care in the different therapeutic indications that this trial was to evaluate    有  38  个tokens\n",
      "fda request    有  3  个tokens\n",
      "technical and financial feasibility of the study cannot be assured by the sponsor    有  13  个tokens\n",
      "site backed out    有  3  个tokens\n",
      "\"company is in a process of being taken over by another pharma and the new one has different ideas on how to pursue studies with this drug\"    有  30  个tokens\n",
      "no physical therapist available    有  4  个tokens\n",
      "did not start study due to ec board rejection    有  9  个tokens\n",
      "please see nct04053868 for the current version of this study    有  14  个tokens\n",
      "mosaic was withdrawn and the study was incorporated into eavi2020-01 (nct03816137) as a substantial amendment    有  27  个tokens\n",
      "unable to proceed due to neulasta difficulties and other complications    有  12  个tokens\n",
      "completed primary objective    有  3  个tokens\n",
      "withdrawn per bayer    有  5  个tokens\n",
      "a feasibility study will be conducted to assess the online administration of the cognitive remediation program circuits    有  18  个tokens\n",
      "replaced with other study    有  5  个tokens\n",
      "the study will not be submitted to authority for ind application    有  11  个tokens\n",
      "interim analysis (n=40 24-hr sessions) yielded biologically implausible data. we do not deem this novel, at-home, participant-led method prudent. study will continue with only secondary objectives; primary objective (rct) terminated    有  50  个tokens\n",
      "unavailable staff to support project    有  6  个tokens\n",
      "protocol undergoing additional revisions    有  4  个tokens\n",
      "the sanitary conditions and material restrictions imposed by the chu and by the university laboratories drastically hampered the realization of this work (with restricted access to the laboratory/department)    有  33  个tokens\n",
      "study was terminated due to sadrs    有  7  个tokens\n",
      "the purpose of this study is no longer maintained    有  9  个tokens\n",
      "machine cannot provide    有  3  个tokens\n",
      "study is currently on hold, pending further evaluation and coordination    有  11  个tokens\n",
      "bristol-myers squibb company terminated this study    有  11  个tokens\n",
      "the study was stopped because of logistical issues with the sites    有  11  个tokens\n",
      "halozyme isn't alpooring this trial to move forward until their current clinical trial results are released    有  21  个tokens\n",
      "there were issues with equipment and team fell apart due to departure of some members from the institution    有  18  个tokens\n",
      "considering the thai fda requirement, changes of malaria cases in thailand and ec recommendation, the decision to withdrawal the study was made    有  27  个tokens\n",
      "study ending early due to program transferring to another site    有  10  个tokens\n",
      "overlapping with another danish questionnaire study    有  8  个tokens\n",
      "foreseen high level of subject burden and non compliance in the clinical trial due to extensive product preparation and the nutritional concept for the improvement of rbc dha is compromised by the change in the product formulation    有  40  个tokens\n",
      "portfolio proritisation    有  5  个tokens\n",
      "never received appropriate formulation    有  4  个tokens\n",
      "talaris decided to discontinue living donor kidney transplant development program    有  13  个tokens\n",
      "pi decision, technical events unrelated to study pooring down the process and ability to accrue    有  18  个tokens\n",
      "the study team was not able to start the study and they never completed the irb submission, so the study was terminated    有  24  个tokens\n",
      "all consented subjects were lost to folpoor up. p.i. stopped due to poor interest    有  20  个tokens\n",
      "drexel oncology was shut down a few days before first patient in    有  15  个tokens\n",
      "the study has been terminated due to key change of protocol    有  11  个tokens\n",
      "cms status changed - 3c patch is now fully covered (ncd) - medicare will no longer be collecting claims under ced    有  28  个tokens\n",
      "reallocation of resources to new hcc study    有  9  个tokens\n",
      "parent study failed to show therapeutic effect    有  7  个tokens\n",
      "study deemed no longer feasible    有  5  个tokens\n",
      "newly available data suggests that measuring proinsulin clearance would not enhance predictive value of serum proinsulin    有  21  个tokens\n",
      "sars-cov-2 has been detected in fecal material. although fmt is screened for sars-cov-2, the team decided to end the study to minimize risk to participants    有  38  个tokens\n",
      "agreement between interested partied ended    有  7  个tokens\n",
      "results from other study suggest no good reason to proceed    有  10  个tokens\n",
      "human subjects protection's soubmission denied    有  8  个tokens\n",
      "unable to secure study medication supply    有  6  个tokens\n",
      "drug supply withdrawn    有  3  个tokens\n",
      "due to changes in the surgical technique, no potential subjects anymore    有  12  个tokens\n",
      "evolution of the treatment procedures so that their is no more benefits for patients    有  15  个tokens\n",
      "in the perioperative setting of radical cystectomy-bladder replacement no improvement of uti was noticed in 10 patients who took urell folpooring the protocol    有  32  个tokens\n",
      "the study achieved n=17 participants (56.6% of the initial proposition) with a mean = 18 months folpoor-up. all patients completed 12 months folpoor-up or deceased. we chose to terminate and publish the data available    有  51  个tokens\n",
      "there is no feasibility to conduct the study    有  8  个tokens\n",
      "no authorization from clsa database scientific committee    有  8  个tokens\n",
      "issues in reserving mri scanner    有  7  个tokens\n",
      "drug development plan has been updated    有  6  个tokens\n",
      "strategic decision due to emerging new data for patients with hr+, her2- metastatic breast cancer    有  20  个tokens\n",
      "drug development strategy adjustment    有  4  个tokens\n",
      "no availability of imp for this study    有  7  个tokens\n",
      "logistical difficulties : protocol never finalized nor submitted    有  9  个tokens\n",
      "there were difficulties in implementation    有  5  个tokens\n",
      "pi is no longer at institution    有  6  个tokens\n",
      "due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time    有  42  个tokens\n",
      "medical practices have evolved and are not conform with the study procedure. actually, all patients receive an ambulatory ecg telemetry monitoring    有  25  个tokens\n",
      "internal competitive study that is open    有  6  个tokens\n",
      "key personnel moving out    有  4  个tokens\n",
      "investigational radiotracer was not approved    有  9  个tokens\n",
      "difficulty with equipment    有  3  个tokens\n",
      "manpower issues    有  3  个tokens\n",
      "study is postponed    有  3  个tokens\n",
      "product complaint    有  2  个tokens\n",
      "the study was conducted in the context of a medical thesis with a deadline    有  14  个tokens\n",
      "inadequate resources to start the study at this site    有  11  个tokens\n",
      "study device lotus edge was removed from the market    有  10  个tokens\n",
      "given the health context and the work overload, this study will not be possible. we therefore abandon this project    有  21  个tokens\n",
      "no longer moving forward with study as of may 2022    有  12  个tokens\n",
      "the sponsor voluntarily terminated the study before it was initiated    有  10  个tokens\n",
      "the trial was terminated for strategic reasons    有  7  个tokens\n",
      "departure of the main investigator    有  5  个tokens\n",
      "the human exposure facility was closed by the university    有  9  个tokens\n",
      "we observed that using the suprathel dressing required additional treatment of the wound and had a longer healing time than the standard of care xeroform dressing; it did not dry the wound out properly to promote healing    有  43  个tokens\n",
      "this type of surgery is no longer done at hmr, relocated to other centers    有  16  个tokens\n",
      "no longer developing for this indication    有  6  个tokens\n",
      "conversion to ide    有  3  个tokens\n",
      "reconsidered significance in light of newly published in vitro data    有  12  个tokens\n",
      "not enough staff to execute study    有  6  个tokens\n",
      "inventional part of the study is registered under nct05195489    有  14  个tokens\n",
      "decided not to open study    有  6  个tokens\n",
      "not performing trabectomes    有  5  个tokens\n",
      "application to a cpp    有  4  个tokens\n",
      "preliminary analysis revealed no difference    有  7  个tokens\n",
      "pi transferred to a different institution prior to starting the intervention    有  11  个tokens\n",
      "due to an issue with the software developer that cannot be resolved    有  12  个tokens\n",
      "prematurely interrupted due to significant difficulties in the completion of the sample size defined by the study protocol    有  21  个tokens\n",
      "pi has decided to withdraw the study    有  7  个tokens\n",
      "the study is stopped based upon strategic considerations impacting the clinical development of exenatide once-weekly suspension in china    有  23  个tokens\n",
      "irb approval has been withdrawn    有  6  个tokens\n",
      "on hold to determine chosen formulations    有  6  个tokens\n",
      "the study never started because one of the collaborators was not able to attend to the study requirements    有  18  个tokens\n",
      "one of the 2 nutritional products is reformulated and withdrawn from the market    有  15  个tokens\n",
      "the trial was discontinued in the interests of patients considering benefit/risk balance    有  14  个tokens\n",
      "the population of target indication is small and screening is difficult    有  11  个tokens\n",
      "practical issues    有  3  个tokens\n",
      "temozolomide does not favour immune response; secondary gbm to be excluded    有  17  个tokens\n",
      "the proposed analysis was not feasible    有  6  个tokens\n",
      "due to the termination of the collaboration of apifix ltd. and the umc utrecht    有  17  个tokens\n",
      "the manufacturer and funder eli lilly requested to terminate the study    有  14  个tokens\n",
      "a high percentage of patients were dropping out of the study and were not able to complete the protocol    有  19  个tokens\n",
      "pi departure, operational issues    有  5  个tokens\n",
      "fda/irb approved but hospital administration vetoed the study fearing litigation of a preterm birth though the electrical uterine pacemaker/ei is not the cause    有  34  个tokens\n",
      "study was stopped because of ineffectiveness of one investigated drug    有  12  个tokens\n",
      "assessment of data shows inadequate brain uptake, suggesting the tracer is inadequate as an imaging biomarker of brain amyloid    有  22  个tokens\n",
      "due to logistical purposes    有  4  个tokens\n",
      "would not substantially add to existing contributions in the literature    有  10  个tokens\n",
      "due to graft failure    有  4  个tokens\n",
      "protocol expired and not renewed    有  5  个tokens\n",
      "technical issues with rsa at main site and departure of principal investigator    有  12  个tokens\n",
      "depuy discontinued this product in 4q 2009.at the time of this decision depuy reviewed all clinical studies for this product and decided to close this study    有  33  个tokens\n",
      "study progress very poor therefore terminated as other projects underway to investigate the same research question which will deliver results earlier    有  21  个tokens\n",
      "withdrawn for problem of logistics with the associated laboratories    有  10  个tokens\n",
      "investigational products has been suspended from the us market    有  11  个tokens\n",
      "after two years of trial initiation, only 27 out of 300 patients were included. during this period, the international recommendations for the use of cool were modified    有  32  个tokens\n",
      "study was combined with mayo protocol 07-003476    有  11  个tokens\n",
      "procedure no longer being done    有  5  个tokens\n",
      "no study population in mexico (h1n1). study withdrawn from irb consideration    有  17  个tokens\n",
      "due to internal reasons study was not performed    有  8  个tokens\n",
      "change in current areas of research interest of the collaborator    有  11  个tokens\n",
      "created extension study - this study was no longer feasible    有  10  个tokens\n",
      "poor complaince    有  4  个tokens\n",
      "no budget    有  2  个tokens\n",
      "upon interim analysis, sufficient data was accrued to assess study hypotheses    有  12  个tokens\n",
      "the study was terminated after the planned interim analysis    有  9  个tokens\n",
      "principle investigator resigned in 2013    有  8  个tokens\n",
      "closed by pharmaceutical sponsor    有  4  个tokens\n",
      "poor sufficient participants meeting the eligibility criteria to complete study in proposed and acceptable time frame    有  17  个tokens\n",
      "statistical interim analysis showed valid and significant results    有  9  个tokens\n",
      "outcome measures are included in another, similar study    有  9  个tokens\n",
      "study withdrawn due to poor staffing resources and subject interest    有  10  个tokens\n",
      "the study stopped after been paused (the patients were switched in the meantime)    有  15  个tokens\n",
      "interim analysis indicated poor probability of clinically significant result    有  10  个tokens\n",
      "unable to get the vaccine on time to offer it to the study population    有  14  个tokens\n",
      "incyte suspended development of the compound    有  7  个tokens\n",
      "hyperintensities of unclear etiology on brain mri. folpoor up revealed no progression    有  20  个tokens\n",
      "at interim analysis the study did not meet the response criteria to continue    有  13  个tokens\n",
      "the enzymatic assay was not sensitive nor spesific for the test    有  14  个tokens\n",
      "study terminated early due to change in sponsorship    有  8  个tokens\n",
      "orphan drug designation for this indication not granted    有  9  个tokens\n",
      "study failed to accrue any patients due to regulatory issues with pr1 vaccine and t cell production    有  19  个tokens\n",
      "this project is no longer being adequately supported to alpoor completion    有  13  个tokens\n",
      "investigator changed location, requires new training effort    有  9  个tokens\n",
      "we decided to alter the intervention    有  6  个tokens\n",
      "the image-guidance system became commercially available    有  8  个tokens\n",
      "principal investigator is leaving moffitt    有  7  个tokens\n",
      "study was terminated due to withdrawal of crada partner    有  10  个tokens\n",
      "the main sponsor of this multi-center trial has submitted this protocol. a single participating site should not register this study    有  22  个tokens\n",
      "primary outcome evaluation determined poor treatment group difference    有  8  个tokens\n",
      "not enough participants for study to be completed    有  8  个tokens\n",
      "principal investigator decided to close the study early    有  8  个tokens\n",
      "no avaliability of melphlan in mainland china    有  10  个tokens\n",
      "portfolio consolidation    有  2  个tokens\n",
      "insufficient time for study extenuating personal circumstances of pi    有  12  个tokens\n",
      "the study was stopped because the sample size was very difficult to achieve    有  13  个tokens\n",
      "withdrawn pending further review of clinical design    有  8  个tokens\n",
      "most pts requested to be treated with versed. it was difficult to randomize pts    有  17  个tokens\n",
      "new provision of supplementary feeds for moderately malnourished children    有  12  个tokens\n",
      "ind for this study remained on clinical hold    有  8  个tokens\n",
      "strategic reasons. seeking partner for future development    有  9  个tokens\n",
      "major protocol changes: new study submitted    有  7  个tokens\n",
      "this study competed with another vicc study    有  8  个tokens\n",
      "study closed prematurely upon pi's departure    有  7  个tokens\n",
      "the proposed work could not be completed    有  7  个tokens\n",
      "study due for continuing review    有  5  个tokens\n",
      "terminated per pi's request at the time of continuing review    有  11  个tokens\n",
      "this study was terminated because the drug company stopped making the study drug    有  13  个tokens\n",
      "drug no longer available by manufacturer    有  6  个tokens\n",
      "study terminated prior to initiation    有  5  个tokens\n",
      "new medications with improved response released    有  6  个tokens\n",
      "clinical department where study was held was unable to continue collaboration    有  11  个tokens\n",
      "unable to develop a rapid & reliable assay to detect sulfide concentrations    有  13  个tokens\n",
      "a study was published regarding the same question this study had    有  11  个tokens\n",
      "fda has placed the trial on full clinical hold    有  10  个tokens\n",
      "this study was terminated on 19 april 2009 due to unfavorable risk benefit ratio of bosutinib in combination with letrozole including one confirmed hy's law case. 37.5% of patients had treatment related liver events with the majority of severe events resulting in permanent study treatment discontinuation    有  61  个tokens\n",
      "investigator decided it was not feasible to conduct this study    有  11  个tokens\n",
      "decision made to close study early    有  6  个tokens\n",
      "it was not possible to get insurance companies to cover bevacizumab    有  15  个tokens\n",
      "endpoints were investigated in parallel in nct00877305    有  12  个tokens\n",
      "the study was terminated on june 25th, 2009 due to strategic decision    有  18  个tokens\n",
      "interim analysis results showed that ixabepilone did not improve survival compared with control chemotherapies    有  22  个tokens\n",
      "study stopped due to poor activity    有  6  个tokens\n",
      "pi moved    有  2  个tokens\n",
      "the whole project was terminated    有  5  个tokens\n",
      "limitation in financial resources    有  5  个tokens\n",
      "part a reached a predefined stopping criteria. relevant doses for part b could not be established based on a and subsequently study was stopped    有  25  个tokens\n",
      "recommendation by data monitoring committee    有  6  个tokens\n",
      "there seemed to be no uptake of the ligand in the areas of the brain expected for subjects with amyloid    有  22  个tokens\n",
      "change in priorities occurred    有  4  个tokens\n",
      "original principal investigator (andrew trout m.d.) left the university    有  13  个tokens\n",
      "study never started. study suspended indefinitely    有  7  个tokens\n",
      "preliminary results indicated no measurable benefit    有  8  个tokens\n",
      "extended obligations of amended medical device law in germany 2010 did not alpoor to continue and complete the trial due to budget limitation    有  27  个tokens\n",
      "never started several reasons    有  4  个tokens\n",
      "study stopped prematurely to test a new formulation of exendin (9-39)    有  17  个tokens\n",
      "pfizer has terminated the execution of this protocol    有  9  个tokens\n",
      "gallium is no longer available for the conduct of this study    有  13  个tokens\n",
      "no potential participants met entry criteria    有  6  个tokens\n",
      "withdrawn due to transfer of investigator    有  7  个tokens\n",
      "poor resources has prevented the study from continuation    有  9  个tokens\n",
      "pi retired    有  2  个tokens\n",
      "to focus on another clinical indication    有  6  个tokens\n",
      "changes to study personnel    有  4  个tokens\n",
      "the trial was terminated early due to inadequate study design    有  10  个tokens\n",
      "per protocol, the study was terminated based on interim analysis results    有  12  个tokens\n",
      "we have found another marker (microrna26) which is more sensitive to evaluate the effect of postoperative ifna treatment in patients with hcc    有  30  个tokens\n",
      "bankruptcy of drug manufacturer: drug not available    有  9  个tokens\n",
      "the chief of gs left the hopsital and the successor did't want to keep on this study    有  19  个tokens\n",
      "departure of the investigator coordinator into other country    有  8  个tokens\n",
      "new data does not support a role of vitamin e in lchad associated neuropathy    有  17  个tokens\n",
      "after an extensive review,the aspire in ckd study was terminated because it was not possible to complete the study in an appropriate time frame    有  26  个tokens\n",
      "because of technical problems (researcher moved to different city)    有  12  个tokens\n",
      "study was terminated after unplanned interim analysis of single centre data and results were reported    有  16  个tokens\n",
      "difficulty in finding eligible subjects    有  5  个tokens\n",
      "prematuration culture with a phosphodiesterase-3 inhibitor (pde3-i) has been replaced by other system    有  25  个tokens\n",
      "study withdrawn from irb    有  5  个tokens\n",
      "subject recuitment halted and won't resume; subjects are no longer being treated    有  16  个tokens\n",
      "the prematuration culture with a phosphodiesterase-3 inhibitor (pde3-i) has been replaced by a different formulation    有  27  个tokens\n",
      "data review showed that the study was underpowered to draw clear conlcusions    有  15  个tokens\n",
      "music therapist left position    有  4  个tokens\n",
      "because it seemed not of interest based on the current literature    有  11  个tokens\n",
      "the main limitations were the small sample size and poor completion rate    有  12  个tokens\n",
      "change of location for investigators    有  5  个tokens\n",
      "the team wasn't able to work effectively with the social worker at the site    有  15  个tokens\n",
      "study was closed    有  3  个tokens\n",
      "pi stopped study to make a more substantial database    有  9  个tokens\n",
      "the 2008-09 north american peak influenza season ended prior to study completion    有  16  个tokens\n",
      "unacceptable morbidity & mortality    有  6  个tokens\n",
      "experimental treatment not feasible due to high rate of drop out    有  11  个tokens\n",
      "due to termination of study d3801c00001, due to reports of turbid urine    有  19  个tokens\n",
      "investigator has left the institution    有  6  个tokens\n",
      "abnormality prevalence revealed to be much poorer than expected    有  11  个tokens\n",
      "preliminary analysis    有  4  个tokens\n",
      "key samples protocols will be provided by a collaborator and we were not able to produce ips lines from human fibroblasts    有  25  个tokens\n",
      "our rct recently started. the rct is similar to the feasibility trial, so it was terminated to avoid 2 trials running simultaniously    有  29  个tokens\n",
      "interim analysis incidence primary endpoint poorer than anticipated. sigicant finding based on secondary endpoint    有  18  个tokens\n",
      "to redefine study population    有  4  个tokens\n",
      "unable to find eligible subjects- study closed    有  8  个tokens\n",
      "protocol not renewed    有  3  个tokens\n",
      "poor sponsor support    有  4  个tokens\n",
      "terminated due to poor staffing    有  5  个tokens\n",
      "not enough interested participants    有  4  个tokens\n",
      "the results obtained 1 year after surgery were clearly indicative of the outcome and the investigators decided to terminate folpoor-up at that point    有  27  个tokens\n",
      "terminated by investigator due to poor eligible subjects    有  8  个tokens\n",
      "we expanded to a bigger, multi-site study & decided to close this study    有  15  个tokens\n",
      "realized there was a design flaw    有  7  个tokens\n",
      "unable to obtain fda approval    有  6  个tokens\n",
      "technology used to obtain/measure cerebral state index is no longer manufactured    有  13  个tokens\n",
      "investigator was not able to maintain irb approval. study never accrued subjects    有  15  个tokens\n",
      "the research is on susoension beacause the poor manpower    有  13  个tokens\n",
      "pi wanted to discontinue study    有  6  个tokens\n",
      "the fda ind application is paused due to additional required testing. the irb protocol was closed prior to research starting    有  23  个tokens\n",
      "finding to be unable to reach the primary endpoint    有  9  个tokens\n",
      "the phase i of the study was completed, but phase 2 has not been activated    有  17  个tokens\n",
      "the sponsor decided to withdraw the study    有  7  个tokens\n",
      "early end of trial notification after termination of long term folpoor up due to poor scientific justification to continue collect information    有  23  个tokens\n",
      "joined another larger group of same study    有  7  个tokens\n",
      "drug supply became unavailable    有  4  个tokens\n",
      "other drugs other studies    有  4  个tokens\n",
      "study has been withdrawn as the h1n1 epidemic made this study redundant    有  15  个tokens\n",
      "unable to isolate sufficient cells from the skin biopsy to perform study related experiments    有  14  个tokens\n",
      "drug withdrawal    有  2  个tokens\n",
      "this study was stopped as no patient asked to participate was prepared to do so    有  15  个tokens\n",
      "could not get imp    有  4  个tokens\n",
      "the study was terminated early because of a related decision to stop the development of ocrelizumab in rheumatoid arthritis    有  26  个tokens\n",
      "to be confirmed    有  3  个tokens\n",
      "new information suggested a more effective treatment protocol    有  8  个tokens\n",
      "sponsor decided they are not interested in the study due to finacial reasons    有  14  个tokens\n",
      "study was stopped due to poor resources (clinical dietitians)    有  13  个tokens\n",
      "the suppliers were unable to provide the investigational medicinal product (imp)    有  14  个tokens\n",
      "suspended for potential change in protocol to include different imaging modalities    有  13  个tokens\n",
      "changes in the lab's focus and needs    有  8  个tokens\n",
      "inefficiency of treatment    有  5  个tokens\n",
      "study terminated at this time by investigator. will create new protocol    有  12  个tokens\n",
      "one of the study drugs is not available    有  8  个tokens\n",
      "higher than projected discontinuation rate during maintenance phase    有  9  个tokens\n",
      "study was never published    有  4  个tokens\n",
      "will be replaced by honest broker program    有  7  个tokens\n",
      "a competing trial has been initiated    有  6  个tokens\n",
      "experimental pain model didn't work as anticipated    有  8  个tokens\n",
      "all of the mentioned aim and objectives were achieved before the february 2007    有  16  个tokens\n",
      "change in available resources for study procedures    有  7  个tokens\n",
      "study reached halfway point in approximately one year time period and was halted to analyze data    有  16  个tokens\n",
      "transitioning from 361 hct/p tissue to a biologic (bla)    有  16  个tokens\n",
      "this study was terminated when the p.i. left the university    有  12  个tokens\n",
      "no more interest to folpoor this study    有  9  个tokens\n",
      "not enough could be recruted    有  7  个tokens\n",
      "randomization flawed. results were poor in the innovative catheter group    有  13  个tokens\n",
      "pi was unable to locate appropriate population    有  7  个tokens\n",
      "1) a delay in obtaining immunoassays to measure serum neopterin 2)altered relevance of the expected experimental results to clinical practice    有  30  个tokens\n",
      "respond was to poor    有  4  个tokens\n",
      "investigator no longer at cleveland clinic    有  8  个tokens\n",
      "the number of participants needed for this study has been met    有  11  个tokens\n",
      "principle investigator retired, resident moved away    有  8  个tokens\n",
      "predefined termination criterion of > 10 patients without cr or pr was matched    有  15  个tokens\n",
      "difficulty in identifying interested subjects    有  5  个tokens\n",
      "the study was terminated by merck usa. the company did not supply drugs for the study    有  18  个tokens\n",
      "the sponsor decided to postpone the performance of this study to after phase 3    有  15  个tokens\n",
      "decided to stop development of this compound globally    有  9  个tokens\n",
      "preliminary analysis showed little or no bioactivity    有  10  个tokens\n",
      "question was no longer committee priority    有  6  个tokens\n",
      "did not get approval    有  4  个tokens\n",
      "market demand from paclitaxel to sirolimus drug-eluting stent    有  17  个tokens\n",
      "we didnt recieved the medicine    有  5  个tokens\n",
      "the patients eligible for this trial do not exist anymore due to change in procedures    有  15  个tokens\n",
      "withdrawn because swog no longer pursuing this study at this time    有  13  个tokens\n",
      "the product was delisted    有  5  个tokens\n",
      "parent study cis001 was completed    有  6  个tokens\n",
      "possibility to discriminate the active drug from placebo    有  9  个tokens\n",
      "study revised to retrospective chart review    有  6  个tokens\n",
      "manufacturing stopped    有  3  个tokens\n",
      "primary investigator is no longer employeed by the va    有  10  个tokens\n",
      "could not get drug    有  4  个tokens\n",
      "due to a single, unexpected serious event, the trial was stopped    有  13  个tokens\n",
      "fda changed classification of device and no longer requires this type of clinical data    有  15  个tokens\n",
      "drug supply was no longer available    有  6  个tokens\n",
      "stop due to recent data in literature questioning the need to continue dap beyond six months in patients with stable coronary artery stenting with des    有  26  个tokens\n",
      "software issues not resolved    有  4  个tokens\n",
      "ontak has been pulled off the market for further testing. subsequently, eisai will no longer be supporting clinical trials that utilize this drug    有  28  个tokens\n",
      "subjects not entered into electronic database due to current construct of database and associated privacy legislations within alberta    有  21  个tokens\n",
      "injection site reaction met protocol-defined stopping criteria    有  9  个tokens\n",
      "the study was withdrawn due to many implementation difficulties    有  9  个tokens\n",
      "new studies are being offered    有  5  个tokens\n",
      "principal investigator has left sponsoring instiution    有  8  个tokens\n",
      "on partial hold for clinical investigation into ae and sae reported    有  12  个tokens\n",
      "poor prevalence of malaria, high prevalence of reported allergy to sulphur drugs, high proportion of women not meeting the inclusion criterea    有  26  个tokens\n",
      "sister trial has sae investigation underway - sponsor elected to withdraw as study expected to be repeated later    有  20  个tokens\n",
      "absence of key personnel to conduct study    有  8  个tokens\n",
      "investigator did not submit an annual continuation report with the institutional review board and the study was officially removed from irb regulatory oversight on sep 2014, based on 32 cfr 219.109e. the study officially expired/terminated    有  49  个tokens\n",
      "terminated due to poor 5 year completer number and not meeting primary objective    有  15  个tokens\n",
      "replaced by a study with a similar design    有  9  个tokens\n",
      "device no longer available    有  4  个tokens\n",
      "modified dose schedule presented no advantage over previously studied schedule    有  10  个tokens\n",
      "terminated (halted prematurely) due to tolerability issues    有  11  个tokens\n",
      "the study was designed again in compliance with the regulatory agency    有  11  个tokens\n",
      "awaiting results from sub analysis to decide if study continuesé    有  12  个tokens\n",
      "early phase i study of [123i]mni-340 did not evidence as marker of disease    有  20  个tokens\n",
      "stability of the dna when admixed with the liposome failed    有  13  个tokens\n",
      "study intervention was approved by the fda    有  8  个tokens\n",
      "we have decided not to pursue the study    有  8  个tokens\n",
      "similar study published results    有  4  个tokens\n",
      "modifications will be necessary before full irb approval will be secured    有  13  个tokens\n",
      "the blood pressure did not decrease folpooring furosemide administration    有  14  个tokens\n",
      "ethics approval not renewed by study group    有  8  个tokens\n",
      "fda drug recall on july 30, 2010    有  13  个tokens\n",
      "early termination was granted by fda based on study results meeting the post approval requirements    有  16  个tokens\n",
      "the manufacturer decided to stop drug production    有  7  个tokens\n",
      "the study was terminated because the required sample size of 240-260 de novo senior renal transplant patients was not achieved within a reasonable time    有  27  个tokens\n",
      "poor staff, time, and resources    有  8  个tokens\n",
      "study stopped due to increased harm and poor progress in the intervention group    有  13  个tokens\n",
      "ind application was withdrawn, and therefore study listing is being withdrawn    有  12  个tokens\n",
      "based on the tolerabilty challenges of the combination    有  10  个tokens\n",
      "after year 1, there was insufficient statistical power to detect a difference in the primary outcome measure during planned study period    有  23  个tokens\n",
      "technical/operational issues    有  5  个tokens\n",
      "didn't have the resources necessary to carry out the study    有  11  个tokens\n",
      "this study is coordinated by the harms study group. it is already registered on this website    有  17  个tokens\n",
      "difference found in interim analysis, not ethical to continue    有  10  个tokens\n",
      "no surgeon available to perfrom gastroscopy    有  8  个tokens\n",
      "principal investigator departed from institution    有  5  个tokens\n",
      "budgetary restrictions    有  3  个tokens\n",
      "altitude trial which used similar drugs was terminated due to increased adr    有  12  个tokens\n",
      "withdrew study    有  4  个tokens\n",
      "study halted by the sponsor    有  5  个tokens\n",
      "faillure to obtain insurance because of refusal from insurance companies    有  12  个tokens\n",
      "numerically modest poorering of hba1c with canakinumab in combination with metformin was inadequate to continue patients with t2dm into period iv of this study    有  36  个tokens\n",
      "difficulties in the department    有  6  个tokens\n",
      "pi terminated employment with the university    有  6  个tokens\n",
      "prematurely stopped, as no beneficial effect was evident for bilateral stimulation after interim analysis of the first 20 patients    有  24  个tokens\n",
      "affiliation's change of the principal investigator need a new review bord    有  13  个tokens\n",
      "failure to mobilize adequate cd34+ stem cells for minimum study treatment dose    有  15  个tokens\n",
      "study terminated due to financial status of sponsor    有  8  个tokens\n",
      "withdrawn as nci rescinded approval for parent study nsabp-b-45    有  17  个tokens\n",
      "drug development suspended    有  3  个tokens\n",
      "ema withdrew the marketing authorisation at the request of agc biologics s.p.a (formerly molmed s.p.a), which decided to permanently discontinue the marketing of the product for commercial reasons    有  40  个tokens\n",
      "did not reach one of the primary endpoints of decreased total acute gvhd    有  14  个tokens\n",
      "failure to meet primary objective    有  5  个tokens\n",
      "the study was terminated on 26 february 2013. risk-benefit assessment is no longer positive and does not support further development    有  27  个tokens\n",
      "before we could start the study, we realized that many of the patients were already getting ergocalciferol. therefore, the study was closed    有  29  个tokens\n",
      "the trial is postponed pending the completion of other ongoing pre-clinical and clinical work    有  17  个tokens\n",
      "no effect of the ace inhibitor evaluated halfway in the study    有  11  个tokens\n",
      "due to unavoidable circumstances relating to logistic issues and regulatory processes in various countries causing unacceptable delays    有  17  个tokens\n",
      "modified formulation under investigation    有  4  个tokens\n",
      "optimal histolgic verification support such as whole mount analysis could not be made available    有  17  个tokens\n",
      "sponsor has decided to not proceed with this study    有  9  个tokens\n",
      "terminated early due to poor clinical response    有  7  个tokens\n",
      "no longer practical to deliver treatment    有  6  个tokens\n",
      "significant difference at interim analysis    有  5  个tokens\n",
      "study closed after completion of phase i    有  7  个tokens\n",
      "suspended pending data analysis    有  5  个tokens\n",
      "did not support the planned development of dccr in the new indication    有  13  个tokens\n",
      "study closed due to feasability    有  6  个tokens\n",
      "caelyx was not available anymore    有  7  个tokens\n",
      "risk/benefit ratio did not indicate further study would be useful, or fair to future subjects    有  18  个tokens\n",
      "the study was terminated on 31 may, 2011, due to strategic considerations    有  17  个tokens\n",
      "pi has relocated    有  3  个tokens\n",
      "dr obel is deceased and no other investigators on study to provide information. old record, irb has no information; outside of retention period    有  28  个tokens\n",
      "suspended trial was not restarted    有  6  个tokens\n",
      "differences between bis and neurosense are important. this study can be terminated    有  15  个tokens\n",
      "pi relocated and reopened trial in new university    有  8  个tokens\n",
      "study closed by irb because a continuing review and/or close-out have not been submitted. study closed by irb    有  23  个tokens\n",
      "department difficulties    有  2  个tokens\n",
      "study not approved by bfarm    有  6  个tokens\n",
      "one of the investigators has left the institution    有  8  个tokens\n",
      "retirement of pi    有  4  个tokens\n",
      "due to the poor rate of primary endpoint events experienced in the study to date    有  15  个tokens\n",
      "the alternative laparoscopic chole, has so little morbidity very few patients opt for a transvaginal approach when presented with the alternative    有  29  个tokens\n",
      "pi closed lab    有  3  个tokens\n",
      "angioscanners in excess of the sna group because of use of thiopental    有  18  个tokens\n",
      "pi is no longer at university of rochester, has moved to university of florida, gainesville. pi email now homonq@ufl.edu. phone is 352-273-7675    有  41  个tokens\n",
      "not awarded    有  2  个tokens\n",
      "primary objective of the trial was not met and so there was no benefit in collecting further information    有  18  个tokens\n",
      "study has now been terminated due to changes in project strategy. current available data will be analysed and reported in a synoptic study report    有  26  个tokens\n",
      "evident advantages of one treatment (seton) over the other (tissucol glue)    有  21  个tokens\n",
      "unable to identify a third subject    有  6  个tokens\n",
      "the hospital had the unit of stem cells tranplantion suspended    有  12  个tokens\n",
      "the institution transitioned from open surgical procedure to robotic procedure    有  11  个tokens\n",
      "the mri company forbidded additional scans with endorectal colil in this machine    有  18  个tokens\n",
      "stopped early    有  2  个tokens\n",
      "loss of principal investigator    有  4  个tokens\n",
      "original principal investigator, g. ashmead, md left the institution    有  14  个tokens\n",
      "study withdrawn as it no longer is deemed necessary per project status    有  12  个tokens\n",
      "patient numbers estimated to be too poor to complete the trial in less than 10 years    有  17  个tokens\n",
      "study was never activated    有  4  个tokens\n",
      "drug was discontinued by manufacturer    有  5  个tokens\n",
      "principal investigator separating employment from university    有  6  个tokens\n",
      "pi separated employment from the university    有  6  个tokens\n",
      "the investigator is negotiating with other company to use flt pet    有  12  个tokens\n",
      "images obtained were non-diagnostic    有  6  个tokens\n",
      "corporate re-prioritization    有  7  个tokens\n",
      "potential for immune stimulation to interfere with further dose escalation    有  10  个tokens\n",
      "suspension of use of medicine containing pioglitazone by french regulatory agency    有  17  个tokens\n",
      "the trial started and halted due sponsor's considerations    有  9  个tokens\n",
      "other new drugs    有  3  个tokens\n",
      "this study was stopped after larger studies published in the nejm failed to show a benefit in treating adpkd    有  22  个tokens\n",
      "study site collaborators withdrew from participating due to time constraints    有  10  个tokens\n",
      "financial problem (not enough budget to continue the study)    有  11  个tokens\n",
      "study did not start up as planned    有  7  个tokens\n",
      "sponsor decided not to pursue market release of prototype device used in this study    有  14  个tokens\n",
      "cryoablation is no longer offered at our hospital, and likely won't be offered in the near future    有  22  个tokens\n",
      "the supply of bl22 has expired and medimmune the sponsor is not interested in producing any new supply    有  20  个tokens\n",
      "this study was terminated after the first patient treated on study died as a result of the treatment    有  18  个tokens\n",
      "this complex study included a pilot and a main part. as the results of the pilot study were satisfying and conclusive, the main study was not performed    有  29  个tokens\n",
      "sponsor closed the trial    有  4  个tokens\n",
      "change in the number of approved drugs for metastatic melanoma    有  12  个tokens\n",
      "study data no longer needed    有  5  个tokens\n",
      "see termination reason in the bepoor purpose statement    有  10  个tokens\n",
      "sponsor changed their study product and halted study    有  8  个tokens\n",
      "project has ended    有  3  个tokens\n",
      "the neutron facility closed down for financial reasons    有  8  个tokens\n",
      "difficulty in obtaining surrogate consent on critically ill subjects    有  9  个tokens\n",
      "interim analysis showed statistically significant results    有  7  个tokens\n",
      "only 2 patients inclued and study principal investigator has left the hospital    有  14  个tokens\n",
      "study drug supplier withdrew support for the study. study was withdrawn from the duke irb    有  17  个tokens\n",
      "pk results demonstrate poor and variable plasma concentrations so that achieving therapeutic concentrations is unlikely    有  15  个tokens\n",
      "no interest to develop the product    有  6  个tokens\n",
      "a sample size recalculation indicated an increase from 154 to 1500 subjects was required so the study stopped as new target was considered unfeasible    有  31  个tokens\n",
      "the study was terminated at 2 years as investigators were unable to continue participation in the study    有  18  个tokens\n",
      "subjects were no longer able to remain compliant with folpoor-up intervals    有  14  个tokens\n",
      "no longer active    有  3  个tokens\n",
      "after a review of status, request of investigators & since similar data was available from other sources    有  18  个tokens\n",
      "the study achieved the stated objective to record pre & post operative outcomes at a minimum 5 years    有  19  个tokens\n",
      "this study was stopped 20 may 2010 due to strategic considerations    有  14  个tokens\n",
      "principal investigator changed    有  3  个tokens\n",
      "withdrawn by the study sponsor    有  6  个tokens\n",
      "license termination    有  2  个tokens\n",
      "due to recently published research, this is no longer a novel study    有  13  个tokens\n",
      "adjustments to ensure clear outcomes and scientific merit integrated. study closed at 14 subjects. new protocol submitted to irb    有  24  个tokens\n",
      "manufacturer is no longer making the drug    有  7  个tokens\n",
      "azd1704 has essentially similar pk profile in japanese subjects as in caucasians. one of the main purposes of the study has thereby been achieved    有  30  个tokens\n",
      "product pre-market approval withdrawn    有  5  个tokens\n",
      "study was stopped due to poor folpoor-up compliance at study sites    有  14  个tokens\n",
      "physician is no longer associated with the univ. of michigan medical center    有  16  个tokens\n",
      "company manufacturing study drug was unable to continue production    有  9  个tokens\n",
      "study dose changed based on recent publications    有  7  个tokens\n",
      "study delayed for over a year by research shutdown at seattle va and other issues. study designer moved to ann arbor in the interim, so the study was closed    有  33  个tokens\n",
      "the primary endpoint at 15 months was not met    有  10  个tokens\n",
      "drug exposure of retaspimycin hcl was superior to ipi-493, infinity will focus exclusively on retaspimycin    有  26  个tokens\n",
      "study terminated prematurely due to financial contraints    有  9  个tokens\n",
      "collaborator withdrew support due to a drug supply interruption    有  11  个tokens\n",
      "termination of the clinical trial by sponsor    有  7  个tokens\n",
      "observed benefit of treatment larger than expected    有  8  个tokens\n",
      "we are underpowered to find a difference in the primary outcome    有  12  个tokens\n",
      "no longer acruing data for this study    有  9  个tokens\n",
      "terminated due to awaiting data from phase ii study    有  9  个tokens\n",
      "personnel involved in this protocol are no longer associated with this study    有  13  个tokens\n",
      "data from other studies showed that study could not be completef successfully    有  13  个tokens\n",
      "high incidence of biloma and liver abscess after tace    有  12  个tokens\n",
      "to conserve remaining capital, sponsor decided to terminate the study early    有  12  个tokens\n",
      "this study will not be conducted. a new study is replacing this one    有  14  个tokens\n",
      "this study has been placed on clinical hold by the sponsor due to operational reasons    有  15  个tokens\n",
      "gsk received exemption from pdfda on conduct of this post-marketing surveillance (pms) study    有  20  个tokens\n",
      "the extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression    有  25  个tokens\n",
      "a higher rate of late rejection was seen in the poor tacrolimus arm    有  15  个tokens\n",
      "investigator moved institutions and did not transfer study    有  9  个tokens\n",
      "other published trials showed definitive expected superiority of group 1    有  11  个tokens\n",
      "drug withdrawn from market    有  4  个tokens\n",
      "interim analysis results were not supportive of primary endpoint    有  10  个tokens\n",
      "the trial was stopped early because there was only one patient with pcr among the first 15 patients randomized to the curcumin arm    有  27  个tokens\n",
      "study stopped based on the recommendation of the idmc after a planned interim analysis    有  15  个tokens\n",
      "primary endpoint not achieved    有  4  个tokens\n",
      "instruments necessary to continue project have been removed via medical center staff. therefore, the project cannot continue until they have been replaced    有  25  个tokens\n",
      "study has been terminated for inadequate results    有  7  个tokens\n",
      "incorporated into other study    有  6  个tokens\n",
      "shortage of increlex supply    有  6  个tokens\n",
      "this project was not a clinical trial requiring registration    有  9  个tokens\n",
      "majority of patients (62%) had been treated with next line therapies, including new highly effective therapies confounding the interpretation of the os results    有  28  个tokens\n",
      "folpooring regulator inspection in 2009, study terminated as inadequate approvals were in place    有  18  个tokens\n",
      "this study is being replaced by another protocol    有  8  个tokens\n",
      "sb-656933 is no longer being developed for ulcerative colitis    有  14  个tokens\n",
      "the data collected are enough to obtain a qualitative analysis    有  10  个tokens\n",
      "it was very difficult to fulfill the inclusion criteria, therefore the expected time of inclusion was delayed so much time    有  21  个tokens\n",
      "challenging data collection    有  5  个tokens\n",
      "not enough personnel to conduct study at site    有  8  个tokens\n",
      "primary investigator retired    有  3  个tokens\n",
      "computers/hardware for data collection/storage are outdated and unserviceable    有  14  个tokens\n",
      "terminated folpooring interim analysis    有  6  个tokens\n",
      "primary endpoint measure not suitable for evaluation    有  7  个tokens\n",
      "principal investigator (central contact) has left the organization and requests the study be terminated    有  16  个tokens\n",
      "drugs unavailable- study terminated 1/2/18    有  12  个tokens\n",
      "study performed in alternative location (beijing china)    有  10  个tokens\n",
      "in preparation for an amendment    有  5  个tokens\n",
      "study terminated early due to sample size, not possible to perform further statistical analysis    有  15  个tokens\n",
      "the study was cancelled due to budget limitations    有  8  个tokens\n",
      "requested by pi    有  3  个tokens\n",
      "believed that a better study was to compare the response to engerix b vs sci-b-vac vaccine in this patient group    有  26  个tokens\n",
      "study terminated due to poor care guidelines in the protocol    有  10  个tokens\n",
      "study stopped due to insufficient personnel required to conduct trial    有  10  个tokens\n",
      "an endpoint difference between 3 energies was not observed at interim analysis    有  13  个tokens\n",
      "absorption of oral sildenafil not consistent    有  7  个tokens\n",
      "no statistical differences on study endpoints between groups    有  8  个tokens\n",
      "decision of independent monitoring committee: risk of non-response to treatment significantly higher in midodrine group than in terlipressin group    有  26  个tokens\n",
      "no investigator to folpoor-up    有  7  个tokens\n",
      "executive committee determined to close study after interim analysis    有  10  个tokens\n",
      "pi determination    有  2  个tokens\n",
      "study never initiated due to contract manufacturing issues    有  8  个tokens\n",
      "this study was stopped 29oct2009 due to strategic drug development considerations    有  15  个tokens\n",
      "recent abstract publication questioning the need for our study    有  9  个tokens\n",
      "funds for this project have been spent, and it is thereby terminated    有  14  个tokens\n",
      "study medication was no longer available for study    有  8  个tokens\n",
      "sponsor decided to withdraw from study    有  6  个tokens\n",
      "study cancelled prior to start due to change in company priorities    有  11  个tokens\n",
      "the trial was stopped based on information from the global phase 3 studies    有  14  个tokens\n",
      "centers would not continue folpoor-up; two centers transitioned patients to a new study    有  18  个tokens\n",
      "the study design failed and the data was not able to be analyzed    有  13  个tokens\n",
      "pentostatin/alemtuzumab regimen had greater risk of graft failure    有  16  个tokens\n",
      "study ended after diabetes development plan review.    有  8  个tokens\n",
      "after a discussion, we decided to withdraw the study    有  10  个tokens\n",
      "this study was terminated on april 22th, 2010, based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm, and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer. patients on sunitinib who are judged by the investigator as receiving clinical benefit may chose to remain on study and continue treatment with sunitinib until clinical benefit as per the investigator's judgment    有  118  个tokens\n",
      "logistical difficulties running the study    有  6  个tokens\n",
      "replaced by a global study protocol nst-ca004    有  11  个tokens\n",
      "change in belgian law on the use of hmg in iui    有  15  个tokens\n",
      "sponsor stopped development of the medtone inhaler in favor of an improved device (gen2 inhaler)    有  21  个tokens\n",
      "progress report requested by dr. abboud decided to close it    有  12  个tokens\n",
      "study was conducted to fulfill a post marketing commitment (pmc 6). fda acknowledged fulfillment of pmc    有  22  个tokens\n",
      "sponsor's strategy    有  3  个tokens\n",
      "dose limiting adverse effects    有  5  个tokens\n",
      "p.i. left university. study terminated    有  8  个tokens\n",
      "sample size was re- calculated considering sucking pattern parameters    有  10  个tokens\n",
      "poor qualified and willing volunteers    有  6  个tokens\n",
      "terminated as the active treatment was associated with an increased hazard    有  11  个tokens\n",
      "withdrawal of drug supply    有  5  个tokens\n",
      "study terminated due to withdrawal from market of daclizumab    有  13  个tokens\n",
      "dr. jorizzo has withdrawn from this study due to time it is taking to start    有  18  个tokens\n",
      "dr. jorizzo has decided to withdraw from this study due to the time it is taking to get the study started    有  24  个tokens\n",
      "study never received irb approval. study was never pursued    有  11  个tokens\n",
      "study was stopped due because recrutation.was much poorer as anticipated    有  14  个tokens\n",
      "higher rate of post-operative infection in the dermal matrix arm of the study    有  15  个tokens\n",
      "the manufacturing of preservative free ketorolac (acular-pf) was discontinued    有  17  个tokens\n",
      "grant was not approved    有  4  个tokens\n",
      "not reached the statistical hypothesis at the interim analysis    有  9  个tokens\n",
      "termination folpooring reassessment of the potential benefit-risk of ave0657    有  15  个tokens\n",
      "study was suspended due to poor resources    有  7  个tokens\n",
      "sponsor decided not to go forward with the study    有  9  个tokens\n",
      "interim analysis showed no difference in outcome between treatment groups    有  11  个tokens\n",
      "failure to include    有  3  个tokens\n",
      "transfer to another institution    有  4  个tokens\n",
      "this study was terminated prematurely due to poor sufficient exposure folpooring single- and repeat-dosing    有  19  个tokens\n",
      "in the intermediate analysis, no effect could be shown, not even a tendency    有  15  个tokens\n",
      "study was not able to be completed, no results analyzed    有  11  个tokens\n",
      "pi is no longer at this institution    有  7  个tokens\n",
      "folpooring an sae, study was put on hold. after performing preclinical folpoor-up studies, volunteers were no longer available for continuation    有  30  个tokens\n",
      "study withdrawn by sponsor    有  4  个tokens\n",
      "male subjects were terminated due to an imbalance in prostate cancer events    有  12  个tokens\n",
      "life shirt technology no longer available    有  6  个tokens\n",
      "ended prematurely - the trial never commenced    有  7  个tokens\n",
      "the co-principal investigator has moved and is no longer interested in continuing this study at this site    有  19  个tokens\n",
      "primary outcome not achieved    有  4  个tokens\n",
      "prematurely terminated due to financial considerations    有  9  个tokens\n",
      "exactech withdrew the pma associated with the study device due to poor market utilization    有  16  个tokens\n",
      "change in resources available for study procedures    有  7  个tokens\n",
      "fpoormedica was purchased by angiodynamics. study will be re-started by angiodynamics    有  20  个tokens\n",
      "the study is terminated due to expiration of study materials    有  10  个tokens\n",
      "third group realisation has not been necessary regarding the results of the first two groups (no sufficient modifications in the immune response)    有  25  个tokens\n",
      "terminated due to withdrawal of support from our collaborator    有  10  个tokens\n",
      "required contrast media (vasovist) withdrawn from market    有  11  个tokens\n",
      "due to unforeseen circumstances this study will not now start    有  11  个tokens\n",
      "new protocol was developed based on preliminary results from this study    有  11  个tokens\n",
      "similar study completed    有  3  个tokens\n",
      "the steering committee of the trio014 study has taken the decision to stop the trio014 trial    有  18  个tokens\n",
      "sponsor will discontinue further development of emd 1201081    有  13  个tokens\n",
      "inability to find qualifying participants    有  6  个tokens\n",
      "a new protocol was developed to replace this protocol in 2008, with removal of atg and extension of mmf duration    有  25  个tokens\n",
      "devices applied in the study were no more available in the market, and medical intervention section was completed    有  19  个tokens\n",
      "major planned study protocol modifications    有  5  个tokens\n",
      "study was stopped by sponsor prior to first patient assignment to groups due to operational reasons    有  16  个tokens\n",
      "results of an interim analysis showed that it was unlikely that creatine was effective in pooring loss of function in early symptomatic huntington's disease    有  29  个tokens\n",
      "withdrawn by investigator, protocol in revision    有  8  个tokens\n",
      "the study was terminated prematurely by the irb due to data integrity and protocol compliance issues    有  17  个tokens\n",
      "new device for dural plaque irradiation was approved by fda    有  13  个tokens\n",
      "not being able to recuit sufficient patients due to a poor complience    有  14  个tokens\n",
      "sponsor making changes to manufacturing of vaginal ring    有  8  个tokens\n",
      "actual sample size of 156 was sufficient to estimate the clinical outcomes    有  13  个tokens\n",
      "phase ii not initiated due to cancellation of supply of poly e by collaborator    有  15  个tokens\n",
      "research administration changes    有  3  个tokens\n",
      "the decision is based on company re-evaluation of indications to be pursued within scchn    有  17  个tokens\n",
      "planning new study protocol    有  5  个tokens\n",
      "study procedures have become standard of care as patients seeking model for end-stage liver disease (meld) exception points for cholangiocarcinoma    有  28  个tokens\n",
      "sponsor withdraw    有  2  个tokens\n",
      "investigator is no longer at study site    有  8  个tokens\n",
      "postmarket study terminated as the sn6ad3 is no longer promoted    有  14  个tokens\n",
      "funds no longer available    有  5  个tokens\n",
      "technical difficulties coordinating study    有  4  个tokens\n",
      "malaria prev. fell in the study area, so we cannot evaluate the primary endpoint    有  17  个tokens\n",
      "terminated to focus on comparable trial, clomds02507    有  12  个tokens\n",
      "study on hold since 2009. awaiting fda approval of sugammdex to complete second arm of study    有  23  个tokens\n",
      "insufficient subject availability/findings for data analysis    有  9  个tokens\n",
      "high rate of drop-out    有  5  个tokens\n",
      "terminated at time of cr - 3.26.2019 - ja    有  15  个tokens\n",
      "folpooring program review within pfizer, decision was made not to go ahead with this study. this study is cancelled    有  24  个tokens\n",
      "supply of lepirudin ended on 01. april 2012, thus trial terminated on 31. march 2012    有  27  个tokens\n",
      "naloxone became unavailable due to manufacturing shortatges requiring the study to be terminated    有  17  个tokens\n",
      "just terminated for the end of the pandemia    有  9  个tokens\n",
      "at time of pre-specified 2nd interim analysis    有  11  个tokens\n",
      "protocol objective could not be met. a new study with amended eligibility criteria will be developed    有  17  个tokens\n",
      "new sponsor's existing product under evaluation for this indication    有  10  个tokens\n",
      "departure of essential co-investigator from mclean hospital    有  11  个tokens\n",
      "organizationally not possible    有  4  个tokens\n",
      "the antibody used did not appear prognostic/predictive based on interim results    有  16  个tokens\n",
      "poor study participants, no data published    有  8  个tokens\n",
      "pk results demonstrated no systemic absorption    有  6  个tokens\n",
      "study moved to alternate site    有  5  个tokens\n",
      "poor availability of iv ibuprofen as of 8/10 due to a manufacturer's recall    有  20  个tokens\n",
      "current treatment regimen of 3 procedures considered acceptable    有  9  个tokens\n",
      "feasibility period ended    有  4  个tokens\n",
      "pending design changes to the device    有  6  个tokens\n",
      "the study was terminated based on a recommendation of the dsmb folpooring the identification of two patients with significant elevations in serum transaminases    有  29  个tokens\n",
      "withdrawn because the research efforts at that time folpoored another path    有  14  个tokens\n",
      "shift in department's research interests    有  6  个tokens\n",
      "principal investigator moved to another region of the country    有  9  个tokens\n",
      "rejected ethics approval in uk and holland    有  7  个tokens\n",
      "after reports of turbidity in urine in 4 of 8 volunteers in the 4th cohort, the study was halted temporarily    有  26  个tokens\n",
      "company ended operations january 2011    有  8  个tokens\n",
      "change in company direction    有  4  个tokens\n",
      "increased lfts    有  4  个tokens\n",
      "terminated early due a shift in resources after lackluster performance of the drug    有  15  个tokens\n",
      "project cancellation    有  2  个tokens\n",
      "nottingham pct withdrew for financial reasons    有  7  个tokens\n",
      "pi did not want to go forward with study at this time    有  12  个tokens\n",
      "results invalid, study closed, analysis cannot proceed    有  9  个tokens\n",
      "interim analyses showed statistically and clinically significant results    有  9  个tokens\n",
      "end of study time and budget permission    有  7  个tokens\n",
      "resident research project limited by restrictions of residency program    有  9  个tokens\n",
      "awaiting decision on financial support by deutsche forschungsgemeinschaft (dfg)    有  19  个tokens\n",
      "loss of study staffing    有  4  个tokens\n",
      "cost prohibitive and company withdrew support    有  7  个tokens\n",
      "difficulty finding a monitor    有  4  个tokens\n",
      "due to the discontinuation of compound development, this study has been terminated    有  14  个tokens\n",
      "principal investigator is leaving the institution to obtain further training    有  10  个tokens\n",
      "due to the clear advantage of carotid endarterectomy    有  12  个tokens\n",
      "the recuiting was to poor to complete the study    有  11  个tokens\n",
      "under additional irb review    有  5  个tokens\n",
      "pi transferred to new institution    有  5  个tokens\n",
      "company ended operations in january 2011    有  9  个tokens\n",
      "study personnel left institution    有  4  个tokens\n",
      "due to unfixable problem in the research machine we had to withdrawn from the study    有  17  个tokens\n",
      "due to poor manpower at the various study sites    有  9  个tokens\n",
      "helical ct scans at our institution preclude the necessity for diagnostic laparoscopy in most cases at our institution    有  23  个tokens\n",
      "the production of the device used in this study has been suspended    有  12  个tokens\n",
      "experimental results were unsatisfatory compared with control    有  9  个tokens\n",
      "trial was terminated due to the need to re-formulate the study drug    有  14  个tokens\n",
      "major protocol changes needeed    有  5  个tokens\n",
      "study stopped because of study personel movement to another institution    有  11  个tokens\n",
      "all subjects transferred to long term study nct00817726 rbd longitudinal    有  15  个tokens\n",
      "marginal statistical significance    有  5  个tokens\n",
      "started a nih study that is competing for same subjects    有  11  个tokens\n",
      "terminated early due to meeting end point with fewer patients than anticipated    有  12  个tokens\n",
      "a similar study was conducted and subsequently published in italy    有  11  个tokens\n",
      "incidence of abnormalities of liver function tests is higher than expected in this population    有  15  个tokens\n",
      "stopped by dsmb for overwhelming benefit of indomethacin (unethical to withhold indomethacin from patients)    有  24  个tokens\n",
      "ind approval for naive t-cell depletion not obtained    有  9  个tokens\n",
      "hoag hospital ceased support    有  5  个tokens\n",
      "the study never started due to the principal investigator leaving the institution    有  12  个tokens\n",
      "early analysis indicated srs not as beneficial post-op as pre-op    有  13  个tokens\n",
      "study device discontinued & insufficient sample size for statistical results    有  10  个tokens\n",
      "manufacturer changed device so no study will be done; ie it was never started    有  15  个tokens\n",
      "alternative trial planned    有  3  个tokens\n",
      "research question was integrated in other study protocol    有  8  个tokens\n",
      "number of known toxicities observed despite a treatment-naïve population    有  13  个tokens\n",
      "study withdrawn prior to initiation    有  5  个tokens\n",
      "time table was unfulfilled due to incompetent research coordinator. inaccurate results and no conclusions can be withdrawn    有  20  个tokens\n",
      "study withdrawn and combined with a new protocol    有  8  个tokens\n",
      "sponsor preferred a better study design    有  6  个tokens\n",
      "publication of ma17 results (similar trial in the extented adjuvant setting with letrozole)    有  21  个tokens\n",
      "pi, dr. k. polonsky has moved to the university of chicago    有  16  个tokens\n",
      "a fluorine-18 labeled version of the radiopharmaceutical (flutemetamol) became available. this version is far superior to the carbon-11 pib. there is no need to make this compound available any longer    有  47  个tokens\n",
      "we are unable to find a clip used to stabilize the epidural needle on the ultrasound probe to alpoor adequate epidural catheter placement    有  28  个tokens\n",
      "criterion according study protocol to end study prematurely was fulfilled    有  11  个tokens\n",
      "study drug currently unavailable    有  4  个tokens\n",
      "terminated at the request of the study sponsor    有  8  个tokens\n",
      "change in cryopreservation protocol    有  6  个tokens\n",
      "university decision    有  3  个tokens\n",
      "problems with data collection    有  4  个tokens\n",
      "study could not be re-supplied with study medication in a timely manner    有  14  个tokens\n",
      "discontinued due to favorable results    有  6  个tokens\n",
      "pma not approved. fda granted permission to close the study    有  13  个tokens\n",
      "was not possible to measure lbp levels because we cannot found the kit    有  14  个tokens\n",
      "irb approval on study expired may 28, 2009    有  13  个tokens\n",
      "persantine is no longer being used at uchc for pharmacological stress testing    有  16  个tokens\n",
      "the study was terminated due to the termination of the clinical development program    有  13  个tokens\n",
      "no data have been obtained at all in this time    有  10  个tokens\n",
      "pi withdrew due to increased responsibilities in clinical department    有  9  个tokens\n",
      "study was withdrawn because of a problem with the software used for generating the aftercare summary    有  17  个tokens\n",
      "ag-1749 superior to gefarnate in ulcer prevention    有  12  个tokens\n",
      "study was not renewed during annual northwestern cancer center review    有  11  个tokens\n",
      "potential participants with copd/asthma unwilling to participate    有  11  个tokens\n",
      "departure of the principal investigator and nobody else was able to continue this study    有  14  个tokens\n",
      "voluntarily terminated based on preliminary non-clinical findings    有  12  个tokens\n",
      "the gynecological laparoscopic surgery transition to day surgery made folpooring the study protocol not possible    有  21  个tokens\n",
      "a similar publication has been released, suggesting a beneficial effect of sartans, and only 15 patients remained to be seen for their visit at 36 months    有  32  个tokens\n",
      "withdrawn as msu approval obained    有  8  个tokens\n",
      "corporate decision to discontinue distribution of mjs knee    有  11  个tokens\n",
      "study re-design    有  3  个tokens\n",
      "site decision    有  2  个tokens\n",
      "preliminary analysis showed no difference    有  7  个tokens\n",
      "problems with irb    有  4  个tokens\n",
      "study drug was not longer available in our country    有  9  个tokens\n",
      "seven years of folpoor-up & final analysis done in dec 2012    有  16  个tokens\n",
      "restructuring and refocus of company    有  7  个tokens\n",
      "no more data collected    有  4  个tokens\n",
      "the sponsor-investigator relocated to a different institution and was not able to continue the study    有  18  个tokens\n",
      "necessity of major revision of the protocol    有  9  个tokens\n",
      "withdrew the ind with the fda    有  9  个tokens\n",
      "product no more sold    有  4  个tokens\n",
      "unable to accrue study participants    有  6  个tokens\n",
      "the site decided to stop the study    有  7  个tokens\n",
      "inadequate support to conduct the study    有  8  个tokens\n",
      "satisfied a post-marketing commitment to canadian health authorities    有  11  个tokens\n",
      "considering more robust design    有  5  个tokens\n",
      "no data so far    有  4  个tokens\n",
      "limited scanner availability    有  3  个tokens\n",
      "no longer pursuing fda submission/approval    有  9  个tokens\n",
      "replaced with an alternate study    有  6  个tokens\n",
      "inappropriate therapy associated with certain right ventricular (rv) lead complications may occur more frequently if the respiratory sensor is programmed on    有  25  个tokens\n",
      "no further contact with the site    有  6  个tokens\n",
      "terminated new protocol developed which incorporated pharmacokinetics    有  9  个tokens\n",
      "prinicipal investigator separating employment from university    有  9  个tokens\n",
      "product withdrawn from distribution    有  4  个tokens\n",
      "study abandoned and was never started    有  6  个tokens\n",
      "terminated by institutional review board    有  5  个tokens\n",
      "it is unethical to continue a study with deactivation of hm in the control arm although a reduced risk of all-cause death has been shown in previous trials    有  31  个tokens\n",
      "al study sites stoped on 15/05/2012 because of insufficient recrutement    有  19  个tokens\n",
      "studies emerged that demonstrated the superiority of vitrification    有  11  个tokens\n",
      "in this feasibility study device did not perform as well as expected    有  12  个tokens\n",
      "closed incomplete due to artes medical closing    有  8  个tokens\n",
      "terminated by sponsor: see details bepoor    有  9  个tokens\n",
      "principal investigator relocated to another institution    有  6  个tokens\n",
      "stopped prematurely in 2008 due to ionsys withdrawal off the market globally    有  15  个tokens\n",
      "study re-designed    有  3  个tokens\n",
      "recent research indicates lucentis to be an effictive treatment    有  13  个tokens\n",
      "no more information will be given. no consequences on security and treatment of patients: standard therapy is already performed for all patients    有  24  个tokens\n",
      "unable to perform study due to unavailable drug, then unable to partner with cath lab    有  16  个tokens\n",
      "final cost of study medication was significantly greater than initial estimate,    有  12  个tokens\n",
      "sponsor elected not to conduct study at this time    有  9  个tokens\n",
      "study design was altered such that a treatment component was removed through the va irb. we did not and will not begin this clinical trial    有  27  个tokens\n",
      "pi moved out of state    有  5  个tokens\n",
      "study has been termination early due to financial contraints    有  11  个tokens\n",
      "the study is not feasible with the number of subjects needed to complete it    有  14  个tokens\n",
      "insufficient dose for mri scanning    有  7  个tokens\n",
      "the sponsor stoppes the study for the security problem    有  10  个tokens\n",
      "study no longer consistent with current clinical practice    有  8  个tokens\n",
      "product class one recall    有  4  个tokens\n",
      "recommendation of dmc    有  5  个tokens\n",
      "study was previously paused and is now terminated    有  8  个tokens\n",
      "the required results were obtained through alternate methodology    有  8  个tokens\n",
      "study revised and reinitiated under another protocol    有  9  个tokens\n",
      "insufficient resources to conduct study    有  6  个tokens\n",
      "all investigators have moved to different oranizations    有  9  个tokens\n",
      "study was withdrawn due to poor resources    有  7  个tokens\n",
      "pi is transitioning to another institution    有  6  个tokens\n",
      "no longer interested in doing the study    有  7  个tokens\n",
      "study was previously suspended and is now terminated    有  8  个tokens\n",
      "this study was not activated, no data was collected    有  10  个tokens\n",
      "investigator took study to university hospital duesseldorf    有  10  个tokens\n",
      "issues with ctm stability    有  5  个tokens\n",
      "decided to conduct study in adults first    有  8  个tokens\n",
      "the bfarm (ca)approved the trial in nov 2008. however, the responsible ec refused approval in march 2009    有  27  个tokens\n",
      "study was put on hold then out of medical plan therefore cancelled    有  12  个tokens\n",
      "two patients in the first dose level be counted as reaching dlt. dsmb recommend terminated early this trial    有  21  个tokens\n",
      "principal investigator moved to chile from argentina    有  9  个tokens\n",
      "the study was terminated after the european medicines evaluation agency recommended to suspend the marketing authorisation of raptiva in the european union    有  25  个tokens\n",
      "study withdrawn from clinicaltrials.gov    有  7  个tokens\n",
      "study determined not to be feasible to continue    有  8  个tokens\n",
      "the objective response rate by more than two people are confirmed    有  11  个tokens\n",
      "terminated prior to its planned completion as anticipated by the protocol)    有  12  个tokens\n",
      "too much variability in the tms measures    有  8  个tokens\n",
      "the field has changed, and we have decided to develop a prep program    有  14  个tokens\n",
      "this study was not feasible due to facility budget and contractual issues    有  12  个tokens\n",
      "with recommendation from idmc, steering committee terminated this trial due to ethical concerns raised by j-art study    有  20  个tokens\n",
      "interim analysis did not reveal of anticipated benefits of intervention    有  11  个tokens\n",
      "due to change in the national policy of medications    有  9  个tokens\n",
      "in the context of the world health organization's (who) phase 6 pandemic influenza declaration the conduct of the study was deemed no longer feasible    有  28  个tokens\n",
      "grant was withdrawn no financial support to conduct the study    有  10  个tokens\n",
      "planned interim analysis: no significant outcome differences between groups    有  11  个tokens\n",
      "inadequate effect size    有  5  个tokens\n",
      "interim analysis showed that the tested protocol did not improve treatment    有  12  个tokens\n",
      "choice of the principal investigator    有  5  个tokens\n",
      "pi moved to different institution. decided to concentrate on different studies    有  12  个tokens\n",
      "payments stopped by grant provider    有  5  个tokens\n",
      "the preliminary result didn't show any benefit    有  8  个tokens\n",
      "there were problems with national reimbursement policies    有  7  个tokens\n",
      "study medication expired    有  3  个tokens\n",
      "not able provide staff for recruting at present    有  10  个tokens\n",
      "not enough data collected to work with    有  7  个tokens\n",
      "grant support ended folpooring which the key personnel (pi) left the institution    有  16  个tokens\n",
      "study was expanded and included in another study    有  8  个tokens\n",
      "the risk of donor blood transfusion was unacceptably high in the short duration group    有  17  个tokens\n",
      "noted increased risks, greater than expected for standard of care therapy    有  13  个tokens\n",
      "study was redesigned based on fda feedback    有  8  个tokens\n",
      "due to discussion regarding the design of the study    有  9  个tokens\n",
      "no resources available at the clinic    有  6  个tokens\n",
      "drug manufacturer could not supply study drug    有  7  个tokens\n",
      "collaborator stopped study    有  5  个tokens\n",
      "dsmb decision    有  3  个tokens\n",
      "laser company cannot provide laser unit for the study    有  10  个tokens\n",
      "concern of detrimental effect    有  5  个tokens\n",
      "siemens management decided not to release the product in the usa    有  12  个tokens\n",
      "this study was terminated due to the decrease in percentage of participants    有  12  个tokens\n",
      "as recommended by the dsmb    有  6  个tokens\n",
      "interim analysis showed no statistical significance achieved    有  8  个tokens\n",
      "the study did not begin and is being terminated from the system    有  12  个tokens\n",
      "terminated due to sibutramine being withdrawn from the market    有  13  个tokens\n",
      "the principal investigator decided to close this study site    有  9  个tokens\n",
      "this study was canceled for operational reasons    有  7  个tokens\n",
      "study terminated early due to manufacturer not replenishing study site supply of inserts, despite repeated requests for more inserts    有  21  个tokens\n",
      "this study was stopped due to an internal reconsideration of priorities of the product portfolio    有  16  个tokens\n",
      "results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase iii    有  23  个tokens\n",
      "this study was terminated based on results of interim analysis    有  10  个tokens\n",
      "cytherissa filed for banckcuptcy in june 2013.subjects treated by cyt 107 were folpoored up for at the least 3 months    有  35  个tokens\n",
      "isotope needed to conduct rbc/pv analysis (primary endpoint) no longer available from manufacturer. no alternatives available for use    有  25  个tokens\n",
      "the study site was closed down    有  6  个tokens\n",
      "completion after 2 patients then stop due to end of validity of vaccine peptide    有  15  个tokens\n",
      "study is officially cancelled bevore fpfv    有  8  个tokens\n",
      "neuronavigation system equipment failure caused unreliable data    有  9  个tokens\n",
      "inadequate number of charts available for test group    有  10  个tokens\n",
      "images not adequate to visualize catheter penetration or obtain measurements    有  11  个tokens\n",
      "drug exposure of retaspimycin hcl was superior to ipi-493, infinity will focus on retaspimycin hcl    有  27  个tokens\n",
      "study stopped to open expanded phase ii study    有  8  个tokens\n",
      "study drug production halted    有  4  个tokens\n",
      "amendment to study compound development programme    有  7  个tokens\n",
      "study being rewritten    有  3  个tokens\n",
      "regulatory agency commitment fulfilled    有  5  个tokens\n",
      "suspended due to change in development plans and investigator    有  10  个tokens\n",
      "6 out of 20 patients were included. the trend towards the treatment of severe asthma has meanwhile developed in a different direction, so that there is no longer any intention to pursue the study objective mentioned here    有  40  个tokens\n",
      "company decided to stop development of drug - 7/31/12    有  14  个tokens\n",
      "drug dose became unavailable    有  4  个tokens\n",
      "dose over mtd reached    有  6  个tokens\n",
      "pilot early noninvasive ventilation on all children who met the criteria was effective    有  16  个tokens\n",
      "departmental financial support withdrawn    有  5  个tokens\n",
      "cip was amended to include long-term fu but, not all sites accepted it so the nr. of pts participating in the extended fu will be small    有  29  个tokens\n",
      "the technology planned to be used in the study got outdated and therefore the study will not be conducted according to the initial protocol    有  24  个tokens\n",
      "the study terminated last week    有  5  个tokens\n",
      "due to poor mechanistic signal and competing industry studies    有  10  个tokens\n",
      "chloroprep wipes no longer available    有  7  个tokens\n",
      "research plan changed; no longer conducting clinical trial    有  9  个tokens\n",
      "not enough confirmed responses to continue treatment    有  7  个tokens\n",
      "it didn't get irb approval    有  7  个tokens\n",
      "pi moved to new institution, unable to complete study    有  10  个tokens\n",
      "enzon pharmaceuticals decided to end its development of ezn-3042    有  15  个tokens\n",
      "study was prematurely terminated because of missing data collection    有  9  个tokens\n",
      "financial and organisational reasons    有  5  个tokens\n",
      "imp used off label by phys. in pat. with psp. thus no more eligible patients were available for the study(pre-treatm.with rasagiline=exclusion criterion    有  36  个tokens\n",
      "interim analysis showed significant effect in favour of full-dose atorvastatin    有  17  个tokens\n",
      "terminated prematurely due to high incidence of postoperative atrial fibrillation    有  13  个tokens\n",
      "study shut-down in 12/2010 when neopharm merged with insys    有  17  个tokens\n",
      "the changing aetiology of squamous cell carcinoma of the head and neck (scchn)    有  19  个tokens\n",
      "2 dlts had been reported from first 4 patients on poorest possible dose cohort    有  16  个tokens\n",
      "institutional review board approval not maintained    有  7  个tokens\n",
      "host site logistical problems    有  4  个tokens\n",
      "the funder never paid for the study    有  8  个tokens\n",
      "part a completed successfully 22 july 2010, part b will be separate pet study    有  19  个tokens\n",
      "institutional issues institution issues    有  5  个tokens\n",
      "terminated after fda agreement    有  5  个tokens\n",
      "new information on imp affected the cost/benefit ratio    有  10  个tokens\n",
      "the stopping rule was met and hence the study was closed    有  11  个tokens\n",
      "the study was closed before 2017 due to inconclusive results from lab    有  15  个tokens\n",
      "study was terminated. p.i. left the institution before completing study    有  13  个tokens\n",
      "the control product was recalled    有  5  个tokens\n",
      "revised project    有  3  个tokens\n",
      "difficulty identifying eligible candidates    有  4  个tokens\n",
      "steering committee accepted dsmb advise to terminate the study after review of data analysis at second interim analysis    有  20  个tokens\n",
      "the trial prematurely terminated on november 1, 2010, due to healthy volunteer participants experiencing non-serious fosamprenavir-related skin rash    有  30  个tokens\n",
      "further internal evaluation of the device was required    有  9  个tokens\n",
      "due to study plan    有  4  个tokens\n",
      "insufficient staff to continue pursuing project    有  7  个tokens\n",
      "the study never opened due to technical upgrades that were needed for the shuti computer system    有  17  个tokens\n",
      "occurrence of retinal hemorrhage , increase in macular edema of some patients in tpa group    有  21  个tokens\n",
      "feasibility/pilot study of 5 subjects registration not required    有  12  个tokens\n",
      "researchers delay    有  3  个tokens\n",
      "the study was terminated because we were not able to obtain the study drug    有  14  个tokens\n",
      "test device not approved to be used    有  7  个tokens\n",
      "stopped due to protocol mistakes    有  5  个tokens\n",
      "awaiting response from fda as to status of parenteral ascorbic acid manufactured by bioniche (ireland)    有  25  个tokens\n",
      "contract negotiations were terminated and study never started    有  8  个tokens\n",
      "caps became unavailable by manufacturer    有  5  个tokens\n",
      "principal investigator terminated study    有  4  个tokens\n",
      "due to reorganisation in the hospital structure    有  8  个tokens\n",
      "solanezumab did not meet the primary endpoint in study h8a-mc-lzax    有  21  个tokens\n",
      "due to poor availability of study participants to accommodate the study design    有  12  个tokens\n",
      "terminated due to software issues    有  5  个tokens\n",
      "developing new formulation of study drug. new study to open next year under a new protocol    有  18  个tokens\n",
      "evotec has indicated that this study was discontinued due to a clinical hold issued by the fda    有  19  个tokens\n",
      "complications to procedure    有  4  个tokens\n",
      "this study did not accrue any subjects and due to this will be closed    有  15  个tokens\n",
      "released by he fda from this post-marketing commitment    有  11  个tokens\n",
      "study never went beyond fda application for an ind #. fdaa required institutional dsmc which this institution then lacked    有  25  个tokens\n",
      "the benefit of halting the study to analyze the available data outweighs the benefit of delaying the analysis to include data from remaining treatment periods    有  27  个tokens\n",
      "study was terminated due to the untimely death of the investigator    有  13  个tokens\n",
      "european drug approval    有  4  个tokens\n",
      "viokase was taken off market during study and remained off over a year    有  15  个tokens\n",
      "issue regarding the stent design    有  6  个tokens\n",
      "masked independent interim analysis: completion of the trial was unlikely    有  11  个tokens\n",
      "the observed event rate is poorer than expected by the protocol hypothesis    有  12  个tokens\n",
      "study was never initiated under new location/provider group. contract to continue was never signed between teva and kennedy headache center    有  24  个tokens\n",
      "the study has been halted prematurely beacuse of the occurence of convulsions in one case after tap block    有  23  个tokens\n",
      "publication of a similar study. not ethical to continue    有  10  个tokens\n",
      "the study was terminated because the rate of prothesis dislocation was too high    有  15  个tokens\n",
      "ind has been withdrawn and the study is closed    有  9  个tokens\n",
      "approval of several new agents for the treatment of hcv infection would mitigate the future need for interferon hcv treatment    有  23  个tokens\n",
      "the sponsor stopped the study    有  5  个tokens\n",
      "we randomized 18 patients, but was impossible to measure adrenomedullin in brazil. however, we analysed some interesting clinical and laboratorial results    有  30  个tokens\n",
      "seems to have simply stopped    有  6  个tokens\n",
      "researchers moved to new institution and did not transfer project    有  11  个tokens\n",
      "extended beyond completion date; chose to close out rather than renew irb review    有  15  个tokens\n",
      "study was never implemented    有  4  个tokens\n",
      "difficulties in logistics handling the very severe patients (travel, hospital stay, folpoor-up)    有  21  个tokens\n",
      "pi not planning to pursue this study and it was never irb approved    有  14  个tokens\n",
      "study was completed in another site    有  6  个tokens\n",
      "fda clinical hold requiring ind submission, product not available in the market anymore    有  15  个tokens\n",
      "recent developments lead to re-evaluation of study    有  9  个tokens\n",
      "population of interest was no longer available    有  7  个tokens\n",
      "study entered twice, please see protocol 0120110047    有  12  个tokens\n",
      "study abandoned; could not obtain final src approval due to ind disagreements    有  13  个tokens\n",
      "pennstate would not alpoor the study to move forward    有  13  个tokens\n",
      "we anticipated that we could not complete this study    有  9  个tokens\n",
      "due to few capacities 2011 to 2016 the study was withdrawn    有  15  个tokens\n",
      "the device is undergoing further study in china, per fda requirements    有  13  个tokens\n",
      "during anticipated study duration trial power was not attained    有  9  个tokens\n",
      "the manufacturer never released the instruments    有  6  个tokens\n",
      "peramivir eua terminated by fda    有  10  个tokens\n",
      "principal investigator    有  2  个tokens\n",
      "gangtrainer gt1 is not state of the art anymore for the principal invesigator    有  17  个tokens\n",
      "early termination due to only 2 subjects completing trial    有  10  个tokens\n",
      "study was stopped and not completed    有  6  个tokens\n",
      "outcome measures for pre-intervention were much poorer than anticipated    有  11  个tokens\n",
      "analysis of the first 10 patients did not show anyt trend toward differences in pk profiles between imatinib vs no imatinib groups    有  28  个tokens\n",
      "changed research plan    有  3  个tokens\n",
      "manufacturer discontinued drug development    有  4  个tokens\n",
      "investigators changed jobs, no longer affiliated with institution    有  10  个tokens\n",
      "fda clinical hold, ind withdrawn    有  7  个tokens\n",
      "end-point reached    有  3  个tokens\n",
      "the study pharmacodynamic stopping criteria were met after the first dosing group    有  14  个tokens\n",
      "the results of the dose escalation phase did not identify a well-tolerated dose that would permit further study in phase 2    有  25  个tokens\n",
      "manufacturer stopped producing rings    有  4  个tokens\n",
      "formulation issues    有  3  个tokens\n",
      "study should not have been listed on clinicaltrials.gov    有  11  个tokens\n",
      "study fp1039-002 was not feasible. the original assumption was at least 5% of patients screened would qualify, but after screening 70 patients, none qualified    有  34  个tokens\n",
      "clinical investigations have been discontinued and transfer to bms 3/24/2015    有  17  个tokens\n",
      "study was not initiated, change in clinical development    有  9  个tokens\n",
      "unacceptable high drop-out rate    有  6  个tokens\n",
      "the doctor who ran this study, left    有  8  个tokens\n",
      "mri scanner de-commissioned and there was no suitable alternative    有  13  个tokens\n",
      "decreased recrucial rate as the likelihood of achieving the envisioned patient number in a realistic time-frame was very poor    有  24  个tokens\n",
      "pi retired, study closed    有  5  个tokens\n",
      "biomet's focus has changed and we no longer expect further developments    有  13  个tokens\n",
      "poor personnel/research time    有  6  个tokens\n",
      "due to a change in the research priorities of the principal investigator in combination with poor subject interest    有  18  个tokens\n",
      "study was terminated by investigator    有  5  个tokens\n",
      "did not begin    有  3  个tokens\n",
      "poor eligible participants to enrol    有  6  个tokens\n",
      "sponsor stopped study to re-design trial    有  7  个tokens\n",
      "monitor manufacturer stopped marketing plan for the product    有  8  个tokens\n",
      "unable to identify eligible subjects with traumatic brain injury who also have banked umbilical cord blood at cbr    有  22  个tokens\n",
      "lost sponsor support    有  3  个tokens\n",
      "change in clinical practice since the start of the trial in 2011 (phenylephrine superior)    有  21  个tokens\n",
      "the device was withdrawn from clinical use    有  7  个tokens\n",
      "study never undertaken    有  3  个tokens\n",
      "replaced by new study    有  5  个tokens\n",
      "study was stopped early due to difficulty finding patients who met i/e criteria    有  14  个tokens\n",
      "i am relocating to johns hopkins medical center    有  11  个tokens\n",
      "unexpected toxicities, likely due to til/il-12 & poor % of durable responses    有  17  个tokens\n",
      "study medication unavailable    有  3  个tokens\n",
      "study never moved past ideation phase    有  7  个tokens\n",
      "protocol completed    有  2  个tokens\n",
      "sponsoring company declared bankrupty    有  8  个tokens\n",
      "test    有  1  个tokens\n",
      "durability of study medications could not be guaranteed after the expire date    有  13  个tokens\n",
      "in order to focus efforts on the combination ring formulation, ipm decided not to move forward with this trial    有  21  个tokens\n",
      "a decision was made to terminate the b1701002 study so that emerging data from the study and from a preclinical study in rats could be further examined and incorporated into a new study design and protocol. this study was previously posted by pfizer, inc. sponsorship of the trial was transferred to biogen    有  61  个tokens\n",
      "some capsules used in this study were been found to be cracked and leaking    有  14  个tokens\n",
      "negative endpoint study resulting in withdrawal of study drug    有  9  个tokens\n",
      "ca approval not obtained    有  4  个tokens\n",
      "results of preliminary analyses showed no reason to continue the study    有  11  个tokens\n",
      "terminated [cytherissa filed for banckcuptcy in june 2013.subjects treated by cyt107 were folpoored up for at the least 3 months.]    有  37  个tokens\n",
      "unable to reliably reproduce, visualize, or quantify microvascular fpoor in the subcutaneous tissue, the skeletal muscle or peri-adventitia    有  29  个tokens\n",
      "key personnel were reassigned to different project    有  8  个tokens\n",
      "study was stopped by the principal investigator due to nonsatisfactory clinical benefit even in patients treated at the highest dose (200 mg )    有  26  个tokens\n",
      "unexpected injection site reactions    有  4  个tokens\n",
      "proposed doses were too large, bolus oxytocin may cause cases of arrythmias, and some even advocate pooring down the infusion rates that are currently used    有  35  个tokens\n",
      "study canceled based on results of different study with similar hypothesis, investigational agent, & patient    有  18  个tokens\n",
      "data suggesting pudendal artery stenosis rarely being cause of ed    有  14  个tokens\n",
      "pi relocated to another institution. no subjects went on treatment    有  11  个tokens\n",
      "the principle investigator decided to change the protocol    有  8  个tokens\n",
      "based on the developments in the treatment of recurrent metastatic renal cancer, the study treatment is no longer considered to be the best treatment option    有  27  个tokens\n",
      "the primary objective was considered sufficient for folpoor-up    有  11  个tokens\n",
      "impossible to retain participants in 3-year longitudinal study    有  11  个tokens\n",
      "no finance    有  2  个tokens\n",
      "this protocol was determined to be not human subjects research    有  10  个tokens\n",
      "terminated after two years by csrd    有  7  个tokens\n",
      "p.i decided to prematurely end this study    有  8  个tokens\n",
      "study treatment did not show clinical activity    有  7  个tokens\n",
      "per protocol, study was terminated due to poor rate of randomized patients    有  13  个tokens\n",
      "sponsor decided to terminate the entire project, and therefore there was no use for the samples collected in the study    有  21  个tokens\n",
      "difficulty to keep children in randomly assigned groups    有  8  个tokens\n",
      "study drug not available at this time    有  7  个tokens\n",
      "error in randomization resulted in early study termination    有  9  个tokens\n",
      "this study is currently suspended due to transition of the investigator    有  11  个tokens\n",
      "poor people to folpoor up the study, work overload    有  13  个tokens\n",
      "the felpoor interested in this project left the institution    有  11  个tokens\n",
      "contract ended    有  2  个tokens\n",
      "bayer terminated the program and sold the ip to medronic    有  12  个tokens\n",
      "terminated due to unachievable sample size and poor resource availability    有  12  个tokens\n",
      "law agreement between triggerfish signal and gat iop during both sessions. however, an increase in the triggerfish signal was observed during jogging phase    有  29  个tokens\n",
      "incyte has suspended development of the compound    有  8  个tokens\n",
      "the study will be rewritten as a data registry study    有  10  个tokens\n",
      "astrazeneca withdrew support for the study    有  8  个tokens\n",
      "drug procurement issues    有  3  个tokens\n",
      "steven johnson's syndrome (sjs) and toxic epidermal necrolysis syndrome (tens) are rare (~3 in 1 million). no eligible subjects have been identified    有  39  个tokens\n",
      "poor eligible subjects    有  4  个tokens\n",
      "the study was terminated approximately 6 months earlier than planned because 227 subjects (59% more than anticipated) had already completed 10-year visits due to poorer than expected subject attrition    有  37  个tokens\n",
      "determined not to be human subject research    有  8  个tokens\n",
      "trial was terminated prior to subjects receiving study drug; no trial results    有  13  个tokens\n",
      "fsi delayed until 15 january 2013    有  11  个tokens\n",
      "in light of protocol changes required due to methodological and operational issues, including background noise in cough recordings which could impact data interpretation, the study has been terminated    有  31  个tokens\n",
      "this study was terminated by the principal investigator    有  8  个tokens\n",
      "according to the nih definition of clinical trial studies, this study does not meet requirement to be a clinical trial study    有  23  个tokens\n",
      "principle investigator moved to an another hospital    有  8  个tokens\n",
      "inability to obtain cms approval    有  6  个tokens\n",
      "terminated early in agreement with health authorities for feasibility reasons    有  10  个tokens\n",
      "results from previous study dfa102 demonstrated neutralizing activity to metreleptin in invitro assay in 2 participants    有  24  个tokens\n",
      "decided not to pursue commercialization of the product    有  10  个tokens\n",
      "contract never executed; withdrawn by sponsor    有  7  个tokens\n",
      "data were published that superseded this study    有  8  个tokens\n",
      "30th november 2012. please see breif summary    有  12  个tokens\n",
      "due to the ubiquitous use of ics in the treatment of copd in 2012, it was hard to find the study population    有  27  个tokens\n",
      "ef decided suspended the study because the investigational product was changed    有  12  个tokens\n",
      "kalobios to wind down operations    有  7  个tokens\n",
      "study never started. study was redesgined    有  9  个tokens\n",
      "poor folpoor up    有  6  个tokens\n",
      "a pilot study of 7 patients did not reveal a temperature dependent difference in glycation rates    有  18  个tokens\n",
      "researchers left institution    有  4  个tokens\n",
      "introduction of national mass drug administration campaign and failure to identify appropriate participants    有  14  个tokens\n",
      "based on idmc decision    有  5  个tokens\n",
      "the same protocol has been launched in united states    有  9  个tokens\n",
      "study c11-01 started    有  6  个tokens\n",
      "cost of conducting the study and increased burden on the clinical trial professionals make it impossible for us to proceed with the development of the drug    有  26  个tokens\n",
      "dsmb stopped the study due to early effectiveness    有  9  个tokens\n",
      "primary objective has been met in the absence of clinically meaningful remissions    有  13  个tokens\n",
      "the experimental design was not sufficient to answer the proposed questions. a new study design is now being considered    有  20  个tokens\n",
      "the study was not feasible to perform at one institution with the amount of subjects that were needed to complete it    有  21  个tokens\n",
      "study terminated due to an unexpected prominent effect of entecavir alone in this patient population    有  18  个tokens\n",
      "the protocol finished    有  3  个tokens\n",
      "changes in practice    有  3  个tokens\n",
      "sara cheng, md has left the univ. of colorado and the study has been closed    有  21  个tokens\n",
      "regulatory reasons    有  3  个tokens\n",
      "pharmaceutical company no longer manufacturing investigational product    有  10  个tokens\n",
      "the requirement for post marketing surveillance was lifted by the philippine fda    有  15  个tokens\n",
      "change in staffing    有  3  个tokens\n",
      "study site compliance    有  3  个tokens\n",
      "drug was no longer available    有  5  个tokens\n",
      "audit pre regulatory inspection    有  4  个tokens\n",
      "parent trials were either not initiated or terminated    有  8  个tokens\n",
      "the study design was changed to a prospective cohort study due to difficulties in using a randomized approach in an emergency setting    有  22  个tokens\n",
      "trial terminated due to focus of primary therapeutic areas    有  9  个tokens\n",
      "withdrawal of support of the drug company for drug and placebo    有  12  个tokens\n",
      "the benefit/ risk profile does not support continuation of this study    有  12  个tokens\n",
      "the ethics committee did not approve the pharmacokinetic part of the study    有  14  个tokens\n",
      "changes in the clinical practice    有  5  个tokens\n",
      "this study was registered with clinical trials.gov by mistake    有  10  个tokens\n",
      "data presented at sabcs 2010 showing that dual blockade is superior to monotherapy    有  17  个tokens\n",
      "sufficient participants for analysis    有  5  个tokens\n",
      "study suspended    有  2  个tokens\n",
      "the study is no longer required for the prea for this product    有  13  个tokens\n",
      "change to study required    有  4  个tokens\n",
      "study discontinued by dsmb due to loss of equipoise    有  11  个tokens\n",
      "qualitative analysis of the study database    有  7  个tokens\n",
      "breakdown of communication between departments involved    有  7  个tokens\n",
      "modified insurance requests by a new law released after its approval    有  11  个tokens\n",
      "unavailable study resources    有  4  个tokens\n",
      "interim analysis found the study drug to be ineffective    有  10  个tokens\n",
      "i withdrew from this study    有  5  个tokens\n",
      "protocol was never implemented as procedures became standard of care    有  10  个tokens\n",
      "study was not a good fit for the patient population seen at this hospital    有  14  个tokens\n",
      "sponsor (intelect medical, inc.) was acquired by boston scientific and study was canceled    有  18  个tokens\n",
      "suspended to determine if mirena device could be charged to patient insurance    有  15  个tokens\n",
      "insufficient study population to meet study objective    有  8  个tokens\n",
      "no objective responses were observed    有  5  个tokens\n",
      "trial has failed to meet primary - and major secondary endpoints    有  11  个tokens\n",
      "costs of study procedures has changed and escalated and became prohibitive    有  13  个tokens\n",
      "study team left institution; no one remaining to finish study    有  11  个tokens\n",
      "ethics board said the study could not be fully justified    有  11  个tokens\n",
      "unable to identify study population to achieve number expected    有  9  个tokens\n",
      "delayed start of the trial, both treatment options already have market authorizations, study medication expired    有  19  个tokens\n",
      "departure without replacement of the principal investigator    有  7  个tokens\n",
      "subjects not interested    有  3  个tokens\n",
      "discontinuation of drug supply from astellas    有  9  个tokens\n",
      "study terminated.priority changes in product development    有  7  个tokens\n",
      "hypoglycaemia is significantly higher in tgc    有  11  个tokens\n",
      "the collaborator, genentech, stopped supplying the study drug to the site    有  16  个tokens\n",
      "due to fda comments, changes required unavailable resources. there are no results for this study    有  18  个tokens\n",
      "surgeon team were not happy with the study protocol, the periarticular injection of local anesthetics    有  22  个tokens\n",
      "compound development discontinued    有  3  个tokens\n",
      "study termination due to negative ph iii of another study product from same technology platform    有  15  个tokens\n",
      "not enough manpower    有  3  个tokens\n",
      "ameriscience went bankrupt    有  5  个tokens\n",
      "company decided to discontinue    有  5  个tokens\n",
      "we completed the 62% of the cases, enough data to get a conclusion of the study    有  19  个tokens\n",
      "a phase 3 study recently reported and demonstrated that the dose of otelixizumab in otx113390 is not effective    有  26  个tokens\n",
      "physycians' refusal to continue the study    有  9  个tokens\n",
      "not enough particpants    有  4  个tokens\n",
      "most potential subjects had already been prescribed cymbalta    有  10  个tokens\n",
      "revised development program    有  4  个tokens\n",
      "the irb considered our trial risky. although there were debates between investigators and irb, we terminated our trial in accordance with the suggestion of irb    有  30  个tokens\n",
      "written here by mistake    有  4  个tokens\n",
      "suspended awaiting ministry of defence ethics approval    有  8  个tokens\n",
      "protocol deviations    有  2  个tokens\n",
      "pi no longer with institution    有  5  个tokens\n",
      "this study was stopped because of poor posterior only major spine surgeries    有  12  个tokens\n",
      "inability to enrole subjucts    有  8  个tokens\n",
      "the trial was terminated before any patients were exposed to the trial drug based on new findings indicating that dose escalation with multiple doses should be performed in a different trial population    有  32  个tokens\n",
      "since the published data resolved the study goals we decided not to start it    有  14  个tokens\n",
      "study closed nov 2000 by amgen, who stopped drug delivery    有  14  个tokens\n",
      "study stopped since it was considered that one of the pre-defined stopping criterion was met    有  16  个tokens\n",
      "protocol proved to be ineffective for adequate sedation for third molar surgery    有  14  个tokens\n",
      "due very high screen fail rate, pre study feasibility not consistent with screened population    有  15  个tokens\n",
      "this study was withdrawn due to study agent availability    有  9  个tokens\n",
      "intermediary analysis was performed and significant results were found for the main objective    有  15  个tokens\n",
      "failed to reach endpoints    有  4  个tokens\n",
      "study was terminated by sponsor due to futile results in nct00849667 study    有  16  个tokens\n",
      "trial was terminated to alpoor sponsors to evaluate the future development of the drug program    有  17  个tokens\n",
      "pi does not have time to continue study    有  8  个tokens\n",
      "preliminary data from study nct00994214 do not support expected inhibition of gh and igf-1    有  23  个tokens\n",
      "arm \"placement periph iv cath\" completed - arm \"blood sampling\" : study will not be performed because of the results of the arm \"placement periph. iv cath\"    有  36  个tokens\n",
      "given the length of time data was collected (i.e. 5 1/3 years), we do not anticipate a change any potential conclusions by completing the final survey    有  34  个tokens\n",
      "stopped for one complication event (arterial occlusion)    有  11  个tokens\n",
      "did not pass set-up phase    有  6  个tokens\n",
      "changes affecting post authorization study regulatory effective from dec09, impacted the requirements for spanish studies at national and regional level    有  22  个tokens\n",
      "scarce interest of centres    有  5  个tokens\n",
      "protocol amended to nct01549366 and participants rolled into study    有  13  个tokens\n",
      "study assessment tool development delayed    有  5  个tokens\n",
      "future development of azd1236 is currently under review by the project team and no new studies will be started until this review is completed    有  27  个tokens\n",
      "specialised equipment required withdrawn from market    有  7  个tokens\n",
      "poor product due to industrial changes in the manufacturing process altering the final product    有  15  个tokens\n",
      "redundant with another study    有  7  个tokens\n",
      "mediators of interest were not consistently detectable with the analytical methods employed    有  14  个tokens\n",
      "the idmc recommended discontinuation of the study, and, the protocol was amended to end study treatment    有  20  个tokens\n",
      "study was terminated early due to poor experimental medication (supply issues)    有  13  个tokens\n",
      "after primary completition date, experimental drug was no longer available    有  12  个tokens\n",
      "the sponsor is currently focusing on different indications    有  8  个tokens\n",
      "pi changed job and project was not economically viable and therefor terminated    有  13  个tokens\n",
      "study was not renewed with the irb    有  8  个tokens\n",
      "study was not initiated as planned    有  6  个tokens\n",
      "for the 2 last patients still on treated nominal therapeutic use of the milciclib was approved at int milano    有  23  个tokens\n",
      "due to participants withdrawal prior to anticipated end of study    有  10  个tokens\n",
      "closed: logistical problems that could not be resolved    有  9  个tokens\n",
      "all active subjects rolled into 209fx303/nct01013480    有  14  个tokens\n",
      "on reviewing of new data    有  5  个tokens\n",
      "the h1n1 pandemic is now over, and fewer cases than expected were observed    有  17  个tokens\n",
      "pi departure from coordinating institution    有  5  个tokens\n",
      "not enough patients within the time frame to alpoor for a meaningful study    有  15  个tokens\n",
      "the last remaining subject withdrew consent because the collaborator genentech stopped supplying study drug    有  17  个tokens\n",
      "administartive and technical problems    有  7  个tokens\n",
      "departure of a collaborator in charge of the data collection    有  11  个tokens\n",
      "issues & unreliability with [11c]carfentanil production    有  16  个tokens\n",
      "this study has been terminated    有  5  个tokens\n",
      "recent improvements in clinical practice have reduced the apparent incidence of amr in renal transplantation    有  16  个tokens\n",
      "based on analyses in phase i, the study did not advance to phase ii    有  15  个tokens\n",
      "this study was temporarily paused due to an unanticipated bioanalytical issue    有  14  个tokens\n",
      "difficulty in accruing subjects    有  5  个tokens\n",
      "based on interim analysis study felt unlikely to reach the primary aim    有  12  个tokens\n",
      "due to poor time    有  4  个tokens\n",
      "internal decision to progress alternate molecule with more preferable profile    有  10  个tokens\n",
      "dsmb recommendation    有  3  个tokens\n",
      "sponsor is no longer pursuing this study    有  7  个tokens\n",
      "did not have the research staff necessary to folpoor through with this study    有  15  个tokens\n",
      "sponsor restructuring    有  2  个tokens\n",
      "similar data obtained in another study [see nct01085045], therefore study not implemented    有  18  个tokens\n",
      "due to an unfavourable benefit-risk profile observed during the phase 1 trial for the obesity project, nn9161, novo nordisk has decided to terminate further clinical development    有  35  个tokens\n",
      "results of the phase iii rtog0525 trial made the manufacturer of cilengitide decide to end their support to the trial    有  26  个tokens\n",
      "a phase iii rct was published showing this approach is effective    有  12  个tokens\n",
      "change in availability of study investigators    有  6  个tokens\n",
      "participants are no longer being folpoored up    有  9  个tokens\n",
      "h1n1 pandemic concluded in early 2010    有  11  个tokens\n",
      "nw center for reproductive sciences was sold and is no longer open    有  12  个tokens\n",
      "imbalance in the # graft infections between the tx's (graft vs. graft + wrap)    有  20  个tokens\n",
      "results of a planned interim analysis did not show significant effects for any of the 3 ain dose regimens versus placebo on any primary or secondary endpoint    有  29  个tokens\n",
      "the data was completed    有  4  个tokens\n",
      "product was not developed and study was cancelled    有  8  个tokens\n",
      "researchers leading this study have left bmc    有  9  个tokens\n",
      "for strategic buisness reasons    有  6  个tokens\n",
      "study is no longer required by brazil health authority    有  9  个tokens\n",
      "withdrawal of support from sponsor    有  6  个tokens\n",
      "study design required a change in device    有  7  个tokens\n",
      "difficult to enrol and as a pilot study sample size was not powered anyway    有  15  个tokens\n",
      "re-definition of mira technology goals    有  7  个tokens\n",
      "unable to complete agreement with sponsor    有  6  个tokens\n",
      "the investigators left the institution    有  5  个tokens\n",
      "shelf life of investigational drug ran out before 90 patients could be included    有  15  个tokens\n",
      "the investigator has left the institution (ucsf) prior to study start-up    有  15  个tokens\n",
      "change in er rules (no longer alpoored endoscopies in er) prevented ability to perform study according to protocol    有  24  个tokens\n",
      "manufacturer discontinued support of the study    有  6  个tokens\n",
      "needed pet facility closed    有  4  个tokens\n",
      "study closed prematurely due to the end of the influenza (h1n1) 2009 pandemic    有  20  个tokens\n",
      "manufacturer unable to produce    有  4  个tokens\n",
      "study will not be intiated    有  6  个tokens\n",
      "a new study had shown that polar body biopsies might negatively effect the implantation potential of the embryo    有  21  个tokens\n",
      "no mec approval    有  3  个tokens\n",
      "decision not to go forth with study    有  7  个tokens\n",
      "decided not to pursue at upci    有  8  个tokens\n",
      "the authors finished their jobs in the hospitals where the study was begun    有  13  个tokens\n",
      "the company dnage is in receivership and no longer functional    有  12  个tokens\n",
      "terminated on 14 sep 2010 due to strategic considerations    有  12  个tokens\n",
      "study did not meet statistical requirements to continue    有  8  个tokens\n",
      "due to changes to the standard of care within the proposed market for cs-7017    有  17  个tokens\n",
      "negative pharmacodynamics due to poor interleukin-13 signature in biomarker data from part i of the study    有  22  个tokens\n",
      "pi deceased; study did not start    有  7  个tokens\n",
      "the sponsor decide to terminate    有  5  个tokens\n",
      "protocol needed major revisions; poor money to institute changes    有  10  个tokens\n",
      "not approved by irb    有  5  个tokens\n",
      "late approval by the secretariat of health, and expiration of vaccine    有  13  个tokens\n",
      "interim analysis results, study terminated 5/2010    有  12  个tokens\n",
      "device not found to be adequate    有  6  个tokens\n",
      "the trial was halted by the dsmb    有  8  个tokens\n",
      "specimens are now collected through the brs protocol    有  10  个tokens\n",
      "new ultra sound technology have made this present study design less relevant and force us to change the design of the study    有  22  个tokens\n",
      "irb ended and nih study ended    有  8  个tokens\n",
      "too few interns willing to consent to wear the actigraph watches    有  12  个tokens\n",
      "the one hospital clinicalservice project involves the provision of services to hospitals, and is not a clinical study. as such, this service offering should not be listed on clinicaltrials.gov    有  36  个tokens\n",
      "pi moving to southern illinois university to start new protocol    有  11  个tokens\n",
      "the intermediate analyses did not alpoored to continue the clinical study    有  13  个tokens\n",
      "did not continue with development of dccr in very high triglycerides    有  14  个tokens\n",
      "amgen has chosen at this time not to continue with amg 745 study 20080733    有  20  个tokens\n",
      "financial shortages due to poor funderx    有  8  个tokens\n",
      "mtd determined sub-optimal as efficacious treatment for renal cell carcinoma    有  14  个tokens\n",
      "toxicities    有  3  个tokens\n",
      "novel hcv daa approved by fda    有  10  个tokens\n",
      "unable to get mhra approval for formulation in present form    有  11  个tokens\n",
      "personal changes in the company    有  5  个tokens\n",
      "difficulties of internal organization    有  6  个tokens\n",
      "initial results suggest no significant trends will be observed with completion of study    有  13  个tokens\n",
      "participants are no longer being examined. the results are published 2016 anticancer research 36: 6431-6438    有  26  个tokens\n",
      "the financial support was withdrawn    有  5  个tokens\n",
      "investigators and resources are no longer available for completion of the study due to retirements, relocations and reassignments    有  23  个tokens\n",
      "1 consented patient never started on study drug, lost to folpoor up    有  16  个tokens\n",
      "tinzaparin will no longer be available in the united states    有  13  个tokens\n",
      "core study unsuccessful    有  3  个tokens\n",
      "deemed ineffective    有  3  个tokens\n",
      "sterility problems in depocyte production    有  7  个tokens\n",
      "not enough tissue for analysis    有  5  个tokens\n",
      "funds needed to carry on the project were not secured    有  11  个tokens\n",
      "interim analysis showed that the odds for proving primary hypothesis are poor    有  13  个tokens\n",
      "changes in the organisation    有  4  个tokens\n",
      "terminated: higher rate of acute rejection in the cyclosporin a group    有  16  个tokens\n",
      "the study was never initiated at any sites    有  8  个tokens\n",
      "not yet started    有  3  个tokens\n",
      "drug provider withdrew support    有  4  个tokens\n",
      "pi has left the umdnj but may resume the study in her new place of employment    有  18  个tokens\n",
      "our co sources were in a state of advanced decay. that prolonged our surgical procedures, making them inconveniently and perhaps dangerously long (> 12 hours)    有  30  个tokens\n",
      "support for investigational products has been withdrawn    有  8  个tokens\n",
      "feasibility /drug availability issues - no study drug sources available    有  12  个tokens\n",
      "clinical trial terminated due to results from recent nonclinical studies    有  11  个tokens\n",
      "increased rate of bacterial infections    有  6  个tokens\n",
      "unanticipated delays due to sterilization/stabilization testing of glp-1    有  16  个tokens\n",
      "ind not obtained    有  3  个tokens\n",
      "problems obtaining the investigational agent, allogenix(tm) plus    有  13  个tokens\n",
      "more possibly treatment-related deaths on tasisulam-sodium arm    有  13  个tokens\n",
      "the study was terminated due to difficulty of find eligible subjects    有  11  个tokens\n",
      "unable to gain approval from commanding army and navy officers to conduct study    有  13  个tokens\n",
      "issues with hospice    有  4  个tokens\n",
      "drug combination is no longer pursued    有  6  个tokens\n",
      "commercial considerations relating to required device modifications    有  7  个tokens\n",
      "however, no intervention reduced the risk of major morbidity or 1 yr mortality    有  16  个tokens\n",
      "maximum tolerated dose not able to be determined    有  8  个tokens\n",
      "this study has never been started    有  6  个tokens\n",
      "costar stent ide failed to meet primary endpoint    有  10  个tokens\n",
      "the investigator has changed institutions    有  5  个tokens\n",
      "study never accrued sufficient subjects    有  5  个tokens\n",
      "preliminary data from this study does not support expected inhibition of gh and igf-1    有  19  个tokens\n",
      "program refocus    有  3  个tokens\n",
      "preserve clinical supplies    有  3  个tokens\n",
      "reached sufficient pharmacokinetic exposures    有  7  个tokens\n",
      "a recommended phase 2 dose and schedule was not identified and the study was terminated before initiation of stage 2b    有  23  个tokens\n",
      "study completed and data was inconclusive    有  7  个tokens\n",
      "drug no longer being supplied by sponsor    有  7  个tokens\n",
      "planned interim analysis showed worse outcomes in experimental group    有  10  个tokens\n",
      "colaborator withdrew support    有  5  个tokens\n",
      "study was withdrawn due issuses related to the science    有  10  个tokens\n",
      "difficulty producing tracer    有  3  个tokens\n",
      "astrazeneca has discontinued the development of azd0530. no new astrazeneca-sponsored clinical studies will be initiated    有  24  个tokens\n",
      "a consequence of the results of the enthuse phase iii study program    有  13  个tokens\n",
      "this trial was never started    有  5  个tokens\n",
      "study was terminated in order to examine study data    有  9  个tokens\n",
      "pi relocated to new university    有  5  个tokens\n",
      "poor statistical difference between both arms of the trial    有  10  个tokens\n",
      "the equipment to be used for the study was inoperable and not repairable    有  16  个tokens\n",
      "the goal of collecting proof-of-concept information was met through additional modeling studies, new published evidence and information collected from the study    有  25  个tokens\n",
      "not enough pts for available to reach goal    有  8  个tokens\n",
      "the study was halted after the first interim analysis as there were significantly more patients who recovered at one month in the control arm    有  24  个tokens\n",
      "an excess of all-cause acute health services utilization in the intervention arm    有  14  个tokens\n",
      "product received approval for commercial distribution    有  6  个tokens\n",
      "hypoxemia(spao2<80%) episodes occured significantly in the arm titration by 0.5ug/ml    有  24  个tokens\n",
      "company decided not to pursue the development of this drug in this patient population at this time    有  17  个tokens\n",
      "core study in non-infectious active uveitis was terminated    有  13  个tokens\n",
      "live h1n1 vaccine expired and unable to get new supply    有  13  个tokens\n",
      "this original design is no longer consistent with current clinical practice    有  11  个tokens\n",
      "need of change to the protocol. as the principal investigator has left the university hospital ghent end 2010, the change of protocol was never submitted    有  30  个tokens\n",
      "a planned interim-analysis revealed increased number of infections in the intervention arm    有  13  个tokens\n",
      "pre-determined stopping point met with signficant difference between intervention and control groups    有  16  个tokens\n",
      "interim analysis did not show good results for main objective    有  11  个tokens\n",
      "ethical commentate has not be obtained by the institution    有  10  个tokens\n",
      "tocilizumab was licenced in canada for children, so the study was not necessary    有  19  个tokens\n",
      "resources not available to complete    有  5  个tokens\n",
      "decided not to pursue study at this time. resources not available    有  13  个tokens\n",
      "not human subject research    有  4  个tokens\n",
      "manufacturer ceased to produce vials used for this study    有  10  个tokens\n",
      "study did not meet its primary objective    有  7  个tokens\n",
      "no difference in outcome between the two groups    有  8  个tokens\n",
      "changed focus of the program    有  5  个tokens\n",
      "needed new ind per fda    有  6  个tokens\n",
      "study transferring to inova health    有  6  个tokens\n",
      "study sponsors withdrew support for the study drug    有  8  个tokens\n",
      "manufacturer asked to close study due to aes experienced by subjects in other studies    有  14  个tokens\n",
      "core study in behcet's disease with mostly active uveitis did not meet its primary endpoint    有  20  个tokens\n",
      "pharmaceutical company did not decide to renew contract    有  10  个tokens\n",
      "couldn't offer patients a high/poor fat meal plan because food service changes    有  15  个tokens\n",
      "planning for randomized phase iii trial for this issue    有  10  个tokens\n",
      "terminated: study in behcet's disease with mostly active uveitis did not meet its primary endpoint    有  21  个tokens\n",
      "my main collaborator got sick and cannot continue the project. the study ended    有  15  个tokens\n",
      "regulatory authorities did not alpoor the entrance of the study drug in the country    有  17  个tokens\n",
      "number of needed participants could not be obtained    有  8  个tokens\n",
      "to many infants in the experimental group developed hypertriglyceridemia    有  14  个tokens\n",
      "protocol as presented by investigator was not approved by the niddk    有  13  个tokens\n",
      "sponsor has taken the decision to terminate further development of the compound    有  12  个tokens\n",
      "awaiting supply of peptide from a different company    有  9  个tokens\n",
      "study drug (ontak) no longer available    有  9  个tokens\n",
      "the study never started since our medical ethic commeettee did not approved it    有  15  个tokens\n",
      "principal investigator and sponsor did not reach an agreement    有  9  个tokens\n",
      "lost sponsorship for study drug    有  5  个tokens\n",
      "colonoscope being used in study not repairable at economic cost    有  12  个tokens\n",
      "the primary objective for high grade gliomas has been met and the fda has now approved the drug (gleolan) for use in the united states    有  30  个tokens\n",
      "change in guidelines by the manufacturer    有  6  个tokens\n",
      "the study was prematurely terminated because of unavailibility of methylnaltrexone in the region    有  20  个tokens\n",
      "withdrawn. not enough time to go through with the study    有  12  个tokens\n",
      "performance of bci switch insufficient in pilot testing    有  9  个tokens\n",
      "no interest from school district    有  5  个tokens\n",
      "this study was terminated. an it injection study of c. novyi-nt in patients with treatment refractory solid tumor malignancies may be viewed at nct01924689    有  35  个tokens\n",
      "interim analysis suggested no differences with whole sample    有  9  个tokens\n",
      "participant attrition before final folpoor-up visit was greater than anticipated    有  14  个tokens\n",
      "termination of further treatment on the study due to the availability of commercial supply or a rollover study (nct05160922) that will alpoor active subjects to continue receiving treatment    有  37  个tokens\n",
      "practices in surgery have evolved and the study has not interest yet    有  13  个tokens\n",
      "the study closed temporarily in february 2012 pending analysis of samples collected. in october, 2012, celgene requested closure of the study    有  31  个tokens\n",
      "stopped prematurely by company due to decision to terminate all ctep supplied drug for further development of ro4929097    有  22  个tokens\n",
      "logistical    有  2  个tokens\n",
      "unable to determine a suitable placebo    有  6  个tokens\n",
      "the ictus 2 portion of the trial has been halted and data will be analyzed    有  18  个tokens\n",
      "this study has been terminated due to poor availability of investigational product    有  13  个tokens\n",
      "the early report didn't show any benefit    有  8  个tokens\n",
      "bad design    有  2  个tokens\n",
      "a sister study using frova at a 10 mg dose had adverse effects    有  15  个tokens\n",
      "study was terminated due to sponsor portfolio decision    有  8  个tokens\n",
      "pi time constraints    有  3  个tokens\n",
      "study never started and therefore terminated    有  6  个tokens\n",
      "path withdrew irb approval    有  5  个tokens\n",
      "drug supply sponsor sent outdated drug    有  6  个tokens\n",
      "timeline to consent prior to intervention start was unfeasible    有  11  个tokens\n",
      "lacking effect of treatment    有  5  个tokens\n",
      "please see \"purpose\" statement bepoor    有  9  个tokens\n",
      "unexpected discordant results between the koh microscopy and mycological culture tests at three study sites in the uk    有  22  个tokens\n",
      "study was withdrawn due to poor eligible population for study    有  10  个tokens\n",
      "unanticipated toxicities    有  4  个tokens\n",
      "unfavourable risk-benefit-ratio    有  9  个tokens\n",
      "a significant reduction in head injuries coupled with more frequent use of crainectomy reduced the number of potential subjects    有  21  个tokens\n",
      "decision to stop development of azd1480    有  9  个tokens\n",
      "poor resources to run the trial    有  7  个tokens\n",
      "several studies going on at the same time    有  9  个tokens\n",
      "end of normal study    有  4  个tokens\n",
      "clinical study in graves' ophthalmopathy terminated until there is a better understanding of an efficacious dose with otelixizumab from other clinical studies    有  30  个tokens\n",
      "no collaboration    有  2  个tokens\n",
      "pharmaceutical company request    有  5  个tokens\n",
      "poor available clinical drug supply    有  6  个tokens\n",
      "this trial was never initiated due to inability to obtain the device    有  12  个tokens\n",
      "decision of study principal investigator    有  5  个tokens\n",
      "termination of the clinical development program by the sponsor    有  9  个tokens\n",
      "drug and placebo unavailable    有  4  个tokens\n",
      "other projects warranted more attention    有  5  个tokens\n",
      "the participants signed an old version of the informed consent    有  10  个tokens\n",
      "reason    有  1  个tokens\n",
      "no improvement in near vision was detected    有  7  个tokens\n",
      "poor subjects and manpower issues    有  6  个tokens\n",
      "preliminary data did not show expected outcomes    有  9  个tokens\n",
      "lead researcher completed felpoorship and never got study off ground    有  13  个tokens\n",
      "all active subjects were rolled into study 209as209/nct01706523    有  16  个tokens\n",
      "principal investigator no longer at institution    有  6  个tokens\n",
      "immunohistochemistry markers are not recieved yet    有  10  个tokens\n",
      "company dissolution    有  2  个tokens\n",
      "phase i/ii study halted as phase i, poor response rate    有  13  个tokens\n",
      "the study was suspended due to poor study drug    有  9  个tokens\n",
      "novartis ended all studies regarding aliskiren    有  10  个tokens\n",
      "temporary hold in may 2010 due to an emerging pk profile that could not be aligned to the known pharmaceutical properties of the imp (azd6553)    有  32  个tokens\n",
      "equipment not functional    有  3  个tokens\n",
      "this treatment is now considered standard of care    有  8  个tokens\n",
      "principal investigator has left institution. ind withdrawn    有  8  个tokens\n",
      "complete per pi    有  3  个tokens\n",
      "primary endpoint not met, remaining long-term folpoor-up not needed    有  14  个tokens\n",
      "data from other trials failed to demonstrate meaningful survival advantage    有  10  个tokens\n",
      "sitaxentan is not commercialized anymore    有  9  个tokens\n",
      "according to retired pi, resident graduated and next resident never carried it to fruition    有  15  个tokens\n",
      "resident left and no one to take over    有  8  个tokens\n",
      "high discontinuation rates mainly due to gi tolerability and implementation of risk mitigation plan to address hypersensitivity reactions    有  21  个tokens\n",
      "study was never started. full ide-approval not obtained. new ide will be submitted    有  17  个tokens\n",
      "now we use better procedures for the patient instead of nasal catheter for epistaxis. so it would be unethical to use the nasal catheter to complete the trial    有  33  个tokens\n",
      "similar study already published    有  4  个tokens\n",
      "pharmaceutical co- re aligned their specialties- no longer will fund h&n ca    有  18  个tokens\n",
      "the sponsor decided to withdraw study drug from market    有  9  个tokens\n",
      "the study was terminated prematurely after three influenza seasons    有  9  个tokens\n",
      "based on analyses of studies separately of the score study, sponsor has decided to discontinue the study. data collected during the study will not be analyzed    有  29  个tokens\n",
      "concern for volume depletion and electrolyte abnormalities in furosemide arm    有  15  个tokens\n",
      "the study was closed due to the departure of several of the co-investigators    有  16  个tokens\n",
      "unanticipated study design flaw; pco evaluator interrater reliability was not performed    有  16  个tokens\n",
      "study closed because of new overlapping study with ribavirin    有  12  个tokens\n",
      "poor support from pharmaceutical collaborator    有  7  个tokens\n",
      "pi re-located    有  4  个tokens\n",
      "other and future studies on lipiview in pterygium will cover this current trial sufficiently    有  18  个tokens\n",
      "changes in preclinical treatment of stroke patients, no more emergency physician will met this patients    有  17  个tokens\n",
      "the compound is being re-evaluated    有  8  个tokens\n",
      "closed due to delay by gsk    有  7  个tokens\n",
      "publication of data from a similar study made the current study redundant    有  12  个tokens\n",
      "financial considerations    有  2  个tokens\n",
      "due to recent strategic policy developments in the national vaccination program it is uncertain preadolescent girls will receive the hbv vaccin    有  26  个tokens\n",
      "withdrawal of sponsorship    有  4  个tokens\n",
      "sponsor is re-evaluating the clinical development path    有  10  个tokens\n",
      "conduct the randomized phase 2 part not recommended due to the achieved mtd for pimasertib (45mg/day) in combination with folfiri    有  31  个tokens\n",
      "study being redesigned in anticipation of new study protocol    有  9  个tokens\n",
      "due to ethical concerns regard to the results from the whi study    有  13  个tokens\n",
      "end of h1n1 swine flu pandemic    有  10  个tokens\n",
      "the dsmb stopped the trial due to unacceptable side effects in the experimental arm which has not yet been verified    有  21  个tokens\n",
      "inadequate number of potential participants    有  7  个tokens\n",
      "delayed inclusion at more than 14 years from the start of the study    有  15  个tokens\n",
      "poor disease incidence rate    有  5  个tokens\n",
      "pi chose not to conduct the study; no data collected    有  11  个tokens\n",
      "novartis is ending their research program for nilotinib in gist    有  15  个tokens\n",
      "drug manufacturer withdrew support for studies not in metastatic breast cancer    有  12  个tokens\n",
      "major change in protocol anticipated    有  5  个tokens\n",
      "the study treminated early according to dsmb recommendantions    有  12  个tokens\n",
      "the study was stopped because there were not enough eligible patients to complete the study    有  15  个tokens\n",
      "sponsor and investigator 's decision    有  6  个tokens\n",
      "protocol revision necessary    有  3  个tokens\n",
      "changes in approach to pda therapy    有  7  个tokens\n",
      "unable to reach target goal    有  5  个tokens\n",
      "study manager could not embark on it during the timeline    有  10  个tokens\n",
      "study was never initiated due to logistic causes    有  8  个tokens\n",
      "sponsor can not supply drugs anymore    有  6  个tokens\n",
      "the study was terminated for logistic reasons    有  7  个tokens\n",
      "amended clinical development plan    有  5  个tokens\n",
      "study was terminated due to increased pvr in one subject from t0-t1 reaching the level of a predetermined stopping rule    有  24  个tokens\n",
      "pilot results in change to protocol, new study needed    有  11  个tokens\n",
      "interim analysis indicated that endpoints can not be analysed with current dataset    有  13  个tokens\n",
      "key investigator relocated    有  3  个tokens\n",
      "study was closed and reopened as nct01717391    有  11  个tokens\n",
      "necessary equipment to perform the study arms was removed by the medical center administration    有  14  个tokens\n",
      "the risk-benefit ratio for patients has changed since we initiated the study, and that the study in its current form cannot be justified    有  26  个tokens\n",
      "no reponse of the of the treatment    有  8  个tokens\n",
      "internal    有  1  个tokens\n",
      "at sponsor's discretion : benefit is not guaranteed    有  9  个tokens\n",
      "the interim analysis showed no tendency in favour of the verum group. therefore it was decided to stop the study prematurely    有  23  个tokens\n",
      "terminated ahead of schedule after completion of the 3-year folpoor-up time point due to sponsor decision    有  21  个tokens\n",
      "the study was terminated due to satisfaction of post-marketing commitments    有  12  个tokens\n",
      "decided not to participate in study per leslie padron-massaro    有  16  个tokens\n",
      "withdrawn in october 2006, no longer of interest    有  13  个tokens\n",
      "preliminary analysis determined there was sufficient data to support objectives and alpoor early completion. the last patient visit occurred on november 6, 2007    有  32  个tokens\n",
      "the trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power    有  21  个tokens\n",
      "no diagnosis of visceral lesion was placed on 18 included patients. the study is thus stopped prematurely for ethical reasons    有  22  个tokens\n",
      "proof of mechanism achieved with fewer subjects than anticipated    有  9  个tokens\n",
      "time to engraftment would not be improved compared to historical controls    有  14  个tokens\n",
      "trial did not move to phase ii portion due to poor tolerance of treatment    有  14  个tokens\n",
      "i am changing locations to johns hopkins medical center    有  11  个tokens\n",
      "suspended until capitalization is completed    有  7  个tokens\n",
      "unable to continue due to medical equipment necessary for research study was removed from facility    有  15  个tokens\n",
      "number included has been reached    有  5  个tokens\n",
      "study terminated due to expiration of irb approval    有  9  个tokens\n",
      "insufficient number of interested potentital subjects    有  8  个tokens\n",
      "manufacturer could not finance the study    有  6  个tokens\n",
      "sponsor decided to terminate the study due to budget consideration    有  10  个tokens\n",
      "problems with planned computer    有  4  个tokens\n",
      "development program ended due to inability to pair with other cytidine analogs and higher risk of hyperlipasemia when not used with 3tc/ftc    有  33  个tokens\n",
      "protocol underwent significant revisions, decision made to terminate study and open as new study listed nct00849459    有  21  个tokens\n",
      "abnormal distribution and poor tumor targeting were observed    有  9  个tokens\n",
      "researchers left the institute    有  5  个tokens\n",
      "required number of subjects to be included could not be accomplished    有  11  个tokens\n",
      "principal investigator moving out of state, no other staff to lead research    有  13  个tokens\n",
      "terminated as marketing of this product will be discontinued    有  9  个tokens\n",
      "due to technical issues relating to the electronic diary data    有  10  个tokens\n",
      "study drug expiry date not extended    有  6  个tokens\n",
      "poor volunteers    有  3  个tokens\n",
      "unable to reconcile record due to age    有  7  个tokens\n",
      "investigator abruptly left carilion    有  6  个tokens\n",
      "study has never started    有  4  个tokens\n",
      "the study was terminated due to logistics at a local hospital    有  11  个tokens\n",
      "record owner no longer with the institution    有  7  个tokens\n",
      "important delays and malaria season missed, due to political changes    有  11  个tokens\n",
      "insufficient potential subjects    有  4  个tokens\n",
      "the doctor performing the study suddenly changed work and moved    有  10  个tokens\n",
      "d hardin not at institution, irb has no record, no other investigators for study information    有  19  个tokens\n",
      "because in a preliminary analysis we would need 1000 patients per group to achieve significative differences in the main end point    有  24  个tokens\n",
      "a decision was made to discontinue the study due to a change in the strategic direction of the company    有  20  个tokens\n",
      "nci stopped supplying fenretinide in november of 2012    有  14  个tokens\n",
      "sponsor no longer pursuing regulatory approval of investigational device    有  10  个tokens\n",
      "2 complications with midazolam    有  7  个tokens\n",
      "withdrawn support for study    有  5  个tokens\n",
      "logistics failure and staff/scanner shortage    有  8  个tokens\n",
      "poor intermediate-term results    有  5  个tokens\n",
      "the sponsor determined that adequate data had been acquired    有  9  个tokens\n",
      "investigator closed study and left vamc    有  9  个tokens\n",
      "the study was terminated on completion of the pilot study phase    有  11  个tokens\n",
      "because of approval of bevacizumab, it was difficult to perform clinical study in 1st line setting    有  23  个tokens\n",
      "due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited clinical responses    有  17  个tokens\n",
      "an interim analysis showed that nitric oxide patches are not enough effective    有  13  个tokens\n",
      "dsmb recommended stopping the trial because of poor effect    有  10  个tokens\n",
      "difficulties in completing the required sample size    有  9  个tokens\n",
      "this was a chart review only and was entered in the system in error    有  14  个tokens\n",
      "the response rate (5/8) had reached a statistical significant endpoint    有  14  个tokens\n",
      "unable to enrol enough people to achieve the full sample size    有  11  个tokens\n",
      "no financial resources were available to complete the study    有  9  个tokens\n",
      "study was terminated due to cardiac toxicities    有  8  个tokens\n",
      "this is only a chart review. this is not a clinical trial and was inadvertently entered in the system    有  20  个tokens\n",
      "this is a chart review only and not a clinical trial. this was inadvertently entered in the system    有  19  个tokens\n",
      "early closure based on audit by study investigators after 3 patients died on study    有  15  个tokens\n",
      "adequate statistical power at 92 dosed pts to meet study objectives    有  14  个tokens\n",
      "collaboration could not be established    有  7  个tokens\n",
      "merged with the study nct00307268    有  9  个tokens\n",
      "sanofi-aventis wanted the study terminated    有  10  个tokens\n",
      "leaving of the person responsible for the data collection    有  10  个tokens\n",
      "bupivacaine has recently been shown to inhibit osteoclast formation in vitro    有  17  个tokens\n",
      "after treatment of 7 patients, it was decided that the handling characteristics of the test device should be upgraded before continuing the trial as planned    有  27  个tokens\n",
      "pi is no longer at the university of minnesota    有  10  个tokens\n",
      "the assistant who was going to do this study moved to a different med center    有  15  个tokens\n",
      "withdrawn due to poor study participants    有  7  个tokens\n",
      "this study should be terminated as the study closed prior to 2007 and the investigator has since retired. no records are available    有  25  个tokens\n",
      "dose levels were determined to be subtherapeutic    有  10  个tokens\n",
      "study stopped as it would not address important survival concerns raised in other recently conducted clinical studies    有  17  个tokens\n",
      "interim analysis has shown that the objectives of this study can not be reached    有  15  个tokens\n",
      "financial support withdrawn    有  3  个tokens\n",
      "study terminated due to withdrawl of participating co-investigators    有  12  个tokens\n",
      "no longer any benefit in collecting data since retigabine has been withdrawn from market    有  17  个tokens\n",
      "withdrawal of support for drug supply    有  7  个tokens\n",
      "steba decided to develop wst11 that is soluble in aqueous solutions. the property of wst 11 make it safer and better candidate for therapeutic applications    有  32  个tokens\n",
      "the study stopped becaust the sponsor did not wish to proceede with the study    有  17  个tokens\n",
      "study was stopped due to restrictions in labeling for the subcutaneous route of administration of eprex    有  20  个tokens\n",
      "study terminated early due to aralast being phased out of the market    有  14  个tokens\n",
      "study was never started because dr. hammerberg left before it could be started    有  15  个tokens\n",
      "ran out of drug    有  4  个tokens\n",
      "senior managemnt decision    有  6  个tokens\n",
      "due to drug unavailability    有  5  个tokens\n",
      "the trial failed to accrue    有  6  个tokens\n",
      "life bronchoscopy equipment no longer functioning and cannot be repaired    有  12  个tokens\n",
      "due to delays with logistics and protocol revision not viable to continue    有  12  个tokens\n",
      "due to the publication of significant literature in this area since commencement of the project which has now rendered the project unnecessary    有  22  个tokens\n",
      "teh priincipal investigator responsible for the trial no longer employed at the study site    有  16  个tokens\n",
      "first postponed then cancelled as national drug authority changed requirements    有  10  个tokens\n",
      "missing financial sponsorship    有  3  个tokens\n",
      "stopped in december 2007    有  6  个tokens\n",
      "the researcher had left the hospital and the project was stopped    有  11  个tokens\n",
      "no difference in primary outcomes at interim analysis    有  8  个tokens\n",
      "ind moved to sponsor    有  4  个tokens\n",
      "it was decided to use a different protocol with a different radioligand    有  15  个tokens\n",
      "this study has been terminated. (interim analysis of preliminary results indicated the need for protocol re-design)    有  21  个tokens\n",
      "data insignificant, study terminated    有  5  个tokens\n",
      "it was found that the devices were not suitable for the application    有  12  个tokens\n",
      "intervention worsened performance for first 17 of 24 planned participants    有  14  个tokens\n",
      "protocol cancelled    有  2  个tokens\n",
      "study drug no longer available resulting in poor study drug for participants    有  12  个tokens\n",
      "stopped due to poor percentage of patients with detectable ctcs at baseline    有  14  个tokens\n",
      "no update for several year, confermed ended by odd edvardsen i march 2020    有  20  个tokens\n",
      "development of this compound was discontinued    有  6  个tokens\n",
      "drugs unavailable:unable to make radioactive topotecan    有  11  个tokens\n",
      "the company which holds the patent was not interested    有  9  个tokens\n",
      "high rate of early drop-outs    有  6  个tokens\n",
      "sponsor cancelled the development program, and never conducted the study    有  11  个tokens\n",
      "the study stopped due to unforeseen circumstances    有  8  个tokens\n",
      "superiority of iv omeprazole to ranitidine has already been proven by others    有  19  个tokens\n",
      "pharmaceutical company no longer manufactures drug    有  8  个tokens\n",
      "never received irb approval    有  5  个tokens\n",
      "we had got enough data, therefore we stopped the study and published the data    有  15  个tokens\n",
      "regulatory issues(trial temporarily suspended december 28, 2005. permanently suspended january 19, 2007. institutional reveiw board informed april 18, 2007    有  38  个tokens\n",
      "inconsistent treatment benefit    有  4  个tokens\n",
      "terminated due to pipeline prioritization    有  6  个tokens\n",
      "insufficient power to show therapy difference at interim analysis    有  10  个tokens\n",
      "data collection completed    有  3  个tokens\n",
      "unm did not proceed with research    有  7  个tokens\n",
      "this is not clinical trial and was inadvertently entered in this system    有  12  个tokens\n",
      "unknown - no record of study conduct in departmental archive    有  11  个tokens\n",
      "study was not renewed timely with irb of record    有  10  个tokens\n",
      "this does not meet the requirement date to be entered into ct.gov    有  13  个tokens\n",
      "failed primary endpoint    有  3  个tokens\n",
      "protocol drug change required new clinicaltrails.gov entry    有  10  个tokens\n",
      "reformulation of test compound    有  6  个tokens\n",
      "stop recommended folpooring the last sequential analysis    有  9  个tokens\n",
      "data collection sufficient    有  3  个tokens\n",
      "the trial was terminated because of deviations from the protocol    有  10  个tokens\n",
      "ended folpoor-up after four years    有  8  个tokens\n",
      "sufficient data collected for significant study results    有  8  个tokens\n",
      "project withdrawn    有  2  个tokens\n",
      "because there were no responses    有  5  个tokens\n",
      "high relapse rate    有  4  个tokens\n",
      "sponsor stopped the study because of poor elligible participants    有  11  个tokens\n",
      "manufacturing change in one of the two lipid emulsion products being studied    有  14  个tokens\n",
      "dr. levy terminated from iu in december 2009. indiana university has no record that this study was initiated prior to his termination    有  28  个tokens\n",
      "poor technical support and supplies    有  6  个tokens\n",
      "data collection ended    有  3  个tokens\n",
      "study was stopped due to time dependent drug accumulation    有  9  个tokens\n",
      "not sufficient time to conduct the study    有  7  个tokens\n",
      "inability to reach statistical significance toward primary endpoint    有  9  个tokens\n",
      "suspended due to data issues revealed at dsmb meeting. planned amendment but was never submitted. study was then closed    有  23  个tokens\n",
      "infeasible    有  3  个tokens\n",
      "terminated early because the first phase didn't meet the endpoint    有  11  个tokens\n",
      "due to a substantial response to placebo an interim analysis indicated the need for a larger than expected study population to achieve the level of significance    有  26  个tokens\n",
      "sufficient mature data to complete a final analysis    有  9  个tokens\n",
      "study was terminated due to cardiac toxicities in the subejcts    有  13  个tokens\n",
      "development of xl999 was stopped due to cardiac toxicities in the subjects    有  14  个tokens\n",
      "preliminary findings did not support purpose    有  8  个tokens\n",
      "because there was no longer an active laboratory component to this study    有  12  个tokens\n",
      "this was a folpoor-on study to biomed 777-clp-029 which did not meet superiority endpoint    有  23  个tokens\n",
      "significant conclusive data has been collected    有  6  个tokens\n",
      "sufficient data collected for analysis    有  6  个tokens\n",
      "swog eliminated its head and neck committee    有  8  个tokens\n",
      "trial closed early because, during an interim analysis, the primary endpoint fell short    有  15  个tokens\n",
      "we believe regional anesth better for tkr,90% patients got epidural. last year we started spinal morphine one shot, and found it very promissing    有  34  个tokens\n",
      "the study was discontinued due to the death of a co-investigator and a second co-investigator leaving the institution    有  24  个tokens\n",
      "it was determined that the study was not appropriate for demonstrating therapeutic benefit in the cardiopulmonary bypass patient population    有  22  个tokens\n",
      "this project is no longer active with dva    有  9  个tokens\n",
      "new study with lenalidomide pending    有  9  个tokens\n",
      "the pi, who was sponsor got retired    有  8  个tokens\n",
      "lundbeck withdrew committment - expiring patents and prolonged inactivity    有  14  个tokens\n",
      "the study was terminated because at least one year folpoor-up was achieved for each patient and the achievement of 965 exposure years to the drug    有  29  个tokens\n",
      "withdrawn due to an excess of toxic deaths    有  9  个tokens\n",
      "results inconclusive    有  3  个tokens\n",
      "drug was not available    有  4  个tokens\n",
      "is involved in nih study    有  6  个tokens\n",
      "the study was limited to irb exempt chart review; not an applicable trial    有  15  个tokens\n",
      "the scientific commitee decided to stop the inclusions and exploit the results    有  15  个tokens\n",
      "per pi, results from another similar study were published prior to study analysis. negative study results were published therefore analysis was not completed    有  25  个tokens\n",
      "other authors showed the same metabolic effect may be obtained when bmmc are delivered peripherally, with poorer risk and cost than through hepatic artery    有  29  个tokens\n",
      "poor response to questionnaire    有  5  个tokens\n",
      "incidence of gi perforation    有  6  个tokens\n",
      "poor recruting    有  5  个tokens\n",
      "insufficient response rate    有  4  个tokens\n",
      "study terminated as a result of the dissolution of the sponsor    有  11  个tokens\n",
      "non-protocol feasibility    有  4  个tokens\n",
      "study did not meet pre-specified objectives    有  8  个tokens\n",
      "terminated by sponsor due to general risk that aranesp caused tumor progression    有  14  个tokens\n",
      "difficulties in finding enough study participants    有  8  个tokens\n",
      "there was a change of sponsor. the new sponsor company did not wish to conduct the study after all    有  20  个tokens\n",
      "cannot get enough plasma to manufacture ivig for human trials    有  11  个tokens\n",
      "change in treatment plan for this population terminated the project    有  10  个tokens\n",
      "in order to join forces with another study already running which aims to answer the same question    有  17  个tokens\n",
      "poor cooperation among centers, financial reasons    有  8  个tokens\n",
      "study closed at mayo prior to completion    有  7  个tokens\n",
      "study product is no longer being considered for further development    有  10  个tokens\n",
      "dosing cohort (650mg) exceeded current 350mg dosing in other trials    有  17  个tokens\n",
      "all consented subjects tested negative for the brca2 mutation, therefore, did not meet criteria to start the study, resulting in withdrawal by pi    有  29  个tokens\n",
      "withdrawn because of poor approvement from local medical authorities    有  11  个tokens\n",
      "wothdrawal of sponsor    有  6  个tokens\n",
      "the study was withrawn do to logistic difficulties    有  9  个tokens\n",
      "the clinical development program for mgcd0103 is being re-evaluated    有  15  个tokens\n",
      "change to investigator's research affiliation and other employment    有  9  个tokens\n",
      "procedure protocol improved - study protocol became obsolete    有  8  个tokens\n",
      "pi no longer has an appointment and has seperated from hines vah and project was not transferred to another pi?    有  24  个tokens\n",
      "due to changes within the research program this study is not feasible at this time    有  15  个tokens\n",
      "poor subject population for pi    有  6  个tokens\n",
      "higher than anticipated rate of increased post-void residual in subjects who received botulinum toxin a injection    有  20  个tokens\n",
      "high incidence of ttp, poor recrual    有  10  个tokens\n",
      "interim analysis showed more lcfs in one of the treatment arms    有  13  个tokens\n",
      "company restructured and protocol restructured. resubmitted with ide approval under new company name-exalenz    有  21  个tokens\n",
      "difficult to achieve the sufficient subjects    有  7  个tokens\n",
      "major difficulties in training investigators in other centers    有  8  个tokens\n",
      "protocol revisions were deemed unable to be completed by 8/2007    有  14  个tokens\n",
      "as specified in the protocol    有  5  个tokens\n",
      "combination formulation concerns    有  3  个tokens\n",
      "the study was not completed as planned and was terminated early with agreement from the european medicines agency (emea)    有  22  个tokens\n",
      "the rate of cure in both arms was higher than expected    有  11  个tokens\n",
      "study pulled due to a grant disagreement between the u of m and smdc    有  15  个tokens\n",
      "similar large study planned by nhlbi    有  8  个tokens\n",
      "the sponsor felt enough information was available for the exploratory assessment of the effect of treatment with fbt on pain anxiety    有  23  个tokens\n",
      "interim data indicated that subjects exhibited no meaningful allergic disease during the first ragweed season, making it impossible to measure treatment effect    有  25  个tokens\n",
      "sponsor voluntarily terminated study    有  4  个tokens\n",
      "pi moved to a new facility    有  6  个tokens\n",
      "inadequate retention of ghd adults to maintain power to study the effect of gh on fibrinolysis. a comparison between ghd adults and controls was completed    有  33  个tokens\n",
      "study was never able to start in iran    有  9  个tokens\n",
      "impossibility to accomplish the sample size in assigned time    有  11  个tokens\n",
      "one of the instruments in the study was withdrawn from the market before the calculated number of persons were included    有  20  个tokens\n",
      "investigator resigned    有  3  个tokens\n",
      "shortage of experienced health care personnel after reorganisation of units    有  12  个tokens\n",
      "termination date was 20-oct-2008. subjects were monitored during the post treatment 90 day folpoor-up period (per protocol) resulting in lplv 19-jan-2009    有  42  个tokens\n",
      "an interim analysis revealed a significantly higher persistence/recurrence of complications of portal hypertension in the 8 mm-stent group    有  23  个tokens\n",
      "the study was terminated after the emea recommended to suspend the marketing authorisation of raptiva in the eu    有  22  个tokens\n",
      "not feasible, did not have the study population    有  9  个tokens\n",
      "drug-related harm    有  3  个tokens\n",
      "the results of a same study design have shown poor response with important side effects. accordingly & ethicly, the study has been stopped    有  26  个tokens\n",
      "change in referral pattern changed the population we were studying    有  10  个tokens\n",
      "emea recommendation to suspend acomplia marketing authorisation    有  12  个tokens\n",
      "it has come to our attention that the site was not necessary for our research project    有  16  个tokens\n",
      "terminated due to the change of supplier and sponsor    有  9  个tokens\n",
      "reports indicating that increased folic acid intake may increase colin cancer    有  13  个tokens\n",
      "mtd not determined    有  4  个tokens\n",
      "imbalance of gastrointestinal and the lipase events    有  9  个tokens\n",
      "grant was not renewed    有  4  个tokens\n",
      "insufficient cell mobilization for tandem transplants    有  9  个tokens\n",
      "sponsor elected to not pursue this indication for the study device    有  11  个tokens\n",
      "different study was designed    有  4  个tokens\n",
      "aoi pharma terminated the license agreement. ind transferred to nci    有  14  个tokens\n",
      "senior management decision    有  4  个tokens\n",
      "a planned interim analysis was performed after approx. 240 subjects completed the trial. the study was stopped, as permitted by protocol, after the analysis    有  29  个tokens\n",
      "study dar-312 did not meet its primary co-endpoints    有  12  个tokens\n",
      "withdrawn because protocol has been discontinued. it was never opened    有  12  个tokens\n",
      "lucentis, a treatment superior to pdt, has become available i sweden    有  16  个tokens\n",
      "preliminary results did not support the utility of combining selegeline + nrt    有  17  个tokens\n",
      "voluntarily by sponsor to investigate an anticipated sae    有  11  个tokens\n",
      "determined not to be human subject reseach    有  10  个tokens\n",
      "trial suspended on 26 february, folpooring the publication of a trial with negative results (ann intern med 146(4), 2007). pending ethics committee re-approval    有  38  个tokens\n",
      "insufficient institutional support    有  4  个tokens\n",
      "protocol approval expired    有  3  个tokens\n",
      "terminated because preliminary data suggested no difference in the strategies    有  10  个tokens\n",
      "data from the c08 study and avant study    有  9  个tokens\n",
      "this project will resume upon the completion of other research committments    有  13  个tokens\n",
      "pharmacy temporarily suspended by fda    有  7  个tokens\n",
      "blinded interim analysis resulted in early termination of the study    有  11  个tokens\n",
      "principle investigator moved, new investigators will join, insurance expired - project needs to be re-examined by an ethic committee    有  25  个tokens\n",
      "was replaced by an other study    有  6  个tokens\n",
      "pi decided to terminate the study at this time    有  9  个tokens\n",
      "logistic difficulties    有  3  个tokens\n",
      "from the interim analysis resulted that more than 1000 patients were required to demonstrate a significant difference between the 2 treatments    有  24  个tokens\n",
      "lapse in irb review    有  6  个tokens\n",
      "classified by the irb as non human subjects research    有  10  个tokens\n",
      "poor vaccine supplies    有  4  个tokens\n",
      "the buccal arm of the study was 30% less effective in stopping seizures within 10 minutes compared with the iv dose. this met a stopping rule for the study    有  35  个tokens\n",
      "fda concerns regarding avandamet    有  8  个tokens\n",
      "increased risk of pml associated with raptiva in other studies    有  14  个tokens\n",
      "potential subjects did not meet eligibility criteria    有  7  个tokens\n",
      "protocol changes underway. trial never started    有  7  个tokens\n",
      "study moved to british columbia    有  6  个tokens\n",
      "protocol closed based on new (and as yet unpublished) information from a phase ii clinical trial    有  18  个tokens\n",
      "stopping rule-acute rejection threshold-was met based on local biopsy results    有  15  个tokens\n",
      "terminated due to suboptimal dosing schedule    有  9  个tokens\n",
      "information was entered by mistake by a research assistant. study never went beyond the initial discussion phase    有  18  个tokens\n",
      "the study was terminated due to difficulties with finding sites and subjects willing to participate    有  15  个tokens\n",
      "terminated early due to regulatory action suspending tegaserod use in 2007    有  16  个tokens\n",
      "change the sample size due to smaller variance than expected    有  10  个tokens\n",
      "study published november 2010 and no further work will be done    有  13  个tokens\n",
      "lead was recalled and manufacturing halted    有  6  个tokens\n",
      "insufficient clinical activity    有  4  个tokens\n",
      "study size reached    有  3  个tokens\n",
      "study was never started due to regional geopolitical conflict    有  9  个tokens\n",
      "sufficient data collected for significant conclusion    有  7  个tokens\n",
      "unable to gather sufficient data    有  5  个tokens\n",
      "personnel shortage    有  3  个tokens\n",
      "please see \"purpose\" statement    有  6  个tokens\n",
      "please see brief summary for termination reason    有  7  个tokens\n",
      "trial was rewritten and will no longer focus on the link between smoking and depression    有  15  个tokens\n",
      "study withdrawn for financial problems. we didnwt get a grant we needed for purchesing the medication for the study    有  23  个tokens\n",
      "study was a f32 felpoorship. trial was proposed however principle investigator does not believe trial took place    有  22  个tokens\n",
      "withdrawn due to inability to reach an acceptable agreement with industry sponsor    有  13  个tokens\n",
      "handylab device did not work for the science    有  10  个tokens\n",
      "unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day    有  18  个tokens\n",
      "handylab device determined to not work for the science    有  11  个tokens\n",
      "subject registration did not proceed as expected; difficult to complete within scheduled time frame; prematurely terminated w/ 21 subjects randomized    有  24  个tokens\n",
      "scientific data called into question the viability of the substance class    有  11  个tokens\n",
      "dr. milla has left university of minnesota. the study is no longer being conducted at this site    有  21  个tokens\n",
      "end of research time, time-resources    有  7  个tokens\n",
      "the intervention could not be successfully carried out in the sadp setting because of issues independent of the cognitive training intervention    有  22  个tokens\n",
      "prematurely terminated due to loss of interest    有  10  个tokens\n",
      "inadequate resources to submit for approval    有  8  个tokens\n",
      "more advanced treatments superceded study design    有  8  个tokens\n",
      "limitted financial resources    有  4  个tokens\n",
      "infusion reactions during re-induction cycles after a period of no treatment. please see \"purpose\" section    有  21  个tokens\n",
      "limited number of subjects    有  4  个tokens\n",
      "could not resolve technical difficulties    有  5  个tokens\n",
      "due to positive preliminary results from other palifermin studies    有  11  个tokens\n",
      "sp arms were stopped due to high levels of treatment failure.cd not available    有  14  个tokens\n",
      "company withdrawal of the drug    有  5  个tokens\n",
      "research never begun    有  3  个tokens\n",
      "no recommended phase ii dose was determined    有  7  个tokens\n",
      "the study was incorporated in another study    有  7  个tokens\n",
      "due to fda comments, protocol changed; new trial will be proposed shortly    有  15  个tokens\n",
      "difficulty obtaining required data    有  4  个tokens\n",
      "new regulatories of the peptides by the pharmaceutical company (the seller)    有  14  个tokens\n",
      "not appropriate to carry on the study    有  7  个tokens\n",
      "we wish to wait until there is more data available using this substance    有  13  个tokens\n",
      "the stopping rule was applied because of poor response rates    有  10  个tokens\n",
      "unable to replace felpoor conducting the study who left institution in 2007    有  16  个tokens\n",
      "withdrawn due to contractual issues    有  6  个tokens\n",
      "withdrawn because of insufficient financial capacities    有  7  个tokens\n",
      "preliminary data showed no survival benefit in the gv1001 group compared to the gemcitabine group    有  22  个tokens\n",
      "large sample size and change in orthopaedic practice to use of ccpm in conjunction with clinical monitoring rendered project less timely    有  24  个tokens\n",
      "design problem    有  2  个tokens\n",
      "pma withdrawn    有  3  个tokens\n",
      "did not meet the criteria for continuation to second stage    有  10  个tokens\n",
      "terminated due to a patent legal settlement    有  7  个tokens\n",
      "this study should be terminated as the study has been closed for years and the investigator has since retired. no records are available. thank you, marlene    有  30  个tokens\n",
      "pi decided to use another product    有  6  个tokens\n",
      "after interim analysis it was determined that the risks were too great in comparision to the results    有  18  个tokens\n",
      "results of the interim analysis suggested no significant diff between study groups    有  12  个tokens\n",
      "technical conflicts    有  2  个tokens\n",
      "new studies were finding that erbitux was not beneficial    有  11  个tokens\n",
      "study dar-312 did not meet primary co-endpoints    有  11  个tokens\n",
      "rate of cure was higher than expected, irb suspended for no additional benefit    有  15  个tokens\n",
      "competing study was started    有  5  个tokens\n",
      "stopped by the dsmb for poor effect per interim stopping rule    有  12  个tokens\n",
      "study closed folpooring phase i portion, insufficient activity to continue to phase ii    有  16  个tokens\n",
      "the fda changed the labeling for this agent, and we felt we could not offer it to patients on a non-surgical study    有  26  个tokens\n",
      "on the basis of published results of smart study, it has been observed that the results are worse in patients who have interrupted their treatments    有  26  个tokens\n",
      "irb terminated study due to non compliance with continuing review date    有  12  个tokens\n",
      "both sponsor and ucsf decided this study was not clinical relevant at this time    有  16  个tokens\n",
      "the maintenance doses were too poor to maintain testosterone suppression    有  10  个tokens\n",
      "expiration of study supply    有  4  个tokens\n",
      "too frequent grade 3-4 toxicities    有  9  个tokens\n",
      "per the division of project management, office of regulatory operations, office of generic drugs, fda there is no regulatory requirement to continue this registry    有  28  个tokens\n",
      "interim analysis showed the primary outcome was not reached    有  10  个tokens\n",
      "sub-investigator reloacted to another institution    有  10  个tokens\n",
      "stopped due to concerns about interaction between st. john's wort and tamoxifen    有  17  个tokens\n",
      "company withdrew drug supply    有  4  个tokens\n",
      "study protocol amended to a new treatment regimen: study davfu-006    有  14  个tokens\n",
      "consenting participants entered tenofovir/emtricitabine oral prophylaxis trial    有  18  个tokens\n",
      "per recommendation of the nhlbi dsmb    有  9  个tokens\n",
      "expiration of medi-507    有  5  个tokens\n",
      "ethical issues of continuing control group without treatment    有  8  个tokens\n",
      "the unpromising experience of the french group with topotecan given at a dosage of 0.4 mg/m2/day over 30 mins w/in 1 hr of radiation (cancer 2005; 104: 2792)    有  51  个tokens\n",
      "due to the meta-analysis about cv adverse effects of rosiglitazone    有  15  个tokens\n",
      "protocol expired. terminated by irb    有  7  个tokens\n",
      "premature closure as study drug is no longer available from the manufacturer    有  14  个tokens\n",
      "due to limited resources available to conduct study    有  8  个tokens\n",
      "could not be completed due to technology problems and cost constraints    有  11  个tokens\n",
      "terminated by irb for non-compliance with human subject regulations    有  12  个tokens\n",
      "positive results from a larger study with same regimen was released    有  11  个tokens\n",
      "dsmb recommended termination due to poorer survival to discharge in primary population and worse discharge cpc scores in the treatment arm than control arm    有  26  个tokens\n",
      "this study of the overall grant was not pursued as the aims were changed    有  14  个tokens\n",
      "sponsor discontinues support    有  4  个tokens\n",
      "sample size is too small to draw a conclusion    有  9  个tokens\n",
      "study terminated by sponsor (29 sep 2010). subjects eligible to continue mepolizumab treatment were transferred into the compassionate use program (mhe104317)    有  35  个tokens\n",
      "it was unlikely that the primary endpoint would be reached based on the fifth interim analysis results    有  17  个tokens\n",
      "poor probability of positive outcome    有  6  个tokens\n",
      "informed by manufacturer that cdb-2914 crosses blood-brain barrier invalidating arm #3 of protocol    有  22  个tokens\n",
      "the risk-benefit ratio for the use of onercept in this condition was not sufficiently favorable to justify continued development    有  23  个tokens\n",
      "ind was terminated for being inactive for more than five years    有  11  个tokens\n",
      "the dsmb concluded that the findings regarding the primary analysis would persist and that no additional study goals would be achieved by continuing the study    有  26  个tokens\n",
      "no longer studying this disease site    有  6  个tokens\n",
      "identical study biomed 777-clp-029 did not meet superiority endpoint    有  16  个tokens\n",
      "ctep initiated action    有  4  个tokens\n",
      "trial stopped june 2007    有  7  个tokens\n",
      "withdrawn as study never opened    有  6  个tokens\n",
      "the hypothesis that probiotics would reduce hepatic steatosis in humans was not supported    有  17  个tokens\n",
      "terminated due to corporate transaction    有  5  个tokens\n",
      "closed due to early stopping rule    有  6  个tokens\n",
      "study terminated per recommendation of data review team    有  8  个tokens\n",
      "dmc recommended stop    有  4  个tokens\n",
      "phase i/ii study that did not progress to phase ii    有  12  个tokens\n",
      "because of the poor probability of achieving the primary endpoint    有  10  个tokens\n",
      "due to the recent meta-analysis about cv adverse effects    有  10  个tokens\n",
      "folpooring dsmb recommandation    有  7  个tokens\n",
      "this study was prematurely discontinued because no improvement was observed in the 800mg dose compared to 400mg dose    有  22  个tokens\n",
      "irb terminated due to no continuation request    有  8  个tokens\n",
      "the study was terminated because of poor resources to complete it    有  11  个tokens\n",
      "unable to determine the optimum tolerated dose    有  7  个tokens\n",
      "the number of actual events was extremely poor. we extended the study period, but it was still not enough. also, many patients were loss of folpoor up    有  33  个tokens\n",
      "study has been completed    有  4  个tokens\n",
      "close-out of the grant - study ceased on 1/1/2010    有  16  个tokens\n",
      "this was not a clinical trial    有  6  个tokens\n",
      "availability of investigational agent    有  5  个tokens\n",
      "due to the principal investigator having left the institution    有  9  个tokens\n",
      "terminated at request of sponsor    有  5  个tokens\n",
      "dr. hladky died sept 2006 prior to study completion    有  14  个tokens\n",
      "to high rejection rate in csa withdrawal arm    有  9  个tokens\n",
      "pi (prof. slavin) not longer work at hadassah    有  14  个tokens\n",
      "non significative preliminary data    有  5  个tokens\n",
      "insurance coverage reached    有  3  个tokens\n",
      "there is no possibility to reach the target patient number within the set time frame    有  15  个tokens\n",
      "due to failure to control sufficient patients in the active arm, this study has now been closed    有  18  个tokens\n",
      "poor enrolement    有  5  个tokens\n",
      "other trials show no survival benefit of bexarotene with platinum-based chemo    有  17  个tokens\n",
      "sponsor decided to terminate the study early so they could begin a second dose-escalation study of egen-001 in combination with standard chemotherapy    有  28  个tokens\n",
      "aims of the study re-evaluated, did not justify allocation of resources    有  15  个tokens\n",
      "no documentation with mhra to support clinical trial of a medicinal product    有  13  个tokens\n",
      "change in clinical practice alpooring chronic therapy at 6 weeks of age, incompatible with possibility of placebo beyond 6 weeks of age on study protocol    有  30  个tokens\n",
      "per data monitoring committee recommendation    有  5  个tokens\n",
      "poor compliance with the therapy and lot of patients were lost to folpoor up    有  17  个tokens\n",
      "a cluster of deaths in the bcg-arm compared with controls    有  12  个tokens\n",
      "no change in primary endpoint at week 48    有  9  个tokens\n",
      "pk results suggested product did not meet requirement for further development    有  11  个tokens\n",
      "based on pk data, product did not meet requirement for further development    有  13  个tokens\n",
      "drug now on market    有  4  个tokens\n",
      "pi moved to oregon    有  5  个tokens\n",
      "company shifted focus    有  3  个tokens\n",
      "new sponsor, other treatments available    有  6  个tokens\n",
      "study no longer at pittsburgh    有  7  个tokens\n",
      "after initiation of study many studies reported an equivalence of snb and alnd which led to widespread adoption of the former as standard procedure    有  26  个tokens\n",
      "unplanned interim analysis by dsmb indicated possible reduced response rate with the addition of ca/mg in pooled population. further analysis pending    有  27  个tokens\n",
      "treatment with chrysalin did not demonstrate benefit compared to placebo    有  14  个tokens\n",
      "did not apply for ethics renewal    有  6  个tokens\n",
      "end of promotion by the sponsor    有  6  个tokens\n",
      "varience of supply chain from that required by protocol    有  10  个tokens\n",
      "the trial was discontinued early due to no confirmed partial responses    有  11  个tokens\n",
      "study was never activated at fox chase cancer center    有  9  个tokens\n",
      "no clinical significant    有  3  个tokens\n",
      "concerns regarding neonatal data    有  7  个tokens\n",
      "the pharmaceutical company discontinued further development of su5416    有  10  个tokens\n",
      "genitope suspend drug development by decision made by the fda march 6, 2008    有  20  个tokens\n",
      "withdrawn due to change in standard of care - new protocol required    有  13  个tokens\n",
      "trial completed prematurely    有  3  个tokens\n",
      "change in corporate priorities    有  4  个tokens\n",
      "medarex (supplier of bsab) stopped study due to toxicities experienced at other sites on unrelated trials halting manufacturing of bsab    有  28  个tokens\n",
      "teminated by the dsmb because there are no differences between the control group and the vapreotide group    有  21  个tokens\n",
      "this is not a clinical trial and was inadvertently entered into ct.gov    有  13  个tokens\n",
      "preliminary results showed increased intraventricular hemorrhage (ivh) in experimental arm    有  19  个tokens\n",
      "withdrawn because treatment guidelines changed    有  6  个tokens\n",
      "cancer therapy evaluation program's (ctep's) termination of drug supply    有  15  个tokens\n",
      "study not activated    有  3  个tokens\n",
      "inadequate eligible subjects to expect sufficient numbers to analyse outcomes    有  12  个tokens\n",
      "effective august 13, 2004: unanticipated high incidence of post-transplant lymphoproliferative disorder    有  23  个tokens\n",
      "withdrawn prior to initiation    有  5  个tokens\n",
      "principle investigator has left the university    有  7  个tokens\n",
      "due to technical and logistical constraints and a change in the study team's focus of research    有  17  个tokens\n",
      "there is another active nhlbi protocol for the collection of stem cells for research from healthy volunteers and no need for this separate protocol    有  26  个tokens\n",
      "study drug became commercially available    有  5  个tokens\n",
      "study terminated as principal investigator [pi] left the university    有  11  个tokens\n",
      "this study was terminated early by genzyme because there were insufficient data to support clinical benefit to hcc patients on the study    有  25  个tokens\n",
      "dsmb recommended closing the study and publishing the results    有  10  个tokens\n",
      "original p.i. left the institution    有  7  个tokens\n",
      "pairing d-cycloserine with clozapine was found to worsen negative side effects in patients with schizophrenia, so the study was suspended    有  29  个tokens\n",
      "record is an acrn grant summary & not reflective of an individual trial. all acts conducted by acrn were individually registered on the prs    有  28  个tokens\n",
      "as of 4/23/97    有  8  个tokens\n",
      "terminated because of poor drug supply    有  6  个tokens\n",
      "protocol has not been used for many years and has outlived it utility    有  15  个tokens\n",
      "closed at the request of the irbo    有  8  个tokens\n",
      "terminated at the direction of the nih irbo    有  10  个tokens\n",
      "interim analysis indicated study should be terminated    有  8  个tokens\n",
      "results showed statistically significant benefit in the experimental group    有  9  个tokens\n",
      "the p.i deceased    有  4  个tokens\n",
      "at this time it is felt that we will not gain further information from an additional patients    有  17  个tokens\n",
      "poor fda approval    有  5  个tokens\n",
      "trial is life long folpoor-up: to reduce ressources and costs - trial terminated prematurely    有  19  个tokens\n",
      "withdrawn because ablatherm devices were not available anymore at trial centers    有  14  个tokens\n",
      "terminated due to the poor conditional power for a positive study    有  11  个tokens\n",
      "unable to accrue subjects in a timely fashion    有  9  个tokens\n",
      "drug was pulled from the market    有  6  个tokens\n",
      "never received final irb approval for amendments, so never opened officially    有  13  个tokens\n",
      "unavailability of study drug    有  5  个tokens\n",
      "vaccine unavailable    有  3  个tokens\n",
      "study stopped due to increased cardiovascular risks associated with celebrex    有  12  个tokens\n",
      "ci left institution    有  3  个tokens\n",
      "discontinued development of g3139 (oblimersen)    有  12  个tokens\n",
      "trial was withdrawn for drug availability issues    有  7  个tokens\n",
      "eortc trail showed tmz & rt conferred significant survivial in this population    有  16  个tokens\n",
      "data submitted for food and drug administration (fda) approval    有  12  个tokens\n",
      "the study is not a clinical trial    有  7  个tokens\n",
      "closed due to competing protocols    有  5  个tokens\n",
      "drug issues    有  2  个tokens\n",
      "closed due to poor availability of vaccine    有  7  个tokens\n",
      "sponsor discontinued providing study drug    有  5  个tokens\n",
      "drug company withdrawal of support for investigational agent in this indication    有  12  个tokens\n",
      "premature closure due to inability to accrue to arm ivd, cohorts 1 and 2    有  21  个tokens\n",
      "unable to identify qualified subjects willing to participate in this study    有  11  个tokens\n",
      "test drug showed poor benefit at interim analysis    有  8  个tokens\n",
      "program discontinued based on gipf-007 results    有  10  个tokens\n",
      "interim analysis, infliximab did not reduce number of first relapses in gca or cumulative glucocorticosteroid dosage    有  27  个tokens\n",
      "protocol development and amended protocol revision    有  6  个tokens\n",
      "concluded - terminated by pi    有  6  个tokens\n",
      "study terminated/withdrawn    有  5  个tokens\n",
      "study closed by the nci    有  6  个tokens\n",
      "drug sold to sanofi-aventis who sold it to gsk; obs no longer owns study and does not have data    有  26  个tokens\n",
      "did not meet interim stopping criteria for continuation to the second stage    有  12  个tokens\n",
      "record created in error - not a research study    有  9  个tokens\n",
      "unlikely to provide evidence of significant effect    有  7  个tokens\n",
      "study was not activated at fox chase cancer center    有  9  个tokens\n",
      "redirection of company goals    有  5  个tokens\n",
      "scientific director request to use resources for other studies    有  9  个tokens\n",
      "closed due to poor drug availability    有  6  个tokens\n",
      "interim data analysis showed no effect between treatment groups    有  10  个tokens\n",
      "principal investigator [pi] has left institution    有  8  个tokens\n",
      "study closed by sponser    有  6  个tokens\n",
      "study design changes were needed based on gipf-001 results    有  13  个tokens\n",
      "prematurely discontinued after results of the eortc phase-3 study defined the soc for newly diagnosed gmb pts as rt plus concomitant and adjuvant tmz    有  37  个tokens\n",
      "withdrawal of pharmaceutical company support for the investigational drug    有  11  个tokens\n",
      "cdc's decision to down-select vaccine development to single candidate, acam2000    有  16  个tokens\n",
      "not opened at fox chase cancer center    有  7  个tokens\n",
      "placebo was better than active drug    有  7  个tokens\n",
      "unable to accrue subjects to the study after 2 years - closed per request by data monitoring committee    有  20  个tokens\n",
      "closed by the research committee    有  5  个tokens\n",
      "short of supply of fibrin glue    有  7  个tokens\n",
      "we can't obtained the test drug (vadenafil) from bayer. they decided not to carry out this trail in taiwan. therefore this trail has never been started    有  35  个tokens\n",
      "part ii was not performed as we could not include enough patients fulfilling the inclusion criteria    有  16  个tokens\n",
      "no invited participants agreed to undertake the proposed intervention    有  9  个tokens\n",
      "inconclusive results, market feasiblity    有  10  个tokens\n",
      "interim analysis results did not meet criteria for second stage of trial    有  13  个tokens\n",
      "the results from the interim analysis were not favorable to continue this trial    有  13  个tokens\n",
      "full clinical hold    有  3  个tokens\n",
      "this study was withdrawn (see nct00181753)    有  12  个tokens\n",
      "roche decided to prematurely terminate study    有  7  个tokens\n",
      "issue of priority of resources    有  5  个tokens\n",
      "in ability to obtain indian governmental approval from the study from naco    有  13  个tokens\n",
      "blood drawing protocol for ruh/adarc. adarc ceasing operations at ruh    有  17  个tokens\n",
      "concerns related to availability of drug product    有  9  个tokens\n",
      "interim analysis showed significant differences between two treatment groups    有  10  个tokens\n",
      "pi move    有  2  个tokens\n",
      "project canceled due to the implementation of imrt, fewer patients reporting xerostomia    有  18  个tokens\n",
      "competitor study about to start    有  6  个tokens\n",
      "the results were not able to be consistantly reproduced. thus the trial was terminated    有  16  个tokens\n",
      "was terminated due to meeting a priori stopping rule set by dsmb    有  14  个tokens\n",
      "due to published data on rosiglitazone    有  10  个tokens\n",
      "investigators left joslin    有  5  个tokens\n",
      "the doses were not effective in maintaining testosterone suppression    有  9  个tokens\n",
      "on of the liners has been taken from the market    有  10  个tokens\n",
      "interim analysis showed significant results, thus study was stopped    有  11  个tokens\n",
      "due to strong side effect    有  5  个tokens\n",
      "no measurable response was detected at the 50% increase threshold    有  12  个tokens\n",
      "primary study outcome achieved; investigator decided to conduct the study without sponsor support after 2009    有  18  个tokens\n",
      "the study was terminated at the point the primary endpoint and early milestones were reached and because long term outcomes were available from other sources    有  25  个tokens\n",
      "the final assessments were conducted late and in a reduced format due to resource limitations at the site    有  18  个tokens\n",
      "study closed after the 5 year end-point was reached after a review of the status further to a request from the investigators to discontinue participation    有  28  个tokens\n",
      "depuy discontinued this product in 2013, the clinical program was reviewed and this study was closed    有  20  个tokens\n",
      "principal investigator peter johnstone, md relocated to another institution    有  11  个tokens\n",
      "difficulty with technical aspect of fmri, resources to complete the study ran out    有  15  个tokens\n",
      "unfortunately, other phase iii clinical study (gem+s-1 vs gem vs s-1) have been started in japan. h    有  27  个tokens\n",
      "the study has concluded normally;    有  6  个tokens\n",
      "registration is less    有  3  个tokens\n",
      "after ielsg25a study amendment, patients subject of the present study were eligible for inclusion in the ielsg25a study    有  27  个tokens\n",
      "limited budget to continue this study    有  6  个tokens\n",
      "we obtained the final results due to the interim analysis    有  10  个tokens\n",
      "study nct01656603 supersedes this study; fda ind 6637    有  18  个tokens\n",
      "pending more information from pi    有  5  个tokens\n",
      "dyspnea    有  4  个tokens\n",
      "end of the folpoor-up period    有  8  个tokens\n",
      "study design was changed and is now insite trial #1634 - see nct00547378    有  20  个tokens\n",
      "pi returned to india    有  4  个tokens\n",
      "alternate study projected to assess imaging endpoints versus clinical endpoints    有  10  个tokens\n",
      "poor data collection    有  4  个tokens\n",
      "structural changes that stopped the type of operations used in the study    有  12  个tokens\n",
      "sponsor discontinued the study folpooring the discovery of a number of incompletely sealed batches that were unusable    有  21  个tokens\n",
      "competing study at site    有  5  个tokens\n",
      "notification from sponsor    有  3  个tokens\n",
      "astrazeneca announced it has decided to stop the crestor jupiter clinical study early based on a recommendation from an independent data monitoring board and the jupiter steering committee, which met on march 29, 2008. the study will be stopped early because there is unequivocal evidence of a reduction in cardiovascular morbidity and mortality amongst patients who received crestor when compared to placebo    有  76  个tokens\n",
      "study team decision-impact(s) of change in hokt3γ1 (ala-ala) manufacturer during study    有  24  个tokens\n",
      "experimental procedure did not induce sufficient craving to determine any possible effect of medication    有  14  个tokens\n",
      "higher incidence of cardiovascular events in the testosterone arm of the trial. decision taken by the dsmb on december 31st, 2009    有  28  个tokens\n",
      "could not find subject population    有  5  个tokens\n",
      "the response rate observed in the phase 1 portion of the study did not merit further evaluation in phase 2 portion of the study    有  26  个tokens\n",
      "drug no longer available in canada    有  6  个tokens\n",
      "due to a poor a referal base, study was terminated    有  12  个tokens\n",
      "the trial could not get permit from department of health, taiwan; furthermore, no research fund could support the expensive (photosensitizer) photosan    有  30  个tokens\n",
      "the study chair changed his employment, the realization of the study was not possible    有  15  个tokens\n",
      "study was discontinued because of high drop out rate    有  9  个tokens\n",
      "the fda has approved kuvan (bh4) as a therapeutic agent for phenylketonuria    有  22  个tokens\n",
      "investigator has left institution    有  5  个tokens\n",
      "study was stopped after pre-definied interim analysis because of no effects    有  14  个tokens\n",
      "recrutment    有  3  个tokens\n",
      "drug availability issues    有  3  个tokens\n",
      "study never activated    有  3  个tokens\n",
      "study terminated due to no apparent benefit    有  7  个tokens\n",
      "mutual agreement between sponsor and investigator    有  7  个tokens\n",
      "study prematurely terminated due to randomization imbalance    有  8  个tokens\n",
      "swog has decided to not pursue this trial    有  9  个tokens\n",
      "study poor to accrue    有  5  个tokens\n",
      "insufficent enrolement    有  7  个tokens\n",
      "national study, local site not responsible for any analysis/results/etc    有  12  个tokens\n",
      "national study, local site not responsible for results/analysis    有  11  个tokens\n",
      "insufficient numbers of eligible patients as laparscopic surgery increased and open surgery decreased    有  17  个tokens\n",
      "limited viral load reduction in hcv subjects    有  8  个tokens\n",
      "there were technical difficulties and the study was terminated in 2008    有  13  个tokens\n",
      "sufficient data was collected    有  5  个tokens\n",
      "sufficient data gathered to support hypothesis    有  7  个tokens\n",
      "sufficient data gathered for study conclusion    有  7  个tokens\n",
      "after 90 charts reviewed, insufficient data to support conclusion    有  11  个tokens\n",
      "sufficient data    有  3  个tokens\n",
      "adverse findings from nonclinical carcinogenicity studies    有  10  个tokens\n",
      "the study was terminated prior to completion to focus on the development of a controlled release formulation    有  17  个tokens\n",
      "terminated after interim analysis    有  4  个tokens\n",
      "end point reached at interim analysis    有  6  个tokens\n",
      "poor a accrul due to many competitive trials    有  10  个tokens\n",
      "inability to attain sufficient numbers of subjects    有  8  个tokens\n",
      "limited clinical staff    有  3  个tokens\n",
      "observational study should not be in ct.gov    有  9  个tokens\n",
      "treatment with thymic shielding found safe, another study started    有  13  个tokens\n",
      "personelle changes mandated suspension    有  5  个tokens\n",
      "closed due to achievement of primary study endpoint    有  8  个tokens\n",
      "trial stopped on sept 24, 2007    有  10  个tokens\n",
      "no financing possible    有  3  个tokens\n",
      "transitioned into a national study through ecog    有  9  个tokens\n",
      "study was suspended because of difficluty maintaining equipment    有  10  个tokens\n",
      "sufficient data collected for significant conclusive results    有  8  个tokens\n",
      "principal investigator has left the umdnj    有  8  个tokens\n",
      "principal investigator is leaving the umdnj    有  8  个tokens\n",
      "replaced by a different study    有  6  个tokens\n",
      "replaced by another study ; trial re-written as mt2015-29    有  15  个tokens\n",
      "irb approval has lapsed    有  6  个tokens\n",
      "roche has withdrawn support    有  5  个tokens\n",
      "study is complete analysis is complete    有  6  个tokens\n",
      "study is completed and analysis completed    有  6  个tokens\n",
      "unable to renegotiate an expired contract w/sponsor providing study med    有  13  个tokens\n",
      "not a clinical trial; human specimens from treatment site for basic research    有  13  个tokens\n",
      "we determined that the results would not be worth reporting    有  10  个tokens\n",
      "for financial and logistical reasons    有  5  个tokens\n",
      "preliminary analyses did not reveal significant associations    有  9  个tokens\n",
      "poor study personel    有  5  个tokens\n",
      "resident graduated; faculty mentor retired    有  6  个tokens\n",
      "regulatory decision not to proceed    有  6  个tokens\n",
      "protocol pre-specified interim analysis showed that difference between groups was too small to reach significance    有  17  个tokens\n",
      "due to existing evidence eligible patients receive crt treatment in first place    有  12  个tokens\n",
      "the study stopped due to marketing approval by the fda    有  11  个tokens\n",
      "lead research left the institute    有  5  个tokens\n",
      "problems with fmiso supply    有  5  个tokens\n",
      "due to continuing review    有  4  个tokens\n",
      "problems with including patients and a large multicenter trial is now starting as folpoor-up    有  18  个tokens\n",
      "active duty principle investigator currently deployed    有  6  个tokens\n",
      "the predecessor study a00309 (nct00152464) did not show statistical significance in time to onset of asthma between the levocetirizine and placebo groups    有  35  个tokens\n",
      "results did not show intervention was beneficial    有  7  个tokens\n",
      "sponsor decided not to continue with the development program    有  9  个tokens\n",
      "pi is no longer work at hadassah    有  9  个tokens\n",
      "terminated by irb for continuing review    有  7  个tokens\n",
      "poor acurral    有  5  个tokens\n",
      "we were unable to receive ivig free from phamaceutical company    有  13  个tokens\n",
      "drs okunieff and odell have left the university of rochester    有  15  个tokens\n",
      "study did not start due to investigator time constraints    有  9  个tokens\n",
      "no data. study never completed    有  6  个tokens\n",
      "may 2007: no annual renewal    有  8  个tokens\n",
      "date: august 2006. no annual renewal    有  10  个tokens\n",
      "opposite result    有  3  个tokens\n",
      "the study is publiched    有  5  个tokens\n",
      "the study population is smaller than expected. no subjects were included    有  12  个tokens\n",
      "an interim data analysis found no significant difference between testing groups    有  11  个tokens\n",
      "reorganization of personnel forced termination    有  6  个tokens\n",
      "pi health issues    有  3  个tokens\n",
      "the trial was terminated due to investigator's decision    有  9  个tokens\n",
      "expired for poor continuing review    有  5  个tokens\n",
      "difficulties in data collection    有  6  个tokens\n",
      "occurrence of 2 dose-limiting toxicities at the initial dose level (60 mg/m2) in part i    有  24  个tokens\n",
      "the study did not achieve the statistical success to continue    有  10  个tokens\n",
      "more important number of sae in one arms    有  9  个tokens\n",
      "we chose to use an exsisting nmr pulse sequence already established and available at the hospital    有  19  个tokens\n",
      "positive predictive value not related to folpoor up duration    有  11  个tokens\n",
      "no further local interest in pursuing the study    有  8  个tokens\n",
      "no resources - no personnel    有  5  个tokens\n",
      "unknown reason    有  2  个tokens\n",
      "budget exceeded for project    有  4  个tokens\n",
      "intervention was taken up as a standard of care    有  10  个tokens\n",
      "study replaced by an observational study    有  6  个tokens\n",
      "unable to fulfill intention of study, lost investigators    有  9  个tokens\n",
      "clinical partner left university,    有  5  个tokens\n",
      "terminated for logistical reasons    有  4  个tokens\n",
      "no longer interest from medical community    有  6  个tokens\n",
      "poor resources research felpoor left    有  8  个tokens\n",
      "coronary fpoor by echo doppler was obtainable in about 50% of subjects. the study was stopped early because of insufficient sample size to achieve adequate power    有  35  个tokens\n",
      "principal investigator moved institutions    有  4  个tokens\n",
      "study drug could not be re-supplied    有  8  个tokens\n",
      "approval of ethical committee was denied    有  6  个tokens\n",
      "insufficient data quality    有  4  个tokens\n",
      "the actual primary goal - establishment of an approved tissue biobank - was reached. 1000 tissue samples were collected. no motivation at this time for continuation as originally planned    有  35  个tokens\n",
      "efalizumab was withdrawn from market; full 2 years folpoor-up only 14 patients    有  22  个tokens\n",
      "terminated due to financial cut    有  5  个tokens\n",
      "analysis was frustrated by inadequate phd's    有  8  个tokens\n",
      "this study was superseded by the subsequent study irb-15919 (nct01050764)    有  21  个tokens\n",
      "primary investigator moved to different university    有  6  个tokens\n",
      "closed, never started    有  4  个tokens\n",
      "the decision to terminate this study after 202 mg/m2 cohort was taken as mtd achieved in other study at 185 mg/m2    有  28  个tokens\n",
      "th trial got cancelled and no subjects signed informed consent form (icf); study design not appropriate any longer    有  21  个tokens\n",
      "based on independent data monitoring committee (idmc) recommendation    有  11  个tokens\n",
      "decided not pursue the study    有  6  个tokens\n",
      "further evaluation of phase i dosing    有  8  个tokens\n",
      "poor quality data    有  4  个tokens\n",
      "pi change in institution    有  4  个tokens\n",
      "no longer could obtain clenbuterol    有  8  个tokens\n",
      "due to poor folpoor-up information    有  8  个tokens\n",
      "stopped by dsmb due to increased wound infection rate    有  10  个tokens\n",
      "due to a poor ip supply and then terminated because they were combined into one new study with the new ip formulation    有  22  个tokens\n",
      "the study is terminated early due to unavailability of investigational product    有  13  个tokens\n",
      "schering-plough discontinued supplying study drug    有  8  个tokens\n",
      "pi terminated at the recommendation of dsmc & irb    有  12  个tokens\n",
      "implantation rate significantly poorer in treatment group than controls    有  11  个tokens\n",
      "data from msk-impact is sufficient for relevant analyses going forward    有  13  个tokens\n",
      "due to inability to get support for the study    有  9  个tokens\n",
      "published data suggest potential harm in other investigations    有  8  个tokens\n",
      "there is a problem in recruting the paricipents    有  12  个tokens\n",
      "sponsor did not fund the study    有  6  个tokens\n",
      "observed poorer cure rates and higher mortality rates in one of the treatment groups    有  15  个tokens\n",
      "poor reducibility - primary endpoint measure not obtainable    有  12  个tokens\n",
      "study has been withdrawn    有  4  个tokens\n",
      "new clinical finding with celebrex and cardiac concerns    有  10  个tokens\n",
      "study investigator has suddenly died, study has no results    有  10  个tokens\n",
      "pi is leaving the institution, irb will close the protocol    有  12  个tokens\n",
      "not nih defined clinical trial    有  6  个tokens\n",
      "the trial was terminated early because fair/poor cosmesis developed in 7 of 32 women    有  20  个tokens\n",
      "concerns about risk of bronchoscopy procedure in the selected patient population and frequency of saes observed to date    有  23  个tokens\n",
      "see 'limitations and caveats' section    有  8  个tokens\n",
      "study completed per investigator    有  4  个tokens\n",
      "pi passed away unexpectedly    有  4  个tokens\n",
      "poor drug supply for doxercalciferol for this study    有  14  个tokens\n",
      "key study staff left foundation    有  5  个tokens\n",
      "this study put on inactive status due to no identifiable subjects to enter the protocol    有  15  个tokens\n",
      "change in imaging priorities    有  4  个tokens\n",
      "pi chose not to proceed with study    有  7  个tokens\n",
      "study withdrawn due to personnel limitations    有  6  个tokens\n",
      "investigator closed study    有  4  个tokens\n",
      "study withdrawn with intent of persuing larger, multi-site study    有  12  个tokens\n",
      "study stopped due to budget (personnel) limitations    有  10  个tokens\n",
      "it was decided to not proceed with the study at this time    有  12  个tokens\n",
      "suspension of licence for rimonabant by european medicines agency    有  13  个tokens\n",
      "study never got started    有  4  个tokens\n",
      "sequencing completed early    有  4  个tokens\n",
      "12/15/2008 voluntarily placed on inactive status-requested by the pi    有  16  个tokens\n",
      "terminated early due to poor change in primary and secondary outcome measures    有  12  个tokens\n",
      "development of product discontinued    有  4  个tokens\n",
      "principal investigator has transferred to another institution    有  7  个tokens\n",
      "drug expired before was completed    有  5  个tokens\n",
      "anticipated that results would not be conclusive    有  7  个tokens\n",
      "another study was opened    有  4  个tokens\n",
      "insufficient expected benefit risk    有  5  个tokens\n",
      "folpooring the termination of development and commercialization agreement for s-1 with taiho pharmaceutical    有  19  个tokens\n",
      "drug side effects leading to premature stop    有  7  个tokens\n",
      "the study was prematurely interrupted because patients randomized to cpap reached the endpoint quicker than anticipated in the protocol    有  20  个tokens\n",
      "higher drop out than expected. poorer statistical power    有  9  个tokens\n",
      "poor personnel to complete trial    有  6  个tokens\n",
      "company could not supply the accommodating intraocular lenses for the study    有  12  个tokens\n",
      "mutual agreement between fda closed the 522 postmarket surveillance registry    有  14  个tokens\n",
      "major planned changes to study design    有  6  个tokens\n",
      "prototype catheter never delivered    有  5  个tokens\n",
      "study was closed due to logistical issues    有  7  个tokens\n",
      "the study was terminated by the sponsor due to budgetary issues    有  12  个tokens\n",
      "this is not a human subject's study. protocol registered in error. this protocol studied nursing homes as a unit    有  22  个tokens\n",
      "interim analysis indicated that sample size of study patients had to be highly increased to obtain significant outcomes    有  19  个tokens\n",
      "the study was discontinued prematurely due to early stopping rules    有  10  个tokens\n",
      "investigator considered the device with no clinical utility    有  9  个tokens\n",
      "the 001 trial did not show benefit versus placebo    有  10  个tokens\n",
      "published study provided evidence that intervention would provide little effect; study not approved by provider community    有  17  个tokens\n",
      "participant lost to folpoorup    有  7  个tokens\n",
      "donor site material (scarlet red ) came back on the market, therefore new treatements for donor sites was not needed    有  25  个tokens\n",
      "logistic problems with adequately timely organ collection and transport    有  10  个tokens\n",
      "preliminary data was inconclusive to warrant keeping the study open    有  13  个tokens\n",
      "key investigator resigned    有  3  个tokens\n",
      "supply omega-3 fatty acids expired and supplier no longer made same composition    有  14  个tokens\n",
      "toxicities were worse than expected    有  7  个tokens\n",
      "poor tolerability of drug and side effects    有  9  个tokens\n",
      "study not started not an act    有  6  个tokens\n",
      "study changed to a placebo controlled trial of dextromethorphan    有  14  个tokens\n",
      "due to loss of key personnel due to illness and sabbatical of thepi    有  16  个tokens\n",
      "reprioritization of study programs    有  7  个tokens\n",
      "sponsor closed the trial before it began    有  7  个tokens\n",
      "principal investigator resigned position with the university of cincinnati, closing study at this site will reopen study in new position    有  22  个tokens\n",
      "for various reasons    有  3  个tokens\n",
      "could not power primary endpoint due to lost to folpoor-up rate    有  14  个tokens\n",
      "poor response rate, no evidence of pfs or os improved    有  13  个tokens\n",
      "the felpoor conducting the study left the institution in 2009    有  14  个tokens\n",
      "irb suspension    有  3  个tokens\n",
      "change in isolation method    有  4  个tokens\n",
      "italian medicines agency decision    有  5  个tokens\n",
      "pi decision to terminate. no usable data collected    有  9  个tokens\n",
      "we are currently modifying the study    有  6  个tokens\n",
      "due to numerous delays in study start-up process    有  9  个tokens\n",
      "main cooperator finished cooperation    有  5  个tokens\n",
      "study terminated due to fda alert regarding fleet phosphosoda    有  12  个tokens\n",
      "avastin approved for first-in-line treatment    有  9  个tokens\n",
      "it was found that 20g of alcohol daily had no effect on abca1 expression or hdl levels    有  22  个tokens\n",
      "protocol changed and a new study using verapamil in epilepsy will be started in the near future    有  19  个tokens\n",
      "drug not being developed for this indication    有  7  个tokens\n",
      "no subject    有  2  个tokens\n",
      "not moving forward with program    有  5  个tokens\n",
      "illogistical results found in interim evaluation    有  8  个tokens\n",
      "this trial discontinued on 20 jun 2008 because the interim immunogenicity results do not justify these formulations as pandemic vaccine candidates    有  26  个tokens\n",
      "closed by the sponsor/dsmb/irb    有  10  个tokens\n",
      "presumed loss of clinical equipoise between the agents being investigated    有  12  个tokens\n",
      "interim analysis found no difference in lb rate and poorer than expected event rate    有  15  个tokens\n",
      "change of practice pattern. green light laser    有  8  个tokens\n",
      "replaced with ongoing study    有  5  个tokens\n",
      "high drop-out rate leads to the conclusion: not enough data will be available to perform proper analyses of data collected after folpoor-up month 24 visit    有  31  个tokens\n",
      "change of dose regimen (new protocol)    有  8  个tokens\n",
      "new research priorities    有  3  个tokens\n",
      "the marketing authorization for intrinsa was withdrawn    有  9  个tokens\n",
      "expired irb approval    有  4  个tokens\n",
      "not enough participants - only 5 since the study started    有  11  个tokens\n",
      "study terminated due to contamination droxidopa    有  9  个tokens\n",
      "difficulty in finding staff to help with study    有  8  个tokens\n",
      "study ended    有  2  个tokens\n",
      "no improvement obtained in 3 cases. retinal detachment observed in 2 cases    有  16  个tokens\n",
      "the study has recently ended, all information gathred as planed    有  14  个tokens\n",
      "logistic reasons, financial contrastraints    有  7  个tokens\n",
      "poor perceived need for domperidone in this population    有  12  个tokens\n",
      "the introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas    有  20  个tokens\n",
      "continuing review not submitted to irb within 365 days    有  12  个tokens\n",
      "\"tapering doses\" protocol arm was not effective for treatment retention outcome    有  15  个tokens\n",
      "the study was terminated after merck serono had taken the decision not to pursue the development of as900672-enriched in ovulation induction    有  29  个tokens\n",
      "high number of withdrawals, appt. no-shows, or those lost to folpoor-up    有  20  个tokens\n",
      "because the sample volume was completed during three years    有  9  个tokens\n",
      "poor study subjects    有  4  个tokens\n",
      "idmc made a recommendation to stop the trial as the target for continuing to the 2nd phase was not met    有  23  个tokens\n",
      "not progressing as anticipated    有  4  个tokens\n",
      "conflicting interim data    有  4  个tokens\n",
      "atypically high dropout rate    有  6  个tokens\n",
      "it has proved extremely difficult    有  5  个tokens\n",
      "irb has requested additional information regarding ide    有  8  个tokens\n",
      "investigator moved to another institution    有  6  个tokens\n",
      "reevaluation of compound development    有  5  个tokens\n",
      "additional research    有  2  个tokens\n",
      "nitric oxide analyzer not functioning properly    有  7  个tokens\n",
      "irb request    有  3  个tokens\n",
      "bayer healthcare is no supplying the study drug    有  9  个tokens\n",
      "this was a dosing study to determine acceptability. participants found protocol burdensome and so we terminated    有  20  个tokens\n",
      "completion not feasible. there are no results from this trial    有  11  个tokens\n",
      "study redesigned and re-submitted to uams irb under different study title and irb number    有  19  个tokens\n",
      "early indication of an unfavorable risk/benefit ratio    有  9  个tokens\n",
      "stem cell transplant was determined soc for this disease (study is not relevant)    有  15  个tokens\n",
      "the study sponsor canceled the study    有  6  个tokens\n",
      "per coordinator: study was closed and no cadaveric implants were performed    有  14  个tokens\n",
      "higher than expected rate of acute rejection    有  7  个tokens\n",
      "study stopped and data not analyzed    有  6  个tokens\n",
      "technical measurement problems led to unreliable or uninterpretable data    有  11  个tokens\n",
      "date of termination was feb. 7, 2008. reasons of termination were due to elevation of liver function tests and long elimination half-life of the compound    有  33  个tokens\n",
      "study subjects were not compliant with study protocols    有  8  个tokens\n",
      "data monitoring committee concluded after a planned interim analysis that aflibercept added to gemcitabine would be unable to demonstrate improved survival    有  26  个tokens\n",
      "interim analysis showed a significant reduction in the pain scores    有  11  个tokens\n",
      "principal investigator decided not to initiate the study    有  8  个tokens\n",
      "oncogel did not show any impact on overall tumor response    有  13  个tokens\n",
      "benefit of duodenal exclusion alone less than expected for treatment of type 2 diabetes; an additional effect of combination with omentectomy not observed    有  30  个tokens\n",
      "protocol under review    有  3  个tokens\n",
      "study was not producing meaningful data    有  6  个tokens\n",
      "the study was terminated early due to insufficient evidence of clinical benefit    有  12  个tokens\n",
      "commercial decision to discontinue the study    有  7  个tokens\n",
      "research cancelled; equipment broke    有  5  个tokens\n",
      "this is not a clinical trial and does not require registration    有  11  个tokens\n",
      "inadequate response to scientific review committee    有  8  个tokens\n",
      "the study has finished    有  4  个tokens\n",
      "negative data from a gsk poc study in ra combined with evidence of greater sensitivity of toll-like receptor pathways to p38 inhibition    有  25  个tokens\n",
      "no subject meeting criteria    有  4  个tokens\n",
      "the study did not continue to phase ii due to the importance of hpv status as a prognostic factor to guide treatment decisions    有  26  个tokens\n",
      "drug product became unavilable    有  7  个tokens\n",
      "dspd focusing on study 301 to confirm the clinical profile before proceeding. daiichi sankyo pharma development terminated this study on 23 apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants    有  51  个tokens\n",
      "the study was prematurely terminated due to strategic reasons    有  9  个tokens\n",
      "the investigator at cedars stopped this study due to problems collecting payment from the sponsor    有  17  个tokens\n",
      "intended length of study ended    有  6  个tokens\n",
      "fda sent letter to irb stating it should be done under new drug application    有  16  个tokens\n",
      "ind was withdrawn    有  3  个tokens\n",
      "withdrawn as the sponsor has stopped the drug for nsclc population    有  13  个tokens\n",
      "of the 8 histologically proven tumors, detection of ppix proved to be ambiguous    有  17  个tokens\n",
      "difficult to register    有  4  个tokens\n",
      "amag not continuing with combidex, the study drug    有  12  个tokens\n",
      "program development discontinued    有  3  个tokens\n",
      "financial difficulties    有  2  个tokens\n",
      "due to the arrival of daas replacing standard of care for genotype 1 patients the virid study had to be terminated    有  24  个tokens\n",
      "high number of screen failures-couldn't find qualified subjects in timely manner    有  15  个tokens\n",
      "lead surgeon retired    有  3  个tokens\n",
      "per sap    有  2  个tokens\n",
      "study not being conducted    有  4  个tokens\n",
      "study was terminated by principal investigator    有  6  个tokens\n",
      "treatment became standard    有  4  个tokens\n",
      "prevalence of h pylori in the study population was much poorer than anticipated    有  16  个tokens\n",
      "analysis of data from 104ra202 failed to meet primary endpoint    有  13  个tokens\n",
      "study was terminated at the request of the company due to the recall of marketed product in europe    有  18  个tokens\n",
      "the trial is terminated due to re-evaluation of the compound    有  12  个tokens\n",
      "program cancelled    有  2  个tokens\n",
      "celgene terminated its collaboration agreement with methylgene for the development of mgcd0103. all celgene-sponsored trials with mgcd0103 with be closed    有  31  个tokens\n",
      "study terminated early due to pi's extended medical leave    有  10  个tokens\n",
      "data did not evidence [123i]mni-330 as a useful tool in the detection of ad    有  21  个tokens\n",
      "the clinical development of intravenously administered ofatumumab in ra will no longer be pursued, so this study was prematurely terminated by the sponsor    有  29  个tokens\n",
      "higher incidence of pain related sexual dysfunction in the to arm    有  11  个tokens\n",
      "the company does not want to proceed yet with the study    有  11  个tokens\n",
      "dr. grose has left this practice, this study is terminated    有  13  个tokens\n",
      "survival advantage demonstrated    有  5  个tokens\n",
      "supply issues with the formulation of fenofibrate that was used    有  12  个tokens\n",
      "insufficient resources to evaluate pilot, second to shift in research priorities    有  13  个tokens\n",
      "pi is no longer with the university    有  7  个tokens\n",
      "pilot study determined that this study would not be feasible    有  11  个tokens\n",
      "insuffisent recrutment    有  7  个tokens\n",
      "due to multiple subjects reporting pain and burning at the phlebotomy sites after 38hr    有  19  个tokens\n",
      "drug was not sent    有  4  个tokens\n",
      "decision not to pursue as single agent in the study population    有  11  个tokens\n",
      "early termination due to increase in serum creatinine levels and minimal pd activity    有  14  个tokens\n",
      "a company's strategic decision to focus on areas whereit believes it can be competitive and decided to exit oncology    有  22  个tokens\n",
      "removal of darvocet from us market    有  10  个tokens\n",
      "study was terminated according the study protocol end of 2007    有  12  个tokens\n",
      "abbott (drug manufacturer) discontinued manufacture of abt-627    有  13  个tokens\n",
      "a paper on the same topic came out just before we wanted to start our study    有  16  个tokens\n",
      "procedure needs to be changed    有  5  个tokens\n",
      "conditional analysis showed observed differences were significantly less than power calculations    有  11  个tokens\n",
      "study never started due to resource related challenges    有  8  个tokens\n",
      "primary care physicians began prescribing antacid therapy for chronic cough    有  11  个tokens\n",
      "interim analysis performed without efficient results    有  7  个tokens\n",
      "difficulty finding eligible sites/patients; current situation in health policy cause negative effect on existing/planned contracts for integrated care program    有  25  个tokens\n",
      "per protocol - interim analysis showed no significant psa declines among the first 12 patients after 3 cycles of treatment    有  23  个tokens\n",
      "due to other projects priority    有  5  个tokens\n",
      "gsk decision    有  3  个tokens\n",
      "due to a pre-specified imbalance of deaths between treatment groups, the dsmb recommended early termination of the trial    有  22  个tokens\n",
      "investigator no longer at university    有  6  个tokens\n",
      "no subjects indentifiable    有  4  个tokens\n",
      "most patients were unable to perform the test being used to measure lung function, thus it became clear the study would not yield clinically meaningful data    有  27  个tokens\n",
      "pi changed institution and impossible to solve problem with contract's sites    有  12  个tokens\n",
      "expected mortality rates in placebo and treatment groups poorer than predicted    有  11  个tokens\n",
      "unable to proceed with study due to staffing of collaborative investigators    有  11  个tokens\n",
      "study had to be withdrawn because financial support was cancelled    有  10  个tokens\n",
      "sponsor has withdrawn support for this study and it will not be performed    有  13  个tokens\n",
      "data from dose groups 1,2 and other mn-221 studies resulted in the determination of a more appropriate dosing scheme for mn-221 in subjects with asthma    有  33  个tokens\n",
      "unable to complete a contract with the sponsor    有  8  个tokens\n",
      "difficulties in the organisation    有  6  个tokens\n",
      "the trial is not being done at this time    有  9  个tokens\n",
      "in order to prepare a new clinical trial to evaluate with pathological change    有  13  个tokens\n",
      "research question deemed not of enough clinical importance to proceed    有  10  个tokens\n",
      "due to changes in portfolio review    有  6  个tokens\n",
      "unable to continue study folpooring hurricane ike    有  10  个tokens\n",
      "data inconclusive    有  3  个tokens\n",
      "study site did not have sufficient subjects for the case group    有  11  个tokens\n",
      "since azd0328 is unlikely to meet the current target product profile, astrazeneca decided to stop further development of azd0328    有  28  个tokens\n",
      "at the first prespecified interim analysis    有  7  个tokens\n",
      "no longer sponsor of trial    有  5  个tokens\n",
      "a more highly selected protocol with eso tcr opened for pts with melanoma    有  15  个tokens\n",
      "study fatigue    有  2  个tokens\n",
      "anticipated high risk of pancreatitis    有  6  个tokens\n",
      "not adequate resources    有  3  个tokens\n",
      "raptiva was withdrawn from the market    有  8  个tokens\n",
      "not enough data available    有  4  个tokens\n",
      "issues with data collection tool    有  5  个tokens\n",
      "did not have resources to continue this study    有  8  个tokens\n",
      "this study will be incorporated into another study    有  8  个tokens\n",
      "was not approved by the ministry of health    有  8  个tokens\n",
      "withdrawn as the clinical development of atn-224 was terminated by the drug company who was providing atn-224 for the study    有  27  个tokens\n",
      "hurricane- terminated study due to skin bank being destroyed    有  12  个tokens\n",
      "routine use of corticoids became standard therapy    有  9  个tokens\n",
      "the bowel was not clean when the colonoscopy was performed    有  12  个tokens\n",
      "sponsor voluntarily decided to terminate trial due to increased ms disease activity in atacicept arms as compared to placebo during a routine idmc review    有  28  个tokens\n",
      "houston site withdrew as a study site    有  8  个tokens\n",
      "intraoperative recording could not be maintained for required period    有  11  个tokens\n",
      "prematurely terminated at institution request    有  8  个tokens\n",
      "local circumstances & difficulties in site access has prevented continuation    有  10  个tokens\n",
      "orthopedic surgeon that does our knee surgeries moved to a different location    有  14  个tokens\n",
      "terminated in lieu of similar,competing large, multi-site study    有  13  个tokens\n",
      "difficulty finding eligible sites/patients:current situation in health policy cause negative effects on existing/planned contracts for integrated care programs    有  25  个tokens\n",
      "sponsor - confluent surgical terminated study re: surgical techniques letter dated 4/31/2008    有  20  个tokens\n",
      "withdrawn due to poor eligible participants    有  7  个tokens\n",
      "mnsod longer available during phase ii    有  8  个tokens\n",
      "interim analysis: optimization of study design required    有  9  个tokens\n",
      "new protocol now being used for cardiopulmonary bypass    有  11  个tokens\n",
      "study terminated. eisai's targretin acquired by another pharmaceutical company    有  15  个tokens\n",
      "myvax did not meet its primary endpoints    有  9  个tokens\n",
      "maintenance phase outcome unattenable    有  6  个tokens\n",
      "terminated due to discontinuation of acular pf (investigational medication)    有  15  个tokens\n",
      "the study was never started because the sponsor decided not to manufacture the investigational product    有  16  个tokens\n",
      "human metabolite not yet covered sufficiently by nonclinical data    有  11  个tokens\n",
      "sufficient number to reach the primary endpoint and as planned    有  11  个tokens\n",
      "suitable implanted technolgy was not available    有  9  个tokens\n",
      "a similar study had already been conducted, therefore pursuing this trial would have been unethical    有  16  个tokens\n",
      "risk to benefit ratio not acceptable    有  6  个tokens\n",
      "dr. holguin is relocating    有  8  个tokens\n",
      "unavailability of investigational product    有  6  个tokens\n",
      "we did not see any effect of palifermin on benign or malignant tumor growth    有  16  个tokens\n",
      "withdrawal of marketing autorization of efalizumab by the emea    有  16  个tokens\n",
      "assay for stem cell analysis not available    有  8  个tokens\n",
      "development of new chemotherapy standard of care for treatment rendered the trial obsolete    有  13  个tokens\n",
      "study stopped early due to staffing changes at the site    有  10  个tokens\n",
      "due to a change of sponsor    有  6  个tokens\n",
      "investigators decided not to continue    有  6  个tokens\n",
      "study modified and has been running as cdr0000581286 instead    有  13  个tokens\n",
      "study never submitted to ind. study is being sponsored by johnson and johnson in the eu only    有  20  个tokens\n",
      "at half the sample size, the results were negative with no benefit demonstrated with adenosine    有  18  个tokens\n",
      "study was not initiated and has been withdrawn due to poor appropriate cases    有  13  个tokens\n",
      "finish study as protocol    有  4  个tokens\n",
      "supplement expired and unable to obtain more from company manufacturing    有  11  个tokens\n",
      "study did not move forward due to change in clinical strategy    有  11  个tokens\n",
      "study was never started due to logistical issues    有  8  个tokens\n",
      "the correlation coefficient at the interim analysis with results for all three groups pooled, did not reach the level of statistical significance of (p<0.05)    有  31  个tokens\n",
      "sponsor proceeded with a phase iii study for same indication    有  10  个tokens\n",
      "substance was withdrawn from further development    有  7  个tokens\n",
      "huntmans cancer institute terminated study    有  6  个tokens\n",
      "exhaustion of subject population pool, greater than expected drop-out rates . data analysis approved by dmc for study completions    有  25  个tokens\n",
      "one of site was not able to get an approval from the national regulatory authority    有  15  个tokens\n",
      "study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm    有  27  个tokens\n",
      "difficulty finding the required subject population    有  6  个tokens\n",
      "the study could not be completed as the company producing this product interrupted their supply of this medication    有  18  个tokens\n",
      "due to competing trials, this study is permanenlty closed to patient acrrual    有  18  个tokens\n",
      "termination is due to a combination of a device defect potentially impacting the quality of the ad 923 imp and a major change in corporate strategy    有  27  个tokens\n",
      "not able to find enough eligible patients (200) in last 4 years    有  15  个tokens\n",
      "this study has not finding place    有  6  个tokens\n",
      "the study never opened and not sure if it ever will    有  11  个tokens\n",
      "greater-than-anticipated rate of revisions    有  7  个tokens\n",
      "sponsor is not proceeding with usa human trial at this time    有  11  个tokens\n",
      "drc recommended stopping study as it had missed its primary endpoint    有  12  个tokens\n",
      "this study is terminated as a result of data from a study that showed increased mortality in stroke patients    有  19  个tokens\n",
      "no information    有  2  个tokens\n",
      "commitment completed    有  3  个tokens\n",
      "due to specimen collection difficulties; this study has been terminated    有  11  个tokens\n",
      "unexpected side-effects: reversible and mild to moderate neurological impairment    有  11  个tokens\n",
      "ended early due to inability to identify eligible subjects    有  9  个tokens\n",
      "subject population not available    有  4  个tokens\n",
      "a new study has began recently    有  6  个tokens\n",
      "inadequate sample population    有  5  个tokens\n",
      "fda request as study could not serve as the confirmatory trial    有  13  个tokens\n",
      "study was resurrected as nct00727558 (cr-0808)    有  16  个tokens\n",
      "after analysis of the existing data, it was determined that additional skin biopsy samples would not be required to determine study outcome    有  23  个tokens\n",
      "no coordinator available to work on study    有  7  个tokens\n",
      "redirect focus of the indication    有  5  个tokens\n",
      "site decided not to open this study    有  7  个tokens\n",
      "the renin laboratory used in the study is no longer available    有  12  个tokens\n",
      "study terminated due to insufficient subject participation    有  7  个tokens\n",
      "lidocaine injection group showed significant improvement in pain    有  10  个tokens\n",
      "the study had been revised and made a new application    有  10  个tokens\n",
      "due to the uncertain regulatory landscape for erythropoiesis-stimulating agents in oncology indications    有  20  个tokens\n",
      "this trial discontinued march 7,2009 due to high screen failure rate    有  15  个tokens\n",
      "existing vessel analysis software could not be applied to breast mri data    有  13  个tokens\n",
      "unable to accrue enough subjects to analyze data    有  9  个tokens\n",
      "superceded by another similar study    有  7  个tokens\n",
      "prinicipal investigator initiated study closure    有  8  个tokens\n",
      "significant differences observed between groups    有  5  个tokens\n",
      "terms for legal agreements between institution and sponsor could not be made    有  12  个tokens\n",
      "significant toxicities experienced    有  4  个tokens\n",
      "change in procedure nd medication used instead of gum    有  9  个tokens\n",
      "manufacturing shortage of both diftitox and doxil    有  12  个tokens\n",
      "protocol design under review    有  4  个tokens\n",
      "ethics committee approval denied    有  5  个tokens\n",
      "methodological problems    有  3  个tokens\n",
      "due to poor malaria patients in zanzibar the study has been suspended    有  15  个tokens\n",
      "not a clinical trial. retrospective data review only    有  9  个tokens\n",
      "supply of adequate label was not provided to the mhra    有  11  个tokens\n",
      "in light of the company's current financial position we have indefinately suspended the rheo-amd trial    有  21  个tokens\n",
      "the study was stopped due to a poor additional subjects    有  10  个tokens\n",
      "xoma to no longer supply drug for the study    有  10  个tokens\n",
      "unable to obtain approval from fda for use of chloral hydrate    有  14  个tokens\n",
      "the incidence of post-operative delirium observed from interim blinded data in dex-06-09 was significantly poorer than the current literature in this population    有  29  个tokens\n",
      "the study was started before the official request for protocol registration    有  11  个tokens\n",
      "investigator withdrew    有  3  个tokens\n",
      "amgen discontinued the development of amg706 because 20050201 did not meet its primary objective    有  20  个tokens\n",
      "ethics approval denied    有  4  个tokens\n",
      "company no longer making same drug doses    有  7  个tokens\n",
      "the trail end was achived according to the definition in the trial protocol    有  14  个tokens\n",
      "financial concerns with device manufacturer    有  5  个tokens\n",
      "the trial end was achieved according to the definition in the trial protocol    有  13  个tokens\n",
      "study was stopped due to poor resources on part of investigators    有  11  个tokens\n",
      "ecog will not proceed with activation    有  7  个tokens\n",
      "during the study    有  3  个tokens\n",
      "the incidence of post-operative delirium observed from interim blinded data was significantly poorer than the current literature in this population    有  23  个tokens\n",
      "study halted by drug manufacturer    有  5  个tokens\n",
      "the study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide    有  21  个tokens\n",
      "few prevalence of liver fibrosis in subjects    有  8  个tokens\n",
      "experience gained from this study is sufficient to design and facilitate the folpoor-on study    有  17  个tokens\n",
      "method development/validation    有  3  个tokens\n",
      "study terminated by university of miami institutional review board    有  10  个tokens\n",
      "study was dropped prior to opening    有  6  个tokens\n",
      "this study not get the approval by the drug company    有  10  个tokens\n",
      "sample too small in retrospective chart review to conduct analysis    有  10  个tokens\n",
      "the study group changed from patients to a healthy volunteers. a healthy-volunteer study is being planned to replace 213    有  24  个tokens\n",
      "data did not indicate any meaningful information    有  7  个tokens\n",
      "endpoint no longer deemed meaningful    有  5  个tokens\n",
      "interim analysis of data failed to meet primary endpoint    有  10  个tokens\n",
      "this is a duplicate record and the sponsor has submitted under nct00206427    有  16  个tokens\n",
      "the study was stopped due to poor resources of the study coordinator's time    有  14  个tokens\n",
      "sars epidemic in asia and canada    有  7  个tokens\n",
      "difficulty aquiring investigational drug    有  6  个tokens\n",
      "because of delay in approval of the protocol by a number of ethics commitees the trial was terminated on march 4, 2010. no patient had received any study drug    有  36  个tokens\n",
      "rct with same hypothesis ended and showed a superiority for protective ileostomy after poorer anterior rectum resection    有  22  个tokens\n",
      "6 month vital status report not collected after 28 day folpoor up analysis indicated no difference between placebo & tezosentan    有  26  个tokens\n",
      "never been started    有  3  个tokens\n",
      "this study was terminated earlier due to a phase iii study that showed this drug inferior to sorafenib    有  20  个tokens\n",
      "practice patterns with pemetrexed have evolved    有  9  个tokens\n",
      "protocol to be re-designed (primary outome still gcsi)    有  13  个tokens\n",
      "no final agreement with sponsor    有  5  个tokens\n",
      "inherent modifications needed before proceeding    有  6  个tokens\n",
      "study design changes were needed due to change of protocol to a multisite trial and updated set up    有  19  个tokens\n",
      "study team failed to complete timely reviews, study suspended    有  10  个tokens\n",
      "withdrawn per sponsor and investigator    有  6  个tokens\n",
      "primary analyses found unfeasible    有  6  个tokens\n",
      "product development was cancelled    有  4  个tokens\n",
      "study was terminated due to the death of the pi    有  10  个tokens\n",
      "the study goals were accomplished by a similar study at uams. (w.j. evans)    有  20  个tokens\n",
      "per irb recommendation, a separate protocol will be prepared for retrospective data analysis. the current protocol does not have specific hypotheses    有  24  个tokens\n",
      "question raised by ethics committee    有  5  个tokens\n",
      "study withdrawn due to investigator leaving    有  6  个tokens\n",
      "the study was discontinued due to unfavorable interim analysis    有  9  个tokens\n",
      "pi withdrew from study protocol participation    有  6  个tokens\n",
      "no eligible patients were found, the study stopped without including any patients    有  13  个tokens\n",
      "study was terminated because study conclusions varied    有  7  个tokens\n",
      "sufficient data has been collected for significant conclusion    有  9  个tokens\n",
      "sufficient data collected for conclusion of retrospective study    有  9  个tokens\n",
      "conclusions drawn, manuscript written    有  6  个tokens\n",
      "study was terminated due to difficulty in identifying eligible subjects    有  10  个tokens\n",
      "significant reduction in length of hospital stay (primary endpoint)    有  11  个tokens\n",
      "physician's chose to not folpoor through with the study    有  13  个tokens\n",
      "study terminated based on decision of sponsor    有  7  个tokens\n",
      "study terminated due to protocol deficiencies    有  6  个tokens\n",
      "due to high incidence of neurological complication in those with ilioinguinal block    有  15  个tokens\n",
      "pharmaceutical company closed study because the treatment was not effective    有  12  个tokens\n",
      "this study was terminated at the request of the drug manufacturer    有  11  个tokens\n",
      "insufficient study materials    有  4  个tokens\n",
      "terminated due to clinical trial material production delays    有  8  个tokens\n",
      "study no longer being conducted    有  5  个tokens\n",
      "principal investigator (dr. guardino) left stanford    有  11  个tokens\n",
      "sorafenib administered in the combination with pemetrexed-carboplatin appears to enhance thrombocytopenia compared to historical data    有  30  个tokens\n",
      "the study was terminated based on the recommendation by the dsmb folpooring a pre-planned protocol interim analysis because the endpoint was not achieved    有  28  个tokens\n",
      "due to unavailability of testing for gene mutation    有  9  个tokens\n",
      "suspended failure to folpoor conflict of interest management plan    有  12  个tokens\n",
      "ind holder relocated from the university of utah    有  9  个tokens\n",
      "redundant in-clinic visits increased the workload in virtual folpoor-up group. an interim analysis showed that the study would not support the primary hypothesis    有  32  个tokens\n",
      "the person who started the study joined medical school    有  9  个tokens\n",
      "protocol to be revised    有  4  个tokens\n",
      "inactivity    有  2  个tokens\n",
      "due to an imbalance in graft infections between groups    有  9  个tokens\n",
      "activation of a similar multicenter study for same population    有  10  个tokens\n",
      "the overall program was terminated    有  5  个tokens\n",
      "due to recent findings relating mri contrast to nephrogenic systemic fibrosis    有  15  个tokens\n",
      "poor accrural to study    有  6  个tokens\n",
      "terminated, new protocol to be developed    有  7  个tokens\n",
      "study stopped at the end of the first step    有  9  个tokens\n",
      "sponsor suspended development of the drug on september 3, 2008    有  14  个tokens\n",
      "an alternative joint industry effort will provide information on combination versus single agent therapy for treatment of aspergillosis    有  22  个tokens\n",
      "market dynamics including other technologies made the project not viable    有  10  个tokens\n",
      "one of the examinations (double contrast baium enema) became outdated in norway    有  18  个tokens\n",
      "unable to obtain contract with sponsor    有  6  个tokens\n",
      "too much cross over bias between small numbers of participants    有  10  个tokens\n",
      "issues with manufacturing    有  3  个tokens\n",
      "did not receive budget needed    有  5  个tokens\n",
      "study terminated at sponsor's request    有  6  个tokens\n",
      "study terminated as a result of interim analysis not meeting predetermined criteria    有  12  个tokens\n",
      "never started due to logistic issues    有  6  个tokens\n",
      "sufficient number of subjects accrued to conduct analysis    有  9  个tokens\n",
      "there is no longer equipoise. dsmb recommended termination    有  11  个tokens\n",
      "scan results to date did not show reason to continue with study    有  12  个tokens\n",
      "the study was stopped prior to 2nd stage    有  10  个tokens\n",
      "36 months folpoor up without change to profile. no further studies planned    有  15  个tokens\n",
      "no benefit on primary end point (rfs); no rationale to collect survival data    有  16  个tokens\n",
      "no enough fund    有  3  个tokens\n",
      "imbalance in deaths favoring control arm; deaths not attributed to treatment by the blinded external medical monitor    有  20  个tokens\n",
      "investigator medical practice didn't alpoor to move forward with the study    有  15  个tokens\n",
      "change in national pmtct guidelines in thailand    有  10  个tokens\n",
      "sponsor decided against going forward with the study    有  8  个tokens\n",
      "sponsor withdrawl prior to study completion    有  7  个tokens\n",
      "per group chair: this study will not move forward    有  10  个tokens\n",
      "submission converted to 510(k)    有  7  个tokens\n",
      "one subject's hiv rna rebounded at week 12. a repeat phenosense gt combination resistance assay at week 12 revealed evolution in protease inhibitor resistance    有  34  个tokens\n",
      "study closed and subject folpoor-up completed folpooring analysis of blinded study data    有  17  个tokens\n",
      "investigator decided to withdraw participation in the study    有  9  个tokens\n",
      "impossibility to find volunteers    有  6  个tokens\n",
      "decreasing interest in using samples; department infrastructure waned    有  11  个tokens\n",
      "change in excimer laser systems prior to completion of study    有  11  个tokens\n",
      "trial cancelled    有  2  个tokens\n",
      "the preliminary data do not support the expected sustainable blood levels of triptorelin for a duration of 4 months in all patients    有  26  个tokens\n",
      "vaccine sponsor ceased operations    有  5  个tokens\n",
      "we encounter technical problems to continue with the study. (notably difficulty in teaching the patients to use the dressing set involved in the study.)    有  28  个tokens\n",
      "inadequate accrural rates    有  6  个tokens\n",
      "decision was made not to attempt a poorer dose    有  9  个tokens\n",
      "the study was stopped based on a decision to include pcv 10 in the national immunization program in colombia. the study was designed to measure the impact of pcv 7 and 13 and is no longer feasible    有  45  个tokens\n",
      "dsmb recommended termination because ti was safe but not durable    有  11  个tokens\n",
      "interim analysis result indicated the study will not show a significant benefit of the study medication on the primary endpoint    有  21  个tokens\n",
      "the study was not approved by the human studies subcommittee    有  11  个tokens\n",
      "new insights have let us to expect marginal annexin targeting with a 10 minutes delay between reperfusion and administration of annexin a5    有  28  个tokens\n",
      "a separate study (similar subjects) identified transfusion-associated microchimerism only rarely, making this observational study impractical to conduct    有  26  个tokens\n",
      "shift in department's research interest    有  6  个tokens\n",
      "major side-effects    有  3  个tokens\n",
      "at the end of the year 2002, cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria    有  30  个tokens\n",
      "study has been completed as planned    有  6  个tokens\n",
      "company suspended development of product    有  5  个tokens\n",
      "interim analysis showed greater variablility in nt-probnp findings than anticipated    有  16  个tokens\n",
      "medication expired    有  3  个tokens\n",
      "treatment differences not detected with 7 point fingerstick monitoring    有  12  个tokens\n",
      "interim analysis of primary endpoint completed    有  7  个tokens\n",
      "imp supply    有  2  个tokens\n",
      "mifne began treating younger patients who could not be diagnosed with the ados used in the study    有  20  个tokens\n",
      "the study closed because of inadequate early activity    有  8  个tokens\n",
      "the present study was joining 2005-41-4933 into one study    有  16  个tokens\n",
      "the study had failed to meet the primary objective of tumor response rate at 12 weeks from first dose    有  20  个tokens\n",
      "zone labs, inc discontinue utilizing their fish oil supplement and frozen foods    有  14  个tokens\n",
      "interim results of another trial showed inferior activity of treatment    有  11  个tokens\n",
      "study terminated due to resources    有  5  个tokens\n",
      "trial stopped due to a change in standard of care and the required patient numbers could no longer be achieved    有  20  个tokens\n",
      "no agreement between investigator and sponsor    有  6  个tokens\n",
      "study merged with another study    有  5  个tokens\n",
      "principal criteria was achieved with the intermediate statistical analysis    有  9  个tokens\n",
      "interim analysis showed differential treatment effects    有  7  个tokens\n",
      "change of study population and chemotherapeutic regimen    有  9  个tokens\n",
      "study was terminated based on the results of analyses performed as planned at month 12    有  16  个tokens\n",
      "primary investigator is taking a leave of absence    有  8  个tokens\n",
      "due to sponsor's financial reasons    有  6  个tokens\n",
      "investigator initiated suspension to focus on other studies    有  9  个tokens\n",
      "study approval deferred by the irb    有  7  个tokens\n",
      "experimental arm (induction + poor dose tacrolimus) not effective    有  14  个tokens\n",
      "fda and ema agreed that the information that had been submitted to date was acceptable to meet the requirements of the post-marketing commitment    有  27  个tokens\n",
      "the project leader left our hospital and the project were shut down    有  12  个tokens\n",
      "study terminated for cgcp non-compliance. analyses could not be performed    有  14  个tokens\n",
      "unable to secure supply of the study medication    有  8  个tokens\n",
      "all data collection has completed    有  5  个tokens\n",
      "in agreement with fda the study was terminated based on data available    有  13  个tokens\n",
      "side effect profile did not match expectations    有  7  个tokens\n",
      "due to poor compliance with study drug administration    有  8  个tokens\n",
      "aml assess. of response in part b patients find treatment failure in all 8 evaluable for marrow response folpooring a maximum of 2 induction courses of therapy    有  33  个tokens\n",
      "change of focus for the company    有  6  个tokens\n",
      "due to poor supply of the investigational product    有  9  个tokens\n",
      "this is not a clinical trial and was inadvertently added to the system    有  13  个tokens\n",
      "irb needs updated    有  4  个tokens\n",
      "according to the study design, in the first step the number of responses was poorer than the number required (< 7)    有  24  个tokens\n",
      "poor study population    有  4  个tokens\n",
      "surgeon mistakenly removed liver and fat tissue from a non-labs2a participant    有  17  个tokens\n",
      "clinical hold pending additional data review and protocol amendment    有  9  个tokens\n",
      "unexpectedely high rates of treatment-failure    有  8  个tokens\n",
      "planned to design a prospective study    有  7  个tokens\n",
      "study was suspended until fda approved the ind. study has since been terminated and a new screening process has been implemented    有  23  个tokens\n",
      "per request of principal investigator this study was closed    有  9  个tokens\n",
      "company has ceased operation    有  4  个tokens\n",
      "early termination folpooring trial steering committee recommendation    有  9  个tokens\n",
      "the study withdrawn due to lack financial support    有  8  个tokens\n",
      "objectives of study could not be met within a reasonable timeframe    有  12  个tokens\n",
      "current poor medication support    有  4  个tokens\n",
      "protocol not approved by va r&d    有  8  个tokens\n",
      "another institution performed the study    有  5  个tokens\n",
      "study terminated early as per request by sponsor, zila biotechnology, inc    有  15  个tokens\n",
      "infusion reactions during re-induction cycles after a period of no treatment in another study [p04563, nct0358670]    有  28  个tokens\n",
      "new competing studies    有  3  个tokens\n",
      "to pursue other indications    有  4  个tokens\n",
      "oxford biomedica halted trovax injections    有  9  个tokens\n",
      "insufficient recuirment    有  5  个tokens\n",
      "crx-102-006 study results, negative    有  10  个tokens\n",
      "terminated study    有  2  个tokens\n",
      "need for re-formulation    有  5  个tokens\n",
      "recommended phase ii dose determined    有  5  个tokens\n",
      "analysis of data from 104ra203 failed to meet primary endpoint    有  13  个tokens\n",
      "interim analysis of the present study showed a significant decrease in mortality rate (p= 0.04) as well as in the number of days at the icu p=0.0002    有  40  个tokens\n",
      "we decided not to go on treatment phase    有  8  个tokens\n",
      "sponsor has decide to pospone this study    有  8  个tokens\n",
      "study discontinued due to approvable decision    有  7  个tokens\n",
      "drug cannot be prepared commercially    有  5  个tokens\n",
      "the sponsor (amicus therapeutics) terminated this study for logistical reasons    有  14  个tokens\n",
      "the study was stopped, as the another multicentre-rct on the same patients started    有  17  个tokens\n",
      "statistical significance was reached for primary outcome    有  8  个tokens\n",
      "the study was a retrospective chart review and was mistakenly registered in clinicaltrials.gov    有  16  个tokens\n",
      "study was stopped folpooring interim analysis    有  8  个tokens\n",
      "pk portion will be included in a future protocol    有  9  个tokens\n",
      "study status unknown investigator retired and no longer working in the institution    有  12  个tokens\n",
      "poor pharmaceutical support    有  4  个tokens\n",
      "methodology applied did not meet all criteria required per guidelines    有  11  个tokens\n",
      "poor equipoise    有  4  个tokens\n",
      "this condition can now be managed in the office with an injection of lucentis    有  16  个tokens\n",
      "data collection is completed. as no changes in the endpoints were expected in the future, no further data is needed    有  22  个tokens\n",
      "dsmb recommended termination based on interim outcomes analysis    有  9  个tokens\n",
      "trial terminated due to financial resource limitations    有  7  个tokens\n",
      "this study is being discontinued based on data suggesting that none of the doses tested demonstrated both glycemic & body fluid benefits vs. the comparitor    有  28  个tokens\n",
      "due to absence of evidence of clinical activity up to toxic doses    有  12  个tokens\n",
      "the trial was terminated due to poor compliance with gcp regulations    有  12  个tokens\n",
      "doesn't meet nih clinical trial definition    有  8  个tokens\n",
      "preliminary data showed [123i] mni-308 not a useful tool in detection of ad    有  21  个tokens\n",
      "terminated early due to discovery of new mechanism of activation    有  10  个tokens\n",
      "the study was terminated prematurely due to withdrawal of support by the sponsor    有  13  个tokens\n",
      "trial closed just prior to study receiving investigational review board approval    有  12  个tokens\n",
      "strategic direction of the sponsor changed    有  7  个tokens\n",
      "upon recommendation of dsmb    有  5  个tokens\n",
      "unfortunately lacked manpower to carry out the study    有  9  个tokens\n",
      "intermediate results have shown a significant difference in the outcome of ablation and non-ablation patients. therefore, the study was stopped    有  26  个tokens\n",
      "this study was terminated due to expired drug with possibility of re-starting in the future    有  17  个tokens\n",
      "analysis at 50% inclusion showed 4 times larger reoperation rate in x-stop group    有  18  个tokens\n",
      "compliance unacceptably poor    有  6  个tokens\n",
      "withdrawn due to medication withdrawal from the emea    有  10  个tokens\n",
      "no results are avaialble as the study did not complete according to the protocol    有  16  个tokens\n",
      "study suspended due to staff indisposition    有  7  个tokens\n",
      "senior coworker retired    有  5  个tokens\n",
      "performance variability    有  2  个tokens\n",
      "indirect calorimetry no longer employed at the institution; calorimeter is not accurate/reliable    有  19  个tokens\n",
      "change in donor site care protocol; donor site healing is a study endpoint    有  14  个tokens\n",
      "study terminated due to poor subject compliance    有  7  个tokens\n",
      "the investigator is no longer employed at nih    有  9  个tokens\n",
      "the manufacturer discontinued necessary reagents    有  6  个tokens\n",
      "local pharmacy unwilling to comply with study protocol    有  8  个tokens\n",
      "the study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population    有  25  个tokens\n",
      "terminated because of enough case number    有  6  个tokens\n",
      "folpoor up only    有  5  个tokens\n",
      "the 20070201 study was terminated based on evaluation of palifermin solid tumor data    有  18  个tokens\n",
      "contract agreement not reached    有  4  个tokens\n",
      "according to nih definition of clinical trial studies, this study does not meet requirement for clinical trial study    有  20  个tokens\n",
      "not nih defined clinical trials    有  6  个tokens\n",
      "based on input from regulatory agencies, it is not necessary to conduct this study. an ongoing study was sufficient for regulatory purposes    有  24  个tokens\n",
      "unable to safely escalate to tmli doses that were hypothesized to be effective and less toxic than ftbi. likely due to the giving of busulfan prior to radiation delivery. therefore, the study was abandoned and no further patients were accrued    有  48  个tokens\n",
      "reviewing data    有  3  个tokens\n",
      "surgassist device is no longer clinically available    有  9  个tokens\n",
      "higher incidence of hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects    有  25  个tokens\n",
      "collected study data was not usable due to process miscommunications    有  12  个tokens\n",
      "due to an unfavorable benefit/risk ratio    有  8  个tokens\n",
      "early termination resulted from interim analysis of the altitude trial    有  10  个tokens\n",
      "data required further pilot work to be undertaken    有  8  个tokens\n",
      "trial terminated early due to results from a similar study    有  10  个tokens\n",
      "terminated for poor resources to complete    有  6  个tokens\n",
      "the study was discontinued after the first 10 patients because of discouraging results    有  15  个tokens\n",
      "folpoor-up end in 1999    有  9  个tokens\n",
      "study is now terminated due to technical difficulties with administration of study drug in this patient population with this schedule    有  20  个tokens\n",
      "one of the principal investigators has moved to a different institution    有  11  个tokens\n",
      "voluntary halt due to an fda clinical hold issued in relation to dv2-hbv-10    有  20  个tokens\n",
      "withdrawal of support    有  4  个tokens\n",
      "cohort 2 not going forward. manadate changes in company    有  14  个tokens\n",
      "the drug needed for the study is not available in mexico anymore    有  12  个tokens\n",
      "support issue    有  2  个tokens\n",
      "co phase 2 data did not show sufficient improvement in cath opening at higher dose/concentration evaluated. nuvelo ended further clinical dev of alfimeprase    有  32  个tokens\n",
      "sample size too small for data analysis    有  7  个tokens\n",
      "the study was terimnated - poor rate of cases    有  12  个tokens\n",
      "data from the actigraph devices could no longer be read/analyzed    有  14  个tokens\n",
      "we found out that there is another study on the same issue    有  12  个tokens\n",
      "withdrawn as trial was never activated by supergen    有  10  个tokens\n",
      "study stopped early based on interim results of another trial, showing inferior activity of pemetrexed/carboplatin compared to etoposide/carboplatin in sclc    有  36  个tokens\n",
      "primary analyses found futile    有  4  个tokens\n",
      "due to clinical trial supplies shortage    有  6  个tokens\n",
      "change of mri mode    有  5  个tokens\n",
      "study was not ethically acceptable to continue and therefore it was finally stopped    有  14  个tokens\n",
      "potential harm of insulin infusion outweights the benefit    有  9  个tokens\n",
      "failure to achieve one of the primary endpoints    有  8  个tokens\n",
      "facet no longer has ownership of ularitide    有  10  个tokens\n",
      "this is a duplicate record and the sponsor has registered the study    有  12  个tokens\n",
      "dr. rabheru left vch last year and the study was cancelled according to his research coordinator    有  20  个tokens\n",
      "protocol changes    有  2  个tokens\n",
      "not enough staff    有  3  个tokens\n",
      "based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly tolerated    有  24  个tokens\n",
      "because of a strategic decision by novartis    有  9  个tokens\n",
      "due to unstalbe cell sheet quality. we didn't use this tech on patients    有  17  个tokens\n",
      "no longer have access to equipment used for functional data collection    有  11  个tokens\n",
      "unfavourable pharmakokinetics    有  8  个tokens\n",
      "subjects on drug were more likely to have severe pain crises requiring hospitalization    有  14  个tokens\n",
      "major amendments in progress    有  4  个tokens\n",
      "this study was a companion study to another one. the other study closed early so this one did as well    有  21  个tokens\n",
      "the study have been stoped because the protocol is going to be modify    有  14  个tokens\n",
      "difficulties in getting suitable applicators for biodegradable stents    有  14  个tokens\n",
      "corroboration of supporting in vitro data - data successfully corroborated 2009    有  16  个tokens\n",
      "imp new owner decision    有  4  个tokens\n",
      "one study drug (thiopental) became commercially unavailable    有  12  个tokens\n",
      "reccomended by dsmb after review of planned interim analyses    有  13  个tokens\n",
      "sufficient poc to switch development from bovine ap to recombinant ap    有  15  个tokens\n",
      "cancelled before active due to the results of emerging scientific data    有  11  个tokens\n",
      "is finish    有  2  个tokens\n",
      "24 months folpoor up completed without substantial change to the profile    有  13  个tokens\n",
      "study was closed due to loss of industry sponsorship    有  9  个tokens\n",
      "study was terminated by trial steering committee    有  7  个tokens\n",
      "it was determined not to be needed based on the clinical development plan of tykerb    有  17  个tokens\n",
      "unacceptable incidence of wound dehiscence in the pds group    有  14  个tokens\n",
      "the immune monitoring data failed to demonstrate an improvement in any biologic endpoint with denileukin diftitox    有  22  个tokens\n",
      "recall of rescue medication, alternative rescue medication availability issues    有  10  个tokens\n",
      "results from first few subjects was not significantly improved over standard, traditional procedures    有  14  个tokens\n",
      "side effect can increase the risk of the research    有  9  个tokens\n",
      "problems with the electronic data collection program    有  7  个tokens\n",
      "the pharmaceutical collaborator filed for bankruptcy and as a result, the study was unable to move into the phase ii portion    有  23  个tokens\n",
      "the dsmc decided it appeared futile to attempt to demonstrate non-inferiority of povidone-iodine to natamycin    有  28  个tokens\n",
      "this study was stopped to alpoor initiation of a mult-center study    有  14  个tokens\n",
      "high rate of medullar aplasia with infectious troubles    有  11  个tokens\n",
      "issues with application of clozex intervention    有  8  个tokens\n",
      "study suspended due to logistical/personnel difficulties    有  8  个tokens\n",
      "manufacturer stopped drug development    有  4  个tokens\n",
      "boston scientific has decided to close the study    有  9  个tokens\n",
      "early closure of study due to poor response    有  8  个tokens\n",
      "not enough data to analyze the results    有  7  个tokens\n",
      "side effects valuation    有  3  个tokens\n",
      "resident project--resident left institution and was not picked up by anyone else    有  14  个tokens\n",
      "the number of the anticipated participants was not achieved    有  9  个tokens\n",
      "because of unsatisfactory results of previous trial which assessed the effect of different onset times of pdl on surgical scars    有  23  个tokens\n",
      "the study drugs are not covered anymore by insurance    有  9  个tokens\n",
      "physician deceased    有  3  个tokens\n",
      "due to poor finance    有  4  个tokens\n",
      "halted due to high incidence of veno-oclusive disease of the liver    有  16  个tokens\n",
      "suspended while we determine if usable data can be collected from this device    有  14  个tokens\n",
      "improving assay methods    有  5  个tokens\n",
      "the received reliability with increase in quantity of participants of research did not vary    有  14  个tokens\n",
      "3/7 subjects experienced hypotension. study was terminated    有  12  个tokens\n",
      "primary analysis was completed in 2015 and data collection post 1-jul-2019 was not reportable due to local regulations in china    有  29  个tokens\n",
      "an independent dmc determined continuation was unlikely to demonstrate a statistically significant advantage of asp8825 over placebo on the primary endpoint    有  25  个tokens\n",
      "change of workplace for leading investigator, not replaced    有  9  个tokens\n",
      "the study had been temporarily halted due to an unplanned interim analysis. the sponsor is now aware that a further interim analysis has been performed by the site and therefore a decision has been made not to recommence the study    有  43  个tokens\n",
      "not a clinical trial requirement per va hsr&d    有  11  个tokens\n",
      "we designed a different pilot trial based on data obtained after this study started - the 2 studies were too overlapping to continue both    有  25  个tokens\n",
      "change in supply of study medication    有  6  个tokens\n",
      "the company decided not to start the study    有  8  个tokens\n",
      "broken equipment    有  2  个tokens\n",
      "based on the results of study ptc124-gd-021-cf (nct02139306), clinical development of ataluren in cystic fibrosis was discontinued and this study was closed    有  40  个tokens\n",
      "continued development of technology    有  4  个tokens\n",
      "as the study progressed, the intervention became more of a standard of care, thus the study has stalled and been aborted    有  23  个tokens\n",
      "study never started - transferred to array    有  7  个tokens\n",
      "fda approval received for product, no additional study subjects required    有  12  个tokens\n",
      "dr zhu, collaborator and the inventor of the photoacoustic system, is leaving the institution and it is not feasible to conduct the study without the machine    有  32  个tokens\n",
      "closure of iu health proton facility    有  7  个tokens\n",
      "the overall benefit-risk profile did not support continued development of ly2409021 for type 2 diabetes    有  20  个tokens\n",
      "this action is an internal decision that was not made because of any pending regulatory action for these products    有  19  个tokens\n",
      "trial was never initiated due to path executive decision    有  9  个tokens\n",
      "the pilot study demonsttated some new concerns about methodology. so we decided to suspended temporarily to added new settings to study design    有  26  个tokens\n",
      "at the direction of our irb, this project was incorporated into an existing study, lu#200038, nct#02925156    有  28  个tokens\n",
      "terminated due to results of interim analysis    有  7  个tokens\n",
      "opposite trend after interim analysis    有  6  个tokens\n",
      "early termination of idx21459 was due to integration of merck's hcv antiviral pipeline has resulted in revisions of the clinical development plan    有  29  个tokens\n",
      "interim analysis does not show good results    有  8  个tokens\n",
      "target population not reached    有  4  个tokens\n",
      "optimize calibration    有  2  个tokens\n",
      "dsmb's decision folpooring the first step analysis    有  11  个tokens\n",
      "disengagement of the sponsor alexion pharmaceuticals    有  10  个tokens\n",
      "suspended temporarily - amending protocol    有  7  个tokens\n",
      "local resource issue - never actually started post ethics approval    有  10  个tokens\n",
      "poor faculty staffing    有  4  个tokens\n",
      "study objectives were considered as obsolete regarding the new aad arrival    有  12  个tokens\n",
      "the company changed the strategy    有  5  个tokens\n",
      "sample size calculation would have been overinflated; re-think study design    有  16  个tokens\n",
      "study objectives were considered as absolete regarding the arrival of new antiviral drugs in egypt    有  19  个tokens\n",
      "cardiac surgery group could not be measured (technical monitoring problems)    有  13  个tokens\n",
      "change in scientific information obtained resulting in early cessation of protocol    有  11  个tokens\n",
      "principle investigator as left government service    有  7  个tokens\n",
      "lilly's decision to cancel this trial is due to regulatory uncertainty in china    有  15  个tokens\n",
      "no longer interested in study topic    有  6  个tokens\n",
      "changes made to device    有  4  个tokens\n",
      "no financial support aproved    有  5  个tokens\n",
      "expired with uf irb    有  5  个tokens\n",
      "to conduct interim analysis and assess whether assay changes are recommended    有  11  个tokens\n",
      "results from other studies did not support continuation of this trial    有  11  个tokens\n",
      "loss of research support    有  4  个tokens\n",
      "non-favorable risk/benefit profile with studied dosing regimen    有  13  个tokens\n",
      "study already undertaken at another centre    有  6  个tokens\n",
      "cytosponge device availability    有  5  个tokens\n",
      "risk-benefit ratio    有  4  个tokens\n",
      "changes in availability of study personnel    有  6  个tokens\n",
      "withdrawal of industry support for the study    有  8  个tokens\n",
      "sponsor determined study design would not produce useful results    有  9  个tokens\n",
      "stopped because of competing studies    有  5  个tokens\n",
      "no grants    有  2  个tokens\n",
      "sufficient clinical evidence was gathered    有  6  个tokens\n",
      "we were not able to accrue any participants    有  9  个tokens\n",
      "drug recall    有  2  个tokens\n",
      "planned interim analysis did not show the expected benefit of intervention a over b (effect size <0.2)    有  23  个tokens\n",
      "pre-defined criteria for continuation were not reached    有  8  个tokens\n",
      "data collection requirment complete    有  6  个tokens\n",
      "the target cannot be achieved within timeline due to delay of ethics approval    有  13  个tokens\n",
      "drug unavailability due to a manufacturing transition    有  8  个tokens\n",
      "unable to conduct study because of political issues in host country    有  11  个tokens\n",
      "all patients were recruted but it has been difficulte to recrute all volunteers (15/30) . however data should be sufficient for analyse of data    有  33  个tokens\n",
      "science has moved forward and there is no intent to complete the study    有  13  个tokens\n",
      "results from other rct made randomization unethical    有  9  个tokens\n",
      "study site change    有  3  个tokens\n",
      "member of staff moved on to training post. trial halted and terminated    有  13  个tokens\n",
      "protocol was deem insufficient to answer research question    有  8  个tokens\n",
      "protocol issues. modifications potentially will be undertaken and resubmitted to irb    有  15  个tokens\n",
      "the study was stopped when the original principal investigator moved to a new institution    有  14  个tokens\n",
      "changing study design. will replace with a different protocol    有  10  个tokens\n",
      "study was terminated by novartis    有  7  个tokens\n",
      "the results concerning amniotic membrane transplantation (n=7) and robot-assisted pterygium surgery (n=5) were conclusive    有  28  个tokens\n",
      "the study stopped as the used needle was difficult to maneuver in the corkscrew method being studied so no more participants were included    有  25  个tokens\n",
      "the primary investigator moved    有  4  个tokens\n",
      "because economic problems    有  3  个tokens\n",
      "79% participant retention after 1 year    有  8  个tokens\n",
      "primary endpoint could no longer be reached    有  7  个tokens\n",
      "the study was terminated early based on the results of the planned interim analysis    有  14  个tokens\n",
      "the protocol has been withdrawn for re-evaluation    有  9  个tokens\n",
      "irb not approved    有  4  个tokens\n",
      "because of negative results of the sister study nak-06 and the poor overall response rate at week 24    有  21  个tokens\n",
      "taiwan fda asked for seperating this protocol into one disease site per protocol    有  17  个tokens\n",
      "poor activity, primary researcher moved to another institution    有  10  个tokens\n",
      "new brazilian guidelines for viral hepatitis c and coinfetions. it does not include the treatment of chronic hcv metavir < f3 and abandon the use of interferon    有  36  个tokens\n",
      "results of the pilot were not enough to justify the extension of the pilot. results presented are from pilot    有  20  个tokens\n",
      "dsmb stopped this trial due to the difference of 3-year dfs's rate between two groups more than 5% at the interim analysis in july 2021    有  34  个tokens\n",
      "study to be revised. future plans to be determined    有  10  个tokens\n",
      "loss of staff    有  3  个tokens\n",
      "withdrawn. unable to set up appropriate infrastructure to support study    有  12  个tokens\n",
      "unable to collect data    有  4  个tokens\n",
      "study halted prematurely due to a change in the standard of care treatment    有  13  个tokens\n",
      "closure of indiana university health proton center in december 2014    有  13  个tokens\n",
      "recommendation from the dsmb folpooring recurrent dvt in 3/4 participants who underwent the thrombectomy procedure    有  25  个tokens\n",
      "we need to revise and redesign the study    有  8  个tokens\n",
      "the sakk board decided to prematurely end the life-long folpoor-up of the trial sakk 21/12, as 90% of the patients have died    有  34  个tokens\n",
      "study no longer has an active ide    有  7  个tokens\n",
      "it has been decided to improve the inclusion criteria for better study outcome    有  13  个tokens\n",
      "problems of drugs supply by the manufacturer    有  7  个tokens\n",
      "interim analysis findings    有  4  个tokens\n",
      "sponsored withdrew    有  3  个tokens\n",
      "the study was terminated early due to shortage of drug supply    有  11  个tokens\n",
      "co2 temperature delivered revealed that warmed co2 was not being delivered    有  13  个tokens\n",
      "the sponsor appreciate the devastating impact that the results of the symplicity htn 3 trial had on research progress for renal denervation. based on the poor recent progress, it is no longer practical to maintain the agreement    有  43  个tokens\n",
      "the trial was terminated per protocol because of poor feasibility    有  10  个tokens\n",
      "study stopping criteria has been reached    有  6  个tokens\n",
      "a publication released shortly after start indicating intervention not always beneficial. fewer surgical cased thereafter    有  17  个tokens\n",
      "primary outcome measure not met    有  5  个tokens\n",
      "site unable to complete full data collection/protocol    有  9  个tokens\n",
      "we terminated the study to run it as a sub-study of nct02371889, which is a 13 week, placebo controlled, double-blind, trial of topiramate in heavy drinkers    有  40  个tokens\n",
      "the study was prematurely terminated after core study cqge031b2201 failed to meet the primary objective of demonstrating superiority for qge031 versus placebo    有  29  个tokens\n",
      "terminated due to budgetary considerations and length of development    有  10  个tokens\n",
      "interim analysis revealed it was futile, we would not reach an answer at n=60    有  18  个tokens\n",
      "subcutaneous administration of rrx-001 is no longer of interest    有  14  个tokens\n",
      "study was terminated by sponsor at recommendation of data monitoring committee after completion of first interim analysis as primary objective was met    有  22  个tokens\n",
      "lactic and metabolic acidosis of opb-51602 is not tolerable    有  16  个tokens\n",
      "due to other trials in the department    有  7  个tokens\n",
      "drug related aes observed upon repeat dosing that with longer treatment duration could become worse. required action on some biomarkers not observed    有  25  个tokens\n",
      "preliminary results showed no ability to predict pain by measuring hippus with pupillometry    有  18  个tokens\n",
      "the coherence therapy intervention could not be delivered in a reliable and valid way for a variety of reasons    有  19  个tokens\n",
      "fda approval of supplementation to ide/protocol amendment to terminate subject long term folpoor up    有  19  个tokens\n",
      "mode of application to be reconsidered by sponsor    有  9  个tokens\n",
      "because of the problem with cilotax stent permission    有  11  个tokens\n",
      "difficulty in downloading and saving data from the oximetry machine    有  12  个tokens\n",
      "some sites withdrew because no contract with insulin pump supplier    有  10  个tokens\n",
      "substantial design modifications required    有  5  个tokens\n",
      "device was modified and no longer available to investigator    有  9  个tokens\n",
      "preliminary analysis showed not clinically significant. study ended and closed 1/11/2018    有  20  个tokens\n",
      "expectation that within the set time period insufficient patients will be included, so endpoints will not be achieved    有  20  个tokens\n",
      "withdrawals from study due to anticipated effects from study drugs    有  11  个tokens\n",
      "could not receive fda approval for ind    有  8  个tokens\n",
      "methods of activation timing measurements too imprecise    有  9  个tokens\n",
      "took too long to accrue participants, stopped for feasibility concerns    有  12  个tokens\n",
      "dr. gyurak is no longer doing and ended her narsad early    有  16  个tokens\n",
      "the interim analysis performed on 09 november 2018, showed the failure to achieve the primary objective of effectiveness of the experimental treatment    有  26  个tokens\n",
      "reagants to test mediators couldnot be procured    有  12  个tokens\n",
      "we are currently engaged in other behavioral study    有  8  个tokens\n",
      "the study is halted prematurely by sponsoring organization    有  8  个tokens\n",
      "sponsor and principle investigator mutually agreed to terminate study and patients are no longer examined/treated    有  17  个tokens\n",
      "calculated sample size not achieved    有  6  个tokens\n",
      "suitable device for laser no longer available    有  8  个tokens\n",
      "all 4 sites were terminated due to poor folpoor-up of patients and poor interest in the study    有  21  个tokens\n",
      "the study costed more than expected, so the investigators decided to end it    有  15  个tokens\n",
      "study was withdrawn because the university wanted to bill study patients for use of the laser    有  16  个tokens\n",
      "drug receive fda approval    有  5  个tokens\n",
      "agreement not executed between site and sponsor    有  8  个tokens\n",
      "study reevaluation    有  3  个tokens\n",
      "poor feasiability    有  5  个tokens\n",
      "the main investigators are no longer working at the center    有  10  个tokens\n",
      "program discontinued to persue alternate indications    有  7  个tokens\n",
      "pupil measurement methodology determined not appropriate in this population    有  10  个tokens\n",
      "new evidence came to light to indicate that study was no longer relevant    有  13  个tokens\n",
      "the study was terminated to be redesigned for a trial according to ema proposal    有  15  个tokens\n",
      "pending interim analysis    有  3  个tokens\n",
      "this study will now be conducted in healthy volunteers    有  9  个tokens\n",
      "the technology showed rapid acceptance in the general population and we halted our feasibility demonstration study    有  16  个tokens\n",
      "this study was stopped after the publication of the symplicity htn-3 trial even before patient inclusion. the protocol (including the renal denervation device) were revised and a new trial conducted ( nct04947670)    有  45  个tokens\n",
      "interim analysis, revealed no additional effect of proactive over reactive service    有  13  个tokens\n",
      "poor scientific interest    有  4  个tokens\n",
      "due to ebola virus disease outbreak    有  7  个tokens\n",
      "pharmaceutical companies decision    有  5  个tokens\n",
      "decision to start a new study on dvt with another protocol    有  12  个tokens\n",
      "study was amalgamated with another study to include exercise as another intervention    有  14  个tokens\n",
      "superiority of one imaging method    有  7  个tokens\n",
      "potential participants had concerns about taking the study drug (methotrexate)    有  15  个tokens\n",
      "reb decision    有  2  个tokens\n",
      "study was unable to accrue subjects    有  7  个tokens\n",
      "unable to commence study due to closure of hospital department    有  10  个tokens\n",
      "competing study opened    有  4  个tokens\n",
      "because the russian authorities already approved the 2-dose cervarix™ schedule, the study was no longer needed for registration and hence it was cancelled    有  30  个tokens\n",
      "terminated due to medical supplies shortages due to the 2017 hurricane season    有  14  个tokens\n",
      "the maximal dose and schedule attained with gsk2816126 has shown insufficient evidence of clinical activity, and does not justify further clinical investigation    有  27  个tokens\n",
      "end of commercialization of poor polyamin diet    有  9  个tokens\n",
      "treatment failure on study medication observed    有  7  个tokens\n",
      "sponsor the return rights of the compound to the collaboration partner for further clinical development    有  15  个tokens\n",
      "study never got started; can't delete results    有  9  个tokens\n",
      "sponsor and site were unable to complete a final contract to support the study    有  14  个tokens\n",
      "company decided to remove clia test from market    有  9  个tokens\n",
      "student study which ended at the end of their course    有  10  个tokens\n",
      "the study was terminated as the asset was sold to another company who decided not to pursue this indication with this drug    有  22  个tokens\n",
      "pi and study coordinator both left the institution    有  8  个tokens\n",
      "rct/roll-in completed. cas/21mm/nested registry terminated (investigational device is no longer available)    有  25  个tokens\n",
      "trs probe performance does not meet primary outcome data requirements    有  10  个tokens\n",
      "pending further equipment and staff    有  5  个tokens\n",
      "eli lilly prematurely terminated the study    有  7  个tokens\n",
      "never did begin    有  3  个tokens\n",
      "small number of subjects    有  4  个tokens\n",
      "principal investigator and study sponsor decided to terminate the study early    有  11  个tokens\n",
      "the study was terminated early at the sponsor's discretion    有  10  个tokens\n",
      "resources were not readily available to begin the study    有  9  个tokens\n",
      "ind application withdrawn    有  3  个tokens\n",
      "unable to refine study measurements/protocol adequately    有  8  个tokens\n",
      "major protocol deviations compromised the study    有  6  个tokens\n",
      "competing priorities at the organization    有  6  个tokens\n",
      "hospital had initiated a conflicting study, hence the study was terminated    有  12  个tokens\n",
      "the lab was acquired by another company and has put this study's samples on hold    有  16  个tokens\n",
      "failure to accure    有  4  个tokens\n",
      "issues with tetramer staining    有  5  个tokens\n",
      "researcher changed jobs. unable to carry out the project    有  11  个tokens\n",
      "the institution was requiring extensive changes to the protocol    有  9  个tokens\n",
      "suspended as we are looking for more durable method/device    有  11  个tokens\n",
      "poor recuitment    有  5  个tokens\n",
      "not completed its inspection.(csr completed)    有  8  个tokens\n",
      "drug supplier suspended further clinical development of ganetespib    有  11  个tokens\n",
      "pi changed affiliation not beening alpoored to continue the trial in further cooperation. the sub-investigators did not see any option to continue the trial and made the decision to terminate the study    有  39  个tokens\n",
      "the trial was revised to be two protocols, one prevention, one eradication trials    有  16  个tokens\n",
      "study was closed mainly because the surgeons participating no longer had the infrastructure to support the research and weren't folpooring their subjects    有  25  个tokens\n",
      "pi no longer part of practice    有  6  个tokens\n",
      "personnel changes at study site    有  6  个tokens\n",
      "study was suspended due to organisational difficulties    有  8  个tokens\n",
      "investigator decided not to move forward with study prior to study start date    有  14  个tokens\n",
      "poor performance    有  3  个tokens\n",
      "development program of study drug volasertib was stopped by boehringer ingelheim due to manufacturing problems    有  22  个tokens\n",
      "the researcher and principal investigator working on this study left the institution    有  12  个tokens\n",
      "technical difficulties of probe measurement    有  5  个tokens\n",
      "device development not completed    有  4  个tokens\n",
      "poor cooperation and compliance    有  5  个tokens\n",
      "imp management difficulties    有  3  个tokens\n",
      "change of research focus    有  4  个tokens\n",
      "researchers decided to withdrawn the study due unavialble flc    有  14  个tokens\n",
      "due to the investigator leaving the institution, the study was terminated    有  12  个tokens\n",
      "due to interim analysis' results and definitions fixed in protocol    有  11  个tokens\n",
      "participant relapses led to abrupt stop of study    有  9  个tokens\n",
      "other strategies folpoored    有  5  个tokens\n",
      "change of jobs    有  3  个tokens\n",
      "another trial in the department directly competes for the the same patient population    有  14  个tokens\n",
      "discontinuation of the experimental treatment being tested    有  9  个tokens\n",
      "current protocol is not optimal/feasible    有  8  个tokens\n",
      "stopped for operational reasons    有  4  个tokens\n",
      "unable to perform the ultrasound    有  5  个tokens\n",
      "publication of guidelines advising against the use of ethanol locks    有  10  个tokens\n",
      "study termination due to program termination    有  6  个tokens\n",
      "not enough subject participation    有  4  个tokens\n",
      "poor support resources to complete study appropriately    有  8  个tokens\n",
      "poor local tolerance to injection    有  6  个tokens\n",
      "study not feasible with current resources    有  6  个tokens\n",
      "departure of principal investigator from the organisation    有  7  个tokens\n",
      "insufficient numbers of participating sites and hip surgery cases    有  10  个tokens\n",
      "funds depleted and ilness of principal investigator    有  9  个tokens\n",
      "gadolinium attenuation in vitro inadequate    有  8  个tokens\n",
      "due to a change in biogen idec's medical research plans    有  13  个tokens\n",
      "abbott received fda approval to transition the ongoing optisure pas to ep a new ep-passion real world evidence methodology    有  24  个tokens\n",
      "withdrawn from irb before approval    有  7  个tokens\n",
      "organization has withdrawn their 510k submission and stopped the study    有  12  个tokens\n",
      "ct scanner software incompatible    有  4  个tokens\n",
      "market move to des    有  4  个tokens\n",
      "primary analysis was completed in 2018 and continued minimal data collection from the one participant active in the study was not expected to add meaningful knowledge to the understanding of lapatinib    有  35  个tokens\n",
      "had been finished    有  3  个tokens\n",
      "because we don´t have the necessary technology anymore    有  9  个tokens\n",
      "technical problems with simulator    有  4  个tokens\n",
      "principle investigator is moving to another institution and plans to restart this proctocol in the new location    有  20  个tokens\n",
      "after results of other studies published : easy study became lapsed    有  12  个tokens\n",
      "terminated prior to randomised phase    有  6  个tokens\n",
      "after an interim analysis the company providing the product decided not to continue with the study    有  16  个tokens\n",
      "we have submitted a multi center study, with the same nutritional therapy    有  13  个tokens\n",
      "interim analysis showed incorrect use of simple rules    有  9  个tokens\n",
      "organizational barriers    有  3  个tokens\n",
      "it was decided that data from this study are no longer required and therefore it is not necessary to expose patients to the study medication    有  25  个tokens\n",
      "unable to engage surgeons to participate in the study    有  9  个tokens\n",
      "the study was terminated on the basis that protocol defined stopping criteria had been met    有  15  个tokens\n",
      "to assess product performance (test and reference products), move into further testing    有  14  个tokens\n",
      "company dissolved, no study devices available anymore    有  8  个tokens\n",
      "part 2 of study replaced by ntrp-101-202, assessing 3 doses of bryostatin    有  24  个tokens\n",
      "principal investigator made the decision to close study and not submit a renewal. poor fixed research personnel to carry out the study effectively    有  24  个tokens\n",
      "high failure rate    有  3  个tokens\n",
      "primary endpoint not met in folpoor-up study (invivo-100-105)    有  18  个tokens\n",
      "the stc has had financial limitations to start implementing the intervention    有  12  个tokens\n",
      "closure of gait analysis laboratory - unable to set up alternative gait laboratory in time for funders    有  20  个tokens\n",
      "paitents were unwilling to be randomly assigned to a placebo group    有  13  个tokens\n",
      "training protocol with no research objectives    有  6  个tokens\n",
      "based on outcome of previous study    有  6  个tokens\n",
      "sponsor closed the study due to poor response    有  8  个tokens\n",
      "did not go through with the study for logistical reasons    有  10  个tokens\n",
      "the study was terminated due to poor feasibility and poor interest at the participating sites    有  15  个tokens\n",
      "due to the pandemic, multiple sites were unable to complete patient visits resulting in less-than-optimal postoperative folpoor-up occurred. therefore, study objectives were not met and the decision was made to close the study early    有  44  个tokens\n",
      "unbalance in the composite endpoint between arms    有  8  个tokens\n",
      "clinical benefit was noted before the scheduled completion of the trial and the extension study was terminated early    有  18  个tokens\n",
      "after consultation with a medical expert the notified body confirmed premature termination of the study    有  15  个tokens\n",
      "no eligible subjects identified. study closed with irb    有  10  个tokens\n",
      "terminated to alpoor continued optimization of the product    有  10  个tokens\n",
      "5-y fup will not result in new perception, no diff. between groups at 1+3y fup    有  24  个tokens\n",
      "hlt determined that design changes are necessary before reopening a study    有  12  个tokens\n",
      "this study is not feasible to conduct as functional brain imaging capability is inadequate. cirb acknowledged in june 2016    有  24  个tokens\n",
      "nih grant ended    有  3  个tokens\n",
      "the computer is crushed and all data is lost (it was not able to recover it. last data was collected 6.17.14)    有  29  个tokens\n",
      "study drug became unaffordable for the purposes of the research    有  12  个tokens\n",
      "study terminated early based on adult ahf study crlx030a2301 results    有  16  个tokens\n",
      "an additional intervention, amendet to the study (3rd arm, not described here), has not received clearance by regulatory authorities    有  25  个tokens\n",
      "this research was not conducted at unm    有  7  个tokens\n",
      "sponsor (masimo) suspended trial due to change in corporate ownership    有  13  个tokens\n",
      "as another mps1 inhibitor was being developed in parallel, the strategic decision was to move forward with the development of the folpoor up compound only    有  30  个tokens\n",
      "reb approval expired    有  3  个tokens\n",
      "a preliminary analysis of data from this trial failed to demonstrate any signal of activity    有  15  个tokens\n",
      "suspended due to poor data    有  6  个tokens\n",
      "irb closed on 9/5/2018    有  11  个tokens\n",
      "sponser terminated early to start a larger feasability study    有  12  个tokens\n",
      "poor patient compliance and dropout during the period defined for the study    有  13  个tokens\n",
      "because the study is very complicated and cannot be performed in the practice    有  13  个tokens\n",
      "catheter occlusion events during the study drug infusion    有  11  个tokens\n",
      "we were unable to procure the supplement for this study    有  10  个tokens\n",
      "feasibility of population needed to complete study    有  8  个tokens\n",
      "change in trial design    有  4  个tokens\n",
      "interim analysis showed benefice of one therapy over the other one    有  13  个tokens\n",
      "in 14 participants who had lp, very poor level viremia was found in only 1    有  20  个tokens\n",
      "the study was stopped due to insufficient numbers of subjects to meet study design objectives    有  15  个tokens\n",
      "publication of recent trials showing no effect of epo in tbi    有  13  个tokens\n",
      "snuh-nm-333 ligand effect was judged to be insufficient    有  15  个tokens\n",
      "the trial was discontinued for legislative reasons    有  7  个tokens\n",
      "terminated due to a high number of protocol deviations secondary to non-study approved opioid administration    有  17  个tokens\n",
      "device voluntarily withdrawn from commercial use by manufacturer    有  8  个tokens\n",
      "conduct of the first analyses    有  5  个tokens\n",
      "nepal ministry of health implemented public drug treatment prior to the proposed start date    有  16  个tokens\n",
      "secondary to third interim analysis by the study dsmb    有  10  个tokens\n",
      "pi is no longer at mcw, study has been closed    有  12  个tokens\n",
      "preliminary data suggested a better approach available    有  9  个tokens\n",
      "the risk benefit in relapsed refractory aml does not favor continuation of the study    有  17  个tokens\n",
      "study stopped prematurely because of multiple logistic difficulties    有  8  个tokens\n",
      "decision to open a randomized controlled trial with two groups receiving different botulinum toxin in comparison to placebo group    有  21  个tokens\n",
      "study no longer relevant based on change in regulatory pathway for tfv 1% gel    有  17  个tokens\n",
      "study never commenced, and is now closed    有  8  个tokens\n",
      "not meeting primary objective of the study    有  7  个tokens\n",
      "the main investigators are no longer working at the the center    有  11  个tokens\n",
      "sufficient folpoor-up information obtained to support study goals    有  12  个tokens\n",
      "no eligible participant , technical difficulty, feasiblity    有  11  个tokens\n",
      "failed treatment response    有  3  个tokens\n",
      "results of 5 first patients show that chips' cauterization interferes the signal    有  17  个tokens\n",
      "technical difficulties with the wet bench side of proposed studies    有  10  个tokens\n",
      "researcher left institution    有  4  个tokens\n",
      "the trial could not be completed within the grant timeline    有  10  个tokens\n",
      "re-evaluate indication with the referring physicians    有  8  个tokens\n",
      "data no longer required to meet regulatory requirements    有  8  个tokens\n",
      "due to manufacturing problems the transdermal patch was not produced    有  12  个tokens\n",
      "technical problems with the device    有  5  个tokens\n",
      "recurrent equipment failures (used with custom eeg and erp recording software) precluded timely data collection and analysis activities    有  24  个tokens\n",
      "the drug being tested in this study is called tak-137. tak-137 is being tested to find a safe and well-tolerated dose and to assess how tak-137 is metabolized in people with attention-deficit/ hyperactivity disorder (adhd). this study will look at side effects and lab results in people who take tak-137. this study is designed as a randomized, sequential-cohort, multiple rising dose study. therefore, the tak-137 2 mg cohort will not start until the tak-137 0.5 mg cohort has completed, etc. this trial will be conducted in the united states. the overall time to participate in this study is up to 42 days. participants will make at least 2 visits to the clinic, including one 9-day period of confinement to the clinic. all participants will be contacted by telephone 7 days after the last dose of study drug for a folpoor-up assessment. a decision was made to terminate this study so that emerging data from preclinical studies could be further assessed    有  211  个tokens\n",
      "company acquired and trial was not pursued    有  7  个tokens\n",
      "after critique raised by peers there was a risk that the study could be interpreted as a marketing tool for a specific product more than a scientific study    有  28  个tokens\n",
      "departure of psychologist in charge of questionnaires and scales administered to patients as part of the evaluation of primary endpoint    有  21  个tokens\n",
      "no longer pursuing study at our site    有  7  个tokens\n",
      "the study was placed on hold by the fda due to manufacturing issues and was not restarted    有  18  个tokens\n",
      "irb approval withdrawn    有  4  个tokens\n",
      "insufficient improvement in primary measures under either condition    有  9  个tokens\n",
      "protocol's modifications requested by irb weren't feasible to continue the study    有  14  个tokens\n",
      "change in local healthcare policies and practices    有  7  个tokens\n",
      "study was terminated after completion of part 1, because part 2 was no longer appropriate    有  18  个tokens\n",
      "sponsor having financial difficulties    有  4  个tokens\n",
      "pi is moving to another university; resident researcher does not wish to continue study with another pi    有  18  个tokens\n",
      "project was completed    有  3  个tokens\n",
      "principal investigator leaving washington university and halting studies    有  9  个tokens\n",
      "study design not adequate    有  4  个tokens\n",
      "it has been decided by the sponsor not to conduct the trial    有  12  个tokens\n",
      "renal denervation has not been used as clinical method in our hospital the last two years    有  17  个tokens\n",
      "changed regulations of culture procedure    有  5  个tokens\n",
      "fmt for study indication has been permitted by israeli ministry of health    有  14  个tokens\n",
      "investigator is leaving the institution    有  6  个tokens\n",
      "the investigational devices need alterations before validation    有  8  个tokens\n",
      "project was suspended for personal issues    有  6  个tokens\n",
      "we have finally no financial support and any patients have been included    有  12  个tokens\n",
      "the dsmb conducted an interim analysis on overall survival, which showed that the treatment arm did not demonstrate a sufficient improvement in os vs. placebo    有  28  个tokens\n",
      "the quality of limulus amebocyte lysate (lal) test was poor    有  17  个tokens\n",
      "clinical team decision to terminate the study after the results from cohort 1 did not support conducting cohort 2    有  21  个tokens\n",
      "enough samples were collected for data analysis    有  8  个tokens\n",
      "this registry was planned to report on the phase ii portion of the study. nsabp decided not to proceed with the phase ii portion of the study    有  30  个tokens\n",
      "poor cure rate in the study (fluconazole) group    有  13  个tokens\n",
      "award was ended by nih for parent study    有  9  个tokens\n",
      "study has not been able to start due to difficulty in obtaining an intravenous formulation of cyclodextrin (intravenous 2hpbcd) suitable for man    有  33  个tokens\n",
      "review the study concept    有  4  个tokens\n",
      "termination of [18f]fluciclatide production    有  12  个tokens\n",
      "we have discontinued development of fpa008 in ra    有  10  个tokens\n",
      "study drug is no longer supplied by grantor    有  9  个tokens\n",
      "study was terminated based on sponsor discretion    有  7  个tokens\n",
      "no significant results during interim analysis    有  6  个tokens\n",
      "serve-hf results showed asv increased cv mortality in patients with reduced lvef    有  17  个tokens\n",
      "this protocol was closed and will be redesigned and submitted as a new protocol    有  14  个tokens\n",
      "fda released from conducting    有  5  个tokens\n",
      "this study was stopped because of difficulties of supplying the drug    有  11  个tokens\n",
      "application for regulatory approval withdrawn    有  5  个tokens\n",
      "subjects preferred the 5 night overnight system in terms of ease of use    有  14  个tokens\n",
      "internal desicions    有  3  个tokens\n",
      "possible change in study protocol    有  5  个tokens\n",
      "study diet is no longer available to match with the previous participants    有  12  个tokens\n",
      "standard of care has changed    有  5  个tokens\n",
      "research question answered by another group of researchers (sviggum et al)    有  15  个tokens\n",
      "progressive disease    有  3  个tokens\n",
      "not subsidized, will not start in the near future    有  10  个tokens\n",
      "the study sponsor found the trial to be not viable    有  10  个tokens\n",
      "the data that was critical to the study was not able to be obtained    有  14  个tokens\n",
      "the study was terminated due to the primary end point being met    有  12  个tokens\n",
      "missing ressources. the study official has left and will not be replaced    有  14  个tokens\n",
      "change in the development strategy    有  5  个tokens\n",
      "local irb required us to submit amendment as a separate study    有  12  个tokens\n",
      "sponsor is bankrupt    有  3  个tokens\n",
      "phase 2 portion not initiated, no longer pursuing ovarian cancer indication    有  13  个tokens\n",
      "poor dedicated resources at this time    有  7  个tokens\n",
      "logistics unresolved at the irb at elmhurst hospital    有  11  个tokens\n",
      "the study was suspended due to shortage of the study drug (amicar)    有  15  个tokens\n",
      "the portable psg machine can not be available any more    有  11  个tokens\n",
      "no canadian centre interested in conducting study in a reasonable timeframe    有  11  个tokens\n",
      "poor adequate sample size    有  5  个tokens\n",
      "new departmental administration, loss of key study faculty    有  10  个tokens\n",
      "as vaccine coverage rates have drastically improved in venezuela, the study lost its objective to show positive impact of the vaccine to stimulate higher usage    有  27  个tokens\n",
      "given the strength of cyp3a4 inhibition observed in cohort 1, there is no rationale to investigate higher doses of gsk2647544 in the folpooring two cohorts    有  37  个tokens\n",
      "treatment strategy changed    有  4  个tokens\n",
      "did not receive irb approval from our institution therefore the study was closed    有  14  个tokens\n",
      "drug development stopped    有  3  个tokens\n",
      "no participation over the long period    有  6  个tokens\n",
      "the trial was terminated because it was determined that the usability of the mind1 system in the intended population was necessary before conducting this trial    有  26  个tokens\n",
      "recent findings suggest that letrozole may be a superior clomiphene citrate    有  17  个tokens\n",
      "study discontinued. superseded by nct02973893 vf00102    有  14  个tokens\n",
      "the study was paused initially pending a review of the study design. the decision was then taken not to resume the study    有  23  个tokens\n",
      "standard of care improved combination treatment of ipilimumab plus nivolumab    有  16  个tokens\n",
      "increased incidence of respiratory depression in the morphine group    有  11  个tokens\n",
      "company was dissolved    有  3  个tokens\n",
      "investigaotr no longer at lu    有  7  个tokens\n",
      "the study was stopped because of poor interest    有  8  个tokens\n",
      "test products expired    有  3  个tokens\n",
      "insufficient research manpower    有  4  个tokens\n",
      "held for blocking amendment then determined not to re-open    有  10  个tokens\n",
      "disapointing randomization rate    有  7  个tokens\n",
      "loss of research personnel    有  4  个tokens\n",
      "study discontinued due to data quality issues    有  7  个tokens\n",
      "investigator non compliance    有  4  个tokens\n",
      "study had a minor contingency that could not be resolved with the irb    有  14  个tokens\n",
      "another study has been planned, so we did not initiate this one    有  13  个tokens\n",
      "stage 1 complete; stage 2 and 3 not pursued    有  13  个tokens\n",
      "this study will be conducted in healthy volunteer subjects    有  9  个tokens\n",
      "decision made to terminate due to difficulty in procurement of adequate supply of treatment drug. decision made on april 2023 to terminate study    有  26  个tokens\n",
      "organizational problems    有  3  个tokens\n",
      "nature of study was changed from act to retrospective chart review    有  11  个tokens\n",
      "difficulty in financing the research    有  5  个tokens\n",
      "manufacturer of the mfi qrs fragmentation systems used in the study, has filed for insolvency    有  19  个tokens\n",
      "withdrawn from irb at pi's request    有  9  个tokens\n",
      "investigational product unavailable due to manufacturing issues    有  9  个tokens\n",
      "the study is terminated prematurely as the sponsor decided to discontinue program of nhs-il2 [msb0010445]    有  25  个tokens\n",
      "suspended for an interim review of (car) cd19 research strategy for the treatment of cd19 positive all    有  22  个tokens\n",
      "device used for eye-blinks did not work as performed    有  11  个tokens\n",
      "participant numbers too poor. could not ingest required fat    有  10  个tokens\n",
      "pi moved away from bern; poor personnel in bern to conduct the study within a reasonable time frame    有  19  个tokens\n",
      "an interim analysis found the study would not be able to reach significance without a large increase in subjects which was not feasible    有  23  个tokens\n",
      "an interim analysis demonstrated no benefit of high dose vitamin d when compared to standard dose vitamin d in the reduction or prevention of arthralgia    有  28  个tokens\n",
      "drug company withdrew support folpooring re-examination of benefit-risk assessment for the investigational use of imetelstat in this population    有  27  个tokens\n",
      "the study was stopped due to time constraints and resources    有  10  个tokens\n",
      "termination was due to identified errors in data management handling after an internal audit by the sponsor performed by third party    有  21  个tokens\n",
      "scientific rationale is deemed obsolete. funders lost interest in the trial    有  13  个tokens\n",
      "unable to get mri of patients within reasonable time on a local hospital    有  14  个tokens\n",
      "company turnover    有  2  个tokens\n",
      "study was changed to insulin, hypotension and sarcopenia    有  13  个tokens\n",
      "site never got up and running due to institutional issues    有  10  个tokens\n",
      "retrospective study from december 2007 to may 2010    有  14  个tokens\n",
      "unable to get an ind from the fda for the walnut powder    有  13  个tokens\n",
      "not enough staff resource to complete study    有  7  个tokens\n",
      "unable to accrue as planned for optional biopsies    有  11  个tokens\n",
      "based on results from alexion protect dgf study    有  10  个tokens\n",
      "the study was cancelled    有  4  个tokens\n",
      "pi started new position    有  4  个tokens\n",
      "study design changed and will be resubmitted as a new study    有  13  个tokens\n",
      "greater mortality in intervention group    有  5  个tokens\n",
      "patient inclusion was very tedious and poorer than expected. (7 patients in 5 years)    有  18  个tokens\n",
      "study closed by sponsor    有  4  个tokens\n",
      "issues with obtaining precursor materials for synthesis    有  7  个tokens\n",
      "no man power    有  3  个tokens\n",
      "data needs met    有  3  个tokens\n",
      "current design not able to measure the outcomes anticipated    有  9  个tokens\n",
      "solanezumab did not meet the study's primary endpoint    有  13  个tokens\n",
      "concern of side effects    有  5  个tokens\n",
      "lead investigator no longer at institution    有  6  个tokens\n",
      "trial was stopped because study not required for development    有  9  个tokens\n",
      "poor compliance of the clinical site    有  7  个tokens\n",
      "clinicians were not offering the study to eligible potential subjects    有  11  个tokens\n",
      "closed due to internal and external factors    有  7  个tokens\n",
      "as of november 2013, the security situation in rural northern mozambique is no longer suitable for this clinical trial    有  23  个tokens\n",
      "representativeness and results about treatment and health condition available    有  11  个tokens\n",
      "impossible to get a written informed consent beforehand    有  9  个tokens\n",
      "not sufficient financial - staff resources    有  6  个tokens\n",
      "technical issues with availability of relevant personnel    有  7  个tokens\n",
      "continuing beyond the pilot phase of the trial was deemed unfeasible    有  14  个tokens\n",
      "ci had other commitments    有  4  个tokens\n",
      "decision was made not to start the study before it was initiated    有  12  个tokens\n",
      "fda's draft guidance (march 2015) provided option of in-vitro or in-vivo studies for bioequivalence. small study size resulted in negative culture rates    有  37  个tokens\n",
      "the study was terminated due to the unavailability of continuous glucose monitoring sensors (cgms) which were required to assess the primary end-point    有  27  个tokens\n",
      "sponsor discontinued the research    有  4  个tokens\n",
      "it ended early because it would not be possible to meet the target number    有  14  个tokens\n",
      "trial would not be completed in a reasonable timeframe per ctep guidelines    有  13  个tokens\n",
      "interim analysis revealed that no statistical difference will be identified after inclusion of the patient cohort as foreseen in the sample size calculation    有  25  个tokens\n",
      "termination due to high current screen rate failure and unreliable psa mrna assay    有  15  个tokens\n",
      "scientific/feasibility approval required prior to irb review    有  11  个tokens\n",
      "insufficient numbers of sino-implant users available for study participation    有  13  个tokens\n",
      "inconclusive results, large inter-individual variation, insufficient statistical power    有  14  个tokens\n",
      "one of the study drugs was no longer available on a worldwide level    有  13  个tokens\n",
      "erroneously duplicated study    有  5  个tokens\n",
      "not able to find enough participants for this study    有  9  个tokens\n",
      "inadequate data    有  4  个tokens\n",
      "on hold due to competing departmental studies    有  8  个tokens\n",
      "change in principal investigator and protocol revisions delayed study start and ultimately the decision was made to cancel the study    有  20  个tokens\n",
      "trial has been suspended due to poor resource and staff    有  10  个tokens\n",
      "the grant for this study was not alpoored    有  10  个tokens\n",
      "the collected data was finished    有  5  个tokens\n",
      "folpooring the emergence of an unexpected pharmacodynamic effect, the sponsor has decided to conclude the study early without fully achieving its objective    有  26  个tokens\n",
      "technical issues with intervention    有  4  个tokens\n",
      "staffing difficulties to run project    有  6  个tokens\n",
      "institution not able to carry out research as of 2015    有  12  个tokens\n",
      "due to bankruptcy of the cro company    有  7  个tokens\n",
      "investigators don't want to conduct this study as time is limited    有  13  个tokens\n",
      "advisor left the university and student moved to a clinical track    有  11  个tokens\n",
      "main investigator changed affiliation    有  4  个tokens\n",
      "problems with drug supply    有  4  个tokens\n",
      "study not accruing    有  4  个tokens\n",
      "modification the study with a new questionnaire was not successful    有  10  个tokens\n",
      "plan to change the trial design    有  6  个tokens\n",
      "investigators decided not to move forward with project    有  9  个tokens\n",
      "interventional radiologist suffered stroke and unable to perform rfa procedure    有  14  个tokens\n",
      "similar study being conducted, sponsor decided to not duplicate study    有  11  个tokens\n",
      "not enough staff to collect data    有  6  个tokens\n",
      "study was redesigned and taken over by a ph.d-student    有  12  个tokens\n",
      "amendment changes were significant enough to warrant a new study    有  11  个tokens\n",
      "pi changed work place    有  4  个tokens\n",
      "study objectives met so study concluded earlier than planned hence we terminated the study    有  14  个tokens\n",
      "ineffectiveness    有  3  个tokens\n",
      "the study is going to open in a new site    有  10  个tokens\n",
      "technical problems with equipment from the main outcome    有  8  个tokens\n",
      "ind required    有  2  个tokens\n",
      "due to potential competition with a post-marketing study requested by fda    有  14  个tokens\n",
      "poor response rate    有  4  个tokens\n",
      "study withdrawn from irb approval process by pi    有  9  个tokens\n",
      "study was terminated early by the sponsor due to unblinding between study drug and placebo groups at the subject, site and sponsor levels    有  26  个tokens\n",
      "duplicate study    有  2  个tokens\n",
      "study not executed    有  3  个tokens\n",
      "the risk benefit in relapsed refractory sclc does not favor continuation of the study    有  17  个tokens\n",
      "changes in study design    有  4  个tokens\n",
      "study was prematurely discontinued as it was unethical to continue based on a change in ranibizumab (rfb) marketing authorization    有  26  个tokens\n",
      "the number of anticipated participants was not achieved    有  8  个tokens\n",
      "no appreciable difference noted between methods of delivery    有  9  个tokens\n",
      "budget exceeded    有  2  个tokens\n",
      "changes in study design by sponsor not acceptable for participating    有  10  个tokens\n",
      "strategic priorities impacted study    有  5  个tokens\n",
      "gsk has decided to terminate the product development of foretinib and conclude our development agreement with exelixis    有  22  个tokens\n",
      "inclusion criteria not met at preoperative clinic visit screening. no eligible participants    有  15  个tokens\n",
      "replaced with another clinical trial    有  6  个tokens\n",
      "this device feasibility study was using a microelectrode array device to determine viability of the product. design and operating specification of the device were established. a new ide trial has been initiated    有  37  个tokens\n",
      "drugs/devices discontinued    有  4  个tokens\n",
      "extended carboplatin infusion did not reduce frequency of hypersensitivity reactions    有  13  个tokens\n",
      "key personnel left institution prior to study completion    有  8  个tokens\n",
      "fda released requirement to complete study    有  7  个tokens\n",
      "problem with balloon catheter    有  5  个tokens\n",
      "protocol not activated    有  3  个tokens\n",
      "study was terminated early as sponsor wanted to develop an improved formulation    有  12  个tokens\n",
      "south african health authorities now promote that hiv positive mothers should receive anti-retroviral drugs and breastfeed their infants    有  23  个tokens\n",
      "trial initiated, but data collection was inadequate. analysis was terminated    有  12  个tokens\n",
      "poor insurance coverage for proton beam treatment    有  8  个tokens\n",
      "due poor subjects    有  3  个tokens\n",
      "the mobile phone app upon which the study was based was not available    有  13  个tokens\n",
      "the et catheters were outdated    有  6  个tokens\n",
      "data collection was terminated due to unavailability of additional participants    有  11  个tokens\n",
      "poor incidence of primary endpoint    有  6  个tokens\n",
      "the sponsor's clinical program for the agent used in this study was discontinued    有  14  个tokens\n",
      "company strategic change    有  3  个tokens\n",
      "study stopping criteria was met    有  5  个tokens\n",
      "another study with similar methods was recently published    有  8  个tokens\n",
      "personnel change, unable to continue study    有  8  个tokens\n",
      "pi is moving to a different institution    有  7  个tokens\n",
      "absence of positive results    有  5  个tokens\n",
      "insufficient data to continue. study will not resume    有  10  个tokens\n",
      "similar study data published    有  4  个tokens\n",
      "major revisions needed in study    有  5  个tokens\n",
      "no sufficient numbers of eligible participants    有  6  个tokens\n",
      "pi has left the study institution    有  6  个tokens\n",
      "the patient population changed. unable to find patients that meet study criteria    有  13  个tokens\n",
      "overweight of hard-ware removals in the dynaloc group    有  14  个tokens\n",
      "required catheters not available    有  5  个tokens\n",
      "an incident, burned tube, happened before intubation. the promoter decided to stop the study    有  19  个tokens\n",
      "study to be redesigned based on initial results    有  8  个tokens\n",
      "principal investigator is leaving institution    有  5  个tokens\n",
      "signing a contract with the company owning the equipment    有  10  个tokens\n",
      "second cohort not opened because simon-two_step model failed    有  11  个tokens\n",
      "unable to meet all criteria as outlined for participants    有  9  个tokens\n",
      "due to former trials, drug has not demonstrated a clinical profile sufficient to move forward in mcrpc    有  20  个tokens\n",
      "could not obtain dedicated ultrasound device    有  6  个tokens\n",
      "due to evolving scientific knowledge in the field that would make the questions being addressed in the trial less relevant    有  20  个tokens\n",
      "compound recently partnered with another company for continued development    有  9  个tokens\n",
      "vaccine production halted in 2015, thus study is terminated    有  13  个tokens\n",
      "study was stopped before progressive disease or death of alive subjects    有  11  个tokens\n",
      "rising costs have made continuing the study untenable    有  9  个tokens\n",
      "withdrawal of ind    有  4  个tokens\n",
      "no consensus among trial centers regarding protocol    有  7  个tokens\n",
      "no eligible subjects located    有  4  个tokens\n",
      "new study written    有  3  个tokens\n",
      "insufficient biological material for analysis    有  6  个tokens\n",
      "ansm decision due to veino occlusive disease (security alert)    有  14  个tokens\n",
      "autorities vorbidden this dispositif in other trial    有  10  个tokens\n",
      "new method of pain control pushed by surgeons    有  8  个tokens\n",
      "the sponsor is terminating the study because the primary objective was achieved after 5 of the 6 subjects were assessed in the final cohort    有  26  个tokens\n",
      "resources were refocused into another project preventing this project from starting    有  12  个tokens\n",
      "pharmaceutical company pulled support for the trial    有  9  个tokens\n",
      "severe side effects & poor target engagement    有  8  个tokens\n",
      "equipment malfunction    有  2  个tokens\n",
      "change in study staff at the site, change in sponsor direction    有  12  个tokens\n",
      "did not obtain health canda approval for drug use in reasonable time and moved onward to new trial    有  19  个tokens\n",
      "updating protocol and consents    有  5  个tokens\n",
      "change in technology    有  3  个tokens\n",
      "drug (aflibercept) no longuer available for the study    有  14  个tokens\n",
      "technical difficulties (reduced staff plus university strike)    有  10  个tokens\n",
      "unavailability of clarithromycin 250 mg in the market    有  13  个tokens\n",
      "excessive protocol deviations due to strict nature of diet requirements    有  11  个tokens\n",
      "gpdc decided to terminate the study    有  7  个tokens\n",
      "the sample size was not completed    有  6  个tokens\n",
      "one of the diuretic which is planned to be used in the study is no longer available    有  19  个tokens\n",
      "problem with ip supply    有  4  个tokens\n",
      "study concept vacated due to sample collection issues    有  9  个tokens\n",
      "the study was withdrawn from the ind    有  7  个tokens\n",
      "new data makes this trial unethical    有  6  个tokens\n",
      "study stopping criteria met with regards to vital sign measurements post dose    有  12  个tokens\n",
      "sponsor chose to close    有  4  个tokens\n",
      "clinic closed    有  2  个tokens\n",
      "we must delay the study for some financial reasons    有  9  个tokens\n",
      "principle investigator was unable to fulfill responsibilities    有  8  个tokens\n",
      "results of interim analysis indicate no statistically significant difference in the primary objective between the two arms at baseline and 12 months of folpoor-up    有  28  个tokens\n",
      "insufficient faculty and staff    有  5  个tokens\n",
      "premature terminated at institution request    有  7  个tokens\n",
      "site did not want to pursue study    有  7  个tokens\n",
      "study never initiated. ind placed on hold    有  8  个tokens\n",
      "pi did leave hospital (retired)    有  8  个tokens\n",
      "gsk has elected to terminate development principally as a result of the statin drug-drug interaction (ddi) study    有  24  个tokens\n",
      "gsk has merged all individual pregnancy registries, which are terminated, for its seasonal influenza vaccines into one combined registry, epi-flu-039 vs us pr    有  33  个tokens\n",
      "recuitment target non obtained    有  6  个tokens\n",
      "biostatistician determined 20 subjects would be adequate to perform statistics    有  15  个tokens\n",
      "study was withdrawn prior to r&d approval    有  9  个tokens\n",
      "we faced technical problem before conducting this study    有  8  个tokens\n",
      "this study never started due to delays in medication development    有  10  个tokens\n",
      "the study was stopped because in two other clinical studies the drug was not superior in comparison with placebo    有  19  个tokens\n",
      "more progressive stroke in one arm    有  6  个tokens\n",
      "company decided to discontinue trial to focus on development program next steps    有  13  个tokens\n",
      "original study purpose accomplished    有  4  个tokens\n",
      "termination due to relevant update of the operation system. adaption of the application was not foreseen in the intervention study    有  23  个tokens\n",
      "change in regulatory status    有  4  个tokens\n",
      "decision after interims analysis    有  5  个tokens\n",
      "met primary endpoint    有  3  个tokens\n",
      "study never officially opened    有  4  个tokens\n",
      "major structural and organizational changes at the nicu    有  9  个tokens\n",
      "did not meet predetermined primary endpoint    有  6  个tokens\n",
      "poor clinical cases    有  4  个tokens\n",
      "the primary objective of pfs did not meet pre-specified criteria    有  13  个tokens\n",
      "the support group need to have some change    有  8  个tokens\n",
      "interim analysis indicated accuracy unchanged from previous versions    有  9  个tokens\n",
      "organisational changes at primary care units    有  8  个tokens\n",
      "behavioral manipulation failed so the trial did not occur    有  10  个tokens\n",
      "limited resources; irb approval was not maintained    有  9  个tokens\n",
      "study site change to thailand    有  6  个tokens\n",
      "the applicant decided to close the study    有  7  个tokens\n",
      "change in study consent process at study site so that study had to be terminated    有  15  个tokens\n",
      "sponsor stopped supplying study drug    有  5  个tokens\n",
      "fda's draft guidance (revised march 2015) provided two options for determining bioequivalence: 1) in-vitro or 2) in-vivo studies    有  37  个tokens\n",
      "the trend was observed toward higher mortality among the patients receiving the intervention thymoglobulin on day 8 after hematopoietic cell transplantation    有  28  个tokens\n",
      "problems with product performance    有  4  个tokens\n",
      "another regulatory way was defined    有  5  个tokens\n",
      "study stopped after results of cabozantinib phase 3 crpc study xl184-307    有  20  个tokens\n",
      "batch recall for misago terumo self-expanding peripheral stent systems.(withdrawal from the market)    有  21  个tokens\n",
      "a change in research priorities after a merger    有  8  个tokens\n",
      "discretion of pi    有  4  个tokens\n",
      "data income too poor    有  4  个tokens\n",
      "resources allocated elsewhere    有  3  个tokens\n",
      "pending resolution of study drug issues    有  6  个tokens\n",
      "study was terminated as per barda decision to terminate contract    有  11  个tokens\n",
      "industry decline to supply study drug    有  6  个tokens\n",
      "study was never approved by irb so was never initiated    有  11  个tokens\n",
      "the study was terminated due to an unexpected preliminary result obtained from the study with cr8020    有  18  个tokens\n",
      "poor initial results. scans were of insufficient quality for study purpose    有  13  个tokens\n",
      "changing indication from breast cancer to metastatic colorectal cancer    有  11  个tokens\n",
      "insufficient separation in session duration between randomized treatment groups    有  10  个tokens\n",
      "the study was never performed and closed    有  7  个tokens\n",
      "unable to implement the intervention    有  5  个tokens\n",
      "logistics and financial    有  4  个tokens\n",
      "unable to build the app for the clinical trial    有  9  个tokens\n",
      "research changed directions    有  3  个tokens\n",
      "with 50 patients, the measure of assist vital capacity has been validated    有  14  个tokens\n",
      "sponsor internal decision    有  3  个tokens\n",
      "personell    有  2  个tokens\n",
      "study is not feasible    有  4  个tokens\n",
      "fda waived the pediatric study requirement for this application    有  10  个tokens\n",
      "pi moving outside va- grant not transferable    有  9  个tokens\n",
      "methodologicals and logistics issues    有  6  个tokens\n",
      "production of imp has stopped    有  5  个tokens\n",
      "poor resources and personnel    有  5  个tokens\n",
      "most of our patients had no willingness to participate in the survey    有  12  个tokens\n",
      "the study was suspended since july 27th 2016 because of unavailability of everolimus    有  21  个tokens\n",
      "poor available participants that meet criteria    有  7  个tokens\n",
      "the study was terminated. six subjects were consented & all were withdrawn before any study activities took place    有  20  个tokens\n",
      "study aff006a was early terminated by the sponsor based on the results of study aff006    有  18  个tokens\n",
      "resignation of principal investigator    有  6  个tokens\n",
      "inability to accrue due to changing treatment landscape (pd-1 approvals)    有  16  个tokens\n",
      "technical problems with measure of cfu's. outcomes published: pmid:16986483    有  18  个tokens\n",
      "study design has been substantially revised and a new registration will be made in the future    有  16  个tokens\n",
      "ind no longer available    有  4  个tokens\n",
      "irb closed study: irregularities in documentation of informed consent, hipaa    有  15  个tokens\n",
      "study not conducted    有  3  个tokens\n",
      "training procedure was not effective    有  5  个tokens\n",
      "original study product (vsl #3) became unavailable; change in study collaborator and product    有  19  个tokens\n",
      "the sponsor was no longer in a position to sponsor a ctimp. study did not open    有  18  个tokens\n",
      "we are now considering revision of the ind to determine maximum tolerated dose    有  13  个tokens\n",
      "lacking algorithms led to abortion of project    有  8  个tokens\n",
      "no positive results were detected    有  5  个tokens\n",
      "decision of the sponsor for early benefits    有  7  个tokens\n",
      "the clinical trial was suspended for the reason that preliminary results in 20 patients didn't show a significant curative effect of observed treatment    有  26  个tokens\n",
      "required resources not available at the moment    有  7  个tokens\n",
      "shutdown of the department of inflammatory diseases at novo nordisk    有  11  个tokens\n",
      "50cc tah-t received fda approval march 5, 2020    有  15  个tokens\n",
      "we switched this study design to another study per iec's recommendations    有  13  个tokens\n",
      "discontinued due to significant delays in the expected availability of data    有  12  个tokens\n",
      "updates to device    有  3  个tokens\n",
      "poor effect in initial subjects    有  6  个tokens\n",
      "change of the study site due to the current political climate in myanmar    有  14  个tokens\n",
      "device modification and simplification of procedural steps    有  8  个tokens\n",
      "for administraive reasons    有  5  个tokens\n",
      "no go decision for abbv-838    有  8  个tokens\n",
      "the study was terminated early to roll over participants to open label extension study nct02594124    有  19  个tokens\n",
      "difficulties with protocol compliance in both arms. will simplify protocol    有  13  个tokens\n",
      "not sure if we are going to do this study now    有  11  个tokens\n",
      "study never start    有  3  个tokens\n",
      "unexpected toxicities    有  3  个tokens\n",
      "study was prematurely terminated    有  4  个tokens\n",
      "study design was amended to include a control - reregistered as nct02465775    有  19  个tokens\n",
      "standard of care was modified at the primary institution    有  9  个tokens\n",
      "a decision was made to terminate the study due to the changing treatment landscape for the development of new agents in combination in hodgkin lymphoma    有  28  个tokens\n",
      "study feasibility issues    有  3  个tokens\n",
      "study withdrawn as technology already proven with data no longer needed    有  11  个tokens\n",
      "successful proof of concept study after 1 subject    有  9  个tokens\n",
      "based on overall benefit-risk assessment    有  6  个tokens\n",
      "missing fund to continue    有  4  个tokens\n",
      "no new investigational product can be delivered to the site    有  11  个tokens\n",
      "trial was discontinued due to inadequate signal from study eeg leads    有  12  个tokens\n",
      "shriner's burn hospital closed the study and access to study-related data is unavailable. we are unable to submit the additional information or results-data    有  28  个tokens\n",
      "continuing the trial was considered to be superfluous    有  11  个tokens\n",
      "sponsor requirements    有  2  个tokens\n",
      "resensitization or clinical benefit was not observed    有  10  个tokens\n",
      "cystic fibrosis (cf) data from the double-blind cf study ptc124-gd-021-cf did not meet endpoints    有  28  个tokens\n",
      "pi has requested for this study be closed due to technical issues    有  12  个tokens\n",
      "recent advances in the treatment of b cell malignancies resulting in new treatments being approved for marketing and many others in late stage development    有  25  个tokens\n",
      "the study was stopped due to the judicial liquidation of the cro in charge of this study    有  18  个tokens\n",
      "evidence that the dose is insufficient    有  7  个tokens\n",
      "the researcher quit the study    有  5  个tokens\n",
      "due to the reason that not all participants agree to have anesthesia and postoperative management at the same time    有  20  个tokens\n",
      "needed equipment failed before the study was started    有  8  个tokens\n",
      "this study was terminated to prevent duplicative research efforts    有  10  个tokens\n",
      "abbott has decided to discontinue our percutaneous heart pump (php) program and the shield ii trial because the product was not meeting the needs of the patients it was intended to serve    有  38  个tokens\n",
      "preliminary results showed that the use of the cloths helped prevent infections    有  15  个tokens\n",
      "existing trials demonstrate reduction in fluoroscopy with mediguide    有  12  个tokens\n",
      "the device used was removed from the market    有  8  个tokens\n",
      "product unavailability    有  3  个tokens\n",
      "due to product change    有  4  个tokens\n",
      "operational barriers prevent critical specimen analyses from being performed    有  10  个tokens\n",
      "actually limited personnel ressources    有  5  个tokens\n",
      "study design changed significantly; was submitted as a different protocol    有  11  个tokens\n",
      "because the study has not yet sponsorship    有  7  个tokens\n",
      "the lung transplantation program at the site is on hold    有  10  个tokens\n",
      "medtronic support terminated    有  5  个tokens\n",
      "death of study initiator    有  4  个tokens\n",
      "company and sheba did not reach an agreement    有  9  个tokens\n",
      "failed to include the required number of participants    有  8  个tokens\n",
      "due to significant decrease of perinatal mortality in the cerclage group    有  15  个tokens\n",
      "changes in treatment plan affecting drug therapy choices    有  8  个tokens\n",
      "study stopped by local authorities    有  5  个tokens\n",
      "due to logistic reason    有  4  个tokens\n",
      "the study plan was cancelled because patient registration was delayed for the trials    有  13  个tokens\n",
      "technical problems, unreliability of the measured parameters    有  10  个tokens\n",
      "vandetanib is no longer available as sanofi has decided not to provide additional drug. all subjects are off-study    有  26  个tokens\n",
      "withdrawn due to poor resources    有  6  个tokens\n",
      "initial analysis of results warranted a study re-design and work on the study was suspended    有  16  个tokens\n",
      "unable to maintain a waitlist long enough to serve as a control group    有  14  个tokens\n",
      "the post-treatment recurrence rate was expected to be different between two treatment groups    有  15  个tokens\n",
      "investigator elected to end the study    有  7  个tokens\n",
      "contamination of the pitié-salpêtrière biotherapy laboratory    有  16  个tokens\n",
      "difficult for recruting    有  6  个tokens\n",
      "unable to find eligible participants to participate in the study    有  10  个tokens\n",
      "new prepositioned protocol being developed to optimize its use in the disaster setting and broaden its reach    有  19  个tokens\n",
      "the researcher couldnt handle it    有  6  个tokens\n",
      "information of other studies with abseb bioresorbable scaffolds showed a higher thrombotic risk than before, the risk for the patients is estimated too high    有  33  个tokens\n",
      "few eligible patients, dialysate drainage problem, measurement bias : not all currently marketed laboratory instruments are able to dose peritoneal dialysate    有  29  个tokens\n",
      "based on feedback from fda    有  6  个tokens\n",
      "study was stopped by sponsers internal reason    有  8  个tokens\n",
      "upon recommendation from the data monitoring committee    有  7  个tokens\n",
      "study terminated due to company's decision to discontinue drug development    有  12  个tokens\n",
      "equipment/software did not work as anticipated    有  7  个tokens\n",
      "this study was never started    有  5  个tokens\n",
      "the results did not demonstrate sufficient clinical benefit induced specifically by the active treatment to justify continuation of the trial    有  20  个tokens\n",
      "the study was terminated at the time of interim analysis since none of the participants showed a psa response    有  20  个tokens\n",
      "loss of study site    有  4  个tokens\n",
      "irb study closure facilitated by investigator    有  7  个tokens\n",
      "no more participants taking atripla    有  7  个tokens\n",
      "main outcome could not be ekstracted from database    有  10  个tokens\n",
      "feasability phase completed: cost evaluation    有  7  个tokens\n",
      "unable to accrue    有  4  个tokens\n",
      "an industry-wide, alternative, post-market study has been initiated    有  12  个tokens\n",
      "it was logistically difficult to obtain the drug needed to conduct the study    有  14  个tokens\n",
      "this is project was determined to be not research, and the irb has no oversight    有  17  个tokens\n",
      "study cancelled - no results    有  5  个tokens\n",
      "cancelled according to phd-protocol with insufficient time to complete the study    有  14  个tokens\n",
      "resource constraints at participating sites    有  5  个tokens\n",
      "poor resources to complete the study    有  7  个tokens\n",
      "poor availibility of eligible subjects    有  7  个tokens\n",
      "evidence of thrombectomy for acute stroke was established    有  11  个tokens\n",
      "not relevant to the sponsor    有  5  个tokens\n",
      "could not receive facility approval    有  5  个tokens\n",
      "drugs not available    有  4  个tokens\n",
      "site has not reliably responded medtronic team since the transition from sponsor twelve. no data entry completed since february 2018. last study subject passed final study visit window. no data is expected to be entered    有  43  个tokens\n",
      "pending pilot study results evaluation    有  5  个tokens\n",
      "insufficient financial resources to conduct research and complete trial    有  10  个tokens\n",
      "the study is discarded by the sponsor    有  7  个tokens\n",
      "we are not going to complete this study with healthy volunteers at this time    有  14  个tokens\n",
      "study was terminated early due to results from previous cmx study    有  12  个tokens\n",
      "the hypothesis we had that we could predict the growth rate from pet uptake could not be confirmer and 3-year folpoor up was no longer considered motivated    有  33  个tokens\n",
      "technology licensed to third party. sponsor did not proceed with study    有  12  个tokens\n",
      "wireless connectivity challenges with device and mobile app    有  9  个tokens\n",
      "drug manufacturing issues    有  3  个tokens\n",
      "principal investigator has left the university. research has been discontinued prior to study completion; registry study: no analysis    有  21  个tokens\n",
      "it was decided that it was not feasible to continue this study    有  12  个tokens\n",
      "phase 2 was not conducted due to a change in the standard of care for newly diagnosed, unresectable stage iii nsclc    有  26  个tokens\n",
      "we opened a competing study with the tacl consortium    有  10  个tokens\n",
      "lorcaserin removed from market    有  7  个tokens\n",
      "overhaul of study design    有  5  个tokens\n",
      "cancelled due to financial reasons    有  5  个tokens\n",
      "feasibility concerns due to changes in standard of care    有  10  个tokens\n",
      "principal investigator is moving to a different institution    有  8  个tokens\n",
      "study drug supply issues    有  4  个tokens\n",
      "no need for a pilot study. new study will be opened    有  12  个tokens\n",
      "the trial ended early due to gi intolerability and treatment-emergent resistance    有  15  个tokens\n",
      "sponsor decided not to go forward with study for fda submission    有  12  个tokens\n",
      "study was closed because we could not find these types of patients    有  12  个tokens\n",
      "another clinical study for regulatory approval is planned    有  8  个tokens\n",
      "pi no longer at facility    有  5  个tokens\n",
      "investigator who manufactured the vaccine left the university    有  9  个tokens\n",
      "per amgen's decision to discontinue co-development and co-commercialization of brodalumab, study is being cancelled/closed    有  26  个tokens\n",
      "response rate in placebo group for primary outcome was 100% on interim analysis    有  15  个tokens\n",
      "after completing the part of assessing lactobacilli transfer, it was decided not to proceed further with the masked part of the study    有  26  个tokens\n",
      "investigator moved institutions    有  4  个tokens\n",
      "withdrawal of supply of investigational product    有  8  个tokens\n",
      "based on newly available preclinical data we changed the car construct to a more effective version and will now study that product on a different protocol    有  27  个tokens\n",
      "study terminated early due to results from another cmx001 study    有  12  个tokens\n",
      "study was terminated early due to results from another cmx001 study    有  13  个tokens\n",
      "this protocol was replaced with a different one and therefore discontinued    有  11  个tokens\n",
      "research staff decision    有  3  个tokens\n",
      "the study is terminated due to cessation of the research collaboration with russian institutions    有  14  个tokens\n",
      "the investigators decided not to proceed with this study    有  9  个tokens\n",
      "trial terminated folpooring dutch dsmb recommendation for their study    有  13  个tokens\n",
      "a priori hypothesis confirmed with interim analysis    有  8  个tokens\n",
      "trial withdrawn due to inability to meet the trial objectives (pilot)    有  14  个tokens\n",
      "recommendation by dsmb, which felt that sufficient data had been obtained    有  14  个tokens\n",
      "study did never start, may be deleted from clinicaltrials.gov if possible    有  15  个tokens\n",
      "after reviewing the interim analysis results the study was terminated as a bigger sample size was needed to find a significant difference between the groups    有  25  个tokens\n",
      "the study is not eligible at present    有  7  个tokens\n",
      "sponsor discretion determined no clinical benefit    有  6  个tokens\n",
      "the results obtained are sufficient    有  5  个tokens\n",
      "original p.i. of this study transferred to a different institution    有  12  个tokens\n",
      "study stopped due to project prioritization    有  7  个tokens\n",
      "collaborator kinemend closed due to finances    有  10  个tokens\n",
      "no objective response was observed at the first step. the treatment was considered ineffective, with a complete clinical trial suspension    有  22  个tokens\n",
      "not approved by cms    有  4  个tokens\n",
      "as of 31 jan 2018, the study was terminated by the sponsor due to pk variability    有  20  个tokens\n",
      "trial never opened    有  3  个tokens\n",
      "not able to get enough participants    有  6  个tokens\n",
      "pi was transferred to another base. no one else available to serve as pi    有  15  个tokens\n",
      "a company in china has decided to license the product    有  10  个tokens\n",
      "concern regarding study design    有  5  个tokens\n",
      "study will no longer take place, the study did not begin or accrue subjects    有  16  个tokens\n",
      "change in goals of pi    有  5  个tokens\n",
      "study was no longer feasible    有  5  个tokens\n",
      "number of candidates for this study is expected to be too small    有  12  个tokens\n",
      "after irb review, this study is no longer considered a clinical trial    有  14  个tokens\n",
      "study terminated when aripiprazole available commercially per protocol    有  12  个tokens\n",
      "study device broke    有  3  个tokens\n",
      "fda determined study device is significant risk. study will not seek ide    有  14  个tokens\n",
      "the effect is poor    有  4  个tokens\n",
      "re-initiate a new trial per the discussion with fda    有  12  个tokens\n",
      "this study would be conducted by a master course student, nevertheless, she was unable to go forward with it    有  21  个tokens\n",
      "primary objective not obtained after interim analysis    有  7  个tokens\n",
      "study never officially began- currently closed with irb    有  10  个tokens\n",
      "due to increased rate of local injection site reactions in the dsji group    有  14  个tokens\n",
      "investigator (dr amit) not interested to carry out the study    有  14  个tokens\n",
      "disparate corneal thickness readings from two measurement techniques employed    有  12  个tokens\n",
      "study has been updated with a new protocol number    有  9  个tokens\n",
      "study was stopped prematurely due to the poor eligible participants    有  10  个tokens\n",
      "change of protocol title    有  4  个tokens\n",
      "higher mortality in another published study    有  6  个tokens\n",
      "after pilot study no difference in the primary end point was found between the two primary. non-inferiority trial not deemed feasible    有  26  个tokens\n",
      "stopped due to limited access to medical technology devices    有  9  个tokens\n",
      "program de-prioritized    有  5  个tokens\n",
      "company is discussing with fda to reinitiate the trial now    有  13  个tokens\n",
      "the goal to match 1000 patients per group could not be achieved with reasonable effort and in reasonable time    有  21  个tokens\n",
      "staff for the study is no longer available    有  8  个tokens\n",
      "study results were too significant    有  5  个tokens\n",
      "study sponsor discontinued    有  3  个tokens\n",
      "the fda issued a crl in response to intercept's nda for oca for the treatment of nash. the fda indicated the review was complete and determined it cannot be approved. sponsor decided to terminate 747-303 before the planned completion date    有  52  个tokens\n",
      "protocol is being reevaluated by sponsor    有  8  个tokens\n",
      "after completing phase 1, the sponsor elected not to move forward with phase 2    有  17  个tokens\n",
      "financial sponsor difficulties    有  3  个tokens\n",
      "lost many participants to folpoor-up    有  8  个tokens\n",
      "new study design will be made    有  6  个tokens\n",
      "the study was suspended because the oncology service decided to adopt the procedure in routine    有  16  个tokens\n",
      "study was halted to make device updates    有  7  个tokens\n",
      "pi no longer at university of maryland. now at fox chase    有  13  个tokens\n",
      "similar large international competing trial with results of strong positive statistically benefit    有  12  个tokens\n",
      "insufficient dermatitis was seen in the controls to alpoor any determination of protection by difinsa53    有  22  个tokens\n",
      "merck no longer providing drug for study    有  8  个tokens\n",
      "study not started, no longer required    有  7  个tokens\n",
      "higher pocd in nimodipine group    有  9  个tokens\n",
      "the pharmaceutical company did not want to folpoor through with support for the study    有  16  个tokens\n",
      "older participants could not tolerate the acidity of the product and withdrew    有  12  个tokens\n",
      "local irb in process to close down study    有  9  个tokens\n",
      "sponsor dissolved before study started    有  5  个tokens\n",
      "poor resources to finance the project    有  7  个tokens\n",
      "during interim analysis, it appeared there were no difference in groups    有  12  个tokens\n",
      "product discontinued in november 2014    有  7  个tokens\n",
      "abandoned folpooring local ethics review    有  8  个tokens\n",
      "sponsor has obtained sufficient case load prematurely    有  7  个tokens\n",
      "the investigators decided not to move forward with this study at this time    有  13  个tokens\n",
      "terminated due to, licensing agreement granting exclusive rights of research, development, manufacture and marketing of eisai's e7046 to adlai nortye biopharma    有  35  个tokens\n",
      "study hypothesis was faulty    有  4  个tokens\n",
      "human resource change in research investigators and seoul fire department    有  11  个tokens\n",
      "data has been published on this study (this would have been a duplicate study)    有  16  个tokens\n",
      "a pilot study is currently in progress    有  7  个tokens\n",
      "the study was terminated early based on the results of a planned interim analysis    有  14  个tokens\n",
      "improved algorithms have resulted in a proposed redesign of detection system. once completed, a new trial will be planned    有  22  个tokens\n",
      "top line analysis indicated that the study had failed to achieve its primary endpoint    有  14  个tokens\n",
      "there was sufficient data to verify the primary endpoint    有  9  个tokens\n",
      "changes to the study design and the cell line    有  9  个tokens\n",
      "we have discovered a too poor prevalence of patent foramen ovale compared to the theoretical % of around 20-25%    有  25  个tokens\n",
      "this study remains on voluntary hold    有  6  个tokens\n",
      "recommendation after interim analysis    有  5  个tokens\n",
      "protocol qualifies as not human subjects research    有  7  个tokens\n",
      "assessing feasibility    有  4  个tokens\n",
      "the study was terminated by takeda due to the discomfort observed in the study participants from the csf collection procedure in part 3 of the study    有  30  个tokens\n",
      "stopped 1 jan 2017, logistical reasons    有  10  个tokens\n",
      "preliminary results acceptable, investigators moved attention to different project    有  12  个tokens\n",
      "this research is not a clinical trial and was inadvertently entered into the system    有  14  个tokens\n",
      "other- protocol moved to disapproved    有  7  个tokens\n",
      "failed to accrue    有  4  个tokens\n",
      "technology transfer    有  2  个tokens\n",
      "discontinued development of sym004 in combination with folfiri    有  12  个tokens\n",
      "the number of subjects were underestimated, which implies a reduction in the number of subjects required    有  17  个tokens\n",
      "there was a problem with the municipality and they have choose to suspend it    有  14  个tokens\n",
      "change of practice in the department    有  6  个tokens\n",
      "due to the departure of study staff and poor interest by potential subjects and the sponsor, the investigators decided to end the study    有  24  个tokens\n",
      "this decision was based upon strategic considerations impacting the clinical development of olaparib in this indication    有  19  个tokens\n",
      "research staffing issues    有  3  个tokens\n",
      "usc has an icoi because the university owns the patent of the interventional dietary supplement    有  18  个tokens\n",
      "changes in treatment plans affecting drug therapy choices    有  8  个tokens\n",
      "prematurely terminated due to organisational reasons    有  10  个tokens\n",
      "unable to obtain a timely newly requested ide    有  8  个tokens\n",
      "the patient population (cll & sll) was included in another ongoing study involving nhl patients    有  20  个tokens\n",
      "the thoracic surgery department has almost stopped completely its surgical activities and the completion of the study doesn't seem to be feasible    有  24  个tokens\n",
      "study never started and was abandoned    有  6  个tokens\n",
      "principal investigator retired    有  3  个tokens\n",
      "no candidats    有  3  个tokens\n",
      "unable to rectuir    有  4  个tokens\n",
      "fda approved synovial biopsy device unavailable    有  9  个tokens\n",
      "dr. alwayn is leaving nsha and canada for a new appointment in europe    有  17  个tokens\n",
      "linked data not available for research within requisite time period    有  10  个tokens\n",
      "the enterprise decided to stop the production of the catheter used for the clinical indicated renal denervation    有  19  个tokens\n",
      "loss of laboratory performing molecular analysis    有  6  个tokens\n",
      "has been terminated before fsfv    有  6  个tokens\n",
      "subjects' not-well compliance due to diarrhea and softening stool after taking perox quench 4 sachets a day    有  25  个tokens\n",
      "due to unwillingness of surgeons to use monopolar energy & technical problems    有  15  个tokens\n",
      "gsk decision to return rights to sirukumab to janssen and discontinue sirukumab development in giant cell arteritis    有  28  个tokens\n",
      "dismissal from the institution    有  5  个tokens\n",
      "poor effect at interims analysis    有  7  个tokens\n",
      "sponsor decided not to run this study    有  7  个tokens\n",
      "the investigator decided not to continue the study    有  8  个tokens\n",
      "collaborator withdrew the study    有  6  个tokens\n",
      "part 1 of the study was completed and the maximum tolerated dose determined. part 2 of the study was terminated and will be conducted under a new protocol    有  31  个tokens\n",
      "development of compound has been put on hold    有  8  个tokens\n",
      "the medical device arrived at expirationand it was not possible to have new one    有  15  个tokens\n",
      "the manufacturer of the device has been bought and the new company does not want to continue the study anymore    有  20  个tokens\n",
      "not enough participants were included    有  5  个tokens\n",
      "this type of surgery is now performed with a surgical robot that no longer alpoors the realization of microdialysis    有  24  个tokens\n",
      "substantial changes were made to the study protocol and a new ethics application will be submitted    有  17  个tokens\n",
      "discontinuation of product development    有  6  个tokens\n",
      "enough data for a publication, decision of sponsor-pi    有  12  个tokens\n",
      "study was canceled    有  3  个tokens\n",
      "the backgroud of this study was not well discussed    有  11  个tokens\n",
      "replace with a new trial    有  5  个tokens\n",
      "interim analysis indicated treatment was effective and statistically significant    有  10  个tokens\n",
      "negativity of the first results of in vivo binding of 18f-pbr06    有  17  个tokens\n",
      "the study was terminated after utsw was informed by novartis that further support for the study would not be provided    有  23  个tokens\n",
      "study initiation at this site fell through    有  7  个tokens\n",
      "there was to much artifact on the readings and could not be interpreted    有  13  个tokens\n",
      "the study did not receive irb approval and was withdrawn    有  11  个tokens\n",
      "study has stopped due to a decision by amgen to terminate the program    有  14  个tokens\n",
      "results were not promising    有  4  个tokens\n",
      "development terminated    有  2  个tokens\n",
      "recent studies suggest that cyclosporine a has a very sharp biphasic dose-response problem that is going to make further clinical translation difficult    有  29  个tokens\n",
      "role of calcium in menopause is not clear. product maybe reformulated and the study relaunched    有  20  个tokens\n",
      "drug intervention no longer relevant for the proposed population    有  9  个tokens\n",
      "understaffing    有  3  个tokens\n",
      "financing delays    有  3  个tokens\n",
      "financial reason    有  2  个tokens\n",
      "general informed consent has been introduced at the hospital, no need for study anymore    有  15  个tokens\n",
      "observation of poor incidence of asymptomatic, transiently elevated liver enzymes in a subset of study subjects    有  19  个tokens\n",
      "suspended by funder    有  5  个tokens\n",
      "company (inovio) is no longer able to support the study    有  14  个tokens\n",
      "difficulty finding participants who fit all criteria    有  7  个tokens\n",
      "results from anchor study showed benefit of treatment over surveillance in preventing anal cancer. that study was similar to the current one    有  23  个tokens\n",
      "discontinuation of the development    有  6  个tokens\n",
      "authorization denied    有  2  个tokens\n",
      "study will not have power to show a difference between groups    有  11  个tokens\n",
      "changes in development plan    有  4  个tokens\n",
      "investigator emigrated    有  4  个tokens\n",
      "early termination due to a suspension of financial support    有  9  个tokens\n",
      "due to a poor laboratory resources, the study was abandoned    有  11  个tokens\n",
      "volasertib no longer available    有  7  个tokens\n",
      "principal investigator has left the university; there were not enough participants to analyze the data    有  16  个tokens\n",
      "unable to obtain mitochondrial samples    有  5  个tokens\n",
      "poor interest by sponsor    有  5  个tokens\n",
      "integrated into another study    有  5  个tokens\n",
      "all parkinson's disease patients have finished training. the ms and ect groups have not finished as these groups had trouble including 20 patients    有  27  个tokens\n",
      "no uptake from potential participants    有  5  个tokens\n",
      "similar study has revealed result of no benefit for participants    有  10  个tokens\n",
      "study design changed, no longer a randomized trial design    有  10  个tokens\n",
      "study terminated early at a time point when sufficient data had been accumulated to inform a decision on further development of volanesoresen in participants with fpl    有  30  个tokens\n",
      "study halted prematurely and will not resume. subjects were seen until february 2017    有  17  个tokens\n",
      "pi has left duke    有  4  个tokens\n",
      "pending financial support    有  3  个tokens\n",
      "no subjects accrued and no potential subjects were identified    有  9  个tokens\n",
      "the study never began    有  4  个tokens\n",
      "the study design was revised so a new protocol will be opened    有  12  个tokens\n",
      "sponsor decided to discontinue development of the study drug    有  10  个tokens\n",
      "the sponsor sold the drug taladegib to another company during the trial and thereafter no drug was available. the sponsor made a decision to stop development of this drug taladegib    有  37  个tokens\n",
      "the protocol was amendment to be stopped after phase i (phase 2 removed from protocol)    有  18  个tokens\n",
      "material issues. re-start in assessment    有  7  个tokens\n",
      "frequent protocol violations    有  4  个tokens\n",
      "industry won't be moving forward with production of bococizumab    有  15  个tokens\n",
      "investigator graduated and is not longer at this institution    有  10  个tokens\n",
      "the paper is about to publish on the same subject abroad, so the investigator decieded to stopped the study    有  22  个tokens\n",
      "study was terminated because of conflicting results from intermediate analysis    有  10  个tokens\n",
      "insufficient clinical response per dsmb    有  7  个tokens\n",
      "preset pharmacokinetic stopping criteria met at poorer doses than expected    有  12  个tokens\n",
      "pi failed to file continuation report    有  6  个tokens\n",
      "interim analysis revealed no significant difference between study groups & increased sample size required to gain significance    有  18  个tokens\n",
      "research personal no longer available    有  5  个tokens\n",
      "pi no longer at this facility    有  6  个tokens\n",
      "ganaxolone missed its primary endpoint in the double-blind portion of the 1042-0603 study. due to this outcome marinus discontinued this extension study    有  33  个tokens\n",
      "company has fulfilled post-marketing requirements    有  7  个tokens\n",
      "amgen prioritization decision    有  5  个tokens\n",
      "designed a new modified/simplified protocol see nct 03180489    有  15  个tokens\n",
      "manufacturer unwilling to provide information needed for ind application    有  9  个tokens\n",
      "decided to redesign the study    有  6  个tokens\n",
      "study not feasible or convenient for the subject    有  8  个tokens\n",
      "a strategic restructuring including the planned conclusion of clinical oncology development programs and no further sponsoring of the development of sd-101    有  24  个tokens\n",
      "failure to maintain access to altitude facility    有  7  个tokens\n",
      "irb suspension, did not resume    有  7  个tokens\n",
      "poor time and participation in the study    有  8  个tokens\n",
      "discontinued program    有  3  个tokens\n",
      "ec did not accept measurement of patient's activity for the primary end-point with a non-validated activity tracking device    有  22  个tokens\n",
      "the study could not be started due to an insufficient number of new evd cases    有  16  个tokens\n",
      "new study initiated to replace this one    有  7  个tokens\n",
      "study is not realised    有  4  个tokens\n",
      "new study with a similar endpoint/protocol was developed (see nct03103061)    有  18  个tokens\n",
      "technology has advanced beyond the applicability of the study    有  10  个tokens\n",
      "study not initiated at our site    有  6  个tokens\n",
      "previous principal investigators left institution    有  5  个tokens\n",
      "bms decision    有  3  个tokens\n",
      "study goals rolled into a broader study    有  7  个tokens\n",
      "departure of chief investigator/principal investigator    有  7  个tokens\n",
      "on going discussions with fda    有  6  个tokens\n",
      "pi relocated to a different country and coi moved to a different lab    有  14  个tokens\n",
      "the trial has been terminated per sponsor direction due to longer than expected clinical and regulatory approvals    有  17  个tokens\n",
      "department chair choose not to participate    有  6  个tokens\n",
      "study registered to wrong sponsor    有  5  个tokens\n",
      "preoperative period is very short time    有  7  个tokens\n",
      "electrodes required gas sterilization before re-use which was not feasible    有  14  个tokens\n",
      "not developing product    有  3  个tokens\n",
      "the probe could not be anchored in place and would rotate about its axis, thus comparison was difficult    有  19  个tokens\n",
      "pi is leaving the university of miami    有  8  个tokens\n",
      "poor surgical controls    有  4  个tokens\n",
      "the manufacturer arog pharmaceuticals inc has terminated the agreement concerning the support of an investigator initiated trial this became valid on 2020/03/09    有  30  个tokens\n",
      "completed stage i without pursuing stage ii    有  7  个tokens\n",
      "unable to get the correct software    有  6  个tokens\n",
      "project never got initiated    有  4  个tokens\n",
      "the study was terminated on expiry of the frozen and stored plasma components    有  13  个tokens\n",
      "could not meet primary and secondary outcome measures    有  8  个tokens\n",
      "pi decided to close study    有  5  个tokens\n",
      "pi no longer at site and he does    有  8  个tokens\n",
      "the study was terminated due to the interim analysis results indicating a weaker correlation than anticipated and reported by other study groups    有  22  个tokens\n",
      "principal investigator and sponsor agreed to termination    有  7  个tokens\n",
      "necessary equipment could not be obtained    有  6  个tokens\n",
      "preliminary analysis showed no difference between groups    有  9  个tokens\n",
      "the research data is not statistically significant    有  7  个tokens\n",
      "withdrawn by investigators    有  4  个tokens\n",
      "terminated due to poor assistance and time to carry out the research    有  12  个tokens\n",
      "protocol failed to accrue sufficient subject to complete meaningful analysis    有  11  个tokens\n",
      "study concept was terminated    有  4  个tokens\n",
      "poor implant success rate(46%). for the successfull implants, 3month fu and available electrical data showed an increase in threshold values for the left atrium    有  33  个tokens\n",
      "development of glembatumumab vedotin was discontinued    有  12  个tokens\n",
      "early analysis showed negative results. it was decided to halt the study    有  13  个tokens\n",
      "no chance to meet the foreseen target of patients with study endpoint    有  13  个tokens\n",
      "the study has been terminated because of operational reasons    有  9  个tokens\n",
      "loss of recrutement    有  5  个tokens\n",
      "change in protocol strategy    有  4  个tokens\n",
      "protocol redesign    有  2  个tokens\n",
      "equipment and personnel discontinuity    有  5  个tokens\n",
      "interim analysis: results of the analysis showed no significant difference between the two study groups    有  17  个tokens\n",
      "the study could not be performed    有  6  个tokens\n",
      "study was closed by the cancer therapy evaluation program (ctep)    有  13  个tokens\n",
      "this study was terminated due to the benefit-risk balance of mt-4666    有  15  个tokens\n",
      "flt production not available    有  4  个tokens\n",
      "interim analysis showed no added value of second look endoscopy    有  13  个tokens\n",
      "do not have a sutable subjects    有  7  个tokens\n",
      "feasibility issues require solutions    有  5  个tokens\n",
      "insufficient equipment    有  3  个tokens\n",
      "results from similar research were already published    有  7  个tokens\n",
      "more preparation needed prior to collecting data    有  7  个tokens\n",
      "pi not longer at site    有  5  个tokens\n",
      "unable to find appropriate candidates    有  5  个tokens\n",
      "patients should have assurance to attend this study, money is the main problem    有  14  个tokens\n",
      "no longer have resources to complete this work    有  8  个tokens\n",
      "stop production prb kit    有  5  个tokens\n",
      "was never initiated    有  3  个tokens\n",
      "pi relocated to another institution; study may be resubmitted at a later date    有  16  个tokens\n",
      "patients are currently being operated in the robot instead due to logistics    有  12  个tokens\n",
      "resources to conduct study withdrawn    有  5  个tokens\n",
      "logistic reasons; amendment pending with irb    有  9  个tokens\n",
      "study stopped and was not completed    有  6  个tokens\n",
      "nih did not fund the study so it never started    有  10  个tokens\n",
      "the study was prematurely terminated because the emerging benefit:risk ratio did not justify continuing dosing patients    有  19  个tokens\n",
      "due to reorganization    有  4  个tokens\n",
      "pi no longer at sight. results not collected    有  9  个tokens\n",
      "study registered elsewhere and is not covered by fda    有  10  个tokens\n",
      "due to a radical change in postoperative care as well as surgical technique    有  14  个tokens\n",
      "pi relocated to uncp; study is not being transferred    有  11  个tokens\n",
      "insufficient eligable subjects and new data on bvs    有  11  个tokens\n",
      "device manufacturer no longer supports implant covered under the ide    有  10  个tokens\n",
      "study topic is no longer being pursued by study team members    有  11  个tokens\n",
      "this study was suspended due to additional time needed for method development    有  12  个tokens\n",
      "new study    有  2  个tokens\n",
      "due to budget limitations as allocated for a given period    有  10  个tokens\n",
      "investigator preference    有  3  个tokens\n",
      "this was the cross over study for 09-1 which was terminated early    有  15  个tokens\n",
      "study protocol was changed    有  4  个tokens\n",
      "the bioassay development is too difficult    有  8  个tokens\n",
      "data for the primary objectives is complete and the mtd identified in stratum ii    有  16  个tokens\n",
      "this was an observational study. the owners of the data refused to give us the data so we could not proceed with the analyses    有  25  个tokens\n",
      "pending final analysis for termination    有  5  个tokens\n",
      "investigator decision - clinical practice change    有  7  个tokens\n",
      "study design improvements    有  3  个tokens\n",
      "device no longer available in singapore    有  6  个tokens\n",
      "waiting on surgeon training    有  4  个tokens\n",
      "sample not reached in traumathology arm    有  9  个tokens\n",
      "shortages of the active comparator drug (bcg) on the market worldwide and a growing uncertainty as to its future supply    有  24  个tokens\n",
      "the study was terminated early after the interim analysis due, in part, to issues with the accuracy and completeness of the data collected    有  25  个tokens\n",
      "development halted    有  2  个tokens\n",
      "awaiting verification of assay    有  5  个tokens\n",
      "expired study    有  2  个tokens\n",
      "insufficient number of eligible and interested partients    有  9  个tokens\n",
      "samuel sigal no longer with nyu    有  9  个tokens\n",
      "decision to not gather further data    有  6  个tokens\n",
      "scientific coordinator left the hospital    有  5  个tokens\n",
      "company terminated drug support    有  4  个tokens\n",
      "study failed to receive final approvement    有  7  个tokens\n",
      "study was redesigned in collaboration with cms before it started    有  10  个tokens\n",
      "transfer of ind to different marketing authorization representative    有  8  个tokens\n",
      "as a result of orthosensor's acquisition by stryker in july 2018.no final mutually agreed (signed) protocol was found and no clear records of the study data can be retrieved. no accurate and reliable results of this study can be posted    有  52  个tokens\n",
      "investigator is leaving the institution and has terminated the study    有  11  个tokens\n",
      "resources not available for the study    有  6  个tokens\n",
      "based on interim anaylsis    有  7  个tokens\n",
      "consolidated study with another protocol    有  7  个tokens\n",
      "will no longer be conducted. we have started a different project    有  12  个tokens\n",
      "poor internal resources    有  4  个tokens\n",
      "poor available study participants    有  5  个tokens\n",
      "study was terminated with the irb ended early as logistical concerns of the sbrt    有  17  个tokens\n",
      "withdrawn due to other initiatives    有  6  个tokens\n",
      "assessment of daptomycin concentrations with microdialysis technically not feasible    有  15  个tokens\n",
      "change in research objectives    有  4  个tokens\n",
      "testing of combination no longer relevant    有  6  个tokens\n",
      "irb approval expired and study ceased    有  7  个tokens\n",
      "transfer of ind to new marketing authorization holder    有  8  个tokens\n",
      "problems with availability of study medicine in clinical center    有  9  个tokens\n",
      "on april 15, 2019, biotronik received fda approval to transition the ongoing protego df4 post approval registry to a new ep passion real-world data methodology    有  36  个tokens\n",
      "the investigators decided to terminate the study early because there were no patient candidates available for registration in the center    有  20  个tokens\n",
      "forum has decided not to proceed with this study at this time    有  12  个tokens\n",
      "equipment was loaned lifglobal, guilford, ct, usa and had to be returned    有  19  个tokens\n",
      "this study was terminated due to internal technical issues at study site    有  12  个tokens\n",
      "unable to meet study requirements    有  5  个tokens\n",
      "pk time points were not being met as expected. determination that risks outweighed benefit    有  16  个tokens\n",
      "could not predict who would respond, relapse or go into remission    有  14  个tokens\n",
      "entry were insufficient as expected    有  5  个tokens\n",
      "feasibility problem    有  3  个tokens\n",
      "study was stopped due to the expected introduction of a next product generation    有  13  个tokens\n",
      "inconsistent and unpredictable exposures were observed. drug needed to be reformulated    有  14  个tokens\n",
      "withdrawal of primary investigators    有  5  个tokens\n",
      "increased local adverse effect (breast inflamation and infection)    有  13  个tokens\n",
      "equality of results between the two groups at interim analysis    有  10  个tokens\n",
      "project never began    有  3  个tokens\n",
      "drug manufacturing logistics; poor access to drug supply    有  9  个tokens\n",
      "technical difficulties have caused this study to be terminated    有  9  个tokens\n",
      "study was found to be non-feasible. not enough patients to perform an adequate study in the allocated time period    有  23  个tokens\n",
      "awaiting new coinvestigator with tte expertise    有  10  个tokens\n",
      "decision made by the principal investigator    有  6  个tokens\n",
      "pilot feasibility for full trial: nct03737799    有  12  个tokens\n",
      "due to cranial nerve palsies observed    有  8  个tokens\n",
      "it was difficult to proceed with the study according to the protocol, the research was terminated early    有  18  个tokens\n",
      "study was on hold for protocol redesign; decided to not move forward with study    有  15  个tokens\n",
      "biotronik received fda approval to transition the ongoing sentus qp study to a new ep passion real-world data methodology    有  24  个tokens\n",
      "irb approved but never implemented    有  6  个tokens\n",
      "results of interim analysis    有  4  个tokens\n",
      "fda issued a clinical hold as pacritinib had increased side effects    有  15  个tokens\n",
      "the sponsor is pursuing a different product for this indication    有  10  个tokens\n",
      "due to pi's change to private practice    有  8  个tokens\n",
      "study drug expired    有  3  个tokens\n",
      "drug manufacturing process and procedure review    有  6  个tokens\n",
      "dovitinib production stopped    有  6  个tokens\n",
      "study redesigned into three separate trials    有  6  个tokens\n",
      "research direction changed    有  3  个tokens\n",
      "study was set up by an msc student who left her post    有  13  个tokens\n",
      "suspended development program    有  4  个tokens\n",
      "some concerns arose for the accumulation of radioactivity in liver and spleen    有  14  个tokens\n",
      "change in methodology too important - end of randomization    有  10  个tokens\n",
      "because there are questions about adjuvant radiotherapy in this study, the clinical trial is under re-design    有  21  个tokens\n",
      "changes in renal function parameters    有  5  个tokens\n",
      "pi's response to epaac, has withdrawn the protocol acknowledging the pi's action    有  16  个tokens\n",
      "project no longer in development    有  5  个tokens\n",
      "the required number of endpoints will be obtained with a sample size poorer than initially planned    有  16  个tokens\n",
      "the study was stopped due to carry over effect in the cross over study design    有  15  个tokens\n",
      "study terminated as sufficient data was collected to determine if impedance measurements with the linq™ device could track body fluid changes    有  23  个tokens\n",
      "transition to a different immunotherapy strategy in the future at our institution    有  13  个tokens\n",
      "expertise resigned    有  3  个tokens\n",
      "no three dimensional transthoracic echo available currently    有  10  个tokens\n",
      "technician left institution    有  4  个tokens\n",
      "part b of the study no longer required due to new information on the study drug    有  16  个tokens\n",
      "logistics and feasibility    有  4  个tokens\n",
      "why study stopped    有  3  个tokens\n",
      "decision of the independent review committee    有  6  个tokens\n",
      "gi intolerability    有  3  个tokens\n",
      "pi departure without replacement    有  4  个tokens\n",
      "consensus brain-af executive steering committee to terminate    有  10  个tokens\n",
      "new relevant data published    有  4  个tokens\n",
      "research idea tabled at this point    有  7  个tokens\n",
      "insufficient    有  2  个tokens\n",
      "study has withdrawn    有  3  个tokens\n",
      "primary study team member left organization, study was not completed    有  11  个tokens\n",
      "terminated this trial and added a lenalidomide arm to kcp-330-017    有  19  个tokens\n",
      "the study was not developed due to the cessation of ionsys marketing    有  13  个tokens\n",
      "did not obtain an ind    有  5  个tokens\n",
      "the study was terminated because preliminary pk and overall clinical data demonstrated compelling similarity between western and asian participant populations    有  20  个tokens\n",
      "study is unlikely to be feasible given the evolving ovarian cancer landscape and alternative studies have the potential to meet future clinical demand    有  23  个tokens\n",
      "at 75% patient completion overall mortality was much poorer than expected and without significant difference at day 90. no chance to reach the primary endpoint    有  29  个tokens\n",
      "problem with medical device provider    有  5  个tokens\n",
      "changed study to an observational study    有  6  个tokens\n",
      "ros1 in ihc and gene rearrangement result can not match。no tumor response。    有  18  个tokens\n",
      "dbs method not be validated against the standard of care venepuncture method due to quality of blood sample and variable tacrolimus extraction    有  27  个tokens\n",
      "the preliminary analysis of study result did not show significant benefit that was anticipate    有  14  个tokens\n",
      "staff changes and retirement of the primary investigator during the study    有  11  个tokens\n",
      "support staff left institution    有  4  个tokens\n",
      "due to insolvency of sponsor    有  6  个tokens\n",
      "study stopped for change in needle usage    有  7  个tokens\n",
      "according to the recommendation of the indipendent data monitoring committee    有  12  个tokens\n",
      "asset terminated by pib    有  5  个tokens\n",
      "change of device used for dual energy computed tomography with xenon    有  13  个tokens\n",
      "discrepancies in medication orders    有  7  个tokens\n",
      "the study was completed. it was fully accrued    有  9  个tokens\n",
      "pi has left the university    有  5  个tokens\n",
      "multiple reminders were carried out but despite these measures, the gp has not enough participated    有  16  个tokens\n",
      "has not begun yet    有  4  个tokens\n",
      "testing required by fda for ind approval was too expensive to move forward with conduct of the study    有  19  个tokens\n",
      "primary endpoint reached based on data projection from interim analysis    有  10  个tokens\n",
      "the study was terminated prematurely on 05may 2015 because of the unavailability of study devices    有  20  个tokens\n",
      "assay difficulties    有  3  个tokens\n",
      "terminated at the request of the financial sponsor    有  8  个tokens\n",
      "it was determined that internal resources to support this population would be better utilized in other injury and violence prevention programs    有  21  个tokens\n",
      "strategic decision - to understand data from psoriasis study - nct02129777 and wait for results of formal proof of concept study - nct02379091    有  33  个tokens\n",
      "sufficient statistical power cannot be met due to poor samples size    有  12  个tokens\n",
      "team's request    有  3  个tokens\n",
      "study is not feasable yet, due to evolution in the patients' care    有  15  个tokens\n",
      "remaining outdated treatments and additional costs too high for new manufacturing    有  11  个tokens\n",
      "to perform a interim analyzes    有  5  个tokens\n",
      "never started or submitted to irb    有  7  个tokens\n",
      "we chose to maximize this iterative treatment development study by terminating the pilot rct in favor of enhancing an initial open trial (increased n 12 to 14)    有  33  个tokens\n",
      "the trial was prematurely terminated as of 22.07.2021 as per sakk board decision board decision from 14th of november 2020. the trial was terminated after the primary endpoint was analyzed, which was the case end of december 2020    有  53  个tokens\n",
      "sponsor stopped producing device    有  4  个tokens\n",
      "potential participants have not yet been identified    有  7  个tokens\n",
      "it was more difficult than planned to find patients filling inclusion criteria and those which corresponded didn't agree to participate    有  22  个tokens\n",
      "bias in the study    有  4  个tokens\n",
      "logistic issues - no available scans for participants at the moment need to postponed starting dates    有  17  个tokens\n",
      "study entered in error    有  4  个tokens\n",
      "strategic closure by sponsor to pursue other indications    有  9  个tokens\n",
      "az discontinued study    有  3  个tokens\n",
      "unresolved issues with a collaborator    有  7  个tokens\n",
      "not able to be completed    有  5  个tokens\n",
      "transition to new position    有  4  个tokens\n",
      "the study was completely redesigned    有  5  个tokens\n",
      "it was determined that one member of the team had falsified data    有  13  个tokens\n",
      "approval of adjuvant durvalumab after rt-ct (not anticipated in the study design) and small number of stage iii nslcl patients with peripheral tumor accessible to sbrt    有  39  个tokens\n",
      "with recent advances in immunotherapy scientific question not significant    有  10  个tokens\n",
      "this study was terminated early due to response rates not meeting the anticipated minimum of 30%    有  18  个tokens\n",
      "unsatisfactory filter deployment in several cases    有  8  个tokens\n",
      "this study is planned for later    有  6  个tokens\n",
      "pre-specified response criteria not met to proceed to next stage of study    有  14  个tokens\n",
      "negative results were obtained in all subjects that were analyzed (n=10)    有  15  个tokens\n",
      "insufficient resource to complete the study    有  7  个tokens\n",
      "after recommendation because of the impossibility to end study with 1 center only. outcomes of patients already included will be evaluated    有  24  个tokens\n",
      "american society of reproductive medicine guidelines, october 2012    有  12  个tokens\n",
      "due to limited resources    有  4  个tokens\n",
      "phase iii study results for the drug tesquinimod were not promising so it was a drug development decision to stop using the drug    有  26  个tokens\n",
      "ip received fda clearance for use in pae as treatment for bph    有  15  个tokens\n",
      "this study was never completed because the company was not able to support the trial with devices    有  17  个tokens\n",
      "trial has been cancelled due to availability of new therapeutic options for patient population    有  14  个tokens\n",
      "research site unable to support further study requirements    有  8  个tokens\n",
      "fda and irb recommended different mode of medication administration    有  11  个tokens\n",
      "company closed may 1, 2019    有  9  个tokens\n",
      "study was closed due to sponsor switched to longeveron. new identifier is ntc03525418    有  20  个tokens\n",
      "the per objective has been integrated into the poorer protocol    有  10  个tokens\n",
      "this study was withdrawn to be replaced with a multi-site phase i trial    有  14  个tokens\n",
      "could not come to budget agreement    有  6  个tokens\n",
      "data from first 12 subjects-primary endpoint not met. data analysis underway    有  14  个tokens\n",
      "interim analysis found study had achieved primary objective    有  9  个tokens\n",
      "the industry sponsor has discontinued the product under evaluation in the study    有  12  个tokens\n",
      "change in surgical implant use, loss of subinvestigator    有  11  个tokens\n",
      "pi no longer at site. data was not collected    有  10  个tokens\n",
      "changing standard of care therapy regimen    有  6  个tokens\n",
      "sponsor has suspended clinical development of mydicar for heart failure    有  12  个tokens\n",
      "due to the koreafda issue    有  8  个tokens\n",
      "budget allocation decision by sponsor    有  5  个tokens\n",
      "pi resignation    有  2  个tokens\n",
      "expired with irb (2/2/2019)    有  12  个tokens\n",
      "fda ind was not obtained    有  6  个tokens\n",
      "a decision to stop the study was made by the site and gsk project team based on pre-defined stopping criteria in the protocol    有  25  个tokens\n",
      "study data do not support development in aml    有  9  个tokens\n",
      "sponsor's discretion to terminate study prematurely for further evaluation    有  10  个tokens\n",
      "company decided not to pursue this study    有  7  个tokens\n",
      "equipment difficulties    有  2  个tokens\n",
      "measurement devices unavailable at this time    有  6  个tokens\n",
      "competition with another study    有  4  个tokens\n",
      "unable to achieve accrural within anticipated timeframe    有  8  个tokens\n",
      "we were unable to run the trial because of inadequate resources (staffing). the principal investigator also moved countries    有  21  个tokens\n",
      "due to a decision by the research team not to continuos the study    有  14  个tokens\n",
      "difficulties to include    有  5  个tokens\n",
      "the sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability    有  21  个tokens\n",
      "inability to complete study according to protocol    有  8  个tokens\n",
      "drug expired    有  2  个tokens\n",
      "similar study in usa published with same protocol    有  8  个tokens\n",
      "this study was terminated early because premedication with tocilizumab was unlikely to reduce the risk of irr    有  23  个tokens\n",
      "standard of care for dressing changes at the institution now includes treatment intervention    有  13  个tokens\n",
      "departure of the principal investigator and poor succession    有  8  个tokens\n",
      "due to the discontinuation of the development of the notch inhibitor pf-03084014-04    有  19  个tokens\n",
      "the device often failed to detect hypoglycemic episodes in glycogen storage disease patients and the rate of false positive alarms was high    有  27  个tokens\n",
      "investigator transferred institutions    有  4  个tokens\n",
      "supporting company withdrew interest    有  5  个tokens\n",
      "to rebalance the study plan because it is not desirable to set up comparators using placebo    有  18  个tokens\n",
      "not clinical trial    有  3  个tokens\n",
      "unable to abstract pulmonary function and some other data from medical records    有  12  个tokens\n",
      "principal no longer interested in conducting study    有  7  个tokens\n",
      "this study did not collect sufficient data for primary endpoint analysis    有  11  个tokens\n",
      "original investigator has left the institution    有  6  个tokens\n",
      "interim analysis was sufficient to demonstrate accuracy of the evaluated test    有  12  个tokens\n",
      "cardiac catheterization no longer part of the anesthesia department a (no belonging to cardiac anesthesia, which is a different department)    有  26  个tokens\n",
      "protocol did not continue once investigator relocated to another institution    有  10  个tokens\n",
      "the sponsor's study closure justification addressed the 522 order's questions    有  13  个tokens\n",
      "mandated by dsmb    有  5  个tokens\n",
      "study not progressing toward scientific goals    有  6  个tokens\n",
      "irb withheld the data due to inadequate supporting documentation    有  10  个tokens\n",
      "poor consistent reference devices    有  5  个tokens\n",
      "protocol not feasible as written    有  5  个tokens\n",
      "pi decision was made to discontinue the study    有  9  个tokens\n",
      "1 day data collection    有  4  个tokens\n",
      "no focus on this topic    有  5  个tokens\n",
      "since the conception of the study, the competitive environment has developed and as a result this study is no longer able to generate the necessary information    有  27  个tokens\n",
      "the study has been officially closed with the irb    有  10  个tokens\n",
      "sponsor decided not to pursue study    有  6  个tokens\n",
      "large non-response rate    有  4  个tokens\n",
      "terminated early for poor study design    有  6  个tokens\n",
      "study not activated due to contract issues    有  7  个tokens\n",
      "dose limiting tox is observed. study put on full clinical hold    有  13  个tokens\n",
      "pi is no longer at institution. irb closed study due to poor response from pi    有  17  个tokens\n",
      "protocol showed to be inappropriate for the evaluation of the selected patients    有  12  个tokens\n",
      "the irb required this protocol to be split into two different protocols    有  13  个tokens\n",
      "estimated gfr was determined not to be a reliable endpoint for this study. we identified significant variabilty in annual egfr that it became inappropriate to randomize to a medication but use egfr as the primary endpoint    有  43  个tokens\n",
      "the data of the paper referenced in the preparation of the protocols in this task were manipulated and the paper was withdrawn    有  22  个tokens\n",
      "study site will join the targit-us trial in lieu of this trial    有  14  个tokens\n",
      "unable to hire qualified personnel to run the study    有  9  个tokens\n",
      "policy approved describing all procedures as standard of care    有  9  个tokens\n",
      "unfavorable results    有  4  个tokens\n",
      "study goals were met with smaller that expected study cohort. last patient completed the study june 201    有  20  个tokens\n",
      "an other study will start with new outcome measures    有  9  个tokens\n",
      "loss of personnel    有  3  个tokens\n",
      "sakk board decision of 14th november 2020 due to financial reasons    有  16  个tokens\n",
      "closed early with no results/no data collected    有  8  个tokens\n",
      "sponsor decides to suspend this trial    有  6  个tokens\n",
      "the drug was ineffective in improving function in pompe's disease    有  12  个tokens\n",
      "pi decided not to proceed    有  5  个tokens\n",
      "the device was under developed with some technical bugs    有  9  个tokens\n",
      "the interim analysis suggested that poor dose lisinopril given to be tube fed older patients with neuroligical dysphagia had increased mortality    有  30  个tokens\n",
      "the study is out of date    有  6  个tokens\n",
      "no subjects consented due to competing studies    有  8  个tokens\n",
      "compound no longer available    有  4  个tokens\n",
      "priorities other studies    有  4  个tokens\n",
      "the study was cancelled due to change in food registration regulations in china    有  13  个tokens\n",
      "(expected) side effects    有  4  个tokens\n",
      "investigator's hospital sold and study cancelled    有  8  个tokens\n",
      "the study was withdrawn prior to irb approval    有  9  个tokens\n",
      "the study has been terminated, due to technically difficulties    有  10  个tokens\n",
      "recuritment challenges    有  4  个tokens\n",
      "the study was formally terminated given that gsk is not submitting an application for regulatory approval for drisapersen in duchenne muscular dystrophy    有  29  个tokens\n",
      "the study has never started    有  5  个tokens\n",
      "poor institutional support and irb related issues    有  9  个tokens\n",
      "further investigations would require changes in study design; the use of different endpoints, a different il-17 antibody or a different patient population    有  27  个tokens\n",
      "project postponed    有  2  个tokens\n",
      "insufficient budget for further study agents    有  7  个tokens\n",
      "treatment was not working    有  5  个tokens\n",
      "ect equipment not available at study center    有  7  个tokens\n",
      "study has been put on clinical hold by fda    有  10  个tokens\n",
      "study was terminated prematurely due to 2 cases of agranulocytosis in a different clinical trial with this same drug    有  25  个tokens\n",
      "the study was terminated before study start, no researcher was attached to the study    有  15  个tokens\n",
      "because of results of altitude trial, this trial was cancelled    有  11  个tokens\n",
      "irb violations    有  3  个tokens\n",
      "pi cited personal reasons    有  4  个tokens\n",
      "new study protocol started including targeted biopsies    有  9  个tokens\n",
      "interim analysis shows harma to one of the study arms    有  12  个tokens\n",
      "fda recall - canadian system did voluntary suspension of study; investigators subsequently decided to terminate the study    有  19  个tokens\n",
      "poor tolerability at highest dose    有  7  个tokens\n",
      "decision by company to cease development of dovitinib    有  11  个tokens\n",
      "the researcher left the organization    有  5  个tokens\n",
      "prematurely halted after interim data analysis    有  9  个tokens\n",
      "there was no clear benefit but numerous side effects    有  9  个tokens\n",
      "not achieved the objective till 4 mg single dose    有  10  个tokens\n",
      "suspended pending internal review/direction of the company's focus. no sites ever engaged or collected data    有  20  个tokens\n",
      "european medicines agency issued a drug/drug interaction: sofosbuvir/modafinil    有  20  个tokens\n",
      "we stop because of problems such as insurance    有  8  个tokens\n",
      "sponsor cancelled study    有  3  个tokens\n",
      "insuffisant personnel    有  5  个tokens\n",
      "phase i portion completed. phase ii will open pending amendment approval    有  12  个tokens\n",
      "zn released from vehicle led to fortification levels higher than planned. new filter will be developed    有  18  个tokens\n",
      "randomization was stopped early because a significant beneficial effect of nutritional intervention was found in the interim analysis    有  19  个tokens\n",
      "calgb 81003 closed about a week after it was activated because of withdrawal of support. no patients were registered on this study    有  26  个tokens\n",
      "study terminated as ongoing analysis suggested objectives not practical to achieve with study as implemented    有  15  个tokens\n",
      "high exclusion rate    有  3  个tokens\n",
      "change in practice occured    有  4  个tokens\n",
      "main investigator has left the department and therefore the study had ended    有  12  个tokens\n",
      "this study had 2 parts. part a was a multicenter, double-blind, randomized, placebo-controlled, non-confirmatory crossover study assessing response to a high-fat meal challenge in the setting of pradigastat versus placebo. part a had 2 cohorts i.e. cohort 1 patients with stable coronary artery disease and hypertriglyceridemia and cohort 2 patients with asymptomatic non-obstructive coronary artery disease or elevated coronary heart disease risk and hypertriglyceridemia. part b was a double blinded phase designed to assess response to three months of chronic treatment with pradigastat versus placebo on a normal diet. the trial was terminated after the interim analysis of part a, cohort 1. the interim analysis results indicated that the high-fat meal challenge did not induce any impairment on either myocardial perfusion reserve index (mpri) or exercise treadmill performance. part b was never started    有  185  个tokens\n",
      "the dsmb felt the risks of the study now outweighed the potential benefits    有  15  个tokens\n",
      "unable to reach sample size to satisfy the primary objective    有  10  个tokens\n",
      "no subjects were found who met criteria    有  7  个tokens\n",
      "protocol violations    有  2  个tokens\n",
      "this study was cancelled    有  4  个tokens\n",
      "celgene would no longer supply lenalidomide for the study    有  14  个tokens\n",
      "the trial was early terminated after it was concluded that there was no added benefit from exposing further participants after an unblinded interim analysis    有  26  个tokens\n",
      "registration poor    有  2  个tokens\n",
      "study did not meet phase ib primary objective to establish the maximum tolerated dose/recommended dose for phase ii    有  20  个tokens\n",
      "due to staff departures we were unable to execute this study    有  12  个tokens\n",
      "pi decided not to pursue this study    有  7  个tokens\n",
      "this study was terminated prematurely due to 2 cases of agranulocytosis    有  17  个tokens\n",
      "difficulties with the center    有  6  个tokens\n",
      "drug support withdrawn    有  3  个tokens\n",
      "need to obtain ide prior to commencement of study    有  9  个tokens\n",
      "longterm abscence of investigator    有  7  个tokens\n",
      "results did not clearly support continuing development in recurrent gbm    有  11  个tokens\n",
      "study halted early due to limited response    有  7  个tokens\n",
      "based on recent publications, determination of natalizumub washout period was no longer relevant    有  19  个tokens\n",
      "recommendations of has have changed, the study is now useless    有  12  个tokens\n",
      "only one subject was studied, who did not respond    有  10  个tokens\n",
      "change of schedule    有  3  个tokens\n",
      "no suitable case available and many techinical error    有  10  个tokens\n",
      "decision of the promoter    有  4  个tokens\n",
      "by the moment nvestigators are not recuiting because logistics issues    有  14  个tokens\n",
      "fast-mag study finished    有  5  个tokens\n",
      "performance did not meet sponsor requirements    有  6  个tokens\n",
      "terminated after placing the study on hold at the request of the fda    有  14  个tokens\n",
      "this study was closed prematurely due study team travel restrictions    有  10  个tokens\n",
      "study was withdrawn due to 2 cases of agranulocytosis in a different clinical trial with this same drug    有  24  个tokens\n",
      "technical difficulty with endo-pat machine    有  8  个tokens\n",
      "difficulty in obtaining specific isotope tracer    有  7  个tokens\n",
      "we could not receive the support from the national medical insurance owing to the changed policy of the government for clincal trials    有  24  个tokens\n",
      "not i    有  2  个tokens\n",
      "device withdrawn from the market    有  5  个tokens\n",
      "change of strategic priorities in the sponsor's clinical development sector    有  11  个tokens\n",
      "device withdrawn from market    有  4  个tokens\n",
      "end of production    有  3  个tokens\n",
      "the results were not significant, therfore the study ended prematurily    有  14  个tokens\n",
      "study stopped for scientific reasons. another study with a new design is in course of authorization and implementation    有  19  个tokens\n",
      "sponsor discontinued the argus ii product    有  7  个tokens\n",
      "study stopped due to issues surrounding development and formulation of olaparib    有  14  个tokens\n",
      "unable to accrue subjects to the study    有  8  个tokens\n",
      "in accordance with the request to close study ep00-402 \"emea/h/c/000607/mea 10.2\" submitted and adopted by the ema    有  34  个tokens\n",
      "upenn suspended production of the ligand necessary to produce the tracer trodat    有  15  个tokens\n",
      "doxil is currently unavailable    有  6  个tokens\n",
      "investigation into serious breach    有  5  个tokens\n",
      "software problem    有  2  个tokens\n",
      "sponsor company was acquired and new owner chose not to proceed with clinical study    有  14  个tokens\n",
      "should not have been listed on clinicaltrials    有  9  个tokens\n",
      "a trial using eci301 & radiation was initiated in japan in 2012. this tested the primary endpoint in a duplicate trial, thus the study was closed    有  32  个tokens\n",
      "facility where study was taking place closed    有  7  个tokens\n",
      "due to poor supply of medication and technical problems with the mri    有  13  个tokens\n",
      "a single cohort, alternative trial was started    有  8  个tokens\n",
      "due to strategic reasons    有  4  个tokens\n",
      "core study 12011.201 was terminated    有  9  个tokens\n",
      "unable to accrue all planned subjects in a timely fashion, but data collected will still be analyzed    有  19  个tokens\n",
      "the study is stopped due to very modest activity compared to competitors    有  12  个tokens\n",
      "preliminary results of mk-5172 pn003 (nct01353911) suggested a possible dose relationship to elevated transaminase levels in treatment with grazoprevir    有  36  个tokens\n",
      "study to be redesigned    有  4  个tokens\n",
      "the study was closed due to a shift in research priorities and a poor resources available for the project    有  19  个tokens\n",
      "results were obtained in another project    有  6  个tokens\n",
      "numer of eligible patients markedly decreased since the initiation of the study    有  12  个tokens\n",
      "the study was prematurely discontinued on 06nov2012 due to tolerability findings in patients treated in part i of the study that have prompted the sponsor to re-evaluate the strategic development of the program. an unexpected frequency of arterial thrombotic events (ates) and venous thrombotic events (vtes) were reported in patients treated in part i    有  72  个tokens\n",
      "2011 thailand flooding led to loss of gmp pharmacy, project delays, and further regulatory challenges    有  20  个tokens\n",
      "developed a better regimen: diad. cast. 2018 nct03593902    有  19  个tokens\n",
      "data monitoring committee recommendation    有  4  个tokens\n",
      "change of design consideration    有  4  个tokens\n",
      "the study was withdrawn because of problems found with the baseplate    有  12  个tokens\n",
      "changes in staff resulted in logistic difficulties to perform the study    有  11  个tokens\n",
      "feasibility of study at single site; changes in clinical practice in opioid use    有  15  个tokens\n",
      "manufacturer did not develop and deliver the necessary biopsy forceps needles in time    有  14  个tokens\n",
      "finances and feasibility    有  4  个tokens\n",
      "terminiated for trial redesign    有  5  个tokens\n",
      "the research questions was changed/de-prioritized. only one subject completed    有  14  个tokens\n",
      "the study was terminated early as the results did not support study objectives and were not as significant as expected    有  20  个tokens\n",
      "the study was terminated because there was insufficient data to complete the study objectives    有  14  个tokens\n",
      "feasibility study, sufficient amount of data collected    有  9  个tokens\n",
      "study was terminated due to cease in manufacturing of study drug    有  11  个tokens\n",
      "another phase 2 randomized study has been started by other investigators    有  12  个tokens\n",
      "due to budgetary issues, the company has decided to focus on other applications at this stage    有  18  个tokens\n",
      "marketing of ce marked device has been discontinued    有  8  个tokens\n",
      "novartis has have decided to terminate all clinical investigator-initiated research projects involving aliskiren    有  19  个tokens\n",
      "guillaume grenier, principal investigator is no longer working at the lab. the lab is now closed    有  20  个tokens\n",
      "the drug will no longer be available in the united states    有  11  个tokens\n",
      "we planed to study later    有  6  个tokens\n",
      "study was terminated by the sponsor early at the end of phase 1b due to a change in corporate strategy    有  22  个tokens\n",
      "modified study; created new study as a result of these modifications    有  12  个tokens\n",
      "the study was terminated because biomarin decided to end the overall development program based on competing corporate priorities    有  19  个tokens\n",
      "drug product no longer available    有  5  个tokens\n",
      "dsmb recommendation to suspend trial due to control device    有  10  个tokens\n",
      "pi didn't have time to finish approval process    有  9  个tokens\n",
      "study was terminated early because the site that administered the hyperbaric oxygen treatment closed and an alternative site could not be identified    有  24  个tokens\n",
      "high mortality rate in intervention arm for patients with rr >40 and spo2 < 90%    有  19  个tokens\n",
      "trial design contingent on rfa optimization    有  7  个tokens\n",
      "investigator has relocated to md anderson    有  8  个tokens\n",
      "currently in the process of submitting ide to the fda    有  11  个tokens\n",
      "fda reclassified so all 522 studies were stopped,    有  12  个tokens\n",
      "this study was halted as the preliminary analysis revealed that the numbers were too poor to warrant continuing the project    有  20  个tokens\n",
      "problem with the candidate (investigator)    有  8  个tokens\n",
      "the study never started due to problems with laboratory facilities in collaborating center    有  13  个tokens\n",
      "the required number of banked samples could not be met due to limited availability. there is no realistic possibility to complete the study succesfully    有  26  个tokens\n",
      "not a required sutudy to be posted    有  8  个tokens\n",
      "the study was halted prematurely at 90 of 105 planned patients due to the beneficial results of embolectomy clinical trials    有  25  个tokens\n",
      "study terminated (halted prematurely) as recomended by the drug supplier and medical agencies    有  17  个tokens\n",
      "interim analysis indicated significant additional subjects needed to demonsate statistical difference in primary outcome    有  16  个tokens\n",
      "limited staff and operating resources    有  5  个tokens\n",
      "study procedures were not feasible    有  5  个tokens\n",
      "terminated early due to change in practice    有  7  个tokens\n",
      "loss of participants to folpoor-up    有  8  个tokens\n",
      "due to the recent change in standard of care for hepatitis c    有  12  个tokens\n",
      "the benefit/risk profile does not support continuation of this study    有  12  个tokens\n",
      "regarding the comments of the idsmb, the sponsor decided to stop the inclusions    有  17  个tokens\n",
      "unable to register treatment ind with the us food and drug administration's new process of establishing tls encryption for email correspondence    有  22  个tokens\n",
      "all trials ojectives were met    有  6  个tokens\n",
      "decision to change trial design    有  5  个tokens\n",
      "this study had an major amendment in 12/2006 introducing risk stratified sequential treatment (rsst). the modified protocol is registered with nct00590447    有  33  个tokens\n",
      "principle investigator changed practice location and discontinued study    有  9  个tokens\n",
      "we didn't have enough financial support    有  7  个tokens\n",
      "the research fund, which is yet to be raised and expected to take for a while    有  17  个tokens\n",
      "unusual high frequency of elevated liver function tests    有  9  个tokens\n",
      "departure of principal investigator    有  4  个tokens\n",
      "terminated by study sponsor    有  4  个tokens\n",
      "no sufficient subjects    有  3  个tokens\n",
      "us fda/ema/sfda decisions to rosiglitazone-containing medicines, ethic    有  19  个tokens\n",
      "given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial    有  26  个tokens\n",
      "the company is no longer pursuing this study    有  8  个tokens\n",
      "we have decided to design a comparative study which is ongoing    有  11  个tokens\n",
      "decision of independent monitoring committee after interim analysis: risk of failure significantly higher in ceftazidime group    有  21  个tokens\n",
      "trial terminated by sponsor after decision to evaluate combination of quaratusugene ozeplasmid and osimertinib instead of further evaluating quaratusugene ozeplasmid and erlotinib    有  43  个tokens\n",
      "loss to folpoor-up rate too high for publication and data on completed patients does not alpoor for a powered analysis    有  25  个tokens\n",
      "protocol never approved by local irb    有  7  个tokens\n",
      "amicus therapeutics discontinued study at1001-041 for logistical reasons    有  14  个tokens\n",
      "on february 28, 2019, capricor ceased ongoing folpoor-up activities and terminated the allstar trial to focus resourcing on its active cap-1002 program, hope-2    有  42  个tokens\n",
      "unable to complete the data collection for this study    有  9  个tokens\n",
      "study methodology redesigned    有  3  个tokens\n",
      "invalid data collection    有  3  个tokens\n",
      "device not available    有  3  个tokens\n",
      "new protocol to start with improved product    有  7  个tokens\n",
      "other more favorable treatments are now available    有  7  个tokens\n",
      "new study created    有  3  个tokens\n",
      "terminated before starting due to need for ind determined by fda    有  12  个tokens\n",
      "device revised    有  2  个tokens\n",
      "due to a poor participants, this study has been closed    有  11  个tokens\n",
      "the budget issues    有  3  个tokens\n",
      "discontinuation of development program    有  6  个tokens\n",
      "trouble with recruting    有  6  个tokens\n",
      "difficulty to include enough subjects    有  5  个tokens\n",
      "sufficient findings to draw conclusions    有  6  个tokens\n",
      "sponsor considered no further meaningful data was being collected, nor were likely to be collected in the future    有  19  个tokens\n",
      "will answer study question through other research means    有  8  个tokens\n",
      "based on analysis of our data after the symplicity-3 trial announcement, decision for study termination was done    有  21  个tokens\n",
      "research staffs unable to continue    有  6  个tokens\n",
      "study medication could not be supplied. an alternative project will be conducted    有  13  个tokens\n",
      "study terminated due to abnormal liver biochemical tests in some participants    有  11  个tokens\n",
      "unable to obtain ind currently    有  5  个tokens\n",
      "in connection with the restructuring of sakk, older ongoing studies were analyzed to determine whether a continuation of the trial would still add value to the data analysis, or whether they do not and could therefore be prematurely terminated    有  42  个tokens\n",
      "als-2158 showed insufficient antiviral activity to warrant proceeding with further clinical development    有  17  个tokens\n",
      "study drugs (oseltamivir suspension from roche) were unavailable    有  15  个tokens\n",
      "sponsor wanted study rewritten    有  4  个tokens\n",
      "protocol no longer meeting sponsor objectives    有  6  个tokens\n",
      "inactivity and unable to complete due to manpower issues    有  10  个tokens\n",
      "p.i. decided to terminate study due to multiple unresolved issues    有  12  个tokens\n",
      "the study stopped due to a death in the arm control    有  11  个tokens\n",
      "intermediary analysis showing increased morbidity in the delayed group    有  12  个tokens\n",
      "judicial liquidation of the society providing dietary supplementation    有  10  个tokens\n",
      "met study stopping rules    有  4  个tokens\n",
      "study was not approved by health surveillance agency    有  8  个tokens\n",
      "problems with availability of cardiac output monitoring system    有  8  个tokens\n",
      "change of cro    有  3  个tokens\n",
      "protocol no longer meets sponsor objectives    有  6  个tokens\n",
      "interim analysis demonstrated the treatment was not effective    有  9  个tokens\n",
      "interim review indicated that the dose selected was too high for diabetics    有  15  个tokens\n",
      "end of study of this product    有  6  个tokens\n",
      "study not performed    有  3  个tokens\n",
      "expired experimental study agent, no additional supply available    有  9  个tokens\n",
      "the chosen intervention was obviously ineffective    有  6  个tokens\n",
      "we did not found voluntary subjects    有  6  个tokens\n",
      "investigational drugs no longer available    有  7  个tokens\n",
      "not enough responses to continue treatment    有  6  个tokens\n",
      "not enough patient population according to selection criteria to complete the study    有  12  个tokens\n",
      "the sponsor discontinued to support the study    有  7  个tokens\n",
      "not required to be registered    有  5  个tokens\n",
      "changes in the sponsorship, design and locations of the study    有  11  个tokens\n",
      "the study was alpoored to expire due to changes in standard care for the patient population within the nch institution    有  23  个tokens\n",
      "main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned    有  24  个tokens\n",
      "study was terminated early to alpoor subjects to roll over to study nct02102204    有  19  个tokens\n",
      "the data showed that pain was higher for our standardized method of sampling    有  13  个tokens\n",
      "study is replaced by some risk manag. activities covering the whole russian federation. primary objectives could not be met due to critical missing information    有  27  个tokens\n",
      "we collected data of a total of 19 patients for an interim analysis. but there are less than 7 responses out of the initial 19 patients    有  30  个tokens\n",
      "astrazeneca sponsored trials of azd8931 have been halted    有  13  个tokens\n",
      "insecticidal treatment of school uniforms did not last through a dengue season    有  17  个tokens\n",
      "recent publication (ghezel-ahmadi. thorac cardiovasc surg. 2014 nov 21)    有  25  个tokens\n",
      "difficulty in selecting the sample and folpoor-up lost    有  11  个tokens\n",
      "parent study (oscillate) stopped by the data monitoring committee    有  13  个tokens\n",
      "interim assessment provided sufficient data to answer study questions    有  10  个tokens\n",
      "the study closed prematurely due to discontinuation of drug supply    有  11  个tokens\n",
      "trial was redesigned as a new trial    有  7  个tokens\n",
      "phase 2 part of the trial will no longer continue since the protocol competes with another tpi287 protocol in outside institution supported by the sponsor    有  29  个tokens\n",
      "principal investigator moved, and the study should have been taken out of unn clincaltrial.gov account 5-6 years back in time    有  28  个tokens\n",
      "interim assessment by sponsor    有  5  个tokens\n",
      "estimated primary completion date: march 2017 (final data collection date for primary outcome measure)    有  19  个tokens\n",
      "difficulty including subjects corresponding to the criteria    有  7  个tokens\n",
      "most of the study team left the institution prior to study initiation    有  12  个tokens\n",
      "missing evidence of the effectiveness of the study medication    有  9  个tokens\n",
      "the study has been terminated due to difficulties in gathering the patient samples    有  13  个tokens\n",
      "de-identified psgs were to be scored by a vendor prior to being sent to the sponsor. issues occurred with vendor and no psgs were analyzed by the sponsor    有  35  个tokens\n",
      "the local authorities did not authorize the use of biofreeze in chile    有  14  个tokens\n",
      "patient's disease progressed and vision dropped which led to exit from the study    有  14  个tokens\n",
      "the unexpected increase in morbidity of the hemoclip group    有  12  个tokens\n",
      "novartis terminated this study due to internal, strategic decisions    有  12  个tokens\n",
      "terminated ( halted prematurely,expiration of investigationnal product)    有  11  个tokens\n",
      "sponsor directive    有  2  个tokens\n",
      "decision from sanofi to withdraw on a worldwide basis the marketing authorisation applications for semuloparin sodium in the adult indication    有  25  个tokens\n",
      "the study could not be performed as planned for organizational reasons    有  11  个tokens\n",
      "resources needed to complete the study were not able to be obtained    有  12  个tokens\n",
      "end of finantial support    有  6  个tokens\n",
      "after over a year no subjects were identified    有  8  个tokens\n",
      "concerns about post vtp mri results being conclusive    有  12  个tokens\n",
      "during the study two patients have experienced serious liver events related to akn-028. the risk-benefit balance was judged to be negative    有  27  个tokens\n",
      "glp-2 drug product stability concerns    有  8  个tokens\n",
      "terminated after aspirin was recommended by the usptf to prevent preeclampsia    有  18  个tokens\n",
      "never approved by irb    有  5  个tokens\n",
      "shortage of required study drug    有  6  个tokens\n",
      "stopped after the outcome of cabozantinib phase 3 crpc study xl184-307    有  20  个tokens\n",
      "study has been updated with new protocol number    有  8  个tokens\n",
      "corporate decision to reformulate the investigational product    有  10  个tokens\n",
      "when a blind review highlighted that at least 43% of patients had a virological response    有  19  个tokens\n",
      "because of the product recall 2005/2006    有  11  个tokens\n",
      "the study was terminated due to company restructuring and changes in drug development priorities    有  14  个tokens\n",
      "study was not given ethical approval- a alternative protocol required    有  11  个tokens\n",
      "remaining patients were offered a similar observational study (alexion m11-001) to alpoor for robust, high quality data collection in a larger, single database    有  33  个tokens\n",
      "change in company plans    有  4  个tokens\n",
      "change development strategy    有  3  个tokens\n",
      "absence of equipoise on the basis of predetermined stopping rules    有  12  个tokens\n",
      "financial hardship    有  2  个tokens\n",
      "new requirements for study approval with the swedish medical products agency    有  12  个tokens\n",
      "r and d approval not forthcoming    有  6  个tokens\n",
      "there were not enough eligible families and trained clinicians to conduct rct    有  13  个tokens\n",
      "the trial was never opened and then withdrawn permanently    有  9  个tokens\n",
      "equipment that was used in the study was discontinued    有  9  个tokens\n",
      "release of post marketing requirement for this study. terminated november 2013    有  14  个tokens\n",
      "study drug no longer available in the united states    有  9  个tokens\n",
      "objectives not met    有  4  个tokens\n",
      "due to an altered benefit/risk assessment    有  8  个tokens\n",
      "interim analysis: no statistically significant difference in the 2 study arms    有  14  个tokens\n",
      "other researchers have published results on a similar trial    有  9  个tokens\n",
      "due to local restructering, further recruting was not possible    有  14  个tokens\n",
      "study drug expiration and supply shortage    有  6  个tokens\n",
      "study should not have been listed on clinicaltrials    有  10  个tokens\n",
      "the study was withdrawn due to change of the study product formulation    有  12  个tokens\n",
      "transferred study sponsor    有  4  个tokens\n",
      "lab unable to measure vancomycin levels in sputum    有  12  个tokens\n",
      "the study was terminated because cell genesys stopped all activities for gvax    有  14  个tokens\n",
      "the primary objective of the study was met    有  8  个tokens\n",
      "research question was answered by acta anaesthesiol scand 2012; 56: 102-109    有  22  个tokens\n",
      "the site closed down, therefore the study has been terminated    有  11  个tokens\n",
      "dsmb recommendation to stop    有  5  个tokens\n",
      "acrrual target was not being met    有  8  个tokens\n",
      "voluntary hold    有  3  个tokens\n",
      "new clinical strategies have rendered the question posed by this study less relevant    有  13  个tokens\n",
      "discontinued due to company's strategic reason    有  8  个tokens\n",
      "pi elected to close study    有  5  个tokens\n",
      "on 05/08/12, team working on revising protocol and re-open study under version 2.0    有  24  个tokens\n",
      "sponsor decided that the results were not significant enough to continue    有  11  个tokens\n",
      "the study was finished since the university has been closed    有  10  个tokens\n",
      "house research no longer conducting research    有  6  个tokens\n",
      "hri no longer conducting research    有  6  个tokens\n",
      "diminished rectruitment    有  4  个tokens\n",
      "principal investigator decided to terminate the study    有  7  个tokens\n",
      "disease site team changed research focus unlikely to have sufficient support to complete study    有  15  个tokens\n",
      "promoter's change    有  4  个tokens\n",
      "study is classified as ancillary / correlative    有  9  个tokens\n",
      "subject withdrew    有  2  个tokens\n",
      "internal decision of the sponsor    有  5  个tokens\n",
      "poor resources to perform the study    有  7  个tokens\n",
      "no patient has been included in 9 months because of strict incl/excl criteria    有  16  个tokens\n",
      "post transfer of company ownership from smith & nephew to bioventus llc    有  14  个tokens\n",
      "terminated due to approved label expansion    有  6  个tokens\n",
      "poor mr scanning capacity    有  5  个tokens\n",
      "the principal investigator withdrew from the study. the study was withdrawn because a qualified replacement was not available    有  19  个tokens\n",
      "the interim analysis (100 patients) revealed a possible harm to patients randomised to the fresh frozen plasma (ffp) treatment arm    有  26  个tokens\n",
      "non-invasive prenatal screening clia test performance validated in other cohort. decided samples not required, study aims achieved through other studies    有  25  个tokens\n",
      "as the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that information gained so far by catchez study is sufficient    有  26  个tokens\n",
      "negative study; principal investigator chose to prematurely terminate the study    有  11  个tokens\n",
      "adjusting minor software glitches    有  5  个tokens\n",
      "repair of minor software glitches    有  5  个tokens\n",
      "after interim results data showed no evidence of a difference between both groups    有  13  个tokens\n",
      "the second intermediary analysis showed no significant difference between both arms    有  11  个tokens\n",
      "transitioned to biometabol    有  6  个tokens\n",
      "an analysis demonstrated that running the final participants was unnecessary    有  10  个tokens\n",
      "the company suspended the persecution of this combination    有  8  个tokens\n",
      "study terminated per principal investigator's request    有  7  个tokens\n",
      "terminated at request of fda    有  6  个tokens\n",
      "negative data from another trial led to termination of this trial by sponsor    有  13  个tokens\n",
      "medical/ethical reasons    有  4  个tokens\n",
      "the interim results suggest that it is unlikely that the primary objective will be achieved at the final analysis    有  19  个tokens\n",
      "the trial was terminated in line with the endpoint committee charter    有  11  个tokens\n",
      "sufficient info    有  3  个tokens\n",
      "unable to execute contract    有  4  个tokens\n",
      "per fda cber letter dated july 15, 2015, kedrion spa was released from the pmc to perform the study with kedbumin 25% in pediatric patients    有  40  个tokens\n",
      "online program required re-design    有  5  个tokens\n",
      "resident project which was not folpoored through after graduation    有  11  个tokens\n",
      "the study was stopped by dsmb based on high treatment failure rate in placebo compared to active drug    有  19  个tokens\n",
      "terminated due to the fact that the required number of trial subjects was not met    有  15  个tokens\n",
      "poor cooperation by the participants    有  6  个tokens\n",
      "drug is backordered;    有  5  个tokens\n",
      "when realized that the target 60% of patients with svr was no more achievable    有  17  个tokens\n",
      "incomplete data set & analysis    有  6  个tokens\n",
      "the study was stopped early due to successfully meeting the primary endpoint    有  12  个tokens\n",
      "utsw family medicine refused to comply with agreement to implement study after department head left university. attempts to implement elsewhere failed    有  23  个tokens\n",
      "preliminary reports of this study was too bad    有  10  个tokens\n",
      "surgeon doing procedures amenable to this study left institution    有  12  个tokens\n",
      "alternative product is now approved and available for use    有  9  个tokens\n",
      "pending further evaluation    有  3  个tokens\n",
      "insufficient study support    有  4  个tokens\n",
      "due to staff changes the study never started    有  8  个tokens\n",
      "job change of responsible investigators    有  5  个tokens\n",
      "a replacement protocol was created to replace this current version of protocol    有  12  个tokens\n",
      "primary endpoint voided. dosimeters did not capture radiation dose as expected    有  14  个tokens\n",
      "study will not be initiated as planned    有  7  个tokens\n",
      "omegaven is now fda approved    有  8  个tokens\n",
      "the sponsor is focusing on prospective randomized studies    有  8  个tokens\n",
      "few patients, time consuming to find suiting blood bags with the \"right\" weight    有  17  个tokens\n",
      "the sponsor did not fund the study    有  7  个tokens\n",
      "the cypher ses is now withdrawing in china market    有  10  个tokens\n",
      "principal investigator relocated to orlando, florida    有  8  个tokens\n",
      "clinical trial being transferred to columbia university with the investigator    有  11  个tokens\n",
      "study concluded prematurly    有  5  个tokens\n",
      "after interims analysis standard errors for inflammatory and nutritional markers varied widely, that the power calculation required unattainable goals    有  24  个tokens\n",
      "due to change in development plan    有  6  个tokens\n",
      "interim analysis demonstrated significant benefit in intervention arm    有  9  个tokens\n",
      "treament with rituximab during maintenance phase was stoped, according to dsmc recommendations, since 3 cases of deaths occured    有  29  个tokens\n",
      "the stopping rule for incidence of acute rejection was met    有  10  个tokens\n",
      "- the research team is not able to obtain the necessary support to continue the study    有  16  个tokens\n",
      "sponsor did not move forward with study    有  7  个tokens\n",
      "patent being pursued prior to trial initiation    有  8  个tokens\n",
      "recommendation by study dsmc to the sponsor folpooring interim analysis of 8 subjects    有  19  个tokens\n",
      "unable to isolate sufficient cells from the skin biopsy to perform study experiments    有  13  个tokens\n",
      "pi decided to not activate    有  5  个tokens\n",
      "corporate decision not to initiate the trial    有  8  个tokens\n",
      "financial assistance financial assistance financial assistance financial assistance financial assistance without financial assistance    有  13  个tokens\n",
      "parent protocol (swog s0816 / amc-073) discontinued    有  15  个tokens\n",
      "disease prevalence poorer than expected in population    有  8  个tokens\n",
      "drug company is no longer making the drug    有  8  个tokens\n",
      "could not be implemented    有  4  个tokens\n",
      "not started and now discontinued    有  5  个tokens\n",
      "study was never initiated and internal decision to discontinue initiation process    有  12  个tokens\n",
      "principal investigator request    有  3  个tokens\n",
      "impossible to start to the study    有  7  个tokens\n",
      "due to mechanical issue with device    有  6  个tokens\n",
      "the study has proven to be infeasible    有  9  个tokens\n",
      "never initiated. withdrawn by sponsor    有  6  个tokens\n",
      "study terminated due to medtronic acquisition    有  8  个tokens\n",
      "due to a development decision by the funder    有  9  个tokens\n",
      "interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature    有  26  个tokens\n",
      "could not get participants    有  4  个tokens\n",
      "the sample size of the planned interims analysis was achieved    有  11  个tokens\n",
      "sufficient information gathered    有  4  个tokens\n",
      "participants lost to folpoor-up;    有  8  个tokens\n",
      "test ingredient production did not meet specification    有  7  个tokens\n",
      "insufficient quality of data    有  5  个tokens\n",
      "loss of study staff    有  4  个tokens\n",
      "could not obtain drug supply from manufacturer    有  7  个tokens\n",
      "lab company that was to do testing was sold    有  9  个tokens\n",
      "pharmaceutical co. withdrew support. study was never activated and did not accrue any patients    有  19  个tokens\n",
      "investigator no longer works fulltime at investigational site    有  11  个tokens\n",
      "the physician responsable for this protocol left our hospital    有  9  个tokens\n",
      "the study never started since it did not receive irb approval    有  12  个tokens\n",
      "the protocol needs to be re-designed    有  7  个tokens\n",
      "technical issues with catheter placement; researcher left institution    有  10  个tokens\n",
      "we didn't start the study    有  6  个tokens\n",
      "due to protocol ac-055b201 (music) not meeting it's primary end point    有  18  个tokens\n",
      "corassist believes that certain improvements are needed to the device    有  11  个tokens\n",
      "change in guidelines favouring newer antiplatelet drugs in acs    有  13  个tokens\n",
      "company supplying drug declared bankruptcy, thus there was no drug supply    有  12  个tokens\n",
      "pharmacokinetic stopping criteria for the study were met    有  11  个tokens\n",
      "sorafenib ineffective for tx of recurrent or progressive plga    有  13  个tokens\n",
      "terminated due to unfavorable human pharmacokinetic properties    有  9  个tokens\n",
      "investigators no longer interested in activating study    有  8  个tokens\n",
      "1)new fds device design 2)improved valsalva procedure 3)improved headbands and earpads    有  25  个tokens\n",
      "the study needed to be terminated due to new knowledge about cancer vaccines. a new protocol with an expected more efficient vaccine is currently being written    有  27  个tokens\n",
      "contract with drug supplier expired and was not renewed    有  9  个tokens\n",
      "technical difficulties perfecting laboratory test used on blood samples    有  10  个tokens\n",
      "interim analysis unfavorable to continue the study    有  8  个tokens\n",
      "change of practice in the department (nerve stimulation technique abandoned)    有  13  个tokens\n",
      "interim analysis results revealed substantial increase of patient number, with unfeasible study prolongation    有  18  个tokens\n",
      "unable to get accurate measurements with existing technology    有  8  个tokens\n",
      "company is redesigning measuring tool    有  6  个tokens\n",
      "the study was scheduled for completion february 2013. because of difficulties encountered in completing the trial the study was terminated by sponsor june 2013    有  31  个tokens\n",
      "interim analysis showed that the primary endpoint would not be met    有  12  个tokens\n",
      "principal investigator has decided not to continue her phd studies    有  11  个tokens\n",
      "the study was not feasible to conduct in the us and abroad    有  12  个tokens\n",
      "reassessment of strategic direction    有  5  个tokens\n",
      "the study drug delayed time of discharge which is clinically impracticable    有  13  个tokens\n",
      "study did not reach primary objective; study did not accrue enough patients    有  14  个tokens\n",
      "the objective of the study has been achieved with fewer subjects than planned    有  13  个tokens\n",
      "the study was terminated by the sponsor due to e7820 plus irinotecan being potentially inferior to folfiri    有  24  个tokens\n",
      "the study was terminated due to participant drop out    有  9  个tokens\n",
      "closure of long term folpoor up (ltfu) and study earlier than previously outlined in the protocol as no beneficial information gained from continuing ltfu    有  31  个tokens\n",
      "doxil shortage    有  4  个tokens\n",
      "in interim analysis, this study met the primary hypothesis    有  10  个tokens\n",
      "this indication is not being pursued at this point in time    有  11  个tokens\n",
      "study not to be initiated    有  5  个tokens\n",
      "study was terminated due to the termination of tasisulam development    有  13  个tokens\n",
      "we were not successful in raising money for this project    有  10  个tokens\n",
      "drug is no longer manufactured    有  5  个tokens\n",
      "poor definitive clinical results    有  5  个tokens\n",
      "study does not meet the new legal requirements set forth in the human research act    有  15  个tokens\n",
      "the study was closed by the sponsor according to the protocol-specified minimum post-treatment folpoor-up period of 3 years    有  26  个tokens\n",
      "pi moved institutions and changed study protocol    有  7  个tokens\n",
      "there were ip availability issues due to which the study could not be started    有  14  个tokens\n",
      "sponsor withdraw from this study    有  5  个tokens\n",
      "sponsor has decided not to support this study    有  8  个tokens\n",
      "changes were made to the which needed an entireley new submission    有  12  个tokens\n",
      "off study clinical use of y90 glass microspheres (therasphere)    有  16  个tokens\n",
      "failure to meet pre-specified endpoint for the day 28 cure rate    有  14  个tokens\n",
      "this database did not have the desired inclusions or results and is therefore not sufficiently usable. this base is therefore abandoned in favor of a base on the pancreas much more promising both nationally and internationally    有  39  个tokens\n",
      "similar study to be completd once kit for new formulation becomes available    有  13  个tokens\n",
      "did not meet criteria laid out in phase 1 to continue to phase 2    有  16  个tokens\n",
      "trial closure for nci nctn transition    有  9  个tokens\n",
      "gsk2248761 development program is on clinical hold    有  11  个tokens\n",
      "the device test article is no longer available    有  8  个tokens\n",
      "non hep c study arm has been completed, hep c study arm has not been completed    有  17  个tokens\n",
      "the study ethics committee recommended concluding the study for longer crying time with benzocaine and very short crying time in all participants    有  24  个tokens\n",
      "drug became available with insurance reimbursement    有  6  个tokens\n",
      "sponsor recalled the study    有  4  个tokens\n",
      "investigator no longer at institution-no data analyzed    有  9  个tokens\n",
      "phase i completed. phase ii is cancelled    有  8  个tokens\n",
      "medtronic terminated the study since foretevo product was no longer marketed    有  15  个tokens\n",
      "pi moving to a different institution    有  6  个tokens\n",
      "a main person involved left the site    有  7  个tokens\n",
      "per memo from study team    有  5  个tokens\n",
      "withdraw the study because further analysis showed that it would be futile    有  12  个tokens\n",
      "study was put on clinical hold on 30 jan 2013 folpooring a subject fatality. study was never restarted and was closed    有  28  个tokens\n",
      "closed prematurely    有  2  个tokens\n",
      "product no longer on market    有  5  个tokens\n",
      "the study was stopped due to the inability to determine an acceptable dose with the potential for further study    有  19  个tokens\n",
      "quantitative assessment of ffn only able to be performed at one laboratory    有  14  个tokens\n",
      "product is no longer on the market    有  7  个tokens\n",
      "the manufacturer is not currently supporting research in this indication    有  10  个tokens\n",
      "closed per local irb due to advancements in standard ovarian cancer screening    有  13  个tokens\n",
      "study was stopped due to non-availability of the lidocaine placebo patches    有  15  个tokens\n",
      "endohpb probe is fda approved and considered standard of care    有  13  个tokens\n",
      "no cases on nma meningitis were recorded folpooring vaccination with menafrivac    有  19  个tokens\n",
      "the final decision of the review of hes-containing solution shall be awaited    有  13  个tokens\n",
      "sponsor determined there was sufficient material collected to answer the study questions    有  12  个tokens\n",
      "not reveal any significant difference between the 2 treatment arms    有  11  个tokens\n",
      "it appears dr. vanderbrink left nationwide children's hospital in 2011 and efforts to reach dr. vanderbrink have been unsuccessful    有  30  个tokens\n",
      "most study procedures incorporated into nct01144741, some in nct01306994    有  18  个tokens\n",
      "it was decided by the trial team to stop the collection of folpoor up data in trial sakk 35/10    有  25  个tokens\n",
      "drug manufacturer - amgen requested study stop, per dsmb observation in power trial    有  16  个tokens\n",
      "study was modified to in vitro design and no longer involves participants    有  12  个tokens\n",
      "merck has decided to discontinue all studies with extended-release niacin/laropiprant.because the hps2-thrive did not meet its primary endpoint    有  33  个tokens\n",
      "study terminated due to change in sponsorship    有  7  个tokens\n",
      "poor subject response    有  4  个tokens\n",
      "could not find interested researchers/clinicians to complete study protocol    有  12  个tokens\n",
      "dsmb recommendation based on programmed interim analysis    有  8  个tokens\n",
      "the study was suspended due to organizational problems    有  8  个tokens\n",
      "prematurely terminated due to failure to meet study objectives    有  12  个tokens\n",
      "difficulty collecting    有  2  个tokens\n",
      "in consequence of termination of altitude. a number of studies were continued in consultation with the altitude data monitoring committee    有  21  个tokens\n",
      "study did not accrue the required number of study subjects    有  11  个tokens\n",
      "for increased induction mortality in older patients due to specific combinations of drugs, other clinical factors such as patient age and comorbidities    有  26  个tokens\n",
      "the intervention could not be performed. all participants received usual clinical practice    有  13  个tokens\n",
      "product development project closed prematurely    有  5  个tokens\n",
      "iac is now recognized as part of standard of care treatment options in the us    有  15  个tokens\n",
      "this is not a clinical trials study    有  7  个tokens\n",
      "do not have necessary resources to continue    有  7  个tokens\n",
      "appropriate study medication supply could not be identified    有  8  个tokens\n",
      "sponsor chose not to move forward with study    有  8  个tokens\n",
      "no significant change for the primary objective at 12 months    有  11  个tokens\n",
      "study terminated due to a technical issue (randomization error)    有  12  个tokens\n",
      "problems implementing the trial    有  4  个tokens\n",
      "unable to complete statistical analysis    有  5  个tokens\n",
      "study did not receive irb approval    有  7  个tokens\n",
      "enough surgeon use to validate the usefulness of the device    有  11  个tokens\n",
      "technical problems with protocol    有  4  个tokens\n",
      "kerasys had more erosions than tutoplast    有  10  个tokens\n",
      "for the last patient still on treated nominal therapeutic use of the milciclib was approved at int milano    有  21  个tokens\n",
      "study is no longer necessary (outmoded, outdated, science has changed)    有  16  个tokens\n",
      "regulatory requirement. a phase iii study is being designed    有  11  个tokens\n",
      "logistic and financial accounting reasons    有  6  个tokens\n",
      "treatment was ineffective    有  4  个tokens\n",
      "the study has been decided to be early terminated for the fas 500 mg has launched in 2015. the use mothod of 250mg per month in clinical practice is off-label    有  38  个tokens\n",
      "not enough data collected    有  4  个tokens\n",
      "institution decided on starting a new protocol of sedation, with another methods and that´s why this study has not started    有  23  个tokens\n",
      "20131209 regulatory authorization is currently blocked at the ansm    有  12  个tokens\n",
      "analysis was not done because only 1 subject was able to come back for the 3 month folpoor up visit    有  24  个tokens\n",
      "in a pilot of early noninvasive positive pressure ventilation, the children did so well that early nppv is now used in all children who meet criteria    有  30  个tokens\n",
      "potential ae    有  2  个tokens\n",
      "we need somebody to replace the principal inestigator    有  10  个tokens\n",
      "study is being redesigned    有  4  个tokens\n",
      "study terminated due to the acquisition of peak surgical by medtronic    有  13  个tokens\n",
      "invalid data    有  2  个tokens\n",
      "on hold pending product development    有  5  个tokens\n",
      "study was non-feasible per dsmb    有  9  个tokens\n",
      "please see 'further study details as provided by acorda therapeutics' for explanation of why study stopped    有  21  个tokens\n",
      "one of the study medications, tacrine, is no longer clinically available    有  14  个tokens\n",
      "study withdrawn due to poor study population    有  7  个tokens\n",
      "because of withdrawal of avandia sale due to its risks outweigh its benefits    有  15  个tokens\n",
      "new technique for administration of drug, this is the old technique of administration    有  14  个tokens\n",
      "study canceled by decision strategically    有  5  个tokens\n",
      "pi/project director no longer at facility    有  7  个tokens\n",
      "there were few eligible subjects from other centers    有  8  个tokens\n",
      "principal investigator withdrew from the study    有  6  个tokens\n",
      "to be compliant with the timelines as agreed with paediatric committee (pc) within the paediatric investigational plan    有  22  个tokens\n",
      "grant ended and faculty has left the institution    有  8  个tokens\n",
      "the study was a collaboration that could not be effectively run    有  11  个tokens\n",
      "antiviral activity was considered insufficient to warrant further clinical development of tmc649128    有  17  个tokens\n",
      "tredaptive has been suspended worldwide    有  7  个tokens\n",
      "irb recommended to stop the trial becasue none of the 4 procedures showed a predictive value for vap, duration of mv or mortality    有  28  个tokens\n",
      "investigator has moved to other state    有  7  个tokens\n",
      "the pharmacokinetic properties of the molecule do not alpoor for further dose escalation or development    有  19  个tokens\n",
      "interim power analysis was prohibitive to continuing the study    有  11  个tokens\n",
      "on further investigation, it was found that the continuous glucose monitors required a calibration period that precluded reliable data collection    有  22  个tokens\n",
      "poor available clinical time to complete    有  7  个tokens\n",
      "insufficient data collection    有  4  个tokens\n",
      "the study had been cancelled and replaced with protocol 20130250    有  13  个tokens\n",
      "statistical significance of the results was reached for the 34 subjects who participated in teh study    有  18  个tokens\n",
      "we will not be pursuing this study    有  7  个tokens\n",
      "the human resources in the organisation are to limited to do the trial    有  13  个tokens\n",
      "study expired    有  2  个tokens\n",
      "this study was closed on february 24, 2015    有  13  个tokens\n",
      "did not achieve statistical significance for primary endpoint    有  8  个tokens\n",
      "the differences seen between treatments led to recalculation of the sample, unattainable in a reasonable time    有  22  个tokens\n",
      "principal investigator was deployed overseas    有  5  个tokens\n",
      "poor adherence and huge loss of folpoor up    有  11  个tokens\n",
      "due to preliminary results of altitude trial    有  7  个tokens\n",
      "components were recalled by depuy    有  6  个tokens\n",
      "study completed at site, no active participants    有  8  个tokens\n",
      "the brazilian regulatory agency - anvisa has requested the cancellation of the phase 3 study for conducting a phase 1 study first    有  26  个tokens\n",
      "the study was combined with our urine and stool study (nct01637506)    有  17  个tokens\n",
      "no reduction in hair loss 1 month after treatment    有  10  个tokens\n",
      "single implant in the mandible was finally not indicated due to poor stability of the denture    有  18  个tokens\n",
      "study stopped due to lost of interest    有  7  个tokens\n",
      "shortage of personnel / main study initiator no longer available    有  11  个tokens\n",
      "short of study staff    有  4  个tokens\n",
      "study was not approved by research ethics board    有  8  个tokens\n",
      "pi decided to terminate the study    有  6  个tokens\n",
      "difficult to obtain informed consent    有  6  个tokens\n",
      "dr. kumar left nationwide children's hospital. the study expired with the nationwide children's hospital on 7/16/14    有  26  个tokens\n",
      "departure of study team    有  4  个tokens\n",
      "the registry was discontinued due to significant resources required    有  9  个tokens\n",
      "the study was terminated before reaching the estimated sample size because of trial fatigue    有  14  个tokens\n",
      "too few of the invited subjects wanted to participate    有  9  个tokens\n",
      "the us fda and the eu chmp provided guidance indicating preference for intereferon-free regimens in pediatric studies of hcv infection    有  28  个tokens\n",
      "ind application was not approved by the us fda - project was never started    有  15  个tokens\n",
      "some of the researchers finished their participation in the study    有  10  个tokens\n",
      "recently published data that has shown hcq to be safe when combined with chemo and or radiation at even higher doses than what is used in this study    有  31  个tokens\n",
      "this record is an additional copy of the study listed above    有  11  个tokens\n",
      "the study was terminated by spiraur (original sponsor). efforts were made to contact the pi/study team members, but were unsuccessful    有  26  个tokens\n",
      "study closed after it became too difficult to interest patients in participating    有  12  个tokens\n",
      "pi has left university of minnesota    有  7  个tokens\n",
      "analysis of designed comparison groups not viable    有  7  个tokens\n",
      "results from interim analysis conducted to study interruption    有  8  个tokens\n",
      "poor support to continue    有  5  个tokens\n",
      "primary endpoint showed no stat significant difference. fu > m12 terminated    有  13  个tokens\n",
      "not enough recources    有  4  个tokens\n",
      "change in company priorities    有  4  个tokens\n",
      "therapy for carotid disease has recently changed. carotid stenting is now restricted to high risk patients that are not eligible for the study    有  29  个tokens\n",
      "preliminary exploration of research concept did not prove to be viable    有  13  个tokens\n",
      "trial closure due to nci nctn transition    有  10  个tokens\n",
      "the ascend study did not achieve statistical significance on the primary or secondary endpoints    有  14  个tokens\n",
      "production of biomarker test discontinued by manufacturer    有  8  个tokens\n",
      "not practical to continue due interim results    有  7  个tokens\n",
      "per irb request    有  4  个tokens\n",
      "change in the development plan for the anti-ox40 antibody    有  12  个tokens\n",
      "neutron therapy has become unavailable    有  6  个tokens\n",
      "the company did not provide the study product    有  8  个tokens\n",
      "unable to record n95 perg peak (primary measure), as lhon subjects are unable to focus on target    有  21  个tokens\n",
      "study only randomized 1 subject and was determined not feasible by dsmb    有  14  个tokens\n",
      "problems with the stability of samples collected    有  7  个tokens\n",
      "the dsaek procedure was discontinued as the standard of care for the intended cohort    有  16  个tokens\n",
      "higher occurrence of complication than expected for both groups    有  9  个tokens\n",
      "re-prioritization lead to study cancellation    有  9  个tokens\n",
      "too poor effect on the output and poor rate of responders    有  11  个tokens\n",
      "poor time and help to continue the study    有  9  个tokens\n",
      "termination of sponsorship    有  3  个tokens\n",
      "patterns of practice changed and this technique is no longer used    有  11  个tokens\n",
      "data did not show that the two biologic treatments impacted pmr disease activity to the same degree as steroid treatment within a 2-week treatment period    有  29  个tokens\n",
      "primary investigator relocated    有  3  个tokens\n",
      "no eligible subjects identified    有  4  个tokens\n",
      "interim analysis determined the study did not meet criteria to proceed    有  12  个tokens\n",
      "results of the study would unfortunately no longer be of any scientific interest to the sponsor and would not be used to inform future studies    有  25  个tokens\n",
      "the retrospective data review did not provide adequate information to continue the investigation    有  13  个tokens\n",
      "because a higher rate of virological failures in study versus control arm    有  14  个tokens\n",
      "study site has terminated the study due to the complexity of the study    有  13  个tokens\n",
      "based on results from an altitude study interim analysis, testing aliskiren concomitantly with an ace inhibitor or arb, in diabetics with renal impairment    有  32  个tokens\n",
      "5 years folpoor up completed in october 2018, long-term folpoor up terminated because of poor data return    有  26  个tokens\n",
      "sponsor seeking additional financial support before starting the study    有  9  个tokens\n",
      "mahnaz kazemipoor has not handed over human subject review board approval letter to her colleague    有  20  个tokens\n",
      "change in clinical practice- both surgeons have left the institution    有  11  个tokens\n",
      "product enhancements completed    有  3  个tokens\n",
      "tenofovir has become available in korea    有  10  个tokens\n",
      "the study medication was no longer available in the market    有  10  个tokens\n",
      "study withdrawn due to volunteer disinterest in participating    有  9  个tokens\n",
      "real trial showed a significant difference in os for reduced eox and standard eox    有  16  个tokens\n",
      "it was decided to discontinue the development in consideration of the results of a p1 study    有  18  个tokens\n",
      "the study was not approved by hospital's medical ethics committee    有  11  个tokens\n",
      "ucl ctc were informed by merck sharp & dohme on 22.08.11 that support for the trial had been withdrawn in light of results from another trial with trial drug    有  39  个tokens\n",
      "primary endpoint (hsp) could not be analyzed with the specified method in the planned interim analysis; a method of increased sensitivity had to be established    有  29  个tokens\n",
      "the trial would be continued if there was a difference of ≥3 % between trial arms. however, the difference between ongoing pregnancy rates was <1 %    有  30  个tokens\n",
      "device was stolen    有  3  个tokens\n",
      "decision of independent monitoring committee:risk of death at 3 months higher in albumin group than in control group, without reaching significance level    有  27  个tokens\n",
      "primary investigator is no longer employed at llu as of 02/29/12    有  17  个tokens\n",
      "the primary endpoint was not met on the double blind data    有  11  个tokens\n",
      "change in strategy regarding the product by the company    有  9  个tokens\n",
      "completion of mk-0431a-235 was rendered unnecessary, as the local oversight authority accepted in its stead the results of another study [mk-0431-234]    有  35  个tokens\n",
      "the study could not be done for every potential participant as planned in the protocol for organizational reasons    有  18  个tokens\n",
      "this study was terminated because the national ethics committee has not approved the protocol    有  14  个tokens\n",
      "assay not evaluated for purpose of clearance    有  8  个tokens\n",
      "the 3rd interim analysis found superiority in the mesh reinforcement arm    有  13  个tokens\n",
      "single subject remained on study - transferred to compassionate use    有  10  个tokens\n",
      "poor new studies contributing subjects to this study    有  9  个tokens\n",
      "premature closure. protocol did not meet its primary objective    有  12  个tokens\n",
      "eyes that received gel had slightly thinner than intended flaps    有  11  个tokens\n",
      "results obtained are sufficient for a publication    有  7  个tokens\n",
      "protocol not progressed. study not implemented    有  7  个tokens\n",
      "study is withdrawn before recruting participants, new trial will be multi centre, sponsored by different organisation    有  20  个tokens\n",
      "results from phase ii study did not support \"dismantling\"    有  14  个tokens\n",
      "unavailability of study drug and matching placebo    有  8  个tokens\n",
      "unable to fill cohort    有  4  个tokens\n",
      "trial not progressing toward scientific goals    有  6  个tokens\n",
      "planned interim analysis-no statistical significance for the primary outcome    有  11  个tokens\n",
      "inconsistent training status of sniffer dogs    有  8  个tokens\n",
      "terminated due to sponsor desicioun    有  7  个tokens\n",
      "new revised saa bmt study opened to take over this study    有  13  个tokens\n",
      "poor access to study drug    有  6  个tokens\n",
      "workforce issues precluding study completion    有  7  个tokens\n",
      "study tasks to difficult for subjects to complete    有  8  个tokens\n",
      "study not launched due to logistical issues that could not be resolved    有  12  个tokens\n",
      "the technique has been approved and validated    有  7  个tokens\n",
      "early termination leading to small number of subjects analyzed    有  9  个tokens\n",
      "bexxar isn't being produced by the manufacturer as of feb. 2014    有  19  个tokens\n",
      "successfull interim analysis    有  4  个tokens\n",
      "pi decided to not initiate this study    有  7  个tokens\n",
      "the trial was stopped due to the toxicities observed with the combination of pimasertib and temsirolimus    有  23  个tokens\n",
      "fda needs more information from the manufacturing company of the supplements    有  12  个tokens\n",
      "trial will not complete until at least 2025 and evolution of immunosuppressant therapy has made it unlikely that patients will convert from modigraf to prograf    有  34  个tokens\n",
      "there was no resources to complete the study at this time    有  11  个tokens\n",
      "study stopped due to early stopping rule    有  7  个tokens\n",
      "referral physician no longer available    有  6  个tokens\n",
      "company did not pursue this indication    有  6  个tokens\n",
      "pi has passed away. requested by department to terminate study    有  11  个tokens\n",
      "other stimulation target (slmfb) more efficacious, unethical to continue with nucleus accumbens    有  20  个tokens\n",
      "research priorities and focus have shifted    有  6  个tokens\n",
      "participants were consented but registry was not developed due to poor numbers    有  13  个tokens\n",
      "were not able to conduct the intervention    有  7  个tokens\n",
      "the study was stopped for not meeting the primary endpoint for pfs    有  13  个tokens\n",
      "proof of principle established with completed sad part    有  8  个tokens\n",
      "inconsistent data taken from phase i cohort    有  8  个tokens\n",
      "early termination due to pi's decision to discontinue research activities    有  12  个tokens\n",
      "it became unlikely to achieve the study objective of 50% reduction over published inhibitor rates. the data monitoring committee supported this decision    有  25  个tokens\n",
      "samples lost during hurricane sandy. study now taking place at other medical centers    有  14  个tokens\n",
      "principal investigator retiring    有  3  个tokens\n",
      "in the absence of benefits and because of a statistically significant excess mortality in the group of patients receiving active stimulation    有  21  个tokens\n",
      "logistical reasons (institutional reorganization of ambulatory surgery)    有  13  个tokens\n",
      "the investigators decided not to proceed this study because of some internal matters    有  13  个tokens\n",
      "change in the company clinical trials priority    有  7  个tokens\n",
      "have been published new studies that it showed the ineffectiveness of the treatments proposed in this study    有  19  个tokens\n",
      "budget issue    有  2  个tokens\n",
      "modifications were made to protocol, new irb pending    有  11  个tokens\n",
      "pi was away on sabbatical for 2 years.protocol is being revised before starting the study    有  19  个tokens\n",
      "study terminated because of differences in the participant population under study compared with indicated zinbryta use in most countries    有  23  个tokens\n",
      "h1n1 pandemic concluded    有  6  个tokens\n",
      "study not required for development    有  5  个tokens\n",
      "modifications are being made to protocol    有  7  个tokens\n",
      "a new protocol was written to replace this protocol    有  9  个tokens\n",
      "participants are no longer being examined and receiving intervention    有  9  个tokens\n",
      "my post-doctoral felpoor did not return from her mat leave and i have no other students to take on this project    有  26  个tokens\n",
      "the trial was terminated for scientific reasons    有  7  个tokens\n",
      "d/t changes in routine modality of milk expression by electric pump    有  13  个tokens\n",
      "this prodect will be transferred to another company    有  9  个tokens\n",
      "poor budget and failure to reach milestones    有  8  个tokens\n",
      "first milestone was not met    有  5  个tokens\n",
      "the study was prematurely discontinued since study medication was no longer available    有  12  个tokens\n",
      "currently closed for data analysis    有  5  个tokens\n",
      "the unit's standard nutrition practices change which impacted our methodology    有  11  个tokens\n",
      "poor subjects to participate    有  5  个tokens\n",
      "changing conditions for the device in one of the participation companies    有  11  个tokens\n",
      "study withdrawn by investigator    有  4  个tokens\n",
      "poor human resources    有  4  个tokens\n",
      "did not have study population to continue    有  7  个tokens\n",
      "patient pathway has become infeasible due to pressure for shorter hospital stays. not enough inclusions    有  19  个tokens\n",
      "pi returned to her home country of japan    有  8  个tokens\n",
      "investigator has left the university    有  6  个tokens\n",
      "revisions to original study protocol underway    有  7  个tokens\n",
      "ide was withdrawn. veniti no longer owns the rights to this device    有  14  个tokens\n",
      "unable to align the study questions with a complementary trial    有  10  个tokens\n",
      "recommendations changing    有  3  个tokens\n",
      "disposables required for the measurements in short supply and not provided by the company / supplier    有  17  个tokens\n",
      "the study has concluded normally    有  5  个tokens\n",
      "not sufficient staff to complete the trial    有  7  个tokens\n",
      "510(k) approval gained for product    有  7  个tokens\n",
      "eclipse shoulder system received 510(k) clearance on july 26, 2019    有  19  个tokens\n",
      "poor events rate. scarce economical resources    有  8  个tokens\n",
      "on april 15, 2019, biotronik received fda approval to transition the ongoing siello post approval registry to a new ep passion real-world data methodology    有  34  个tokens\n",
      "adjustment of company focus due to acquision by valeant pharmaceuticals    有  14  个tokens\n",
      "the study is no longer feasible    有  6  个tokens\n",
      "participants found the study procedures to be too cumbersome and no longer wanted to participate    有  15  个tokens\n",
      "the study did not meet endpoint    有  6  个tokens\n",
      "development of srm003 was discontinued based on portfolio prioritization    有  12  个tokens\n",
      "dr. higgins does not have a sub-investigator that can complete the study    有  17  个tokens\n",
      "increased number of oxygen desaturation in tilt down position    有  12  个tokens\n",
      "this study never initiated    有  4  个tokens\n",
      "the interim analysis has shown a significative difference between the two groups of patients    有  15  个tokens\n",
      "optimal response: 63% nomogram, 42% controls, overcoming the stopping rule for interim analysis    有  22  个tokens\n",
      "early findings showed trial was not feasible    有  7  个tokens\n",
      "due to participants not completing the cognitive training requirement    有  9  个tokens\n",
      "the independent data monitoring committee recommended an early termination    有  9  个tokens\n",
      "folpoor up period after primary analysis was prematurely stopped because more mature data will not impact the study outcome    有  21  个tokens\n",
      "protocol study design was re-worked in collaboration with cms    有  11  个tokens\n",
      "we observed a very high referral rate for patients with hf in the duke health system, eliminating the need for an automated referral process    有  25  个tokens\n",
      "poor to accrue, poor qualified participants    有  9  个tokens\n",
      "exposure to radiation due to repetitive pet evaluation    有  9  个tokens\n",
      "study no longer at lu    有  5  个tokens\n",
      "analysis showed no clinically or statistically significant effects    有  8  个tokens\n",
      "due to insufficient quality of biopsy samples    有  7  个tokens\n",
      "interferon use for hepatitis c plummeted, eliminating the need for study drug    有  16  个tokens\n",
      "poor referral rate due to new therapeutic options    有  9  个tokens\n",
      "this study was never initiated    有  5  个tokens\n",
      "the remaining eligible participants declined to participate    有  7  个tokens\n",
      "reprioritization of company activities    有  7  个tokens\n",
      "aripiprazole arm had obvious adverse reactions,especially akathisia    有  15  个tokens\n",
      "effects of aripiprazole was not obvious and showed adverse reaction obviously    有  15  个tokens\n",
      "healthy volonteers study results show that the device is not enough reliable    有  14  个tokens\n",
      "gsk confirmed misrepresentation of preclinical data that supported the rationale for gsk2618960 in ms. this decreased benefit assessment for ms    有  28  个tokens\n",
      "tecnical problem    有  4  个tokens\n",
      "end of inclusing period    有  5  个tokens\n",
      "study team decision because of ip supply issue and necessary amendment to protocol    有  13  个tokens\n",
      "unable to secure drug    有  4  个tokens\n",
      "the study was stopped due to methodological issues that require additional consideration prior to resuming the trial    有  19  个tokens\n",
      "re-assessment of study    有  5  个tokens\n",
      "scientific review positive from 3 manufacturers; internal committees did not support due to deploying new flu vaccines in hiv+ pregnant women in kenya    有  28  个tokens\n",
      "study no longer required as optivate german license expired in sep-2017    有  15  个tokens\n",
      "inability to retain study drug with comparable placebo    有  9  个tokens\n",
      "inclusions objectives raised but patient folpoor-up reduced to 6 months (impossible to raised secondary objectives)    有  23  个tokens\n",
      "the study had to stop due to organizational changes in nordsjællands hospital    有  17  个tokens\n",
      "early termination of study due to fewer subjects available than expected resulting in small sample size    有  16  个tokens\n",
      "our anesthesiologist was no longer available to assist    有  11  个tokens\n",
      "study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. there is no data collected    有  23  个tokens\n",
      "no benefit of intravesical instillation of hyaluronic acid/chondroitin sulfate    有  19  个tokens\n",
      "technical complications    有  2  个tokens\n",
      "leakage    有  3  个tokens\n",
      "problems with ensuring patient examinations defined in the protocol of the study    有  12  个tokens\n",
      "6 patients were recuited. due to inability of the tracer to detect regions of interest sufficiently, the trial was closed early    有  25  个tokens\n",
      "study terminated early due to decision by sponsor    有  8  个tokens\n",
      "changes in available treatments for melanoma    有  7  个tokens\n",
      "ide not submitted    有  3  个tokens\n",
      "poor pre-treatment tissue to make the study plan feasible    有  12  个tokens\n",
      "due to poor volunteer facilitators to deliver the intervention    有  10  个tokens\n",
      "research site no longer available    有  5  个tokens\n",
      "amgen determined no further need for this study    有  9  个tokens\n",
      "dsmb interim analyses    有  4  个tokens\n",
      "focus resources in the allogeneic platform and provide optimal value for patients    有  15  个tokens\n",
      "the results were disappointing    有  4  个tokens\n",
      "unable to continue research due to time constraints    有  8  个tokens\n",
      "unable to continue study due to time constraints    有  8  个tokens\n",
      "no logistical support to carry out the study fairly    有  9  个tokens\n",
      "amendment of study protocol    有  5  个tokens\n",
      "the principal investigator of the study relocated to another institution    有  10  个tokens\n",
      "this study has been terminated; alternative study designs are being considered. fusidic acid remains available under an expanded access protocol    有  24  个tokens\n",
      "already several publications in the literature    有  6  个tokens\n",
      "discontinuation of this study was based on novartis decision to discontinue development of fingolimod for the treatment of adon    有  28  个tokens\n",
      "non-compliance issues    有  4  个tokens\n",
      "the study will be part of a european multicenter trial (infliximab top-down study in kids with crohn's disease)    有  27  个tokens\n",
      "grant ended before study could be initiated    有  7  个tokens\n",
      "the study met the pre-specified criteria for stopping the trial    有  12  个tokens\n",
      "logistics regarding pet/ct portion of study    有  9  个tokens\n",
      "decided not tostart study because of unavailability of staff    有  12  个tokens\n",
      "inacceptable oxygen saturation values in one study group    有  9  个tokens\n",
      "the study was stopped for technical reasons    有  7  个tokens\n",
      "the intervention (pulsepoint application) could not be implemented in toronto as planned    有  16  个tokens\n",
      "occurrence of severe respiratory depression in the remifentanil group    有  14  个tokens\n",
      "treatment effects not as desired    有  6  个tokens\n",
      "trial operational issues    有  3  个tokens\n",
      "it was decided not to proceed with the study at this time    有  12  个tokens\n",
      "study terminated for commercial reasons    有  5  个tokens\n",
      "the protocol has undergone significant changes and the investigator feels that it is reasonable to submit a new protocol for review and approval    有  23  个tokens\n",
      "study being continued as a multi centre ma3rs study.the patients will be folpoored up under ma3rs and aaa pet    有  26  个tokens\n",
      "the protocol design is being reconfigured in order to open a new study    有  14  个tokens\n",
      "the intervention becomes obsolete for participating centres pending regulatories    有  10  个tokens\n",
      "the cytokines in the samples were undetectable    有  10  个tokens\n",
      "pi and lab have re-located study to the ohio state university    有  13  个tokens\n",
      "left institution where study was approved    有  6  个tokens\n",
      "investigator no longer available on site    有  7  个tokens\n",
      "changes in country regulation    有  4  个tokens\n",
      "interim analysis showed no significant difference between study arms    有  10  个tokens\n",
      "organisatory reason    有  4  个tokens\n",
      "no subjects agreed to participate    有  5  个tokens\n",
      "pi relocated to a different country    有  6  个tokens\n",
      "the data did not show clear results    有  7  个tokens\n",
      "comparator sawblade no longer available    有  7  个tokens\n",
      "no clinical investigator present    有  4  个tokens\n",
      "no statistical difference observed for outcomes    有  6  个tokens\n",
      "this program was terminated for financial reasons    有  7  个tokens\n",
      "study was terminated by sponsor without any aes to review the device design    有  13  个tokens\n",
      "study did not pass stage 1 interim analysis    有  9  个tokens\n",
      "no medication    有  2  个tokens\n",
      "the stereotaxis can be threatful for the patients because of respiratory insufficiency    有  17  个tokens\n",
      "unable to get required research materials    有  6  个tokens\n",
      "analysing images ongoing    有  5  个tokens\n",
      "the study was terminated due to time constraints and the withdrawal of stress control from the nhs greater glasgow and clyde services    有  27  个tokens\n",
      "changes in standards of care    有  5  个tokens\n",
      "this is a basic research study with no clinical data to report    有  12  个tokens\n",
      "co-investigators left the institution    有  7  个tokens\n",
      "primary investigator has changed his employee and the country of residence    有  11  个tokens\n",
      "sensor calibration and other r&d activities    有  8  个tokens\n",
      "irb terminated study    有  4  个tokens\n",
      "assay being revised and re-validated    有  8  个tokens\n",
      "never initiated, did different study    有  6  个tokens\n",
      "interim results showed that the hatcp material was not non-inferior to the auto graft    有  19  个tokens\n",
      "no signal on pain-score    有  5  个tokens\n",
      "because of logistic and practical reasons    有  6  个tokens\n",
      "sponsor decided to stop the study due to expiration of blinded placebo    有  12  个tokens\n",
      "development halted by management    有  4  个tokens\n",
      "study was activated initially. however, the necessary resources were not available to complete the research    有  17  个tokens\n",
      "difficulty to identify eligible patients: 8 centers contributed 54 patients in 6 months    有  17  个tokens\n",
      "there were a number of bugs in the game that meant the participants were not getting the intended intervention    有  19  个tokens\n",
      "due to difficulty in purchasing reagents, study canceled without subject registration    有  13  个tokens\n",
      "unobtainable sample size    有  6  个tokens\n",
      "awaiting fda approval for next dose group    有  9  个tokens\n",
      "no correlation between fiau uptake and bone biopsy results    有  11  个tokens\n",
      "primary objective not met after planned interim analysis    有  8  个tokens\n",
      "practical problems    有  3  个tokens\n",
      "poor the subjects    有  4  个tokens\n",
      "study team will review the collected data and make any necessary changes to the educational tool    有  16  个tokens\n",
      "planned future study    有  4  个tokens\n",
      "study medication no longer available at institution    有  7  个tokens\n",
      "dose escalation ended after cohort b1, rux 10 mg bid - gcsf in october 2014    有  25  个tokens\n",
      "problems with execution    有  3  个tokens\n",
      "primary researcher not able to continue research at the moment    有  10  个tokens\n",
      "all investigators/co-investigators relocating to other institutions    有  11  个tokens\n",
      "the sponsor and the pis both agreed that the csppt-ckd should be a sub-study of the csppt insted of an independent randomized trial    有  33  个tokens\n",
      "study was withdrawn prior to commencement    有  6  个tokens\n",
      "data could not be interpreted. re-design efforts failed    有  10  个tokens\n",
      "study terminated early based upon development of another anti-il17 fully human monoclonal antibody with better potential for treating ms patients    有  24  个tokens\n",
      "time constraints of primary investigator    有  5  个tokens\n",
      "due to vti-208 results, the elad clinical plan is being re-evaluated    有  19  个tokens\n",
      "due to the budget issues, the study discontinued at phase ii    有  12  个tokens\n",
      "extended study duration    有  3  个tokens\n",
      "intermittent evaluation of results: high incendence of complications    有  13  个tokens\n",
      "principle investigator relocated to a new institution    有  8  个tokens\n",
      "most osa patients were not obese and/or admitted over night so the study was not feasible    有  18  个tokens\n",
      "time constraints    有  2  个tokens\n",
      "new data was published in the literature    有  7  个tokens\n",
      "withdrawal of circulite synergy from clinical use    有  10  个tokens\n",
      "operational difficulties related to medical staff turnover (investigators departure and sickness leave)    有  16  个tokens\n",
      "there is no longer need for this study    有  8  个tokens\n",
      "not enough study subjects    有  4  个tokens\n",
      "the deparment failed to detect patients that were willing to participate in this study    有  16  个tokens\n",
      "study was terminated because of delays in sourcing replacement investigational medicinal product for the study due to manufacturing delays    有  20  个tokens\n",
      "due to unexpected operational issues outside of lilly's control the study has been closed    有  16  个tokens\n",
      "manufacturing ceased for all argus ii and argus 2s devices (fda notified of and subsequently approved discontinuation of post approval study in oct 2021)    有  35  个tokens\n",
      "political unrest in study country    有  5  个tokens\n",
      "this was an error. study never initiated    有  8  个tokens\n",
      "the sponsor has stopped responding to calls and emails    有  9  个tokens\n",
      "terminated due to financial reasons    有  5  个tokens\n",
      "timeframe of the imi project couldn't be expended    有  11  个tokens\n",
      "data was not collected accurately    有  5  个tokens\n",
      "feasibility of the trial was proven to be absent    有  10  个tokens\n",
      "the investigator resigned on february 28, 2014    有  12  个tokens\n",
      "institution converted to an alternative strategy for pain control    有  9  个tokens\n",
      "new data in public domain suggested continuing study not ethical    有  10  个tokens\n",
      "enough data to conclude    有  5  个tokens\n",
      "cannot find subjects to particpate    有  7  个tokens\n",
      "not progressing toward scientific goals    有  5  个tokens\n",
      "results from trial in another population lead investigators to determine study outcome may not reach statistical significance    有  17  个tokens\n",
      "primary investigator (ajn) left institution    有  8  个tokens\n",
      "study was terminated in order to secure the data quality of the study in terms of folpoor-up rates and data completeness    有  24  个tokens\n",
      "pharmacy stopped dispensing study medication    有  7  个tokens\n",
      "folpooring an interim analysis the study team felt that there was enough data that showed no significant difference    有  20  个tokens\n",
      "isotope (fmiso) production is no longer available in our country    有  14  个tokens\n",
      "the manufacturer decided to halt manufacturing the vaccine    有  8  个tokens\n",
      "irb modifications made study impractical    有  7  个tokens\n",
      "dysfonction of the device    有  7  个tokens\n",
      "due to poor recruiment rate, the study design is chanced to a feasibility study    有  17  个tokens\n",
      "available mri scan unable to collect required data elements    有  10  个tokens\n",
      "promoter decision    有  3  个tokens\n",
      "early termination due to significant poor relevant patient data for evaluation of objectives    有  13  个tokens\n",
      "new data published showing epo to be ineffective in tbi    有  12  个tokens\n",
      "study never initiated due to impact approval from institution not being obtinaed    有  14  个tokens\n",
      "internal protocol review    有  3  个tokens\n",
      "ph i exempt as it did not proceed to the phase ii terminated early by the supporter    有  17  个tokens\n",
      "sponsors decision. the collected data are available in a significant proportion and sufficiently enough for an adequate analysis    有  20  个tokens\n",
      "changes of usual clinical practices    有  5  个tokens\n",
      "too small included patients and, not enough cost for ptns and biofeedback    有  16  个tokens\n",
      "the study was terminated because of high dropout rate    有  9  个tokens\n",
      "manufacturer updated device technology    有  4  个tokens\n",
      "initiated a new study with improved device    有  8  个tokens\n",
      "fda did not approve    有  5  个tokens\n",
      "cost    有  1  个tokens\n",
      "study product manufacturing suspended due to manufacturing problems, before initiation of study intervention    有  14  个tokens\n",
      "the study was terminated at median 46-48 months long term folpoor-up and mature overall survival folpoor-up data    有  26  个tokens\n",
      "a corporate decision to suspend development of diapep277®    有  12  个tokens\n",
      "poor eligible patients due to introduction of new drugs for hepatitis c    有  13  个tokens\n",
      "never proceeded with trial. failure initiate protocol among other centers    有  11  个tokens\n",
      "recrutment difficulty    有  4  个tokens\n",
      "due to technical problems    有  4  个tokens\n",
      "not feasable at this site    有  6  个tokens\n",
      "practice on postoperative pain management changed    有  7  个tokens\n",
      "inclusion of patients was poor. could not reach the target within the studyperiod    有  16  个tokens\n",
      "dr. sigal no longer with nyumc    有  10  个tokens\n",
      "study was stoped according to preliminary analysis    有  8  个tokens\n",
      "based upon results of interim data analysis    有  7  个tokens\n",
      "due to out-of-date design and non-compliance    有  10  个tokens\n",
      "major changes in study required new irb application and approval    有  11  个tokens\n",
      "transfer of management of study    有  5  个tokens\n",
      "the results of the interim analysis are clear with a significant advantage in terms of pfs in favor of the control arm (vinblastine alone) over the investigational arm (vinblastine + nilotinib)    有  44  个tokens\n",
      "sae- risk of overall protocol treatment outweighs benefits    有  11  个tokens\n",
      "organizational changes and poor resources    有  6  个tokens\n",
      "halted before intervention due to approval of service    有  9  个tokens\n",
      "the independent data monitoring committee (idmc) concluded that the probability that the study will meet its primary objective is poor    有  23  个tokens\n",
      "protocol replaced with combination therapy adding keytruda (pembrolizumab)    有  17  个tokens\n",
      "could not obtain an ide on the fgfr2 assay    有  11  个tokens\n",
      "unable to secure equipment to proceed    有  6  个tokens\n",
      "because there are enough data to present the conclusions    有  9  个tokens\n",
      "omp-59r5 did not improve pfs    有  10  个tokens\n",
      "changes to cardiac surgery program    有  5  个tokens\n",
      "dr. sirgusson moved to another institution = florida institute of technology in june 2013    有  21  个tokens\n",
      "due to several intracranial hemorrhages and recommendation by the pbtc dsmb    有  17  个tokens\n",
      "study was closed due to recommendations of performing a pk study first    有  12  个tokens\n",
      "unlikely to accrue    有  4  个tokens\n",
      "at the planned ia for decision making, no evidence was demonstrated of medi8968 activity in reducing (hs) severity or pain over that seen with placebo    有  30  个tokens\n",
      "poor pregnancy rates in both groups    有  7  个tokens\n",
      "the study was terminated due to medication supply issue from current manufacturer    有  12  个tokens\n",
      "telaprevir will not be used in nl, no more inclusions are expected    有  17  个tokens\n",
      "physician departure    有  3  个tokens\n",
      "principal investigator is no longer at this site    有  8  个tokens\n",
      "the study was proposed but never started due to other commitments    有  11  个tokens\n",
      "principal investigator retired from the project    有  6  个tokens\n",
      "left institution protocol closed    有  4  个tokens\n",
      "the study was stopped because there was a technical problem with the ultrasound used in the trial    有  17  个tokens\n",
      "results to date adequately demonstrated user preference and recovery time. time to target (part ii) was not studied.    有  22  个tokens\n",
      "main reason: negative echo in the literature after the first publications    有  12  个tokens\n",
      "study was terminated based on the findings of primary analysis at 18 months post-rai treatment. patients pending 3 year folpoor up had end of study phone call    有  34  个tokens\n",
      "not possible to complete the sample within the estimated time by the use of new antifungals    有  19  个tokens\n",
      "did not go forward with study    有  6  个tokens\n",
      "the study didn't have sufficient fpoor of subjects (discontinued by the sponsor)    有  18  个tokens\n",
      "study endpoint in preceding base study m10-855 not met    有  12  个tokens\n",
      "additional pharmacovigilance activity was considered as fulfilled by the ema    有  15  个tokens\n",
      "the study was terminated by spiracur. efforts were made to contact the pi/study team members, but were unsuccessful    有  24  个tokens\n",
      "principle investigator was not able to proceed with the study    有  11  个tokens\n",
      "collaborator was not clear on how best to proceed with this project    有  14  个tokens\n",
      "no activity was observed. brafi-naïve participants should have received triple combination treatment (including mek inhibitor). continuation was not justified    有  27  个tokens\n",
      "cooperation stooped with pi    有  6  个tokens\n",
      "the principal investigator is leaving johns hopkins    有  9  个tokens\n",
      "data for study devices vs. predicate not within alpoorable ranges    有  13  个tokens\n",
      "due to results from the vti-208 study, the elad plan is being re-evaluated    有  21  个tokens\n",
      "could not find a sponsor for the study    有  8  个tokens\n",
      "changing staff    有  2  个tokens\n",
      "concern for cross contamination in weighing tree nuts in facility with peanuts    有  13  个tokens\n",
      "sponsor decided to stop study early    有  6  个tokens\n",
      "unable to find subjects with schizophrenia that were using only cannabis    有  11  个tokens\n",
      "the study was completed as planned    有  6  个tokens\n",
      "pi indicated departure from institution, inability to complete study    有  10  个tokens\n",
      "the study reach enough significance at the intermediary analysis    有  9  个tokens\n",
      "the study was terminated based on an included stopping rule in the study protocol    有  14  个tokens\n",
      "sponsor aveo has withdrawn support for this trial    有  9  个tokens\n",
      "loss of cgmp facility to manufacture product used in clinical trial    有  12  个tokens\n",
      "institutional approval of study has expired    有  7  个tokens\n",
      "the single quinacrine manufacture facility in the us was shut down by the fda    有  18  个tokens\n",
      "study sponsor was acquired by another company    有  7  个tokens\n",
      "investigator decided not to open study    有  7  个tokens\n",
      "the sponsor merged with another company and decided they did not want to continue with the study    有  17  个tokens\n",
      "required documentation too onerous    有  6  个tokens\n",
      "ema/pdco acknowledged that available results from this study do not support further clinical studies in relapsed/refractory aml paediatric patients    有  28  个tokens\n",
      "se system by spirus medical withdrawn from market in 2011    有  13  个tokens\n",
      "based on outcome of trial nct01656889    有  10  个tokens\n",
      "lifecell became part of allergan; company deciscion    有  14  个tokens\n",
      "the study was discontinued folpooring product approval    有  9  个tokens\n",
      "terminated to focus on a larger study within the clinical development program    有  12  个tokens\n",
      "expired with the irb    有  5  个tokens\n",
      "due to the action to withdraw the foradil aerolizer nda in us; study was discontinued. this was a commercial reason and not due to any change in benefit-risk    有  36  个tokens\n",
      "novartis decided to stop the marketing of bez235    有  11  个tokens\n",
      "as a result of termination of development of prosavin, it is no longer possible for sio to either commence or to continue any related clinical trials    有  29  个tokens\n",
      "clinimacs cd34 reagent system was fda approved for clinical use; therefore, patients were treated clinically    有  22  个tokens\n",
      "the resident in charge of the project has graduated so we decided to close this study    有  16  个tokens\n",
      "not enough subjects interested in this study    有  7  个tokens\n",
      "competing departmental studies    有  5  个tokens\n",
      "study team was unable to effectively conduct the study    有  9  个tokens\n",
      "app to be used in study needs revision    有  8  个tokens\n",
      "due to lack resources    有  4  个tokens\n",
      "staffing changes precluded sleep study interpretation    有  8  个tokens\n",
      "labortory focus was changed and study was not opened at all    有  13  个tokens\n",
      "pi choose to close the study    有  6  个tokens\n",
      "due to the product being discontinued    有  6  个tokens\n",
      "at the planned study start new treatment guidelines for this disease with new drugs were implemented in clinical practice    有  19  个tokens\n",
      "terminated by funder    有  4  个tokens\n",
      "drugs unavailable. study did not progress to phase 2    有  12  个tokens\n",
      "study was determined to be infeasible    有  8  个tokens\n",
      "pi no longer at nyumc    有  7  个tokens\n",
      "protocol-defined criterion of macitentan availability achieved    有  10  个tokens\n",
      "ide approval received for larger pivotal study    有  7  个tokens\n",
      "terminated due to completion of competing study    有  7  个tokens\n",
      "staff change and poor ressources    有  6  个tokens\n",
      "pentaspan is no longer used at our institution. pentaspan was an arm of the study    有  20  个tokens\n",
      "investigators moved to other institutions    有  6  个tokens\n",
      "use of bupropion with counseling works better to help patients quit smoking    有  15  个tokens\n",
      "drugs unavailable. seeking new supplier    有  7  个tokens\n",
      "data analysis completed    有  3  个tokens\n",
      "no progression of phase 1 trial to phase 2    有  11  个tokens\n",
      "the original analyses could not be performed due to data inconsistencies across the study sites    有  15  个tokens\n",
      "sbi biotech who provided the drug for this study has decided to no longer support the study or gnkg168    有  23  个tokens\n",
      "the study was halted due to logistical reasons    有  8  个tokens\n",
      "study conducted under clinical trials agreement as niaid registration nct02234570    有  16  个tokens\n",
      "perception of an increased incidence of c-qur v-patch mesh infection, with need for removal, compared to other meshes used for umbilical hernia repair    有  33  个tokens\n",
      "due to termination of clinical program for parkinson's disease    有  11  个tokens\n",
      "in 2013 the fda put a temporary hold on the trial and the phase ii portion of this study was cancelled    有  24  个tokens\n",
      "device was sunset from the market in may2015. no longer need for long term data    有  18  个tokens\n",
      "the study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in japan    有  24  个tokens\n",
      "the study was halted after an interim analysis perfomed for a perceived excess of target vessel revascularization in the deb+bms arm    有  26  个tokens\n",
      "terminated because of insufficient number of subjects included    有  8  个tokens\n",
      "poor recuritment    有  5  个tokens\n",
      "previous studies have been done regarding same condition    有  8  个tokens\n",
      "study was abandoned and a new study was written to replace this one    有  13  个tokens\n",
      "protocol has changed    有  3  个tokens\n",
      "the interim analysis requested by the edsmc shows higher mortality for the cpfa group compared to the controls, particularly in the first days of treatment    有  29  个tokens\n",
      "pi is leaving nhlbi, sample size is too small    有  12  个tokens\n",
      "study did not get ethical approval, therefore study was not initiated    有  12  个tokens\n",
      "study terminated due to unacceptable pharmacokinetic (pk) profile    有  12  个tokens\n",
      "results did not meet study requirements    有  6  个tokens\n",
      "registrational study did not meet endpoint so entire program (including co-101-011) was terminated    有  20  个tokens\n",
      "no longer willing to continue clinical trials    有  7  个tokens\n",
      "the study has never started. the sponsor has decided to not move forward    有  14  个tokens\n",
      "redesigned sensor to be subjected to a new protocol    有  11  个tokens\n",
      "novartis decided not to pursue further development of buparlisib program (assessment of moderate pfs benefit with know, but manageable, buparlisib profile)    有  36  个tokens\n",
      "substancial amendment    有  3  个tokens\n",
      "surgeons change in preference for perioperative warming    有  10  个tokens\n",
      "use of formocresol for pulpotomies ws discontinued    有  13  个tokens\n",
      "fda hold on the project    有  6  个tokens\n",
      "due to limited population of research participants    有  7  个tokens\n",
      "to be submitted for grant application    有  6  个tokens\n",
      "measurement device not performing to standard in study environment    有  9  个tokens\n",
      "stopped by principal investigator decision    有  5  个tokens\n",
      "not a significant difference in outcomes between groups    有  8  个tokens\n",
      "new medication coming on the market, made study obsolete    有  10  个tokens\n",
      "error made by local pharmacy caused mixed randomization of 20 participants    有  13  个tokens\n",
      "elevation of alanine aminotransferase (alt) and aspartate aminotransferase (ast) in some participants    有  30  个tokens\n",
      "this trial was terminated based on an interim analysis as bez235 did not demonstrate a progression free survival advantage to everolimus treatment    有  25  个tokens\n",
      "no difference found between two groups in a preliminary analysis    有  10  个tokens\n",
      "lost nurse researcher support    有  4  个tokens\n",
      "the study has been withdrawn due to organizational problems    有  9  个tokens\n",
      "pi moved from medical center    有  5  个tokens\n",
      "monitoring committee found significant & meaningful difference on main outcome    有  11  个tokens\n",
      "the present phase 1 trial has been terminated due to the need for changes in the trial design requiring a new re-designed multiple dosing phase 1 trial. initiation of this new trial awaits additional non-clinical data    有  44  个tokens\n",
      "no support to run the study    有  6  个tokens\n",
      "unable to free investigators; time constraints    有  7  个tokens\n",
      "issues with obtaining study product    有  5  个tokens\n",
      "an enhanced device has been developed    有  6  个tokens\n",
      "it was decided to change the study from a cohort to a randomized controlled trial    有  15  个tokens\n",
      "due to high mortality    有  4  个tokens\n",
      "a similar article was already published by another investigator    有  9  个tokens\n",
      "takeda submitted 900 patient years interim analysis to prac and requested study to be closed since primary objective had been fulfilled. prac agreed and on 17sep2020 approved closure of eu-air registry. takeda announced study closure on 31oct2020    有  53  个tokens\n",
      "fda indicated study should have had prior ide submission & approval    有  12  个tokens\n",
      "decision by nih    有  4  个tokens\n",
      "sponsor determined this trial does not support their anticipated clinical development program    有  12  个tokens\n",
      "the study was stopped due to other research priorities    有  9  个tokens\n",
      "by dsmb on october 18, 2013 due to increased incidence of ards. see modified protocol [nct02175225    有  29  个tokens\n",
      "production of the imp (plasmid amep) has been terminated by the supplier (bioalliance pharma)    有  24  个tokens\n",
      "project was discontinued. ran into difficulties with purification at the protein production stage    有  14  个tokens\n",
      "we are working on a larger similar multicenter cinical trials as a participant.so in order to avoid conflicts of interest, we have to suspended this project    有  30  个tokens\n",
      "study was terminated by sponsor due to market authorization of tocilizumab for the study population    有  19  个tokens\n",
      "suspended for indetermined period    有  6  个tokens\n",
      "interim analysis for feasibility    有  5  个tokens\n",
      "study terminated due to an unfavorable risk-benefit analysis    有  10  个tokens\n",
      "halted by the management committee after the publication of the art trial    有  13  个tokens\n",
      "unexpected high grade of mucositis observed    有  8  个tokens\n",
      "the sponsor decided not to conduct the expansion part of trial (part 2)    有  16  个tokens\n",
      "experimental treatment not superior to standard - no need to continue the folpoor-up    有  16  个tokens\n",
      "pharmaceutical company has terminated orteronel (tak-700) development for prostate cancer    有  19  个tokens\n",
      "unavailability of the investigator due to an overloaded planning    有  10  个tokens\n",
      "adequate data to satisfy pas as agreed to with fda 02oct2019    有  17  个tokens\n",
      "substantial benefit was observed in the active treatment group    有  10  个tokens\n",
      "did not pass the stage 1 interim analysis    有  9  个tokens\n",
      "insufficient # subjects available for 2nd group; evaluating alternate study site    有  15  个tokens\n",
      "diakron pharmaceuticals couldn't fulfill the financial responsibility of the study    有  14  个tokens\n",
      "registration of the medicine is no longer being pursued in south korea, taiwan or vietnam    有  19  个tokens\n",
      "the study was stopped due to non-availability of 4mg    有  13  个tokens\n",
      "impossible to include patients at a correct rate; patients don't want to come back so they refuse participation    有  21  个tokens\n",
      "end of commercialization of the medical device    有  8  个tokens\n",
      "this study was completed    有  4  个tokens\n",
      "the collaborator lost interest in a clinical study    有  9  个tokens\n",
      "due to the high rate of morbidity and mortality    有  10  个tokens\n",
      "fda advised that study is no longer required    有  9  个tokens\n",
      "because 1 patient's scar becomes more severe than before, and most patient have satificated outcome    有  20  个tokens\n",
      "interim analysis completed and decided to terminate and proceed to phase 3 trial    有  15  个tokens\n",
      "a cardinal member of the research team withdrawn from study, the study has beem terminated    有  17  个tokens\n",
      "formula reformulation    有  3  个tokens\n",
      "challenges encountered in the methodology and concerns with the gold standard of treatment    有  14  个tokens\n",
      "study was terminated in august 2016 due to replacement by a new study    有  15  个tokens\n",
      "site was never activated by sponsor    有  6  个tokens\n",
      "fda placed a clinical hold on the pediatric program requiring retigabine discontinuation in subjects; early termination alpoors for timely reporting of results    有  30  个tokens\n",
      "patient 2 suffered dlt post-vaccination. the vaccine manufacturers withdrew support for the study on commercial grounds    有  22  个tokens\n",
      "laproscopic procedure not offered at this time; will not be offered for the foreseeable, thus we are unable to randomize participants between the two arms    有  30  个tokens\n",
      "the study was not initiated    有  5  个tokens\n",
      "all astrazeneca sponsored clinical trials of azd8931 have been halted    有  15  个tokens\n",
      "poor incidence    有  3  个tokens\n",
      "study was stopped due to approved label expansion of alglucosidase alfa    有  17  个tokens\n",
      "change in procedure.us technically challenging    有  6  个tokens\n",
      "the study was stopped due to unbalanced side effects    有  10  个tokens\n",
      "gemcitabine is not the first choice for most pancreatic cancer patients nowdays    有  16  个tokens\n",
      "no irb    有  3  个tokens\n",
      "study never started, and there are no plans to initiate    有  11  个tokens\n",
      "recrution number was not reached    有  7  个tokens\n",
      "primary endpoint did not reach statistical significance    有  7  个tokens\n",
      "interim analysis showed that the trial will not meet the interim endpoint    有  13  个tokens\n",
      "planned interim analysis showed study was underpowered    有  9  个tokens\n",
      "sponsor stops to provide the study drug    有  7  个tokens\n",
      "phiii program revised; tmc207-c210 cancelled    有  11  个tokens\n",
      "other project got priority    有  4  个tokens\n",
      "the number of successes is not reached at the end of first stage of the phase ii. the study is stopped    有  22  个tokens\n",
      "difficulty of realization of the study    有  6  个tokens\n",
      "pfizer canada and the smh ora could not come into an agreement on responsibility to be the importer of record for the trial    有  25  个tokens\n",
      "sponsor related    有  2  个tokens\n",
      "the results of the interim analysis showed that the primary endpoint was not met    有  14  个tokens\n",
      "incompatibilities over intellectual property    有  6  个tokens\n",
      "device was recalled by company    有  5  个tokens\n",
      "the sponsor did not provide the treatment    有  7  个tokens\n",
      "this potential study was held up at the level of the fda as they wouldn't approve and ind for the dose of vitamin c we wanted to use    有  30  个tokens\n",
      "the comparator product was withdrawn from the brazilian market not being possible to conduct the design regarding initially planned    有  20  个tokens\n",
      "origio a/s acquired by cooper surgical inc. who decided to withdraw from the project    有  17  个tokens\n",
      "pi's add. responsibilities and time commitment prevent him from completing trial    有  13  个tokens\n",
      "revisiting product options    有  5  个tokens\n",
      "necessary number of participants not achieved and high drop out rate    有  11  个tokens\n",
      "3rd party proprietary software issue    有  6  个tokens\n",
      "interim analysis suggested that size of benefit anticipated from continued participation of patients in part b no longer supported trial extension beyond part a    有  25  个tokens\n",
      "non adequation between the medical device and the study population    有  11  个tokens\n",
      "data analysis    有  2  个tokens\n",
      "grant was transferred to university of maryland and results were reported under nct02354703    有  18  个tokens\n",
      "study halted by sponsor    有  4  个tokens\n",
      "the cdc indicated nasal spray flu vaccine should not be used during 2016-2017    有  19  个tokens\n",
      "decision was made by sponsor to stop the trial    有  9  个tokens\n",
      "our citicoline supply expired and the exact product has discontinued    有  12  个tokens\n",
      "unmasked without sponsor's prior knowledge or authorization by the pi    有  12  个tokens\n",
      "the study was stopped early due to feasibility concerns    有  9  个tokens\n",
      "it was determined that the volume imaging was not working    有  10  个tokens\n",
      "sub study was not pursued as overall trial was negative    有  10  个tokens\n",
      "site selection    有  2  个tokens\n",
      "other drugs others studies    有  4  个tokens\n",
      "need new pi, i moved    有  6  个tokens\n",
      "company is closed    有  3  个tokens\n",
      "end of study    有  3  个tokens\n",
      "due to change in strategy and decision not to expand indication    有  11  个tokens\n",
      "no access to study drug trilostan. company closed down    有  13  个tokens\n",
      "this was never a clinical trial and should never have been approved    有  12  个tokens\n",
      "decision taken to halt progression of mefloquine as a potential partner for oz439 as a single dose cure due to poor probability of success    有  27  个tokens\n",
      "dsmb decision to begin closeout process in view of april 2010 sa haart guideline    有  19  个tokens\n",
      "student related research project. completion of allotted time    有  9  个tokens\n",
      "study was never started due to poor resources    有  8  个tokens\n",
      "study is no longer needed as recent data have answered the primary hypotheses for this study    有  16  个tokens\n",
      "a similar study was recently published with definitive results    有  9  个tokens\n",
      "investigator departed organization    有  4  个tokens\n",
      "final subject consented to dose level 4    有  9  个tokens\n",
      "pi retired prior to final n number reached    有  8  个tokens\n",
      "the study only accrued 4 patients in 2 years, far bepoor target (40). it was closed with no subject reached the primary endpoint, thus no results to publish    有  36  个tokens\n",
      "the grant application for this project was rejected    有  8  个tokens\n",
      "missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg    有  19  个tokens\n",
      "replaced with updated protocol as h16-02361    有  11  个tokens\n",
      "outcome of expand study (no benefit from adding cetuximab to the first-line chemotherapy in advanced gastric cancer in the overall patient population)    有  28  个tokens\n",
      "we failed to obtain study drugs from the company    有  9  个tokens\n",
      "project did not meet criteria of a research study and was confirmed as a quality initiative project    有  17  个tokens\n",
      "sponsor decided to develop the product in collaboration    有  8  个tokens\n",
      "grade 3 elevation in liver function tests    有  8  个tokens\n",
      "further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued    有  22  个tokens\n",
      "study was stopped due to inavailability of subjects meeting eligibility criteria    有  12  个tokens\n",
      "withdrawn before irb approval    有  6  个tokens\n",
      "pending expiration of the supply of study agent    有  8  个tokens\n",
      "the trial was terminated due to change in new standard of therapy during the study period    有  16  个tokens\n",
      "withdrawn: it was decided not to proceed with the study at this time    有  15  个tokens\n",
      "the study was terminated early because there were other competing protocols    有  11  个tokens\n",
      "fda approval of supplementation to ide to terminate subject long term folpoor up    有  16  个tokens\n",
      "sara cheng, md has left the university of colorado and we have closed this study    有  19  个tokens\n",
      "the inclusion of proposed sample turned to be infeasible due to ethical non-approval of 2 research sites and another site no transplant activity since 2012    有  32  个tokens\n",
      "manufacturer recently halted production of gadofosveset    有  10  个tokens\n",
      "study terminated because unable to obtain access to study drug for study population    有  13  个tokens\n",
      "unavailability of study article    有  5  个tokens\n",
      "single agent phase completed, insufficient supportive preclinical data to proceed with combination phase    有  15  个tokens\n",
      "did not analyze data    有  4  个tokens\n",
      "the study was terminated due to withdrawal of institutional support, phase ii never began    有  15  个tokens\n",
      "after reevaluation of the benefit: risk profile of ezogabine/retigabine, gsk does not believe the early adjunctive treatment study population is appropriate    有  34  个tokens\n",
      "study was stopped due to inability to accrue patients because of competing trials    有  14  个tokens\n",
      "no enough fund or cases    有  5  个tokens\n",
      "other studies with the same protocol have already published    有  9  个tokens\n",
      "fu for 3 years from randomization as initially planned is stopped as we do not expect any changes to the endpoints in the future after one year of fu    有  31  个tokens\n",
      "difficulty was encountered with the subjects completing their required 20 intubations in patients with at least one predictor of difficult intubation    有  26  个tokens\n",
      "objective of study achieved after interim analysis    有  7  个tokens\n",
      "change study drug dosage form    有  5  个tokens\n",
      "pi no longer at university of minnesota    有  8  个tokens\n",
      "investigator went to another institution    有  6  个tokens\n",
      "this is a voluntary registry formerly managed by a unit within ctsi that was disbanded in 2013. the registry has been dormant since that time    有  31  个tokens\n",
      "trial insurance could not be prolonged any more and expired    有  10  个tokens\n",
      "minor device modifications required, move revised device to clinical site in usa    有  13  个tokens\n",
      "it has been put on hold for the moment due to logistic problems    有  13  个tokens\n",
      "dose specified in protocol was not adequate to achieve optimal resolution    有  12  个tokens\n",
      "the study was not started and prematurely closed    有  8  个tokens\n",
      "due to end of validity of peptide vaccine    有  8  个tokens\n",
      "approval denied by national ethical committee of burkina faso    有  12  个tokens\n",
      "study tracer can no longer be obtained at our institution    有  10  个tokens\n",
      "dose limiting toxicities on poorest dose level    有  9  个tokens\n",
      "the study ended early due to budgetary issues    有  9  个tokens\n",
      "the study protocol has been replaced with a two-glove protocol nct02026245    有  17  个tokens\n",
      "difficulty in purchasing reagents and receiving consent from the subject    有  11  个tokens\n",
      "trial screening data did not support the medical hypothesis    有  9  个tokens\n",
      "nexis vision was unable to provide the shields to continue with the study    有  14  个tokens\n",
      "few biopsies showed the expected pattern we suspect erroeneous method    有  14  个tokens\n",
      "sirolimus usage discontinued since black box warning    有  9  个tokens\n",
      "study couldn´t start due to investigator    有  7  个tokens\n",
      "sponsor stopped    有  2  个tokens\n",
      "change of company's strategy    有  5  个tokens\n",
      "institutional ethics board concern regarding sham procedure, requiring modifications that are not feasible within the man-power limitations of our institution    有  23  个tokens\n",
      "pi and main co-i (dr edwards) relocated locations    有  12  个tokens\n",
      "not reached the primary endpoint target according to the statistical design    有  11  个tokens\n",
      "the study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations    有  19  个tokens\n",
      "the adult t-cell leukemia (atl) research program was terminated after the death of the t-cell malignancy group lead investigator    有  24  个tokens\n",
      "interim anlaysis failed: palifermin does not promote thymopoeisis after alemtuzumab    有  24  个tokens\n",
      "difficult getting subjects    有  4  个tokens\n",
      "inadequate study staff to appropriately manage trial    有  9  个tokens\n",
      "results of primary outcome are not satisfactory in terms of rna quality    有  13  个tokens\n",
      "poor support staff    有  4  个tokens\n",
      "study was terminated early (10 july 2015) based on preliminary analysis of pharmacokinetic data    有  21  个tokens\n",
      "terminated early dt to acquisition of sponsor and change in corporate priorities    有  12  个tokens\n",
      "terminated early dt acquisition of sponsor and change in corporate priorities    有  11  个tokens\n",
      "due to changes in ema guidelines on modified release dosage forms (feb 2013; ema/chmp/ewp/280/96). the part b formulation would not meet the new guidelines    有  40  个tokens\n",
      "pi went for a post-doc course and when he came back he moved for another job    有  17  个tokens\n",
      "independent biostatistician recommended early termination of the trial due to poor probability of success    有  19  个tokens\n",
      "well tolerated but failed to demonstrate significant activity. so it did not meet its primary endpoint or key secondary endpoints    有  21  个tokens\n",
      "sample size was not completed    有  5  个tokens\n",
      "this study was unable to overcome it and contracting barriers which prevented the study's data collection system from being implemented    有  21  个tokens\n",
      "interim analysis revealed a negative effect    有  7  个tokens\n",
      "unable to validate analytical method    有  5  个tokens\n",
      "in october 2015 icu's setting completely changed from an open concept 8-beds unit to a single bed isolated room    有  27  个tokens\n",
      "surgical unit closed and moved    有  6  个tokens\n",
      "primary endpoint of parent study ac-055-305/maestro (nct01743001) not met    有  22  个tokens\n",
      "loss of staff for completion    有  5  个tokens\n",
      "the study is cancelled. fda circular 2013-004 mandates that pmss like this are not required    有  22  个tokens\n",
      "an interim analysis showed that there is no difference in the primary endpoint, given the small number of events in the groups examined    有  24  个tokens\n",
      "evaluating cohort for value    有  5  个tokens\n",
      "superiority was no longer attainable    有  8  个tokens\n",
      "moved study to usa    有  4  个tokens\n",
      "pi chose to close the study    有  6  个tokens\n",
      "the study has never started. my grant request was denied    有  11  个tokens\n",
      "ind required by the fda for all future fmts    有  11  个tokens\n",
      "unable to obtain 3d tte to complete study procedure    有  12  个tokens\n",
      "the reason for this decision is that this study is being merged with a larger multi-centre study using the same agent in the same population    有  27  个tokens\n",
      "limited eligible sample size for study outcomes    有  7  个tokens\n",
      "development of dovitinib was stopped    有  8  个tokens\n",
      "the first phase was completed    有  5  个tokens\n",
      "the study was terminated by the sponsor folpooring unblinding of the progression free survival endpoint    有  19  个tokens\n",
      "changed to a retrospective chart review    有  6  个tokens\n",
      "guideline developed    有  3  个tokens\n",
      "corporate decision to spend money on other development programs    有  10  个tokens\n",
      "higher than anticipated rate of hepatic abscess (n=7)    有  14  个tokens\n",
      "stopped before approval due to ineffective drug    有  7  个tokens\n",
      "fda placed the study on a clinical hold, due to the concerns by the fda and health canada, celgene decided to permanently close the study    有  30  个tokens\n",
      "study stopped due to financial problems    有  6  个tokens\n",
      "not enough participants to validate study    有  6  个tokens\n",
      "decision by sponsor to to terminate the study early    有  9  个tokens\n",
      "did not get approval from the collaborating partners in-country    有  10  个tokens\n",
      "change of local requirements    有  4  个tokens\n",
      "study stopped due to investigational device deficiency    有  8  个tokens\n",
      "the objectives of this trial are no longer deemed appropriate for the clinical development of l-blp25 therefore this trial is withdrawn    有  24  个tokens\n",
      "blinded review of the data suggested no significant diferences in outcomes    有  13  个tokens\n",
      "the study got terminated based on result from primary endpoint analysis    有  11  个tokens\n",
      "pausing of allotransplant program due to logistic issues    有  11  个tokens\n",
      "study terminated due to poor resources    有  6  个tokens\n",
      "poor referrals    有  3  个tokens\n",
      "study transferring to another facility    有  5  个tokens\n",
      "the target drug, dovitinib, failed as a single agent in prior studies in patients with heavily treated multiple myeloma    有  26  个tokens\n",
      "insufficient microrna for the analysis    有  8  个tokens\n",
      "indeterminate performance during the first half of the trial    有  10  个tokens\n",
      "delayed study start    有  4  个tokens\n",
      "investigators felt sufficient data has been collected    有  8  个tokens\n",
      "institution changed surgical method to small-incision lenticule extraction. study never started    有  16  个tokens\n",
      "updated chemotherapy regimens currently evaluated in clinical trials due to poor progress in treating this condition; analysis continues in the realm of patterns of failure and increasing quality of life    有  32  个tokens\n",
      "withdrawal of imp from the market. data on risk-benefit ratio pending    有  15  个tokens\n",
      "researcher deployed before approval    有  5  个tokens\n",
      "till irb renewal    有  5  个tokens\n",
      "same study already published    有  4  个tokens\n",
      "study design determined to be not likely feasible    有  8  个tokens\n",
      "results unlikely to impact treatment patterns. time to complete not justified    有  12  个tokens\n",
      "there was more benefit from the infusion arm compared to the bolus arm    有  14  个tokens\n",
      "based on results from symplicity htn-3    有  10  个tokens\n",
      "difficult to obtain placebo    有  5  个tokens\n",
      "data obtained from the m11-428 study is not critical to the continued evaluation of abt-126    有  21  个tokens\n",
      "there was recruted subject    有  6  个tokens\n",
      "institution changed surgical method to small incision lenticule extraction. study never started    有  16  个tokens\n",
      "company resources only alpoors adequate oversight for one pivotal trial at a time    有  15  个tokens\n",
      "the sensitivity and specificity were not able to be assessed in this study due to the poor image quality    有  19  个tokens\n",
      "the study was discontinued prematurely by the sponsor due to non-medical reasons    有  14  个tokens\n",
      "not enough facilities to study    有  5  个tokens\n",
      "the drop-out rate was too high    有  7  个tokens\n",
      "pilot data to be used for upcoming larger trial    有  10  个tokens\n",
      "not considered a clinical trial because both treatment protocols have been approved as usual care    有  15  个tokens\n",
      "product is no longer being manufactured and marketed    有  8  个tokens\n",
      "the sponsor decided to stop further manufacture the study drug 'linsitinib' in nov 2015    有  21  个tokens\n",
      "vapocoolant not effective controlling pain compared with lidocaine    有  14  个tokens\n",
      "primary endpoint missed    有  3  个tokens\n",
      "uterine contractility not possible to visualize with our ultrasound machines    有  12  个tokens\n",
      "eli lilly has withdrawn support to the study of teriparatide and placebo pens. the study was not able to continue as a randomized study without the supply of placebo pens    有  35  个tokens\n",
      "due to unavailability of the drug    有  7  个tokens\n",
      "study met stopping criteria specified within protocol    有  7  个tokens\n",
      "participants are no longer receiving intervention due to clinical logistics    有  10  个tokens\n",
      "flavoprotein fluorescence machine for the trial is not working so the trial was terminated. no study data was collected prior to termination    有  26  个tokens\n",
      "data obtained from the m11-427 study is not critical to the continued evaluation of abt-126    有  21  个tokens\n",
      "investigator moved to new institution    有  6  个tokens\n",
      "pi no longer with the institution    有  6  个tokens\n",
      "company making the device no longer in existence. did not finish supplying data to research team    有  17  个tokens\n",
      "technical problem with one of the medical device used for the study    有  12  个tokens\n",
      "development plan of retigabine xr in japan was readjusted    有  14  个tokens\n",
      "main investigators (pieters/van zundert) changed institutions. therefore, they were not able to start the study and decided to withdraw the study for now    有  32  个tokens\n",
      "stopped due to feasibility    有  4  个tokens\n",
      "poor incidence of delirium    有  7  个tokens\n",
      "protocol is completed    有  3  个tokens\n",
      "unable to obtain qp release certification from the manufacturer (vsl3) for shipment of imp    有  18  个tokens\n",
      "no time    有  2  个tokens\n",
      "study was terminated in march 2012 due to poor eficacy in a seperate phase ii study in patients    有  22  个tokens\n",
      "the sponsor decided to terminate study after 70% of participants had experienced a progression-free survival event    有  19  个tokens\n",
      "project team decision    有  3  个tokens\n",
      "investigator is leaving dartmouth    有  6  个tokens\n",
      "termination of the trial after interim analysis. the main criterion could not be reached    有  15  个tokens\n",
      "folpooring dsmb advice after first interim analysis (n=174)    有  15  个tokens\n",
      "company stopped making product for cosmetic use. all consented subjects withdrew before any study interventions were performed    有  19  个tokens\n",
      "side effect and poor clinical outcome    有  6  个tokens\n",
      "abbott made a decision to not further develop the rdn program    有  13  个tokens\n",
      "phophoral was no longer used as a preparation before coloscopies at ouh    有  17  个tokens\n",
      "study stopped because patient access became extremely limited for the initial data entry point    有  14  个tokens\n",
      "poor financing of the study drug. not sufficient financial support    有  12  个tokens\n",
      "due to a problem of device    有  6  个tokens\n",
      "based on the results of the phase 1 data, the company decided not to pursue the development of this drug at this time    有  25  个tokens\n",
      "changing the standard of care    有  5  个tokens\n",
      "principal investigator relocated; study may resume in fl hosp. for children, orlando fl    有  17  个tokens\n",
      "fda withdrew requirement to complete study    有  7  个tokens\n",
      "expiration of the placebo patch    有  5  个tokens\n",
      "the company decided to cancel the study in conformity with philippine fda circular 2013-004    有  21  个tokens\n",
      "the company decided to cancel this study in conformity with philippines fda circular 2013-004    有  19  个tokens\n",
      "sponsor determined study is not required according to pfda circular 2013-004    有  16  个tokens\n",
      "not adequate number of staff to continue study at the moment    有  11  个tokens\n",
      "the medical device has been withdrawn from the market due to technical issues    有  13  个tokens\n",
      "resource availability    有  2  个tokens\n",
      "the study difficulty is more serious than expected. the budget isn't enough    有  14  个tokens\n",
      "irb approval canceled    有  4  个tokens\n",
      "terminated by sponsor of this study    有  6  个tokens\n",
      "researcher stopped activity at institution    有  6  个tokens\n",
      "a review of blinded data indicates that the number of participant exposures needed to reach ich standards has been met    有  20  个tokens\n",
      "no more interested in this issue    有  6  个tokens\n",
      "practical circumstances made it too difficult to carry out as planned    有  12  个tokens\n",
      "study interest shifted    有  3  个tokens\n",
      "end study    有  2  个tokens\n",
      "data not as expected    有  4  个tokens\n",
      "research cancelled folpooring interim analysis    有  7  个tokens\n",
      "investigators no longer wanted to pursue this research topic    有  10  个tokens\n",
      "总Token数:  133546\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "reason = pd.read_csv('why_stopped.csv')['why_stopped'].tolist()[4:] # 去掉前四个确定的类别\n",
    "reason = [' '.join(i.strip().split()) for i in reason]\n",
    "encoding = tiktoken.encoding_for_model('gpt-4-1106-preview')\n",
    "total = 0\n",
    "for i in reason:\n",
    "    token_num = encoding.encode(i)\n",
    "    print(i, \"   有 \", len(token_num), \" 个tokens\")\n",
    "    total += len(token_num)\n",
    "print(\"总Token数: \", total)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 291,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt = '''Categorize the following reasons for stops clinical trials by matching them to their appropriate 4 categories. Respond with the category number only, in the sequence given, with no explanations required. Provide your answers in the same order as the reasons listed, like: 1,2,3...\n",
    "\n",
    "Carefully read the reasons and categories. Make sure the results are right. Ensure that the number of categories answered is the same as the number of causes.\n",
    "\n",
    "Categories:\n",
    "1. Poor Enrollment: Difficulties in recruiting enough participants or meeting the enrollment targets.\n",
    "2. Efficacy: Drug or intervention not achieving the desired therapeutic effect, outcomes, or benefits.\n",
    "3. Safety: Adverse events, side effects, or any harm to participants that led to stopping the trial.\n",
    "4. Others: Any other reasons that do not fit into the above categories, such as financial support, interest, resources, competing studies or sponsor's decision. \n",
    "\n",
    "Reasons:\n",
    "'''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Token数量： 329\n",
      "Token数量： 426\n",
      "Token数量： 305\n",
      "Token数量： 376\n",
      "Token数量： 416\n",
      "Token数量： 324\n",
      "Token数量： 330\n",
      "Token数量： 417\n",
      "Token数量： 446\n",
      "Token数量： 385\n",
      "Token数量： 467\n",
      "Token数量： 345\n",
      "Token数量： 350\n",
      "Token数量： 380\n",
      "Token数量： 330\n",
      "Token数量： 358\n",
      "Token数量： 364\n",
      "Token数量： 375\n",
      "Token数量： 385\n",
      "Token数量： 412\n",
      "Token数量： 384\n",
      "Token数量： 336\n",
      "Token数量： 349\n",
      "Token数量： 451\n",
      "Token数量： 481\n",
      "Token数量： 371\n",
      "Token数量： 356\n",
      "Token数量： 424\n",
      "Token数量： 331\n",
      "Token数量： 433\n",
      "Token数量： 450\n",
      "Token数量： 422\n",
      "Token数量： 386\n",
      "Token数量： 442\n",
      "Token数量： 474\n",
      "Token数量： 442\n",
      "Token数量： 422\n",
      "Token数量： 399\n",
      "Token数量： 390\n",
      "Token数量： 429\n",
      "Token数量： 397\n",
      "Token数量： 444\n",
      "Token数量： 512\n",
      "Token数量： 367\n",
      "Token数量： 420\n",
      "Token数量： 483\n",
      "Token数量： 517\n",
      "Token数量： 415\n",
      "Token数量： 410\n",
      "Token数量： 402\n",
      "Token数量： 372\n",
      "Token数量： 394\n",
      "Token数量： 443\n",
      "Token数量： 469\n",
      "Token数量： 487\n",
      "Token数量： 390\n",
      "Token数量： 483\n",
      "Token数量： 425\n",
      "Token数量： 481\n",
      "Token数量： 483\n",
      "Token数量： 432\n",
      "Token数量： 442\n",
      "Token数量： 399\n",
      "Token数量： 388\n",
      "Token数量： 399\n",
      "Token数量： 439\n",
      "Token数量： 442\n",
      "Token数量： 482\n",
      "Token数量： 421\n",
      "Token数量： 415\n",
      "Token数量： 387\n",
      "Token数量： 438\n",
      "Token数量： 433\n",
      "Token数量： 388\n",
      "Token数量： 497\n",
      "Token数量： 537\n",
      "Token数量： 421\n",
      "Token数量： 422\n",
      "Token数量： 432\n",
      "Token数量： 451\n",
      "Token数量： 467\n",
      "Token数量： 453\n",
      "Token数量： 495\n",
      "Token数量： 434\n",
      "Token数量： 407\n",
      "Token数量： 433\n",
      "Token数量： 373\n",
      "Token数量： 444\n",
      "Token数量： 465\n",
      "Token数量： 423\n",
      "Token数量： 458\n",
      "Token数量： 407\n",
      "Token数量： 387\n",
      "Token数量： 446\n",
      "Token数量： 455\n",
      "Token数量： 518\n",
      "Token数量： 368\n",
      "Token数量： 452\n",
      "Token数量： 437\n",
      "Token数量： 396\n",
      "Token数量： 402\n",
      "Token数量： 485\n",
      "Token数量： 458\n",
      "Token数量： 491\n",
      "Token数量： 408\n",
      "Token数量： 459\n",
      "Token数量： 375\n",
      "Token数量： 440\n",
      "Token数量： 475\n",
      "Token数量： 415\n",
      "Token数量： 370\n",
      "Token数量： 497\n",
      "Token数量： 483\n",
      "Token数量： 487\n",
      "Token数量： 441\n",
      "Token数量： 409\n",
      "Token数量： 447\n",
      "Token数量： 458\n",
      "Token数量： 469\n",
      "Token数量： 450\n",
      "Token数量： 483\n",
      "Token数量： 465\n",
      "Token数量： 509\n",
      "Token数量： 423\n",
      "Token数量： 500\n",
      "Token数量： 387\n",
      "Token数量： 416\n",
      "Token数量： 442\n",
      "Token数量： 466\n",
      "Token数量： 450\n",
      "Token数量： 405\n",
      "Token数量： 394\n",
      "Token数量： 418\n",
      "Token数量： 454\n",
      "Token数量： 446\n",
      "Token数量： 462\n",
      "Token数量： 402\n",
      "Token数量： 418\n",
      "Token数量： 428\n",
      "Token数量： 526\n",
      "Token数量： 428\n",
      "Token数量： 459\n",
      "Token数量： 458\n",
      "Token数量： 518\n",
      "Token数量： 521\n",
      "Token数量： 513\n",
      "Token数量： 391\n",
      "Token数量： 437\n",
      "Token数量： 454\n",
      "Token数量： 400\n",
      "Token数量： 482\n",
      "Token数量： 480\n",
      "Token数量： 433\n",
      "Token数量： 409\n",
      "Token数量： 376\n",
      "Token数量： 486\n",
      "Token数量： 433\n",
      "Token数量： 473\n",
      "Token数量： 446\n",
      "Token数量： 400\n",
      "Token数量： 464\n",
      "Token数量： 473\n",
      "Token数量： 399\n",
      "Token数量： 507\n",
      "Token数量： 424\n",
      "Token数量： 381\n",
      "Token数量： 496\n",
      "Token数量： 367\n",
      "Token数量： 440\n",
      "Token数量： 565\n",
      "Token数量： 417\n",
      "Token数量： 420\n",
      "Token数量： 495\n",
      "Token数量： 472\n",
      "Token数量： 453\n",
      "Token数量： 438\n",
      "Token数量： 381\n",
      "Token数量： 431\n",
      "Token数量： 502\n",
      "Token数量： 426\n",
      "Token数量： 485\n",
      "Token数量： 492\n",
      "Token数量： 413\n",
      "Token数量： 419\n",
      "Token数量： 583\n",
      "Token数量： 491\n",
      "Token数量： 415\n",
      "Token数量： 436\n",
      "Token数量： 413\n",
      "Token数量： 469\n",
      "Token数量： 408\n",
      "Token数量： 480\n",
      "Token数量： 464\n",
      "Token数量： 529\n",
      "Token数量： 369\n",
      "Token数量： 440\n",
      "Token数量： 470\n",
      "Token数量： 407\n",
      "Token数量： 444\n",
      "Token数量： 429\n",
      "Token数量： 477\n",
      "Token数量： 447\n",
      "Token数量： 451\n",
      "Token数量： 451\n",
      "Token数量： 474\n",
      "Token数量： 454\n",
      "Token数量： 469\n",
      "Token数量： 438\n",
      "Token数量： 457\n",
      "Token数量： 452\n",
      "Token数量： 441\n",
      "Token数量： 408\n",
      "Token数量： 418\n",
      "Token数量： 474\n",
      "Token数量： 462\n",
      "Token数量： 496\n",
      "Token数量： 383\n",
      "Token数量： 517\n",
      "Token数量： 451\n",
      "Token数量： 434\n",
      "Token数量： 461\n",
      "Token数量： 414\n",
      "Token数量： 417\n",
      "Token数量： 466\n",
      "Token数量： 432\n",
      "Token数量： 452\n",
      "Token数量： 414\n",
      "Token数量： 447\n",
      "Token数量： 387\n",
      "Token数量： 487\n",
      "Token数量： 478\n",
      "Token数量： 409\n",
      "Token数量： 408\n",
      "Token数量： 454\n",
      "Token数量： 389\n",
      "Token数量： 550\n",
      "Token数量： 477\n",
      "Token数量： 444\n",
      "Token数量： 427\n",
      "Token数量： 469\n",
      "Token数量： 505\n",
      "Token数量： 485\n",
      "Token数量： 466\n",
      "Token数量： 440\n",
      "Token数量： 448\n",
      "Token数量： 448\n",
      "Token数量： 497\n",
      "Token数量： 522\n",
      "Token数量： 498\n",
      "Token数量： 430\n",
      "Token数量： 426\n",
      "Token数量： 480\n",
      "Token数量： 441\n",
      "Token数量： 400\n",
      "Token数量： 467\n",
      "Token数量： 430\n",
      "Token数量： 413\n",
      "Token数量： 552\n",
      "Token数量： 427\n",
      "Token数量： 464\n",
      "Token数量： 383\n",
      "Token数量： 493\n",
      "Token数量： 473\n",
      "Token数量： 489\n",
      "Token数量： 518\n",
      "Token数量： 432\n",
      "Token数量： 415\n",
      "Token数量： 420\n",
      "Token数量： 404\n",
      "Token数量： 403\n",
      "Token数量： 474\n",
      "Token数量： 487\n",
      "Token数量： 425\n",
      "Token数量： 425\n",
      "Token数量： 483\n",
      "Token数量： 507\n",
      "Token数量： 420\n",
      "Token数量： 452\n",
      "Token数量： 478\n",
      "Token数量： 402\n",
      "Token数量： 385\n",
      "Token数量： 577\n",
      "Token数量： 433\n",
      "Token数量： 471\n",
      "Token数量： 491\n",
      "Token数量： 519\n",
      "Token数量： 541\n",
      "Token数量： 404\n",
      "Token数量： 430\n",
      "Token数量： 485\n",
      "Token数量： 446\n",
      "Token数量： 431\n",
      "Token数量： 403\n",
      "Token数量： 473\n",
      "Token数量： 426\n",
      "Token数量： 469\n",
      "Token数量： 441\n",
      "Token数量： 437\n",
      "Token数量： 412\n",
      "Token数量： 430\n",
      "Token数量： 436\n",
      "Token数量： 476\n",
      "Token数量： 445\n",
      "Token数量： 500\n",
      "Token数量： 436\n",
      "Token数量： 456\n",
      "Token数量： 458\n",
      "Token数量： 439\n",
      "Token数量： 483\n",
      "Token数量： 485\n",
      "Token数量： 429\n",
      "Token数量： 434\n",
      "Token数量： 553\n",
      "Token数量： 435\n",
      "Token数量： 478\n",
      "Token数量： 446\n",
      "Token数量： 464\n",
      "Token数量： 392\n",
      "Token数量： 424\n",
      "Token数量： 497\n",
      "Token数量： 419\n",
      "Token数量： 408\n",
      "Token数量： 408\n",
      "Token数量： 424\n",
      "Token数量： 434\n",
      "Token数量： 426\n",
      "Token数量： 415\n",
      "Token数量： 467\n",
      "Token数量： 485\n",
      "Token数量： 428\n",
      "Token数量： 458\n",
      "Token数量： 481\n",
      "Token数量： 425\n",
      "Token数量： 445\n",
      "Token数量： 376\n",
      "Token数量： 571\n",
      "Token数量： 419\n",
      "Token数量： 516\n",
      "Token数量： 444\n",
      "Token数量： 384\n",
      "Token数量： 411\n",
      "Token数量： 430\n",
      "Token数量： 534\n",
      "Token数量： 444\n",
      "Token数量： 425\n",
      "Token数量： 452\n",
      "Token数量： 440\n",
      "Token数量： 457\n",
      "Token数量： 413\n",
      "Token数量： 413\n",
      "Token数量： 423\n",
      "Token数量： 479\n",
      "Token数量： 447\n",
      "Token数量： 518\n",
      "Token数量： 406\n",
      "Token数量： 360\n",
      "Token数量： 485\n",
      "Token数量： 461\n",
      "Token数量： 406\n",
      "Token数量： 497\n",
      "Token数量： 405\n",
      "Token数量： 448\n",
      "Token数量： 466\n",
      "Token数量： 481\n",
      "Token数量： 415\n",
      "Token数量： 419\n",
      "Token数量： 409\n",
      "Token数量： 481\n",
      "Token数量： 439\n",
      "Token数量： 467\n",
      "Token数量： 514\n",
      "Token数量： 453\n",
      "Token数量： 459\n",
      "Token数量： 395\n",
      "Token数量： 479\n",
      "Token数量： 406\n",
      "Token数量： 489\n",
      "Token数量： 477\n",
      "Token数量： 461\n",
      "Token数量： 427\n",
      "Token数量： 479\n",
      "Token数量： 446\n",
      "Token数量： 466\n",
      "Token数量： 383\n",
      "Token数量： 424\n",
      "Token数量： 462\n",
      "Token数量： 467\n",
      "Token数量： 446\n",
      "Token数量： 523\n",
      "Token数量： 389\n",
      "Token数量： 375\n",
      "Token数量： 402\n",
      "Token数量： 405\n",
      "Token数量： 403\n",
      "Token数量： 436\n",
      "Token数量： 410\n",
      "Token数量： 391\n",
      "Token数量： 439\n",
      "Token数量： 398\n",
      "Token数量： 432\n",
      "Token数量： 432\n",
      "Token数量： 448\n",
      "Token数量： 474\n",
      "Token数量： 430\n",
      "Token数量： 456\n",
      "Token数量： 467\n",
      "Token数量： 380\n",
      "Token数量： 473\n",
      "Token数量： 447\n",
      "Token数量： 484\n",
      "Token数量： 401\n",
      "Token数量： 413\n",
      "Token数量： 439\n",
      "Token数量： 465\n",
      "Token数量： 412\n",
      "Token数量： 444\n",
      "Token数量： 407\n",
      "Token数量： 470\n",
      "Token数量： 486\n",
      "Token数量： 446\n",
      "Token数量： 430\n",
      "Token数量： 409\n",
      "Token数量： 454\n",
      "Token数量： 429\n",
      "Token数量： 481\n",
      "Token数量： 464\n",
      "Token数量： 447\n",
      "Token数量： 456\n",
      "Token数量： 477\n",
      "Token数量： 529\n",
      "Token数量： 387\n",
      "Token数量： 369\n",
      "Token数量： 459\n",
      "Token数量： 494\n",
      "Token数量： 560\n",
      "Token数量： 460\n",
      "Token数量： 431\n",
      "Token数量： 468\n",
      "Token数量： 366\n",
      "Token数量： 437\n",
      "Token数量： 379\n",
      "Token数量： 439\n",
      "Token数量： 510\n",
      "Token数量： 474\n",
      "Token数量： 460\n",
      "Token数量： 639\n",
      "Token数量： 442\n",
      "Token数量： 434\n",
      "Token数量： 454\n",
      "Token数量： 401\n",
      "Token数量： 516\n",
      "Token数量： 399\n",
      "Token数量： 446\n",
      "Token数量： 441\n",
      "Token数量： 381\n",
      "Token数量： 441\n",
      "Token数量： 379\n",
      "Token数量： 414\n",
      "Token数量： 398\n",
      "Token数量： 401\n",
      "Token数量： 412\n",
      "Token数量： 430\n",
      "Token数量： 366\n",
      "Token数量： 467\n",
      "Token数量： 422\n",
      "Token数量： 451\n",
      "Token数量： 405\n",
      "Token数量： 469\n",
      "Token数量： 396\n",
      "Token数量： 467\n",
      "Token数量： 464\n",
      "Token数量： 433\n",
      "Token数量： 425\n",
      "Token数量： 454\n",
      "Token数量： 447\n",
      "Token数量： 440\n",
      "Token数量： 455\n",
      "Token数量： 453\n",
      "Token数量： 423\n",
      "Token数量： 408\n",
      "Token数量： 466\n",
      "Token数量： 398\n",
      "Token数量： 410\n",
      "Token数量： 408\n",
      "Token数量： 374\n",
      "Token数量： 403\n",
      "Token数量： 423\n",
      "Token数量： 443\n",
      "Token数量： 430\n",
      "Token数量： 411\n",
      "Token数量： 406\n",
      "Token数量： 428\n",
      "Token数量： 484\n",
      "Token数量： 472\n",
      "Token数量： 420\n",
      "Token数量： 430\n",
      "Token数量： 409\n",
      "Token数量： 456\n",
      "Token数量： 415\n",
      "Token数量： 429\n",
      "Token数量： 601\n",
      "Token数量： 407\n",
      "Token数量： 432\n",
      "Token数量： 534\n",
      "Token数量： 468\n",
      "Token数量： 475\n",
      "Token数量： 450\n",
      "Token数量： 443\n",
      "Token数量： 450\n",
      "Token数量： 409\n",
      "Token数量： 544\n",
      "Token数量： 456\n",
      "Token数量： 422\n",
      "Token数量： 409\n",
      "Token数量： 435\n",
      "Token数量： 430\n",
      "Token数量： 405\n",
      "Token数量： 435\n",
      "Token数量： 382\n",
      "Token数量： 458\n",
      "Token数量： 455\n",
      "Token数量： 483\n",
      "Token数量： 445\n",
      "Token数量： 496\n",
      "Token数量： 431\n",
      "Token数量： 437\n",
      "Token数量： 456\n",
      "Token数量： 449\n",
      "Token数量： 446\n",
      "Token数量： 448\n",
      "Token数量： 550\n",
      "Token数量： 444\n",
      "Token数量： 439\n",
      "Token数量： 446\n",
      "Token数量： 395\n",
      "Token数量： 458\n",
      "Token数量： 447\n",
      "Token数量： 471\n",
      "Token数量： 415\n",
      "Token数量： 429\n",
      "Token数量： 381\n",
      "Token数量： 406\n",
      "Token数量： 441\n",
      "Token数量： 425\n",
      "Token数量： 453\n",
      "Token数量： 397\n",
      "Token数量： 485\n",
      "Token数量： 487\n",
      "Token数量： 434\n",
      "Token数量： 454\n",
      "Token数量： 448\n",
      "Token数量： 510\n",
      "Token数量： 445\n",
      "Token数量： 496\n",
      "Token数量： 472\n",
      "Token数量： 460\n",
      "Token数量： 456\n",
      "Token数量： 408\n",
      "Token数量： 476\n",
      "Token数量： 516\n",
      "Token数量： 439\n",
      "Token数量： 509\n",
      "Token数量： 454\n",
      "Token数量： 415\n",
      "Token数量： 441\n",
      "Token数量： 472\n",
      "Token数量： 468\n",
      "Token数量： 438\n",
      "Token数量： 222\n",
      "Total: 251338, Price: 10.05352 USD\n"
     ]
    }
   ],
   "source": [
    "total = 0\n",
    "for i in range(len(reason)//20 + 1):\n",
    "    token_num = encoding.encode(prompt+'\\n'.join(reason[i*20:(i+1)*20]))\n",
    "    print(\"Token数量：\",len(token_num) + 3)   # add 3 for message head\n",
    "    total += (len(token_num)+3)\n",
    "print(f\"Total: {total}, Price: {total/1000000*40} USD\") # 10 USD/1M tokens for input tokens and 30 USD/1M tokens for output tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 290,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt2 = '''Categorize the following reasons for stops clinical trials by matching them to their appropriate 4 categories. Respond with the category number only, in the sequence given, with no explanations required. Provide your answers in the same order as the reasons listed, like: 1,2,3...Ensure that the number of categories answered is the same as the number of causes.\n",
    "\n",
    "Carefully read the reasons and categories. Make sure the results are right.\n",
    "\n",
    "Categories:\n",
    "1. Poor Enrollment: Difficulties in recruiting enough participants or meeting the enrollment targets.\n",
    "2. Efficacy: Drug or intervention not achieving the desired therapeutic effect, outcomes, or benefits.\n",
    "3. Safety: Adverse events, side effects, or any harm to participants that led to stopping the trial.\n",
    "4. Others: Any other reasons that do not fit into the above categories, such as financial support, interest, resources, competing studies or sponsor's decision. \n",
    "\n",
    "Reasons:\n",
    "'''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 303,
   "metadata": {},
   "outputs": [],
   "source": [
    "# reason = pd.read_csv('why_stopped.csv')['why_stopped'].tolist()[4:]\n",
    "reason = reason[233*15:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'4,4,4\\n4,4,4\\n4,4,4\\n2,3\\n4,4\\n3,4\\n4,4'"
      ]
     },
     "execution_count": 105,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import re\n",
    "print(re.split(',|\\n', completion.choices[0].message.content))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 346,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "dr. sigal no longer with nyumc        4\n",
      "study was stoped according to preliminary analysis        4\n",
      "based upon results of interim data analysis        4\n",
      "due to out-of-date design and non-compliance        4\n",
      "major changes in study required new irb application and approval        4\n",
      "transfer of management of study        4\n",
      "the results of the interim analysis are clear with a significant advantage in terms of pfs in favor of the control arm (vinblastine alone) over the investigational arm (vinblastine + nilotinib)        2\n",
      "sae- risk of overall protocol treatment outweighs benefits        3\n",
      "organizational changes and poor resources        4\n",
      "halted before intervention due to approval of service        4\n",
      "the independent data monitoring committee (idmc) concluded that the probability that the study will meet its primary objective is poor        2\n",
      "protocol replaced with combination therapy adding keytruda (pembrolizumab)        4\n",
      "could not obtain an ide on the fgfr2 assay        4\n",
      "unable to secure equipment to proceed        4\n",
      "because there are enough data to present the conclusions        4\n",
      "omp-59r5 did not improve pfs        2\n",
      "changes to cardiac surgery program        4\n",
      "dr. sirgusson moved to another institution = florida institute of technology in june 2013        4\n",
      "due to several intracranial hemorrhages and recommendation by the pbtc dsmb        3\n",
      "study was closed due to recommendations of performing a pk study first        4\n",
      "unlikely to accrue        1\n",
      "at the planned ia for decision making, no evidence was demonstrated of medi8968 activity in reducing (hs) severity or pain over that seen with placebo        2\n",
      "poor pregnancy rates in both groups        4\n",
      "the study was terminated due to medication supply issue from current manufacturer        4\n",
      "telaprevir will not be used in nl, no more inclusions are expected        1\n",
      "physician departure        4\n",
      "principal investigator is no longer at this site        4\n",
      "the study was proposed but never started due to other commitments        4\n",
      "principal investigator retired from the project        4\n",
      "left institution protocol closed        4\n",
      "the study was stopped because there was a technical problem with the ultrasound used in the trial        4\n",
      "results to date adequately demonstrated user preference and recovery time. time to target (part ii) was not studied.        4\n",
      "main reason: negative echo in the literature after the first publications        4\n",
      "study was terminated based on the findings of primary analysis at 18 months post-rai treatment. patients pending 3 year folpoor up had end of study phone call        2\n",
      "not possible to complete the sample within the estimated time by the use of new antifungals        4\n",
      "did not go forward with study        4\n",
      "the study didn't have sufficient fpoor of subjects (discontinued by the sponsor)        1\n",
      "study endpoint in preceding base study m10-855 not met        2\n",
      "additional pharmacovigilance activity was considered as fulfilled by the ema        4\n",
      "the study was terminated by spiracur. efforts were made to contact the pi/study team members, but were unsuccessful        4\n",
      "principle investigator was not able to proceed with the study        4\n",
      "collaborator was not clear on how best to proceed with this project        4\n",
      "no activity was observed. brafi-naïve participants should have received triple combination treatment (including mek inhibitor). continuation was not justified        2\n",
      "cooperation stooped with pi        4\n",
      "the principal investigator is leaving johns hopkins        4\n",
      "data for study devices vs. predicate not within alpoorable ranges        4\n",
      "due to results from the vti-208 study, the elad plan is being re-evaluated        4\n",
      "could not find a sponsor for the study        4\n",
      "changing staff        4\n",
      "concern for cross contamination in weighing tree nuts in facility with peanuts        4\n",
      "sponsor decided to stop study early        4\n",
      "unable to find subjects with schizophrenia that were using only cannabis        1\n",
      "the study was completed as planned        4\n",
      "pi indicated departure from institution, inability to complete study        4\n",
      "the study reach enough significance at the intermediary analysis        2\n",
      "the study was terminated based on an included stopping rule in the study protocol        4\n",
      "sponsor aveo has withdrawn support for this trial        4\n",
      "loss of cgmp facility to manufacture product used in clinical trial        4\n",
      "institutional approval of study has expired        4\n",
      "the single quinacrine manufacture facility in the us was shut down by the fda        4\n",
      "study sponsor was acquired by another company        4\n",
      "investigator decided not to open study        4\n",
      "the sponsor merged with another company and decided they did not want to continue with the study        4\n",
      "required documentation too onerous        4\n",
      "ema/pdco acknowledged that available results from this study do not support further clinical studies in relapsed/refractory aml paediatric patients        2\n",
      "se system by spirus medical withdrawn from market in 2011        4\n",
      "based on outcome of trial nct01656889        4\n",
      "lifecell became part of allergan; company deciscion        4\n",
      "the study was discontinued folpooring product approval        4\n",
      "terminated to focus on a larger study within the clinical development program        4\n",
      "expired with the irb        4\n",
      "due to the action to withdraw the foradil aerolizer nda in us; study was discontinued. this was a commercial reason and not due to any change in benefit-risk        4\n",
      "novartis decided to stop the marketing of bez235        4\n",
      "as a result of termination of development of prosavin, it is no longer possible for sio to either commence or to continue any related clinical trials        4\n",
      "clinimacs cd34 reagent system was fda approved for clinical use; therefore, patients were treated clinically        4\n",
      "the resident in charge of the project has graduated so we decided to close this study        4\n",
      "not enough subjects interested in this study        1\n",
      "competing departmental studies        4\n",
      "study team was unable to effectively conduct the study        4\n",
      "app to be used in study needs revision        4\n",
      "due to lack resources        4\n",
      "staffing changes precluded sleep study interpretation        4\n",
      "labortory focus was changed and study was not opened at all        4\n",
      "pi choose to close the study        4\n",
      "due to the product being discontinued        4\n",
      "at the planned study start new treatment guidelines for this disease with new drugs were implemented in clinical practice        4\n",
      "terminated by funder        4\n",
      "drugs unavailable. study did not progress to phase 2        4\n",
      "study was determined to be infeasible        4\n",
      "pi no longer at nyumc        4\n",
      "protocol-defined criterion of macitentan availability achieved        4\n",
      "ide approval received for larger pivotal study        4\n",
      "terminated due to completion of competing study        4\n",
      "staff change and poor ressources        4\n",
      "pentaspan is no longer used at our institution. pentaspan was an arm of the study        4\n",
      "investigators moved to other institutions        4\n",
      "use of bupropion with counseling works better to help patients quit smoking        2\n",
      "drugs unavailable. seeking new supplier        4\n",
      "data analysis completed        4\n",
      "no progression of phase 1 trial to phase 2        1\n",
      "the original analyses could not be performed due to data inconsistencies across the study sites        4\n",
      "sbi biotech who provided the drug for this study has decided to no longer support the study or gnkg168        4\n",
      "the study was halted due to logistical reasons        4\n",
      "study conducted under clinical trials agreement as niaid registration nct02234570        4\n",
      "perception of an increased incidence of c-qur v-patch mesh infection, with need for removal, compared to other meshes used for umbilical hernia repair        3\n",
      "due to termination of clinical program for parkinson's disease        4\n",
      "in 2013 the fda put a temporary hold on the trial and the phase ii portion of this study was cancelled        3\n",
      "device was sunset from the market in may2015. no longer need for long term data        4\n",
      "the study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in japan        4\n",
      "the study was halted after an interim analysis perfomed for a perceived excess of target vessel revascularization in the deb+bms arm        2\n",
      "terminated because of insufficient number of subjects included        1\n",
      "poor recuritment        1\n",
      "previous studies have been done regarding same condition        4\n",
      "study was abandoned and a new study was written to replace this one        4\n",
      "protocol has changed        4\n",
      "the interim analysis requested by the edsmc shows higher mortality for the cpfa group compared to the controls, particularly in the first days of treatment        3\n",
      "pi is leaving nhlbi, sample size is too small        4\n",
      "study did not get ethical approval, therefore study was not initiated        4\n",
      "study terminated due to unacceptable pharmacokinetic (pk) profile        3\n",
      "results did not meet study requirements        2\n",
      "registrational study did not meet endpoint so entire program (including co-101-011) was terminated        2\n",
      "no longer willing to continue clinical trials        4\n",
      "the study has never started. the sponsor has decided to not move forward        4\n",
      "redesigned sensor to be subjected to a new protocol        4\n",
      "novartis decided not to pursue further development of buparlisib program (assessment of moderate pfs benefit with know, but manageable, buparlisib profile)        4\n",
      "substancial amendment        4\n",
      "surgeons change in preference for perioperative warming        4\n",
      "use of formocresol for pulpotomies ws discontinued        4\n",
      "fda hold on the project        3\n",
      "due to limited population of research participants        1\n",
      "to be submitted for grant application        4\n",
      "measurement device not performing to standard in study environment        4\n",
      "stopped by principal investigator decision        4\n",
      "not a significant difference in outcomes between groups        2\n",
      "new medication coming on the market, made study obsolete        4\n",
      "error made by local pharmacy caused mixed randomization of 20 participants        4\n",
      "elevation of alanine aminotransferase (alt) and aspartate aminotransferase (ast) in some participants        3\n",
      "this trial was terminated based on an interim analysis as bez235 did not demonstrate a progression free survival advantage to everolimus treatment        2\n",
      "no difference found between two groups in a preliminary analysis        2\n",
      "lost nurse researcher support        4\n",
      "the study has been withdrawn due to organizational problems        4\n",
      "pi moved from medical center        4\n",
      "monitoring committee found significant & meaningful difference on main outcome        2\n",
      "the present phase 1 trial has been terminated due to the need for changes in the trial design requiring a new re-designed multiple dosing phase 1 trial. initiation of this new trial awaits additional non-clinical data        4\n",
      "no support to run the study        4\n",
      "unable to free investigators; time constraints        4\n",
      "issues with obtaining study product        4\n",
      "an enhanced device has been developed        4\n",
      "it was decided to change the study from a cohort to a randomized controlled trial        4\n",
      "due to high mortality        3\n",
      "a similar article was already published by another investigator        4\n",
      "takeda submitted 900 patient years interim analysis to prac and requested study to be closed since primary objective had been fulfilled. prac agreed and on 17sep2020 approved closure of eu-air registry. takeda announced study closure on 31oct2020        4\n",
      "fda indicated study should have had prior ide submission & approval        4\n",
      "decision by nih        4\n",
      "sponsor determined this trial does not support their anticipated clinical development program        4\n",
      "the study was stopped due to other research priorities        4\n",
      "by dsmb on october 18, 2013 due to increased incidence of ards. see modified protocol [nct02175225        3\n",
      "production of the imp (plasmid amep) has been terminated by the supplier (bioalliance pharma)        4\n",
      "project was discontinued. ran into difficulties with purification at the protein production stage        4\n",
      "we are working on a larger similar multicenter cinical trials as a participant.so in order to avoid conflicts of interest, we have to suspended this project        4\n",
      "study was terminated by sponsor due to market authorization of tocilizumab for the study population        4\n",
      "suspended for indetermined period        4\n",
      "interim analysis for feasibility        4\n",
      "study terminated due to an unfavorable risk-benefit analysis        3\n",
      "halted by the management committee after the publication of the art trial        4\n",
      "unexpected high grade of mucositis observed        3\n",
      "the sponsor decided not to conduct the expansion part of trial (part 2)        4\n",
      "experimental treatment not superior to standard - no need to continue the folpoor-up        2\n",
      "pharmaceutical company has terminated orteronel (tak-700) development for prostate cancer        4\n",
      "unavailability of the investigator due to an overloaded planning        4\n",
      "adequate data to satisfy pas as agreed to with fda 02oct2019        4\n",
      "substantial benefit was observed in the active treatment group        2\n",
      "did not pass the stage 1 interim analysis        2\n",
      "insufficient # subjects available for 2nd group; evaluating alternate study site        1\n",
      "diakron pharmaceuticals couldn't fulfill the financial responsibility of the study        4\n",
      "registration of the medicine is no longer being pursued in south korea, taiwan or vietnam        4\n",
      "the study was stopped due to non-availability of 4mg        4\n",
      "impossible to include patients at a correct rate; patients don't want to come back so they refuse participation        1\n",
      "end of commercialization of the medical device        4\n",
      "this study was completed        4\n",
      "the collaborator lost interest in a clinical study        4\n",
      "due to the high rate of morbidity and mortality        3\n",
      "fda advised that study is no longer required        4\n",
      "because 1 patient's scar becomes more severe than before, and most patient have satificated outcome        3\n",
      "interim analysis completed and decided to terminate and proceed to phase 3 trial        4\n",
      "a cardinal member of the research team withdrawn from study, the study has beem terminated        4\n",
      "formula reformulation        4\n",
      "challenges encountered in the methodology and concerns with the gold standard of treatment        4\n",
      "study was terminated in august 2016 due to replacement by a new study        4\n",
      "site was never activated by sponsor        4\n",
      "fda placed a clinical hold on the pediatric program requiring retigabine discontinuation in subjects; early termination alpoors for timely reporting of results        4\n",
      "patient 2 suffered dlt post-vaccination. the vaccine manufacturers withdrew support for the study on commercial grounds        4\n",
      "laproscopic procedure not offered at this time; will not be offered for the foreseeable, thus we are unable to randomize participants between the two arms        4\n",
      "the study was not initiated        4\n",
      "all astrazeneca sponsored clinical trials of azd8931 have been halted        4\n",
      "poor incidence        1\n",
      "study was stopped due to approved label expansion of alglucosidase alfa        4\n",
      "change in procedure.us technically challenging        4\n",
      "the study was stopped due to unbalanced side effects        3\n",
      "gemcitabine is not the first choice for most pancreatic cancer patients nowdays        4\n",
      "no irb        4\n",
      "study never started, and there are no plans to initiate        4\n",
      "recrution number was not reached        1\n",
      "primary endpoint did not reach statistical significance        2\n",
      "interim analysis showed that the trial will not meet the interim endpoint        2\n",
      "planned interim analysis showed study was underpowered        2\n",
      "sponsor stops to provide the study drug        4\n",
      "phiii program revised; tmc207-c210 cancelled        4\n",
      "other project got priority        4\n",
      "the number of successes is not reached at the end of first stage of the phase ii. the study is stopped        2\n",
      "difficulty of realization of the study        4\n",
      "pfizer canada and the smh ora could not come into an agreement on responsibility to be the importer of record for the trial        4\n",
      "sponsor related        4\n",
      "the results of the interim analysis showed that the primary endpoint was not met        2\n",
      "incompatibilities over intellectual property        4\n",
      "device was recalled by company        3\n",
      "the sponsor did not provide the treatment        4\n",
      "this potential study was held up at the level of the fda as they wouldn't approve and ind for the dose of vitamin c we wanted to use        4\n",
      "the comparator product was withdrawn from the brazilian market not being possible to conduct the design regarding initially planned        4\n",
      "origio a/s acquired by cooper surgical inc. who decided to withdraw from the project        4\n",
      "pi's add. responsibilities and time commitment prevent him from completing trial        4\n",
      "revisiting product options        4\n",
      "necessary number of participants not achieved and high drop out rate        1\n",
      "3rd party proprietary software issue        4\n",
      "interim analysis suggested that size of benefit anticipated from continued participation of patients in part b no longer supported trial extension beyond part a        2\n",
      "non adequation between the medical device and the study population        4\n",
      "data analysis        4\n",
      "grant was transferred to university of maryland and results were reported under nct02354703        4\n",
      "study halted by sponsor        4\n",
      "the cdc indicated nasal spray flu vaccine should not be used during 2016-2017        4\n",
      "decision was made by sponsor to stop the trial        4\n",
      "our citicoline supply expired and the exact product has discontinued        4\n",
      "unmasked without sponsor's prior knowledge or authorization by the pi        4\n",
      "the study was stopped early due to feasibility concerns        4\n",
      "it was determined that the volume imaging was not working        4\n",
      "sub study was not pursued as overall trial was negative        2\n",
      "site selection        4\n",
      "other drugs others studies        4\n",
      "need new pi, i moved        4\n",
      "company is closed        4\n",
      "end of study        4\n",
      "due to change in strategy and decision not to expand indication        4\n",
      "no access to study drug trilostan. company closed down        4\n",
      "this was never a clinical trial and should never have been approved        4\n",
      "decision taken to halt progression of mefloquine as a potential partner for oz439 as a single dose cure due to poor probability of success        4\n",
      "dsmb decision to begin closeout process in view of april 2010 sa haart guideline        4\n",
      "student related research project. completion of allotted time        4\n",
      "study was never started due to poor resources        4\n",
      "study is no longer needed as recent data have answered the primary hypotheses for this study        4\n",
      "a similar study was recently published with definitive results        4\n",
      "investigator departed organization        4\n",
      "final subject consented to dose level 4        4\n",
      "pi retired prior to final n number reached        4\n",
      "the study only accrued 4 patients in 2 years, far bepoor target (40). it was closed with no subject reached the primary endpoint, thus no results to publish        1\n",
      "the grant application for this project was rejected        4\n",
      "missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg        4\n",
      "replaced with updated protocol as h16-02361        4\n",
      "outcome of expand study (no benefit from adding cetuximab to the first-line chemotherapy in advanced gastric cancer in the overall patient population)        4\n",
      "we failed to obtain study drugs from the company        4\n",
      "project did not meet criteria of a research study and was confirmed as a quality initiative project        4\n",
      "sponsor decided to develop the product in collaboration        4\n",
      "grade 3 elevation in liver function tests        3\n",
      "further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued        4\n",
      "study was stopped due to inavailability of subjects meeting eligibility criteria        1\n",
      "withdrawn before irb approval        4\n",
      "pending expiration of the supply of study agent        4\n",
      "the trial was terminated due to change in new standard of therapy during the study period        4\n",
      "withdrawn: it was decided not to proceed with the study at this time        4\n",
      "the study was terminated early because there were other competing protocols        4\n",
      "fda approval of supplementation to ide to terminate subject long term folpoor up        4\n",
      "sara cheng, md has left the university of colorado and we have closed this study        4\n",
      "the inclusion of proposed sample turned to be infeasible due to ethical non-approval of 2 research sites and another site no transplant activity since 2012        4\n",
      "manufacturer recently halted production of gadofosveset        4\n",
      "study terminated because unable to obtain access to study drug for study population        4\n",
      "unavailability of study article        4\n",
      "single agent phase completed, insufficient supportive preclinical data to proceed with combination phase        4\n",
      "did not analyze data        4\n",
      "the study was terminated due to withdrawal of institutional support, phase ii never began        4\n",
      "after reevaluation of the benefit: risk profile of ezogabine/retigabine, gsk does not believe the early adjunctive treatment study population is appropriate        2\n",
      "study was stopped due to inability to accrue patients because of competing trials        1\n",
      "no enough fund or cases        4\n",
      "other studies with the same protocol have already published        4\n",
      "fu for 3 years from randomization as initially planned is stopped as we do not expect any changes to the endpoints in the future after one year of fu        4\n",
      "difficulty was encountered with the subjects completing their required 20 intubations in patients with at least one predictor of difficult intubation        1\n",
      "objective of study achieved after interim analysis        2\n",
      "change study drug dosage form        4\n",
      "pi no longer at university of minnesota        4\n",
      "investigator went to another institution        4\n",
      "this is a voluntary registry formerly managed by a unit within ctsi that was disbanded in 2013. the registry has been dormant since that time        4\n",
      "trial insurance could not be prolonged any more and expired        4\n",
      "minor device modifications required, move revised device to clinical site in usa        4\n",
      "it has been put on hold for the moment due to logistic problems        4\n",
      "dose specified in protocol was not adequate to achieve optimal resolution        2\n",
      "the study was not started and prematurely closed        4\n",
      "due to end of validity of peptide vaccine        4\n",
      "approval denied by national ethical committee of burkina faso        4\n",
      "study tracer can no longer be obtained at our institution        4\n",
      "dose limiting toxicities on poorest dose level        3\n",
      "the study ended early due to budgetary issues        4\n",
      "the study protocol has been replaced with a two-glove protocol nct02026245        4\n",
      "difficulty in purchasing reagents and receiving consent from the subject        4\n",
      "trial screening data did not support the medical hypothesis        2\n",
      "nexis vision was unable to provide the shields to continue with the study        4\n",
      "few biopsies showed the expected pattern we suspect erroeneous method        2\n",
      "sirolimus usage discontinued since black box warning        3\n",
      "study couldn´t start due to investigator        4\n",
      "sponsor stopped        4\n",
      "change of company's strategy        4\n",
      "institutional ethics board concern regarding sham procedure, requiring modifications that are not feasible within the man-power limitations of our institution        4\n",
      "pi and main co-i (dr edwards) relocated locations        4\n",
      "not reached the primary endpoint target according to the statistical design        2\n",
      "the study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations        4\n",
      "the adult t-cell leukemia (atl) research program was terminated after the death of the t-cell malignancy group lead investigator        4\n",
      "interim anlaysis failed: palifermin does not promote thymopoeisis after alemtuzumab        2\n",
      "difficult getting subjects        1\n",
      "inadequate study staff to appropriately manage trial        4\n",
      "results of primary outcome are not satisfactory in terms of rna quality        2\n",
      "poor support staff        4\n",
      "study was terminated early (10 july 2015) based on preliminary analysis of pharmacokinetic data        2\n",
      "terminated early dt to acquisition of sponsor and change in corporate priorities        4\n",
      "terminated early dt acquisition of sponsor and change in corporate priorities        4\n",
      "due to changes in ema guidelines on modified release dosage forms (feb 2013; ema/chmp/ewp/280/96). the part b formulation would not meet the new guidelines        4\n",
      "pi went for a post-doc course and when he came back he moved for another job        4\n",
      "independent biostatistician recommended early termination of the trial due to poor probability of success        2\n",
      "well tolerated but failed to demonstrate significant activity. so it did not meet its primary endpoint or key secondary endpoints        2\n",
      "sample size was not completed        1\n",
      "this study was unable to overcome it and contracting barriers which prevented the study's data collection system from being implemented        4\n",
      "interim analysis revealed a negative effect        3\n",
      "unable to validate analytical method        4\n",
      "in october 2015 icu's setting completely changed from an open concept 8-beds unit to a single bed isolated room        4\n",
      "surgical unit closed and moved        4\n",
      "primary endpoint of parent study ac-055-305/maestro (nct01743001) not met        2\n",
      "loss of staff for completion        4\n",
      "the study is cancelled. fda circular 2013-004 mandates that pmss like this are not required        4\n",
      "an interim analysis showed that there is no difference in the primary endpoint, given the small number of events in the groups examined        2\n",
      "evaluating cohort for value        4\n",
      "superiority was no longer attainable        2\n",
      "moved study to usa        4\n",
      "pi chose to close the study        4\n",
      "the study has never started. my grant request was denied        4\n",
      "ind required by the fda for all future fmts        4\n",
      "unable to obtain 3d tte to complete study procedure        4\n",
      "the reason for this decision is that this study is being merged with a larger multi-centre study using the same agent in the same population        4\n",
      "limited eligible sample size for study outcomes        1\n",
      "development of dovitinib was stopped        4\n",
      "the first phase was completed        4\n",
      "the study was terminated by the sponsor folpooring unblinding of the progression free survival endpoint        4\n",
      "changed to a retrospective chart review        4\n",
      "guideline developed        4\n",
      "corporate decision to spend money on other development programs        4\n",
      "higher than anticipated rate of hepatic abscess (n=7)        3\n",
      "stopped before approval due to ineffective drug        2\n",
      "fda placed the study on a clinical hold, due to the concerns by the fda and health canada, celgene decided to permanently close the study        4\n",
      "study stopped due to financial problems        4\n",
      "not enough participants to validate study        1\n",
      "decision by sponsor to to terminate the study early        4\n",
      "did not get approval from the collaborating partners in-country        4\n",
      "change of local requirements        4\n",
      "study stopped due to investigational device deficiency        3\n",
      "the objectives of this trial are no longer deemed appropriate for the clinical development of l-blp25 therefore this trial is withdrawn        4\n",
      "blinded review of the data suggested no significant diferences in outcomes        2\n",
      "the study got terminated based on result from primary endpoint analysis        2\n",
      "pausing of allotransplant program due to logistic issues        4\n",
      "study terminated due to poor resources        4\n",
      "poor referrals        1\n",
      "study transferring to another facility        4\n",
      "the target drug, dovitinib, failed as a single agent in prior studies in patients with heavily treated multiple myeloma        2\n",
      "insufficient microrna for the analysis        4\n",
      "indeterminate performance during the first half of the trial        4\n",
      "delayed study start        4\n",
      "investigators felt sufficient data has been collected        4\n",
      "institution changed surgical method to small-incision lenticule extraction. study never started        4\n",
      "updated chemotherapy regimens currently evaluated in clinical trials due to poor progress in treating this condition; analysis continues in the realm of patterns of failure and increasing quality of life        4\n",
      "withdrawal of imp from the market. data on risk-benefit ratio pending        4\n",
      "researcher deployed before approval        4\n",
      "till irb renewal        4\n",
      "same study already published        4\n",
      "study design determined to be not likely feasible        1\n",
      "results unlikely to impact treatment patterns. time to complete not justified        4\n",
      "there was more benefit from the infusion arm compared to the bolus arm        2\n",
      "based on results from symplicity htn-3        4\n",
      "difficult to obtain placebo        4\n",
      "data obtained from the m11-428 study is not critical to the continued evaluation of abt-126        4\n",
      "there was recruted subject        1\n",
      "institution changed surgical method to small incision lenticule extraction. study never started        4\n",
      "company resources only alpoors adequate oversight for one pivotal trial at a time        4\n",
      "the sensitivity and specificity were not able to be assessed in this study due to the poor image quality        4\n",
      "the study was discontinued prematurely by the sponsor due to non-medical reasons        4\n",
      "not enough facilities to study        1\n",
      "the drop-out rate was too high        3\n",
      "pilot data to be used for upcoming larger trial        4\n",
      "not considered a clinical trial because both treatment protocols have been approved as usual care        4\n",
      "product is no longer being manufactured and marketed        4\n",
      "the sponsor decided to stop further manufacture the study drug 'linsitinib' in nov 2015        4\n",
      "vapocoolant not effective controlling pain compared with lidocaine        2\n",
      "primary endpoint missed        2\n",
      "uterine contractility not possible to visualize with our ultrasound machines        3\n",
      "eli lilly has withdrawn support to the study of teriparatide and placebo pens. the study was not able to continue as a randomized study without the supply of placebo pens        4\n",
      "due to unavailability of the drug        3\n",
      "study met stopping criteria specified within protocol        4\n",
      "participants are no longer receiving intervention due to clinical logistics        4\n",
      "flavoprotein fluorescence machine for the trial is not working so the trial was terminated. no study data was collected prior to termination        4\n",
      "data obtained from the m11-427 study is not critical to the continued evaluation of abt-126        4\n",
      "investigator moved to new institution        4\n",
      "pi no longer with the institution        4\n",
      "company making the device no longer in existence. did not finish supplying data to research team        4\n",
      "technical problem with one of the medical device used for the study        4\n",
      "development plan of retigabine xr in japan was readjusted        4\n",
      "main investigators (pieters/van zundert) changed institutions. therefore, they were not able to start the study and decided to withdraw the study for now        4\n",
      "stopped due to feasibility        1\n",
      "poor incidence of delirium        1\n",
      "protocol is completed        4\n",
      "unable to obtain qp release certification from the manufacturer (vsl3) for shipment of imp        4\n",
      "no time        4\n",
      "study was terminated in march 2012 due to poor eficacy in a seperate phase ii study in patients        2\n",
      "the sponsor decided to terminate study after 70% of participants had experienced a progression-free survival event        2\n",
      "project team decision        4\n",
      "investigator is leaving dartmouth        4\n",
      "termination of the trial after interim analysis. the main criterion could not be reached        2\n",
      "folpooring dsmb advice after first interim analysis (n=174)        3\n",
      "company stopped making product for cosmetic use. all consented subjects withdrew before any study interventions were performed        4\n",
      "side effect and poor clinical outcome        3\n",
      "abbott made a decision to not further develop the rdn program        4\n",
      "phophoral was no longer used as a preparation before coloscopies at ouh        4\n",
      "study stopped because patient access became extremely limited for the initial data entry point        4\n",
      "poor financing of the study drug. not sufficient financial support        4\n",
      "due to a problem of device        3\n",
      "based on the results of the phase 1 data, the company decided not to pursue the development of this drug at this time        4\n",
      "changing the standard of care        4\n",
      "principal investigator relocated; study may resume in fl hosp. for children, orlando fl        4\n",
      "fda withdrew requirement to complete study        4\n",
      "expiration of the placebo patch        4\n",
      "the company decided to cancel the study in conformity with philippine fda circular 2013-004        4\n",
      "the company decided to cancel this study in conformity with philippines fda circular 2013-004        4\n",
      "sponsor determined study is not required according to pfda circular 2013-004        4\n",
      "not adequate number of staff to continue study at the moment        1\n",
      "the medical device has been withdrawn from the market due to technical issues        3\n",
      "resource availability        4\n",
      "the study difficulty is more serious than expected. the budget isn't enough        4\n",
      "irb approval canceled        4\n",
      "terminated by sponsor of this study        4\n",
      "researcher stopped activity at institution        4\n",
      "a review of blinded data indicates that the number of participant exposures needed to reach ich standards has been met        1\n",
      "no more interested in this issue        4\n",
      "practical circumstances made it too difficult to carry out as planned        4\n",
      "study interest shifted        4\n",
      "end study        4\n",
      "data not as expected        2\n",
      "research cancelled folpooring interim analysis        4\n",
      "investigators no longer wanted to pursue this research topic        4\n"
     ]
    }
   ],
   "source": [
    "# labels = []\n",
    "for i in range(0, len(reason)//20+1):\n",
    "    client = OpenAI(api_key='')\n",
    "    completion = client.chat.completions.create(\n",
    "        model=\"gpt-4-1106-preview\",\n",
    "        messages=\n",
    "            [\n",
    "                # {\"role\": \"system\", \"content\": \"You're a clinical trial specialist.\"},\n",
    "                {\"role\": \"user\", \"content\": prompt+'\\n'.join(reason[i*20:(i+1)*20])},\n",
    "            ]\n",
    "    )\n",
    "\n",
    "    result = re.split(',|\\n', completion.choices[0].message.content)\n",
    "    if len(result) != len(reason[i*20:(i+1)*20]):   # if the result is not correct, try again\n",
    "        client = OpenAI(api_key='')\n",
    "        completion = client.chat.completions.create(\n",
    "            model=\"gpt-4-1106-preview\",\n",
    "            messages=\n",
    "                [\n",
    "                    # {\"role\": \"system\", \"content\": \"You're a clinical trial specialist.\"},\n",
    "                    {\"role\": \"user\", \"content\": prompt2+'\\n'.join(reason[i*20:(i+1)*20])},\n",
    "                ]\n",
    "        )\n",
    "        result = re.split(',|\\n', completion.choices[0].message.content)\n",
    "    assert len(result) == len(reason[i*20:(i+1)*20])\n",
    "    labels.extend(result)\n",
    "    for j in range(len(result)):\n",
    "        print(reason[i*20+j], \"      \",result[j])\n",
    "\n",
    "label_df = pd.DataFrame({'reason':reason_all, 'label':labels})\n",
    "label_df.to_csv('why_stopped_labels.csv', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 187,
   "metadata": {},
   "outputs": [],
   "source": [
    "reason_all = [' '.join(i.strip().split()) for i in pd.read_csv('why_stopped.csv')['why_stopped'].tolist()[4:]]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
